
<html lang="en"     class="pb-page"  data-request-id="c18a8f17-2b07-4193-88b0-b556db41b77d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;article:article:10.1021/acs.jmedchem.1c00135;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2021.64.issue-7;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Revisiting Pyrazolo[3,4-d]pyrimidine Nucleosides as Anti-Trypanosoma cruzi and Antileishmanial Agents" /></meta><meta name="dc.Creator" content="Jakob  Bouton" /></meta><meta name="dc.Creator" content="Ludmila  Ferreira de Almeida Fiuza" /></meta><meta name="dc.Creator" content="Camila  Cardoso Santos" /></meta><meta name="dc.Creator" content="Maria Angela  Mazzarella" /></meta><meta name="dc.Creator" content="Maria de Nazaré Correia  Soeiro" /></meta><meta name="dc.Creator" content="Louis  Maes" /></meta><meta name="dc.Creator" content="Izet  Karalic" /></meta><meta name="dc.Creator" content="Guy  Caljon" /></meta><meta name="dc.Creator" content="Serge  Van Calenbergh" /></meta><meta name="dc.Description" content="Chagas disease and visceral leishmaniasis are two neglected tropical diseases responsible for numerous deaths around the world. For both, current treatments are largely inadequate, resulting in a c..." /></meta><meta name="Description" content="Chagas disease and visceral leishmaniasis are two neglected tropical diseases responsible for numerous deaths around the world. For both, current treatments are largely inadequate, resulting in a c..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 30, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00135" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00135" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00135" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00135" /></link>
        
    
    

<title>Revisiting Pyrazolo[3,4-d]pyrimidine Nucleosides as Anti-Trypanosoma cruzi and Antileishmanial Agents | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00135" /></meta><meta property="og:title" content="Revisiting Pyrazolo[3,4-d]pyrimidine Nucleosides as Anti-Trypanosoma cruzi and Antileishmanial Agents" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0017.jpeg" /></meta><meta property="og:description" content="Chagas disease and visceral leishmaniasis are two neglected tropical diseases responsible for numerous deaths around the world. For both, current treatments are largely inadequate, resulting in a continued need for new drug discovery. As both kinetoplastid parasites are incapable of de novo purine synthesis, they depend on purine salvage pathways that allow them to acquire and process purines from the host to meet their demands. Purine nucleoside analogues therefore constitute a logical source of potential antiparasitic agents. Earlier optimization efforts of the natural product tubercidin (7-deazaadenosine) involving modifications to the nucleobase 7-position and the ribofuranose 3′-position led to analogues with potent anti-Trypanosoma brucei and anti-Trypanosoma cruzi activities. In this work, we report the design and synthesis of pyrazolo[3,4-d]pyrimidine nucleosides with 3′- and 7-modifications and assess their potential as anti-Trypanosoma cruzi and antileishmanial agents. One compound was selected for in vivo evaluation in an acute Chagas disease mouse model." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00135"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00135">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00135&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00135&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00135&amp;href=/doi/10.1021/acs.jmedchem.1c00135" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 4206-4238</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.1c00123" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00268" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Revisiting Pyrazolo[3,4-<i>d</i>]pyrimidine Nucleosides as Anti-<i>Trypanosoma cruzi</i> and Antileishmanial Agents</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Jakob Bouton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jakob Bouton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory for Medicinal Chemistry (Campus Heymans), Ghent University, Ottergemsesteenweg 460, B-9000 Gent, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jakob++Bouton">Jakob Bouton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ludmila Ferreira de Almeida Fiuza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ludmila Ferreira de Almeida Fiuza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratório de Biologia Celular, Instituto Oswaldo Cruz (FIOCRUZ), Fundação Oswaldo Cruz, Rio de Janeiro, Avenida Brasil 4365, Manguinhos, 21040-360 Rio de Janeiro, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ludmila++Ferreira+de+Almeida+Fiuza">Ludmila Ferreira de Almeida Fiuza</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Camila Cardoso Santos</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Camila Cardoso Santos</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratório de Biologia Celular, Instituto Oswaldo Cruz (FIOCRUZ), Fundação Oswaldo Cruz, Rio de Janeiro, Avenida Brasil 4365, Manguinhos, 21040-360 Rio de Janeiro, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Camila++Cardoso+Santos">Camila Cardoso Santos</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria Angela Mazzarella</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria Angela Mazzarella</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia 06100, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria+Angela++Mazzarella">Maria Angela Mazzarella</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria de Nazaré Correia Soeiro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria de Nazaré Correia Soeiro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratório de Biologia Celular, Instituto Oswaldo Cruz (FIOCRUZ), Fundação Oswaldo Cruz, Rio de Janeiro, Avenida Brasil 4365, Manguinhos, 21040-360 Rio de Janeiro, Brazil</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria+de+Nazar%C3%A9+Correia++Soeiro">Maria de Nazaré Correia Soeiro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Louis Maes</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Louis Maes</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Louis++Maes">Louis Maes</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Izet Karalic</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Izet Karalic</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory for Medicinal Chemistry (Campus Heymans), Ghent University, Ottergemsesteenweg 460, B-9000 Gent, Belgium</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Izet++Karalic">Izet Karalic</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Guy Caljon</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Guy Caljon</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#6d2a1814432e0c010702032d180c03191a081f1d0803430f08"><span class="__cf_email__" data-cfemail="a3e4d6da8de0c2cfc9cccde3d6c2cdd7d4c6d1d3c6cd8dc1c6">[email protected]</span></a>. Tel.: +32 (0)3 265 26 01.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Guy++Caljon">Guy Caljon</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Serge Van Calenbergh</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Serge Van Calenbergh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Laboratory for Medicinal Chemistry (Campus Heymans), Ghent University, Ottergemsesteenweg 460, B-9000 Gent, Belgium</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#6536001702004b33040b260409000b070017020d253022000b114b0700"><span class="__cf_email__" data-cfemail="a6f5c3d4c1c388f0c7c8e5c7cac3c8c4c3d4c1cee6f3e1c3c8d288c4c3">[email protected]</span></a>. Tel.: +32 (0)9 264 81 24. Fax: +32 (0)9 264 81 46.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Serge++Van+Calenbergh">Serge Van Calenbergh</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4201-1264" title="Orcid link">http://orcid.org/0000-0002-4201-1264</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00135&amp;href=/doi/10.1021%2Facs.jmedchem.1c00135" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 4206–4238</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 30, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>24 January 2021</li><li><span class="item_label"><b>Published</b> online</span>30 March 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 8 April 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00135" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00135</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4206%26pageCount%3D33%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJakob%2BBouton%252C%2BLudmila%2BFerreira%2Bde%2BAlmeida%2BFiuza%252C%2BCamila%2BCardoso%2BSantos%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D7%26contentID%3Dacs.jmedchem.1c00135%26title%3DRevisiting%2BPyrazolo%255B3%252C4-d%255Dpyrimidine%2BNucleosides%2Bas%2BAnti-Trypanosoma%2Bcruzi%2Band%2BAntileishmanial%2BAgents%26numPages%3D33%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4238%26publicationDate%3DApril%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00135"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">584</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00135" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Revisiting Pyrazolo[3,4-d]pyrimidine Nucleosides as Anti-Trypanosoma cruzi and Antileishmanial Agents&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Jakob&quot;,&quot;last_name&quot;:&quot;Bouton&quot;},{&quot;first_name&quot;:&quot;Ludmila&quot;,&quot;last_name&quot;:&quot;Ferreira de Almeida Fiuza&quot;},{&quot;first_name&quot;:&quot;Camila&quot;,&quot;last_name&quot;:&quot;Cardoso Santos&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;Angela Mazzarella&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;de Nazaré Correia Soeiro&quot;},{&quot;first_name&quot;:&quot;Louis&quot;,&quot;last_name&quot;:&quot;Maes&quot;},{&quot;first_name&quot;:&quot;Izet&quot;,&quot;last_name&quot;:&quot;Karalic&quot;},{&quot;first_name&quot;:&quot;Guy&quot;,&quot;last_name&quot;:&quot;Caljon&quot;},{&quot;first_name&quot;:&quot;Serge&quot;,&quot;last_name&quot;:&quot;Van Calenbergh&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;4206-4238&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00135&quot;},&quot;abstract&quot;:&quot;Chagas disease and visceral leishmaniasis are two neglected tropical diseases responsible for numerous deaths around the world. For both, current treatments are largely inadequate, resulting in a continued need for new drug discovery. As both kinetoplastid parasites are incapable of de novo purine synthesis, they depend on purine salvage pathways that allow them to acquire and process purines from the host to meet their demands. Purine nucleoside analogues therefore constitute a logical source of potential antiparasitic agents. Earlier optimization efforts of the natural product tubercidin (7-deazaadenosine) involving modifications to the nucleobase 7-position and the ribofuranose 3′-position led to analogues with potent anti-Trypanosoma brucei and anti-Trypanosoma cruzi activities. In this work, we report the design and synthesis of pyrazolo[3,4-d]pyrimidine nucleosides with 3′- and 7-modifications and assess their potential as anti-Trypanosoma cruzi and antileishmanial agents. One compound was selected for &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00135&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00135" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00135&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00135" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00135&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00135" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00135&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00135&amp;href=/doi/10.1021/acs.jmedchem.1c00135" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00135" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00135" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00135&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00135%26sid%3Dliteratum%253Aachs%26pmid%3D33784107%26genre%3Darticle%26aulast%3DBouton%26date%3D2021%26atitle%3DRevisiting%2BPyrazolo%255B3%252C4-d%255Dpyrimidine%2BNucleosides%2Bas%2BAnti-Trypanosoma%2Bcruzi%2Band%2BAntileishmanial%2BAgents%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D7%26spage%3D4206%26epage%3D4238%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292065" title="Nucleobases">Nucleobases</a>,</li><li><a href="/action/doSearch?ConceptID=291308" title="Nucleic acids">Nucleic acids</a>,</li><li><a href="/action/doSearch?ConceptID=290676" title="Substituents">Substituents</a>,</li><li><a href="/action/doSearch?ConceptID=292529" title="Aromatic compounds">Aromatic compounds</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/jmcmar.2021.64.issue-7/20210408/jmcmar.2021.64.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Chagas disease and visceral leishmaniasis are two neglected tropical diseases responsible for numerous deaths around the world. For both, current treatments are largely inadequate, resulting in a continued need for new drug discovery. As both kinetoplastid parasites are incapable of <i>de novo</i> purine synthesis, they depend on purine salvage pathways that allow them to acquire and process purines from the host to meet their demands. Purine nucleoside analogues therefore constitute a logical source of potential antiparasitic agents. Earlier optimization efforts of the natural product tubercidin (7-deazaadenosine) involving modifications to the nucleobase 7-position and the ribofuranose 3′-position led to analogues with potent anti-<i>Trypanosoma</i> brucei and anti-<i>Trypanosoma cruzi</i> activities. In this work, we report the design and synthesis of pyrazolo[3,4-<i>d</i>]pyrimidine nucleosides with 3′- and 7-modifications and assess their potential as anti-<i>Trypanosoma cruzi</i> and antileishmanial agents. One compound was selected for <i>in vivo</i> evaluation in an acute Chagas disease mouse model.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28488" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28488" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Chagas disease and leishmaniasis are two vector-borne communicable diseases responsible for numerous deaths every year. Characterized by the WHO as neglected tropical diseases (NTDs), they occur mainly in populations living in poverty in developing regions around the world and have a severe impact on the lives of affected persons and their families.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Chagas disease, caused by <i>Trypanosoma cruzi</i>, is endemic to Latin America, where it is still one of the most prevalent public health problems.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Migration and specific transmission modes have enabled spreading beyond these geographical boundaries so that it is now considered a global issue.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Chagas disease starts with an acute symptomatic phase characterized by high-grade parasitemia, which progresses into an asymptomatic chronic state after a few weeks. While most people stay asymptomatic for life, 30–40% will develop severe clinical manifestations after 10–30 years.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> Treatment options are limited to nifurtimox and benznidazole, two old drugs that have only limited efficacy in the chronic disease phase and are associated with severe adverse reactions.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> At present, no vaccine is available and effective antiparasitic chemotherapy is therefore key in eliminating this NTD. As the current Chagas disease pipeline is almost empty, there is a pressing need to develop novel, safe, and efficacious treatments.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a></div><div class="NLM_p">Leishmaniasis is endemic in 60 countries with Brazil, India, Ethiophia, Somalia, Kenya, South Sudan, and Sudan reporting more than 90% of all cases.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Depending on the causative <i>Leishmania</i> species, the disease exists in two main clinical forms: visceral leishmaniasis (VL) and cutaneous leishmaniasis (CL). The most severe systemic VL form is usually fatal within two years without treatment<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and is responsible for up to 30 000 deaths every year. Most antileishmanial drugs have been repurposed from other indications. Efficacy varies by geographical region, and treatment courses are long, require hospitalization, and are associated with significant side effects.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> While several new chemical entities with distinct mechanisms of action have recently entered clinical trials,<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19">(14−19)</a> new drug discovery efforts are required to fill the early-stage pipeline.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> New drug candidates should be suitable for field conditions and allow for global use, oral dosing, and a short treatment course.<a onclick="showRef(event, 'ref7 ref20'); return false;" href="javascript:void(0);" class="ref ref7 ref20">(7,20)</a></div><div class="NLM_p">Unlike their mammalian hosts, both <i>Trypanosoma cruzi</i> and <i>Leishmania</i> spp. are obligate auxotrophs for purine<i>s</i>, meaning that they lack <i>de novo</i> purine biosynthesis and rely on the salvage of purines (nucleosides and/or nucleobases) to meet their purine demand.<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> Consequently, they have developed a complex set of purine salvage enzymes that allows them to acquire and process purines from their hosts. Purine (nucleoside) analogues therefore constitute an interesting pool of potential antiparasitic agents. Indeed, several analogues have been reported that act as inhibitors of enzymes of the purine salvage pathway or as “subversive substrates”, which are selectively activated by salvage enzymes of the invading parasite.<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24−26)</a></div><div class="NLM_p">An example of such a subversive substrate is allopurinol (<b>1</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a). Next to its use as a treatment for gout, allopurinol inhibits the growth of several <i>Leishmania</i> and <i>Trypanosoma</i> species<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> in which its mechanism of action has been well-investigated.<a onclick="showRef(event, 'ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref28 ref29">(28,29)</a> It is selectively metabolized by the parasite to inosine- and adenosine-like nucleotide derivatives <b>5</b> and <b>6</b> and ultimately to an ATP analogue (i.e., APPR-TP) that is incorporated in RNA (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c).<a onclick="showRef(event, 'ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref28 ref29 ref30">(28−30)</a> Allopurinol has been evaluated in humans for VL treatment with mixed results. Although it achieved full cures in some patients, it was not satisfactory in monotherapy as first-line treatment due to its static rather than cidal character.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Nevertheless, allopurinol is still used in certain combination regimens for the treatment of CL,<a onclick="showRef(event, 'ref11 ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref11 ref32 ref33">(11,32,33)</a> and it is the treatment of choice for VL and CL in dogs.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Allopurinol has also been investigated for the treatment of Chagas disease with mixed outcomes.<a onclick="showRef(event, 'ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37">(35−37)</a> For example, it proved effective in treating reactivation after heart transplantation.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Both in leishmaniasis<a onclick="showRef(event, 'ref33 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref33 ref40 ref41 ref42">(33,40−42)</a> and in Chagas disease,<a onclick="showRef(event, 'ref43 ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref44 ref45">(43−45)</a> allopurinol has demonstrated synergism with currently used drugs, demonstrating that a nucleobase/nucleoside analogue could be a valuable addition to the therapeutic arsenal. The <i>in vitro</i> antileishmanial activity of the ribonucleoside of allopurinol (<b>2</b>) is several times higher than allopurinol, but <b>2</b> was not further evaluated <i>in vivo</i> due to production difficulties and limited benefit over allopurinol.<a onclick="showRef(event, 'ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref46 ref47 ref48">(46−48)</a> The 6-amino congeners aminopurinol <b>3</b> and riboside derivative <b>4</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a) were generally more active <i>in vitro</i> than allopurinol and <b>2</b>,<a onclick="showRef(event, 'ref46 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref46 ref49 ref50">(46,49,50)</a> which may be due to faster conversion to the same active triphosphate. However, <b>3</b> and <b>4</b> suffered from cytotoxicity and selectivity concerns. Yet, Avila et al. found aminopurinol to be effective in animal models of both VL and Chagas disease at dosages as much as 300-fold lower than used for allopurinol and well below the toxic dose in humans.<a onclick="showRef(event, 'ref46 ref51'); return false;" href="javascript:void(0);" class="ref ref46 ref51">(46,51)</a> Despite these promising data, neither aminopurinol <b>3</b> nor its ribonucleoside <b>4</b> was further evaluated for the treatment of leishmaniasis or Chagas disease.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0002.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Structures of pyrazolo[3,4-<i>d</i>]pyrimidines. (b) Antitrypanosomal 7-deazapurine nucleosides previously reported by our group. (c) Metabolism of allopurinol in <i>Leishmania</i> spp. and <i>T. cruzi</i>. (c, d) Pyrazolo[3,4-<i>d</i>]pyrimidine nucleosides reported in this study. Throughout the text, purine numbering is used as shown in Figure 1d, while in the experimental part, systematic numbering is employed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our group recently reported several 7-deazapurine nucleosides derived from the natural product tubercidin (<b>7</b>) that display potent activity against <i>Typanosoma brucei</i> and <i>T. cruzi</i> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b).<a onclick="showRef(event, 'ref52 ref53 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54 ref55 ref56">(52−56)</a> The introduction of selected substituents on the 7-position (as in <b>8, 9</b>) led to selective anti-<i>T. cruzi</i> and anti-<i>T. brucei</i> agents.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Further deletion of the hydroxyl group on position 3′ afforded compound <b>10</b>, which was able to fully cure mice with CNS-stage sleeping sickness,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and <b>9</b>, which displayed high potency against <i>T. cruzi</i>.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> A fluorine atom in position 3′ also proved favorable, with <b>11</b> displaying high anti-<i>T. cruzi</i> activity.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Compound <b>9</b> was evaluated in a Chagas mouse model but failed to deliver sterile cure. Furthermore, none of these 7-deazapurine nucleosides displayed selective activity against the phylogenetically related <i>Leishmania</i>, which is remarkable given that several nucleoside analogues display antileishmanial potential,<a onclick="showRef(event, 'ref47 ref48 ref58 ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref47 ref48 ref58 ref59 ref60 ref61">(47,48,58−61)</a> and many nucleosides combine antichagasic and antileishmanial activities.<a onclick="showRef(event, 'ref46 ref48 ref61'); return false;" href="javascript:void(0);" class="ref ref46 ref48 ref61">(46,48,61)</a> Nevertheless, known antileishmanial nucleoside analogues (<i>e.g</i>., the pyrazolo[3,4-<i>d</i>]pyrimidines (<i>vide supra</i>), carbocyclic inosine,<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> 9-deazainosine,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Formycin B<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a>) contain nucleobase surrogates other than 7-deazapurine, leading us to assume that a 7-deazapurine base is detrimental for antileishmanial activity.</div><div class="NLM_p">In the search for nucleoside analogues with improved antileismanial activity, we decided to explore nucleosides featuring a pyrazolo[3,4-<i>d</i>]pyrimidine (8-aza-7-deazapurine) nucleobase. Next to 7-deazapurines, pyrazolo[3,4-<i>d</i>]pyrimidines are the only purine isosteres that allow derivatization <i>via</i> 7-modifications,<a onclick="showRef(event, 'ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref63 ref64">(63,64)</a> such as the ones found beneficial to increase the potency and selectivity of (3′-deoxy)tubercidin. Compared to tubercidin <b>1</b>,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> aminopurinol riboside <b>4</b> is significantly less toxic.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Although several 7-modified and 3′-modified pyrazolo[3,4-<i>d</i>]pyrimidine nucleosides have been reported,<a onclick="showRef(event, 'ref66 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68">(66−68)</a> they have not been explored for antiparasitic activity. One exception is 7-bromo-allopurinol riboside, which proved more potent than allopurinol.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p last">In this study, we describe the synthesis and initial evaluation of a library of 7-substituted and ribofuranose-modified pyrazolo[3,4-<i>d</i>]pyrimidine nucleosides, comprising both inosine-like (allopurinol riboside) and adenosine-like (aminopurinol riboside) analogues. The structure–activity relationships for anti-<i>T. cruzi</i> and antileishmanial activity are discussed, and one analogue was evaluated in an acute Chagas disease mouse model.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The required brominated and iodinated nucleobase analogues <b>12</b> and <b>13</b> were readily obtained from aminopurinol <b>3</b><i>via</i> reaction with <i>N</i>-bromosuccinimide (NBS) or <i>N</i>-iodosuccinimide (NIS) in <i>N</i>,<i>N</i>-dimethylformamide (DMF) at elevated temperature (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). While we were also interested in the chloro and fluoro derivatives, chlorination of aminopurinol <b>3</b> with <i>N</i>-chlorosuccinimide (NCS) or fluorination with diethylaminosulfur trifluoride (DAST) failed to deliver the desired halogenated heterocycles. Bromination of allopurinol with bromine in water at 90 °C afforded <b>14</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Ribofuranose-Modified Pyrazolo[3,4-<i>d</i>]pyrimidine Nucleosides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, DMF, 60 °C, 91% (for <b>12</b>), NIS, DMF, 80 °C, 93% (for <b>13</b>); (b) NBS, water, 90 °C, 87%; (c) <b>12</b> (for <b>18</b>–<b>20</b>), <b>14</b> (for <b>26</b>–<b>28</b>), or <b>13</b> (for <b>34</b>) BF<sub>3</sub>·OEt<sub>2</sub>, MeNO<sub>2</sub>, reflux, 77% (<b>34</b>); (d) 0.5 M NaOMe in MeOH, 70% over 2 steps (<b>21</b>), 19% over 2 steps (<b>22</b>), 20% over 2 steps (<b>23</b>), 38% over 2 steps (<b>29</b>), 11% over 2 steps (<b>30</b>), 6% over 2 steps (<b>31</b>), 64% (<b>36</b>); (e) Pd/C, H<sub>2</sub>, 1 M aq. NaOAc, MeOH, 61% (<b>4</b>), 82% (<b>24</b>), 66% (<b>25</b>), 54% (<b>2</b>), 83% (<b>32</b>), 80% (<b>33</b>).</p></p></figure><div class="NLM_p">7-Bromoallopurinol <b>14</b> and 7-bromoaminopurinol <b>12</b> were coupled with 1-<i>O</i>-acetyl-2,3,5-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose, its 3′-deoxy counterpart <b>17</b>,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and 3′-deoxy-3′-fluoro analogue <b>16</b>.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Coupling of these three donors with 7-bromoaminopurinol <b>12</b> was performed with BF<sub>3</sub>·OEt<sub>2</sub> in refluxing nitromethane, as described for <b>18</b>.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> For the 7-bromoaminopurinol nucleosides <b>18</b>–<b>20</b>, a single product was obtained and no regioisomers were observed. Deprotection with sodium methoxide resulted in <b>21–23</b>, and reductive dehalogenation with H<sub>2</sub> and Pd/C in buffered methanol afforded <b>4, 24</b>, and <b>25</b>. Remarkably, the combined glycosylation-deprotection yields were much lower (∼20%) for the 3′-modified analogues compared to that of the ribofuranose <b>4</b> (∼70%). The correct regiochemistry of the final compounds was confirmed <i>via</i> comparison of the <sup>13</sup>C NMR spectra of <b>24</b> and <b>25</b> with that of the literature compound <b>4</b>. The chemical shifts of <i>C</i>-7 (∼133 ppm) and <i>C</i>-5 (∼154 ppm) (systematic numbering) were identical to reported values, whereas in the <i>N</i>-8 regioisomer, <i>C</i>-7 would be shifted upfield about 10 ppm and <i>C</i>-5 shifted downfield about 5–6 ppm.<a onclick="showRef(event, 'ref70 ref71'); return false;" href="javascript:void(0);" class="ref ref70 ref71">(70,71)</a> In the <sup>1</sup>H-<sup>13</sup>C HMBC spectra, <i>H</i>-1′–<i>C</i>-7 coupling was absent, providing further evidence of the desired <i>N</i>-9 regiochemistry.</div><div class="NLM_p">7-Bromoallopurinol <b>14</b> was glycosylated under the same conditions, but for each donor three different products with the same mass were observed on thin-layer chromatography (TLC), corresponding to the <i>N</i>-9, <i>N</i>-8, and <i>N</i>-1 regioisomers. The higher-running, less polar spot was the major product and was presumed to be the correct regioisomer<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> and was isolated. Glycosylation yields were generally lower (∼50%) than for the corresponding aminopurinols. The correct regiochemistries of <b>32</b> and <b>33</b> were verified <i>via</i> comparison of their <sup>13</sup>C NMR spectra with that of <b>2</b>.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Compared to the 6-aminonucleosides, the upfield shift of <i>C</i>-7 in the <i>N</i>-8 isomer is reported to be less pronounced,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> but the values of <i>C</i>-7 (∼135 ppm) and <i>C</i>-5 (∼148 ppm) (systematic numbering) were again very similar. Similarly, in this case, <i>H</i>-1′–<i>C</i>-7 coupling was again absent in the <sup>1</sup>H-<sup>13</sup>C HMBC spectra, further confirming <i>N</i>-9 attachment of the heterocycle.</div><div class="NLM_p">Glycosylation of <b>15</b> with 7-iodoaminopurinol afforded <b>34</b> in high yield, and deprotection in methanolic ammonia furnished <b>36</b>. Both <b>34</b> and <b>36</b> were used for further modifications (<i>vide infra</i>). Compound <b>4</b> could also be obtained from direct glycosylation of 4-aminopyrazolo[3,4-<i>d</i>]pyrimidine, followed by deprotection.</div><div class="NLM_p">The 2′-deoxy analogues were prepared as described by Seela et al. (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).<a onclick="showRef(event, 'ref64 ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref64 ref73 ref74 ref75">(64,73−75)</a> Compound <b>38</b> was obtained efficiently by bromination of 4-chloro-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine with NBS, followed by nucleophilic aromatic substitution with sodium methoxide. Anion glycosylation of <b>38</b> with commercially available Hoffer’s chlorosugar afforded <b>39</b> in 8% yield. Simultaneous deprotection and introduction of the 6-amino group to afford <b>40</b> was achieved by overnight heating in methanolic ammonia. Reductive dehalogenation <i>via</i> hydrogenation over Pd/C in buffered methanol afforded <b>41</b>. Attempted conversion of <b>39</b> to the corresponding 6-oxo congener in dilute NaOH solution, as described by Seela for the 3-unsubstituted analogue,<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> resulted in glycosidic bond breakage.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions: (a) NBS, DMF, 50 °C; (b) NaOMe, MeOH, 70 °C, 51% Over 2 steps; (c) <b>38</b>, KOH, TDA-1, MeCN, 8%; (d) 7 N NH<sub>3</sub> in MeOH, 90 °C, 76%; (e) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, NaOAc, MeOH, 46%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further modifications focused on the introduction of substituents on the 7-position of <b>21</b>. Different phenyl rings were introduced <i>via</i> aqueous Suzuki coupling reactions with the appropriate arylboronic acids to furnish <b>42</b>–<b>63</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Reaction with 4-chloro-3-cyano-phenylboronic acid gave rise to significant amounts of biphenyl product <b>75</b>, which was also isolated. Except for the 2-pyridyl and 2-thiophene substituents in <b>65</b> and <b>67</b>, which were introduced <i>via</i> Stille coupling, other heterocyclic substituents were also introduced under aqueous Suzuki coupling conditions to furnish <b>64</b>, <b>66</b>, and the substituted 2-thienyl analogues <b>68–70</b>. The vinyl- and isopropenyl-compounds <b>71</b> and <b>72</b> were synthesized <i>via</i> the Suzuki reaction with the respective potassium trifluoroborate salts, while <i>trans</i>-2-vinylphenylboronic acid was used to obtain <b>73</b>. The synthesis of <b>74</b> required multiple additions of cyclopropylboronic acid, since reaction with potassium cyclopropyltrifluoroborate proved unsuccessful. Likewise, the 3′-deoxy and 2′-deoxy bromonucleosides <b>23</b> and <b>40</b> were subjected to the Suzuki reaction with 4-chlorophenylboronic acid to afford <b>76</b> and <b>41</b>. Finally, the isopropenyl group of previously obtained <b>72</b> was reduced <i>via</i> catalytic hydrogenation to afford <b>78</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0006.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Reagents and Conditions: (a) Boronic Acid or Trifluoroborate Salt, Pd(OAc)<sub>2</sub>, TPPTS, Na<sub>2</sub>CO<sub>3</sub> (in the Case of a Boronic Acid) or Cs<sub>2</sub>CO<sub>3</sub> (When a Trifluoroborate Salt Was Used), MeCN/H<sub>2</sub>O 1:2, 16–81% (For All Compounds Except for <b>67</b> and <b>65</b>); (b) Tributylstannylated Heterocycle, Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, DMF, 24% (<b>67</b>)*, 66% (<b>65</b>)*; (c) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, MeOH, 81%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ullman coupling of <b>21</b> with phenol or 4-chlorophenol under conditions described for other pyrazolo[3,4-<i>d</i>]pyrimidines<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> afforded <b>79</b> and <b>80</b>, respectively (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). The yields were very low (5 and 3%) but provided sufficient amounts of product for preliminary evaluation. The synthesis of <b>81</b><i>via</i> Ullman coupling in aqueous ammonia has already been described,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and methylamine and pyrrolidine could be coupled under similar conditions to furnish <b>82</b> and <b>83</b>. To introduce a 7-chloro, <b>18</b> was subjected to a copper-catalyzed <i>retro</i>-Finkelstein reaction.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Although this reaction was sluggish, <b>85</b> was obtained in decent yield after deprotection.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0007.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Reagents and Conditions: (a) Phenol (for <b>79</b>) or 4-Chlorophenol (for <b>80</b>), CuI, <i>N</i>,<i>N</i>-Dimethylglycine, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 120 °C, 5% (<b>79</b>), 3% (<b>80</b>); (b) CuCl, aq. NH<sub>4</sub>OH (for <b>81</b>) or aq. NHMe (for <b>82</b>) or Pyrrolidine, 1,4-Dioxane/H<sub>2</sub>O 1:2 (for <b>83</b>), 120 °C, 19% (<b>81</b>), 5% (<b>82</b>), 16% (<b>83</b>); (c) Me<sub>4</sub>NCl, Cu<sub>2</sub>O, <span class="smallcaps smallerCapital">l</span>-Proline, 2-Methoxyethanol, 120 °C, 7 days; (d) 0.5 M NaOMe in MeOH, 34% Over 2 Steps</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The 7-iodo analogue <b>36</b> served as a useful precursor for another set of analogues (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). The Sonogashira reaction with phenylacetylene furnished <b>86</b>, which was further reduced to <b>87</b><i>via</i> catalytic hydrogenation. The Sonogashira reaction with ethynyltrimethylsilane yielded <b>88</b>, which was either further reduced to <b>89</b> or reacted with azidotrimethylsilane in a copper(I)-catalyzed azide-alkyne cycloaddition to <b>90</b>. A nitrile substituent was introduced <i>via</i> a palladium-catalyzed coupling reaction with Zn(CN)<sub>2</sub> to furnish <b>91</b>.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The nitrile group was further transformed to a tetrazole <b>92</b><i>via</i> a 1,3-dipolar cycloaddition reaction or reduced to the aminomethyl analogue <b>93</b><i>via</i> hydrogenation over Raney nickel. Alternatively, hydration of the nitrile in basic hydrogen peroxide solution furnished <b>94</b>. Attempted hydrolysis of nitrile <b>91</b><a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> failed to deliver the carboxylic acid but resulted in cleavage of the <i>N</i>-glycosidic bond instead. A trifluoromethyl substituent was introduced <i>via</i> a cross-coupling reaction with <i>in situ</i>-formed CuCF<sub>3</sub><a onclick="showRef(event, 'ref56 ref78'); return false;" href="javascript:void(0);" class="ref ref56 ref78">(56,78)</a> to afford <b>95</b>. Deprotection using sodium methoxide then furnished <b>96</b>.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0008.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Reagents and Conditions: (a) Phenylacetylene, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, DMF/Et<sub>3</sub>N 4:1, 40%; (b) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, MeOH, 89% (<b>87</b>), 74% (<b>89</b>); (c) (i) Ethynyltrimethylsilane, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, DMF/Et<sub>3</sub>N 4:1; (ii) 7 N NH<sub>3</sub> in MeOH, 19%; (d) TMSN<sub>3</sub>, CuI, DMF/MeOH 9:1, 100 °C, 40%; (e) Zn(CN)<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, DMF, 150 °C, 28%; (f) NaN<sub>3</sub>, NH<sub>4</sub>Cl, LiCl, DMF, 100 °C, 25%; (g) H<sub>2</sub>, Raney Nickel, MeOH, 10%; (h) NH<sub>4</sub>OH, H<sub>2</sub>O<sub>2</sub>, 25%; (i) TMSCF<sub>3</sub>, CuI, KF, DMF/NMP 1:1, Reflux; (j) 0.5 M NaOMe in MeOH, 14% Over 2 Steps</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To gain access to the methyl-substituted base <b>98</b>, 5-amino-4-cyano-3-methyl-1<i>H</i>-pyrazole <b>97</b> was synthesized <i>de novo</i> from malonitrile and acetyl chloride according to the method of Haneman (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Ring closure of <b>97</b> with thioacetamide instead of formamide furnished the bismethylated heterocycle <b>99</b>. Glycosylation of <b>98</b> afforded <b>100</b>, which was deprotected to <b>101</b>. Unfortunately, attempted glycosylation of <b>99</b> under the same conditions was not successful.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0009.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Reagents and Conditions: (a)(i) NaH, AcCl, Tetrahydrofuran (THF), 0 °C to RT, (ii) Dimethyl Sulfate, Reflux, (iii) H<sub>2</sub>NNH<sub>2</sub>·H<sub>2</sub>O, Et<sub>3</sub>N, 38% Over 3 Steps; (b) Formamide, 180 °C, 23%; (c) Thioacetamide, Reflux, 36%; (d) <b>98</b>, BF<sub>3</sub>·OEt<sub>2</sub>, MeNO<sub>2</sub>, Reflux; (e) 0.5 M NaOMe in MeOH, 21% Over 2 Steps</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since a carboxylic acid could not be obtained from the cyano analogue <b>91</b>, we looked at other methods to introduce a carbonyl group on the 7-position. Vilsmeier–Haack formylation of <b>35</b> failed and only led to <i>N</i>-formylation of the 6-amino group. Palladium-catalyzed carbonylation reactions of <b>34</b> with different CO equivalents were also unsuccessful.<a onclick="showRef(event, 'ref80 ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref80 ref81 ref82">(80−82)</a> Finally, we tried to convert a vinyl substituent into the corresponding aldehyde (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). To minimize side reactions, we chose to start from the benzoyl-protected iodide precursor <b>36</b>. Suzuki reaction with potassium vinyl trifluoroborate<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> afforded <b>102</b> in acceptable yields. Oxidative cleavage of the vinyl group <b>102</b> was accomplished <i>via</i> the Lemieux–Johnson oxidation to afford aldehyde <b>103</b>. The carboxylic acid analogue <b>108</b> could now efficiently be obtained <i>via</i> the Pinnick oxidation of <b>103</b>. Alternatively, the aldehyde functionality of <b>103</b> was further elaborated to a methyl-<i>N</i>-morpholino substituent <i>via</i> reductive amination (<b>104</b>) or to a difluoromethyl substituent <i>via</i> reaction with DAST (<b>106</b>). Deprotection under basic conditions afforded <b>105</b> and <b>107</b>. The carboxylic acid functionality was further derivatized to different amides <i>via</i> HCTU-mediated coupling to afford analogues <b>113</b>–<b>116</b> after benzoate deprotection. Attempted cyclopropanation of <b>102</b> with <i>in situ</i>-generated difluorocarbene (from BrCF<sub>2</sub>CO<sub>2</sub>Na<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a>) or dichlorocarbene (generated from CHCl<sub>3</sub> and NaOH) failed.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0010.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Reagents and Conditions: (a) Potassium Vinyl Trifluoroborate, Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O 9:1, 100 °C, 38%; (b) K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, NaIO<sub>4</sub>, 2,6-Lutidine, 1,4-Dioxane/H<sub>2</sub>O 3:1, 48%; (c) Morpholine, NaBH<sub>3</sub>CN, AcOH, MeOH/THF 2:1; (d) 0.5 M NaOMe in MeOH, 64% Over 2 Steps (<b>105</b>), 58% Over 2 Steps (<b>107</b>), 29% Over 2 Steps (<b>113</b>), 28% Over 2 Steps (<b>114</b>), 61% Over 2 Steps (<b>115</b>), 44% Over 2 Steps (<b>116</b>); (e) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>O<sub>2</sub>, THF/H<sub>2</sub>O 6:1, 94%; (f) DAST, CH<sub>2</sub>Cl<sub>2</sub>; (g) Aq. NHMe (<b>109</b>), Pyrrolidine (<b>110</b>), Aniline (<b>111</b>), or Benzylamine (<b>112</b>), HCTU, <i>N</i>,<i>N</i>-Diisopropylethylamine (DIPEA), DMF</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Biological Evaluation</h3><div class="NLM_p">The prepared nucleoside analogues were evaluated <i>in vitro</i> for their activity against <i>T. cruzi</i> and <i>Leishmania infantum</i>. Cytotoxicity was assayed against MRC-5<sub>SV2</sub> cells (<i>T. cruzi</i> host cell) and primary mouse macrophages (PMM, <i>L. infantum</i> host cell) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Evaluation of Drug Sensitivity of Ribofuranose-Modified Nucleoside Analogues against <i>T. cruzi</i> and <i>L. inf.</i><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0011.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd.</th><th class="colsep0 rowsep0" align="center">structure</th><th class="colsep0 rowsep0" align="center"><i>T. cruzi</i> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">MRC-5 CC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">SI</th><th class="colsep0 rowsep0" align="center"><i>L. infantum.</i> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">PMM CC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">SI</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left"><i>Nucleobases</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">R = H</td><td class="colsep0 rowsep0" align="left"><i>0.57</i></td><td class="colsep0 rowsep0" align="left"><i>2.46</i></td><td class="colsep0 rowsep0" align="left"><i>5</i></td><td class="colsep0 rowsep0" align="left"><i>0.18</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>355</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">R = Br</td><td class="colsep0 rowsep0" align="left"><i>38.1</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>1</i></td><td class="colsep0 rowsep0" align="left"><i>22.6</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>2</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">R = H</td><td class="colsep0 rowsep0" align="left">9.75 ± 1.75</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>7</td><td class="colsep0 rowsep0" align="left">3.51 ± 1.77</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">R = Br</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left"><i>Ribonucleosides</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">X = H</td><td class="colsep0 rowsep0" align="left">0.29 ± 0.03</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>219</td><td class="colsep0 rowsep0" align="left">1.06 ± 0.35</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">X = Br</td><td class="colsep0 rowsep0" align="left">4.37 ± 0.55</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>15</td><td class="colsep0 rowsep0" align="left">29.4 ± 21.4</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">R = I</td><td class="colsep0 rowsep0" align="left"><i>12.62</i></td><td class="colsep0 rowsep0" align="left"><i>25.4</i></td><td class="colsep0 rowsep0" align="left"><i>2</i></td><td class="colsep0 rowsep0" align="left"><i>25.4</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>2</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">R = H</td><td class="colsep0 rowsep0" align="left">7.18 ± 3.66</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">6.66 ± 4.66</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">R = Br</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left"><i>3</i>′<i>-Deoxy-3</i>′<i>-Fluoronucleosides</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">X = H</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">X = Br</td><td class="colsep0 rowsep0" align="left"><i>1.06</i></td><td class="colsep0 rowsep0" align="left"><i>0.23</i></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left"><i>0.08</i></td><td class="colsep0 rowsep0" align="left"><i>0.13</i></td><td class="colsep0 rowsep0" align="left"><i>1</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">X = H</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">R = Br</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left"><i>3</i>′<i>-Deoxynucleosides</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">R = H</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">R = Br</td><td class="colsep0 rowsep0" align="left"><i>38.5</i></td><td class="colsep0 rowsep0" align="left"><i>2.2</i></td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">R = H</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">R = Br</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="8" align="left"><i>2</i>′<i>-Deoxynucleosides</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">R = H</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">R = Br</td><td class="colsep0 rowsep0" align="left">53.2 ± 10.8</td><td class="colsep0 rowsep0" align="left">24.9 ± 14.0</td><td class="colsep0 rowsep0" align="left">0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Cytotoxicity Was Assayed against Human MRC-5<sub>SV2</sub> Cells and Primary Mouse Macrophages (PMMs). Values represent mean ± SEM, which originate from 2–3 independent experiments and are expressed in μM. Values in italics represent the result of a single determination because of inactivity or overt cytotoxicity. SI: <i>in vitro</i> selectivity index is the ratio of CC<sub>50</sub> for the host cell (MRC-5<sub>SV2</sub> for <i>T. cruzi</i>, PMM for <i>L. inf.</i>) and IC<sub>50</sub> of the parasite. Benznidazole was included as a reference for <i>T. cruzi</i> (IC<sub>50</sub> = 2.02 ± 0.28 μM) and miltefosine as a reference for <i>L. infantum</i> (IC<sub>50</sub> = 7.47 ± 2.23 μM).</p></div></div></div><div class="NLM_p">Although the anti-<i>T. cruzi</i> and antileishmanial activities of allopurinol (<b>1</b>), aminopurinol (<b>3</b>), and their ribonucleosides <b>2</b> and <b>4</b> are already known, they were included in this study as reference compounds. In accordance with various literature reports,<a onclick="showRef(event, 'ref46 ref51 ref85'); return false;" href="javascript:void(0);" class="ref ref46 ref51 ref85">(46,51,85)</a><b>1</b> and <b>3</b> displayed good activity against <i>T. cruzi</i> and <i>L. infantum</i>. Yet, the 20-fold higher activity and selectivity of aminopurinol (<b>3</b>) compared to allopurinol (<b>1</b>) against <i>L. infantum</i> is striking. As mentioned before, <b>3</b> has never been evaluated in an <i>in vivo</i> VL model although it is known to be safe at low doses.<a onclick="showRef(event, 'ref46 ref51'); return false;" href="javascript:void(0);" class="ref ref46 ref51">(46,51)</a> Introduction of a bromo substituent in position 7 of allopurinol (<b>1</b>) or aminopurinol (<b>3</b>) led to a drastic drop in activity, possibly due to impeded conversion by PRTases, which are essential for the activation of nucleobase analogues. The 4-APP ribonucleoside <b>4</b> displayed potent activity against both <i>T. cruzi</i> and <i>L. infantum</i> intracellular amastigotes, as could be expected from literature reports on its activity against <i>T. cruzi</i> epimastigotes and <i>Leishmania</i> promastigotes.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> In both MRC-5<sub>SV2</sub> cells and PMM cells, <b>4</b> failed to show cytotoxicity up to 64 μM, but similar to <b>3</b>, it has never been evaluated <i>in vivo</i>. Introduction of a halogen atom on the 7-position of <b>4</b> (compounds <b>21</b> and <b>36</b>) led to a severe decrease in activity against <i>T. cruzi</i> and <i>L. infantum</i>. This is different from earlier reported results in <i>T. cruzi</i> epimastigotes and <i>Leishmania</i> promastigotes, where the activity was more comparable to the parent compound <b>4</b>.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Activity of allopurinol ribonucleoside <b>2</b> was comparable to allopurinol.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> In our hands, introduction of a bromide on the 7-position of <b>2</b> (compound <b>29</b>) rendered the compound inactive, which conflicts with a report stating it to be more active than <b>2</b> against <i>L. tropica</i> intracellular amastigotes.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div><div class="NLM_p">The combination of aminopurinol (<b>3</b>) and allopurinol (<b>1</b>) with a 3′-deoxy-3′-fluororibofuranose moiety (<b>24</b> and <b>32</b>) resulted in inactive compounds. Introduction of a bromide on the 3-position of <b>24</b> rendered the compound highly cytotoxic (<b>22</b>). It did not display any selective activity, contrasting with the matched 7-deazapurine nucleoside.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> The same was true for the 3′-deoxynucleosides <b>23</b>, <b>25</b>, <b>31</b>, and <b>33</b>. While the inactivity of <b>33</b> was already noted by Moorman et al.,<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> the inactivity of <b>25</b> was more surprising, as removal of the 3′-hydroxy group resulted in a major increase in activity against <i>T. brucei</i> or <i>T. cruzi</i> in earlier 7-deazapurine nucleoside series.<a onclick="showRef(event, 'ref53 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref55">(53,55)</a> Again, the introduction of a 7-bromo substituent (<b>23</b>) afforded a cytotoxic compound without any specific antiparasitic activity. The 2′-deoxynucleosides <b>41</b> and <b>40</b> were also inactive, as was already reported for <b>41</b>.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">Based on the structure–activity relationship (SAR) of earlier nucleoside series,<a onclick="showRef(event, 'ref52 ref53 ref57 ref78'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref57 ref78">(52,53,57,78)</a> which demonstrated that modifications of the 7-position could improve activity, we performed an extensive substituent screen. In a first set of analogues, different substituted phenyl rings were introduced on the 7-position (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Remarkably, also in this series, a 4-chlorophenyl (<b>44)</b> proved to confer the best antitrypanosomal activity (IC<sub>50</sub> = 0.32 μM) and was about 50-fold more active than the 7-phenyl analogue <b>42</b>. The second most potent para-substituted analogue was the 4-methylphenyl substituted compound <b>45</b>. Further substitution of the 4-chlorophenyl substituent with a 3-fluoro (<b>53</b>), methyl (<b>57</b>), or methoxy group (<b>56</b>) failed to potentiate its activity. The 2,4-substituted analogues <b>62</b> and <b>63</b> were less active than the 3,4-disubstituted analogues. Strikingly, the superiority of this 4-chlorophenyl modification has also been observed for other 7-deazapurine nucleosides and suggests that the chloro substituent is involved in a crucial interaction with a parasitic target or transporter, rather than just reducing the electron density of the phenyl ring. Removal of the 3′-OH group as in <b>76</b> was expected to result in increased anti-<i>T. cruzi</i> activity, based on earlier observations with 7-deazapurine nucleosides,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> but surprisingly led to a compound that was 3-fold less active than <b>44</b>. Nevertheless, <b>44</b> is more potent than its 7-deazapurine congener<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and displays an improved selectivity profile, with no <i>in vitro</i> toxicity in MRC-5<sub>SV2</sub> or PMM cells in concentrations up to 64 μM. The 2′-deoxy analogue <b>77</b> displayed reasonably good anti-<i>T. cruzi</i> activity but was less potent than both <b>44</b> and <b>76</b>. All phenyl-substituted analogues displayed in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> were inactive against <i>L. infantum.</i></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Evaluation of Drug Sensitivity of 7-Modified Nucleoside Analogues against <i>T. cruzi</i> and <i>L. infantum</i><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0012.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd.</th><th class="colsep0 rowsep0" align="center">structure (R =)</th><th class="colsep0 rowsep0" align="center"><i>T. cruzi</i> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">MRC-5 CC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">SI</th><th class="colsep0 rowsep0" align="center"><i>L. inf.</i> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">PMM CC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">SI</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>13.1</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>5</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">18.2</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>4</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">0.32 ± 0.02</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>197</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="left">1.77 ± 0.92</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>36</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="left">3.36 ± 1.88</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>19</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">4-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">10.3 ± 5.8</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>6</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">4-<i>t</i>-Bu</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">4-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">6.34 ± 1.90</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="left">57.0 ± 9.3</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">4-OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">15.6 ± 6.2</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>4</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">4-CN</td><td class="colsep0 rowsep0" align="left"><i>32.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>2</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">3,4-diCl</td><td class="colsep0 rowsep0" align="left">2.82 ± 1.94</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>23</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">3-Cl-4-F</td><td class="colsep0 rowsep0" align="left">4.66 ± 2.71</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>14</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3-F</td><td class="colsep0 rowsep0" align="left">1.19 ± 0.92</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>54</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">3,4-diF</td><td class="colsep0 rowsep0" align="left">4.24 ± 1.55</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>15</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3-OMe</td><td class="colsep0 rowsep0" align="left">1.14 ± 1.02</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>56</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3-Me</td><td class="colsep0 rowsep0" align="left">0.81 ± 0.13</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>79</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"><i>43.8</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>1</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3-CN</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3,5-diF</td><td class="colsep0 rowsep0" align="left">1.33 ± 0.51</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>17</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">4-Cl-3-OEt</td><td class="colsep0 rowsep0" align="left">45.3</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>1</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">2,4-diCl</td><td class="colsep0 rowsep0" align="left">6.06 ± 2.69</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>11</td><td class="colsep0 rowsep0" align="left">52.8 ± 11.2</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">4-Cl-2-Me</td><td class="colsep0 rowsep0" align="left">3.76 ± 0.61</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>17</td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>75</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>77</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">2.49 ± 0.42</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>22</td><td class="colsep0 rowsep0" align="left">[32.5, >64.0]</td><td class="colsep0 rowsep0" align="left">[32.0, >64.0]</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1.04 ± 0.32</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>61</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Cytotoxicity was assayed against human MRC-5SV2 cells and primary mouse macrophages (PMMs). Values represent mean ± SEM, which originate from 2–3 independent experiments and are expressed in μM. Values in parentheses represent the values of the different determinations, as no correct average can be calculated. Values in italics represent the result of a single determination because of inactivity or overt cytotoxicity. SI: <i>in vitro</i> selectivity index is the ratio of CC<sub>50</sub> for the host cell (MRC-5<sub>SV2</sub> for <i>T. cruzi</i>, PMM for <i>L. inf.</i>) and IC<sub>50</sub> of the parasite. Benznidazole was included as a reference for <i>T. cruzi</i> (IC<sub>50</sub> = 2.02 ± 0.28 μM) and miltefosine as a reference for <i>L. infantum</i> (IC<sub>50</sub> = 7.47 ± 2.23 μM).</p></div></div></div><div class="NLM_p">Bioisosteric replacement of the phenyl ring by a thiophene resulted in a loss of activity (<b>67</b>–<b>70</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The 5-chlorothiophene and 5-methylthiophene analogues <b>69</b> and <b>68</b> were 5–10-fold less active than their phenyl counterparts and displayed lower selectivity. Introducing an extra atom or linker between the nucleobase and the phenyl ring was also not tolerated, as illustrated by the inactivity of the phenoxy analogues <b>79</b> and <b>80</b> and the low activity of elongated phenyl analogues <b>86</b>, <b>73</b>, and <b>87</b>. None of these analogues showed any activity against <i>L. infantum</i>. A number of nitrogen-containing heterocycles were also introduced on the 7-position (<b>64–66</b>, <b>90</b>, and <b>92</b>). A 2- or 4-pyridyl substituent (<b>65</b> and <b>66</b>), an <i>N</i>-methylpyrazole (<b>64</b>), and tetrazole (<b>92</b>) did not lead to any specific activity against <i>T. cruzi</i> or <i>L. infantum</i>. While <b>64</b> and <b>92</b> were devoid of MRC-5<sub>SV2</sub> cytotoxicity, the triazole analogue <b>90</b> was highly cytotoxic and also did not display any specific antiparasitic activity.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Evaluation of Drug Sensitivity of 7-Modified Pyrazolo[3,4-<i>d</i>]pyrimidine Nucleoside Analogues against <i>T. cruzi</i> and <i>L. infantum</i><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0013.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd.</th><th class="colsep0 rowsep0" align="center"><i>T. cruzi</i> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">MRC-5 CC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">SI</th><th class="colsep0 rowsep0" align="center"><i>L. infantum.</i> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">PMM CC<sub>50</sub> (μM)</th><th class="rowsep0 colsep0" align="center">SI</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left"><i>Thiophenes</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left"><i>10.4</i></td><td class="colsep0 rowsep0" align="left"><i>32</i></td><td class="colsep0 rowsep0" align="left"><i>3</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="rowsep0 colsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="left">2.56 ± 1.12</td><td class="colsep0 rowsep0" align="left">47.3 ± 6.12</td><td class="colsep0 rowsep0" align="left"><i>14</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0 colsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68</b></td><td class="colsep0 rowsep0" align="left">7.10 ± 4.2</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>9</td><td class="colsep0 rowsep0" align="left">[32.0,>64.0]</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0 colsep0" align="left">>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70</b></td><td class="colsep0 rowsep0" align="left"><i>32</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>2</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="rowsep0 colsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="7" align="left"><i>Elongated phenyls</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>32</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="rowsep0 colsep0" align="left"><i>>2</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0 colsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>86</b></td><td class="colsep0 rowsep0" align="left">29.4 ± 11.1</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">49.4 ± 8.7</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0 colsep0" align="left">>1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left"><i>16.5</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>4</i></td><td class="colsep0 rowsep0" align="left"><i>50.8</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="rowsep0 colsep0" align="left"><i>>1</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>87</b></td><td class="colsep0 rowsep0" align="left"><i>52.3</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>1</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0 colsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="6" align="left"><i>Nitrogen-containing heterocycles</i></td><td class="rowsep0 colsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left">30.1 ± 17.8</td><td class="colsep0 rowsep0" align="left">36.4 ± 4.1</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">[50.8, >64.0, >64.0]</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0 colsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left"><i>21.5</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>3</i></td><td class="colsep0 rowsep0" align="left"><i>25.4</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="rowsep0 colsep0" align="left"><i>>3</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left"><i>45.3</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>>1</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0 colsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>90</b></td><td class="colsep0 rowsep0" align="left"><i>0.43</i></td><td class="colsep0 rowsep0" align="left"><i>0.6</i></td><td class="colsep0 rowsep0" align="left"><i>1</i></td><td class="colsep0 rowsep0" align="left"><i>43.1</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="rowsep0 colsep0" align="left"><i>>1</i></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>92</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Cytotoxicity was assayed against human MRC-5<sub>SV2</sub> cells and primary mouse macrophages (PMMs). Values represent mean ± SEM, which originate from 2–3 independent experiments and are expressed in μM. Values in parentheses represent the values of the different determinations, as no correct average can be calculated. Values in italics represent the result of a single determination because of inactivity or overt cytotoxicity. SI: <i>in vitro</i> selectivity index is the ratio of CC<sub>50</sub> for the host cell (MRC-5<sub>SV2</sub> for <i>T. cruzi</i>, PMM for <i>L. inf.</i>) and IC<sub>50</sub> of the parasite. Benznidazole was included as a reference for <i>T. cruzi</i> (IC<sub>50</sub> = 2.02 ± 0.28 μM) and miltefosine as a reference for <i>L. infantum</i> (IC<sub>50</sub> = 7.47 ± 2.23 μM).</p></div></div></div><div class="NLM_p">Among a series of analogues with small substituents on the 7-position, a nitrile (<b>91</b>) led to reasonable activity against both <i>T. cruzi</i> and <i>L. infantum</i> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The chloro analogue <b>85</b> was less active against <i>T. cruzi</i> but displayed higher selectivity toward MRC-5<sub>SV2</sub> cells. A trifluoromethyl (<b>96</b>) or difluoromethyl (<b>107</b>) substituent resulted in cytotoxic compounds that did not display selective antiparasitic activity. Among the carbon-based substituents, the methyl analogue <b>101</b> and the ethynyl analogue <b>88</b> displayed moderate anti-<i>T. cruzi</i> activity. A vinyl (<b>71</b>), ethyl (<b>89</b>), or cyclopropyl (<b>74</b>) substituent led to inactive compounds, while an isopropenyl (<b>72</b>) or isopropyl (<b>78</b>) group resulted in cytotoxic compounds with no specific antiparasitic activity. An amine (<b>81</b>), methylamine (<b>82</b>), or pyrrolidine group (<b>83</b>) on the 7-position did not lead to any significant antiparasitic activity, as was the case for an aminomethyl (<b>93</b>) or morpholinomethyl (<b>105</b>) substituent. The activity of the amide-substituted nucleosides (<b>94, 113</b>–<b>116</b>) varied: a carboxamide group (<b>94</b>) again resulted in a cytotoxic compound, while adding a methyl group on the amide nitrogen (<b>113)</b> removed all cytotoxic effects and provided a compound with moderate anti-<i>T. cruzi</i> activity. Amide analogues with bigger groups (<b>114</b>–<b>116</b>) were inactive.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Evaluation of Drug Sensitivity of 7-Modified Nucleoside Analogues against <i>T. cruzi</i> and <i>L. infantum</i><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0015.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="bottom"><th class="colsep0 rowsep0" align="center" valign="bottom">cpd.</th><th class="colsep0 rowsep0" align="center" valign="bottom"><i>T. cruzi</i> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" valign="bottom">MRC-5 CC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" valign="bottom">SI</th><th class="colsep0 rowsep0" align="center" valign="bottom"><i>L. infantum.</i> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" valign="bottom">PMM CC<sub>50</sub> (μM)</th><th class="rowsep0" align="center" valign="bottom">SI</th></tr></thead><tbody><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="left">2.89 ± 0.23</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>22</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left">>1</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>91</b></td><td class="colsep0 rowsep0" align="left"><i>0.95</i></td><td class="colsep0 rowsep0" align="left"><i>34.6</i></td><td class="colsep0 rowsep0" align="left"><i>36</i></td><td class="colsep0 rowsep0" align="left"><i>8</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="rowsep0" align="left"><i>>8</i></td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>96</b></td><td class="colsep0 rowsep0" align="left"><i>27</i></td><td class="colsep0 rowsep0" align="left"><i>13.3</i></td><td class="colsep0 rowsep0" align="left"><i><1</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left"> </td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>107</b></td><td class="colsep0 rowsep0" align="left"><i>8.3</i></td><td class="colsep0 rowsep0" align="left"><i>2.42</i></td><td class="colsep0 rowsep0" align="left"><i><1</i></td><td class="colsep0 rowsep0" align="left"><i>0.25</i></td><td class="colsep0 rowsep0" align="left"><i>0.25</i></td><td class="rowsep0" align="left"><i>1</i></td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>101</b></td><td class="colsep0 rowsep0" align="left">4.68 ± 1.33</td><td class="colsep0 rowsep0" align="left">57.5 ± 6.5</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">32.7 ± 15.5</td><td class="colsep0 rowsep0" align="left">40.0 ± 12</td><td class="rowsep0" align="left">1</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>88</b></td><td class="colsep0 rowsep0" align="left">2.78 ± 0.04</td><td class="colsep0 rowsep0" align="left">[46.5, >64.0]</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">10.4 ± 2.3</td><td class="colsep0 rowsep0" align="left">[8.00, >64.0]</td><td class="rowsep0" align="left">1</td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>12.7</i></td><td class="colsep0 rowsep0" align="left"><i>32</i></td><td class="rowsep0" align="left"><i>3</i></td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>89</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left"> </td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left"> </td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left"><i>29.5</i></td><td class="colsep0 rowsep0" align="left"><i>0.35</i></td><td class="colsep0 rowsep0" align="left"><i><1</i></td><td class="colsep0 rowsep0" align="left"><i>24.1</i></td><td class="colsep0 rowsep0" align="left"><i>32</i></td><td class="rowsep0" align="left"><i>1</i></td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>10.6</i></td><td class="colsep0 rowsep0" align="left"><i><1</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left"> </td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left"><i>7.64</i></td><td class="colsep0 rowsep0" align="left"><i>23</i></td><td class="colsep0 rowsep0" align="left"><i>3</i></td><td class="colsep0 rowsep0" align="left"><i>6.82</i></td><td class="colsep0 rowsep0" align="left"><i>8</i></td><td class="rowsep0" align="left"><i>1</i></td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>50.8</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="rowsep0" align="left"><i>>1</i></td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>83</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left"> </td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>93</b></td><td class="colsep0 rowsep0" align="left"><i>11.1</i></td><td class="colsep0 rowsep0" align="left"><i>59.3</i></td><td class="colsep0 rowsep0" align="left"><i>5</i></td><td class="colsep0 rowsep0" align="left"><i>2</i></td><td class="colsep0 rowsep0" align="left"><i>8</i></td><td class="rowsep0" align="left"><i>4</i></td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>105</b></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left"> </td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>94</b></td><td class="colsep0 rowsep0" align="left"><i>0.25</i></td><td class="colsep0 rowsep0" align="left"><i>0.25</i></td><td class="colsep0 rowsep0" align="left"><i>1</i></td><td class="colsep0 rowsep0" align="left"><i>8.11</i></td><td class="colsep0 rowsep0" align="left"><i>8</i></td><td class="rowsep0" align="left"><i>1</i></td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>113</b></td><td class="colsep0 rowsep0" align="left"><i>4</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left"><i>16</i></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left"> </td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>114</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="rowsep0" align="left"> </td></tr><tr valign="top"><td class="colsep0 rowsep0" align="left"><b>115</b></td><td class="colsep0 rowsep0" align="left"><i>>64.0</i></td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>32.5</i></td><td class="colsep0 rowsep0" align="left"><i>32</i></td><td class="rowsep0" align="left"><i>1</i></td></tr><tr valign="top"><td class="colsep0" align="left"><b>116</b></td><td class="colsep0" align="left"><i>>64.0</i></td><td class="colsep0" align="left">>64.0</td><td class="colsep0" align="left"> </td><td class="colsep0" align="left"><i>>64.0</i></td><td class="colsep0" align="left">>64.0</td><td align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Cytotoxicity was assayed against human MRC-5<sub>SV2</sub> cells and primary mouse macrophages (PMMs). Values represent mean ± SEM, which originate from 2–3 independent experiments and are expressed in μM. Values in parentheses represent the values of the different determinations, as no correct average can be calculated. Values in italics represent the result of a single determination because of inactivity or overt cytotoxicity. SI: <i>in vitro</i> selectivity index is the ratio of CC<sub>50</sub> for the host cell (MRC-5<sub>SV2</sub> for <i>T. cruzi</i>, PMM for <i>L. inf.</i>) and IC<sub>50</sub> of the parasite. Benznidazole was included as a reference for <i>T. cruzi</i> (IC<sub>50</sub> = 2.02 ± 0.28 μM) and miltefosine as a reference for <i>L. infantum</i> (IC<sub>50</sub> = 7.47 ± 2.23 μM).</p></div></div></div><div class="NLM_p last">Overall, the SAR of the pyrazolo[3,4-<i>d</i>]pyrimidine nucleosides for anti-<i>T. cruzi</i> and anti-<i>L. infantum</i> activities turned out to be completely different from previously reported 7-deazapurine<a onclick="showRef(event, 'ref52 ref53 ref57'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref57">(52,53,57)</a> and 1,7-dideazapurine<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> nucleoside series. As already known from several literature reports, the parent nucleosides aminopurinol riboside <b>4</b> and allopurinol riboside <b>2</b> displayed good <i>in vitro</i> activity against both <i>T. cruzi</i> and <i>L. infantum</i>. Introduction of a halogen atom on the 7-position had a detrimental effect on the activity against both <i>T. cruzi</i> and <i>L. infantum</i> and modifications at the 3′-position of the ribose moiety, expected to result in more potent compounds based on SAR studies of earlier nucleoside series, completely abolished activity, or resulted in cytotoxic compounds. A substituent screen of the 7-position of <b>4</b> revealed highly varying effects on the antiparasitic activity and cytotoxicity to MRC-5<sub>SV2</sub> and PMM. A 4-chlorophenyl substituent resulted in a compound with potent anti-<i>T. cruzi</i> activity and devoid of cytotoxic effects in MRC-5<sub>SV2</sub> or PMM at concentrations up to 64 μM. Contrary to expectations, removal of the 3′-hydroxyl group of <b>44</b> resulted in a compound that was 2–3-fold less potent (<b>76</b>). The insertion of a linker (oxygen, carbon-based, amide) between the oxygen and the phenyl ring was not tolerated. Bioisosteric replacement of the phenyl ring with a thiophene was also not tolerated and resulted in a 10-fold decrease in activity. Other heterocycles in the 7-position resulted in compounds with low antiparasitic activity. The effect of other, smaller substituents varied greatly. Some resulted in moderate anti-<i>T. cruzi</i> activity (<i>e.g</i>., chloride, methyl, ethynyl), while other substituents afforded highly cytotoxic nonselective compounds. Overall, none of the 7-modified analogues displayed good activity against <i>L. infantum</i>, suggesting that, regardless of the nature of the heterocyclic nucleobase, substituents on this position are not tolerated. <b>44</b> was the most potent analogue for <i>T. cruzi</i> and was more active and more selective than its matched 7-deazapurine nucleoside congener.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Because of its potent anti-<i>T. cruzi</i> activity and favorable selectivity profile, <b>44</b> was selected for further evaluation in an acute Chagas disease mouse model.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Metabolic Stability of Compound <b>44</b></h3><div class="NLM_p">The <i>in vitro</i> metabolic stability of <b>44</b> was evaluated using male mice and pooled human liver microsomes (S9 fraction) (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Compound <b>44</b> was not susceptible to Phase-I and Phase-II metabolism in both mouse and human microsomes with 100% of the parent drug remaining after 60 min. These results favored further evaluation of <b>44</b> in an <i>in vivo</i> laboratory rodent model.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>In Vitro</i> Metabolic Stability of Compound <b>44</b> Using Male Mouse and Pooled Human S9 Microsomal Fractions<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="left"> </th><th class="colsep0 rowsep0" align="left" char="."> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">mouse % 44 remaining</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">human % 44 remaining</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">phase-I/II</th><th class="colsep0 rowsep0" align="center" char=".">time</th><th class="colsep0 rowsep0" align="center" char=".">mean</th><th class="colsep0 rowsep0" align="center">STDEV</th><th class="colsep0 rowsep0" align="center" char=".">mean</th><th class="colsep0 rowsep0" align="center">STDEV</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">CYP450-NADPH</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="left">11.4</td><td class="colsep0 rowsep0" align="char" char=".">102</td><td class="colsep0 rowsep0" align="left">10.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="left">12.8</td><td class="colsep0 rowsep0" align="char" char=".">101</td><td class="colsep0 rowsep0" align="left">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">108</td><td class="colsep0 rowsep0" align="left">16.1</td><td class="colsep0 rowsep0" align="char" char=".">101</td><td class="colsep0 rowsep0" align="left">8.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">UGT enzymes</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">103</td><td class="colsep0 rowsep0" align="left">3.2</td><td class="colsep0 rowsep0" align="char" char=".">100</td><td class="colsep0 rowsep0" align="left">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">115</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="char" char=".">106</td><td class="colsep0 rowsep0" align="left">9.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">60</td><td class="colsep0 rowsep0" align="char" char=".">115</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="char" char=".">104</td><td class="colsep0 rowsep0" align="left">7.2</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">The depicted values are the percentage of remaining parent compound at the various time points of incubation (0–15–30–60 min). Data originate from two independent experiments of two biological replicates. Diclofenac (susceptible to Phase-I and Phase-II metabolism) was included as reference to ensure proper assay performance (data not shown).</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> <i>In Vivo</i> Evaluation of Compound <b>44</b></h3><div class="NLM_p">To determine its efficacy <i>in vivo</i>, <b>44</b> was evaluated in an acute Chagas disease model using the Y strain of <i>T. cruzi</i> in Swiss male mice.<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a><b>44</b> was evaluated at 0.25, 2.5, or 25 mg/kg b.i.d or in combination with benznidazole (<b>44</b> at 2.5 mg/kg b.i.d + benznidazole at 10 mg/kg q.d.). Compounds were administered orally for 5 consecutive days, starting the administration at parasitemia onset on day 6 postinfection (dpi), which peaked at 8 dpi in untreated animals. <b>44</b> at 25 mg/kg gave 99% reduction in the parasitemia peak at 8 dpi, which was similar to the optimal q.d. dose of benznidazole at 100 mg/kg. Lower dosages (0.25 and 2.5 mg/kg) only gave partial reduction of parasitemia (43%). Coadministration of <b>44</b> (2.5 mg/kg) and benznidazole (10 mg/kg) reached 71% reduction, which was slightly better than benznidazole alone. However, no mice sustained negative parasitemia, hence failing parasitological cure. In the 2.5 mg/mk and 25 mg/kg treatment groups, 5 out of 6 mice (83%) survived until the end of the experiment (34 dpi), similar to benznidazole at 10 mg/kg. In the benznidazole 100 mg/kg group, all mice survived. In the untreated control group, all mice succumbed to the infection by day 27. In the 0.25 mg/kg, only one mouse survived at 34 dpi (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0003.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>In vivo</i> efficacy of <b>44</b> administered orally for 5 days in Swiss mice infected with the Y strain of <i>T. cruzi</i>. Parasitemia curve for <b>44</b> at (A) 0.25 mg/kg/b.i.d, (B) 2.5 mg/kg/b.i.d, (C) 25 mg/kg/b.i.d, and (D) coadministration of <b>44</b> at 2.5 mg/kg + benznidazole (Bz) at 10 mg/kg/b.i.d. Mortality rates were up to 35 dpi (E). ** <i>p</i> value ≤ 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As the <i>in vitro</i><i>T. cruzi</i> screening was performed with the Tulahuen strain (DTU IV) and <i>in vivo</i> assays with the Y strain (DTU II), additional <i>in vitro</i> screens were conducted with the latter. The findings confirmed the high potency of <b>44</b> against intracellular forms (IC<sub>50</sub> = 0.26 ± 0.03 μM, SI > 1900) present in cardiomyocytes (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), similar to the values obtained with the Tulahuen strain intracellular amastigotes. In addition, <b>44</b> did not exert cardiotoxicity in two-dimensional (2D) and three-dimensional (3D) cardiac cell cultures, giving CC<sub>50</sub> values up to 500 and 200 μM, respectively. After discarding the potential impact of parasite strain on the <i>in vitro</i> and <i>in vivo</i> outcomes, we next evaluated the activity of <b>44</b> (as well as <b>4</b>) against the nondividing and highly infective bloodstream trypomastigote form. Both compounds proved to be inactive (IC<sub>50</sub> > 81 μM), while benznidazole gave an IC<sub>50</sub> of 5.7 ± 0.6 μM. These results corroborate former studies using pyrrolo[2,3-<i>b</i>]pyridine (1,7-dideazapurine) nucleoside analogues that failed to achieve parasitological cure in treated mice despite parasitemia suppression and high animal survival rates.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> The inability to kill bloodstream trypomastigotes may explain the parasitemia recrudescence and thus lack of sterile cure, as has also been reported for other nucleoside analogues.<a onclick="showRef(event, 'ref53 ref78'); return false;" href="javascript:void(0);" class="ref ref53 ref78">(53,78)</a> The lack or low activity against bloodstream trypomastigotes resembles that of the azole ergosterol biosynthesis inhibitors that failed in clinical trials for Chagas disease,<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> raising the potential relevance of targeting both the intracellular multiplicative amastigotes and the nonreplicative trypomastigote forms. Recent findings also highlighted the role of metabolic heterogeneity in drug efficacy upon recalcitrant <i>T. cruzi</i> infection.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> The authors reported that limiting exogenous glutamine impairs ergosterol biosynthesis inhibitors (azoles) to act upon intracellular amastigotes. In addition to the occurrence of nonreplicative forms (like dormant amastigotes and trypomastigotes), the impact of metabolic and environmental heterogeneity must be considered in the search for novel anti-<i>T. cruzi</i> agents as these factors can modulate drug efficacy.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. <i>In Vitro</i> Efficacy of <b>4</b> and <b>44</b> against <i>T. cruzi</i> Y-Strain Bloodstream Trypomastigotes and Intracellular Amastigotes in Cardiac Cells<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd.</th><th class="colsep0 rowsep0" align="center"><i>T. cruzi</i> Y bloodstream trypomastigotes IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char="±"><i>T. cruzi</i> Y intracellular amastigotes IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center">primary cardiac cells LC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">>81</td><td class="colsep0 rowsep0" align="char" char="±">2.46 ± 0.3</td><td class="colsep0 rowsep0" align="left">>500</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">44</td><td class="colsep0 rowsep0" align="left">>81</td><td class="colsep0 rowsep0" align="char" char="±">0.26 ± 0.03</td><td class="colsep0 rowsep0" align="left">500</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values are depicted as means ± SEM of two independent determinations, using duplicates.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Effect of the <i>T. cruzi</i> Host Cell on Drug Sensitivity to Compound <b>44</b></h3><div class="NLM_p">To investigate whether host cell permeability could be a limiting factor for the <i>in vivo</i><i>T. cruzi</i> efficacy or lack of antileishmanial activity of compound <b>44</b>, we evaluated the effect of <b>44</b> against <i>T. cruzi</i> in PMM host cells (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Surprisingly, <b>44</b> was completely inactive against <i>T. cruzi</i> in PMM cells, while benznidazole retained its activity in both cell types. To rule out drug efflux as the cause of this effect, the experiment was repeated in the presence of the ABC transporter inhibitors verapamil, cyclosporine A, and probenecid. In all cases, <b>44</b> was inactive, indicating that its inactivity in PMM cells is likely due to permeability issues. These findings might offer further explanation as to why <b>44</b> was not able to fully clear <i>T. cruzi</i> infection <i>in vivo</i>. Tissue tropism in Chagas disease has been demonstrated to play an important role in persistence,<a onclick="showRef(event, 'ref90 ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref90 ref91 ref92">(90−92)</a> and limited permeability in certain tissues has also been implicated in the ineffectivity of Posaconazole in curing <i>T. cruzi</i> infections.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> These results could also offer an explanation as to why several of the herein-reported nucleoside analogues, as well as others that were previously found to display potent anti-<i>T. cruzi</i> activity, are inactive when evaluated against <i>L. infantum</i> intracellular amastigotes in PMM host cells.<a onclick="showRef(event, 'ref52 ref94'); return false;" href="javascript:void(0);" class="ref ref52 ref94">(52,94)</a> The origins of this lack of permeability in PMM cells are currently unclear and require further study. Furthermore, it would be worthwhile to evaluate if certain nucleoside prodrugs could lead to improved permeability and/or improved <i>in vivo</i> efficacy.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Evaluation of Drug Sensitivity of <b>44</b> and Benznidazole (Bz) against <i>T. cruzi</i> in PMM Host Cells, Alone or with Coadministration of Verapamil (8 μM), Probenecid (700 μM), or Cyclosporin A (2 μM)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cpd.</th><th class="colsep0 rowsep0" align="center" char="±"><i>T. cruzi</i> (MRC-5) IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>T. cruzi</i> (PMM) IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>T. cruzi</i> (PMM) + verapamil IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>T. cruzi</i> (PMM) + probenecid IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center"><i>T. cruzi</i> (PMM) + cyclosporin A IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="char" char="±">0.32 ± 0.02</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td><td class="colsep0 rowsep0" align="left">>64.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>Bz</b></td><td class="colsep0 rowsep0" align="char" char="±">2.02 ± 0.28</td><td class="colsep0 rowsep0" align="left">1.96 ± 0.25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We described the design and synthesis of a library of pyrazolo[3,4-<i>d</i>]pyrimidine nucleosides that were evaluated for <i>in vitro</i> activity against <i>T. cruzi</i> and <i>L. infantum</i> intracellular amastigotes. SAR trends were highly different from earlier reported nucleoside series. Modifications of the 3′-position of the parent adenosine- and inosine-like analogues aminopurinol riboside <b>4</b> and allopurinol riboside <b>2</b> were detrimental to activity and led to inactive compounds. The introduction of a halogen atom on the 7-position led to a significant decrease in activity. An extensive screen of substituents on the 7-position <b>4</b> revealed varying effects on antiparasitic activity and selectivity toward MRC-5<sub>SV2</sub> and PMM cells. A 4-chlorophenyl substituent on the 7-position (<b>44</b>) afforded good anti-<i>T. cruzi</i> activity and selectivity and was also metabolically stable in human and mouse liver microsomes. <b>44</b> was next evaluated in an acute Chagas disease model, resulting in a rapid, almost complete reduction in parasitemia. Treatment with <b>44</b> led to the survival of 5 out of 6 mice but failed to induce sterile parasitological cure. None of the new analogues showed good <i>in vitro</i> activity against <i>L. infantum</i>, which could potentially be attributed to limited permeability in the PMM host cell.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18154" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18154" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Chemistry</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General</h4><div class="NLM_p last">All reagents and solvents were obtained from standard commercial sources and were of analytical grade. Unless otherwise specified, they were used as received. All moisture-sensitive reactions were carried out under an argon atmosphere. Reactions were carried out at ambient temperature, unless otherwise indicated. Reactions were monitored <i>via</i> analytical TLC or analytical LCMS. Analytical TLC was performed on Machery–Nagel precoated F254 aluminum plates and visualized by UV followed by staining with basic aq. KMnO<sub>4</sub>, cerium-molybdate, or sulfuric acid-anisaldehyde spray. Analytical LCMS was performed on a Waters AutoPurification system (equipped with ACQUITY QDa (mass; 100–1000 amu)) and 2998 Photodiode Array (220–400 nm) using a Waters Cortecs C18 (2.7 μm, 100 mm × 4.6mm) column and a gradient system of HCOOH in H<sub>2</sub>O (0.2%, v/v)/MeCN at a flow rate of 1.44 mL/min (95:05–00:100 in 6.5 min or 50:50–00:100 in 6.5 min), or a Waters Alliance XE separation module using a Phenomenex Kinetix C8 (2.6 μm, 50 mm × 2.10 mm) column and the same gradient system. Preparative HPLC was performed on the same system, using a Phenomenex Luna Omega Polar column (250 mm × 21 mm, 5 μm) and a gradient system of 0.2% formic acid in water/MeCN at a flow rate of 20 mL/min (gradients are specified in the individual procedures). Column chromatography was performed manually using Machery–Nagel 60 M silica gel (40–63 μm) or on a Reveleris X2 (Grace/Büchi) automated flash unit employing prepacked silica columns. Exact mass measurements were performed on a Waters LCT Premier XE time-of-flight (ToF) mass spectrometer equipped with a standard electrospray (ESI) and a modular Lockspray interface. Samples were infused in a MeCN/water (1:1) + 0.1% formic acid mixture at 100 μL/min. NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer or a Bruker Avance Neo 400 MHz spectrometer. Chemical shifts (δ) are given in ppm, and spectra are referenced to the residual solvent peak. Coupling constants are given in Hz. Systematic numbering is employed for NMR assignments in the individual procedures. Melting points were determined on a Büchi-545 apparatus and are uncorrected. Purity was assessed by means of liquid chromatography–mass spectrometry (LCMS). All obtained final compounds had purity >95%, as assayed by analytical HPLC (UV), unless otherwise indicated.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Procedure A: Large-Scale BF<sub>3</sub>·OEt<sub>2</sub>-Mediated Glycosylation with Commercially Available 1-<i>O</i>-Acetyl-2,3,5-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose</h4><div class="NLM_p last">The respective pyrazolo[3,4-<i>d</i>]pyrimidine (1.0 equiv) and 1-<i>O</i>-acetyl-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose (1.5 equiv) were added to dry nitromethane (2.5 mL/mmol). The mixture was heated to reflux, when BF<sub>3</sub>·OEt<sub>2</sub> (1.5 equiv) was added, upon which the solids started to dissolve. After 90 min of heating at reflux, the solvent was removed <i>in vacuo</i>. The resulting oil was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (sonicate until fully dissolved) and directly poured on a silica column (preconditioned with CH<sub>2</sub>Cl<sub>2</sub>). The column was eluted with 100% CH<sub>2</sub>Cl<sub>2</sub> until all excess 1-<i>O</i>-acetyl-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose had eluted and then with 5% acetone in CH<sub>2</sub>Cl<sub>2</sub> to collect the product.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Procedure B: Small-Scale BF<sub>3</sub>·OEt<sub>2</sub>-Mediated Glycosylation with Protected Ribose Derivative</h4><div class="NLM_p last">The respective pyrazolo[3,4-<i>d</i>]pyrimidine (1.1 equiv) and ribose derivative (1.0 equiv) were added to dry nitromethane (2.5 mL/mmol). The mixture was heated to reflux, when BF<sub>3</sub>·OEt<sub>2</sub> (1.0 equiv) was added, upon which the solids started to dissolve. After 90 min of heating at reflux, the solvent was removed <i>in vacuo</i>. The resulting oil was dissolved in CH<sub>2</sub>Cl<sub>2</sub>, celite (1.5 g/g starting material) was added, and the solvent was removed <i>in vacuo</i>. The resulting solid was purified by flash column chromatography to afford the protected nucleoside.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <b>General Procedure C</b>: Deprotection with NaOMe</h4><div class="NLM_p last">Protected nucleoside (1.0 equiv) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL/mmol). MeOH (5 mL/mmol) was added, followed by NaOMe in MeOH (5.4 M, 0.2 mL/mmol). The mixture was stirred at room temperature or 60 °C (for <b>36</b>) until TLC analysis (20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) indicated completion of the reaction. The reaction was neutralized to pH 7 <i>via</i> the addition of 4 N HCl, celite (1.5 g/g starting material) was added, and the solvents were removed <i>in vacuo</i>. The solid residue was brought onto a silica column and eluted with a mixture of MeOH and CH<sub>2</sub>Cl<sub>2</sub> to isolate the final product.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <b>General Procedure D</b>: Catalytic Hydrogenation in Buffered MeOH</h4><div class="NLM_p last">The nucleoside analogue was dissolved in a mixture of MeOH (8 mL/mmol) and aq. 1M NaOAc (2 mL/mmol). The flask was placed under a nitrogen atmosphere, and a catalytic amount of Pd/C was added. The atmosphere was exchanged for H<sub>2</sub> and the mixture was stirred until TLC analysis (20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) indicated completion of the reaction. The mixture was then filtered over celite, celite was added to the filtrate, and the solvents were removed <i>in vacuo</i>. The resulting solid was purified <i>via</i> flash column chromatography to afford the final product.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedure E: Suzuki Reaction</h4><div class="NLM_p last">Compound <b>21</b> (1 equiv) or <b>23</b> (in the case of <b>76</b>, 1 equiv), boronic acid (1.5 equiv) or trifluoroborate salt (1.5 equiv) Na<sub>2</sub>CO<sub>3</sub> (when a boronic acid was used, 3 equiv) or Cs<sub>2</sub>CO<sub>3</sub> (when a trifluoroborate salt was used, 3 equiv), Pd(OAc)<sub>2</sub> (0.05 equiv), and TPPTS (0.12 equiv) were added to a 10 mL round-bottom flask, equipped with a stir bar. Next, the flask was evacuated and refilled with argon. This procedure was repeated three times in total. Next, MeCN (2 mL/mmol SM) and H<sub>2</sub>O (4 mL/mmol SM) were added to the solids under argon. After 5 min of stirring, the mixture was heated to reflux. When the starting material was fully consumed (usually 1–3 h; as monitored by LCMS analysis), the mixture was cooled to ambient temperature and neutralized (pH ∼ 7) with 4 M aq. HCl. Celite (5 g/mmol) was added, and the mixture was concentrated <i>in vacuo</i>. The residue was purified by flash column chromatography.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Procedure F: Amide Coupling</h4><div class="NLM_p">The nucleoside carboxylic acid (1.0 equiv) was dissolved in DMF (10 mL/mmol). DIPEA (3.0 equiv) was added, followed by HCTU (2.5 equiv). After 5 min, the respective amine (5.0 equiv) was added and the reaction mixture was stirred overnight. When TLC or LCMS analysis indicated full conversion, the reaction mixture was diluted with excess EtOAc and transferred to a separation funnel. The organic phase was washed with 1 N HCl, aq. sat. NaHCO<sub>3</sub>, and brine sequentially. The organic phase was then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was used directly in the next reaction, without purification.</div><div id="sec4_1_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> 3-Bromo-4-amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (<b>12</b>)</h5><div class="NLM_p last">4-Amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine <b>3</b> (8.26 g, 61.1 mmol, 1.0 equiv) was dissolved in DMF (60 mL). NBS (11.4 g, 64.2 mmol, 1.05 equiv) was added, and the mixture was heated at 60 °C overnight. The mixture was cooled to room temperature and poured into ice-cold water (350 mL). The resulting suspension was stirred for 10 min at 0 °C and filtered overnight. The solids were collected and dried under a high vacuum overnight to afford <b>12</b> (11.9 g, 55.7 mmol, 91% yield) as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.91 (1H, br. s, NH<sub>2</sub>′), 7.72 (1H, br. s, NH<sub>2</sub>″), 8.16 (1H, s, C-6), 13.75 (1H, br. s, NH) ppm. HRMS (ESI): calcd for C<sub>5</sub>H<sub>5</sub>BrN<sub>5</sub> ([M + H]<sup>+</sup>): 213.9728, found: 213.9731.</div></div><div id="sec4_1_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> 3-Iodo-4-amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (<b>13</b>)</h5><div class="NLM_p last">4-Amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine <b>3</b> (5.68 g, 42.1 mmol, 1.0 equiv) was dissolved in DMF (40 mL). NIS (10.4 g, 46.3 mmol, 1.1 equiv) was added, and the mixture was heated at 80 °C overnight. The mixture was cooled to room temperature and poured into ice-cold water (350 mL). The resulting suspension was stirred for 10 min at 0 °C and filtered overnight. The solids were collected and dried under a high vacuum overnight to afford <b>13</b> (10.2 g, 39.1 mmol, 93% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.16 (1H, s, C-6), 13.80 (1H, br. s, NH) ppm. HRMS (ESI): calcd for C<sub>5</sub>H<sub>5</sub>IN<sub>5</sub> ([M + H]<sup>+</sup>): 261.9590, found: 261.9594.</div></div><div id="sec4_1_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> 3-Bromo-allopurinol (<b>14</b>)</h5><div class="NLM_p last">Allopurinol (4.55 g, 33.4 mmol, 1.0 equiv) was suspended in water (300 mL). Bromine (4.29 mL, 83.6 mmol, 2.5 equiv) was added carefully, and a reflux cooler with a septum was placed on top of the flask. The reflux cooler was connected <i>via</i> vacuum tubing to a large flask containing excess aq. 2 M Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution. The reaction mixture was heated at 90 °C overnight and cooled down to room temperature. A mixture of aq. sat. NaHCO<sub>3</sub> (75 mL) and aq. 2 M Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (75 mL) was added through the reflux cooler, after which the reaction mixture turned white. The suspension was cooled down further to 0 °C, stirred for 10 min, and filtered. The solids were washed with ice-cold water (3×), collected, and dried over a high vacuum overnight to afford <b>14</b> (6.26 g, 29.1 mmol, 87%) as a light-yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.04 (1H, d, <i>J</i> = 3.8 Hz), 12.22 (1H, br. s.), 13.98 (1H, br. s) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 104.5 (C-3a), 121.9 (C-3), 149.4 (C-7a), 154.6 (C-6), 157.0 (C-4) ppm. HRMS (ESI): calcd for C<sub>5</sub>H<sub>4</sub>BrN<sub>4</sub>O ([M + H]<sup>+</sup>): 214.9568, found: 214.9572.</div></div><div id="sec4_1_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> 3-Bromo-4-amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> (<b>18</b>)</h5><div class="NLM_p last">Compound <b>12</b> (10.3 g, 48.1 mmol, 1.0 equiv) and 1-<i>O</i>-acetyl-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose (36.4 g, 72.2 mmol, 1.5 equiv) were subjected to general procedure A to afford <b>18</b> (20.3 g, 30.8 mmol, 64% yield) as a brown oil. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.51–4.67 (2 H, m, H-5′, H-5″), 4.82–4.89 (1H, m, H-4′), 6.10 (1H, t, <i>J</i> = 5.7 Hz, H-3′), 6.25 (1H, dd, <i>J</i> = 5.4, 3.4 Hz, H-2′), 6.67 (1H, d, <i>J</i> = 3.2 Hz, H-1′), 7.38–7.70 (9H, m, H<sub>Phe</sub>), 7.84–8.05 (6H, m, H<sub>Phe</sub>), 8.24 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 63.6 (C-5′), 71.3 (C-3′), 74.2 (C-2′), 79.5 (C-4′), 86.4 (C-1′), 100.3 (C-3a), 121.2 (C-3) 128.8 (C<sub>Phe</sub>), 129.0 (C<sub>Phe</sub>), 129.2 (C<sub>Phe</sub>), 129.2 (C<sub>Phe</sub>), 129.7 (C<sub>Phe</sub>), 129.8 (C<sub>Phe</sub>), 129.8 (C<sub>Phe</sub>), 129.8 (C<sub>Phe</sub>), 133.9 (C<sub>Phe</sub>), 134.3 (C<sub>Phe</sub>), 134.4(C<sub>Phe</sub>), 155.5 (C-7a), 157.7 (C-6), 157.8 (C-4), 165.0 (C═O), 165.1 (C═O), 165.9 (C═O) ppm. HRMS (ESI): calcd for C<sub>31</sub>H<sub>25</sub>BrN<sub>5</sub>O<sub>7</sub> ([M + H]<sup>+</sup>): 658.0937, found: 658.0925.</div></div><div id="sec4_1_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> 3-Bromo-4-amino-1-(2′,5′-di-<i>O</i>-benzoyl-3′-deoxy-3′-fluoro-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>19</b>)</h5><div class="NLM_p last">Compound <b>12</b> (0.330 g, 1.54 mmol, 1.1 equiv) and compound <b>16</b> (0.563 g, 1.40 mmol) were subjected to general procedure B. Purification by flash column chromatography (automated, 0 → 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded semipure <b>19</b>, which was used as such in the next reaction. HRMS (ESI): calcd for C<sub>24</sub>H<sub>20</sub>BrFN<sub>5</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 556.0632, found: 556.0590.</div></div><div id="sec4_1_7_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 3-Bromo-4-amino-1-(2′,5′-di-<i>O</i>-benzoyl-3′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>20</b>)</h5><div class="NLM_p last">Compound <b>12</b> (0.395 g, 1.84 mmol, 1.1 equiv) and compound <b>17</b> (0.643 g, 1.67 mmol, 1.0 equiv) were subjected to general procedure B. Purification by flash column chromatography (automated, 0 → 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded semipure <b>20</b>, which was used as such in the next reaction. HRMS (ESI): calcd for C<sub>24</sub>H<sub>21</sub>BrN<sub>5</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 538.726, found: 538.0706.</div></div><div id="sec4_1_7_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 3-Bromo-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>21</b>)</h5><div class="NLM_p last">Compound <b>18</b> (12.7 g, 19.4 mmol) was subjected to general procedure C (reaction time: 2 h). Purification was performed <i>via</i> flash column chromatography (manual, first 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to remove higher-running impurities, and then 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to isolate <b>21</b> (4.68 g, 13.5 mmol, 70% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.38–3.47 (1H, m, H-5′), 3.50–3.60 (1H, m, H-5″), 3.89 (1H, dd, <i>J</i> = 10.0, 4.7 Hz, H-4′), 4.16 (1H, dd, <i>J</i> = 9.4, 4.7 Hz, H-3′), 4.55 (1H, dd, <i>J</i> = 10.8, 5.6 Hz, H-2′), 4.81 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.16 (1H, d, <i>J</i> = 5.3 Hz, OH), 5.40 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.06 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 8.24 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.2 (C-5′), 70.6 (C-3′), 72.9 (C-2′), 85.3 (C-4′), 88.1 (C-1′), 99.7 (C-3a), 119.3 (C-3), 155.0 (C-7a), 157.0 (C-6), 157.4 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>13</sub>BrN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 330.0202, found: 330.0198.</div></div><div id="sec4_1_7_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 3-Bromo-4-amino-1-(3′-deoxy-3′-fluoro-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>22</b>)</h5><div class="NLM_p last">Compound <b>19</b> (used directly from the previous reaction) was subjected to general procedure C (reaction time: 90 min). Purification <i>via</i> flash column chromatography (automated, 0 →10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>22</b> (97 mg, 0.279 mmol, 20% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.47–3.54 (2H, m, H-5′, H-5″), 4.11–4.27 (1H, m, H-4′), 4.84–5.18 (3H, m, H-3′, H-2′, OH), 5.87 (1H, d, <i>J</i> = 6.7 Hz, OH), 6.06 (1H, d, <i>J</i> = 7.3 Hz, H-1′) ppm, 6.99 (1H, br. s, OH), 8.09 (1H, br. s, OH), 8.24 (1H, s, H-6). <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 61.4 (d, <i>J</i> = 10.4 Hz, C-5′), 71.6 (d, <i>J</i> = 16.1 Hz, C-2′), 83.8 (d, <i>J</i> = 20.7 Hz, C-4′), 87.5 (C-1′), 92.9 (d, <i>J</i> = 182.0 Hz, C-3′), 100.5 (C-3a), 120.2 (C-3), 155.9 (C-7a), 157.6 (C-6), 157.9 (C-4) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −198.19 (1F, dt, <i>J</i> = 54.1, 25.2 Hz) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>12</sub>BrFN<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 348.0108, found: 348.0090.</div></div><div id="sec4_1_7_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 3-Bromo-4-amino-1-(3′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>23</b>)</h5><div class="NLM_p last">Compound <b>20</b> (used directly from the previous reaction) was subjected to general procedure C (reaction time: 2 h). Flash column chromatography (automated, 2 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>23</b> (0.106 g, 0.321 mmol, 19% yield over 2 steps). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.98 (1H, ddd, <i>J</i> = 12.7, 6.3, 2.1 Hz, H-3′), 2.25 (1H, ddd, <i>J</i> = 12.8, 9.0, 5.7 Hz, H-3″), 3.38–3.50 (2H, m, H-5′, H-5″), 4.31 (1H, ddd, <i>J</i> = 11.6, 9.3, 5.8 Hz, H-4′), 4.55 (1H, dt, <i>J</i> = 5.4, 1.8 Hz, H-2′), 6.11 (1H, d, <i>J</i> = 1.8 Hz, H-1′), 8.24 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 36.3 (C-3′), 64.4 (C-5′), 74.6, (C-2′) 81.6 (C-4′), 91.0 (C-1′), 99.8 (C-3a), 119.6 (C-3), 155.0 (C-7a), 157.5 (C-6), 157.7 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>13</sub>BrN<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 330.0202, found: 330.0195.</div></div><div id="sec4_1_7_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 4-Amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> (<b>4</b>)</h5><div class="NLM_p last">Compound <b>21</b> (120 mg, 0.347 mmol) was subjected to general procedure D (reaction time: 2 h). Flash column chromatography (automated, 4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>4</b> (57 mg, 0.213 mmol, 61% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.38–3.64 (2H, m, H-5′, H-5″), 3.87–3.96 (1H, m, H-4′), 4.22 (1H, dd, <i>J</i> = 9.7, 4.4 Hz, H-3′), 4.60 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-2′), 4.88 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.14 (1H, d, <i>J</i> = 4.7 Hz, OH), 5.36 (1H, d, <i>J</i> = 6.4 Hz, OH), 6.09 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 8.18 (1H, s, H-3), 8.20 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 62.5 (C-5′), 71.0 (C-2′), 73.2 (C-3′), 85.1 (C-4′), 88.6 (C-1′), 100.5 (C-3a), 133.5 (C-3), 154.1 (C-7a), 156.2 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>14</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 268.1046, found: 268.1032. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div></div><div id="sec4_1_7_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 4-Amino-1-(3′-deoxy-3′-fluoro-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>24</b>)</h5><div class="NLM_p last">Compound <b>22</b> (0.058 g, 0.167 mmol) was subjected to general procedure D (reaction time: 15 min). Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>24</b> (37 mg, 0.137 mmol, 82% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.47–3.65 (2H, m, H-5′, H-5″), 4.21 (1H, dt, <i>J</i> = 24.9, 4.7 Hz, H-4′), 4.93–5.31 (3H, m, H-3′, H-2′, OH), 5.83 (1H, d, <i>J</i> = 6.4 Hz, OH), 6.10 (1H, d, <i>J</i> = 7.0 Hz, H-1′), 7.50–8.07 (2H, m, NH<sub>2</sub>), 8.20 (2H, s, H-6, H-3) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 61.2 (d, <i>J</i> = 10.4 Hz, C-5′), 71.3 (d, <i>J</i> = 17.3 Hz, C-2′), 83.2 (d, <i>J</i> = 21.9 Hz, C-4′), 87.7 (C-1′), 92.7 (d, <i>J</i> = 182.0 Hz, C-3′), 100.8 (C-3a), 133.6 (C-3), 154.3 (C-7a), 156.2 (C-6), 158.1 (C-4) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −198.52 (1F, dt, <i>J</i> = 54.1, 25.2 Hz) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>13</sub>FN<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 270.1002, found: 270.0998.</div></div><div id="sec4_1_7_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 4-Amino-1-(3′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>25</b>)</h5><div class="NLM_p last">Compound <b>23</b> (0.050 g, 0.151 mmol) was subjected to general procedure D (reaction time: 3 h). Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>25</b> (26 mg, 0.100 mmol, 66% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.98 (1H, ddd, <i>J</i> = 12.7, 6.2, 2.2 Hz, H-3′), 2.33 (1H, ddd, <i>J</i> = 12.7, 9.1, 5.7 Hz, H-3″), 3.36–3.53 (2H, m, H-5′, H-5″), 4.32 (1H, ddd, <i>J</i> = 11.4, 9.1, 5.9 Hz, H-4′), 4.51–4.61 (1H, m, H-2′), 4.74 (1H, t, <i>J</i> = 5.7 Hz, OH), 5.53 (1H, d, <i>J</i> = 3.8 Hz, OH), 6.14 (1H, d, <i>J</i> = 1.5 Hz, H-1′), 7.50–7.98 (2H, br. m, NH<sub>2</sub>), 8.15 (1H, s, H-3), 8.19 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 36.1 (C-3′), 64.2 (C-5′), 74.5 (C-2′), 81.0 (C-4′), 90.7 (C-1′), 100.1 (C-3a), 133.2 (C-3a), 153.7 (C-7a), 156.1 (C-6), 158.0 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>14</sub>N<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 252.1079, found: 252.1075.</div></div><div id="sec4_1_7_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 3-Bromo-4-oxo-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> (<b>26</b>)</h5><div class="NLM_p last">Compound <b>14</b> (6.45 g, 30.0 mmol, 1.0 equiv) and 1-<i>O</i>-acetyl-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose (22.7 g, 45.0 mmol, 1.5 equiv) were subjected to general procedure A to afford, after recrystallization from MeOH, <b>26</b> (6.26 g, 9.49 mmol, 32% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 4.66 (1H, dd, <i>J</i> = 12.2, 4.6 Hz, H-5′), 4.80 (1H, dd, <i>J</i> = 12.3, 3.8 Hz, H-5″), 4.84–4.89 (1H, m, H-4′), 6.26 (1H, dd, <i>J</i> = 6.1, 5.3 Hz, H-3′), 6.34 (1H, dd, <i>J</i> = 5.3, 3.0 Hz, H-2′), 6.72 (1H, d, <i>J</i> = 2.9 Hz, H-1), 7.34–7.62 (9H, m, H<sub>Phe</sub>), 7.94–8.15 (7H, m, H<sub>Phe</sub>, H-6), 11.91 (1H, br. s., NH) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 63.5 (C-5′), 71.6 (C-2′), 74.6 (C-3′), 80.4 (C-4′), 87.2 (C-1′), 106.0 (C-3a), 124.5 (C-3), 128.5 (C<sub>Phe</sub>), 128.5 (C<sub>Phe</sub>), 128.5 (C<sub>Phe</sub>), 128.6 (C<sub>Phe</sub>), 128.7 (C<sub>Phe</sub>), 129.5 (C<sub>Phe</sub>), 129.8 (C<sub>Phe</sub>), 129.8 (C<sub>Phe</sub>), 129.9 (C<sub>Phe</sub>), 133.2 (C<sub>Phe</sub>), 133.6 (C<sub>Phe</sub>), 133.7 (C<sub>Phe</sub>), 148.1 (H-7a), 153.9 (H-6), 158.5 (H-4), 165.1 (C═O), 165.2 (C═O), 166.3 (C═O) ppm. HRMS (ESI): calcd for C<sub>31</sub>H<sub>24</sub>BrN<sub>4</sub>O<sub>8</sub> ([M + H]<sup>+</sup>): 659.0778, found: 659.0774.</div></div><div id="sec4_1_7_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 3-Bromo-4-oxo-1-(2′,5′-tri-<i>O</i>-benzoyl-3′-deoxy-3′-fluoro-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>27</b>)</h5><div class="NLM_p last">Compounds <b>14</b> (0.338 g, 1.57 mmol, 1.1 equiv) and <b>16</b> (0.575 g, 1.43 mmol, 1.0 equiv) were subjected to general procedure B. TLC analysis (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) indicated the presence of a major apolar spot and two smaller more polar spots. The major apolar spot was presumed to be the desired <i>N</i>-1 regioisomer<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a><b>27</b> and was isolated <i>via</i> flash chromatography (automated, 0 → 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) and used as such in the next reaction. HRMS (ESI): calcd for C<sub>24</sub>H<sub>19</sub>BrFN<sub>4</sub>O<sub>6</sub> ([M + H]<sup>+</sup>): 557.0472, found: 557.0457.</div></div><div id="sec4_1_7_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 3-Bromo-4-oxo-1-(2′,5′-tri-<i>O</i>-benzoyl-3′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>28</b>)</h5><div class="NLM_p last">Compounds <b>14</b> (0.348 g, 1.62 mmol, 1.1 equiv) and <b>17</b> (0.565 g, 1.47 mmol, 1.0 equiv) were subjected to general procedure B. TLC analysis (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) indicated the presence of a major apolar spot and two smaller more polar spots. The major apolar spot was presumed to be the desired N-1 regioisomer<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a><b>28</b> and was isolated <i>via</i> flash chromatography (automated, 0 → 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) and used as such in the next reaction. HRMS (ESI): calcd for C<sub>24</sub>H<sub>20</sub>BrN<sub>4</sub>O<sub>6</sub> ([M + H]<sup>+</sup>): 539.0566, found: 539.0552.</div></div><div id="sec4_1_7_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 3-Bromo-4-oxo-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl-pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> (<b>29</b>)</h5><div class="NLM_p last">Compound <b>26</b> (0.530 g, 0.804 mmol) was subjected to general procedure C (reaction time: 1 h). Purification <i>via</i> flash column chromatography (automated, 4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>29</b> (105 mg, 0.302 mmol, 38% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.36–3.47 (1H, m, H-5′), 3.48–3.59 (1H, m, H-5″), 3.88 (1H, dd, <i>J</i> = 10.3, 4.7 Hz, H-4′), 4.10–4.18 (1H, m, H-3′), 4.44–4.53 (1H, m, H-2′), 4.66–4.80 (1H, m, OH), 5.16 (1H, br. s., OH), 5.42 (1H, br. s., OH), 6.00 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 8.15 (1H, s, H-6), 12.41 (1H, br. s, NH) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>12</sub>BrN<sub>4</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 346.9991, found: 347.0004. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a></div></div><div id="sec4_1_7_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 3-Bromo-4-oxo-1-(3′-deoxy-3′-fluoro-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>30</b>)</h5><div class="NLM_p last">Compound <b>27</b> (used directly from the previous step) was subjected to general procedure C (reaction time: 3 h). Flash column chromatography (automated, 2 → 12% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification <i>via</i> preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 0:100 in 18 min) afforded <b>30</b> (56 mg, 0.160 mmol, 11% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.44–3.62 (2H, m, H-5′, H-5″), 4.21 (1H, dt, <i>J</i> = 25.8, 5.3 Hz, H-4′), 4.90 (1H, ddd, <i>J</i> = 24.6, 7.0, 4.4 Hz, H-2′), 5.08 (1H, dd, <i>J</i> = 54.2, 4.1 Hz, H-3′), 6.03 (1H, d, <i>J</i> = 7.0 Hz, H-1′), 8.18 (1H, s, H-6), 12.43 (1H, br. s, NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 60.9 (d, <i>J</i> = 10.4 Hz, C-5′), 71.5 (d, <i>J</i> = 16.1 Hz, C-2′), 83.6 (d, <i>J</i> = 20.7 Hz, C-4′), 87.0 (C-1′), 92.3 (d, <i>J</i> = 183.1 Hz, C-3′), 105.4 (C-3a), 122.8 (C-3), 150.3 (C-7a), 154.5 (C-6), 156.3 (C-4) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −198.39 (1F, dt, <i>J</i> = 54.1, 25.2 Hz) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>11</sub>BrFN<sub>4</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 348.9948, found: 348.9996.</div></div><div id="sec4_1_7_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 3-Bromo-4-oxo-1-(3′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>31</b>)</h5><div class="NLM_p last">Compound <b>28</b> (used directly from the previous step) was subjected to general procedure C (reaction time: 3 h). Flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification <i>via</i> preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 30:70 in 18 min) afforded <b>31</b> (31 mg, 0.093 mmol, 6% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 2.10 (1H, ddd, <i>J</i> = 13.1, 6.4, 1.9 Hz, H-3′), 2.48 (1H, ddd, <i>J</i> = 13.2, 9.4, 5.6 Hz, H-3″), 3.62 (1H, dd, <i>J</i> = 11.7, 5.9 Hz, H-5′), 3.70 (1H, dd, <i>J</i> = 11.7, 4.1 Hz, H-5″), 4.46–4.56 (1H, m, H-4′), 4.67 (1H, dt, <i>J</i> = 5.6, 1.6 Hz, H-2′), 6.24 (1H, d, <i>J</i> = 1.5 Hz, H-1′), 8.05 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, CD<sub>3</sub>OD) δ 37.0 (C-3′), 66.1 (C-5′), 77.3 (C-2′), 83.6 (C-4′), 93.3 (C-1′), 107.0 (C-3a), 124.4 (C-3), 150.5 (C-7a), 155.5 (C-6), 159.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>12</sub>BrN<sub>4</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 331.0042, found: 331.0047.</div></div><div id="sec4_1_7_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 4-Oxo-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (Allopurinol Riboside)<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> (<b>2</b>)</h5><div class="NLM_p last">Compound <b>29</b> (65 mg, 0.187 mmol) was submitted to general procedure D (reaction time: 1 h). Flash column chromatography (automated, 10 → 35% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>2</b> (27 mg, 0.101 mmol, 54% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.43 (1H, dd, <i>J</i> = 11.7, 5.9 Hz, H-5′), 3.57 (1H, dd, <i>J</i> = 11.7, 4.4 Hz, H-5″), 3.91 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-4′), 4.21 (1H, t, <i>J</i> = 4.8 Hz, H-3′), 4.54 (1H, m, <i>J</i> = 4.5, 4.5 Hz, H-2′), 4.77 (1H, br. s., OH), 4.96–5.63 (2H, m, OH, OH), 6.07 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 8.13 (1H, s, H-3), 8.17 (1H, s, H-6), 12.37 (1H, br. s, NH) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>13</sub>N<sub>4</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 269.0886, found: 269.0891. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></div></div><div id="sec4_1_7_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 4-Oxo-1-(3′-deoxy-3′-fluoro-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>32</b>)</h5><div class="NLM_p last">Compound <b>30</b> (0.031 g, 0.089 mmol) was subjected to general procedure D (reaction time: 30 min). Purification <i>via</i> flash column chromatography afforded <b>32</b> (20 mg, 0.074 mmol, 83% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.47–3.57 (2H, m, H-5′, H-5″), 4.13–4.29 (1H, m, H-4′), 4.89–5.22 (2H, m, H-3′, H-2′), 6.09 (1H, d, <i>J</i> = 7.0 Hz, H-1′), 8.15 (1H, s, H-6), 8.22 (1H, s, H-4), 12.22 (1H, br. s, NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 61.0 (d, <i>J</i> = 10.4 Hz, C-5′), 71.6 (d, <i>J</i> = 16.1 Hz, C-2′), 83.4 (d, <i>J</i> = 20.7 Hz, C-4′), 87.1 (C-1′), 92.5 (d, <i>J</i> = 182.0 Hz, C-3′), 106.6 (C-3a), 135.8 (C-3), 148.9 (C-7a), 153.5 (C-6), 157.0 (C-4) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −198.82 (1F, dt, <i>J</i> = 54.1, 24.8 Hz) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>12</sub>FN<sub>4</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 271.0843, found: 271.0834.</div></div><div id="sec4_1_7_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 4-Oxo-1-(3′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>33</b>)</h5><div class="NLM_p last">Compound <b>31</b> (0.023 g, 0.069 mmol) was subjected to general procedure D (reaction time: 30 min). Purification <i>via</i> flash column chromatography afforded <b>33</b> (14 mg, 0.056 mmol, 80% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.91–2.05 (1H, m, H-3′), 2.23–2.37 (1H, m, H-3″), 3.33–3.56 (2H, m, H-5′, H-5″), 4.25–4.42 (1H, m, H-4′), 4.49–4.63 (1H, m, H-2′), 4.85 (1H, br. s, OH), 5.59 (1H, br. s, OH), 6.12 (1H, s, H-1′), 8.13 (1H, s, H-3), 8.14 (1H, s, H-6), 12.2 (1H, s, NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 36.0 (C-3′), 64.1 (C-5′), 74.7 (C-2′), 81.4 (C-4′), 90.7 (C-1′), 105.9 (C-3a), 135.4 (C-3), 148.5 (C-7a), 152.4 (C-6), 157.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>13</sub>N<sub>4</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 253.0937, found: 253.0921.</div></div><div id="sec4_1_7_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 3-Iodo-4-amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> (<b>34</b>)</h5><div class="NLM_p last">Compound <b>13</b> (10.1 g, 39.1 mmol, 1.0 equiv) and 1-<i>O</i>-acetyl-2,3,5-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose (29.6 g, 58.7 mmol, 1.5 equiv) were subjected to general procedure A to afford <b>34</b> (21.2 g, 30.0 mmol, 77% yield) as a yellow oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.56–4.90 (3H, m, H-5′, H-5″, H-4′), 6.20 (1H, t, <i>J</i> = 5.6 Hz, H-3′), 6.36 (1H, dd, <i>J</i> = 5.0, 3.2 Hz, H-2′), 6.76 (1H, d, <i>J</i> = 2.9 Hz, H-2′), 7.35–7.62 (9H, m, H<sub>Phe</sub>), 7.91–8.14 (6H, m, H<sub>Phe</sub>), 8.34 (1H, s, H-6) ppm. HRMS (ESI): calcd for C<sub>31</sub>H<sub>25</sub>IN<sub>5</sub>O<sub>7</sub> ([M + H]<sup>+</sup>): 706.0799, found: 706.0824. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div></div><div id="sec4_1_7_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> 4-Amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> (<b>35</b>)</h5><div class="NLM_p last">4-Aminopyrazolo[3,4-<i>d</i>]pyrimidine <b>3</b> (3.16 g, 23.4 mmol, 1.0 equiv) and 1-<i>O</i>-acetyl-2,3,5-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose (17.7 g, 35.1 mmol, 1.5 equiv) were subjected to general procedure A to afford <b>35</b> (8.06 g, 13.9 mmol, 59% yield) as a colorless foam. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ ppm 4.54 (1H, dd, <i>J</i> = 12.3, 4.4 Hz, H-5′), 4.68 (1H, dd, <i>J</i> = 12.3, 3.5 Hz, H-5″), 4.89–4.95 (1H, m, H-4′), 6.17–6.33 (2H, m, H-2′, H-3′), 6.75 (1H, d, <i>J</i> = 2.6 Hz, H-1′), 7.40–7.56 (6H, m, H<sub>Phe</sub>), 7.59–7.72 (3H, m, H<sub>Phe</sub>), 7.87–8.03 (6H, m, H<sub>Phe</sub>), 8.47 (1H, br. s, NH<sub>2</sub>), 8.40 (1H, s, H-3), 8.43 (1H, s, H-6), 9.13 (1H, br. s., NH<sub>2</sub>′) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 63.2 (C-5′), 71.0 (C-2′), 74.2 (C-3′), 79.1 (C-4′), 86.2 (C-1′), 100.3 (-3a), 128.4 (C<sub>Phe</sub>), 128.5 (C<sub>Phe</sub>), 128.6 (C<sub>Phe</sub>), 128.7 (C<sub>Phe</sub>), 128.8 (C<sub>Phe</sub>), 129.2 (C<sub>Phe</sub>), 129.3 (C<sub>Phe</sub>), 129.4 (C<sub>Phe</sub>), 133.5 (C<sub>Phe</sub>), 133.9 (C<sub>Phe</sub>), 134.0 (C<sub>Phe</sub>), 135.7 (C-3), 152.0 (C-7a), 152.8 (C-6), 154.5 (C-4), 164.6 (C═O), 164.7 (C═O), 165.4 (C═O) ppm. HRMS (ESI): calcd for C<sub>31</sub>H<sub>26</sub>N<sub>5</sub>O<sub>7</sub> ([M + H]<sup>+</sup>): 580.1832, found: 580.1793. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></div></div><div id="sec4_1_7_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> 3-Iodo-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> (<b>36</b>)</h5><div class="NLM_p last">Compound <b>34</b> (7.43 g, 10.5 mmol) was subjected to general procedure C, with the exception that the temperature was raised to 60 °C to aid dissolution, (reaction time: 2 h). Purification <i>via</i> flash column chromatography (manual, 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> to remove higher-running impurities and then 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>36</b> (2.63 g, 6.69 mmol, 64% yield) as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.43 (1H, dd, <i>J</i> = 11.7, 5.6 Hz, H-5′), 3.55 (1H, dd, <i>J</i> = 11.7, 4.4 Hz, H-5″), 3.89 (1H, dd, <i>J</i> = 10.0, 4.4 Hz, H-4′), 4.16 (1H, t, <i>J</i> = 4.7 Hz, H-3′), 4.53–4.60 (1H, m, H-2′), 4.82 (1H, br. s, OH), 5.15 (1H, br. s, OH), 5.38 (1H, br. s, OH), 6.03 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 8.23 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.7 (C-5′), 71.1 (C-2′), 73.3 (C-3′), 85.7 (C-4′), 88.7 (C-1′), 103.9 (C-3a), 121.0 (C-3), 154.9 (C-7a), 156.8 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>13</sub>IN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 394.0012, found: 394.0021.</div></div><div id="sec4_1_7_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> 3-Bromo-4-chloropyrazolo[3,4-<i>d</i>]pyrimidine (<b>37</b>)</h5><div class="NLM_p last">4-Chloropyrazolo[3,4-<i>d</i>]pyrimidine (5.00 g, 32.4 mmol, 1.0 equiv) was dissolved in DMF (50 mL). NBS (6.33 g, 35.6 mmol, 1.1 equiv) was added, and the mixture was heated at 50 °C for 3 h. H<sub>2</sub>O (100 mL) was added, and the mixture was extracted with EtOAc (3 ×150 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was used crude in the next reaction. HRMS (ESI): calcd for C<sub>5</sub>H<sub>2</sub>BrClN<sub>4</sub> ([M + H]<sup>+</sup>): 232.9230, found: 232.9242.</div></div><div id="sec4_1_7_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> 3-Bromo-4-methoxypyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> (<b>38</b>)</h5><div class="NLM_p last">Compound <b>37</b> (crude) was dissolved in MeOH (50 mL). NaOMe (5.4 M in MeOH, 20 mL) was added, and the mixture was heated at 70 °C for 2 h. The reaction was quenched <i>via</i> the addition of aq. sat. NH<sub>4</sub>Cl (200 mL) and H<sub>2</sub>O (50 mL). The mixture was extracted with EtOAc (3 × 250 mL), and the combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was purified by flash column chromatography (manual, petroleum ether/EtOAc 60:40) to afford <b>38</b> (3.76 g, 16.4 mmol, 51% yield over 2 steps) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.10 (3H, s, CH<sub>3</sub>), 8.56 (1H, s, H-6), 14.27 (1H, br. s., NH) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 54.4 (C-5′), 101.4 (C-3a), 118.1 (C-3), 156.0 (C-7a), 156.4 (C-6), 163.0 (C-4) ppm. HRMS (ESI): calcd for C<sub>6</sub>H<sub>6</sub>BrN<sub>4</sub>O ([M + H]<sup>+</sup>): 228.9725, found: 228.9738. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div></div><div id="sec4_1_7_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> 3-Bromo-4-methoxy-1-(2′-deoxy-3′,5′-di-<i>O</i>-(<i>p</i>-toluoyl)-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> (<b>39</b>)</h5><div class="NLM_p last">Powdered KOH (1.60 g, 28.6 mmol, 4.0 equiv) and TDA-1 (0.227 mL, 0.71 mmol, 0.1 equiv) were added to a suspension of <b>38</b> (1.64 g, 7.14 mmol, 1.0 equiv) in MeCN (250 mL). The mixture was stirred for 20 min before Hoffer’s chlorosugar (2.64 g, 6.78 mmol, 0.95 equiv) was added. The mixture was stirred for another 30 min and filtered over celite. The filtrate was concentrated <i>in vacuo</i>, and the residue was adsorbed onto celite and purified <i>via</i> flash column chromatography (automated, 5 → 35% EtOAc in petroleum ether) to afford <b>39</b> (310 mg, 0.55 mmol, 8% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.41 (3H, s, CH<sub>3 toluoyl</sub>), 2.44 (3H, s, CH<sub>3 toluoyl</sub>), 2.67 (1H, ddd, <i>J</i> = 14.3, 6.4, 3.0 Hz, H-2′), 3.52 (1H, dt, <i>J</i> = 14.0, 6.8 Hz, H-2″), 4.19 (3H, s, OCH<sub>3</sub>), 4.47–4.68 (3H, m, H-5′, H-5″, H-4′), 5.80–5.92 (1H, m, H-3′), 6.91 (1H, t, <i>J</i> = 6.7 Hz, H-1′), 7.18–7.33 (4H, m, H<sub>toluoyl</sub>), 7.88–7.99 (2H, m, H<sub>toluoyl</sub>), 8.00–8.07 (2H, m, H<sub>toluoyl</sub>), 8.51–8.63 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 21.7 (2 × CH<sub>3 toluoyl</sub>), 35.8 (OCH<sub>3</sub>), 54.6 (C-2′), 64.1 (C-5′), 75.4 (C-3′), 82.8 (C-4′), 85.0 (C-1′), 103.8 (C-3a), 120.4 (C-3), 126.6 (C<sub>toluoyl</sub>), 127.0 (C<sub>toluoyl</sub>), 129.1 (C<sub>toluoyl</sub>), 129.2 (C<sub>toluoyl</sub>), 129.8 (C<sub>toluoyl</sub>), 129.9 (C<sub>toluoyl</sub>), 143.7 (C<sub>toluoyl</sub>), 144.3 (C<sub>toluoyl</sub>), 156.4 (-6), 163.9 (C-4), 165.9 (C═O), 166.3 (C═O) ppm. HRMS (ESI): calcd for C<sub>27</sub>H<sub>26</sub>BrN<sub>4</sub>O<sub>6</sub> ([M + H]<sup>+</sup>): 581.1036, found: 581.1009. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div></div><div id="sec4_1_7_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> 4-Amino-3-bromo-1-(2′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> (<b>40</b>)</h5><div class="NLM_p last">Compound <b>39</b> (0.310 g, 0.48 mmol) was stirred in 7 N NH<sub>3</sub> in MeOH (20 mL) in a pressure tube at 90 °C for 24 h. The reaction vessel was cooled down to room temperature before it was opened, and its contents were transferred to a pear-shaped flask. The volatiles were removed <i>in vacuo</i>, and the residue was adsorbed onto celite and purified by flash column chromatography (automated, 2 → 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> + 1% NH<sub>4</sub>OH) to afford <b>40</b> (120 mg, 0.363 mmol, 76% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.25 (1H, m, <i>J</i> = 13.3, 6.8, 4.2 Hz, H-2′), 2.74 (1H, dt, <i>J</i> = 13.0, 6.3 Hz, H-2″), 3.36 (1H, dt, <i>J</i> = 11.6, 5.9 Hz, H-5′), 3.50 (1H, dt, <i>J</i> = 11.4, 5.6 Hz, H-5″), 3.80 (1H, td, <i>J</i> = 5.7, 3.6 Hz, H-4′), 4.34–4.46 (1H, m, H-3′), 4.75 (1H, t, <i>J</i> = 5.8 Hz, OH), 5.27 (1H, d, <i>J</i> = 4.6 Hz, OH), 6.51 (1H, t, <i>J</i> = 6.4 Hz, H-1′), 8.23 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 37.8 (C-2′), 62.3 (C-5′), 70.8 (C-3′), 83.9 (C-4′), 87.7 (C-1′), 99.8 (C-3a), 119.0 (C-3), 154.5 (C-7a), 157.0 (C-6), 157.4 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>13</sub>BrN<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 330.0202, found: 330.0231. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a></div></div><div id="sec4_1_7_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> 4-Amino-1-(2′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> (<b>41</b>)</h5><div class="NLM_p last">Compound <b>40</b> (72 mg, 0.218 mmol) was subjected to general procedure D (reaction time: 30 min). Purification <i>via</i> flash column chromatography (automated, 5 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>41</b> (52 mg, 0.100 mmol, 46% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.23 (1H, ddd, <i>J</i> = 13.1, 6.7, 3.9 Hz, H-2′), 2.80 (1H, dt, <i>J</i> = 13.0, 6.3 Hz, H-2″), 3.33–3.41 (1H, m, H-5′, partially under water peak), 3.52 (1H, dd, <i>J</i> = 11.4, 5.3 Hz, H-5″), 3.81 (1H, td, <i>J</i> = 5.6, 3.5 Hz, H-4′), 4.43 (1H, br. s., H-3′), 4.80 (1H, br. s., OH), 5.24 (1H, br. s., OH), 6.54 (1H, t, <i>J</i> = 6.5 Hz, H-1′), 7.45–7.98 (2H, m, NH<sub>2</sub>), 8.15 (1H, s, H-3), 8.19 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 38.0 (C-2′), 62.5 (C-5′), 71.1 (C-3′), 84.0 (C-4′), 87.6 (C-1′), 100.5 (C-3a), 133.1 (C-3), 153.7 (C-7a), 156.0 (C-6), 158.0 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>14</sub>N<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 252.1097, found: 252.1084. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div></div><div id="sec4_1_7_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> 3-Phenyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> (<b>42</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.132 g, 0.38 mmol) was subjected to general procedure E, using phenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 0:100 to 49:51 in 18 min) afforded <b>42</b> (44 mg, 0.118 mmol, 34% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.42–3.53 (1H, m, H-5′), 3.55–3.67 (1H, m, H-5″), 3.93 (1H, dd, <i>J</i> = 10.0, 4.7 Hz, H-4′), 4.22–4.30 (1H, m, H-3′), 4.60–4.70 (1H, m, H-2′), 4.77–4.89 (1H, m, OH), 5.06–5.20 (1H, m, OH), 5.33–5.49 (1H, m, OH), 6.19 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.47–7.62 (3H, m, H<sub>Phe</sub>), 7.65–7.72 (2H, m, H<sub>Phe</sub>), 8.29 (1H, s, H-6) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 344.1359, found: 344.1356. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div></div><div id="sec4_1_7_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> 3-(4-Methoxyphenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>43</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.087 g, 0.25 mmol) was subjected to general procedure E, using 4-methoxyphenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 1 → 12% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 41:59 in 10.5 min) afforded <b>43</b> (42 mg, 0.112 mmol, 45% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.46 (1H, dd, <i>J</i> = 11.7, 5.6 Hz, H-5′), 3.60 (1H, dd, <i>J</i> = 11.7, 4.1 Hz, H-5″), 3.84 (3H, s, CH<sub>3</sub>), 3.93 (1H, dd, <i>J</i> = 9.6, 4.7 Hz, H-4′), 4.26 (1H, t, <i>J</i> = 4.8 Hz, H-3′), 4.65 (1H, t, <i>J</i> = 4.8 Hz, H-2′), 6.18 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.05–7.19 (2H, m, H<sub>Phe</sub>), 7.55–7.67 (2H, m, H<sub>Phe</sub>), 8.27 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 55.7 (CH<sub>3</sub>), 62.8 (C-5′), 71.4 (C-2′), 73.7 (C-3′), 85.6 (C-4′), 88.8 (C-1′), 98.2 (C-3a), 115.1 (C<sub>Phe</sub>), 125.3 (C<sub>Phe</sub>), 130.0 (C<sub>Phe</sub>), 145.2 (C-3), 155.7 (C-7a), 156.4 (C-6), 158.7 (C-4), 160.3 (C<sub>Phe</sub>) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>20</sub>N<sub>5</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 374.1464, found: 374.1455.</div></div><div id="sec4_1_7_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> 3-(4-Chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>44</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.087 g, 0.25 mmol) was subjected to general procedure E, using 4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 1 → 12% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 0:100 to 41:59 in 10.5 min) afforded <b>44</b> (38 mg, 0.101 mmol, 40% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.44 (1H, dd, <i>J</i> = 11.7, 5.6 Hz, H-5′), 3.58 (1H, dd, <i>J</i> = 12.0, 4.7 Hz, H-5″), 3.91 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-4′), 4.25 (1H, t, <i>J</i> = 4.7 Hz, H-3′), 4.63 (1H, t, <i>J</i> = 4.8 Hz, H-2′), 4.86 (1H, br. s, OH), 5.33 (2H, br. s, OH, OH), 6.17 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 6.99 (2H, br. s, NH<sub>2</sub>), 7.57–7.70 (4H, m, H<sub>Phe</sub>), 8.26 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.3 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 97.8 (C-3a), 129.2 (C<sub>Phe</sub>), 130.0 (C<sub>Phe</sub>), 131.4 (C<sub>Phe</sub>), 133.7 (C<sub>Phe</sub>), 143.8 (C-3), 155.4 (C-7a), 156.1 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>17</sub>ClN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 378.0969, found: 378.0981.</div></div><div id="sec4_1_7_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> 3-(4-Methylphenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>45</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.094 g, 0.27 mmol) was subjected to general procedure E, using 4-methylphenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 41:59 in 10.5 min) afforded <b>45</b> (40 mg, 0.112 mmol, 42% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.40 (3H, s, CH<sub>3</sub>), 3.40–3.52 (1H, m, H-5′), 3.54–3.67 (1H, m, H-5″), 3.93 (1H, dd, <i>J</i> = 9.1, 5.0 Hz, H-4′), 4.27 (1H, q, <i>J</i> = 4.7 Hz, H-3′), 4.65 (1H, q, <i>J</i> = 5.0 Hz, H-2′), 4.85 (1H, t, <i>J</i> = 5.7 Hz, OH), 5.14 (1H, d, <i>J</i> = 5.3 Hz, OH), 5.41 (1H, d, <i>J</i> = 5.6 Hz, OH), 6.19 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.38 (2H, d, <i>J</i> = 7.9 Hz, H<sub>Phe</sub>), 7.57 (2H, d, <i>J</i> = 7.9 Hz, H<sub>Phe</sub>), 8.27 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 20.9 (CH<sub>3</sub>), 62.4 (C-5′), 70.9 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 97.8 (C-3a), 128.1 (C<sub>Phe</sub>), 129.8 (C<sub>Phe</sub>), 138.4 (C<sub>Phe</sub>), 144.9 (C-3), 155.3 (C-7a), 156.0 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 358.1515, found: 358.1500.</div></div><div id="sec4_1_7_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> 3-(4-Fluorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>46</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 4-fluorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 32:68 in 12 min) afforded <b>46</b> (66 mg, 0.183 mmol, 52% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.46 (1H, dd, <i>J</i> = 11.9, 5.7 Hz, H-5′), 3.60 (1H, dd, <i>J</i> = 11.7, 4.4 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 10.0, 4.4 Hz, H-4′), 4.26 (1H, t, <i>J</i> = 4.7 Hz, H-3′), 4.65 (1H, t, <i>J</i> = 4.7 Hz, H-2′), 4.85 (1H, br. s, OH), 5.13 (1H, br. s, OH), 5.40 (1H, br. s, OH), 6.18 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 6.97 (2H, br. s, NH<sub>2</sub>), 7.32–7.47 (2H, m, H<sub>Phe</sub>), 7.63–7.76 (2H, m, H<sub>Phe</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.8 (C-5′), 71.3 (C-2′), 73.6 (C-3′), 85.6 (C-4′), 88.8 (C-1′), 98.3 (C-3a), 116.6 (d, <i>J</i> = 21.9 Hz, C-3<sub>Phe,</sub> C-5<sub>Phe</sub>), 129.5 (d, <i>J</i> = 3.5 Hz, C-1<sub>Phe</sub>),130.9 (d, <i>J</i> = 9.2 Hz, C-2<sub>Phe,</sub> C-6<sub>Phe</sub>), 144.4 (C-3), 155.8 (C-7a), 156.5 (C-6), 158.6 (C-4), 163.0 (d, <i>J</i> = 245.0 Hz, C-4<sub>Phe</sub>) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −113.07 to −112.95 (1F, m) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 362.1265, found: 362.1265.</div></div><div id="sec4_1_7_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> 3-(4-Nitrophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>47</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 4-nitrophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 32:68 in 12 min) afforded <b>47</b> (70 mg, 0.181 mmol, 52% yield) as a light-brown solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.47 (1H, dd, <i>J</i> = 11.7, 5.9 Hz, H-5′), 3.61 (1H, dd, <i>J</i> = 11.7, 4.7 Hz, H-5″), 3.95 (1H, dd, <i>J</i> = 10.0, 4.7 Hz, H-4′), 4.28 (1H, t, <i>J</i> = 4.4 Hz, H-3′), 4.67 (1H, br. s., H-2′), 4.84 (1H, br. s., OH), 5.16 (1H, br. s., OH), 5.43 (1H, br. s., OH), 6.22 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.94 (2H, d, <i>J</i> = 8.8 Hz, H<sub>Phe</sub>), 8.31 (1H, s, H-6), 8.37–8.45 (2H, m, H<sub>Phe</sub>) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.3 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.3 (C-4′), 88.5 (C-1′), 98.0 (C-3a), 124.3 (C-3<sub>Phe</sub>, C-5<sub>Phe</sub>), 129.6 (C-2<sub>Phe</sub>, C-6<sub>Phe</sub>), 138.9 (C-1<sub>Phe</sub>), 143.1 (C-3), 147.4 (C-4<sub>Phe</sub>), 155.6 (C-7a), 156.2 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>17</sub>N<sub>6</sub>O<sub>6</sub> ([M + H]<sup>+</sup>): 389.1210, found: 389.1211.</div></div><div id="sec4_1_7_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 3-(4-<i>tert</i>-Butylphenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>48</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 4-<i>tert</i>-butylphenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>48</b> (55 mg, 0.138 mmol, 39% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.35 (9H, s, 3 × CH<sub>3</sub>), 3.45 (1H, dd, <i>J</i> = 11.7, 5.9 Hz, H-5′), 3.61 (1H, dd, <i>J</i> = 11.7, 4.1 Hz, H-5″), 3.95 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.27 (1H, t, <i>J</i> = 4.7 Hz, H-3′), 4.64 (1H, t, <i>J</i> = 5.0 Hz, H-2′), 4.86 (1H, br. s, OH), 5.17 (1H, br. s, OH), 5.44 (1H, br. s, OH), 6.19 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.54–7.68 (4H, m, H<sub>Phe</sub>), 8.28 (1H, s, C-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 31.0 (CH(CH<sub>3</sub>)<sub>3</sub>), 34.5 (<u class="uu">C</u>H(CH<sub>3</sub>)<sub>3</sub>), 62.4 (C-5′), 70.9 (C-2′), 73.3 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 97.8 (C-3a), 126.0 (C-3<sub>Phe</sub>, C-5<sub>Phe</sub>), 127.9 (C-2<sub>Phe</sub>,C-6<sub>Phe</sub>), 129.8 (C-1<sub>Phe</sub>), 144.8 (C-3), 151.4 (C-4<sub>Phe</sub>), 155.3 (C-7a), 156.0 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>20</sub>H<sub>26</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 400.1985, found: 400.1972.</div></div><div id="sec4_1_7_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 3-(4-Trifluoromethylphenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>49</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 4-trifluoromethylphenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>49</b> (67 mg, 0.163 mmol, 47% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.48 (1H, dd, <i>J</i> = 11.7, 5.0 Hz, H-5′), 3.60 (1H, dd, <i>J</i> = 11.4, 3.5 Hz, H-5″), 3.94 (1H, dd, <i>J</i> = 10.0, 4.7 Hz, H-4′), 4.27 (1H, t, <i>J</i> = 4.5 Hz, H-3′), 4.66 (1H, t, <i>J</i> = 4.5 Hz, H-2′), 4.84 (1H, br. s., OH), 5.18 (1H, br. s., OH), 5.45 (1H, br. s., OH), 6.21 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.86–7.96 (4H, m, H<sub>Phe</sub>), 8.30 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.8 (C-5′), 71.3 (C-2′), 73.7 (C-3′), 85.7 (C-4′), 88.9 (C-1′), 98.3 (C-3a), 126.5 (q, <i>J</i> = 3.5 Hz, C-3Phe, C-5Phe), 129.4 (q, <i>J</i> = 32.2 Hz, C-4Phe), 129.5 (C-2Phe, C-6Phe), 137.0 (C-4Phe), 144.0 (C-3), 156.0 (C-7a), 156.6 (C-6), 158.6 (C-4) ppm. 1 quaternary carbon (<u class="uu">C</u>F<sub>3</sub>) missing. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −61.06 (1F, s) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 412.1233, found: 412.1225.</div></div><div id="sec4_1_7_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 3-(4-Trifluoromethoxyphenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>50</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 4-trifluoromethoxyphenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 4 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 0:100 in 18 min) afforded <b>50</b> (40 mg, 0.094 mmol, 27% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.37–3.50 (1H, m, H-5′), 3.53–3.66 (1H, m, H-5″), 3.93 (1H, dd, <i>J</i> = 10.0, 5.6 Hz, H-4′), 4.26 (1H, dd, <i>J</i> = 7.0, 5.0 Hz, H-3′), 4.65 (0 H, dd, <i>J</i> = 8.2, 4.1 Hz, H-2′), 4.84 (1H, t, <i>J</i> = 5.3 Hz, OH), 5.18 (1H, br. s., OH), 5.45 (1H, d, <i>J</i> = 4.4 Hz, OH), 6.19 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.54 (2H, dd, <i>J</i> = 8.8, 0.9 Hz, H<sub>Phe</sub>), 7.71–7.89 (2H, m, H<sub>Phe</sub>), 8.29 (1H, s, H<sub>Phe</sub>) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.8 (C-5′), 71.3 (C-2′), 73.7 (C-3′), 85.7 (C-4′), 88.9 (C-1), 98.3 (C-3a), 120.60 (q, <i>J</i> = 255.0 Hz, <u class="uu">C</u>F<sub>3</sub>), 122.1 (C-3<sub>Phe</sub>, C-5<sub>Phe</sub>), 130.7 (C-2<sub>Phe</sub>, C-6<sub>Phe</sub>), 132.3 (C-1), 144.1 (C-3), 149.1 (C-4<sub>Phe</sub>), 155.9 (C-7a), 156.5 (C-6), 158.7 (C-4) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −56.61 (1F, s) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>17</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 428.1182, found: 428.1204.</div></div><div id="sec4_1_7_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 3-(4-Cyanophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>51</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 4-cyanophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 4 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>51</b> (56 mg, 0.152 mmol, 43% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.46 (1H, dd, <i>J</i> = 10.9, 5.2 Hz, H-5′), 3.60 (1H, dd, <i>J</i> = 11.6, 3.6 Hz, H-5″), 3.94 (1H, dd, <i>J</i> = 9.9, 4.8 Hz, H-4′), 4.27 (1H, dd, <i>J</i> = 8.6, 3.6 Hz, H-3′), 4.65 (1H, dd, <i>J</i> = 8.6, 4.9 Hz, H-2′), 4.75–4.90 (1H, m, OH), 5.16 (1H, d, <i>J</i> = 4.0 Hz, OH), 5.43 (1H, d, <i>J</i> = 5.4 Hz, OH), 6.21 (1H, d, <i>J</i> = 4.5 Hz, H-1′), 7.07 (2H, br. s, NH<sub>2</sub>), 7.85 (2H, d, <i>J</i> = 8.3 Hz, H-3<sub>Phe</sub>, H-5<sub>Phe</sub>), 8.02 (2H, d, <i>J</i> = 8.3 Hz, H-2<sub>Phe</sub>, H-6<sub>Phe</sub>), 8.30 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.3 (C-5′), 70.9 (C-2′), 73.3 (C-3′), 85.3 (C-4′), 88.5 (C-1′), 97.9 (C-3a), 111.3 (C-4<sub>Phe</sub>), 118.8 (<u class="uu">C</u>N), 129.1 (C-2<sub>Phe</sub>, C-6<sub>Phe</sub>), 133.1 (C-3<sub>Phe</sub>, C-5<sub>Phe</sub>), 137.1 (C-1<sub>Phe</sub>), 143.4 (C-3), 155.6 (C-7a), 156.2 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>17</sub>N<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 369.1311, found: 369.1241.</div></div><div id="sec4_1_7_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 3-(3,4-Dichlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>52</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.118 g, 0.34 mmol) was subjected to general procedure E, using 3,4-dichlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 0 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 41:59 in 10.5 min) afforded <b>52</b> (45 mg, 0.109 mmol, 32% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.40–3.52 (1H, m, H-5′), 3.55–3.65 (1H, m, H-5″), 3.93 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.26 (1H, t, <i>J</i> = 4.5 Hz, H-3′), 4.65 (1H, t, <i>J</i> = 3.8 Hz, H-2′), 4.83 (1H, br. s., OH), 5.17 (1H, br. s., OH), 5.43 (1H, br. s., OH), 6.18 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 6.95–7.37 (2H, m, NH<sub>2</sub>), 7.63 (1H, dd, <i>J</i> = 8.2, 2.1 Hz, H-6<sub>Phe</sub>), 7.81 (1H, d, <i>J</i> = 8.5 Hz, H-5<sub>Phe</sub>), 7.85 (1H, d, <i>J</i> = 2.1 Hz, H-2<sub>Phe</sub>), 8.29 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.2 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 97.8 (C-3a), 128.5 (C-6<sub>Phe</sub>), 130.1 (C-2<sub>Phe</sub>), 131.3 (C-5<sub>Phe</sub>), 131.6 (C-3<sub>Phe</sub>) 131.7 (C-4<sub>Phe</sub>), 133.1 (C-1<sub>Phe</sub>), 142.6 (C-3), 155.4 (C-7a), 156.1 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 412.0579, found: 412.0575.</div></div><div id="sec4_1_7_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 3-(3-Chloro-4-fluorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>53</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3-chloro-4-fluorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 0 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 32:68 in 12 min) afforded <b>53</b> (75 mg, 0.197 mmol, 56% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.40–3.51 (1H, m, H-5′), 3.54–3.67 (1H, m, H-5″), 3.93 (1H, dd, <i>J</i> = 10.0, 5.3 Hz, H-4′), 4.26 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-3′), 4.64 (1H, dd, <i>J</i> = 10.5, 5.6 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.14 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.40 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.18 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 6.79–7.38 (2H, br. s, NH<sub>2</sub>), 7.52–7.69 (2H, m, H-5<sub>Phe</sub>, H-6<sub>Phe</sub>), 7.80 (1H, dd, <i>J</i> = 7.0, 2.1 Hz, H-2<sub>Phe</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.2 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 97.8 (C-3a), 117.5 (d, <i>J</i> = 21.9 Hz, C-5<sub>Phe</sub>), 120.1 (d, <i>J</i> = 20.7 Hz, C-3<sub>Phe</sub>), 129.1 (d, <i>J</i> = 8.1 Hz, C-6<sub>Phe</sub>), 130.3 (d, <i>J</i> = 3.5 Hz, C-1<sub>Phe</sub>), 130.4 (C-2<sub>Phe</sub>), 142.8 (C-3), 155.4 (C-7a), 156.1 (C-6), 158.2 (C-4) ppm. 1 quaternary carbon (C-4<sub>Phe</sub>) missing. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −118.16 to −115.34 (142 F, m) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>16</sub>ClFN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 396.0875, found: 396.0891.</div></div><div id="sec4_1_7_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 3-(3-Fluoro-4-chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>54</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3-fluoro-4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 0 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>54</b> (82 mg, 0.207 mmol, 59% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.39–3.52 (1H, m, H-5′), 3.59 (1H, dt, <i>J</i> = 12.0, 4.7 Hz, H-5″), 3.93 (1H, q, <i>J</i> = 4.7 Hz, H-4′), 4.26 (1H, q, <i>J</i> = 5.0 Hz, H-3′), 4.65 (1H, q, <i>J</i> = 5.2 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.7 Hz, OH), 5.14 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.41 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.18 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.20 (2H, br. s, NH<sub>2</sub>), 7.51 (1H, ddd, <i>J</i> = 8.2, 2.1, 0.6 Hz, H-5<sub>Phe</sub>), 7.63 (1H, dd, <i>J</i> = 10.1, 2.1 Hz, H-2<sub>Phe</sub>), 7.76 (1H, t, <i>J</i> = 8.1 Hz, H-6<sub>Phe</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.3 (C-5′), 70.8 (C-2′), 73.3 (C-3′), 84.8 (C-4′), 88.3 (C-1′) 97.8 (C-3a), 116.8 (d, <i>J</i> = 20.7 Hz, C-2<sub>Phe</sub>), 120.0 (d, <i>J</i> = 18.4 Hz, C-4<sub>Phe</sub>), 125.5 (d, <i>J</i> = 3.5 Hz, C-5<sub>Phe</sub>), 131.3 (C-6<sub>Phe</sub>), 133.4 (d, <i>J</i> = 8.1 Hz, C-1<sub>Phe</sub>), 142.9 (C-3), 155.4 (C-7a), 156.1 (C-6), 158.1 (C-4), 157.4 (d, <i>J</i> = 244.5 Hz, C-3<sub>Phe</sub>) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −115.13 (dd, <i>J</i> = 10.2, 7.8 Hz) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>16</sub>ClFN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 396.0875, found: 396.0860.</div></div><div id="sec4_1_7_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> 3-(3,4-Difluorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>55</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3,4-difluorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 0 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>55</b> (66 mg, 0.174 mmol, 50% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.40–3.51 (1H, m, H-5′), 3.58 (1H, d, <i>J</i> = 3.8 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 10.0, 5.3 Hz, H-4′), 4.26 (1H, t, <i>J</i> = 4.5 Hz, H-3′), 4.64 (1H, t, <i>J</i> = 4.7 Hz, H-2′), 4.74–4.88 (1H, m, OH), 5.03–5.29 (1H, m, OH), 5.33–5.51 (1H, m, OH), 6.18 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 6.90–7.33 (2H, m, H<sub>Phe</sub>), 7.40–7.55 (1H, m, H<sub>Phe</sub>), 7.55–7.73 (1H, m, H<sub>Phe</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.3 (C-5′), 70.4 (C-2′), 73.3 (C-3′) 85.2 (C-4′), 88.4 (C-1′), 97.8 (C-3a), 117.3–118.7 (C<sub>Phe</sub>), 124.9–125.9 (C<sub>Phe</sub>), 129.5–130.4 (C<sub>Phe</sub>), 143.0 (d, <i>J</i> = 2.3 Hz, C-3), 147.9–148.8 (C<sub>Phe</sub>), 151.3 (C-7a), 155.0–155.6 (C<sub>Phe</sub>), 156.1 (C-6), 158.1 (C-4) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −138.90 to −138.66 (1F, m), −137.66 to −137.43 (1F, m) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>16</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 380.1170, found: 380.1185.</div></div><div id="sec4_1_7_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 3-(3-Methoxy-4-chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>56</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3-methoxy-4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 0 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>56</b> (86 mg, 0.211 mmol, 60% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.47 (1H, dd, <i>J</i> = 11.0, 5.4 Hz, H-5′), 3.61 (1H, dd, <i>J</i> = 11.0, 4.7 Hz, H-5″), 3.82–4.04 (4H, m, H-4′, C<u class="uu">H</u><sub>3</sub>), 4.27 (1H, t, <i>J</i> = 4.7 Hz, H-3′), 4.66 (1H, t, <i>J</i> = 4.7 Hz, H-2′), 4.85 (1H, br. s., OH), 5.03–5.24 (1H, m, OH), 5.31–5.57 (1H, m, OH), 6.19 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.25 (1H, dd, <i>J</i> = 8.1, 1.9 Hz, H-6<sub>Phe</sub>), 7.36 (1H, d, <i>J</i> = 1.8 Hz, H-2<sub>Phe</sub>), 7.59 (1H, d, <i>J</i> = 7.9 Hz, H-5<sub>Phe</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 56.0 (CH<sub>3</sub>), 62.3 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.5 (C-1′), 97.8 (C-3a), 112.8 (C-2<sub>Phe</sub>), 121.0 (C-6<sub>Phe</sub>), 121.7 (C-4<sub>Phe</sub>), 130.5 (C-5<sub>Phe</sub>), 132.6 (C-1<sub>Phe</sub>), 144.0 (C-3), 154.8 (C-7a), 155.3 (C-3<sub>Phe</sub>), 156.0 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>19</sub>ClN<sub>5</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 408.1075, found: 408.1099.</div></div><div id="sec4_1_7_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 3-(3-Methyl-4-chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>57</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3-methyl-4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>57</b> (88 mg, 0.224 mmol, 64% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.56 (3H, s, CH<sub>3</sub>), 3.54 (1H, dt, <i>J</i> = 11.8, 6.0 Hz, H-5′), 3.68 (1H, dt, <i>J</i> = 12.0, 4.7 Hz, H-5″), 4.01 (1H, dd, <i>J</i> = 9.4, 4.7 Hz, H-4′), 4.34 (1H, q, <i>J</i> = 5.2 Hz, H-3′), 4.73 (1H, q, <i>J</i> = 5.2 Hz, H-2′), 4.92 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.22 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.48 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.26 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 6.57–7.45 (2H, m, NH<sub>2</sub>), 7.55–7.77 (3H, m, H<sub>Phe</sub>), 8.36 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 19.8 (CH<sub>3</sub>), 62.3 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 97.8 (C-3a), 127.4 (C<sub>Phe</sub>), 129.6 (C<sub>Phe</sub>), 130.9 (C<sub>Phe</sub>), 131.4 (C<sub>Phe</sub>), 134.0 (C<sub>Phe</sub>), 136.3 (C<sub>Phe</sub>), 143.9 (C-3), 155.4 (C-7a), 156.1 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>19</sub>ClN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 392.1126, found: 392.1073.</div></div><div id="sec4_1_7_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 3-(3-Trifluoromethyl-4-chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>58</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3-trifluoromethyl-4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>58</b> (50 mg, 0.112 mmol, 32% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.46 (1H, dd, <i>J</i> = 11.6, 5.7 Hz, H-5′), 3.60 (1H, dd, <i>J</i> = 11.7, 4.1 Hz, H-5″), 3.94 (1H, dd, <i>J</i> = 9.7, 5.0 Hz, H-4′), 4.27 (1H, t, <i>J</i> = 4.5 Hz, H-3′), 4.66 (1H, t, <i>J</i> = 4.4 Hz, H-2′), 4.83 (1H, br. s., OH), 5.16 (1H, br. s., OH), 5.40 (1H, br. s., OH), 6.20 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.23 (2H, br. s., NH<sub>2</sub>), 7.77–8.10 (3H, m, H<sub>Phe</sub>), 8.30 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.2 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.3 (C-4′), 88.5 (C-1′), 97.9 (C-3a), 122.7 (q, <i>J</i> = 275.0 Hz, <u class="uu">C</u>F<sub>3</sub>), 127.0 (C<sub>Phe</sub>), 127.5 (d, <i>J</i> = 4.6 Hz, C<sub>Phe</sub>), 131.1 (C<sub>Phe</sub>), 132.0 (C<sub>Phe</sub>), 132.4 (C<sub>Phe</sub>), 133.6 (C<sub>Phe</sub>), 142.6 (C-3), 155.5 (C-7a), 156.1 (C-6), 158.2 (C-4) ppm. <sup>19</sup>F NMR (377 MHz, DMSO-<i>d</i><sub>6</sub>) δ −61.4 (s) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>16</sub>F<sub>3</sub>ClN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 446.0843, found: 446.0853.</div></div><div id="sec4_1_7_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> 3-(3-Cyano-4-chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>59</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3-cyano-4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 40:60 in 12 min) afforded <b>59</b> (25 mg, 0.062 mmol, 18% yield) as a white solid and <b>75</b> (7 mg, 0.014 mmol, 4% yield) as a white solid. <u class="uu">Analytical data</u><b><u class="uu">59</u></b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.37–3.51 (1H, m, H-5′), 3.59 (1H, ddd, <i>J</i> = 11.5, 9.6, 4.3 Hz, H-5″), 3.93 (1H, q, <i>J</i> = 4.8 Hz, H-4′), 4.26 (1H, q, <i>J</i> = 4.8 Hz, H-3′), 4.65 (1H, q, <i>J</i> = 5.0 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.8 Hz, OH), 5.15 (1H, d, <i>J</i> = 5.4 Hz, OH), 5.42 (1H, d, <i>J</i> = 5.6 Hz, OH), 6.19 (1H, d, <i>J</i> = 4.5 Hz, H-1′), 6.79–7.65 (2H, m, NH<sub>2</sub>), 7.90 (1H, d, <i>J</i> = 8.1 Hz, H<sub>Phe</sub>), 7.96 (H, dd, <i>J</i> = 8.3, 2.4 Hz, H<sub>Phe</sub>), 8.17 (1H, d, <i>J</i> = 2.0 Hz, H<sub>Phe</sub>), 8.29 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 60.3 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 97.9 (C-3a), 112.9 (C<sub>Phe</sub>), 116.0 (C<sub>Phe</sub>), 130.7 (C<sub>Phe</sub>), 132.3 (C<sub>Phe</sub>), 134.2 (C<sub>Phe</sub>), 134.4 (C<sub>Phe</sub>), 135.6 (C<sub>Phe</sub>), 142.1 (C-3), 155.5 (C-7a), 156.2 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>16</sub>ClN<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 403.0922, found: 403.0929. <u class="uu">Analytical data</u><b><u class="uu">75</u></b>: <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.41–3.53 (1H, m, H-5′), 3.61 (1H, dt, <i>J</i> = 11.8, 4.8 Hz, H-5″), 3.95 (1H, dd, <i>J</i> = 10.0, 4.9 Hz, H-4′), 4.29 (1H, dd, <i>J</i> = 10.4, 5.1 Hz, H-3′), 4.65 (1H, dd, <i>J</i> = 10.3, 5.0 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.4 Hz, OH), 5.16 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.43 (1H, d, <i>J</i> = 5.8 Hz, OH), 6.22 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.15 (2H, br. s, NH<sub>2</sub>), 7.84–8.23 (5H, m, H<sub>Phe</sub>), 8.30 (1H, d, <i>J</i> = 2.0 Hz, H<sub>Phe</sub>), 8.32 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.2 (C-5′), 70.8 (C-2′), 73.3 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 98.0 (C-3a), 111.3 (C<sub>Phe</sub>), 112.6 (C<sub>Phe</sub>), 115.6 (C<sub>Phe</sub>), 118.0 (C<sub>Phe</sub>), 130.6 (C<sub>Phe</sub>), 131.0 (C<sub>Phe</sub>), 133.1 (C<sub>Phe</sub>), 133.4 (C<sub>Phe</sub>), 133.4 (C<sub>Phe</sub>), 134.7 (C<sub>Phe</sub>), 135.1 (C<sub>Phe</sub>), 136.0 (C<sub>Phe</sub>), 137.3 (C<sub>Phe</sub>), 141.1 (C<sub>Phe</sub>), 142.5 (C-3), 155.5 (C-7a), 156.2 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>24</sub>H<sub>19</sub>ClN<sub>7</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 504.1187, found: 504.1199.</div></div><div id="sec4_1_7_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 3-(3,5-Difluoro-4-chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>60</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3,5-difluoro-4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>60</b> (70 mg, 0.169 mmol, 48% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.40–3.52 (1H, m, H-5′), 3.60 (1H, dt, <i>J</i> = 11.8, 4.8 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 10.0, 4.7 Hz, H-4′), 4.27 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-3′), 4.65 (1H, dd, <i>J</i> = 10.5, 5.3 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.14 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.41 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.18 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.24 (2H, br. s., NH<sub>2</sub>), 7.46–7.65 (2H, m, H<sub>Phe</sub>), 8.28 (H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.2 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.5 (C-1′), 97.9 (C-3a), 108.8 (t, <i>J</i> = 20.7 Hz, C<sub>Phe</sub>), 112.8 (dd, <i>J</i> = 23.0, 2.3 Hz, C<sub>Phe</sub>), 133.1 (t, <i>J</i> = 10.4 Hz, C<sub>Phe</sub>), 142.1 (d, <i>J</i> = 2.3 Hz, C-3), 155.7 (C-7a), 156.2 (C-6), 156.6 (d, <i>J</i> = 3.5 Hz, C<sub>Phe</sub>), 158.0 (C-4), 159.9 (d, <i>J</i> = 4.6 Hz) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −112.93 (2F, d, <i>J</i> = 7.2 Hz) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>15</sub>ClF<sub>2</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 414.0781, found: 414.0733.</div></div><div id="sec4_1_7_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 3-(3-Ethoxy-4-chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>61</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 3-ethoxy-4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>61</b> (108 mg, 0.256 mmol, 73% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.40 (3H, t, <i>J</i> = 6.9 Hz, CH<sub>3</sub>), 3.60 (1H, ddd, <i>J</i> = 12.0, 10.0, 4.7 Hz, H-5′), 3.94 (1H, dd, <i>J</i> = 10.0, 4.4 Hz, H-5″), 4.20 (2H, q, <i>J</i> = 6.9 Hz, CH<sub>2</sub>), 4.27 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-4′), 4.66 (1H, dd, <i>J</i> = 10.3, 5.0 Hz, H-3′), 4.85 (1H, dd, <i>J</i> = 6.4, 5.6 Hz, H-2′), 5.14 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.40 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.19 (1H, d, <i>J</i> = 4.4 Hz, OH), 6.69–7.23 (2H, m, NH<sub>2</sub>), 7.24 (1H, dd, <i>J</i> = 8.2, 1.8 Hz, H-6<sub>Phe</sub>), 7.34 (1H, d, <i>J</i> = 1.8 Hz, H-2<sub>Phe</sub>), 7.59 (1H, d, <i>J</i> = 8.2 Hz, H-5<sub>Phe</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.6 (CH<sub>3</sub>), 62.3 (C-5′), 64.3 (CH<sub>2</sub>), 70.8 (C-2′), 73.2 (C-3′), 85.3 (C-4′), 88.5 (C-5′), 97.8 (C-3a), 113.6 (C-2 <sub>Phe</sub>), 120.9 (C-6<sub>Phe</sub>), 121.9 (C-4 <sub>Phe</sub>), 130.5 (C-5 <sub>Phe</sub>), 132.5 (C-1<sub>Phe</sub>), 144.1 (C-3), 154.1 (C-3), 155.3 (C-7a), 156.0 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>18</sub>H<sub>21</sub>ClN<sub>5</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 422.1231, found: 422.1141.</div></div><div id="sec4_1_7_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> 3-(2,4-Dichlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>62</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 2,4-dichlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>62</b> (42 mg, 0.102 mmol, 29% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.37–3.48 (1H, m, H-5′), 3.52–3.63 (1H, m, H-5″), 3.92 (1H, dd, <i>J</i> = 10.0, 4.8 Hz, H-4′), 4.22 (1H, dd, <i>J</i> = 9.7, 5.0 Hz, H-3′), 4.61 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.14 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.41 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.16 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.52 (1H, d, <i>J</i> = 8.5 Hz, H-3<sub>Phe</sub>), 7.57 (1H, dd, <i>J</i> = 8.2, 2.1 Hz, H-5<sub>Phe</sub>), 7.79 (1H, d, <i>J</i> = 2.1 Hz, H-6<sub>Phe</sub>), 8.25 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.4 (C-5′), 70.9 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.6 (C-1′), 99.4 (C-3a), 127.8 (C-3<sub>Phe</sub>), 129.7 (C-6<sub>Phe</sub>), 130.3 (C-1<sub>Phe</sub>), 133.2 (C-2<sub>Phe</sub>), 133.9 (C-5<sub>Phe</sub>), 134.7 (C-4<sub>Phe</sub>), 141.2 (C-3), 154.7 (C-7a), 156.2 (C-6), 157.8 (C-4) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 412.0579, found: 412.0586.</div></div><div id="sec4_1_7_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> 3-(2-Methyl-4-chlorophenyl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>63</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 2-methyl-4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>63</b> (83 mg, 0.212 mmol, 61% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.18–2.37 (3H, m, CH<sub>3</sub>), 3.42 (1H, dd, <i>J</i> = 11.7, 5.9 Hz, H-5′), 3.58 (1H, dd, <i>J</i> = 11.7, 4.4 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 9.1, 4.7 Hz, H-4′), 4.23 (1H, t, <i>J</i> = 5.0 Hz, H-3′), 4.60 (1H, t, <i>J</i> = 4.5 Hz, H-2′), 6.19 (1H, d, <i>J</i> = 4.1 Hz, H-1′), 7.30–7.45 (2H, m, NH<sub>2,</sub> H<sub>Phe</sub>), 7.49 (1H, s, H<sub>Phe</sub>), 8.30 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 19.9 (CH<sub>3</sub>), 62.8 (C-5′), 71.4 (C-2′), 73.9 (C-3′), 85.6 (C-4′), 88.9 (C-1′), 99.4 (C-3a), 126.7 (C<sub>Phe</sub>), 131.0 (C<sub>Phe</sub>), 132.1 (C<sub>Phe</sub>), 134.1 (C<sub>Phe</sub>), 139.8 (C<sub>Phe</sub>), 143.8 (C-3), 155.0 (C-7a), 156.0 (C-6), 157.9 (C-4) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>19</sub>ClN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 392.1126, found: 392.1077.</div></div><div id="sec4_1_7_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> 3-(1-Methylpyrazol-4-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>64</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 1-methylpyrazole-4-boronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>64</b> (65 mg, 0.187 mmol, 53% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.45 (1H, dt, <i>J</i> = 11.2, 5.4 Hz, H-5′), 3.59 (1H, dt, <i>J</i> = 12.0, 4.2 Hz, H-5″), 3.80–4.02 (4H, m, CH<sub>3</sub>, H-4′), 4.24 (1H, dd, <i>J</i> = 9.7, 5.0 Hz, H-3′), 4.62 (1H, dd, <i>J</i> = 9.7, 5.1 Hz, H-2′), 4.86 (1H, t, <i>J</i> = 5.2 Hz, OH), 5.12 (1H, d, <i>J</i> = 5.3 Hz, OH), 5.38 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.13 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 6.67–7.46 (2H, m, NH<sub>2</sub>), 7.74 (1H, s, H-5<sub>pyrazole</sub>), 8.10 (1H, s, H-3<sub>pyrazole</sub>), 8.24 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.4 (C-5′), 70.9 (C-2′), 73.1 (C-3′), 85.2 (C-4′), 88.4 (C-1′), 98.1 (C-3a), 113.3 (C-4<sub>pyrazole</sub>), 130.4 (C-5<sub>pyrazole</sub>), 137.7 (C-3<sub>pyrazole</sub>), 155.0 (C-7a), 156.0 (C-6), 158.3 (C-4) ppm. 1 quaternary carbon (C-3) missing. HRMS (ESI): calcd for C<sub>14</sub>H<sub>18</sub>N<sub>7</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 348.1420, found: 348.1418.</div></div><div id="sec4_1_7_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> 3-(Pyridin-2-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine, Formic Acid Salt (<b>65</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.173 g, 0.50 mmol, 1.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.087 g, 0.075 mmol, 0.15 equiv), and CuI (0.010 g, 0.05 mmol, 0.1 equiv) were dissolved in dry degassed DMF (2 mL) under argon. 2-(Tributylstannyl)pyridine was added, and the mixture was warmed to 100 °C. After 2 h, LCMS analysis indicated completion of the reaction. The mixture was cooled to room temperature, diluted with MeOH (15 mL) and MeCN (15 mL), and washed with hexanes (2 × 15 mL). The MeOH/MeCN phase was concentrated <i>in vacuo</i>. The residue was adsorbed onto celite and purified by flash column chromatography (automated, 4 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) to afford <b>67</b> (80 mg, 0.232 mmol, 66% yield) as a white solid. NMR analysis showed the presence of an extra proton, indicating that <b>65</b> was isolated as its formic acid salt. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.43–3.58 (1H, m, H-5′), 3.60–3.74 (1H, m, H-5″), 3.97 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.27–4.41 (1H, m, H-3′), 4.60–4.74 (1H, m, H-2′), 4.88 (1H, br. s., OH), 5.17 (1H, br. s., OH), 5.47 (1H, br. s., OH), 6.21 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.51 (1H, ddd, <i>J</i> = 7.5, 5.1, 1.2 Hz, H-4<sub>pyr</sub>), 8.04 (1H, td, <i>J</i> = 7.8, 1.8 Hz, H-5<sub>pyr</sub>), 8.11 (1H, d, <i>J</i> = 3.2 Hz), 8.24 (1H, s, H-6), 8.28 (1H, d, <i>J</i> = 7.9 Hz, H-3<sub>pyr</sub>), 8.74 (1H, dd, <i>J</i> = 4.1, 0.9 Hz, H-6<sub>pyr</sub>), 9.93 (1H, d, <i>J</i> = 3.8 Hz, NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.4 (C-5′), 71.0 (C-2′), 73.4 (C-3′), 85.4 (C-4′), 88.6 (C-1′), 98.5 (C-3a), 121.0 (C-3<sub>pyr</sub>), 124.1 (C-5<sub>pyr</sub>), 138.3 (C-3), 143.7 (C-4<sub>pyr</sub>), 148.5 (C-6<sub>pyr</sub>), 150.7 (C-2<sub>pyr</sub>), 155.7 (C-7a), 156.6 (C-6), 158.8 (C-4)ppm. HRMS (ESI): calcd for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 345.1311, found: 345.1312.</div></div><div id="sec4_1_7_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> 3-(Pyridin-4-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>66</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using pyridine-4-boronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>66</b> (37 mg, 0.056 mmol, 16% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.39–3.55 (1H, m, H-5′), 3.55–3.70 (1H, m, H-5″), 3.94 (1H, dd, <i>J</i> = 9.7, 4.8 Hz, H-4′), 4.28 (1H, dd, <i>J</i> = 10.0, 5.2 Hz, H-3′), 4.66 (1H, dd, <i>J</i> = 9.7, 5.0 Hz, H-2′), 4.84 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.16 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.43 (1H, d, <i>J</i> = 5.6 Hz, OH), 6.21 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.18 (2H, br. s., NH<sub>2</sub>), 7.67 (2H, d, <i>J</i> = 5.9 Hz, H-3<sub>pyr</sub>, H-5<sub>pyr</sub>), 8.31 (1H, s, H-6), 8.74 (2H, d, <i>J</i> = 5.3 Hz, H-2<sub>pyr</sub>, H-6<sub>pyr</sub>) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.3 (C-5′), 70.8 (C-2′), 73.2 (C-3′), 85.3 (C-4′), 88.6 (C-1′), 97.9 (C-3a), 122.8 (C-3<sub>pyr</sub>, C-5<sub>pyr</sub>), 139.8 (C-3), 142.6 (C-4<sub>pyr</sub>), 150.3 (C-2<sub>pyr</sub>, C-6<sub>pyr</sub>), 155.6 (C-7a), 156.2 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>15</sub>H<sub>17</sub>N<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 345.1311, found: 345.1317.</div></div><div id="sec4_1_7_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 3-(Thiophen-2-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>67</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.173 g, 0.50 mmol, 1.0 equiv), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.087 g, 0.075 mmol, 0.15 equiv), and CuI (0.010 g, 0.05 mmol, 0.1 equiv) were dissolved in dry degassed DMF (2 mL) under argon. 2-(Tributylstannyl)thiophene (0.238 mL, 0.75 mmol, 1.5 equiv) was added, and the mixture was warmed to 100 °C. After 2 h, LCMS analysis indicated completion of the reaction. The mixture was cooled to room temperature, diluted with MeOH (15 mL) and MeCN (15 mL), and washed with hexanes (2 × 15 mL). The MeOH/MeCN phase was concentrated <i>in vacuo</i>. The residue was adsorbed onto celite and purified by flash column chromatography (automated, 4 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) to afford <b>67</b> (42 mg, 0.120 mmol, 24% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.46 (1H, dt, <i>J</i> = 11.4, 5.4 Hz, H-5′), 3.60 (1H, dt, <i>J</i> = 11.7, 3.8 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 10.0, 4.7 Hz, H-4′), 4.14–4.31 (1H, m, H-3′), 4.62 (1H, dd, <i>J</i> = 7.3, 3.2 Hz, H-2′), 4.84 (1H, t, <i>J</i> = 6.2 Hz, OH), 5.16 (1H, br. s., OH), 5.42 (1H, br. s., OH), 6.16 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 6.83–7.19 (2H, m, NH<sub>2</sub>), 7.25 (2H, dd, <i>J</i> = 5.0, 3.5 Hz, C-4<sub>Het</sub>), 7.50 (1H, dd, <i>J</i> = 3.7, 1.0 Hz, C-3<sub>Het</sub>), 7.72 (1H, dd, <i>J</i> = 5.1, 1.0 Hz, C-5<sub>Het</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.9 (C-5′), 71.3 (C-2′), 73.6 (C-3′), 85.8 (C-4′), 88.9 (C-1′), 98.1 (C-3a), 128.3 (C-3<sub>Het</sub>), 128.5(C-4<sub>Het</sub>), 128.9 (C-5<sub>Het</sub>), 134.3 (C-2<sub>Het</sub>), 139.4 (C-3), 155.7 (C-7a), 156.6 (C-6), 158.6 (C-4) ppm. HRMS (ESI): calcd for C<sub>14</sub>H<sub>16</sub>N<sub>5</sub>O<sub>4</sub>S ([M + H]<sup>+</sup>): 350.0923, found: 350.0932.</div></div><div id="sec4_1_7_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> 3-(5-Methylthiophen-2-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>68</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 5-methylthiophene-2-boronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>64</b> (65 mg, 0.187 mmol, 53% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.34 (3H, s, CH<sub>3</sub>), 3.44 (1H, dt, <i>J</i> = 11.9, 6.1 Hz, H-5′), 3.59 (1H, dt, <i>J</i> = 11.4, 4.7 Hz, H-5″), 3.91 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.23 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-3′), 4.58 (1H, dd, <i>J</i> = 9.7, 5.0 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.13 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.40 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.13 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 6.82–6.97 (1H, m, C-4<sub>Het</sub>), 6.99–7.21 (2H, m, NH<sub>2</sub>), 7.27 (1H, d, <i>J</i> = 3.5 Hz, C-3<sub>Het</sub>), 8.25 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.9 (CH<sub>3</sub>), 62.5 (C-5′), 70.9 (C-2′), 73.2 (C-3′), 85.3 (C-4′), 88.4 (C-1′), 97.5 (C-3a), 126.8 (C-4<sub>Het</sub>), 128.0 (C-5<sub>Het</sub>), 131.5 (C-3<sub>Het</sub>), 139.1 (C-2<sub>Het</sub>), 141.3 (C-3), 155.2 (C-7a), 156.2 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>15</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub>S ([M + H]<sup>+</sup>): 364.1079, found: 364.1088.</div></div><div id="sec4_1_7_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> 3-(5-Chlorothiophen-2-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>69</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 5-chlorothiophene-2-boronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 40:60 in 12 min) afforded <b>69</b> (55 mg, 0.143 mmol, 41% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.36–3.51 (1H, m, H-5′), 3.59 (1H, dt, <i>J</i> = 11.6, 5.0 Hz, H-5″), 3.92 (1H, dd, <i>J</i> = 10.3, 5.1 Hz, H-4′), 4.23 (1H, dd, <i>J</i> = 10.0, 5.1 Hz, H-3′), 4.60 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.8 Hz, OH), 5.15 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.42 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.15 (1H, d, <i>J</i> = 4.5 Hz, H-1′), 7.25 (2H, d, <i>J</i> = 4.0 Hz, H-4<sub>Het</sub>), 7.35 (1H, d, <i>J</i> = 3.9 Hz, H-3<sub>Het</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.3 (C-5′), 70.9 (C-2′), 73.2 (C-3′), 85.3 (C-4′), 88.4 (C-1′), 97.5 (C-3a), 128.0 (C-3<sub>Het</sub>), 128.2 (C-5<sub>Het</sub>), 129.3 (C-4<sub>Het</sub>), 132.8 (C-2<sub>Het</sub>), 138.1 (C-3), 155.3 (C-7a), 156.3 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>14</sub>H<sub>15</sub>ClN<sub>5</sub>O<sub>4</sub>S ([M + H]<sup>+</sup>): 384.0533, found: 384.0550.</div></div><div id="sec4_1_7_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> 3-(4-Methylthiophen-2-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>70</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to general procedure E, using 4-methylthiophene-2-boronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 40:60 in 12 min) afforded <b>70</b> (38 mg, 0.105 mmol, 30% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.29 (3H, d, <i>J</i> = 0.5 Hz, CH<sub>3</sub>), 3.40–3.50 (1H, m, H-5′), 3.59 (1H, dt, <i>J</i> = 11.9, 4.8 Hz, H-5″), 3.92 (1H, dd, <i>J</i> = 10.1, 4.9 Hz, H-4′), 4.24 (1H, dd, <i>J</i> = 10.3, 5.0 Hz, H-3′), 4.61 (1H, dd, <i>J</i> = 9.9, 5.1 Hz, H-2′), 4.83 (1H, t, <i>J</i> = 5.8 Hz, OH), 5.15 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.41 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.15 (1H, d, <i>J</i> = 4.5 Hz, H-1′), 7.28 (1H, t, <i>J</i> = 1.1 Hz, H-3<sub>Het</sub>), 7.30 (1H, d, <i>J</i> = 1.1 Hz, H-5<sub>Het</sub>), 8.27 (1H, s) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.5 (CH<sub>3</sub>), 62.4 (C-5′), 70.9 (C-2′), 73.1 (C-3′), 85.3 (C-4′), 88.4 (C-1′), 97.5 (C-3a), 122.8 (C-5<sub>Het</sub>), 130.0 (C-3<sub>Het</sub>), 133.5 (C-4<sub>Het</sub>), 138.5 (C-3), 139.1 (C-2<sub>Het</sub>), 155.2 (C-7a), 156.2 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>15</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub>S ([M + H]<sup>+</sup>): 364.1079, found: 364.1081.</div></div><div id="sec4_1_7_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> 3-Vinyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>71</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.118 g, 0.34 mmol) was subjected to general procedure E, using potassium vinyl trifluoroborate as the coupling partner and Cs<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>71</b> (60 mg, 0.205 mmol, 58% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.41–3.50 (1H, m, H-5′), 3.60 (1H, dt, <i>J</i> = 11.6, 4.8 Hz, H-5″), 3.92 (1H, dd, <i>J</i> = 9.4, 4.8 Hz, H-4′), 4.24 (1H, dd, <i>J</i> = 9.9, 5.5 Hz, h-3′), 4.57 (1H, dd, <i>J</i> = 10.1, 5.0 Hz, H-2′), 4.87 (1H, t, <i>J</i> = 5.8 Hz, OH), 5.12 (1H, d, <i>J</i> = 5.4 Hz, OH), 5.36 (1H, d, <i>J</i> = 5.9 Hz, OH), 5.46 (1H, dd, <i>J</i> = 11.8, 1.0 Hz, CH═C<u class="uu">H</u><sub><u class="uu">2</u></sub>), 6.05 (1H, dd, <i>J</i> = 17.1, 1.0 Hz, CH═C<u class="uu">H</u><sub><u class="uu">2</u></sub>), 6.12 (1H, d, <i>J</i> = 4.3 Hz, H-1′), 7.28 (1H, dd, <i>J</i> = 17.1, 11.0 Hz, C<u class="uu">H</u>═CH<sub>2</sub>), 7.54 (2H, br. s, NH<sub>2</sub>), 8.18 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.4 (C-5′), 70.9 (C-2′), 73.2 (C-3′), 85.3 (C-4′), 88.5 (C-1′), 98.1 (C-3a), 118.5 (CH═<u class="uu">C</u>H<sub>2</sub>), 127.3 (C<u class="uu">H</u>═CH<sub>2</sub>), 141.9 (C-3), 155.0 (C-7a), 155.9 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>12</sub>H<sub>16</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 294.1202, found: 294.1213.</div></div><div id="sec4_1_7_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> 3-Isopropenyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>72</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.250 g, 0.72 mmol) was subjected to general procedure E, using potassium isopropenyltrifluoroborate as the coupling partner and Cs<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>72</b> (170 mg, 0.553 mmol, 77% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.18 (3H, s, C<u class="uu">H</u><sub><u class="uu">3</u></sub>C═CH<sub>2</sub>), 3.45 (1H, dt, <i>J</i> = 11.6, 5.9 Hz, H-5′), 3.55–3.65 (1H, m, H-5″), 3.92 (1H, dd, <i>J</i> = 9.7, 4.4 Hz, H-4′), 4.23 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-3′), 4.59 (1H, dd, <i>J</i> = 9.4, 5.0 Hz, H-2′), 4.84 (1H, t, <i>J</i> = 5.6 Hz, OH), 5.12 (1H, d, <i>J</i> = 5.3 Hz, OH), 5.29–5.45 (2H, m, OH, CH<sub>3</sub>C═C<u class="uu">H</u><sub>2</sub>), 5.53 (1H, br. s., CH<sub>3</sub>C═C<u class="uu">H</u><sub>2</sub>), 6.13 (1H, d, <i>J</i> = 4.1 Hz, H-1′), 7.16 (2H, br. s., NH<sub>2</sub>), 8.23 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 21.7 (<u class="uu">C</u>H<sub>3</sub>C═CH<sub>2</sub>), 62.4 (C-5′), 70.9 (C-2′), 73.2 (C-3′), 85.2 (C-4′), 88.5 (C-1′), 97.3 (C-3a), 118.6 (CH<sub>3</sub>C═<u class="uu">C</u>H<sub>2</sub>), 137.2 (CH<sub>3</sub><u class="uu">C</u>═CH<sub>2</sub>), 146.2 (C-3), 154.9 (C-7a), 155.9 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>13</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 308.1359, found: 308.1367.</div></div><div id="sec4_1_7_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> 3-(<i>E</i>-Styryl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>73</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to a slightly modified general procedure E, using <i>trans</i>-2-vinylphenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>72</b> (55 mg, 0.149 mmol, 43% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.48 (1H, dd, <i>J</i> = 11.7, 5.9 Hz, H-5′), 3.62 (1H, dd, <i>J</i> = 11.7, 4.4 Hz, H-5″), 3.92 (1H, dd, <i>J</i> = 10.0, 4.7 Hz, H-4′), 4.26 (1H, t, <i>J</i> = 4.7 Hz, H-3′), 4.65 (1H, t, <i>J</i> = 5.0 Hz, H-2′), 6.12 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.26–7.49 (4H, m, H<sub>Phe</sub>), 7.53–7.71 (3H, m, NH<sub>2</sub>, H<sub>Phe</sub>), 7.74–7.83 (2H, m, 2 × H<sub>viny</sub>l), 8.18 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.4 (C-5′), 70.9 (C-2′), 73.1 (C-3′), 85.3 (C-4′), 88.6 (C-1′), 98.5 (C-3a), 118.0 (C<sub>vinyl</sub>), 127.4 (C<sub>Phe</sub>), 128.0 (C<sub>Phe</sub>), 128.3 (C<sub>Phe</sub>), 128.6 (C<sub>Phe</sub>), 132.2 (C<sub>vinyl</sub>), 141.8 (C-3), 155.1 (C-7a), 155.9 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>18</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 370.1515, found: 370.1509.</div></div><div id="sec4_1_7_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> 3-Cyclopropyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>74</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.120 g, 0.35 mmol) was subjected to a slightly modified general procedure E, using cyclopropylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. After 8 h, a second portion of cyclopropylboronic acid (1.5 equiv) was added, and the reaction was stirred for another 16 h, before LCMS analysis indicated full conversion. Purification <i>via</i> flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>74</b> (72 mg, 0.234 mmol, 67% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 0.77–1.07 (4H, m, 2 × CH<sub>2 cyclopropyl</sub>), 2.39–2.48 (1H, m, CH<sub>cyclopropyl</sub>), 3.40 (1H, dt, <i>J</i> = 12.0, 6.0 Hz, H-5′), 3.57 (1H, dt, <i>J</i> = 11.7, 4.7 Hz, H-5″), 3.87 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.20 (1H, dd, <i>J</i> = 10.0, 5.2 Hz, H-3′), 4.49 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-2′), 4.81 (1H, dd, <i>J</i> = 6.6, 5.1 Hz, OH), 5.06 (1H, d, <i>J</i> = 5.9 Hz, OH), 5.30 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.01 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.41 (2H, br. s., NH<sub>2</sub>), 8.15 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.7 (C<sub>cyclopropyl</sub>), 7.9 (C<sub>cyclopropyl</sub>), 8.5 (C<sub>cyclopropyl</sub>), 62.4 (C-5′), 71.0 (C-2′), 73.2 (C-3′), 85.0 (C-4′), 88.4 (C-1′), 99.5 (C-3a), 147.0 (C-3), 154.9 (C-7a), 155.9 (C-6), 158.3 (C-4) ppm. HRMS (ESI): calcd for C<sub>13</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 308.1359, found: 308.1342.</div></div><div id="sec4_1_7_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> 3-(4-Chlorophenyl)-4-amino-1-(3′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>76</b>)</h5><div class="NLM_p last">Compound <b>23</b> (0.026 g, 0.079 mmol) was subjected to general procedure E, using 4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 0 → 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> + 1% NH<sub>4</sub>OH) afforded <b>76</b> (23 mg, 0.064 mmol, 81% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.00 (1H, ddd, <i>J</i> = 12.3, 6.2, 1.6 Hz, H-3′), 2.28–2.46 (1H, m, H-3″), 3.39–3.58 (2H, m, H-5′, H-5″), 4.29–4.41 (1H, m, H-2′), 4.62 (1H, br. s., H-4′), 4.75 (1H, t, <i>J</i> = 5.7 Hz, OH), 5.59 (1H, d, <i>J</i> = 3.8 Hz, OH), 6.24 (1H, s, H-1′), 7.61 (2H, d, <i>J</i> = 8.4 Hz, H<sub>Phe</sub>), 7.67 (2H, d, <i>J</i> = 8.4 Hz, H<sub>Phe</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 36.1 (C-3′), 64.1 (C-5′), 74.5 (C-2′), 81.2 (C-4′), 90.6 (C-1′), 97.5 (C-3a), 129.2 (C<sub>Phe</sub>), 130.0 (C<sub>Phe</sub>), 131.5 (C<sub>Phe</sub>), 133.6 (C<sub>Phe</sub>), 143.7 (C-3), 155.0 (C-7a), 156.1 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>17</sub>ClN<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 362.1020, found: 362.0999.</div></div><div id="sec4_1_7_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 3-(4-Chlorophenyl)-4-amino-1-(2′-deoxy-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>77</b>)</h5><div class="NLM_p last">Compound <b>23</b> (0.042 g, 0.127 mmol) was subjected to general procedure E, using 4-chlorophenylboronic acid as the coupling partner and Na<sub>2</sub>CO<sub>3</sub> as the base. Purification <i>via</i> flash column chromatography (automated, 1 → 8% MeOH in CH<sub>2</sub>Cl<sub>2</sub> + 1% NH<sub>4</sub>OH) afforded <b>76</b> (28 mg, 0.098 mmol, 81% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.29 (1H, ddd, <i>J</i> = 13.2, 6.8, 4.3 Hz, H-2′), 2.85 (1H, dt, <i>J</i> = 12.9, 6.0 Hz, H-2″), 3.40 (1H, dt, <i>J</i> = 11.7, 6.0 Hz, H-5′), 3.55 (1H, dt, <i>J</i> = 11.4, 5.5 Hz, H-5″), 3.84 (1H, td, <i>J</i> = 5.4, 3.6 Hz, H-4′), 4.42–4.51 (1H, m, H-3′), 4.77 (1H, t, <i>J</i> = 5.8 Hz, OH), 5.27 (1H, d, <i>J</i> = 4.6 Hz, OH), 6.64 (1H, t, <i>J</i> = 6.4 Hz, H-1′), 7.58–7.64 (2H, m, H<sub>Phe</sub>), 7.65–7.72 (2H, m, H<sub>Phe</sub>), 8.27 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 38.0 (C-2′), 62.4 (C-5′), 71.1 (C-3′), 83.9 (C-4′), 87.7 (C-1′), 97.8 (C-3a), 129.2 (C<sub>Phe</sub>), 130.0 (C<sub>Phe</sub>), 131.5 (C<sub>Phe</sub>), 133.6 (C<sub>Phe</sub>), 143.6 (C-3), 155.0 (C-7a), 156.0 (C-6), 158.1 (C-4) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>17</sub>ClN<sub>5</sub>O<sub>3</sub> ([M + H]<sup>+</sup>): 362.1020, found: 362.1004.</div></div><div id="sec4_1_7_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> 3-Isopropyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>78</b>)</h5><div class="NLM_p last">Compound <b>72</b> (0.060 g, 0.195 mmol) was dissolved in MeOH (5 mL). The flask was placed under a nitrogen atmosphere, and a catalytic amount of Pd(OH)<sub>2</sub>/C was added. The atmosphere was exchanged for H<sub>2</sub>, and the mixture was stirred for 1 h until TLC analysis (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) indicated completion of the reaction. The mixture was filtered over celite, celite was added to the filtrate, and the solvents were removed under reduced pressure. The solid residue was purified <i>via</i> flash column chromatography (automated, 4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>78</b> (49 mg, 0.158 mmol, 81% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.26 (6H, d, <i>J</i> = 6.7 Hz, CH(C<u class="uu">H</u><sub><u class="uu">3</u></sub><u class="uu">)</u><sub><u class="uu">2</u></sub>), 3.38–3.65 (3H, m, H-5′, H-5″, C<u class="uu">H</u>(CH<sub>3</sub>)<sub>2</sub>), 3.90 (1H, dd, <i>J</i> = 9.4, 4.7 Hz, H-4′), 4.25 (1H, dd, <i>J</i> = 10.3, 5.0 Hz, H-3′), 4.56 (1H, dd, <i>J</i> = 10.0, 5.3 Hz, H-2′), 4.85 (1H, dd, <i>J</i> = 6.7, 5.0 Hz, OH), 5.07 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.32 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.06 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.30 (2H, br. s, NH<sub>2</sub>), 8.15 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 22.3 (CH(<u class="uu">C</u>H<sub>3</sub>)<sub>2</sub>), 27.4 (<u class="uu">C</u>H(CH<sub>3</sub>)<sub>2</sub>), 63.0 (C-5′), 71.5 (C-2′), 73.7 (C-3′), 85.6 (C-4′), 89.1 (C-1′), 98.6 (C-3a), 151.6 (C-3), 155.5 (C-7a), 156.2 (C-6), 158.5 (C-4) ppm. HRMS (ESI): calcd for C<sub>13</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 310.1515, found: 310.1494.</div></div><div id="sec4_1_7_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> 3-<i>O</i>-Phenyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>79</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.220 g, 0.64 mmol, 1.0 equiv), phenol (0.090 g, 0.96 mmol, 1.5 equiv), CuI (0.024 g, 0.13 mmol, 0.2 equiv), <i>N</i>,<i>N</i>-dimethylglycine (0.040 g, 0.38 mmol, 0.6 equiv), and Cs<sub>2</sub>CO<sub>3</sub> (0.417 g, 1.28 mmol, 2.0 equiv) were dissolved in dry degassed DMA (4 mL) under argon. The reaction was heated at 120 °C overnight, cooled down to room temperature, and concentrated <i>in vacuo</i>. The residue was taken up in MeOH, celite was added, and the mixture was concentrated under reduced pressure. The solid residue was purified by flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>79</b> (12 mg, 0.033 mmol, 5% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.34–3.42 (1H, m, H-5′, underwater peak), 3.48 (1H, dd, <i>J</i> = 12.0, 4.4 Hz, H-5″), 3.84 (1H, dd, <i>J</i> = 10.3, 4.7 Hz, H-4′), 4.07 (1H, t, <i>J</i> = 4.8 Hz, H-3′), 4.43 (1H, t, <i>J</i> = 4.7 Hz, H-2′), 6.02 (1H, d, <i>J</i> = 4.1 Hz, H-1′), 7.14–7.26 (1H, m, H<sub>Phe</sub>), 7.33–7.49 (4H, m, H<sub>Phe</sub>), 8.22 (1H, br. s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 62.3 (C-5′), 70.7 (C-2′), 73.1 (C-3′), 84.9 (C-4′), 88.1 (C-1′), 119.1 (C<sub>Phe</sub>), 124.5 (C<sub>Phe</sub>), 129.6 (C<sub>Phe</sub>), 152.8 (C<sub>Phe</sub>), 154.7 (C-7a), 155.0 (C-6), 157.4 (C-4), 157.4 (C-3) ppm. Two quaternary carbons missing (C-3, C-3a). HRMS (ESI): calcd for C<sub>16</sub>H<sub>18</sub>N<sub>5</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 360.1308, found: 360.1308.</div></div><div id="sec4_1_7_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> 3-<i>O</i>-(4-Chlorophenyl)-4-amino1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>80</b>)</h5><div class="NLM_p last">Compound <b>21</b> (0.220 g, 0.64 mmol, 1.0 equiv), 4-chlorophenol (0.123 g, 0.96 mmol, 1.5 equiv), CuI (0.024 g, 0.13 mmol, 0.2 equiv), <i>N</i>,<i>N</i>-dimethylglycine (0.040 g, 0.38 mmol, 0.6 equiv), and Cs<sub>2</sub>CO<sub>3</sub> (0.417 g, 1.28 mmol, 2.0 equiv) were dissolved in dry degassed DMA (4 mL) under argon. The reaction was heated at 120 °C overnight, cooled down to room temperature, and concentrated <i>in vacuo</i>. The residue was taken up in MeOH, celite was added, and the mixture was concentrated under reduced pressure. The solid residue was purified by flash column chromatography (automated, 2 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification <i>via</i> preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) to afford <b>80</b> (8 mg, 0.020 mmol, 3% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.34–3.42 (1H, m, H-5′), 3.46–3.54 (1H, m, H-5″.), 3.84 (1H, dd, <i>J</i> = 10.0, 5.3 Hz, H-4′), 4.02–4.16 (1H, m, H-3′), 4.31–4.52 (1H, m, H-2′), 4.64–4.75 (1H, m, OH), 4.96–5.18 (1H, m, OH), 5.26–5.50 (1H, m, OH), 6.02 (1H, d, <i>J</i> = 4.1 Hz, H-1′), 7.48 (4H, s, H<sub>Phe</sub>), 8.21 (1H, s, H<sub>Phe</sub>) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.1 (C-5′), 70.6 (C-2′), 73.0 (C-3′), 84.8 (C-4′), 88.0 (C-1′), 89.8 (C-3a), 120.9 (C<sub>Phe</sub>), 128.2 (<sub>CPhe</sub>), 129.3 (C<sub>Phe</sub>), 152.3 (C<sub>Phe</sub>), 153.4 (C-7a), 154.9 (C-6), 157.3 (C-4), 157.4 (C-3) ppm. HRMS (ESI): calcd for C<sub>16</sub>H<sub>17</sub>ClN<sub>5</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 394.0918, found: 394.0927.</div></div><div id="sec4_1_7_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> 3,4-Diamino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> (<b>81</b>)</h5><div class="NLM_p last">A mixture of <b>21</b> (145 mg, 0.42 mmol, 1.0 equiv), CuCl (0.006 g, 0.042 mmol, 0.1 equiv), and aq. NH<sub>4</sub>OH (20–30% wt, 30 mL) was heated in a pressure reactor at 130 °C overnight. The vessel was cooled to room temperature, and the contents were diluted with MeOH and transferred to a pear-shaped flask. Celite was added, and the mixture was concentrated <i>in vacuo</i> slowly (NH<sub>3</sub> evolution!). The solid residue was purified by flash column chromatography (4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 40:60 in 12 min) to afford <b>81</b> (23 mg, 0.082 mmol, 19% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.32–3.45 (1H, m, H-5′), 3.54 (1H, dd, <i>J</i> = 11.7, 4.1 Hz, H-5″), 3.81 (1H, dd, <i>J</i> = 9.4, 4.4 Hz, H-4′), 4.11 (1H, t, <i>J</i> = 4.8 Hz, H-3′), 4.44 (1H, t, <i>J</i> = 5.0 Hz, H-2′), 4.82 (1H, br. s, OH), 5.03 (1H, br. s, OH), 5.23 (1H, br. s, OH), 5.84 (2H, br. s, NH<sub>2</sub>), 5.93 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.29 (2H, br. s., NH<sub>2</sub>), 8.02 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.7 (C-5′), 71.0 (C-2′), 72.6 (C-3′), 84.5 (C-4′), 87.4 (C-1′), 90.6 (C-3a), 148.1 (C-3), 155.0 (C-7a), 156.1 (C-6), 157.8 (C-4) ppm. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> HRMS (ESI): calcd for C<sub>10</sub>H<sub>15</sub>N<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 283.1155, found: 283.1179.</div></div><div id="sec4_1_7_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> 3-<i>N</i>-Methylamino-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>82</b>)</h5><div class="NLM_p last">A mixture of <b>21</b> (150 mg, 0.43 mmol, 1.0 equiv), CuCl (0.006 g, 0.043 mmol, 0.1 equiv), and aqueous methylamine (40%, 30 mL) was heated in a pressure reactor at 130 °C over the weekend. The vessel was cooled to room temperature, and the contents were diluted with MeOH and transferred to a pear-shaped flask. Celite was added, and the mixture was concentrated <i>in vacuo</i> slowly (NHMe evolution!). The solid residue was purified by flash column chromatography (4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) to afford <b>82</b> (6 mg, 0.020 mmol, 5% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, D<sub>2</sub>O) δ 2.85 (3H, s, CH<sub>3</sub>), 3.76 (1H, dd, <i>J</i> = 12.6, 4.1 Hz, H-5′), 3.82–3.92 (1H, m, H-5″), 4.17 (1H, dd, <i>J</i> = 7.0, 3.8 Hz, H-4′), 4.45 (1H, dd, <i>J</i> = 5.0, 3.8 Hz, H-3′), 4.71–4.80 (1H, m, H-2′, partially underwater peak), 6.07 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 8.04 (1H, s, H-6) ppm. A qualitative <sup>13</sup>C NMR spectrum could not be obtained from the amount of product available. HRMS (ESI): calcd for C<sub>11</sub>H<sub>17</sub>N<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 297.1311, found: 297.1318.</div></div><div id="sec4_1_7_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> 3-(1-Pyrrolidin-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>83</b>)</h5><div class="NLM_p last">A mixture of <b>21</b> (150 mg, 0.43 mmol, 1.0 equiv), CuCl (0.006 g, 0.043 mmol, 0.1 equiv), pyrrolidine (0.706 mL, 8.60 mmol, 20.0 equiv) in 1,4-dioxane (1.5 mL) and H<sub>2</sub>O (3 mL) was heated in at 120 °C over the weekend. The mixture was cooled to room temperature and diluted with MeOH. Celite was added, and the mixture was concentrated <i>in vacuo</i>. The solid residue was purified by flash column chromatography (4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) to afford <b>83</b> (23 mg, 0.068 mmol, 16% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.83–1.96 (4H, m, 2 × CH<sub>2 pyrrolidine</sub>), 3.29–3.40 (4H, m, 2 × CH<sub>2 pyrrolidine</sub>), 3.45 (1H, dd, <i>J</i> = 11.7, 5.6 Hz, H-5′), 3.59 (1H, dd, <i>J</i> = 11.7, 4.1 Hz, H-5″), 3.87 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.21 (1H, t, <i>J</i> = 4.8 Hz, H-3′), 4.50 (1H, t, <i>J</i> = 4.5 Hz, H-2′), 4.81 (1H, br. s, OH), 5.02 (1H, br. s, OH), 5.28 (1H, br. s, OH), 6.02 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 6.98 (2H, br. s, NH<sub>2</sub>), 8.09 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 24.7 (2 × C<sub>pyrrolidine</sub>), 50.3 (2 × C<sub>pyrrolidine</sub>), 62.6 (C-5′), 71.1 (C-2′), 73.1 (C-3′), 84.9 (C-4′), 87.9 (C-1′), 92.1 (C-3a), 150.7 (C-3), 155.4 (C-7a), 155.8 (C-6), 157.8 (C-4) ppm. HRMS (ESI): calcd for C<sub>14</sub>H<sub>21</sub>N<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 337.1624, found: 337.1630.</div></div><div id="sec4_1_7_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> 3-Chloro-4-amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>84</b>)</h5><div class="NLM_p last">Compound <b>18</b> (0.223 g, 0.339 mmol, 1.0 equiv), Cu<sub>2</sub>O (0.012 g, 0.085 mmol, 0.25 equiv), Me<sub>4</sub>NCl (0.111 g, 1.02 mmol, 3.0 equiv), and <span class="smallcaps smallerCapital">l</span>-proline (0.020 g, 0.17 mmol, 0.5 equiv) were suspended in dry degassed 2-methoxy-ethanol (2 mL) under argon. The mixture was heated at 120 °C for 7 days until LCMS analysis indicated ∼80% conversion and further progression had ceased. The mixture was cooled to room temperature and concentrated <i>in vacuo</i>. The residue was used crude in the next reaction. HRMS (ESI): calcd for C<sub>31</sub>H<sub>25</sub>ClN<sub>5</sub>O<sub>7</sub> ([M + H]<sup>+</sup>): 614.1443, found: 614.2593.</div></div><div id="sec4_1_7_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> 3-Chloro-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>85</b>)</h5><div class="NLM_p last">The crude <b>84</b> from the previous reaction was subjected to general procedure C (reaction time: 1 h). Flash column chromatography (automated, 4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by an additional purification <i>via</i> preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 88:12 in 4 min, then to 77:23 in 5 min, and then to 33:67 in 3 min) afforded <b>85</b> (35 mg, 0.116 mmol, 34% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.42 (1H, dt, <i>J</i> = 12.0, 5.9 Hz, H-5′), 3.55 (1H, dt, <i>J</i> = 11.7, 5.0 Hz, H-5″), 3.89 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.16 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-3′), 4.54 (1H, dd, <i>J</i> = 10.5, 5.3 Hz, H-2′), 4.80 (1H, t, <i>J</i> = 5.7 Hz, OH), 5.16 (1H, d, <i>J</i> = 5.3 Hz, OH), 5.40 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.05 (1H, d, <i>J</i> = 4.7 Hz, OH), 7.23 (1H, br. s, NH), 8.03 (1H, s, NH), 8.24 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.2 (C-5′), 70.6 (C-2′), 72.9 (C-3′), 85.2 (C-4′), 88.0 (C-1′), 97.5 (C-3a), 132.0 (C-3), 155.1 (C-7a), 157.2 (C-6), 157.3 (C-4) ppm. HRMS (ESI): calcd for C<sub>10</sub>H<sub>13</sub>ClN<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 302.0656, found: 302.0652.</div></div><div id="sec4_1_7_73" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> 3-Phenylethynyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>86</b>)</h5><div class="NLM_p last">Compound <b>36</b> (0.250 g, 0.636 mmol, 1.0 equiv), PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> (0.022 g, 0.032 mmol, 0.05 equiv), and CuI (0.012 g, 0.1 equiv) were added to a 10 mL round-bottom flask. The flask was evacuated and backfilled with argon three times. Then, anhydrous, degassed DMF (2 mL), Et<sub>3</sub>N (0.5 mL), and phenylacetylene (0.105 mL, 0.96 mmol, 1.5 equiv) were added. The resulting solution was stirred at room temperature for 3 h until LCMS analysis indicated completion of the reaction. The mixture was concentrated <i>in vacuo</i>, and the residue was taken up in MeOH, adsorbed onto celite, and purified <i>via</i> flash column chromatography (automated, 2 → 12% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>86</b> (93 mg, 0.253 mmol, 40% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.46 (1H, dt, <i>J</i> = 11.8, 6.0 Hz, H-5′), 3.59 (1H, dt, <i>J</i> = 11.9, 4.9 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.21 (1H, dd, <i>J</i> = 9.4, 5.0 Hz, H-3′), 4.63 (1H, dd, <i>J</i> = 10.8, 5.0 Hz, H-2′), 4.86 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.18 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.43 (1H, d, <i>J</i> = 6.2 Hz, OH), 6.13 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 7.27–7.55 (3H, m, H<sub>Phe</sub>), 7.67–7.84 (2H, m, H<sub>Phe</sub>), 8.28 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.7 (C-5′), 71.2 (C-2′), 73.5 (C-3′), 81.1 (C<sub>ethynyl</sub>), 85.8 (C-4′), 88.9 (C-1′), 94.1 (C<sub>ethynyl</sub>), 101.2 (C-3a), 121.5 (C-3), 127.3 (C<sub>Phe</sub>), 129.1 (C<sub>Phe</sub>), 130.1 (C<sub>Phe</sub>), 132.4 (C<sub>Phe</sub>), 154.7 (C-7a), 157.2 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>18</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 368.1359, found: 368.1355.</div></div><div id="sec4_1_7_74" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> 3-Phenylethyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>87</b>)</h5><div class="NLM_p">Compound <b>86</b> (0.051 g, 0.139 mmol) was dissolved in MeOH (5 mL). The flask was placed under a nitrogen atmosphere, and a catalytic amount of Pd(OH)<sub>2</sub>/C was added. The atmosphere was exchanged for H<sub>2</sub> and the mixture was stirred for 1 h until TLC analysis (20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) indicated completion of the reaction. The mixture was filtered over celite, celite was added to the filtrate, and the solvents were removed under reduced pressure. The solid residue was purified <i>via</i> flash column chromatography (automated, 2 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>87</b> (46 mg, 0.124 mmol, 89% yield) as a white solid.</div><div class="NLM_p last"><sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.02 (2H, dd, <i>J</i> = 8.6, 7.0 Hz, CH<sub>2</sub>), 3.28 (2H, dd, <i>J</i> = 9.2, 7.0 Hz, CH<sub>2</sub>), 3.42 (1H, dt, <i>J</i> = 12.2, 6.3 Hz, H-5′), 3.58 (1H, dt, <i>J</i> = 11.7, 4.7 Hz, H-5″), 3.89 (1H, dd, <i>J</i> = 10.3, 4.6 Hz, H-4′), 4.22 (1H, dd, <i>J</i> = 10.5, 5.0 Hz, H-3′), 4.54 (1H, dd, <i>J</i> = 10.3, 5.0 Hz, H-2′), 4.83 (1H, dd, <i>J</i> = 6.4, 5.3 Hz, OH), 5.08 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.31 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.06 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 7.15–7.32 (5H, m, H<sub>Phe</sub>), 8.16 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 29.4 (CH<sub>2</sub>), 33.4 (CH<sub>2</sub>), 62.6 (C-5′), 71.0 (C-2′), 73.2 (C-3′), 85.0 (C-4′), 88.3 (C-1′), 98.8 (C-3a), 125.8 (C<sub>Phe</sub>), 128.1 (C<sub>Phe</sub>), 128.5 (C<sub>Phe</sub>), 141.1 (C<sub>Phe</sub>), 145.2 (C-3), 155.0 (C-7a), 155.8 (C-6), 158.3 (C-4) ppm. HRMS (ESI): calcd for C<sub>18</sub>H<sub>22</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 372.1672, found: 372.1684.</div></div><div id="sec4_1_7_75" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> 3-Ethynyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>88</b>)</h5><div class="NLM_p last">Compound <b>36</b> (0.250 g, 0.636 mmol, 1.0 equiv), PdCl<sub>2</sub>(PPh)<sub>3</sub> (0.022 g, 0.032 mmol, 0.05 equiv), and CuI (0.012 g, 0.1 equiv) were added to a 10 mL round-bottom flask. The flask was evacuated and backfilled with argon three times. Then, anhydrous, degassed DMF (2 mL), Et<sub>3</sub>N (0.5 mL), and ethynyltrimethylsilane (0.881 mL, 6.36 mmol, 10 equiv) were added. The resulting solution was stirred at room temperature for 3 h until LCMS analysis indicated completion of the reaction. The mixture was concentrated <i>in vacuo</i>, and the residue was taken up in MeOH, adsorbed onto celite, and purified <i>via</i> flash column chromatography (automated, 2 → 12% MeOH in CH<sub>2</sub>Cl<sub>2</sub>). The intermediate TMS-ethynyl nucleoside was stirred overnight in 7 N NH<sub>3</sub> in MeOH (10 mL). The mixture was concentrated <i>in vacuo</i>, and the residue was purified again by flash column chromatography (automated, 2 → 12% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>88</b> (35 mg, 0.120 mmol, 19% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.43 (1H, dt, <i>J</i> = 11.7, 6.0 Hz, H-5′), 3.57 (1H, dt, <i>J</i> = 11.7, 5.0 Hz, H-5″), 3.91 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.19 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-3′), 4.57 (1H, dd, <i>J</i> = 10.7, 5.2 Hz, H-2′), 4.70 (1H, s, H<sub>ethynyl</sub>), 4.83 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.16 (1H, d, <i>J</i> = 5.3 Hz, OH), 5.41 (1H, d, <i>J</i> = 6.2 Hz, OH), 6.09 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 6.79 (2H, br. s, NH<sub>2</sub>), 8.25 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.2 (C-5′), 70.7 (C-2′), 73.0 (C-3′), 74.9 (C<sub>ethynyl</sub>), 85.4 (C-4′), 86.7 (C<sub>ethynyl</sub>), 88.4 (C-1′), 101.1 (C-3a), 126.3 (C-3), 154.0 (C-7a), 156.8 (C-6), 157.7 (C-4) ppm. HRMS (ESI): calcd for C<sub>12</sub>H<sub>14</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 292.1046, found: 292.1049.</div></div><div id="sec4_1_7_76" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> 3-Ethyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>89</b>)</h5><div class="NLM_p last">Compound <b>88</b> (47 mg, 0.161 mmol) was dissolved in MeOH (5 mL). The flask was placed under a nitrogen atmosphere, and a catalytic amount of Pd(OH)<sub>2</sub>/C was added. The atmosphere was exchanged for H<sub>2</sub> and the mixture was stirred for 1 h until TLC analysis (20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) indicated completion of the reaction. The mixture was filtered over celite, celite was added to the filtrate, and the solvents were removed under reduced pressure. The solid residue was purified <i>via</i> flash column chromatography (automated, 2 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>87</b> (35 mg, 0.119 mmol, 74% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1.22 (3H, t, <i>J</i> = 7.5 Hz, CH<sub>2</sub>C<u class="uu">H</u><sub><u class="uu">3</u></sub>), 2.96 (2H, q, <i>J</i> = 7.5 Hz, C<u class="uu">H</u><sub><u class="uu">2</u></sub>CH<sub>3</sub>), 3.43 (1H, dt, <i>J</i> = 12.0, 6.0 Hz, H-5′), 3.59 (1H, dt, <i>J</i> = 12.0, 4.7 Hz, H-5″), 3.89 (1H, dd, <i>J</i> = 9.7, 4.5 Hz, H-4′), 4.21 (1H, dd, <i>J</i> = 10.3, 5.3 Hz, H-3′), 4.57 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-2′), 4.86 (1H, t, <i>J</i> = 6.0 Hz, OH), 5.08 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.30 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.04 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.32 (2H, br. s., NH<sub>2</sub>), 8.15 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.0 (CH<sub>2</sub><u class="uu">C</u>H<sub>3</sub>), 21.4 (<u class="uu">C</u>H<sub>2</sub>CH<sub>3</sub>), 62.5 (C-5′), 70.9 (C-2′), 73.0 (C-3′), 85.0 (C-4′), 88.3 (C-1′), 98.6 (C-3a), 147.2 (C-3), 155.1 (C-7a), 155.9 (C-6), 158.2 (C-4) ppm. HRMS (ESI): calcd for C<sub>12</sub>H<sub>18</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 296.1359, found: 296.1363.</div></div><div id="sec4_1_7_77" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> 3-(1<i>H</i>-1,2,3-Triazol-4-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>90</b>)</h5><div class="NLM_p last">Compound <b>88 (</b>0.125 g, 0.429 mmol, 1.0 equiv) and CuI (0.004 g, 0.021 mmol, 0.05 equiv) were dissolved in MeOH (0.2 mL) and DMF (1.8 mL). TMSN<sub>3</sub> (0.085 mL, 0.644 mmol, 1.5 equiv) was added, and the mixture was heated at 100 °C overnight. The mixture was cooled to room temperature and concentrated <i>in vacuo</i>. The residue was dissolved in MeOH, celite was added, and the solvents were removed under reduced pressure. The solid residue was purified by flash column chromatography (4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>90</b> (57 mg, 0.170 mmol, 40% yield) as a light-brown solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.48 (1H, dt, <i>J</i> = 12.0, 5.6 Hz, H-5′), 3.62 (1H, dt, <i>J</i> = 12.0, 4.7 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 9.4, 4.6 Hz, H-4′), 4.26 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-3′), 4.66 (1H, dd, <i>J</i> = 10.3, 5.2 Hz, H-2′), 4.88 (1H, t, <i>J</i> = 5.6 Hz, OH), 5.13 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.43 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.14 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 8.14 (1H, br. s., CH<sub>triazole</sub>), 8.25 (1H, s, H-6), 8.54 (1H, br. s, NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.4 (C-5′), 70.9 (C-2′), 73.0 (C-3′), 85.4 (C-4′), 88.8 (C-), 98.0 (C-3a), 131.1 (C<sub>triazole</sub>), 136.3 (C-3), 140.3 (C<sub>triazole</sub>), 155.1 (C-7a), 156.7 (C-6), 158.4 (C-4) ppm. HRMS (ESI): calcd for C<sub>12</sub>H<sub>15</sub>N<sub>8</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 335.1216, found: 335.1205.</div></div><div id="sec4_1_7_78" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> 3-Cyano-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> (<b>91</b>)</h5><div class="NLM_p last">Compound <b>36</b> (2.73 g, 6.95 mmol, 1.0 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.382 g, 0.417 mmol, 0.06 equiv), dppf (0.771 g, 1.39 mmol, 0.2 equiv), and Zn(CN)<sub>2</sub> (0.490 g, 4.17 mmol, 0.6 equiv) were dissolved in dry degassed DMF (30 mL) in a flame-dried flask under argon. The mixture was stirred at 150 °C for 90 min until LCMS analysis indicated completion of the reaction. The mixture was cooled to room temperature and concentrated <i>in vacuo</i>. The residue was taken up in MeOH, celite was added, and the solvents were removed under reduced pressure. The solid residue was purified first by manual flash column chromatography (5 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) and then by automated flash column chromatography (4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>91</b> (570 mg, 1.95 mmol, 28% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.45 (1H, dt, <i>J</i> = 11.7, 5.9 Hz, H-5′), 3.58 (1H, dt, <i>J</i> = 12.0, 5.0 Hz, H-5″), 3.95 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.22 (1H, dd, <i>J</i> = 9.7, 5.0 Hz, H-3′), 4.60 (1H, dd, <i>J</i> = 10.3, 5.2 Hz, H-2′), 4.82 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.23 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.50 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.17 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 8.35 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.0 (C-5′), 70.6 (C-2′), 73.3 (C-3′), 85.8 (C-4′), 89.1 (C-1′), 101.2 (C-3), 113.0 (CN), 116.9 (C-3a), 154.4 (C-7a), 157.1 (C-6), 157.4 (C-4) ppm. HRMS (ESI): calcd for C<sub>11</sub>H<sub>13</sub>N<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 293.0998, found: 293.1002. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div></div><div id="sec4_1_7_79" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> 3-(1<i>H</i>-Tetrazol-5-yl)-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>92</b>)</h5><div class="NLM_p last">Compound <b>91</b> (0.074 g, 0.253 mmol), NaN<sub>3</sub> (0.021 g, 0.329 mmol, 1.3 equiv), NH<sub>4</sub>Cl (0.018 g, 0.329 mmol, 1.3 equiv), and a catalytic amount of LiCl were suspended in DMF (3 mL). The mixture was heated at 100 °C overnight, cooled down to room temperature, and concentrated <i>in vacuo</i>. The residue was taken up in MeOH, adsorbed onto celite, and purified by flash column chromatography (2 → 40% MeOH in CH<sub>2</sub>Cl<sub>2</sub> + 0.1% AcOH) to afford <b>92</b> (21 mg, 0.063 mmol, 25% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.50 (1H, dd, <i>J</i> = 11.7, 6.2 Hz, H-5′), 3.65 (1H, dd, <i>J</i> = 11.9, 4.5 Hz, H-5″), 3.97 (1H, dd, <i>J</i> = 10.3, 5.0 Hz, H-4′), 4.34 (1H, t, <i>J</i> = 4.8 Hz, H-3′), 4.70 (1H, t, <i>J</i> = 4.8 Hz, H-2′), 6.20 (1H, d, <i>J</i> = 4.4 Hz, H-1′), 8.34 (1H, s, H-6), 8.45 (1H, br. s., H<sub>tetrazole</sub>), 9.12 (1H, br. s., NH<sub>tetrazole</sub>) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.4 (C-5′), 70.7 (C-2′), 73.1 (C-3′), 85.7 (C-4′), 89.1 (C-1′), 98.6 (C-3a), 131.3 (C-3), 150.4 (C<sub>tetrazole</sub>), 155.0 (C-7a), 156.4 (C-6), 157.5 (C-4) ppm. HRMS (ESI): calcd for C<sub>11</sub>H<sub>14</sub>N<sub>9</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 336.1169, found: 336.1176.</div></div><div id="sec4_1_7_80" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> 3-Aminomethyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>93</b>)</h5><div class="NLM_p last"><b>88</b> (47 mg, 0.161 mmol) was dissolved in MeOH (5 mL). The flask was placed under a nitrogen atmosphere, and Raney nickel (slurry in H<sub>2</sub>O, 1 mL) was added. The atmosphere was exchanged for H<sub>2</sub> and the mixture was stirred for 1 h until TLC analysis (20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) indicated completion of the reaction. The mixture was filtered over celite, celite was added to the filtrate, and the solvents were removed under reduced pressure. The solid residue was purified <i>via</i> flash column chromatography (automated, NH<sub>4</sub>OH/MeOH/CH<sub>2</sub>Cl<sub>2</sub> 1/0/99 → 1/25/74), followed by an additional purification <i>via</i> preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 95:05 to 68:32 in 6 min) to afford <b>93</b> (5 mg, 0.017 mmol, 10% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 2.66 (2H, s, C<u class="uu">H</u><sub><u class="uu">2</u></sub>NH<sub>2</sub>), 3.69 (1H, dd, <i>J</i> = 12.3, 4.4 Hz, H-5′), 3.81 (1H, dd, <i>J</i> = 12.3, 3.2 Hz, H-5″), 4.10 (1H, dd, <i>J</i> = 7.9, 3.5 Hz, H-4′), 4.38–4.51 (1H, m, H-3′), 4.73–4.80 (1H, m, H-2′), 6.23 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 8.20 (1H, s, H-6), 8.50 (4H, br. s., 2 × NH<sub>2</sub>) ppm. A qualitative <sup>13</sup>C NMR spectrum could not be obtained from the amount of product available. HRMS (ESI): calcd for C<sub>11</sub>H<sub>17</sub>N<sub>6</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 297.1311, found: 297.1314.</div></div><div id="sec4_1_7_81" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> 3-Carboxamido-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> (<b>94</b>)</h5><div class="NLM_p last">Compound <b>91</b> (55 mg, 0.188 mmol) was dissolved in aq. NH<sub>4</sub>OH (28–30% wt 4 mL). Aq. H<sub>2</sub>O<sub>2</sub> (30% w/w, 1 mL) was added, and the mixture was stirred for 2 h until LCMS analysis indicated full conversion. The residue was diluted with MeOH, celite was added, and the solvents were removed under reduced pressure. The solid residue was purified by flash column chromatography (automated, 2 → 40% MeOH in CH<sub>2</sub>Cl<sub>2</sub> + 0.1% AcOH) to afford <b>92</b> (21 mg, 0.063 mmol, 25% yield) as a brown solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.47 (1H, dt, <i>J</i> = 12.0, 6.2 Hz, H-5′), 3.62 (1H, dt, <i>J</i> = 12.0, 5.3 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 10.3, 4.7 Hz, H-4′), 4.30 (1H, dd, <i>J</i> = 10.3, 4.7 Hz, H-3′), 4.68 (1H, dd, <i>J</i> = 10.5, 5.3 Hz, H-2′), 4.84 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.08 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.44 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.14 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.99 (1H, s, NH<sub>2</sub>), 8.07 (1H, br. s., NH<sub>2</sub>), 8.19 (1H, br. s., NH<sub>2</sub>), 8.24 (1H, s, H-6), 8.86 (1H, br. s., NH<sub>2</sub>) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 62.3 (C-5′), 70.8 (C-2′), 73.1 (C-3′), 85.7 (C-4′), 88.9 (C-1′), 99.5 (C-3a), 139.0 (C-3), 155.4 (C-7a), 156.9 (C-6), 158.2 (C-4), 163.8 (C═O) ppm. HRMS (ESI): calcd for C<sub>11</sub>H<sub>15</sub>N<sub>6</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 311.1104, found: 311.1110. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div></div><div id="sec4_1_7_82" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> 3-Trifluoromethyl-4-amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl)-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>95</b>)</h5><div class="NLM_p last">TMSCF<sub>3</sub> (0.315 mL, 2.13 mmol, 3.0 equiv) was added dropwise over the course of 1 h to a suspension of CuI (0.406 g, 2.13 mmol, 3.0 equiv) and KF (0.124 g, 2.13 mmol, 3.0 equiv) in a mixture of dry degassed DMF/NMP 1:1 (3 mL). When all solids had dissolved, <b>34</b> (0.500 g, 0.709 mmol, 1.0 equiv) in dry degassed DMF/NMP 1:1 (3 mL) was added, and the mixture was heated to reflux. After 3 h, LC/MS analysis showed full conversion of the starting material, and the reaction was cooled to room temperature. The mixture was diluted with EtOAc (15 mL) and water (5 mL), and the solids were filtered off over Celite. The filter cake was washed extensively with additional EtOAc (3 × 25 mL), and the combined filtrates were transferred to a separation funnel. Additional water (40 mL) was added, the phases were separated, and the organic phase was washed twice more with water (25 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was used as such in the next reaction. HRMS (ESI): calcd for C<sub>32</sub>H<sub>25</sub>F<sub>3</sub>N<sub>5</sub>O<sub>7</sub> ([M + H]<sup>+</sup>): 648.1706, found: 648.1723.</div></div><div id="sec4_1_7_83" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> 3-Trifluoromethyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>96</b>)</h5><div class="NLM_p last">Crude <b>95</b> was subjected to general procedure C (reaction time: 1 h). Purification by flash column chromatography (4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>), followed by additional purification by preparative RP-HPLC (0.2% formic acid in H<sub>2</sub>O/MeCN 98:02 to 33:67 in 12 min) afforded <b>96</b> (33 mg, 0.098 mmol, 14% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.44 (1H, dt, <i>J</i> = 12.0, 5.6 Hz, H-5′), 3.58 (1H, dt, <i>J</i> = 12.0, 4.7 Hz, H-5″), 3.94 (1H, dd, <i>J</i> = 9.7, 5.0 Hz, H-4′), 4.22 (1H, dd, <i>J</i> = 8.5, 4.1 Hz, H-3′), 4.61 (1H, dd, <i>J</i> = 9.4, 4.7 Hz, H-2′), 4.83 (1H, t, <i>J</i> = 5.6 Hz, OH), 5.23 (1H, d, <i>J</i> = 5.0 Hz, OH), 5.48 (1H, d, <i>J</i> = 5.6 Hz, OH), 6.18 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 8.36 (1H, s, H-6) ppm. <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.1 (C-5′), 70.7 (C-2′), 73.1 (C-3′), 85.7 (C-4′), 88.8 (C-1′), 96.6 (C-3a), 120.7 (q, <i>J</i> = 269.0 Hz, CF<sub>3</sub>), 132.8 (q, <i>J</i> = 38.5 Hz, C-3), 155.6 (C-7a), 156.7 (C-6), 157.2 (C-4). <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −59.61 (1F, s) ppm. HRMS (ESI): calcd for C<sub>11</sub>H<sub>13</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 336.0920, found: 336.0917.</div></div><div id="sec4_1_7_84" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> 5-Amino-3-methyl-1<i>H</i>-pyrazole-4-carbonitrile<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> (<b>97</b>)</h5><div class="NLM_p last">A solution of malonitrile (1.11 mL, 20.0 mmol, 1.0 equiv) in THF (20 mL) was cooled to 0 °C. NaH (60% wt in mineral oil, 1.60 g, 40.0 mmol, 2.0 equiv) was added slowly, and the mixture was stirred for 10 min. Acetyl chloride (1.43 mL, 20.0 mmol, 1.0 equiv) was added, and the mixture was gradually warmed to room temperature. After 1 h, dimethyl sulfate (2.28 mL, 24.0 mmol, 1.2 equiv) was added and the mixture was heated to reflux. After 3 h, the mixture was cooled down to room temperature, and Et<sub>3</sub>N (6.97 mL, 50.0 mmol, 2.0 equiv) was added, followed by hydrazine hydrate (1.0 mL, 20.0 mmol, 1.0 equiv). The mixture was again heated at reflux temperature for 1 h and cooled down to room temperature. The mixture was concentrated <i>in vacuo</i>, diluted with H<sub>2</sub>O and EtOAc, and transferred to a separation funnel. The phases were separated, and the aqueous phase was extracted twice more with EtOAc. The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was taken up in MeCN, celite was added, and the solvent was removed under reduced pressure. The solid residue was purified by flash column chromatography (manual, petroleum ether/EtOAc 1:1 and 3:7) to afford <b>97</b> (0.930 g, 7.61 mmol, 38% yield) as a yellow sticky foam. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.12 (3H, br. s.), 5.72 (2H, br. s), 11.51 (1H, br. s) ppm. HRMS (ESI): calcd for C<sub>5</sub>H<sub>7</sub>N<sub>4</sub> ([M + H]<sup>+</sup>): 123.0671, found: 123.0662. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div></div><div id="sec4_1_7_85" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> 3-Methyl-4-amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> (<b>98</b>)</h5><div class="NLM_p last">Compound <b>97</b> (0.441 g, 3.61 mmol, 1.0 equiv) was dissolved in formamide (2 mL). The mixture was heated at 180 °C for 24 h and cooled down to room temperature by pouring into ice-cold water (25 mL). The resulting solids were filtered off and dried under a high vacuum overnight to afford <b>98</b> (126 mg, 0.84 mmol, 23% yield) as a brown solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.52 (3H, s, CH<sub>3</sub>), 7.15 (2H, br. s., NH<sub>2</sub>), 8.09 (1H, s, H-6), 12.91 (1H, br. s., NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.9 (CH<sub>3</sub>), 98.8 (C-3a), 141.3 (C-3), 156.1 (C-7a), 156.3 (C-6), 158.8 (C-4) ppm. HRMS (ESI): calcd for C<sub>6</sub>H<sub>8</sub>N<sub>5</sub> ([M + H]<sup>+</sup>): 150.0780, found: 150.0768. Spectral data are in accordance with literature values.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div></div><div id="sec4_1_7_86" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> 3,6-Dimethyl-4-amino-1<i>H</i>-pyrazolo[3,4-<i>d</i>]pyrimidine (<b>99</b>)</h5><div class="NLM_p last">Compound <b>97</b> (0.206 g, 1.69 mmol, 1.0 equiv) was dissolved in 2-methoxy-ethanol (3 mL). Thioacetamide (0.253 g, 3.37 mmol, 2.0 equiv) was added, and the mixture was heated at reflux overnight. The mixture was cooled down to room temperature, and the solvent was removed <i>in vacuo</i>. The residue was taken up in MeOH, adsorbed onto celite, and purified by flash column chromatography (manual, 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>99</b> (100 mg, 0.61 mmol, 36% yield) as a light-purple solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.06 (3H, s, CH<sub>3</sub>), 2.36 (3H, s, CH<sub>3</sub>), 7.14 (2H, br. s, NH<sub>2</sub>), 12.80 (1H, br. s, NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.6 (CH<sub>3</sub>) 21.8 (CH<sub>3</sub>), 97.0 (C-3a), 141.1 (C-3), 157.3 (C-7a), 158.5 (C-4), 164.9 (C-6) ppm. HRMS (ESI): calcd for C<sub>7</sub>H<sub>10</sub>N<sub>5</sub> ([M + H]<sup>+</sup>): 164.0936, found: 164.0914.</div></div><div id="sec4_1_7_87" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> 3-Methyl-4-amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>100</b>)</h5><div class="NLM_p last">Compound <b>98</b> (0.100 g, 0.67 mmol) and 1-<i>O</i>-acetyl-2,3,5-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranose (0.406 g, 0.8 mmol, 1.2 equiv) were subjected to general procedure B. Purification by flash column chromatography (automated, 0 → 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>100</b>, which was used as such in the next reaction. HRMS (ESI): calcd for C<sub>32</sub>H<sub>28</sub>N<sub>5</sub>O<sub>7</sub> ([M + H]<sup>+</sup>): 594.1989, found: 594.2010.</div></div><div id="sec4_1_7_88" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> 3-Methyl-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl-pyrazolo[3,4-<i>d</i>]pyrimidine (<b>101</b>)</h5><div class="NLM_p last">Compound <b>98</b> (used directly from the previous reaction) was subjected to general procedure C (reaction time: 1 h). Purification by flash column chromatography (automated, 4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>101</b> (40 mg, 0.142 mmol, 21% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.53 (3H, s, CH<sub>3</sub>), 3.42 (1H, dt, <i>J</i> = 11.9, 6.1 Hz, H-5′), 3.56 (1H, dt, <i>J</i> = 11.4, 4.7 Hz, H-5″), 3.87 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.17 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-3′), 4.56 (1H, dd, <i>J</i> = 10.5, 5.3 Hz, H-2′), 4.86 (1H, t, <i>J</i> = 5.9 Hz, OH), 5.10 (1H, d, <i>J</i> = 5.3 Hz, OH), 5.30 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.02 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 7.35 (2H, br. s., NH<sub>2</sub>), 8.14 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 14.5 (CH<sub>3</sub>), 62.4 (C-5′), 70.8 (C-2′), 72.8 (C-3′), 84.9 (C-4′), 88.0 (C-1′), 99.3 (C-3a), 141.9 (C-3), 155.1 (C-7a), 156.0 (C-6), 158.4 (C-4) ppm. HRMS (ESI): calcd for C<sub>11</sub>H<sub>16</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 282.1202, found: 282.1216.</div></div><div id="sec4_1_7_89" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> 3-Vinyl-4-amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>102</b>)</h5><div class="NLM_p last">Compound <b>34</b> (5.66 g, 8.03 mmol, 1.0 equiv), Pd(OAc)<sub>2</sub> (0.090 g, 0.40 mmol, 0.05 equiv), PPh<sub>3</sub> (0.316 g, 1.20 mmol, 0.15 equiv), potassium vinyl trifluoroborate (2.92 g, 10.0 mmol, 1.25 equiv), and Cs<sub>2</sub>CO<sub>3</sub> (7.85 g, 24.1 mmol, 3.0 equiv) were dissolved in degassed DMF/H<sub>2</sub>O 9:1 (20 mL) under argon. The mixture was stirred at 100 °C for 72 h, cooled down to room temperature, and transferred to a separation funnel. Water (50 mL) was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was purified by flash column chromatography (automated, 40 → 100% EtOAc in petroleum ether) to afford <b>102</b> (1.85 g, 3.05 mmol, 38% yield) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.64 (1H, dd, <i>J</i> = 11.7, 4.7 Hz, H-5′), 4.73–4.89 (2H, m, H-5″, H-4′), 5.66 (1H, dd, <i>J</i> = 11.1, 1.2 Hz, HC=C<u class="uu">H</u><sub>2</sub>), 5.98 (1H, dd, <i>J</i> = 17.7, 1.2 Hz, HC=C<u class="uu">H</u><sub>2</sub>), 6.10 (2H, br. s, NH<sub>2</sub>), 6.34 (1H, t, <i>J</i> = 5.7 Hz, H-3′), 6.44 (1H, dd, <i>J</i> = 5.3, 3.2 Hz, H-2′), 6.87 (1H, d, <i>J</i> = 3.2 Hz, H-1′), 6.87 (1H, dd, <i>J</i> = 17.9, 11.4 Hz, <u class="uu">H</u>C=CH<sub>2</sub>), 7.30–7.45 (6H, m, H<sub>Bz</sub>), 7.48–7.61 (3H, m, H<sub>Bz</sub>), 7.92–8.03 (4H, m, H<sub>Bz</sub>), 8.05–8.14 (2H, m, H<sub>Bz</sub>), 8.35 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 64.0 (C-5′), 72.0 (C-2′), 74.5 (C-3′), 80.0 (C-4′), 86.7 (C-1′), 98.9 (C-3a), 121.8 (HC=<u class="uu">C</u>H<sub>2</sub>), 128.2 (H<u class="uu">C</u>=CH<sub>2</sub>), 128.3 (C<sub>Bz</sub>), 128.4 (C<sub>Bz</sub>), 128.4 (C<sub>Bz</sub>), 128.8 (C<sub>Bz</sub>), 128.9 (C<sub>Bz</sub>), 129.6 (C<sub>Bz</sub>), 129.8 (C<sub>Bz</sub>), 129.8 (C<sub>Bz</sub>), 133.0 (C<sub>Bz</sub>), 133.5 (C<sub>Bz</sub>), 133.6 (C<sub>Bz</sub>), 144.3 (C-3), 155.4 (C-7a), 155.4 (C-6), 157.5 (C-4), 165.1 (C═O), 165.3 (C═O), 166.2 (C═O) ppm. HRMS (ESI): calcd for C<sub>33</sub>H<sub>28</sub>N<sub>5</sub>O<sub>7</sub> ([M + H]<sup>+</sup>): 606.1989, found: 606.1978.</div></div><div id="sec4_1_7_90" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> 4-Amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine-3-carbaldehyde (<b>103</b>)</h5><div class="NLM_p last">Compound <b>102</b> (1.53 g, 2.52 mmol, 1.0 equiv) and K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O (0.019 g, 0.05 mmol, 0.02 equiv) were dissolved in a mixture of dioxane (18.9 mL, 7.5 mL/mmol) and water (6.3 mL, 2.5 mL/mmol). 2.6-Lutidine (0.584 mL, 5.04 mmol, 2.0 equiv) and NaIO<sub>4</sub> (2.16 g, 10.1 mmol, 4.0 equiv) were added, and the mixture was stirred for 3 h until TLC analysis (petroleum ether/EtOAc 50:50) indicated full conversion. Aq. sat. Na<sub>2</sub>SO<sub>3</sub> (25 mL) was added, and the mixture was stirred for 1 more hour before it was transferred to a separation funnel. The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 60 mL). The combined organic fractions were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was purified by flash column chromatography (automated, 15 → 70% EtOAc in petroleum ether) to afford 103 (0.731 g, 1.20 mmol, 48% yield) as a white solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.62 (1H, dd, <i>J</i> = 13.2, 5.3 Hz, H-5′), 4.85–4.94 (2H, m, H-5″, H-4′), 6.32 (1H, t, <i>J</i> = 5.6 Hz, H-3′), 6.49 (1H, dd, <i>J</i> = 5.4, 3.7 Hz, H-2′), 6.58 (1H, br. s, NH<sub>2</sub>), 6.91 (1H, d, <i>J</i> = 3.5 Hz, H-1′), 7.34–7.47 (6H, m, H<sub>Bz</sub>), 7.52–7.63 (3H, m, H<sub>Bz</sub>), 7.90 (1H, br. s., NH<sub>2</sub>), 7.94–8.05 (4H, m, H<sub>Bz</sub>), 8.05–8.16 (2H, m, H<sub>Bz</sub>), 8.40 (1H, s, H-6), 9.70 (1H, s, C<u class="uu">H</u>O) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 63.3 (C-5′), 71.8 (C-2′), 74.3 (C-3′), 80.8 (C-4′), 87.3 (C-1′), 99.4 (C-3a), 128.4 (C<sub>Phe</sub>), 128.5 (C<sub>Phe</sub>) (C<sub>Phe</sub>), 129.6 (C<sub>Phe</sub>), 129.8 (C<sub>Phe</sub>), 129.8 (C<sub>Phe</sub>), 133.3 (C<sub>Phe</sub>), 133.7 (C<sub>Phe</sub>), 133.8 (C<sub>Phe</sub>), 144.9 (C-3), 156.1 (C-7a), 156.7 (C-6), 157.5 (C-4), 165.1 (C═O), 165.3 (C═O), 166.0 (C═O), 187.9 (<u class="uu">C</u>HO) ppm. HRMS (ESI): calcd for C<sub>32</sub>H<sub>26</sub>N<sub>5</sub>O<sub>8</sub> ([M + H]<sup>+</sup>): 608.1781, found: 608.1792.</div></div><div id="sec4_1_7_91" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> 3-(Morpholinomethyl)-4-amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>104</b>)</h5><div class="NLM_p last">Compound <b>103</b> (0.125 g, 0.206 mmol, 1.0 equiv) was dissolved in a mixture of MeOH (2 mL) and THF (1 mL). Morpholine (0.089 mL, 1.03 mmol, 5.0 equiv) and AcOH (0.236 mL, 4.12 mmol, 20.0 equiv) were added, followed by NaBH<sub>3</sub>CN (0.039 g, 0.62 mmol, 3.0 equiv). After 2 h, LCMS analysis indicated completion of the reaction. The reaction mixture was diluted with water (15 mL) and extracted with EtOAc (3 × 25 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated <i>in vacuo</i>, and used crude in the next reaction. HRMS (ESI): calcd for C<sub>36</sub>H<sub>35</sub>N<sub>6</sub>O<sub>8</sub> ([M + H]<sup>+</sup>): 679.2516, found: 679.2631.</div></div><div id="sec4_1_7_92" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> 3-(Morpholinomethyl)-4-amino-1-(β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>105</b>)</h5><div class="NLM_p last">Compound <b>104</b> (crude) was subjected to general procedure C (reaction time: 90 min). Purification by flash column chromatography (automated, 4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>105</b> (48 mg, 0.131 mmol, 64% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.38–2.58 (4H, m, 2 × CH<sub>2 morpholine</sub>, under DMSO peak), 3.42 (1H, dt, <i>J</i> = 10.5, 5.0 Hz, H-5′), 3.49–3.69 (5H, m, H-5″, 2 × CH<sub>2 morpholine</sub>), 3.75 (1H, d, <i>J</i> = 14.4 Hz, CH<sub>2</sub>N), 3.80 (1H, d, <i>J</i> = 14.4 Hz, CH<sub>2</sub>N), 3.88 (1H, dd, <i>J</i> = 9.4, 4.7 Hz, H-4′), 4.18 (1H, dd, <i>J</i> = 8.2, 4.4 Hz, H-3′), 4.58 (1H, dd, <i>J</i> = 9.7, 3.8 Hz, H-2′), 4.87 (1H, t, <i>J</i> = 6.2 Hz, OH), 5.10 (1H, d, <i>J</i> = 3.5 Hz, OH), 5.31 (1H, d, <i>J</i> = 4.1 Hz, OH), 6.02 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 7.79 (1H, br. s., NH<sub>2</sub>), 8.17 (1H, s, H-6), 8.55 (1H, br. s., NH<sub>2</sub>) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub><i>6</i></sub>) δ 52.9 (2 × CH<sub>2 morpholine</sub>), 56.1 (CH<sub>2</sub>N), 62.4 (C-5′), 66.0 (2 × CH<sub>2 morpholine</sub>), 70.8 (C-2′), 72.8 (C-3′), 85.1 (C-4′), 88.4 (C-1′), 99.4 (C-3a), 143.5 (C-3), 155.2 (C-7a), 156.2 (C-6), 158.6 (C-4) ppm. HRMS (ESI): calcd for C<sub>15</sub>H<sub>23</sub>N<sub>6</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 367.1730, found: 367.1727.</div></div><div id="sec4_1_7_93" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> 3-Difluoromethyl-4-amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>106</b>)</h5><div class="NLM_p last">Compound <b>103</b> (0.143 g, 0.235 mmol, 1.0 equiv) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL). DAST (0.155 mL, 1.18 mmol, 5.0 equiv) was added, and the mixture was stirred overnight at room temperature. The reaction was quenched <i>via</i> the slow addition of aq. sat. NaHCO<sub>3</sub> (20 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub>, adsorbed onto celite, and purified <i>via</i> flash column chromatography (5 → 65% EtOAc in petroleum ether). The obtained product was used directly in the next reaction. HRMS (ESI): calcd for C<sub>32</sub>H<sub>26</sub>F<sub>2</sub>N<sub>5</sub>O<sub>7</sub> ([M + H]<sup>+</sup>): 630.1800, found: 630.1808.</div></div><div id="sec4_1_7_94" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> 3-Difluoromethyl-4-amino-1-(β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>107</b>)</h5><div class="NLM_p last">Compound <b>106</b> (used directly from the previous reaction) was subjected to general procedure C (reaction time: 30 min). Purification <i>via</i> flash column chromatography (4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>107</b> (43 mg, 0.136 mmol, 58% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.44 (1H, dt, <i>J</i> = 11.8, 6.0 Hz, H-5′), 3.57 (1H, dt, <i>J</i> = 11.7, 5.0 Hz, H-5″), 3.93 (1H, dd, <i>J</i> = 10.0, 4.7 Hz, H-2′), 4.20 (1H, dd, <i>J</i> = 10.0, 5.0 Hz, H-3′), 4.61 (1H, dd, <i>J</i> = 10.5, 5.3 Hz, H-2′), 4.84 (1H, t, <i>J</i> = 5.7 Hz, OH), 5.19 (1H, d, <i>J</i> = 5.3 Hz, OH), 5.43 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.14 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 6.72 (1H, br. s), 7.42 (1H, t, <i>J</i> = 53.3 Hz), 7.94 (1H, br. s), 8.32 (1H, s) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.6 (C-5′), 71.2 (C-2′), 73.4 (C-3′), 85.9 (C-4′), 89.0 (C-1′) 97.4 (C-3a), 111.5 (t, <i>J</i> = 232.6 Hz, <u class="uu">C</u>F<sub>2</sub>H), 138.5 (t, <i>J</i> = 28.8 Hz, C-3), 155.8 (C-7a), 157.2 (C-6), 157.6 (C-4) ppm. <sup>19</sup>F NMR (282 MHz, DMSO-<i>d</i><sub>6</sub>) δ −110.91 (2F, d, <i>J</i> = 52.9 Hz) ppm. HRMS (ESI): calcd for C<sub>11</sub>H<sub>14</sub>F<sub>2</sub>N<sub>5</sub>O<sub>4</sub> ([M + H]<sup>+</sup>): 318.1014, found: 318.1019.</div></div><div id="sec4_1_7_95" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> 4-Amino-1-(2′,3′,5′-tri-<i>O</i>-benzoyl-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine-3-carboxylic Acid (<b>108</b>)</h5><div class="NLM_p last">Compound <b>103</b> (0.588 g, 0.968 mmol, 1.0 eq) and NaH<sub>2</sub>PO<sub>4</sub> (0.035 g, 0.291 mmol, 0.3 equiv) were dissolved in a mixture of THF (9 mL) and H<sub>2</sub>O (1.5 mL). Aq. H<sub>2</sub>O<sub>2</sub> (30% w/w, 0.110 mL, 0.968 mmol, 1.0 equiv) was added, followed by dropwise addition of a solution of NaClO<sub>2</sub> (0.123 g, 1.36 mmol, 1.4 equiv) in H<sub>2</sub>O (1.5 mL). The reaction mixture was stirred overnight, diluted with 0.5 M HCl (20 mL), and extracted with EtOAc (3 × 50 mL). The combined organic phases were dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated <i>in vacuo</i>. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> and adsorbed onto celite. The solid residue was purified by flash column chromatography (0 → 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub> + 0.1% HOAc) to afford <b>108</b> (0.570 g, 0.914 mmol, 94%) as a colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 4.72 (1H, dd, <i>J</i> = 13.2, 6.4 Hz, H-5′), 4.82–4.94 (2H, m, H-5″, H-4′), 6.32 (1H, t, <i>J</i> = 5.6 Hz, H-3′), 6.58 (1H, dd, <i>J</i> = 5.3, 4.1 Hz, H-2′), 6.83 (1H, d, <i>J</i> = 3.8 Hz, H-1′), 7.31–7.70 (9H, m, H<sub>Bz</sub>), 7.89–8.13 (6H, m, H<sub>Bz</sub>), 8.18 (1H, s, H-6), 11.50 (2H, br. s, NH<sub>2</sub>), 12.60 (1H, br. s, COOH) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 63.8 (C-5′), 71.8 (C-2′), 74.1 (C-3′), 80.7 (C-4′), 89.1 (C-1′), 101.0 (C-3a), 128.4 (C<sub>Bz</sub>), 128.5 (C<sub>Bz</sub>), 128.6 (C<sub>Bz</sub>), 128.8 (C<sub>Bz</sub>), 129.5 (C<sub>Bz</sub>), 129.8 (C<sub>Bz</sub>), 129.9 (C<sub>Bz</sub>), 132.0 (C<sub>Bz</sub>), 132.2 (C<sub>Bz</sub>), 133.2 (C<sub>Bz</sub>), 133.6 (C<sub>Bz</sub>), 133.7 (C<sub>Bz</sub>), 147.0 (C-3), 152.5 (C-7a), 154.1 (C-6), 155.7 (C-4), 165.0 (COOH), 165.1 (C═O), 166.1 (C═O) ppm. HRMS (ESI): calcd for C<sub>32</sub>H<sub>26</sub>N<sub>5</sub>O<sub>9</sub> ([M + H]<sup>+</sup>): 624.1731, found: 624.1745.</div></div><div id="sec4_1_7_96" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> 3-Methylamido-4-amino-1-(β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>113</b>)</h5><div class="NLM_p last">Compound <b>108</b> (0.125 g, 0.20 mmol) was subjected to general procedure F, with methylamine (40% wt in H<sub>2</sub>O) as the coupling partner. The obtained residue was subjected to general procedure C (reaction time: 1 h). Purification <i>via</i> flash column chromatography (automated, 4 → 20% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>113</b> (0.019 g, 0.059 mmol, 29% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 2.85 (3H, s, CH<sub>3</sub>) 3.35–3.50 (1H, m, H-5′, partially underwater peak), 3.63 (1H, dd, <i>J</i> = 12.0, 4.7 Hz, H-5′), 3.93 (2H, dd, <i>J</i> = 10.3, 4.7 Hz, H-4′), 4.30 (1H, t, <i>J</i> = 4.7 Hz, H-3′), 4.67 (2H, t, <i>J</i> = 4.7 Hz, H-2′), 6.13 (1H, d, <i>J</i> = 4.7 Hz, H-1′), 8.24 (1H, s, H-6) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 26.0 (CH<sub>3</sub>), 62.4 (C-5′), 70.8 (C-2′), 73.1 (C-3′), 85.7 (C-4′), 89.0 (C-1′), 99.3 (C-3a), 139.0 (C-3), 155.4 (C-7a), 157.0 (C-6), 158.1 (C-4), 162.1 (C═O) ppm. HRMS (ESI): calcd for C<sub>12</sub>H<sub>17</sub>N<sub>6</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 325.1260, found: 325.1265.</div></div><div id="sec4_1_7_97" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> 3-Pyrrolidinamido-4-amino-1-(β-<span class="smallcaps smallerCapital">d</span>-ribofuranosyl)pyrazolo[3,4-<i>d</i>]pyrimidine (<b>114</b>)</h5><div class="NLM_p last">Compound <b>108</b> (0.080 g, 0.128 mmol) was subjected to general procedure F, with pyrrolidine as the coupling partner. The obtained residue was subjected to general procedure C (reaction time: 1 h). Purification <i>via</i> flash column chromatography (automated, 1 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>114</b> (0.006 g, 0.016 mmol, 28% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, CD<sub>3</sub>OD) δ 1.90–2.12 (4H, m, 2 × CH<sub>2 pyrrolidine</sub>), 3.60–3.74 (3H, m, H-5′, CH<sub>2 pyrrolidine</sub>), 3.78 (1H, dd, <i>J</i> = 12.3, 3.2 Hz, H-5″), 4.05–4.21 (3H, m, H-4′, CH<sub>2 pyrrolidine</sub>), 4.50 (1H, t, <i>J</i> = 5.1 Hz, H-3′), 4.75 (1H, t, <i>J</i> = 4.7 Hz, H-2′) 6.34 (1H, d, <i>J</i> = 3.8 Hz, H-1′), 8.20 (1H, s, H-6) ppm. A qualitative <sup>13</sup>C NMR spectrum could not be obtained from the amount of product available. HRMS (ESI): calcd for C<sub>15</sub>H<sub>21</sub>N<sub>6</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 365.1573, found: 365.1567.</div></div><div id="sec4_1_7_98" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> 3-Anilinamido-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>115</b>)</h5><div class="NLM_p last">Compound <b>108</b> (0.125 g, 0.20 mmol) was subjected to general procedure F, with aniline as the coupling partner. The obtained residue was subjected to general procedure C (reaction time: 1 h). Purification <i>via</i> flash column chromatography (automated, 1 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>115</b> (0.047 g, 0.122 mmol, 61% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.52 (1H, dt, <i>J</i> = 11.6, 6.0 Hz, H-5′), 3.68 (1H, dt, <i>J</i> = 11.7, 5.0 Hz, H-5″), 3.97 (1H, dd, <i>J</i> = 8.8, 4.4 Hz, H-4′), 4.33 (1H, dd, <i>J</i> = 9.1, 4.7 Hz, H-3′), 4.75–5.00 (2H, m, H-2′, OH), 5.15 (1H, d, <i>J</i> = 5.6 Hz, OH), 5.46 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.19 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 7.20 (1H, t, <i>J</i> = 7.3 Hz, H-4<sub>aniline</sub>), 7.41 (2H, t, <i>J</i> = 7.8 Hz, H-2<sub>aniline</sub>, H-6<sub>aniline</sub>), 7.78 (2H, d, <i>J</i> = 7.9 Hz, H-3<sub>aniline</sub>, H-5<sub>aniline</sub>), 8.20 (1H, br. s., NH<sub>2</sub>′), 8.29 (1H, s, H-6), 8.54 (1H, br. s., NH<sub>2</sub>), 10.45 (1H, s, NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 62.1 (C-5′), 70.7 (C-2′), 72.8 (C-3′), 85.9 (C-4′), 89.4 (C-1′), 99.7 (C-3a), 121.7 (C-2<sub>aniline</sub>, C-6<sub>aniline</sub>), 124.8 (C-4<sub>aniline</sub>), 128.7 (C-3<sub>aniline</sub>, C-5<sub>aniline</sub>), 137.4 (C-1aniline), 138.7 (C-3), 155.5 (C-7a), 157.0 (C-6), 158.1 (C-4), 160.4 (C═O) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>19</sub>N<sub>6</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 387.1417, found: 387.1422.</div></div><div id="sec4_1_7_99" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> 3-Benzylamido-4-amino-1-β-<span class="smallcaps smallerCapital">d</span>-ribofuranosylpyrazolo[3,4-<i>d</i>]pyrimidine (<b>116</b>)</h5><div class="NLM_p last">Compound <b>108</b> (0.125 g, 0.20 mmol) was subjected to general procedure F, with benzylamine as the coupling partner. The obtained residue was subjected to general procedure C (reaction time: 1 h). Purification <i>via</i> flash column chromatography (automated, 1 → 15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) afforded <b>116</b> (0.035 g, 0.087 mmol, 44% yield over 2 steps) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 3.48 (1H, dt, <i>J</i> = 12.3, 6.2 Hz, H-5′), 3.63 (1H, dt, <i>J</i> = 12.0, 5.3 Hz, H-5″), 3.94 (1H, dd, <i>J</i> = 9.7, 4.7 Hz, H-4′), 4.32 (1H, dd, <i>J</i> = 10.3, 5.0 Hz, H-3′), 4.46–4.63 (2H, m, CH<sub>2 benzyl</sub>), 4.72 (1H, dd, <i>J</i> = 10.3, 5.0 Hz, H-2′), 4.85 (1H, t, <i>J</i> = 6.2 Hz, OH), 5.10 (1H, d, <i>J</i> = 5.9 Hz, OH), 5.47 (1H, d, <i>J</i> = 5.9 Hz, OH), 6.16 (1H, d, <i>J</i> = 5.0 Hz, H-1′), 7.19–7.38 (5H, m, H<sub>Phe</sub>), 8.11 (1H, d, <i>J</i> = 3.2 Hz, NH<sub>2</sub>), 8.26 (1H, s, H-6), 8.80 (1H, d, <i>J</i> = 3.2 Hz, NH<sub>2</sub>′), 9.38 (1H, t, <i>J</i> = 6.2 Hz, NH) ppm. <sup>13</sup>C NMR (75 MHz, DMSO-<i>d</i><sub>6</sub>) δ 42.3 (CH<sub>2 benzyl</sub>), 62.3 (C-5′), 70.7 (C-2′), 73.0 (C-3′), 85.7 (C-4′), 89.0 (C-1′), 99.4 (C-3a), 126.9 (C-4<sub>Phe</sub>), 127.3 (C-2<sub>Phe</sub>, C-6<sub>Phe</sub>), 128.4 (C-3<sub>Phe</sub>, C-5<sub>Phe</sub>), 138.7 (C-1<sub>Phe</sub>), 139.1 (C-3), 155.4 (C-7a), 156.9 (C-6), 158.1 (C-4), 161.7 (C═O) ppm. HRMS (ESI): calcd for C<sub>17</sub>H<sub>19</sub>N<sub>6</sub>O<sub>5</sub> ([M + H]<sup>+</sup>): 401.1573, found: 401.1571.</div></div></div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> Biological Evaluation</h3><div class="NLM_p last">All animal experiments were conducted in compliance with institutional guidelines.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> Drug Sensitivity Assays</h3><div class="NLM_p">Compound stock solutions were prepared at 20 mM in 100% dimethyl sulfoxide (DMSO). The compounds were serially prediluted (2-fold or 4-fold) in DMSO followed by a further (intermediate) dilution in demineralized water to assure a final in-test DMSO concentration of <1%. Compounds were assayed in 10 concentrations of a 4-fold compound dilution series starting at 64 μM.</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> <i>L. infantum</i></h4><div class="NLM_p last"><i>L. infantum</i> [MHOM/MA(BE)/67] was used. This strain was maintained in golden hamsters (<i>Mesocricetus auratus</i>) obtained from Janvier (Le Genest Saint Isle, France) following approval by the Ethical Committee of the University of Antwerp (ECD2019–10). Amastigotes were collected from the spleens of infected donor hamsters as described elsewhere,<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> and spleen parasite burdens were assessed using the Stauber technique. Primary peritoneal mouse macrophages (PMMs) were used as host cells and obtained from Swiss mice (Janvier; ethical approval ECD2019–10) after a 2-day peritoneal stimulation with a 2% potato starch suspension. All cultures and assays were conducted at 37 °C under an atmosphere of 5% CO<sub>2</sub>. Assays were performed in 96-well microtiter plates, each well containing 10 μL of the compound dilutions together with 190 μL of macrophage/parasite inoculum (3 × 10<sup>4</sup> cells + 4.5 × 10<sup>5</sup> parasites/well). The inoculum was prepared in RPMI-1640 medium, supplemented with 200 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 16.5 mM NaHCO<sub>3</sub>, and 5% inactivated fetal calf serum. The macrophages were infected after 48 h. The compounds were added after 2 h of infection. Parasite multiplication was compared to untreated-infected controls (100% growth) and uninfected controls (0% growth). After 5 days incubation, parasite burdens (mean number of amastigotes/macrophage) were microscopically assessed after staining with a 10% Giemsa solution. The results were expressed as % reduction in parasite burden compared to untreated control wells, and an IC<sub>50</sub> value was calculated.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> PMM Cytotoxicity</h4><div class="NLM_p last">PMM toxicity was assessed during the <i>in vitro Leishmania</i> susceptibility assays <i>via</i> microscopic evaluation of cell detachment, lysis, and granulation. Evaluation was done by semiquantitative scoring (no exact counting was performed) of at least 500 cells distributed over adjacent microscopic fields. The results were expressed as % reduction in normal cells compared to untreated control wells, and a CC<sub>50</sub> value was determined.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> <i>T. cruzi</i></h4><div class="NLM_p">The β-galactosidase expressing <i>T. cruzi</i> Tulahuen CL2 strain (nifurtimox-sensitive) was used. This strain was maintained in MRC-5<sub>SV2</sub> (human lung fibroblast) cells in MEM medium, supplemented with 200 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 16.5 mM NaHCO<sub>3</sub>, and 5% inactivated fetal calf serum. All cultures and assays were conducted at 37 °C under an atmosphere of 5% CO<sub>2</sub>.</div><div class="NLM_p last">Assays were performed in sterile 96-well microtiter plates, each well containing 10 μL of the watery compound dilutions together with 190 μL of MRC-5<sub>SV2</sub> cell/parasite inoculum (4 × 10<sup>3</sup> cells/well + 4 × 10<sup>4</sup> parasites/well). For some assays, PMMs were used as <i>T. cruzi</i> host cells. For this purpose, 3 × 10<sup>4</sup> cells were plated per well and infected two days later with 1.5 × 10<sup>4</sup> parasites. To explore the involvement of ABC transporters, compound exposure was also combined with established inhibitors verapamil (8 μM), probenecid (700 μM), or cyclosporine A (2 μM). <i>T. cruzi</i> growth was compared to untreated-infected controls (100% growth) and noninfected controls (0% growth) after 7 days incubation at 37 °C and 5% CO<sub>2</sub>. Parasite burdens were assessed after adding the substrate CPRG (chlorophenolred ß-<span class="smallcaps smallerCapital">d</span>-galactopyranoside): 50 μL/well of a stock solution containing 15.2 mg of CPRG + 250 μL of Nonidet in 100 mL of PBS. The change in color was measured spectrophotometrically at 540 nm after 4 h incubation at 37 °C. The results were expressed as % reduction in parasite burdens compared to control wells, and an IC<sub>50</sub> value was calculated.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> MRC-5<sub>SV2</sub> Cytotoxicity</h4><div class="NLM_p last">MRC-5<sub>SV2</sub> cells were cultured in MEM + Earl’s salts-medium, supplemented with <span class="smallcaps smallerCapital">l</span>-glutamine, NaHCO<sub>3</sub>, and 5% inactivated fetal calf serum. All cultures and assays were conducted at 37 °C under an atmosphere of 5% CO<sub>2</sub>. Assays were performed in sterile 96-well microtiter plates, each well containing 10 μL of the watery compound dilutions together with 190 μL of MRC-5<sub>SV2</sub> inoculum (1.5 × 10<sup>5</sup> cells/mL). Cell growth was compared to untreated control wells (100% cell growth) and medium-control wells (0% cell growth). After 3 days incubation, cell viability was assessed fluorimetrically after addition of 50 μL of resazurin per well. After 4 h at 37 °C, fluorescence was measured (λ<sub>ex</sub> 550 nm, λ<sub>em</sub> 590 nm). The results were expressed as % reduction in cell growth/viability compared to control wells, and an IC<sub>50</sub> value was determined.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> Metabolic Stability</h4><div class="NLM_p last">Male mouse and pooled human liver microsomes were purchased from a commercial source (Corning) and stored at −80 °C. NADPH generating system solutions A and B and UGT reaction mix solutions A and B (Corning) were kept at −20 °C. The test compound and the reference compound diclofenac were formulated in DMSO at 10 mM. The microsomal stability assay was carried out based on the BD Biosciences Guidelines for Use (TF000017 Rev1.0) with minor adaptations. The metabolic stability of the compounds was studied through the CYP450 superfamily (Phase-I metabolism) by fortification with reduced nicotinamide adenine dinucleotide phosphate (NADPH) and through uridine glucuronosyl-transferase (UGT) enzymes (Phase-II metabolism) by fortification with uridine diphosphate glucuronic acid (UDPGA). For the CYP450 and other NADPH-dependent enzymes, both compounds were incubated at 5 μM together with 0.5 mg/mL liver microsomes in potassium phosphate buffer in a reaction started by the addition of 1 mM NADPH and stopped at the above-listed sampling times. At these time points, 20 μL was withdrawn from the reaction mixture and 80 μL of cold acetonitrile (ACN), containing the internal standard tolbutamide, was added to inactivate the enzymes and precipitate the protein. The mixture was vortexed for 30 s and centrifuged at 4 °C for 5 min at 15 000 rpm. The supernatant was stored at −80 °C until analysis. For the UGT enzymes, both compounds were incubated at 5 μM together with 0.5 mg/mL liver microsomes in a reaction started by the addition of 2 mM UDPGA cofactor. The corresponding loss of the parent compound was determined using liquid chromatography (UPLC) (Waters Aquity) coupled with tandem quadrupole mass spectrometry (MS<sup>2</sup>) (Waters Xevo), equipped with an electrospray ionization (ESI) interface and operated in the multiple reaction monitoring (MRM) mode. The optimal MS parameters and control of the chromatographic separation conditions were tuned in a preceding experiment.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> <i>T. cruzi</i> Y-Strain Bloodstream Trypomastigote Activity</h4><div class="NLM_p last">Bloodstream trypomastigotes of the Y strain were obtained by cardiac puncture of infected Swiss Webster mice on the parasitaemia peak, and drug sensitivity assays were performed as described.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> <i>T. cruzi</i> Y-Strain Intracellular Amastigote Activity</h4><div class="NLM_p last">After 24 h of plating, 2D cardiac cell cultures were infected for 24 h at 37 °C with bloodstream trypomastigotes of <i>T. cruzi</i> (Y strain) employing a parasite/host cell ratio of 10:1. Then, the cultures were washed to remove free parasites and treated for 48 h at 37 °C with a serial dilution of the compound in culture medium. After drug exposure, the cultures were rinsed using phosphate-buffered saline, fixed, and stained with Giemsa as described previously.<a onclick="showRef(event, 'ref78 ref101'); return false;" href="javascript:void(0);" class="ref ref78 ref101">(78,101)</a> The mean numbers of infected host cells and of parasites per infected cell were scored in 200 host cells in two independent experiments each run in duplicate. Only characteristic parasite nuclei and kinetoplasts were considered as surviving parasites since irregular structures could represent parasites undergoing cell death. The compound activity was estimated by calculating the inhibition levels of the inhibition index (II, percentage of infected cells vs the mean number of parasites per infected cell).</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> Cytotoxicity on Cardiac Cells</h4><div class="NLM_p last">Cardiac 2D and 3D cell cultures were obtained from the heart of Swiss Webster mice embryos, as reported.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> To prepare the three-dimensional cultures, isolated cardiac cells were seeded in 96-well U plates (25 × 10<sup>3</sup> cell/well), previously coated with 1% agarose. Both cardiac cultures were sustained in Dulbecco’s modified Eagle’s medium (DMEM; without phenol red; Sigma-Aldrich) supplemented with 5% fetal bovine serum, 2.5 mM CaCl<sub>2</sub>, 1 mM <span class="smallcaps smallerCapital">l</span>-glutamine, streptomycin, and 2% chicken embryo extract, at 37 °C. Noninfected cultures were incubated for 48 h at 37 °C with crescent concentrations of <b>44</b> diluted in supplemented DMEM medium. Morphology was evaluated by light microscopy, and cellular viability was determined using PrestoBlue.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The results are expressed as the difference in reduction between treated and nontreated cultures adopting the manufacturer’s instructions. The CC<sub>50</sub> (minimum concentration that reduces 50% of the cellular viability) was then determined.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i142" class="anchor-spacer"></div><h3 class="article-section__title" id="_i142"> <i>In Vivo</i> Evaluation</h3><div id="sec4_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> Compounds</h4><div class="NLM_p">Bz (2-nitroimidazole; Laboratório Farmacêutico do Estado de Pernambuco [LAFEPE], Brazil) was used as a reference drug and was formulated using 3% Tween 80 in distilled water. The nucleoside analogue <b>44</b> was diluted using 10% Tween 80 in sterile water.</div><div id="sec4_4_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> Mouse Infection and Treatment</h5><div class="NLM_p last">Male Swiss Webster mice (18–20 g; 4–5 weeks of age) were obtained from the animal facilities of ICTB (Institute of Science and Biomodels Technology/Fiocruz/RJ/Brazil). Housing of animals was with a maximum of 6 animals per cage, in a specific-pathogen-free (SPF) room at 20–24 °C under a 12 h light and 12 h dark cycle. All animals were provided sterilized water and chow ad libitum. The animals were acclimatized for 7 days before the experiments. On the day of infection (0 dpi), animals were infected by i.p. administration of 10<sup>4</sup> bloodstream trypomastigotes (Y strain) originating from an infected donor mouse. Noninfected control mice were age-matched and housed under identical conditions.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Each experimental group consisted of six animals: untreated (infected vehicle-treated control) and treated (infected and treated with 44 or with benznidazole). Treatment was initiated at the onset of parasitemia (6 dpi) only using mice with detectable parasitemia. <b>44</b> was administered by oral gavage for five consecutive days at 25, 2.5, and 0.25 mg/kg twice daily. Benznidazole treatments at 10 mg/kg and at the optimal dose (100 mg/kg p.o.) were run in parallel. The efficacy of <b>44</b> in coadministration with benznidazole was also evaluated (<b>44</b> at 2.5 mg/kg b.i.d + benznidazole at 10 mg/kg/day). All treatments followed a 5-day (6<sup>th</sup> to 10<sup>th</sup> dpi) dosing regimen, and all compound formulations were freshly prepared before administration. Parasitemia levels in <i>T. cruzi</i> assays were individually checked by light microscopic counting of parasites in 5 μL of blood, and mortality rates were checked daily until 34 dpi and expressed as a percentage of cumulative mortality, as described previously.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i145"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00135" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36106" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36106" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00135?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00135</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">HPLC traces of selected final compounds and copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra of synthesized compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00135/suppl_file/jm1c00135_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00135/suppl_file/jm1c00135_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00135/suppl_file/jm1c00135_si_001.pdf">jm1c00135_si_001.pdf (8.54 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00135/suppl_file/jm1c00135_si_002.csv">jm1c00135_si_002.csv (10.71 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.1c00135" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78447" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78447" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guy Caljon</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a0e7d5d98ee3c1cccacfcee0d5c1ced4d7c5d2d0c5ce8ec2c5"><span class="__cf_email__" data-cfemail="511624287f12303d3b3e3f1124303f2526342321343f7f3334">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Serge Van Calenbergh</span> - <span class="hlFld-Affiliation affiliation">Laboratory
for Medicinal Chemistry (Campus Heymans), Ghent University, Ottergemsesteenweg
460, B-9000 Gent, Belgium</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4201-1264" title="Orcid link">http://orcid.org/0000-0002-4201-1264</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#95c6f0e7f2f0bbc3f4fbd6f4f9f0fbf7f0e7f2fdd5c0d2f0fbe1bbf7f0"><span class="__cf_email__" data-cfemail="d182b4a3b6b4ff87b0bf92b0bdb4bfb3b4a3b6b9918496b4bfa5ffb3b4">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jakob Bouton</span> - <span class="hlFld-Affiliation affiliation">Laboratory
for Medicinal Chemistry (Campus Heymans), Ghent University, Ottergemsesteenweg
460, B-9000 Gent, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ludmila Ferreira de Almeida Fiuza</span> - <span class="hlFld-Affiliation affiliation">Laboratório
de Biologia Celular, Instituto Oswaldo Cruz (FIOCRUZ), Fundação Oswaldo Cruz, Rio de Janeiro, Avenida Brasil 4365, Manguinhos, 21040-360 Rio de Janeiro, Brazil</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Camila Cardoso Santos</span> - <span class="hlFld-Affiliation affiliation">Laboratório
de Biologia Celular, Instituto Oswaldo Cruz (FIOCRUZ), Fundação Oswaldo Cruz, Rio de Janeiro, Avenida Brasil 4365, Manguinhos, 21040-360 Rio de Janeiro, Brazil</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria Angela Mazzarella</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Sciences, University of
Perugia, Via del Liceo 1, Perugia 06100, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria de Nazaré Correia Soeiro</span> - <span class="hlFld-Affiliation affiliation">Laboratório
de Biologia Celular, Instituto Oswaldo Cruz (FIOCRUZ), Fundação Oswaldo Cruz, Rio de Janeiro, Avenida Brasil 4365, Manguinhos, 21040-360 Rio de Janeiro, Brazil</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Louis Maes</span> - <span class="hlFld-Affiliation affiliation">Laboratory
of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, B-2610 Wilrijk, Belgium</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Izet Karalic</span> - <span class="hlFld-Affiliation affiliation">Laboratory
for Medicinal Chemistry (Campus Heymans), Ghent University, Ottergemsesteenweg
460, B-9000 Gent, Belgium</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e16978-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i146">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53112" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53112" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors would like to thank An Matheeussen, Natascha Van Pelt, Pim-Bart Feijens, and Margot Vleminckx for excellent technical assistance.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">APP(R)</td><td class="NLM_def"><p class="first last">aminopyrazolo[3,4-<i>d</i>]pyrimidine (riboside)</p></td></tr><tr><td class="NLM_term">Bz</td><td class="NLM_def"><p class="first last">benznidazole</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">cutaneous leishmaniasis</p></td></tr><tr><td class="NLM_term">DTU</td><td class="NLM_def"><p class="first last">discrete typing unit</p></td></tr><tr><td class="NLM_term">PMM</td><td class="NLM_def"><p class="first last">primary mouse macrophage</p></td></tr><tr><td class="NLM_term">PRTase</td><td class="NLM_def"><p class="first last">phosphoribosyltransferase</p></td></tr><tr><td class="NLM_term"><i>L. infantum</i></td><td class="NLM_def"><p class="first last"><i>Leishmania infantum</i></p></td></tr><tr><td class="NLM_term">SI</td><td class="NLM_def"><p class="first last">selectivity index</p></td></tr><tr><td class="NLM_term">T. cruzi</td><td class="NLM_def"><p class="first last"><i>Trypanosoma cruzi</i></p></td></tr><tr><td class="NLM_term">TDA-1</td><td class="NLM_def"><p class="first last">tris[2-(2-methoxyethoxy)ethyl]amine</p></td></tr><tr><td class="NLM_term">TPPTS</td><td class="NLM_def"><p class="first last">triphenylphosphine-3,3′,3″-trisulfonic acid trisodium salt</p></td></tr><tr><td class="NLM_term">VL</td><td class="NLM_def"><p class="first last">visceral leishmaniasis</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i148">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38043" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38043" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 102 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molyneux, D.</span></span> <span> </span><span class="NLM_article-title">Neglected Tropical Diseases</span>. <i>Community Eye Health</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=24023397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC3sbntVKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=21-24&author=D.+Molyneux&title=Neglected+Tropical+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neglected tropical diseases</span></div><div class="casAuthors">Molyneux David</div><div class="citationInfo"><span class="NLM_cas:title">Community eye health</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">82</span>),
    <span class="NLM_cas:pages">21-4</span>
        ISSN:<span class="NLM_cas:issn">0953-6833</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTShQOFaBBa1bBItaL1WaVAfW6udTcc2ebbf3rcyI25ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbntVKhsg%253D%253D&md5=14d2a88bbd27f805c505b2cb5070b31d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMolyneux%26aufirst%3DD.%26atitle%3DNeglected%2520Tropical%2520Diseases%26jtitle%3DCommunity%2520Eye%2520Health%26date%3D2013%26volume%3D26%26spage%3D21%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houweling, T. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim-Kos, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolk, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haagsma, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenk, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardus, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlas, S. J. de.</span></span> <span> </span><span class="NLM_article-title">Socioeconomic Inequalities in Neglected Tropical Diseases: A Systematic Review</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0004546</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0004546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1371%2Fjournal.pntd.0004546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=27171166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVOksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&author=T.+A.+J.+Houwelingauthor=H.+E.+Karim-Kosauthor=M.+C.+Kulikauthor=W.+A.+Stolkauthor=J.+A.+Haagsmaauthor=E.+J.+Lenkauthor=J.+H.+Richardusauthor=S.+J.+de.+Vlas&title=Socioeconomic+Inequalities+in+Neglected+Tropical+Diseases%3A+A+Systematic+Review&doi=10.1371%2Fjournal.pntd.0004546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Socioeconomic inequalities in neglected tropical diseases: a systematic review</span></div><div class="casAuthors">Houweling, Tanja A. J.; Kos, Henrike E. Karim; Kulik, Margarete C.; Stolk, Wilma A.; Haagsma, Juanita A.; Lenk, Edeltraud J.; Richardus, Jan Hendrik; de Vlas, Sake J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0004546/1-e0004546/28</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Neglected tropical diseases (NTDs) are generally assumed to be concd. in poor populations, but evidence on this remains scattered.  We describe within-country socioeconomic inequalities in nine NTDs listed in the London Declaration for intensified control and/or elimination: lymphatic filariasis (LF), onchocerciasis, schistosomiasis, soil-transmitted helminthiasis (STH), trachoma, Chagas' disease, human African trypanosomiasis (HAT), leprosy, and visceral leishmaniasis (VL).  Methodol. We conducted a systematic literature review, including publications between 2004-2013 found in Embase, Medline (OvidSP), Cochrane Central, Web of Science, Popline, Lilacs, and Scielo.  We included publications in international peer-reviewed journals on studies concerning the top 20 countries in terms of the burden of the NTD under study.  Principal findings We identified 5,516 publications, of which 93 met the inclusion criteria.  Of these, 59 papers reported substantial and statistically significant socioeconomic inequalities in NTD distribution, with higher odds of infection or disease among poor and less-educated people compared with better-off groups.  The findings were mixed in 23 studies, and 11 studies showed no substantial or statistically significant inequality.  Most information was available for STH, VL, schistosomiasis, and, to a lesser extent, for trachoma.  For the other NTDs, evidence on their socioeconomic distribution was scarce.  The magnitude of inequality varied, but often, the odds of infection or disease were twice as high among socioeconomically disadvantaged groups compared with better-off strata.  Inequalities often took the form of a gradient, with higher odds of infection or disease each step down the socioeconomic hierarchy.  Notwithstanding these inequalities, the prevalence of some NTDs was sometimes also high among better-off groups in some highly endemic areas.  Conclusions While recent evidence on socioeconomic inequalities is scarce for most individual NTDs, for some, there is considerable evidence of substantially higher odds of infection or disease among socioeconomically disadvantaged groups.  NTD control activities as proposed in the London Declaration, when set up in a way that they reach the most in need, will benefit the poorest populations in poor countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR1bhLRV4WVrVg90H21EOLACvtfcHk0lhJgBLVQJXGSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVOksr4%253D&md5=fa759eb40feb2067544edadf955eb9f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0004546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0004546%26sid%3Dliteratum%253Aachs%26aulast%3DHouweling%26aufirst%3DT.%2BA.%2BJ.%26aulast%3DKarim-Kos%26aufirst%3DH.%2BE.%26aulast%3DKulik%26aufirst%3DM.%2BC.%26aulast%3DStolk%26aufirst%3DW.%2BA.%26aulast%3DHaagsma%26aufirst%3DJ.%2BA.%26aulast%3DLenk%26aufirst%3DE.%2BJ.%26aulast%3DRichardus%26aufirst%3DJ.%2BH.%26aulast%3DVlas%26aufirst%3DS.%2BJ.%2Bde.%26atitle%3DSocioeconomic%2520Inequalities%2520in%2520Neglected%2520Tropical%2520Diseases%253A%2520A%2520Systematic%2520Review%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2016%26volume%3D10%26doi%3D10.1371%2Fjournal.pntd.0004546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottazzi, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotez, P. J.</span></span> <span> </span><span class="NLM_article-title">Global Economic Burden of Chagas Disease: A Computational Simulation Model</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(13)70002-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS1473-3099%2813%2970002-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=23395248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC3szmvV2quw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=342-348&author=B.+Y.+Leeauthor=K.+M.+Baconauthor=M.+E.+Bottazziauthor=P.+J.+Hotez&title=Global+Economic+Burden+of+Chagas+Disease%3A+A+Computational+Simulation+Model&doi=10.1016%2FS1473-3099%2813%2970002-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Global economic burden of Chagas disease: a computational simulation model</span></div><div class="casAuthors">Lee Bruce Y; Bacon Kristina M; Bottazzi Maria Elena; Hotez Peter J</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  As Chagas disease continues to expand beyond tropical and subtropical zones, a growing need exists to better understand its resulting economic burden to help guide stakeholders such as policy makers, funders, and product developers.  We developed a Markov simulation model to estimate the global and regional health and economic burden of Chagas disease from the societal perspective.  METHODS:  Our Markov model structure had a 1 year cycle length and consisted of five states: acute disease, indeterminate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death.  Major model parameter inputs, including the annual probabilities of transitioning from one state to another, and present case estimates for Chagas disease came from various sources, including WHO and other epidemiological and disease-surveillance-based reports.  We calculated annual and lifetime health-care costs and disability-adjusted life-years (DALYs) for individuals, countries, and regions.  We used a discount rate of 3% to adjust all costs and DALYs to present-day values.  FINDINGS:  On average, an infected individual incurs US$474 in health-care costs and 0·51 DALYs annually.  Over his or her lifetime, an infected individual accrues an average net present value of $3456 and 3·57 DALYs.  Globally, the annual burden is $627·46 million in health-care costs and 806,170 DALYs.  The global net present value of currently infected individuals is $24·73 billion in health-care costs and 29,385,250 DALYs.  Conversion of this burden into costs results in annual per-person costs of $4660 and lifetime per-person costs of $27,684.  Global costs are $7·19 billion per year and $188·80 billion per lifetime.  More than 10% of these costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic.  A substantial proportion of the burden emerges from lost productivity from cardiovascular disease-induced early mortality.  INTERPRETATION:  The economic burden of Chagas disease is similar to or exceeds those of other prominent diseases globally (eg, rotavirus $2·0 billion, cervical cancer $4·7 billion) even in the USA (Lyme disease $2·5 billion), where Chagas disease has not been traditionally endemic, suggesting an economic argument for more attention and efforts towards control of Chagas disease.  FUNDING:  Bill & Melinda Gates Foundation, the National Institute of General Medical Sciences Models of Infectious Disease Agent Study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS55IbG9bEjhrqxQ2mb9Pu8fW6udTcc2ebxmlGp-12ImLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szmvV2quw%253D%253D&md5=5d35649aeaa5fe129246096e3f9d43f6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2813%2970002-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252813%252970002-1%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DBacon%26aufirst%3DK.%2BM.%26aulast%3DBottazzi%26aufirst%3DM.%2BE.%26aulast%3DHotez%26aufirst%3DP.%2BJ.%26atitle%3DGlobal%2520Economic%2520Burden%2520of%2520Chagas%2520Disease%253A%2520A%2520Computational%2520Simulation%2520Model%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2013%26volume%3D13%26spage%3D342%26epage%3D348%26doi%3D10.1016%2FS1473-3099%2813%2970002-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lidani, K. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damasceno, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrame, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messias-Reason, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandri, T. L.</span></span> <span> </span><span class="NLM_article-title">Chagas Disease: From Discovery to a Worldwide Health Problem</span>. <i>Front. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">166</span>, <span class="refDoi"> DOI: 10.3389/fpubh.2019.00166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.3389%2Ffpubh.2019.00166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=31312626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BB3MzotVGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=166&author=K.+C.+F.+Lidaniauthor=F.+A.+Andradeauthor=L.+Baviaauthor=F.+S.+Damascenoauthor=M.+H.+Beltrameauthor=I.+J.+Messias-Reasonauthor=T.+L.+Sandri&title=Chagas+Disease%3A+From+Discovery+to+a+Worldwide+Health+Problem&doi=10.3389%2Ffpubh.2019.00166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chagas Disease: From Discovery to a Worldwide Health Problem</span></div><div class="casAuthors">Lidani Karita Claudia Freitas; Andrade Fabiana Antunes; Bavia Lorena; Messias-Reason Iara J; Sandri Thaisa Lucas; Damasceno Flavia Silva; Beltrame Marcia Holsbach; Sandri Thaisa Lucas</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in public health</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">166</span>
        ISSN:<span class="NLM_cas:issn">2296-2565</span>.
    </div><div class="casAbstract">Carlos Chagas discovered American trypanosomiasis, also named Chagas disease (CD) in his honor, just over a century ago.  He described the clinical aspects of the disease, characterized by its etiological agent (Trypanosoma cruzi) and identified its insect vector.  Initially, CD occurred only in Latin America and was considered a silent and poorly visible disease.  More recently, CD became a neglected worldwide disease with a high morbimortality rate and substantial social impact, emerging as a significant public health threat.  In this context, it is crucial to better understand better the epidemiological scenarios of CD and its transmission dynamics, involving people infected and at risk of infection, diversity of the parasite, vector species, and T. cruzi reservoirs.  Although efforts have been made by endemic and non-endemic countries to control, treat, and interrupt disease transmission, the cure or complete eradication of CD are still topics of great concern and require global attention.  Considering the current scenario of CD, also affecting non-endemic places such as Canada, USA, Europe, Australia, and Japan, in this review we aim to describe the spread of CD cases worldwide since its discovery until it has become a global public health concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdNDVSKB6ie-Lt9HypzAgQfW6udTcc2ebxmlGp-12ImLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzotVGruw%253D%253D&md5=e22d46895f7c7162d2a98b8787ea6637</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3389%2Ffpubh.2019.00166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpubh.2019.00166%26sid%3Dliteratum%253Aachs%26aulast%3DLidani%26aufirst%3DK.%2BC.%2BF.%26aulast%3DAndrade%26aufirst%3DF.%2BA.%26aulast%3DBavia%26aufirst%3DL.%26aulast%3DDamasceno%26aufirst%3DF.%2BS.%26aulast%3DBeltrame%26aufirst%3DM.%2BH.%26aulast%3DMessias-Reason%26aufirst%3DI.%2BJ.%26aulast%3DSandri%26aufirst%3DT.%2BL.%26atitle%3DChagas%2520Disease%253A%2520From%2520Discovery%2520to%2520a%2520Worldwide%2520Health%2520Problem%26jtitle%3DFront.%2520Public%2520Health%26date%3D2019%26volume%3D7%26spage%3D166%26doi%3D10.3389%2Ffpubh.2019.00166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konar, N.</span></span> <span> </span><span class="NLM_article-title">Translational Challenges of Animal Models in Chagas Disease Drug Development: A Review</span>. <i>Drug Des. Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4807</span>– <span class="NLM_lpage">4823</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S90208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.2147%2FDDDT.S90208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=26316715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=4807-4823&author=E.+Chatelainauthor=N.+Konar&title=Translational+Challenges+of+Animal+Models+in+Chagas+Disease+Drug+Development%3A+A+Review&doi=10.2147%2FDDDT.S90208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Translational challenges of animal models in Chagas disease drug development: a review</span></div><div class="casAuthors">Chatelain, Eric; Konar, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4807-4823</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Chagas disease, or American trypanosomiasis, caused by Trypanosoma cruzi parasite infection is endemic in Latin America and presents an increasing clin. challenge due to migrating populations.  Despite being first identified over a century ago, only two drugs are available for its treatment, and recent outcomes from the first clin. trials in 40 years were lackluster.  There is a crit. need to develop new drugs to treat Chagas disease.  This requires a better understanding of the progression of parasite infection, and standardization of animal models designed for Chagas disease drug discovery.  Such measures would improve comparison of generated data and the predictability of test hypotheses and models designed for translation to human disease.  Existing animal models address both disease pathol. and treatment efficacy.  Available models have limited predictive value for the preclin. evaluation of novel therapies and need to more confidently predict the efficacy of new drug candidates in clin. trials.  This review highlights the overall lack of standardized methodol. and assessment tools, which has hampered the development of efficacious compds. to treat Chagas disease.  We provide an overview of animal models for Chagas disease, and propose steps that could be undertaken to reduce variability and improve predictability of drug candidate efficacy.  New technol. developments and tools may contribute to a much needed boost in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYtSQwJPq3xrVg90H21EOLACvtfcHk0lhEpWZaIQCR8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOhs74%253D&md5=085f540a8f4e5cd0ce50dbd7f135468a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S90208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S90208%26sid%3Dliteratum%253Aachs%26aulast%3DChatelain%26aufirst%3DE.%26aulast%3DKonar%26aufirst%3DN.%26atitle%3DTranslational%2520Challenges%2520of%2520Animal%2520Models%2520in%2520Chagas%2520Disease%2520Drug%2520Development%253A%2520A%2520Review%26jtitle%3DDrug%2520Des.%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D4807%26epage%3D4823%26doi%3D10.2147%2FDDDT.S90208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Molina, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span> <span> </span><span class="NLM_article-title">Chagas Disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31612-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0140-6736%2817%2931612-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=28673423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=82-94&author=J.+A.+P%C3%A9rez-Molinaauthor=I.+Molina&title=Chagas+Disease&doi=10.1016%2FS0140-6736%2817%2931612-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chagas disease</span></div><div class="casAuthors">Perez-Molina Jose A; Molina Israel</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10115</span>),
    <span class="NLM_cas:pages">82-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chagas disease is an anthropozoonosis from the American continent that has spread from its original boundaries through migration.  It is caused by the protozoan Trypanosoma cruzi, which was identified in the first decade of the 20th century.  Once acute infection resolves, patients can develop chronic disease, which in up to 30-40% of cases is characterised by cardiomyopathy, arrhythmias, megaviscera, and, more rarely, polyneuropathy and stroke.  Even after more than a century, many challenges remain unresolved, since epidemiological control and diagnostic, therapeutic, and prognostic methods must be improved.  In particular, the efficacy and tolerability profile of therapeutic agents is far from ideal.  Furthermore, the population affected is older and more complex (eg, immunosuppressed patients and patients with cancer).  Nevertheless, in recent years, our knowledge of Chagas disease has expanded, and the international networking needed to change the course of this deadly disease during the 21st century has begun.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsXELvajU9pjPfW6udTcc2ea2eV6W_pZ2XLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCrsA%253D%253D&md5=780546343990bf2d1774a418bf7f8091</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931612-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931612-4%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Molina%26aufirst%3DJ.%2BA.%26aulast%3DMolina%26aufirst%3DI.%26atitle%3DChagas%2520Disease%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D82%26epage%3D94%26doi%3D10.1016%2FS0140-6736%2817%2931612-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraday, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimpelewicz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hailu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazdins-Helds, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowbray, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacks, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Späth, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarleton, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery for Kinetoplastid Diseases: Future Directions</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSjs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=152-157&author=S.+P.+S.+Raoauthor=M.+P.+Barrettauthor=G.+Dranoffauthor=C.+J.+Faradayauthor=C.+R.+Gimpelewiczauthor=A.+Hailuauthor=C.+L.+Jonesauthor=J.+M.+Kellyauthor=J.+K.+Lazdins-Heldsauthor=P.+M%C3%A4serauthor=J.+Mengelauthor=J.+C.+Mottramauthor=C.+E.+Mowbrayauthor=D.+L.+Sacksauthor=P.+Scottauthor=G.+F.+Sp%C3%A4thauthor=R.+L.+Tarletonauthor=J.+M.+Spectorauthor=T.+T.+Diagana&title=Drug+Discovery+for+Kinetoplastid+Diseases%3A+Future+Directions&doi=10.1021%2Facsinfecdis.8b00298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery for Kinetoplastid Diseases: Future Directions</span></div><div class="casAuthors">Rao, Srinivasa P. S.; Barrett, Michael P.; Dranoff, Glenn; Faraday, Christopher J.; Gimpelewicz, Claudio R.; Hailu, Asrat; Jones, Catherine L.; Kelly, John M.; Lazdins-Helds, Janis K.; Maser, Pascal; Mengel, Jose; Mottram, Jeremy C.; Mowbray, Charles E.; Sacks, David L.; Scott, Phillip; Spath, Gerald F.; Tarleton, Rick L.; Spector, Jonathan M.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-157</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Kinetoplastid parasites have caused human disease for millennia.  Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT).  Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality.  Despite the gains, no new chem. or biol. entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis.  Advances in tools for drug discovery and novel insights into the biol. of the host-parasite interaction may provide opportunities for accelerated progress.  Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wyT4PtSqeLVg90H21EOLACvtfcHk0lhEpWZaIQCR8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSjs7bK&md5=022096794907a0266ed69859bafc7040</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00298%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DBarrett%26aufirst%3DM.%2BP.%26aulast%3DDranoff%26aufirst%3DG.%26aulast%3DFaraday%26aufirst%3DC.%2BJ.%26aulast%3DGimpelewicz%26aufirst%3DC.%2BR.%26aulast%3DHailu%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DC.%2BL.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DLazdins-Helds%26aufirst%3DJ.%2BK.%26aulast%3DM%25C3%25A4ser%26aufirst%3DP.%26aulast%3DMengel%26aufirst%3DJ.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26aulast%3DMowbray%26aufirst%3DC.%2BE.%26aulast%3DSacks%26aufirst%3DD.%2BL.%26aulast%3DScott%26aufirst%3DP.%26aulast%3DSp%25C3%25A4th%26aufirst%3DG.%2BF.%26aulast%3DTarleton%26aufirst%3DR.%2BL.%26aulast%3DSpector%26aufirst%3DJ.%2BM.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DDrug%2520Discovery%2520for%2520Kinetoplastid%2520Diseases%253A%2520Future%2520Directions%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26spage%3D152%26epage%3D157%26doi%3D10.1021%2Facsinfecdis.8b00298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrie, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Anti-Trypanosomatid Drug Discovery: An Ongoing Challenge and a Continuing Need</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/nrmicro.2016.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fnrmicro.2016.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=28239154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=217-231&author=M.+C.+Fieldauthor=D.+Hornauthor=A.+H.+Fairlambauthor=M.+A.+J.+Fergusonauthor=D.+W.+Grayauthor=K.+D.+Readauthor=M.+De+Ryckerauthor=L.+S.+Torrieauthor=P.+G.+Wyattauthor=S.+Wyllieauthor=I.+H.+Gilbert&title=Anti-Trypanosomatid+Drug+Discovery%3A+An+Ongoing+Challenge+and+a+Continuing+Need&doi=10.1038%2Fnrmicro.2016.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need</span></div><div class="casAuthors">Field, Mark C.; Horn, David; Fairlamb, Alan H.; Ferguson, Michael A. J.; Gray, David W.; Read, Kevin D.; De Rycker, Manu; Torrie, Leah S.; Wyatt, Paul G.; Wyllie, Susan; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-231</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases.  These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal.  Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them.  In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled.  In addn., we consider the important challenges to drug discovery strategies and the new technologies that can address them.  The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIBpRGL7YaP7Vg90H21EOLACvtfcHk0lgSn4ezPsFRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D&md5=1585d954d6eb695196a6c8921a84e300</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro.2016.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro.2016.193%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BC.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DTorrie%26aufirst%3DL.%2BS.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DAnti-Trypanosomatid%2520Drug%2520Discovery%253A%2520An%2520Ongoing%2520Challenge%2520and%2520a%2520Continuing%2520Need%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2017%26volume%3D15%26spage%3D217%26epage%3D231%26doi%3D10.1038%2Fnrmicro.2016.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baragaña, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Challenges and Recent Progress in Drug Discovery for Tropical Diseases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0327-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fs41586-018-0327-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30046073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=498-506&author=M.+De%0ARyckerauthor=B.+Baraga%C3%B1aauthor=S.+L.+Duceauthor=I.+H.+Gilbert&title=Challenges+and+Recent+Progress+in+Drug+Discovery+for+Tropical+Diseases&doi=10.1038%2Fs41586-018-0327-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and recent progress in drug discovery for tropical diseases</span></div><div class="casAuthors">De Rycker, Manu; Baragana, Beatriz; Duce, Suzanne L.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7715</span>),
    <span class="NLM_cas:pages">498-506</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries.  These diseases predominantly affect the world's poorest people.  Currently available drugs are inadequate for the majority of these diseases, and there is an urgent need for new treatments.  This Review discusses some of the challenges involved in developing new drugs to treat these diseases and highlights recent progress.  While there have been notable successes, there is still a long way to go.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-L8-tHy6aTbVg90H21EOLACvtfcHk0lgSn4ezPsFRvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zP&md5=3bc57ce68776462cf6a053efa276a989</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0327-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0327-4%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DBaraga%25C3%25B1a%26aufirst%3DB.%26aulast%3DDuce%26aufirst%3DS.%2BL.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DChallenges%2520and%2520Recent%2520Progress%2520in%2520Drug%2520Discovery%2520for%2520Tropical%2520Diseases%26jtitle%3DNature%26date%3D2018%26volume%3D559%26spage%3D498%26epage%3D506%26doi%3D10.1038%2Fs41586-018-0327-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">WHO</span>.  <i>Regional Strategic Framework for Elimination of Kala-Azar
from the
Sout-East Asia Region (2005-2015)</i>; New Delhi, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=WHO&title=Regional+Strategic+Framework+for+Elimination+of+Kala-Azar%0Afrom+the%0ASout-East+Asia+Region+%282005-2015%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DRegional%2520Strategic%2520Framework%2520for%2520Elimination%2520of%2520Kala-Azar%250Afrom%2520the%250ASout-East%2520Asia%2520Region%2520%25282005-2015%2529%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boelaert, M.</span></span> <span> </span><span class="NLM_article-title">Leishmaniasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">951</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31204-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0140-6736%2818%2931204-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30126638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BB3c7pvFyrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=951-970&author=S.+Burzaauthor=S.+L.+Croftauthor=M.+Boelaert&title=Leishmaniasis&doi=10.1016%2FS0140-6736%2818%2931204-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Leishmaniasis</span></div><div class="casAuthors">Burza Sakib; Croft Simon L; Boelaert Marleen</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10151</span>),
    <span class="NLM_cas:pages">951-970</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leishmaniasis is a poverty-related disease with two main clinical forms: visceral leishmaniasis and cutaneous leishmaniasis.  An estimated 0·7-1 million new cases of leishmaniasis per year are reported from nearly 100 endemic countries.  The number of reported visceral leishmaniasis cases has decreased substantially in the past decade as a result of better access to diagnosis and treatment and more intense vector control within an elimination initiative in Asia, although natural cycles in transmission intensity might play a role.  In east Africa however, the case numbers of this fatal disease continue to be sustained.  Increased conflict in endemic areas of cutaneous leishmaniasis and forced displacement has resulted in a surge in these endemic areas as well as clinics across the world.  WHO lists leishmaniasis as one of the neglected tropical diseases for which the development of new treatments is a priority.  Major evidence gaps remain, and new tools are needed before leishmaniasis can be definitively controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKr3d5VSglcRJ5E29YNGvQfW6udTcc2eb5mFXItQXfrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7pvFyrtw%253D%253D&md5=48f443a91163f1595a494000eb21f877</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931204-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931204-2%26sid%3Dliteratum%253Aachs%26aulast%3DBurza%26aufirst%3DS.%26aulast%3DCroft%26aufirst%3DS.%2BL.%26aulast%3DBoelaert%26aufirst%3DM.%26atitle%3DLeishmaniasis%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D951%26epage%3D970%26doi%3D10.1016%2FS0140-6736%2818%2931204-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span> <span> </span><span class="NLM_article-title">Chemotherapeutics of Visceral Leishmaniasis: Present and Future Developments</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1017/S0031182017002116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1017%2FS0031182017002116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=29215329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=481-489&author=S.+Sundarauthor=A.+Singh&title=Chemotherapeutics+of+Visceral+Leishmaniasis%3A+Present+and+Future+Developments&doi=10.1017%2FS0031182017002116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapeutics of visceral leishmaniasis: present and future developments</span></div><div class="casAuthors">Karunaweera, Nadira D.; Ferreira, Marcelo U.; Sundar, Shyam; Singh, Anup</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">481-489</span>CODEN:
                <span class="NLM_cas:coden">PARAAE</span>;
        ISSN:<span class="NLM_cas:issn">0031-1820</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  SUMMARY : Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options.  Long duration of treatment and drug toxicity further limit the target of achieving VL elimination.  Chemotherapy remains the treatment of choice.  Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent.  Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice.  Various drugs having anti-leishmania properties are in preclin. phase and need further development.  An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9DhyRkDYkJbVg90H21EOLACvtfcHk0lgWgoV0cpv24A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjs7zK&md5=de333aebe0baa82c8c005e2138ecf5b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1017%2FS0031182017002116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182017002116%26sid%3Dliteratum%253Aachs%26aulast%3DSundar%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DA.%26atitle%3DChemotherapeutics%2520of%2520Visceral%2520Leishmaniasis%253A%2520Present%2520and%2520Future%2520Developments%26jtitle%3DParasitology%26date%3D2018%26volume%3D145%26spage%3D481%26epage%3D489%26doi%3D10.1017%2FS0031182017002116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, S.</span></span> <span> </span><span class="NLM_article-title">Current and Emerging Medications for the Treatment of Leishmaniasis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1080/14656566.2019.1609940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1080%2F14656566.2019.1609940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=31063412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlert7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1251-1265&author=J.+Chakravartyauthor=S.+Sundar&title=Current+and+Emerging+Medications+for+the+Treatment+of+Leishmaniasis&doi=10.1080%2F14656566.2019.1609940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Current and emerging medications for the treatment of leishmaniasis</span></div><div class="casAuthors">Chakravarty, Jaya; Sundar, Shyam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1251-1265</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Leishmaniasis is a vector-borne neglected tropical disease which manifests as visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous leishmaniasis (MCL).  The current drugs are toxic, duration of treatment is long, there is regional variation in efficacy, and emergence of resistance is common.  This manuscript is based on literature derived from PubMed and reviews the current and emerging medications for the treatment of leishmaniasis.  A single dose of liposomal amphotericin B (L-AmB) and multidrug therapy are the best options for VL in the Indian subcontinent (ISC), while a combination of pentavalent antimonials and paromomycin remains the treatment of choice for VL in Africa where efficacious and safe regimens are needed for HIV-VL coinfection.  L-AmB at a total dose of 18-21 mg/kg is the recommended regimen for VL in the Mediterranean region, South America and for HIV-VL coinfection.  Treatment of CL varies from observation, local or systemic therapy depending on severity of lesions, etiol. species and its potential to develop into mucosal leishmaniasis.  The monitoring of single-dose L-AmB and combination therapy in the ISC is essential.  Effective short-course combination therapy is needed for the treatment of post-kala-azar dermal leishmaniasis and HIV-VL.  Better evidence for treatment is still needed along with safer and shorter treatment options for CL and MCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKTdQKa9ror7Vg90H21EOLACvtfcHk0lgWgoV0cpv24A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlert7k%253D&md5=e7e601b3669b6ae0ef17173d757958ba</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F14656566.2019.1609940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2019.1609940%26sid%3Dliteratum%253Aachs%26aulast%3DChakravarty%26aufirst%3DJ.%26aulast%3DSundar%26aufirst%3DS.%26atitle%3DCurrent%2520and%2520Emerging%2520Medications%2520for%2520the%2520Treatment%2520of%2520Leishmaniasis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2019%26volume%3D20%26spage%3D1251%26epage%3D1265%26doi%3D10.1080%2F14656566.2019.1609940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">DNDi</span>. <span> </span><span class="NLM_article-title">2019 R&D portfolio
in review: Leishmaniasis
– DNDi</span>. <a href="https://www.dndi.org/2020/media-centre/news-views-stories/news/leishmaniasis-rnd-portfolio-update/" class="extLink">https://www.dndi.org/2020/media-centre/news-views-stories/news/leishmaniasis-rnd-portfolio-update/</a> (accessed Apr 20, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=DNDi&title=2019+R%26D+portfolio%0Ain+review%3A+Leishmaniasis%0A%E2%80%93+DNDi"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3D2019%2520R%2526D%2520portfolio%250Ain%2520review%253A%2520Leishmaniasis%250A%25E2%2580%2593%2520DNDi%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Be, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caridha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pybus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreishman-Deitrick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathison, C. J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerario, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chianelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggimann, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luneau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudewicz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10773</span>– <span class="NLM_lpage">10781</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10773-10781&author=A.+Nagleauthor=A.+Biggartauthor=C.+Beauthor=H.+Srinivasauthor=A.+Heinauthor=D.+Caridhaauthor=R.+J.+Sciottiauthor=B.+Pybusauthor=M.+Kreishman-Deitrickauthor=B.+Bursulayaauthor=Y.+H.+Laiauthor=M.-Y.+Gaoauthor=F.+Liangauthor=C.+J.+N.+Mathisonauthor=X.+Liuauthor=V.+Yehauthor=J.+Smithauthor=I.+Lerarioauthor=Y.+Xieauthor=D.+Chianelliauthor=M.+Gibneyauthor=A.+Bermanauthor=Y.-L.+Chenauthor=J.+Jiricekauthor=L.+C.+Davisauthor=X.+Liuauthor=J.+Ballardauthor=S.+Khareauthor=F.+K.+Eggimannauthor=A.+Luneauauthor=T.+Groesslauthor=M.+Shapiroauthor=W.+Richmondauthor=K.+Johnsonauthor=P.+J.+Rudewiczauthor=S.+P.+S.+Raoauthor=C.+Thompsonauthor=T.+Tuntlandauthor=G.+Spraggonauthor=R.+J.+Glynneauthor=F.+Supekauthor=C.+Wiesmannauthor=V.+Molteni&title=Discovery+and+Characterization+of+Clinical+Candidate+LXE408+as+a+Kinetoplastid-Selective+Proteasome+Inhibitor+for+the+Treatment+of+Leishmaniases&doi=10.1021%2Facs.jmedchem.0c00499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases</span></div><div class="casAuthors">Nagle, Advait; Biggart, Agnes; Be, Celine; Srinivas, Honnappa; Hein, Andreas; Caridha, Diana; Sciotti, Richard J.; Pybus, Brandon; Kreishman-Deitrick, Mara; Bursulaya, Badry; Lai, Yin H.; Gao, Mu-Yun; Liang, Fang; Mathison, Casey J. N.; Liu, Xiaodong; Yeh, Vince; Smith, Jeffrey; Lerario, Isabelle; Xie, Yongping; Chianelli, Donatella; Gibney, Michael; Berman, Ashley; Chen, Yen-Liang; Jiricek, Jan; Davis, Lauren C.; Liu, Xianzhong; Ballard, Jaime; Khare, Shilpi; Eggimann, Fabian Kurt; Luneau, Alexandre; Groessl, Todd; Shapiro, Michael; Richmond, Wendy; Johnson, Kevin; Rudewicz, Patrick J.; Rao, Srinivasa P. S.; Thompson, Christopher; Tuntland, Tove; Spraggon, Glen; Glynne, Richard J.; Supek, Frantisek; Wiesmann, Christian; Molteni, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10773-10781</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Visceral leishmaniasis is responsible for up to 30,000 deaths every year.  Current treatments have shortcomings that include toxicity and variable efficacy across endemic regions.  Previously, we reported the discovery of GNF6702, a selective inhibitor of the kinetoplastid proteasome, which cleared parasites in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis.  Here, we describe the discovery and characterization of LXE408(I), a structurally related kinetoplastid-selective proteasome inhibitor currently in Phase 1 human clin. trials.  Furthermore, we present high-resoln. cryo-EM structures of the Leishmania tarentolae proteasome in complex with LXE408, which provides a compelling explanation for the noncompetitive mode of binding of this novel class of inhibitors of the kinetoplastid proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFHqvdoR1fT7Vg90H21EOLACvtfcHk0ljRKRcHg3YVhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jurzM&md5=30d8293eed0e94a7bdb75c9d794f52ce</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00499%26sid%3Dliteratum%253Aachs%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DBiggart%26aufirst%3DA.%26aulast%3DBe%26aufirst%3DC.%26aulast%3DSrinivas%26aufirst%3DH.%26aulast%3DHein%26aufirst%3DA.%26aulast%3DCaridha%26aufirst%3DD.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DPybus%26aufirst%3DB.%26aulast%3DKreishman-Deitrick%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DMathison%26aufirst%3DC.%2BJ.%2BN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYeh%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLerario%26aufirst%3DI.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DChianelli%26aufirst%3DD.%26aulast%3DGibney%26aufirst%3DM.%26aulast%3DBerman%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.-L.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DEggimann%26aufirst%3DF.%2BK.%26aulast%3DLuneau%26aufirst%3DA.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DRudewicz%26aufirst%3DP.%2BJ.%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DSupek%26aufirst%3DF.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DMolteni%26aufirst%3DV.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520Clinical%2520Candidate%2520LXE408%2520as%2520a%2520Kinetoplastid-Selective%2520Proteasome%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Leishmaniases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10773%26epage%3D10781%26doi%3D10.1021%2Facs.jmedchem.0c00499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajakane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez-Pedraglio, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleghorn, L. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Siles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada-Campos, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Gomez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span> <span> </span><span class="NLM_article-title">Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1202</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFGhtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1180-1202&author=M.+G.+Thomasauthor=M.+De+Ryckerauthor=M.+Ajakaneauthor=S.+Albrechtauthor=A.+I.+%C3%81lvarez-Pedraglioauthor=M.+Boescheauthor=S.+Brandauthor=L.+Campbellauthor=J.+Cantizani-Perezauthor=L.+A.+T.+Cleghornauthor=R.+C.+B.+Copleyauthor=S.+D.+Crouchauthor=A.+Dauganauthor=G.+Drewesauthor=S.+Ferrerauthor=S.+Ghidelli-Disseauthor=S.+Gonzalezauthor=S.+L.+Greshamauthor=A.+P.+Hillauthor=S.+J.+Hindleyauthor=R.+M.+Loweauthor=C.+J.+MacKenzieauthor=L.+MacLeanauthor=S.+Manthriauthor=F.+Martinauthor=J.+Miguel-Silesauthor=V.+L.+Nguyenauthor=S.+Norvalauthor=M.+Osuna-Cabelloauthor=A.+Woodlandauthor=S.+Pattersonauthor=I.+Penaauthor=M.+T.+Quesada-Camposauthor=I.+H.+Reidauthor=C.+Revillauthor=J.+Rileyauthor=J.+R.+Ruiz-Gomezauthor=Y.+Shishikuraauthor=F.+R.+C.+Simeonsauthor=A.+Smithauthor=V.+C.+Smithauthor=D.+Spinksauthor=L.+Stojanovskiauthor=J.+Thomasauthor=S.+Thompsonauthor=T.+Underwoodauthor=D.+W.+Grayauthor=J.+M.+Fiandorauthor=I.+H.+Gilbertauthor=P.+G.+Wyattauthor=K.+D.+Readauthor=T.+J.+Miles&title=Identification+of+GSK3186899%2FDDD853651+as+a+Preclinical+Development+Candidate+for+the+Treatment+of+Visceral+Leishmaniasis&doi=10.1021%2Facs.jmedchem.8b01218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GSK3186899/DDD853651 as a preclinical development candidate for the treatment of visceral leishmaniasis</span></div><div class="casAuthors">Thomas, Michael G.; De Rycker, Manu; Ajakane, Myriam; Albrecht, Sebastian; Alvarez-Pedraglio, Ana Isabel; Boesche, Markus; Brand, Stephen; Campbell, Lorna; Cantizani-Perez, Juan; Cleghorn, Laura A. T.; Copley, Royston C. B.; Crouch, Sabrinia D.; Daugan, Alain; Drewes, Gerard; Ferrer, Santiago; Ghidelli-Disse, Sonja; Gonzalez, Silvia; Gresham, Stephanie L.; Hill, Alan P.; Hindley, Sean J.; Lowe, Rhiannon M.; MacKenzie, Claire J.; MacLean, Lorna; Manthri, Sujatha; Martin, Franck; Miguel-Siles, Juan; Nguyen, Van Loc; Norval, Suzanne; Osuna-Cabello, Maria; Woodland, Andrew; Patterson, Stephen; Pena, Imanol; Quesada-Campos, Maria Teresa; Reid, Iain H.; Revill, Charlotte; Riley, Jennifer; Ruiz-Gomez, Jose Ramon; Shishikura, Yoko; Simeons, Frederick R. C.; Smith, Alasdair; Smith, Victoria C.; Spinks, Daniel; Stojanovski, Laste; Thomas, John; Thompson, Stephen; Underwood, Tim; Gray, David W.; Fiandor, Jose M.; Gilbert, Ian H.; Wyatt, Paul G.; Read, Kevin D.; Miles, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1180-1202</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The leishmaniases are diseases that affect millions of people across the world, in particular visceral leishmaniasis (VL) which is fatal unless treated.  Current std. of care for VL suffers from multiple issues and there is a limited pipeline of new candidate drugs.  As such, there is a clear unmet medical need to identify new treatments.  This paper describes the optimization of a phenotypic hit against Leishmania donovani, the major causative organism of VL.  The key challenges were to balance soly. and metabolic stability while maintaining potency.  Herein, strategies to address these shortcomings and enhance efficacy are discussed, culminating in the discovery of preclin. development candidate GSK3186899/DDD853651 (1) for VL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3K_YbhzFzXbVg90H21EOLACvtfcHk0ljRKRcHg3YVhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFGhtLfP&md5=6c0c7ed8d7b5b38b6fe1eb5bbe655bb1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01218%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%2BG.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DAjakane%26aufirst%3DM.%26aulast%3DAlbrecht%26aufirst%3DS.%26aulast%3D%25C3%2581lvarez-Pedraglio%26aufirst%3DA.%2BI.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DL.%26aulast%3DCantizani-Perez%26aufirst%3DJ.%26aulast%3DCleghorn%26aufirst%3DL.%2BA.%2BT.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DCrouch%26aufirst%3DS.%2BD.%26aulast%3DDaugan%26aufirst%3DA.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DGonzalez%26aufirst%3DS.%26aulast%3DGresham%26aufirst%3DS.%2BL.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DHindley%26aufirst%3DS.%2BJ.%26aulast%3DLowe%26aufirst%3DR.%2BM.%26aulast%3DMacKenzie%26aufirst%3DC.%2BJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DMiguel-Siles%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DV.%2BL.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DWoodland%26aufirst%3DA.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DPena%26aufirst%3DI.%26aulast%3DQuesada-Campos%26aufirst%3DM.%2BT.%26aulast%3DReid%26aufirst%3DI.%2BH.%26aulast%3DRevill%26aufirst%3DC.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DRuiz-Gomez%26aufirst%3DJ.%2BR.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DV.%2BC.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DUnderwood%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26atitle%3DIdentification%2520of%2520GSK3186899%252FDDD853651%2520as%2520a%2520Preclinical%2520Development%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Visceral%2520Leishmaniasis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1180%26epage%3D1202%26doi%3D10.1021%2Facs.jmedchem.8b01218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbaniak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflaumer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 12 Is a Drug Target for Visceral Leishmaniasis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>560</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0356-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fs41586-018-0356-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30046105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=560&publication_year=2018&pages=192-197&author=S.+Wyllieauthor=M.+Thomasauthor=S.+Pattersonauthor=S.+Crouchauthor=M.+De+Ryckerauthor=R.+Loweauthor=S.+Greshamauthor=M.+D.+Urbaniakauthor=T.+D.+Ottoauthor=L.+Stojanovskiauthor=F.+R.+C.+Simeonsauthor=S.+Manthriauthor=L.+M.+MacLeanauthor=F.+Zuccottoauthor=N.+Homeyerauthor=H.+Pflaumerauthor=M.+Boescheauthor=L.+Sastryauthor=P.+Connollyauthor=S.+Albrechtauthor=M.+Berrimanauthor=G.+Drewesauthor=D.+W.+Grayauthor=S.+Ghidelli-Disseauthor=S.+Dixonauthor=J.+M.+Fiandorauthor=P.+G.+Wyattauthor=M.+A.+J.+Fergusonauthor=A.+H.+Fairlambauthor=T.+J.+Milesauthor=K.+D.+Readauthor=I.+H.+Gilbert&title=Cyclin-Dependent+Kinase+12+Is+a+Drug+Target+for+Visceral+Leishmaniasis&doi=10.1038%2Fs41586-018-0356-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis</span></div><div class="casAuthors">Wyllie, Susan; Thomas, Michael; Patterson, Stephen; Crouch, Sabrinia; De Rycker, Manu; Lowe, Rhiannon; Gresham, Stephanie; Urbaniak, Michael D.; Otto, Thomas D.; Stojanovski, Laste; Simeons, Frederick R. C.; Manthri, Sujatha; MacLean, Lorna M.; Zuccotto, Fabio; Homeyer, Nadine; Pflaumer, Hannah; Boesche, Markus; Sastry, Lalitha; Connolly, Paul; Albrecht, Sebastian; Berriman, Matt; Drewes, Gerard; Gray, David W.; Ghidelli-Disse, Sonja; Dixon, Susan; Fiandor, Jose M.; Wyatt, Paul G.; Ferguson, Michael A. J.; Fairlamb, Alan H.; Miles, Timothy J.; Read, Kevin D.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">560</span>
        (<span class="NLM_cas:issue">7717</span>),
    <span class="NLM_cas:pages">192-197</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world.  There is an urgent need for the development of new, effective treatments for this disease.  Here we describe the development of an anti-leishmanial drug-like chem. series based on a pyrazolopyrimidine scaffold.  The leading compd. from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochem., pharmacokinetic and toxicol. properties for further development, and has been declared a preclin. candidate.  Detailed mode-of-action studies indicate that compds. from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWvpd9EzGFxLVg90H21EOLACvtfcHk0lhQprZdmyfmQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt77I&md5=bea43a232049ade6ed9abea3e0510221</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0356-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0356-z%26sid%3Dliteratum%253Aachs%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DCrouch%26aufirst%3DS.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DLowe%26aufirst%3DR.%26aulast%3DGresham%26aufirst%3DS.%26aulast%3DUrbaniak%26aufirst%3DM.%2BD.%26aulast%3DOtto%26aufirst%3DT.%2BD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMacLean%26aufirst%3DL.%2BM.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DHomeyer%26aufirst%3DN.%26aulast%3DPflaumer%26aufirst%3DH.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DSastry%26aufirst%3DL.%26aulast%3DConnolly%26aufirst%3DP.%26aulast%3DAlbrecht%26aufirst%3DS.%26aulast%3DBerriman%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DDixon%26aufirst%3DS.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DCyclin-Dependent%2520Kinase%252012%2520Is%2520a%2520Drug%2520Target%2520for%2520Visceral%2520Leishmaniasis%26jtitle%3DNature%26date%3D2018%26volume%3D560%26spage%3D192%26epage%3D197%26doi%3D10.1038%2Fs41586-018-0356-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathison, C. J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myburgh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, H. X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span> <span> </span><span class="NLM_article-title">Proteasome Inhibition for Treatment of Leishmaniasis, Chagas Disease and Sleeping Sickness</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nature19339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fnature19339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=27501246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=229-233&author=S.+Khareauthor=A.+S.+Nagleauthor=A.+Biggartauthor=Y.+H.+Laiauthor=F.+Liangauthor=L.+C.+Davisauthor=S.+W.+Barnesauthor=C.+J.+N.+Mathisonauthor=E.+Myburghauthor=M.-Y.+Gaoauthor=J.+R.+Gillespieauthor=X.+Liuauthor=J.+L.+Tanauthor=M.+Stinsonauthor=I.+C.+Riveraauthor=J.+Ballardauthor=V.+Yehauthor=T.+Groesslauthor=G.+Federeauthor=H.+X.+Y.+Kohauthor=J.+D.+Venableauthor=B.+Bursulayaauthor=M.+Shapiroauthor=P.+K.+Mishraauthor=G.+Spraggonauthor=A.+Brockauthor=J.+C.+Mottramauthor=F.+S.+Bucknerauthor=S.+P.+S.+Raoauthor=B.+G.+Wenauthor=J.+R.+Walkerauthor=T.+Tuntlandauthor=V.+Molteniauthor=R.+J.+Glynneauthor=F.+Supek&title=Proteasome+Inhibition+for+Treatment+of+Leishmaniasis%2C+Chagas+Disease+and+Sleeping+Sickness&doi=10.1038%2Fnature19339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness</span></div><div class="casAuthors">Khare, Shilpi; Nagle, Advait S.; Biggart, Agnes; Lai, Yin H.; Liang, Fang; Davis, Lauren C.; Barnes, S. Whitney; Mathison, Casey J. N.; Myburgh, Elmarie; Gao, Mu-Yun; Gillespie, J. Robert; Liu, Xianzhong; Tan, Jocelyn L.; Stinson, Monique; Rivera, Ianne C.; Ballard, Jaime; Yeh, Vince; Groessl, Todd; Federe, Glenn; Koh, Hazel X. Y.; Venable, John D.; Bursulaya, Badry; Shapiro, Michael; Mishra, Pranab K.; Spraggon, Glen; Brock, Ansgar; Mottram, Jeremy C.; Buckner, Frederick S.; Rao, Srinivasa P. S.; Wen, Ben G.; Walker, John R.; Tuntland, Tove; Molteni, Valentina; Glynne, Richard J.; Supek, Frantisek</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths annually.  The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp., resp.  These parasites have similar biol. and genomic sequence, suggesting that all three diseases could be cured with drugs that modulate the activity of a conserved parasite target.  However, no such mol. targets or broad spectrum drugs have been identified to date.  Here we describe a selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection.  GNF6702 inhibits the kinetoplastid proteasome through a non-competitive mechanism, does not inhibit the mammalian proteasome or growth of mammalian cells, and is well-tolerated in mice.  Our data provide genetic and chem. validation of the parasite proteasome as a promising therapeutic target for treatment of kinetoplastid infections, and underscore the possibility of developing a single class of drugs for these neglected diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PXMn1-tj_7Vg90H21EOLACvtfcHk0lhQprZdmyfmQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL&md5=a05e7ce0f6b912b3003c5b3f42a005bb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature19339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19339%26sid%3Dliteratum%253Aachs%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DNagle%26aufirst%3DA.%2BS.%26aulast%3DBiggart%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DMathison%26aufirst%3DC.%2BJ.%2BN.%26aulast%3DMyburgh%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DGillespie%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DJ.%2BL.%26aulast%3DStinson%26aufirst%3DM.%26aulast%3DRivera%26aufirst%3DI.%2BC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DYeh%26aufirst%3DV.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DFedere%26aufirst%3DG.%26aulast%3DKoh%26aufirst%3DH.%2BX.%2BY.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DP.%2BK.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBrock%26aufirst%3DA.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DWen%26aufirst%3DB.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DSupek%26aufirst%3DF.%26atitle%3DProteasome%2520Inhibition%2520for%2520Treatment%2520of%2520Leishmaniasis%252C%2520Chagas%2520Disease%2520and%2520Sleeping%2520Sickness%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D229%26epage%3D233%26doi%3D10.1038%2Fnature19339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den Kerkhof, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowbray, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braillard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickx, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Pharmacodynamics of Three Novel Antileishmanial Lead Series</span>. <i>Int. J. Parasitol. Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.ijpddr.2018.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ijpddr.2018.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=29425734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC1MvpvVGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=81-86&author=M.+Van%0Aden+Kerkhofauthor=D.+Mabilleauthor=E.+Chatelainauthor=C.+E.+Mowbrayauthor=S.+Braillardauthor=S.+Hendrickxauthor=L.+Maesauthor=G.+Caljon&title=In+Vitro+and+in+Vivo+Pharmacodynamics+of+Three+Novel+Antileishmanial+Lead+Series&doi=10.1016%2Fj.ijpddr.2018.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series</span></div><div class="casAuthors">Van den Kerkhof M; Mabille D; Hendrickx S; Maes L; Chatelain E; Mowbray C E; Braillard S; Caljon G</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Three new chemical series (bicyclic nitroimidazoles, aminopyrazoles and oxaboroles) were selected by Drugs for Neglected Diseases initiative as potential new drug leads for leishmaniasis.  Pharmacodynamics studies included both in vitro and in vivo efficacy, cross-resistance profiling against the current antileishmanial reference drugs and evaluation of their cidal activity potential.  METHODS:  Efficacy against the reference laboratory strains of Leishmania infantum (MHOM/MA(BE)/67/ITMAP263) and L. donovani (MHOM/ET/67/L82) was evaluated in vitro on intracellular amastigotes and in vivo in the early curative hamster model.  Cidal activity was assessed over a period of 15 days in an in vitro 'time-to-kill' assay.  Cross-resistance was assessed in vitro on a panel of L. infantum strains with different degrees of resistance to either antimony, miltefosine or paromomycin.  RESULTS:  All lead compounds showed potent and selective in vitro activity against the Leishmania strains tested and no cross-resistance could be demonstrated against any of the current antileishmanial drugs.  Cidal activity was obtained in vitro for all series within 15 days of exposure with some differences noted between L. donovani and L. infantum.  When evaluated in vivo, all lead compounds showed high efficacy and no adverse effects were observed.  CONCLUSIONS:  The new lead series were shown to have cidal pharmacodynamic activity.  The absence of cross-resistance with any of the current antileishmanial drugs opens possibilities for combination treatment to reduce the likelihood of treatment failures and drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQt-RwWhLKvZ9FxYDaSSP8XfW6udTcc2eZjds0xnk0nyrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvpvVGksA%253D%253D&md5=5f9deeb9bb4c0be92959b159b4008452</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2018.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2018.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BKerkhof%26aufirst%3DM.%26aulast%3DMabille%26aufirst%3DD.%26aulast%3DChatelain%26aufirst%3DE.%26aulast%3DMowbray%26aufirst%3DC.%2BE.%26aulast%3DBraillard%26aufirst%3DS.%26aulast%3DHendrickx%26aufirst%3DS.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DCaljon%26aufirst%3DG.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Pharmacodynamics%2520of%2520Three%2520Novel%2520Antileishmanial%2520Lead%2520Series%26jtitle%3DInt.%2520J.%2520Parasitol.%2520Drugs%2520Drug%2520Resist.%26date%3D2018%26volume%3D8%26spage%3D81%26epage%3D86%26doi%3D10.1016%2Fj.ijpddr.2018.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Huijsduijnen, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowbray, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmatz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingsby, B. T.</span></span> <span> </span><span class="NLM_article-title">Hit and Lead Criteria in Drug Discovery for Infectious Diseases of the Developing World</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/nrd4683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fnrd4683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=26435527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1SitL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=751-758&author=K.+Katsunoauthor=J.+N.+Burrowsauthor=K.+Duncanauthor=R.+H.+Van+Huijsduijnenauthor=T.+Kanekoauthor=K.+Kitaauthor=C.+E.+Mowbrayauthor=D.+Schmatzauthor=P.+Warnerauthor=B.+T.+Slingsby&title=Hit+and+Lead+Criteria+in+Drug+Discovery+for+Infectious+Diseases+of+the+Developing+World&doi=10.1038%2Fnrd4683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Hit and lead criteria in drug discovery for infectious diseases of the developing world</span></div><div class="casAuthors">Katsuno, Kei; Burrows, Jeremy N.; Duncan, Ken; van Huijsduijnen, Rob Hooft; Kaneko, Takushi; Kita, Kiyoshi; Mowbray, Charles E.; Schmatz, Dennis; Warner, Peter; Slingsby, B. T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">751-758</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts.  The quality of the chem. starting points for such projects is a key factor in improving the likelihood of clin. success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compds.  With this in mind, the Japanese Global Health Innovative Technol. (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases initiative and the TB Alliance, together with representatives from the Bill & Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishmaniasis and Chagas disease.  Here, we present the agreed criteria and discuss the underlying rationale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFQHFz6z3D_rVg90H21EOLACvtfcHk0lhbw_AjPkjtYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1SitL7O&md5=6cd6d7c8ca3a85d64f24915da8e1120c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd4683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4683%26sid%3Dliteratum%253Aachs%26aulast%3DKatsuno%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DDuncan%26aufirst%3DK.%26aulast%3DVan%2BHuijsduijnen%26aufirst%3DR.%2BH.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DMowbray%26aufirst%3DC.%2BE.%26aulast%3DSchmatz%26aufirst%3DD.%26aulast%3DWarner%26aufirst%3DP.%26aulast%3DSlingsby%26aufirst%3DB.%2BT.%26atitle%3DHit%2520and%2520Lead%2520Criteria%2520in%2520Drug%2520Discovery%2520for%2520Infectious%2520Diseases%2520of%2520the%2520Developing%2520World%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D751%26epage%3D758%26doi%3D10.1038%2Fnrd4683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span> <span> </span><span class="NLM_article-title">Purine Metabolism in Trypanosoma Cruzi</span>. <i>Mol. Biochem. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1016/0166-6851(81)90049-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0166-6851%2881%2990049-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6166862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3MXkvFelsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1981&pages=187-196&author=R.+L.+Berensauthor=J.+J.+Marrauthor=S.+W.+LaFonauthor=D.+J.+Nelson&title=Purine+Metabolism+in+Trypanosoma+Cruzi&doi=10.1016%2F0166-6851%2881%2990049-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Purine metabolism in Trypanosoma cruzi</span></div><div class="casAuthors">Berens, Randolph L.; Marr, J. Joseph; LaFon, Stephen W.; Nelson, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Biochemical Parasitology</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-96</span>CODEN:
                <span class="NLM_cas:coden">MBIPDP</span>;
        ISSN:<span class="NLM_cas:issn">0166-6851</span>.
    </div><div class="casAbstract">Culture forms of T. cruzi are incapable of synthesizing purines de novo from formate, glycine, or serine and require an exogenous purine for growth.  Adenine, hypoxanthine, guanine, xanthine, and their resp. ribonucleosides are equal in their abilities to support growth.  Radiolabeled purine bases, with the exception of guanine, are stable and are converted to their resp. ribonucleotides directly by phosphoribosyltransferase activity.  Guanine is both converted to its ribonucleotide and deaminated to xanthine.  Purine nucleosides are not hydrolyzed to any extent but are converted to their resp. ribonucleotides.  This conversion may involve a rate-limiting ribonucleoside cleaving activity or a purine nucleoside kinase or phosphotransferase activity.  The apparent order of salvage efficiency for the bases and their resp. ribonucleosides is adenine > hypoxanthine > guanine > xanthine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtRLwTwe5Mk7Vg90H21EOLACvtfcHk0lhbw_AjPkjtYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXkvFelsLo%253D&md5=bb238018e74aa307b1651f2242ef76aa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0166-6851%2881%2990049-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-6851%252881%252990049-9%26sid%3Dliteratum%253Aachs%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DLaFon%26aufirst%3DS.%2BW.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26atitle%3DPurine%2520Metabolism%2520in%2520Trypanosoma%2520Cruzi%26jtitle%3DMol.%2520Biochem.%2520Parasitol.%26date%3D1981%26volume%3D3%26spage%3D187%26epage%3D196%26doi%3D10.1016%2F0166-6851%2881%2990049-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, N. S.</span>; <span class="NLM_string-name">Yates, P.</span>; <span class="NLM_string-name">Arendt, C. S.</span>; <span class="NLM_string-name">Boitz, J. M.</span>; <span class="NLM_string-name">Ullman, B.</span></span> <span> </span><span class="NLM_article-title">Purine and Pyrimidine Metabolism in Leishmania</span>. In  <i>Drug Targets in Kinetoplastid Parasites</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumder, H. K.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">154</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1007%2F978-0-387-77570-8_12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=141-154&author=N.+S.+Carter&author=P.+Yates&author=C.+S.+Arendt&author=J.+M.+Boitz&author=B.+Ullmanauthor=H.+K.+Majumder&title=Drug+Targets+in+Kinetoplastid+Parasites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-77570-8_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-77570-8_12%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DN.%2BS.%26atitle%3DPurine%2520and%2520Pyrimidine%2520Metabolism%2520in%2520Leishmania%26btitle%3DDrug%2520Targets%2520in%2520Kinetoplastid%2520Parasites%26aulast%3DMajumder%26aufirst%3DH.%2BK.%26pub%3DSpringer%26date%3D2008%26spage%3D141%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boitz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jardim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, N. S.</span></span> <span> </span><span class="NLM_article-title">Purine Salvage in Leishmania: Complex or Simple by Design?</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2012.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.pt.2012.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22726696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGntb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=345-352&author=J.+M.+Boitzauthor=B.+Ullmanauthor=A.+Jardimauthor=N.+S.+Carter&title=Purine+Salvage+in+Leishmania%3A+Complex+or+Simple+by+Design%3F&doi=10.1016%2Fj.pt.2012.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Purine salvage in Leishmania: complex or simple by design?</span></div><div class="casAuthors">Boitz, Jan M.; Ullman, Buddy; Jardim, Armando; Carter, Nicola S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">345-352</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Purine nucleotides function in a variety of vital cellular and metabolic processes including energy prodn., cell signaling, synthesis of vitamin-derived cofactors and nucleic acids, and as determinants of cell fate.  Unlike their mammalian and insect hosts, Leishmania cannot synthesize the purine ring de novo and are absolutely dependent upon them to meet their purine requirements.  The obligatory nature of purine salvage in these parasites, therefore, offers an attractive paradigm for drug targeting and, consequently, the delineation of the pathway has been under scientific investigation for over 30 years.  Here, we review recent developments that reveal how purines flux in Leishmania and offer a potential Achilles' heel' for future validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX93wTv2RJSbVg90H21EOLACvtfcHk0li7ge7_cPe-cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGntb3I&md5=9a95c3fbcc61a93d668ca813ad971c07</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2012.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2012.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBoitz%26aufirst%3DJ.%2BM.%26aulast%3DUllman%26aufirst%3DB.%26aulast%3DJardim%26aufirst%3DA.%26aulast%3DCarter%26aufirst%3DN.%2BS.%26atitle%3DPurine%2520Salvage%2520in%2520Leishmania%253A%2520Complex%2520or%2520Simple%2520by%2520Design%253F%26jtitle%3DTrends%2520Parasitol.%26date%3D2012%26volume%3D28%26spage%3D345%26epage%3D352%26doi%3D10.1016%2Fj.pt.2012.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goeminne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haemers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2456</span>– <span class="NLM_lpage">2481</span>, <span class="refDoi"> DOI: 10.2174/092986710791556023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.2174%2F092986710791556023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=20491648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2456-2481&author=M.+Bergauthor=P.+Van+der+Vekenauthor=A.+Goeminneauthor=A.+Haemersauthor=K.+Augustyns&title=Inhibitors+of+the+Purine+Salvage+Pathway%3A+A+Valuable+Approach+for+Antiprotozoal+Chemotherapy%3F&doi=10.2174%2F092986710791556023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy?</span></div><div class="casAuthors">Berg, M.; Van der Veken, P.; Goeminne, A.; Haemers, A.; Augustyns, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2456-2481</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  For many years, the purine salvage pathway of parasitic protozoa has been regarded as an attractive chemotherapeutic target.  Parasitic protozoa lack de novo synthesis and rely entirely on the purine salvage pathway to meet their purine demands.  Because of the great phylogenetic difference between parasite and host, there are often sufficient distinctions that can be exploited to design specific inhibitors for the parasitic enzymes.  As a result, this pathway has been thoroughly investigated over the last twenty years.  It is only quite recently that the genome studies of Trypanosoma, Leishmania and Plasmodium have been published.  Based on these genomic data however, the existence of bypass mechanisms by other enzymes and transporter systems could be suggested.  Taking into account such proposition, the question might arise as to whether inhibition of a single salvage enzyme will be able or not to cause parasite death or growth arrest.  In this paper, the key enzymes in the purine salvage pathways of relevant pathogenic species from the genera Trypanosoma, Leishmania and Plasmodium are reviewed.  Their potential as drug targets is critically evaluated and where possible, correlated to literature data on antiparasitic activity of their inhibitors.  While many studies over the past ten years have yielded contradictory results, this review attempts to clarify these findings by discussing the latest elements of progress in the field.  Addnl., as part of a broader discussion on substrate analog types of inhibitors, special attention is paid to iminoribitol derivs., serving as transition state analogs of nucleoside-processing enzymes and comprising the most potent inhibitors reported for purine salvage enzymes.  More specifically, the development of three generations of immucillins and a newer series of N-(arylmethyl-) substituted iminoribitol derivs. will be discussed.  Finally, this review also covers subversive substrates of salvage enzymes: compds. that are transformed by enzymic activity into cytotoxic agents.  Although not by directly intervening in the process of purine recovery, the subversive substrate approach might deliver antiprotozoal compds. that rely on salvage enzymes for their activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwcrBmQ1eWHbVg90H21EOLACvtfcHk0li7ge7_cPe-cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslSksL4%253D&md5=7fde49d9ce5a02260ec9ea9ae21e9d44</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F092986710791556023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791556023%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DM.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DGoeminne%26aufirst%3DA.%26aulast%3DHaemers%26aufirst%3DA.%26aulast%3DAugustyns%26aufirst%3DK.%26atitle%3DInhibitors%2520of%2520the%2520Purine%2520Salvage%2520Pathway%253A%2520A%2520Valuable%2520Approach%2520for%2520Antiprotozoal%2520Chemotherapy%253F%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D2456%26epage%3D2481%26doi%3D10.2174%2F092986710791556023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Kouni, M. H.</span></span> <span> </span><span class="NLM_article-title">Potential Chemotherapeutic Targets in the Purine Metabolism of Parasites</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(03)00071-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0163-7258%2803%2900071-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=12951162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvV2qs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=283-309&author=M.+H.+El%0AKouni&title=Potential+Chemotherapeutic+Targets+in+the+Purine+Metabolism+of+Parasites&doi=10.1016%2FS0163-7258%2803%2900071-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Potential chemotherapeutic targets in the purine metabolism of parasites</span></div><div class="casAuthors">el Kouni, Mahmoud H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-309</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Parasites are responsible for a wide variety of infectious diseases in human as well as in domestic and wild animals, causing an enormous health and economical blight.  Current containment strategies are not entirely successful and parasitic infections are on the rise.  In the absence of availability of antiparasitic vaccines, chemotherapy remains the mainstay for the treatment of most parasitic diseases.  However, there is an urgent need for new drugs to prevent or combat some major parasitic infections because of lack of a single effective approach for controlling the parasites (e.g., trypanosomiasis) or because some serious parasitic infections developed resistance to presently available drugs (e.g., malaria).  The rational design of a drug is usually based on biochem. and physiol. differences between pathogens and host.  Some of the most striking differences between parasites and their mammalian host are found in purine metab.  Purine nucleotides can be synthesized by the de novo and/or the so-called "salvage" pathways.  Unlike their mammalian host, most parasites studied lack the pathways for de novo purine biosynthesis and rely on the salvage pathways to meet their purine demands.  Moreover, because of the great phylogenic sepn. between the host and the parasite, there are in some cases sufficient distinctions between corresponding enzymes of the purine salvage from the host and the parasite that can be exploited to design specific inhibitors or "subversive substrates" for the parasitic enzymes.  Furthermore, the specificities of purine transport, the first step in purine salvage, diverge significantly between parasites and their mammalian host.  This review highlights the unique transporters and enzymes responsible for the salvage of purines in parasites that could constitute excellent potential targets for the design of safe and effective antiparasitic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoihVOC8nfcRbVg90H21EOLACvtfcHk0li7ge7_cPe-cA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvV2qs7c%253D&md5=5555db1e6dcb372302fbbdfb1e868371</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900071-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900071-8%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BKouni%26aufirst%3DM.%2BH.%26atitle%3DPotential%2520Chemotherapeutic%2520Targets%2520in%2520the%2520Purine%2520Metabolism%2520of%2520Parasites%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D99%26spage%3D283%26epage%3D309%26doi%3D10.1016%2FS0163-7258%2803%2900071-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Datta, A. K.</span>; <span class="NLM_string-name">Datta, R.</span>; <span class="NLM_string-name">Sen, B.</span></span> <span> </span><span class="NLM_article-title">Antiparasitic Chemotherapy</span>. In  <i>Drug Targets in Kinetoplastid Parasites</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumder, H. K.</span></span>, Ed.; <span class="NLM_series">Advances In Experimental Medicine and Biology</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">132</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1007%2F978-0-387-77570-8_10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=116-132&author=A.+K.+Datta&author=R.+Datta&author=B.+Senauthor=H.+K.+Majumder&title=Drug+Targets+in+Kinetoplastid+Parasites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-77570-8_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-77570-8_10%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DA.%2BK.%26atitle%3DAntiparasitic%2520Chemotherapy%26btitle%3DDrug%2520Targets%2520in%2520Kinetoplastid%2520Parasites%26aulast%3DMajumder%26aufirst%3DH.%2BK.%26pub%3DSpringer%26date%3D2008%26spage%3D116%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span> <span> </span><span class="NLM_article-title">Antileishmanial Effect of Allopurinol</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1128/AAC.5.5.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.5.5.469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=4462464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaE2cXkvVKnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1974&pages=469-472&author=M.+A.+Pfallerauthor=J.+J.+Marr&title=Antileishmanial+Effect+of+Allopurinol&doi=10.1128%2FAAC.5.5.469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Antileishmanial effect of allopurinol</span></div><div class="casAuthors">Pfaller, Michael A.; Marr, J. Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-72</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Allopurinol (I) [315-30-0] inhibited the growth of Leishmania braziliensis in vitro at concns. attainable in human tissues and body fluids.  I apparently acted by blocking the de novo synthesis of pyrimidines as a result of allopurinol ribonucleotide formation.  Although I is a known inhibitor of xanthine oxidase, the absence of this enzyme in L. braziliensis suggests that the toxicity of I is not due to inhibition of the interconversion of pteridines.  I is not toxic to humans, indicating its potential clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQcPhCgTcE77Vg90H21EOLACvtfcHk0liwCipeQ2l8bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXkvVKnsbo%253D&md5=7ae6fecd4f42670a310d37371288ad26</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FAAC.5.5.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.5.5.469%26sid%3Dliteratum%253Aachs%26aulast%3DPfaller%26aufirst%3DM.%2BA.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26atitle%3DAntileishmanial%2520Effect%2520of%2520Allopurinol%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1974%26volume%3D5%26spage%3D469%26epage%3D472%26doi%3D10.1128%2FAAC.5.5.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Looker, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Action of Pyrazolopyrimidines in Leishmania Donovani</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">9412</span>– <span class="NLM_lpage">9415</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)67670-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0021-9258%2818%2967670-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2424909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL28XkvFCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1986&pages=9412-9415&author=D.+L.+Lookerauthor=J.+J.+Marrauthor=R.+L.+Berens&title=Mechanisms+of+Action+of+Pyrazolopyrimidines+in+Leishmania+Donovani&doi=10.1016%2FS0021-9258%2818%2967670-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of action of pyrazolopyrimidines in Leishmania donovani</span></div><div class="casAuthors">Looker, Douglas L.; Marr, J. Joseph; Berens, Randolph L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9412-15</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The antileishmanial actions were investigated of the pyrazolopyrimidines allopurinol, thiopurinol, and aminopurinol.  These compds. affect several metabolic processes.  The first is the inhibition of GMP reductase by the IMP analogs allopurinol ribonucleoside monophosphate and thiopurinol ribonucleoside monophosphate, which reduces the organism's ability to synthesize ATP from guanine.  Second, interconversion of adenine nucleotides to guanine nucleotides is curtailed by the inhibition of IMP dehydrogenase by these same IMP analogs.  Third, the IMP analogs reduce intracellular UTP content.  The 4th affect is increased catabolism of RNA and consequent redn. of protein synthesis.  This latter effect is due to the adenine nucleotide analogs aminopurinol ribonucleoside mono-, di-, and(or) triphosphates, metabolic products of both allopurinol and aminopurinol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondHCSHPGLe7Vg90H21EOLACvtfcHk0liwCipeQ2l8bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XkvFCgtb4%253D&md5=712ea292003f95dbb21b134793341855</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2967670-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252967670-7%26sid%3Dliteratum%253Aachs%26aulast%3DLooker%26aufirst%3DD.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26atitle%3DMechanisms%2520of%2520Action%2520of%2520Pyrazolopyrimidines%2520in%2520Leishmania%2520Donovani%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1986%26volume%3D261%26spage%3D9412%26epage%3D9415%26doi%3D10.1016%2FS0021-9258%2818%2967670-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele
da Cruz, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span> <span> </span><span class="NLM_article-title">Effect of Allopurinol on Trypanosoma Cruzi: Metabolism and Biological Activity in Intracellular and Bloodstream Forms</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1128/AAC.22.4.657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.22.4.657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6817705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL38XmtFags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1982&pages=657-661&author=R.+L.+Berensauthor=J.+J.+Marrauthor=F.+S.+Steele%0Ada+Cruzauthor=D.+J.+Nelson&title=Effect+of+Allopurinol+on+Trypanosoma+Cruzi%3A+Metabolism+and+Biological+Activity+in+Intracellular+and+Bloodstream+Forms&doi=10.1128%2FAAC.22.4.657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of allopurinol on Trypanosoma cruzi:  metabolism and biological activity in intracellular and bloodstream forms</span></div><div class="casAuthors">Berens, Randolph L.; Marr, J. Joseph; Da Cruz, Fernando Steele; Nelson, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">657-61</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Expts. with radiolabeled allopurinol (I) and anal. of the metabolic products of I. by high-performance liq. chromatog. showed that both the blood stream and the intracellular forms of T. cruzi metabolize I in the same manner in tissue culture as has been shown for the epimastigotes in vitro.  The metabolic pathways for pyrazolopyrimidines in the pathogenic forms were demonstrated with organisms isolated from infected animals and a tissue culture system infected with T. cruzi.  Treatment of infected tissue culture with I eradicated the infection.  Thus I may be useful in chemotherapy of T. cruzi infections, a supposition which has been borne out in one animal study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokkGfe4ULE87Vg90H21EOLACvtfcHk0liwCipeQ2l8bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XmtFags7s%253D&md5=393810b236a94152f70d9c3a22f64be3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.22.4.657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.22.4.657%26sid%3Dliteratum%253Aachs%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DSteele%2Bda%2BCruz%26aufirst%3DF.%2BS.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26atitle%3DEffect%2520of%2520Allopurinol%2520on%2520Trypanosoma%2520Cruzi%253A%2520Metabolism%2520and%2520Biological%2520Activity%2520in%2520Intracellular%2520and%2520Bloodstream%2520Forms%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1982%26volume%3D22%26spage%3D657%26epage%3D661%26doi%3D10.1128%2FAAC.22.4.657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugge, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elion, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span> <span> </span><span class="NLM_article-title">Metabolism of Pyrazolo(3,4-d)Pyrimidines in Leishmania Braziliensis and Leishmania Donovani. Allopurinol, Oxipurinol, and 4-Aminopyrazolo(3,4-d)Pyrimidine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">3959</span>– <span class="NLM_lpage">3964</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)50680-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0021-9258%2818%2950680-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=438170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaE1MXksFans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=3959-3964&author=D.+J.+Nelsonauthor=C.+J.+Buggeauthor=G.+B.+Elionauthor=R.+L.+Berensauthor=J.+J.+Marr&title=Metabolism+of+Pyrazolo%283%2C4-d%29Pyrimidines+in+Leishmania+Braziliensis+and+Leishmania+Donovani.+Allopurinol%2C+Oxipurinol%2C+and+4-Aminopyrazolo%283%2C4-d%29Pyrimidine&doi=10.1016%2FS0021-9258%2818%2950680-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of pyrazolo(3,4-d)pyrimidines in Leishmania braziliensis and Leishmania donovani.  Allopurinol, oxipurinol, and 4-aminopyrazol(3,4-d)pyrimidine</span></div><div class="casAuthors">Nelson, Donald J.; Bugge, Christopher J. L.; Elion, Gertrude B.; Berens, Randolph L.; Marr, J. Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3959-64</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">L. donovani And L. brasiliensis grown in culture formed mM concns. of allopurinol ribonucleoside 5'-monophosphate from allopurinol.  In addn., allopurinol 1-ribonucleoside, oxipurinol riboside 5'-monophosphate, and 3 new metabolites of allopurinol, namely, 4-aminopyrazolo[3,4-d]pyrimidine ribonucleoside 5'-monophosphate and the corresponding di- and triphosphates (1-ribosyl 4-aminopyrazolo[3,4-d]pyrimidine 5'-diphosphate and 1-ribosyl 4-aminopyrazolo[3,4-d]pyrimidine 5'-triphosphate) were identified in the parasitic cells.  They were formed via a unique amination reaction from 1-ribosyl allopurinol 5'-phosphate, analogous to the conversion of IMP to AMP.  Allopurinol was incorporated into RNA of L. donovani in the form of 4-aminopyrazolo[3,4-d]pyrimidine.  Adenine reversed the growth inhibition of allopurinol and prevented its metab. to all of the ribonucleotide metabolites.  L. donovani Was 2-4-fold more active in its metab. of allopurinol to ribonucleotides than L. brasiliensis.  4-Aminopyrazolo[3,4-d]pyrimidine inhibited cell growth and resulted in high intracellular levels of 1-ribosyl allopurinol 5'-phosphate and smaller amts. of the 4-aminopyrazolo[3,4-d]pyrimidine ribonucleotides.  The metab. of allopurinol to 4-aminopyrazolo[3,4-d]pyrimidine ribonucleotides and its resultant cytotoxicity occurs in these parasitic protozoans, but not in mammalian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3nzWss9u057Vg90H21EOLACvtfcHk0liwCipeQ2l8bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXksFans7w%253D&md5=00cc84c89faddbeb85965cca4c4139e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2950680-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252950680-3%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26aulast%3DBugge%26aufirst%3DC.%2BJ.%26aulast%3DElion%26aufirst%3DG.%2BB.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26atitle%3DMetabolism%2520of%2520Pyrazolo%25283%252C4-d%2529Pyrimidines%2520in%2520Leishmania%2520Braziliensis%2520and%2520Leishmania%2520Donovani.%2520Allopurinol%252C%2520Oxipurinol%252C%2520and%25204-Aminopyrazolo%25283%252C4-d%2529Pyrimidine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D3959%26epage%3D3964%26doi%3D10.1016%2FS0021-9258%2818%2950680-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kager, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellde, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockmeyer, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyerly, W. H.</span></span> <span> </span><span class="NLM_article-title">Allopurinol in the Treatment of Visceral Leishmaniasis</span>. <i>Trans. R. Soc. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1016/0035-9203(81)90198-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0035-9203%2881%2990198-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6275579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaL387gvVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1981&pages=556-559&author=P.+A.+Kagerauthor=P.+H.+Reesauthor=B.+T.+Welldeauthor=W.+T.+Hockmeyerauthor=W.+H.+Lyerly&title=Allopurinol+in+the+Treatment+of+Visceral+Leishmaniasis&doi=10.1016%2F0035-9203%2881%2990198-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Allopurinol in the treatment of visceral leishmaniasis</span></div><div class="casAuthors">Kager P A; Rees P H; Wellde B T; Hockmeyer W T; Lyerly W H</div><div class="citationInfo"><span class="NLM_cas:title">Transactions of the Royal Society of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">556-9</span>
        ISSN:<span class="NLM_cas:issn">0035-9203</span>.
    </div><div class="casAbstract">Allopurinol was used in the treatment of 10 patients with kala-azar.  Of six patients who had previously failed to respond satisfactorily to Pentostam, "cures" were achieved in four.  However, it was necessary to add Pentostam to the allopurinol in one, and another relapsed after apparent "cure" but again responded to allopurinol.  The response of four patients who had had no previous treatment for kala-azar was less satisfactory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpqVgoOiW2dWGmni0r9GoKfW6udTcc2eY42HgUp4CB07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL387gvVKqsg%253D%253D&md5=2383fe9c6e0a82b7d67293208441e0ee</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2F0035-9203%2881%2990198-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0035-9203%252881%252990198-X%26sid%3Dliteratum%253Aachs%26aulast%3DKager%26aufirst%3DP.%2BA.%26aulast%3DRees%26aufirst%3DP.%2BH.%26aulast%3DWellde%26aufirst%3DB.%2BT.%26aulast%3DHockmeyer%26aufirst%3DW.%2BT.%26aulast%3DLyerly%26aufirst%3DW.%2BH.%26atitle%3DAllopurinol%2520in%2520the%2520Treatment%2520of%2520Visceral%2520Leishmaniasis%26jtitle%3DTrans.%2520R.%2520Soc.%2520Trop.%2520Med.%2520Hyg.%26date%3D1981%26volume%3D75%26spage%3D556%26epage%3D559%26doi%3D10.1016%2F0035-9203%2881%2990198-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span> <span> </span><span class="NLM_article-title">Allopurinol in the Treatment of American Cutaneous Leishmaniasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>326</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1056/NEJM199203123261105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1056%2FNEJM199203123261105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1738379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaK387kvFKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=1992&pages=741-744&author=S.+Martinezauthor=J.+J.+Marr&title=Allopurinol+in+the+Treatment+of+American+Cutaneous+Leishmaniasis&doi=10.1056%2FNEJM199203123261105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Allopurinol in the treatment of American cutaneous leishmaniasis</span></div><div class="casAuthors">Martinez S; Marr J J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">741-4</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Pentavalent antimony, the generally accepted treatment for leishmaniasis, is given parenterally, and it is expensive and not readily available in developing countries.  An inexpensive, orally administered compound would be a substantial advance in treatment.  Previous studies in vitro have shown synergism between allopurinol and pentavalent antimony in tissue-culture systems.  We designed this clinical study to determine whether synergism could be demonstrated in patients.  METHODS:  We performed a randomized, controlled study of the efficacy of allopurinol plus meglumine antimoniate (Glucantime), as compared with meglumine antimoniate alone, in patients with cutaneous leishmaniasis, who were recruited from a village in southeastern Colombia.  In addition, those who declined injections were treated with allopurinol alone, and those who declined any treatment were considered controls.  All the patients were followed for one year after the completion of treatment.  Lesions that healed completely at three months and remained healed during follow-up were considered to be cured.  RESULTS:  The cure rate for patients treated with meglumine antimoniate was 36 percent; the addition of allopurinol increased the rate to 74 percent (P less than 0.001).  Treatment with allopurinol alone yielded a cure rate of 80 percent (P less than 0.001).  There were no cures among the untreated patients.  There was no significant difference between the cure rate with allopurinol plus meglumine antimoniate and that with allopurinol alone.  No major toxic effects were observed.  CONCLUSIONS:  For the treatment of American cutaneous leishmaniasis, the combination of allopurinol and meglumine antimoniate is significantly more effective than meglumine antimoniate alone, probably because of the efficacy of allopurinol alone, which appears to be as good as the combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNXdU_H-LfSresJRIHUP1ofW6udTcc2eY42HgUp4CB07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387kvFKhsg%253D%253D&md5=efec3086cf1e7e43210c1b6aeeff5cc8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1056%2FNEJM199203123261105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199203123261105%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26atitle%3DAllopurinol%2520in%2520the%2520Treatment%2520of%2520American%2520Cutaneous%2520Leishmaniasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1992%26volume%3D326%26spage%3D741%26epage%3D744%26doi%3D10.1056%2FNEJM199203123261105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yaich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charfeddine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masmoudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masmoudi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaghdhane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachicha, J.</span></span> <span> </span><span class="NLM_article-title">Atypical Presentation of Cutaneous Leishmaniasis in a Renal Transplant Recipient Successfully Treated with Allopurinol and Fluconazole</span>. <i>Ann. Saudi Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.5144/0256-4947.2012.01.7.1510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.5144%2F0256-4947.2012.01.7.1510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22750767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC38jmsVanuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=187-191&author=S.+Yaichauthor=K.+Charfeddineauthor=A.+Masmoudiauthor=M.+Masmoudiauthor=S.+Zaghdhaneauthor=H.+Turkiauthor=J.+Hachicha&title=Atypical+Presentation+of+Cutaneous+Leishmaniasis+in+a+Renal+Transplant+Recipient+Successfully+Treated+with+Allopurinol+and+Fluconazole&doi=10.5144%2F0256-4947.2012.01.7.1510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Atypical presentation of cutaneous leishmaniasis in a renal transplant recipient successfully treated with allopurinol and fluconazole</span></div><div class="casAuthors">Yaich Soumaya; Charfeddine Khaled; Masmoudi Abderrahmen; Masmoudi Mondher; Zaghdhane Sawssen; Turki Hamida; Hachicha Jamil</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Saudi medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leishmaniasis is a zoonotic infection acquired through the bite of a female sandfly, which introduces the amastigotes of Leishmania into the bloodstream.  Cutaneous leishmaniasis is rare after solid organ transplantation.  Its diagnosis is difficult in immunosuppressed patients.  We report a case of isolated cutaneous leishmaniasis in a renal transplant patient resident in an endemic area.  The patient was successfully treated with allopurinol and fluconazole and has remained relapse-free for 44 months.  The diagnosis of cutaneous leishmaniasis must be considered in immunosuppressed patients living in endemic areas.  Our report shows that cutaneous leishmaniasis may complicate the clinical course of kidney transplant recipients and its presentation can be atypical.  Conventional treatment with pen.tavalent antimonial agents can cause many side effects; of particular concern in renal transplant pa.tients are pancreatitis and nephrotoxicity.  These latter may be avoided by using a combination of allopurinol and fluconazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTr0KPWBOwAdySm0e6ZOaemfW6udTcc2eY42HgUp4CB07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jmsVanuw%253D%253D&md5=8aa65523822398d80f82b375413be1bd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.5144%2F0256-4947.2012.01.7.1510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5144%252F0256-4947.2012.01.7.1510%26sid%3Dliteratum%253Aachs%26aulast%3DYaich%26aufirst%3DS.%26aulast%3DCharfeddine%26aufirst%3DK.%26aulast%3DMasmoudi%26aufirst%3DA.%26aulast%3DMasmoudi%26aufirst%3DM.%26aulast%3DZaghdhane%26aufirst%3DS.%26aulast%3DTurki%26aufirst%3DH.%26aulast%3DHachicha%26aufirst%3DJ.%26atitle%3DAtypical%2520Presentation%2520of%2520Cutaneous%2520Leishmaniasis%2520in%2520a%2520Renal%2520Transplant%2520Recipient%2520Successfully%2520Treated%2520with%2520Allopurinol%2520and%2520Fluconazole%26jtitle%3DAnn.%2520Saudi%2520Med.%26date%3D2013%26volume%3D33%26spage%3D187%26epage%3D191%26doi%3D10.5144%2F0256-4947.2012.01.7.1510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Travi, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeiro-da-Silva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantas-Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, G.</span></span> <span> </span><span class="NLM_article-title">Canine Visceral Leishmaniasis: Diagnosis and Management of the Reservoir Living among Us</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0006082</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0006082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1371%2Fjournal.pntd.0006082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=29324838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlCqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&author=B.+L.+Traviauthor=A.+Cordeiro-da-Silvaauthor=F.+Dantas-Torresauthor=G.+Mir%C3%B3&title=Canine+Visceral+Leishmaniasis%3A+Diagnosis+and+Management+of+the+Reservoir+Living+among+Us&doi=10.1371%2Fjournal.pntd.0006082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us</span></div><div class="casAuthors">Travi, Bruno L.; Cordeiro-Da-silva, Anabela; Dantas-Torres, Filipe; Miro, Guadalupe</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0006082/1-e0006082/13</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">This article reviews essential topics of canine visceral leishmaniasis (CVL) due to Leishmania infantum infection.  It focuses on the current serol. and mol. diagnostic methods used in epidemiol. research and veterinary clinics to diagnose CVL and includes new point-of-care (POC) tests under development.  The efficacy of different treatment regimens on the clin. improvement and infectiousness of dogs is also addressed.  In the last section, the review provides a crit. appraisal of the effectiveness of different control measures that have been implemented to curb disease transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxMU6S0x9PM7Vg90H21EOLACvtfcHk0lgiqShdZbCOPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlCqsbw%253D&md5=736a08d02966c55d51dc5497f2019b0c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0006082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0006082%26sid%3Dliteratum%253Aachs%26aulast%3DTravi%26aufirst%3DB.%2BL.%26aulast%3DCordeiro-da-Silva%26aufirst%3DA.%26aulast%3DDantas-Torres%26aufirst%3DF.%26aulast%3DMir%25C3%25B3%26aufirst%3DG.%26atitle%3DCanine%2520Visceral%2520Leishmaniasis%253A%2520Diagnosis%2520and%2520Management%2520of%2520the%2520Reservoir%2520Living%2520among%2520Us%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2018%26volume%3D12%26doi%3D10.1371%2Fjournal.pntd.0006082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallerano, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, R. R.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Efficacy of Allopurinol in Patients with Chronic Chagas’ Disease</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.1990.43.159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.4269%2Fajtmh.1990.43.159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2117857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaK3czlvVaqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1990&pages=159-166&author=R.+H.+Galleranoauthor=J.+J.+Marrauthor=R.+R.+Sosa&title=Therapeutic+Efficacy+of+Allopurinol+in+Patients+with+Chronic+Chagas%E2%80%99+Disease&doi=10.4269%2Fajtmh.1990.43.159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease</span></div><div class="casAuthors">Gallerano R H; Marr J J; Sosa R R</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of tropical medicine and hygiene</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-66</span>
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    </div><div class="casAbstract">Laboratory and animal studies have demonstrated that pyrazolopyrimidines have significant activity against Trypanosoma cruzi.  This clinical investigation was to ascertain the efficacy of allopurinol in the treatment of chronic Chagas' disease.  Of 307 patients studied, 91 were untreated; the remaining 216 were divided into 4 treatment groups.  These corresponded to 600 or 900 mg/day of allopurinol for 60 days and benznidazole or nifurtimox at conventional dosage regimens.  Patients were evaluated clinically, serologically, and parasitologically.  Allopurinol was found to be as efficacious as the conventional therapeutic modalities in eliminating the parasitemia and rendering patients seronegative.  Adverse reactions occurred in 11% of patients who received allopurinol and in 30% of those receiving nitrofurans.  Reactions with the conventional therapy were more frequent and of a more serious nature.  Oral allopurinol is as effective as the nitrofurans, but has none of the side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4Xi6EugJj5A20zIbnCCI3fW6udTcc2eZcyC202JcjO7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czlvVaqtg%253D%253D&md5=eab7ec02286f0b682174021e0ef2a918</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.1990.43.159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.1990.43.159%26sid%3Dliteratum%253Aachs%26aulast%3DGallerano%26aufirst%3DR.%2BH.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DSosa%26aufirst%3DR.%2BR.%26atitle%3DTherapeutic%2520Efficacy%2520of%2520Allopurinol%2520in%2520Patients%2520with%2520Chronic%2520Chagas%25E2%2580%2599%2520Disease%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D1990%26volume%3D43%26spage%3D159%26epage%3D166%26doi%3D10.4269%2Fajtmh.1990.43.159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luquetti, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DA Silva, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A. G.</span></span> <span> </span><span class="NLM_article-title">Specific Treatment for Trypanosoma Cruzi: Lack of Efficacy of Allopurinol in the Human Chronic Phase of Chagas Disease</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.2007.76.58</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.4269%2Fajtmh.2007.76.58" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=17255230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktlejt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=58-61&author=A.+Rassiauthor=A.+O.+Luquettiauthor=A.+Rassiauthor=G.+G.+Rassiauthor=S.+G.+Rassiauthor=I.+G.+DA+Silvaauthor=A.+G.+Rassi&title=Specific+Treatment+for+Trypanosoma+Cruzi%3A+Lack+of+Efficacy+of+Allopurinol+in+the+Human+Chronic+Phase+of+Chagas+Disease&doi=10.4269%2Fajtmh.2007.76.58"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Short report: specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease</span></div><div class="casAuthors">Rassi, Anis; Luquetti, Alejandro Ostermayer; Rassijr, Anis; Rassi, Gustavo Gabriel; Rassi, Sergio Gabriel; Garcia Da Silva, Ionizete; Rassi, Alexandre Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    
            (<span class="NLM_cas:orgname">American Society of Tropical Medicine and Hygiene</span>)
        </div><div class="casAbstract">Thirty-five individuals from endemic areas of Central Brazil (age range, 18-64 years; 19 women) in the chronic phase of Chagas disease, with pos. serol. and presence of circulating parasites detected by one or more recent pos. xenodiagnosis, were selected for this study.  Allopurinol (900 mg/d) or placebo was administered in a double-blind clin. trial for 60 days.  After codes were broken, 23 had been allocated to the intervention group and 12 to the placebo group.  Side effects were obsd. in 11 patients in the intervention group and in 1 in the placebo group.  Seventeen patients in the intervention group and 10 in the placebo group completed the trial.  Follow-up was performed by monthly xenodiagnosis and serol. tests every 3 mo during the first year and at the end of the trial.  Xenodiagnosis remained pos. in all 17 of the treated group and in all 10 of the placebo group.  Serol. tests were persistently pos. in both groups after treatment.  We concluded that, at the doses used, allopurinol was not effective to clear, in our region, Trypanosoma cruzi from peripheral blood of infected individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDebZNxHa-QbVg90H21EOLACvtfcHk0lgiqShdZbCOPA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktlejt7s%253D&md5=e482171bd4958bf756d26502c242db6c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.2007.76.58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.2007.76.58%26sid%3Dliteratum%253Aachs%26aulast%3DRassi%26aufirst%3DA.%26aulast%3DLuquetti%26aufirst%3DA.%2BO.%26aulast%3DRassi%26aufirst%3DA.%26aulast%3DRassi%26aufirst%3DG.%2BG.%26aulast%3DRassi%26aufirst%3DS.%2BG.%26aulast%3DDA%2BSilva%26aufirst%3DI.%2BG.%26aulast%3DRassi%26aufirst%3DA.%2BG.%26atitle%3DSpecific%2520Treatment%2520for%2520Trypanosoma%2520Cruzi%253A%2520Lack%2520of%2520Efficacy%2520of%2520Allopurinol%2520in%2520the%2520Human%2520Chronic%2520Phase%2520of%2520Chagas%2520Disease%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2007%26volume%3D76%26spage%3D58%26epage%3D61%26doi%3D10.4269%2Fajtmh.2007.76.58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arribada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulantay, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundaca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coronado, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna, A.</span></span> <span> </span><span class="NLM_article-title">Itraconazole or Allopurinol in the Treatment of Chronic American Trypanosomiasis: The Results of Clinical and Parasitological Examinations 11 Years Post-Treatment</span>. <i>Ann. Trop. Med. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1179/136485905X75403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1179%2F136485905X75403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=16297286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD28XislymsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2005&pages=733-741&author=W.+Aptauthor=A.+Arribadaauthor=I.+Zulantayauthor=A.+Solariauthor=G.+S%C3%A1nchezauthor=K.+Mundacaauthor=X.+Coronadoauthor=J.+Rodr%C3%ADguezauthor=L.+C.+Gilauthor=A.+Osuna&title=Itraconazole+or+Allopurinol+in+the+Treatment+of+Chronic+American+Trypanosomiasis%3A+The+Results+of+Clinical+and+Parasitological+Examinations+11+Years+Post-Treatment&doi=10.1179%2F136485905X75403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment</span></div><div class="casAuthors">Apt, W.; Arribada, A.; Zulantay, I.; Solari, A.; Sanchez, G.; Mundaca, K.; Coronado, X.; Rodriguez, J.; Gil, L. C.; Osuna, A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Tropical Medicine & Parasitology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">733-741</span>CODEN:
                <span class="NLM_cas:coden">ATMPA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-4983</span>.
    
            (<span class="NLM_cas:orgname">Maney Publishing</span>)
        </div><div class="casAbstract">Eleven years after they had been given itraconazole or allopurinol for the treatment of chronic American trypanosomiasis, 109 adult patients were checked for electrocardiog. abnormalities and evidence of Trypanosoma cruzi infection.  The parasitol. investigations included xenodiagnosis, in which the feces of Triatoma infestans that had fed on the patients were checked under the microscope for flagellates.  In addn., a PCR-based assay and a hybridization assay were used to test blood samples from the patients, and feces from the Tri. infestans that had fed on the patients, for Try. cruzi DNA.  For the data anal., the patients were divided into four groups known as normal/normal, abnormal/normal, normal/abnormal and abnormal/abnormal, according to whether the patients had been found to have normal or abnormal electrocardiograms (ECG) shortly before the first treatment and to have normal or abnormal ECG when checked at the 11-yr follow-up.  The 51 normal/normal and 24 normal/abnormal patients were assumed to have been in the 'indeterminate' phase of the disease when they were treated, whereas the 16 abnormal/normal and 18 abnormal/abnormal patients all had evidence of chagasic cardiopathy at that time.  When checked 11 years post-treatment, 40 (78.4%), 17 (70.8%), 14 (87.5%) and 17 (94.4%) of these patients, resp., were each found pos. for Try. cruzi in at least one of the parasitol. tests.  The hybridization assay, whether applied to human blood or bug feces, appeared a significantly more sensitive test than the PCR-based assays or microscopically assessed xenodiagnosis (P<0.05).  Only the 21 patients who appeared to be neg. for Try. cruzi could be considered parasitol. cured (although all still appeared to have anti-Try. cruzi antibodies in their blood).  Only 13 of these parasitol. cured patients (seven of those treated with itraconazole and six of those given allopurinol) had normal ECG at the 11-yr follow-up.  In Chile at least, itraconazole, which caused fewer adverse effects than the allopurinol while being no less effective at preventing cardiopathy, appears to be the drug of choice to treat chronic American trypanosomiasis in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrckGyi5P5YE7Vg90H21EOLACvtfcHk0lgHYTeZh4V6LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislymsA%253D%253D&md5=23cc548c5a9b02864044d5c0a5138e60</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1179%2F136485905X75403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1179%252F136485905X75403%26sid%3Dliteratum%253Aachs%26aulast%3DApt%26aufirst%3DW.%26aulast%3DArribada%26aufirst%3DA.%26aulast%3DZulantay%26aufirst%3DI.%26aulast%3DSolari%26aufirst%3DA.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DG.%26aulast%3DMundaca%26aufirst%3DK.%26aulast%3DCoronado%26aufirst%3DX.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DJ.%26aulast%3DGil%26aufirst%3DL.%2BC.%26aulast%3DOsuna%26aufirst%3DA.%26atitle%3DItraconazole%2520or%2520Allopurinol%2520in%2520the%2520Treatment%2520of%2520Chronic%2520American%2520Trypanosomiasis%253A%2520The%2520Results%2520of%2520Clinical%2520and%2520Parasitological%2520Examinations%252011%2520Years%2520Post-Treatment%26jtitle%3DAnn.%2520Trop.%2520Med.%2520Parasitol.%26date%3D2005%26volume%3D99%26spage%3D733%26epage%3D741%26doi%3D10.1179%2F136485905X75403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branco, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianna, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffolo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, E. E.</span></span> <span> </span><span class="NLM_article-title">Chagas’ Disease Reactivation after Heart Transplantation: Efficacy of Allopurinol Treatment</span>. <i>J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">992</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=8913915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaK2s%252FntV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=988-992&author=D.+R.+Almeidaauthor=A.+C.+Carvalhoauthor=J.+N.+Brancoauthor=A.+P.+Pereiraauthor=L.+Correaauthor=P.+V.+Viannaauthor=E.+Buffoloauthor=E.+E.+Martinez&title=Chagas%E2%80%99+Disease+Reactivation+after+Heart+Transplantation%3A+Efficacy+of+Allopurinol+Treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Chagas' disease reactivation after heart transplantation: efficacy of allopurinol treatment</span></div><div class="casAuthors">Almeida D R; Carvalho A C; Branco J N; Pereira A P; Correa L; Vianna P V; Buffolo E; Martinez E E</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">988-92</span>
        ISSN:<span class="NLM_cas:issn">1053-2498</span>.
    </div><div class="casAbstract">BACKGROUND:  Chagas' disease is a parasitic infection that provokes a severe form of dilated cardiomyopathy.  In the initial experience with heart transplantation with Chagas' disease, a high rate of acute reactivation has been reported.  Although benzinidazole and nifurtimox are effective in the treatment of reactivation or of the acute phase of the disease they are associated with important adverse effects.  Allopurinol has substantial activity against Trypanosoma cruzi in vitro, in the experimental laboratory and in chronic human Chagas' disease; however, there is no information regarding its action in Chagas' reactivation after heart transplantation.  METHODS AND RESULTS:  We describe two patients with Chagas' disease who underwent heart transplantation.  The first one had asthenia, anorexia, and several painful subcutaneous nodules in the legs after transplantation; biopsy showed an inflammatory infiltrate with intracytoplasmatic nests of Trypanosoma cruzi, confirmed by immunohistochemical stains with monoclonal antibodies specific to parasitic antigens.  Allopurinol (600 mg/day) produced complete regression of the symptoms and the nodules with a negative control biopsy within 2 weeks.  Treatment was maintained for 2 months.  Mild leukopenia developed which improved after azathioprine reduction, and no further side-effects were noted.  The second patient had sudden heart failure months after transplantation; endomyocardial biopsy showed myocardial fibers infested with Trypanosoma, and a concomitantly performed right heart catheterization showed a low cardiac index and highfilling pressures.  The patient received allopurinol at a daily dose of 900 mg and conventional treatment for heart failure.  Echocardiogram showed improved wall motion and decreased left ventricular dimensions, and control biopsy showed no inflammatory activity; cardiac index and filling pressures normalized.  Treatment was maintained for 2 months without side effects.  The two patients have not had recurrences and were in New York Heart Association functional class I 12 and 3 months, respectively, after discontinuation of allopurinol.  CONCLUSIONS:  Allopurinol seems to be safe and effective in treating Chagas' disease reactivation after heart transplantation.  A larger number of case studies seems to be necessary to properly evaluate its role in the treatment of Chagas' disease reactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQy3SAtRClh_oJKJbLTgsvCfW6udTcc2eamcdVQ9al-r7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FntV2ruw%253D%253D&md5=58ba77e146289080606ef7faddc4b487</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlmeida%26aufirst%3DD.%2BR.%26aulast%3DCarvalho%26aufirst%3DA.%2BC.%26aulast%3DBranco%26aufirst%3DJ.%2BN.%26aulast%3DPereira%26aufirst%3DA.%2BP.%26aulast%3DCorrea%26aufirst%3DL.%26aulast%3DVianna%26aufirst%3DP.%2BV.%26aulast%3DBuffolo%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DE.%2BE.%26atitle%3DChagas%25E2%2580%2599%2520Disease%2520Reactivation%2520after%2520Heart%2520Transplantation%253A%2520Efficacy%2520of%2520Allopurinol%2520Treatment%26jtitle%3DJ.%2520Heart%2520Lung%2520Transplant.%2520Off.%2520Publ.%2520Int.%2520Soc.%2520Heart%2520Transplant.%26date%3D1996%26volume%3D15%26spage%3D988%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bestetti, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoropoulos, T. A. D.</span></span> <span> </span><span class="NLM_article-title">A Systematic Review of Studies on Heart Transplantation for Patients with End-Stage Chagas’ Heart Disease</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1016/j.cardfail.2008.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.cardfail.2008.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=19327627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BD1M3ktFWnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=249-255&author=R.+B.+Bestettiauthor=T.+A.+D.+Theodoropoulos&title=A+Systematic+Review+of+Studies+on+Heart+Transplantation+for+Patients+with+End-Stage+Chagas%E2%80%99+Heart+Disease&doi=10.1016%2Fj.cardfail.2008.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic review of studies on heart transplantation for patients with end-stage Chagas' heart disease</span></div><div class="casAuthors">Bestetti Reinaldo B; Theodoropoulos Tatiana A D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cardiac failure</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Uncertainties regarding indications for the procedure, proper immunosuppressive regimen, and the fear of Trypanosoma cruzi infection reactivation are major concerns regarding heart transplantation (HTx) for patients with end-stage Chagas' heart disease.  METHODS AND RESULTS:  To review indications for HTx, current immunosuppressive therapy, posttransplant morbidities, and outcome in Chagas' heart transplant recipients.  Review of articles linking HTx and Chagas' disease at PubMed and Scielo database from 1966 onward.  HTx can reasonably be indicated in patients with an annual probability of death of 70%.  HTx has been associated with a similar incidence of rejection episodes in Chagas' and non-Chagas' heart transplant recipients.  A lower incidence of infection episodes has been observed in Chagas' in comparison to non-Chagas' heart transplant recipients.  T. cruzi infection reactivation is easily treated with either benznidazole or allopurinol and portends a very low mortality rate.  Other posttransplant morbidities have a similar incidence in Chagas' and in non-Chagas' patients.  Survival probability for Chagas' HTx recipients at 1 month, 1 year, 4 years, and 10 years follow-up is 83%, 71%, 57%, and 46%, respectively.  Such an outcome is better than that seen in non-Chagas' heart transplant recipients.  CONCLUSIONS:  HTx is safe and efficacious for patients with end-stage Chagas' heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgfCKqUWhJHq91pGlMMoT5fW6udTcc2eZMuocBYU3mFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3ktFWnuw%253D%253D&md5=41735832c552e0a1802103ffa849dc9c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2008.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2008.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DBestetti%26aufirst%3DR.%2BB.%26aulast%3DTheodoropoulos%26aufirst%3DT.%2BA.%2BD.%26atitle%3DA%2520Systematic%2520Review%2520of%2520Studies%2520on%2520Heart%2520Transplantation%2520for%2520Patients%2520with%2520End-Stage%2520Chagas%25E2%2580%2599%2520Heart%2520Disease%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2009%26volume%3D15%26spage%3D249%26epage%3D255%26doi%3D10.1016%2Fj.cardfail.2008.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looker, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span> <span> </span><span class="NLM_article-title">The Synergistic Action of Pyrazolopyrimidines and Pentavalent Antimony against Leishmania Donovani and L. braziliensis</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.1988.39.250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.4269%2Fajtmh.1988.39.250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2845824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL1cXmt1WqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1988&pages=250-255&author=S.+Martinezauthor=D.+L.+Lookerauthor=R.+L.+Berensauthor=J.+J.+Marr&title=The+Synergistic+Action+of+Pyrazolopyrimidines+and+Pentavalent+Antimony+against+Leishmania+Donovani+and+L.+braziliensis&doi=10.4269%2Fajtmh.1988.39.250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis</span></div><div class="casAuthors">Martinez, Samuel; Looker, Douglas L.; Berens, Randolph L.; Marr, J. Joseph</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">250-5</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    </div><div class="casAbstract">When tested in a human macrophage tissue culture system infected with L. dinovani and L. braziliensis, pentostam showed inhibitory synergism with both allopurinol and allopurinol riboside.  Thus, pyrazolopyrimidines and pentavalent antimony appear to show promise for the treatment of Leishmania infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrICtFk7Kp1fLVg90H21EOLACvtfcHk0lh022EC63qc7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmt1WqtbY%253D&md5=0e8a2ee40d6d178316cfd2779fa2fef8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.1988.39.250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.1988.39.250%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DLooker%26aufirst%3DD.%2BL.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Synergistic%2520Action%2520of%2520Pyrazolopyrimidines%2520and%2520Pentavalent%2520Antimony%2520against%2520Leishmania%2520Donovani%2520and%2520L.%2520braziliensis%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D1988%26volume%3D39%26spage%3D250%26epage%3D255%26doi%3D10.4269%2Fajtmh.1988.39.250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chunge, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gacmra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muigai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasunna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chulay, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anabwani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oster, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryceson, A. D. M.</span></span> <span> </span><span class="NLM_article-title">Visceral Leishmaniasis Unresponsive to Antimonial Drugs III. Successful Treatment Using a Combination of Sodium Stibogluconate plus Allopurinol</span>. <i>Trans. R. Soc. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1016/0035-9203(85)90200-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0035-9203%2885%2990200-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=3006296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaL287lt1ykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1985&pages=715-718&author=C.+N.+Chungeauthor=G.+Gacmraauthor=R.+Muigaiauthor=K.+Wasunnaauthor=J.+R.+Rashidauthor=J.+D.+Chulayauthor=G.+Anabwaniauthor=C.+N.+Osterauthor=A.+D.+M.+Bryceson&title=Visceral+Leishmaniasis+Unresponsive+to+Antimonial+Drugs+III.+Successful+Treatment+Using+a+Combination+of+Sodium+Stibogluconate+plus+Allopurinol&doi=10.1016%2F0035-9203%2885%2990200-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol</span></div><div class="casAuthors">Chunge C N; Gachihi G; Muigai R; Wasunna K; Rashid J R; Chulay J D; Anabwani G; Oster C N; Bryceson A D</div><div class="citationInfo"><span class="NLM_cas:title">Transactions of the Royal Society of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">715-8</span>
        ISSN:<span class="NLM_cas:issn">0035-9203</span>.
    </div><div class="casAbstract">Five patients with long-standing visceral leishmaniasis who were unresponsive to sodium stibogluconate, 20 mg antimony/kg body-weight once or twice daily, were treated for 14 to 54 days with a combination of sodium stibogluconate at the same dose plus allopurinol at a dose of 20 mg/kg body-weight per day in three divided doses.  This combination was safe and effective.  Negative splenic aspirate smears were obtained from all patients within 19 days, and none has relapsed in at least 12 months of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm7dzyzHzslEPI-fCgwosgfW6udTcc2eZMuocBYU3mFrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL287lt1ykuw%253D%253D&md5=0849a550325dbdfa335b3e4cf2b34f41</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0035-9203%2885%2990200-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0035-9203%252885%252990200-7%26sid%3Dliteratum%253Aachs%26aulast%3DChunge%26aufirst%3DC.%2BN.%26aulast%3DGacmra%26aufirst%3DG.%26aulast%3DMuigai%26aufirst%3DR.%26aulast%3DWasunna%26aufirst%3DK.%26aulast%3DRashid%26aufirst%3DJ.%2BR.%26aulast%3DChulay%26aufirst%3DJ.%2BD.%26aulast%3DAnabwani%26aufirst%3DG.%26aulast%3DOster%26aufirst%3DC.%2BN.%26aulast%3DBryceson%26aufirst%3DA.%2BD.%2BM.%26atitle%3DVisceral%2520Leishmaniasis%2520Unresponsive%2520to%2520Antimonial%2520Drugs%2520III.%2520Successful%2520Treatment%2520Using%2520a%2520Combination%2520of%2520Sodium%2520Stibogluconate%2520plus%2520Allopurinol%26jtitle%3DTrans.%2520R.%2520Soc.%2520Trop.%2520Med.%2520Hyg.%26date%3D1985%26volume%3D79%26spage%3D715%26epage%3D718%26doi%3D10.1016%2F0035-9203%2885%2990200-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torrus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boix, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Mateo, M.</span></span> <span> </span><span class="NLM_article-title">Fluconazole plus Allopurinol in Treatment of Visceral Leishmanlasis</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1042</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1093/jac/37.5.1042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1093%2Fjac%2F37.5.1042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=8737162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK28XjvVWqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1996&pages=1042-1043&author=D.+Torrusauthor=V.+Boixauthor=B.+Massaauthor=J.+Portillaauthor=M.+P%C3%A9rez-Mateo&title=Fluconazole+plus+Allopurinol+in+Treatment+of+Visceral+Leishmanlasis&doi=10.1093%2Fjac%2F37.5.1042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Fluconazole plus allopurinol in treatment of visceral leishmaniasis</span></div><div class="casAuthors">Torrus, Diego; Boix, Vicente; Massa, Beatriz; Portilla, Joaquin; Perez-Mateo, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1042-1043</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">A review with 6 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrop-7LawXHPbVg90H21EOLACvtfcHk0ljsIim9V1cV-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVWqsL8%253D&md5=3fbde71c3bc66ff1bb495c958a34b9fc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F37.5.1042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F37.5.1042%26sid%3Dliteratum%253Aachs%26aulast%3DTorrus%26aufirst%3DD.%26aulast%3DBoix%26aufirst%3DV.%26aulast%3DMassa%26aufirst%3DB.%26aulast%3DPortilla%26aufirst%3DJ.%26aulast%3DP%25C3%25A9rez-Mateo%26aufirst%3DM.%26atitle%3DFluconazole%2520plus%2520Allopurinol%2520in%2520Treatment%2520of%2520Visceral%2520Leishmanlasis%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1996%26volume%3D37%26spage%3D1042%26epage%3D1043%26doi%3D10.1093%2Fjac%2F37.5.1042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcon, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laucella, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichera, L. E.</span></span> <span> </span><span class="NLM_article-title">Combined Treatment with Benznidazole and Allopurinol in Mice Infected with a Virulent Trypanosoma Cruzi Isolate from Nicaragua</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">1225</span>– <span class="NLM_lpage">1233</span>, <span class="refDoi"> DOI: 10.1017/S0031182013000176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1017%2FS0031182013000176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=23507037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCltr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=1225-1233&author=N.+L.+Grossoauthor=M.+L.+Alarconauthor=J.+Buaauthor=S.+A.+Laucellaauthor=A.+Riarteauthor=L.+E.+Fichera&title=Combined+Treatment+with+Benznidazole+and+Allopurinol+in+Mice+Infected+with+a+Virulent+Trypanosoma+Cruzi+Isolate+from+Nicaragua&doi=10.1017%2FS0031182013000176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Combined treatment with benznidazole and allopurinol in mice infected with a virulent Trypanosoma cruzi isolate from Nicaragua</span></div><div class="casAuthors">Grosso, Noelia L.; Alarcon, Micaela Lopez; Bua, Jaqueline; Laucella, Susana A.; Riarte, Adelina; Fichera, Laura E.</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1225-1233</span>CODEN:
                <span class="NLM_cas:coden">PARAAE</span>;
        ISSN:<span class="NLM_cas:issn">0031-1820</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">We evaluated the effect of chemotherapy with a sequential combined treatment of a low dose of benznidazole and allopurinol, in different schedules of administration, in exptl. models of acute and chronic Trypanosoma cruzi infection.  Mice were infected with Nicaragua T. cruzi isolate, a virulent parasite from an endemic area of Nicaragua, genotyped as TcI (Grosso et al. ).  We assessed survival rate, IgG levels, histopathol. studies and quantified parasitemia.  A 15% survival rate was recorded in untreated mice during the acute phase of T. cruzi infection.  Allopurinol administered immediately after benznidazole treatment was able to reduce parasitemia and attenuate tissue damage by reducing inflammation.  Trypanosoma cruzi-specific antibodies also decreased in 40-50% of the treated mice.  The addn. of allopurinol during the chronic phase showed the highest beneficial effect, not only by reducing parasitemia but also by lowering the degree of inflammation and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2L191XBdRfrVg90H21EOLACvtfcHk0ljsIim9V1cV-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCltr7L&md5=f64cd4f947f6831f22bbb3c3355afb65</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1017%2FS0031182013000176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182013000176%26sid%3Dliteratum%253Aachs%26aulast%3DGrosso%26aufirst%3DN.%2BL.%26aulast%3DAlarcon%26aufirst%3DM.%2BL.%26aulast%3DBua%26aufirst%3DJ.%26aulast%3DLaucella%26aufirst%3DS.%2BA.%26aulast%3DRiarte%26aufirst%3DA.%26aulast%3DFichera%26aufirst%3DL.%2BE.%26atitle%3DCombined%2520Treatment%2520with%2520Benznidazole%2520and%2520Allopurinol%2520in%2520Mice%2520Infected%2520with%2520a%2520Virulent%2520Trypanosoma%2520Cruzi%2520Isolate%2520from%2520Nicaragua%26jtitle%3DParasitology%26date%3D2013%26volume%3D140%26spage%3D1225%26epage%3D1233%26doi%3D10.1017%2FS0031182013000176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Mazliah, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lococo, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertocchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albareda, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armenti, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarleton, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laucella, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viotti, R.</span></span> <span> </span><span class="NLM_article-title">Sequential Combined Treatment with Allopurinol and Benznidazole in the Chronic Phase of Trypanosoma Cruzi Infection: A Pilot Study</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1093/jac/dks390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1093%2Fjac%2Fdks390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=23104493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=424-437&author=D.+E.+Perez-Mazliahauthor=M.+G.+Alvarezauthor=G.+Cooleyauthor=B.+E.+Lococoauthor=G.+Bertocchiauthor=M.+Pettiauthor=M.+C.+Albaredaauthor=A.+H.+Armentiauthor=R.+L.+Tarletonauthor=S.+A.+Laucellaauthor=R.+Viotti&title=Sequential+Combined+Treatment+with+Allopurinol+and+Benznidazole+in+the+Chronic+Phase+of+Trypanosoma+Cruzi+Infection%3A+A+Pilot+Study&doi=10.1093%2Fjac%2Fdks390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study</span></div><div class="casAuthors">Perez-Mazliah, D. E.; Alvarez, M. G.; Cooley, G.; Lococo, B. E.; Bertocchi, G.; Petti, M.; Albareda, M. C.; Armenti, A. H.; Tarleton, R. L.; Laucella, S. A.; Viotti, R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">424-437</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: Even though the use of combined drugs has been proved to be effective in other chronic infections, assessment of combined treatment of antiparasitic drugs in human Chagas' disease has not been performed.  Herein, a pilot study was conducted to evaluate the tolerance and side effects of a sequential combined treatment of two antiparasitic drugs, allopurinol and benznidazole, in the chronic phase of Trypanosoma cruzi infection.  Patients and methods Changes in total and T. cruzi-specific T and B cells were monitored during a median follow-up of 36 mo.  Allopurinol was administered for 3 mo (600 mg/day) followed by 30 days of benznidazole (5 mg/kg/day) in 11 T. cruzi-infected subjects.  Results The combined sequential treatment of allopurinol and benznidazole was well tolerated.  The levels of T. cruzi-specific antibodies significantly decreased after sequential combined treatment, as detd. by conventional serol. and by a multiplex assay using recombinant proteins.  The frequency of T. cruzi-specific interferon-γ-producing T cells significantly increased after allopurinol treatment and decreased to background levels following benznidazole administration in a substantial proportion of subjects evaluated.  The levels of total naive (CD45RA + CCR7 + CD62L+) CD4 + and CD8 + T cells were restored after allopurinol administration and maintained after completion of the combined drug protocol, along with a decrease in T cell activation in total peripheral CD4 + and CD8 + T cells.  Conclusions This pilot study shows that the combination of allopurinol and benznidazole induces significant modifications in T and B cell responses indicative of a redn. in parasite burden, and sustains the feasibility of administration of two antiparasitic drugs in the chronic phase of Chagas' disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgcoMlINj1t7Vg90H21EOLACvtfcHk0ljsIim9V1cV-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVerug%253D%253D&md5=2530fe5c18a45bd862bd6f85e23799b7</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdks390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdks390%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Mazliah%26aufirst%3DD.%2BE.%26aulast%3DAlvarez%26aufirst%3DM.%2BG.%26aulast%3DCooley%26aufirst%3DG.%26aulast%3DLococo%26aufirst%3DB.%2BE.%26aulast%3DBertocchi%26aufirst%3DG.%26aulast%3DPetti%26aufirst%3DM.%26aulast%3DAlbareda%26aufirst%3DM.%2BC.%26aulast%3DArmenti%26aufirst%3DA.%2BH.%26aulast%3DTarleton%26aufirst%3DR.%2BL.%26aulast%3DLaucella%26aufirst%3DS.%2BA.%26aulast%3DViotti%26aufirst%3DR.%26atitle%3DSequential%2520Combined%2520Treatment%2520with%2520Allopurinol%2520and%2520Benznidazole%2520in%2520the%2520Chronic%2520Phase%2520of%2520Trypanosoma%2520Cruzi%2520Infection%253A%2520A%2520Pilot%2520Study%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2013%26volume%3D68%26spage%3D424%26epage%3D437%26doi%3D10.1093%2Fjac%2Fdks390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rial, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scalise, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López Alarcón, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteva, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Búa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benatar, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prado, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riarte, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichera, L. E.</span></span> <span> </span><span class="NLM_article-title">Experimental Combination Therapy Using Low Doses of Benznidazole and Allopurinol in Mouse Models of Trypanosoma Cruzi Chronic Infection</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1017/S0031182018001567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1017%2FS0031182018001567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30301480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFOitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2019&pages=305-313&author=M.+S.+Rialauthor=M.+L.+Scaliseauthor=M.+L%C3%B3pez+Alarc%C3%B3nauthor=M.+I.+Estevaauthor=J.+B%C3%BAaauthor=A.+F.+Benatarauthor=N.+G.+Pradoauthor=A.+R.+Riarteauthor=L.+E.+Fichera&title=Experimental+Combination+Therapy+Using+Low+Doses+of+Benznidazole+and+Allopurinol+in+Mouse+Models+of+Trypanosoma+Cruzi+Chronic+Infection&doi=10.1017%2FS0031182018001567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection</span></div><div class="casAuthors">Rial, Marcela Silvina; Scalise, Maria Lujan; Lopez Alarcon, Micaela; Esteva, Monica Ines; Bua, Jacqueline; Benatar, Alejandro Francisco; Prado, Nilda Graciela; Riarte, Adelina Rosa; Fichera, Laura Edith</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-313</span>CODEN:
                <span class="NLM_cas:coden">PARAAE</span>;
        ISSN:<span class="NLM_cas:issn">0031-1820</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">This study evaluated the effectiveness of low doses of benznidazole (BNZ) on continuous administration (BNZc), combined with allopurinol (ALO), in C57BL/6J and C3H/HeN mice infected with Trypanosoma cruzi Nicaragua strain and T. cruzi Sylvio-X10/4 clone.  TcN-C57BL/6J was also treated with intermittent doses of BNZ (BNZit).  The drug therapy started 3 mo post infection (pi) in the chronic phase of mice with heart disease progression, followed-up at 6 mo pi.  TcN-C57BL/6J treated with BNZc was also monitored up to 12 mo pi by serol. and ECG.  These mice showed severe elec. abnormalities, which were not obsd. after BNZc or BNZit.  ALO only showed pos. interaction with the lowest dose of BNZ.  A clear parasitic effect, with significant redns. in antibody titers and parasitic loads, was achieved in all models with low doses of BNZ, and a 25% redn. of the conventional dose showed more efficacy to inhibit the development of the pathol.  However, BNZ 75 showed partial efficacy in the TcSylvio-X10/4-C3H/HeN model.  In our exptl. designs, C57BL/6J allowed to clearly define a chronic phase, and through reproducible efficacy indicators, it can be considered a good preclin. model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocelUukkwBSbVg90H21EOLACvtfcHk0lgbJingXLUI6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFOitLo%253D&md5=9551e9f9b2c8ec872dd373627290ec25</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1017%2FS0031182018001567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182018001567%26sid%3Dliteratum%253Aachs%26aulast%3DRial%26aufirst%3DM.%2BS.%26aulast%3DScalise%26aufirst%3DM.%2BL.%26aulast%3DL%25C3%25B3pez%2BAlarc%25C3%25B3n%26aufirst%3DM.%26aulast%3DEsteva%26aufirst%3DM.%2BI.%26aulast%3DB%25C3%25BAa%26aufirst%3DJ.%26aulast%3DBenatar%26aufirst%3DA.%2BF.%26aulast%3DPrado%26aufirst%3DN.%2BG.%26aulast%3DRiarte%26aufirst%3DA.%2BR.%26aulast%3DFichera%26aufirst%3DL.%2BE.%26atitle%3DExperimental%2520Combination%2520Therapy%2520Using%2520Low%2520Doses%2520of%2520Benznidazole%2520and%2520Allopurinol%2520in%2520Mouse%2520Models%2520of%2520Trypanosoma%2520Cruzi%2520Chronic%2520Infection%26jtitle%3DParasitology%26date%3D2019%26volume%3D146%26spage%3D305%26epage%3D313%26doi%3D10.1017%2FS0031182018001567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, M. A.</span></span> <span> </span><span class="NLM_article-title">Comparative Effects of 4-Aminopyrazolopyrimidine, Its 2′-Deoxyriboside Derivative, and Allopurinol on in Vitro Growth of American Leishmania Species</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1128/AAC.22.3.380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.22.3.380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6982678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL38XlslylsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1982&pages=380-385&author=J.+L.+Avilaauthor=M.+A.+Casanova&title=Comparative+Effects+of+4-Aminopyrazolopyrimidine%2C+Its+2%E2%80%B2-Deoxyriboside+Derivative%2C+and+Allopurinol+on+in+Vitro+Growth+of+American+Leishmania+Species&doi=10.1128%2FAAC.22.3.380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effects of 4-aminopyrazolopyrimidine, its 2'-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species</span></div><div class="casAuthors">Avila, Jose L.; Casanova, Maria A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">380-5</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">When assayed on promastigotes of 10 American Leishmania isolates (including L. brasiliensis and L. mexicana), 4-aminopyrazolopyrimidine (APP) was severalfold more active than allopurinol (HPP) as a leishmanistatic drug.  There were some intraspecific and interspecific differences among the isolates in their susceptibility to the inhibitory effects of APP and allopurinol.  APP-2'-deoxyriboside did not affect the 10 isolates tested.  This was surprising, because allopurinol riboside has previously been shown to be more active than allopurinol.  In all of the American Leishmania isolates tested, the metab. of [14C]6-APP resulted in a high level of HPP-ribose-5'-P and lower levels of APP-ribose-5'-P, APP-ribose-5'-PP, and APP-ribose-5'-PPP.  MP, LR, LBY, and JAP isolates strongly converted APP into APP derivs., thus perhaps explaining their greater susceptibility to the inhibitory effects of APP.  With the 10 American Leishmania isolates tested, several purines reversed the inhibitory effects of HPP, but only adenine countered the inhibitory effects of APP.  This suggests biochem. differences in the mechanisms of action of HPP and APP.  Finally, and contrary to previous claims, the reversal by purines of the HPP-induced growth inhibition was not a Leishmania species-specific effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWCnonE7IZHrVg90H21EOLACvtfcHk0lgbJingXLUI6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlslylsLk%253D&md5=78ba3b1320b477b70702262f95c68246</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FAAC.22.3.380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.22.3.380%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DJ.%2BL.%26aulast%3DCasanova%26aufirst%3DM.%2BA.%26atitle%3DComparative%2520Effects%2520of%25204-Aminopyrazolopyrimidine%252C%2520Its%25202%25E2%2580%25B2-Deoxyriboside%2520Derivative%252C%2520and%2520Allopurinol%2520on%2520in%2520Vitro%2520Growth%2520of%2520American%2520Leishmania%2520Species%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1982%26volume%3D22%26spage%3D380%26epage%3D385%26doi%3D10.1128%2FAAC.22.3.380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revankar, G. R.</span></span> <span> </span><span class="NLM_article-title">Activity of Purine Analogs against Leishmania Tropica within Human Macrophages in Vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1128/AAC.24.2.233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.24.2.233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6638989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3sXltlegsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1983&pages=233-236&author=J.+D.+Bermanauthor=L.+S.+Leeauthor=R.+K.+Robinsauthor=G.+R.+Revankar&title=Activity+of+Purine+Analogs+against+Leishmania+Tropica+within+Human+Macrophages+in+Vitro&doi=10.1128%2FAAC.24.2.233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of purine analogs against Leishmania tropica within human macrophages in vitro</span></div><div class="casAuthors">Berman, Jonathan D.; Lee, Linda S.; Robins, Roland K.; Revankar, Ganapathi R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-6</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The activity of purine analogs against L. tropica in human monocyte-derived macrophages in vitro was detd.  Formycin B  [13877-76-4], formycin A  [6742-12-7], their monophosphates, and formycin A triphosphate  [19495-11-5] all had ED50 of 0.02-0.04 μM and eliminated 90% of organisms at ≤0.5 μM.  Allopurinol ribonucleoside  [16220-07-8] was much less active; the ED50 was 76-190 μM.  7-Deazainosine  [2862-16-0] had a low ED50 (0.2 μM), but only 80% of organisms were eliminated at 4 μM.  Thio derivs. were as active as or less active than the parent compds.  Certain inosine analogs appear to be much more active than others against macrophage-contained Leishmania specie that are found in human lesions.  However, because toxicity to the human macrophage hosts generally paralleled antileishmanial activity, the more active compds. might also be more toxic to human cells.  The activity of 3-deazaguanosine (50% ED, 3.6 μM) in this model suggests that guanosine derivs. may have potential as antileishmanial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolOvj1aH11z7Vg90H21EOLACvtfcHk0lgbJingXLUI6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXltlegsLk%253D&md5=7c0af1e0c9cf1b459849a062c50d2799</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1128%2FAAC.24.2.233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.24.2.233%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DJ.%2BD.%26aulast%3DLee%26aufirst%3DL.%2BS.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DRevankar%26aufirst%3DG.%2BR.%26atitle%3DActivity%2520of%2520Purine%2520Analogs%2520against%2520Leishmania%2520Tropica%2520within%2520Human%2520Macrophages%2520in%2520Vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1983%26volume%3D24%26spage%3D233%26epage%3D236%26doi%3D10.1128%2FAAC.24.2.233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J.</span></span> <span> </span><span class="NLM_article-title">Purine Analogs as Chemotherapeutic Agents in Leishmaniasis and American Trypanosomiasis</span>. <i>J. Lab. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1906917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1KhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1991&pages=111-119&author=J.+Marr&title=Purine+Analogs+as+Chemotherapeutic+Agents+in+Leishmaniasis+and+American+Trypanosomiasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis</span></div><div class="casAuthors">Marr, J. Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Laboratory and Clinical Medicine</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-19</span>CODEN:
                <span class="NLM_cas:coden">JLCMAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2143</span>.
    </div><div class="casAbstract">A review with 36 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_-WLUULNBu7Vg90H21EOLACvtfcHk0lh0mtwUVNLyUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1KhsLc%253D&md5=909fb57d877c9d8d2227d939da69fb4c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarr%26aufirst%3DJ.%26atitle%3DPurine%2520Analogs%2520as%2520Chemotherapeutic%2520Agents%2520in%2520Leishmaniasis%2520and%2520American%2520Trypanosomiasis%26jtitle%3DJ.%2520Lab.%2520Clin.%2520Med.%26date%3D1991%26volume%3D118%26spage%3D111%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polegre, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span> <span> </span><span class="NLM_article-title">Biological Action of Pyrazolopyrimidine Derivatives against Trypanosoma Cruzi. Studies in Vitro and in Vivo</span>. <i>Comp. Biochem. Physiol., Part C: Comp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/0742-8413(87)90143-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0742-8413%2887%2990143-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2881726" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1987&pages=49-54&author=J.+Avilaauthor=M.+A.+Polegreauthor=R.+K.+Robins&title=Biological+Action+of+Pyrazolopyrimidine+Derivatives+against+Trypanosoma+Cruzi.+Studies+in+Vitro+and+in+Vivo&doi=10.1016%2F0742-8413%2887%2990143-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2F0742-8413%2887%2990143-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0742-8413%252887%252990143-5%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DPolegre%26aufirst%3DM.%2BA.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26atitle%3DBiological%2520Action%2520of%2520Pyrazolopyrimidine%2520Derivatives%2520against%2520Trypanosoma%2520Cruzi.%2520Studies%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DComp.%2520Biochem.%2520Physiol.%252C%2520Part%2520C%253A%2520Comp.%2520Pharmacol.%26date%3D1987%26volume%3D86%26spage%3D49%26epage%3D54%26doi%3D10.1016%2F0742-8413%2887%2990143-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polegre, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span> <span> </span><span class="NLM_article-title">Action of Pyrazolopyrimidine Derivatives on American Leishmania Spp. Promastigotes</span>. <i>Comp. Biochem. Physiol., Part C: Comp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1016/0742-8413(86)90124-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0742-8413%2886%2990124-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2871990" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=285-289&author=J.+Avilaauthor=M.+A.+Polegreauthor=A.+Avilaauthor=R.+K.+Robins&title=Action+of+Pyrazolopyrimidine+Derivatives+on+American+Leishmania+Spp.+Promastigotes&doi=10.1016%2F0742-8413%2886%2990124-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2F0742-8413%2886%2990124-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0742-8413%252886%252990124-6%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DPolegre%26aufirst%3DM.%2BA.%26aulast%3DAvila%26aufirst%3DA.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26atitle%3DAction%2520of%2520Pyrazolopyrimidine%2520Derivatives%2520on%2520American%2520Leishmania%2520Spp.%2520Promastigotes%26jtitle%3DComp.%2520Biochem.%2520Physiol.%252C%2520Part%2520C%253A%2520Comp.%2520Pharmacol.%26date%3D1986%26volume%3D83%26spage%3D285%26epage%3D289%26doi%3D10.1016%2F0742-8413%2886%2990124-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mun̅oz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monzón, H.</span></span> <span> </span><span class="NLM_article-title">Trypanosoma Cruzi: 4-Aminopyrazolopyrimidine in the Treatment of Experimental Chagas’ Disease</span>. <i>Exp. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/0014-4894(83)90067-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0014-4894%2883%2990067-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6413238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2cXislE%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1983&pages=236-240&author=J.+Avilaauthor=A.+Avilaauthor=E.+Mun%CC%85ozauthor=H.+Monz%C3%B3n&title=Trypanosoma+Cruzi%3A+4-Aminopyrazolopyrimidine+in+the+Treatment+of+Experimental+Chagas%E2%80%99+Disease&doi=10.1016%2F0014-4894%2883%2990067-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Trypanosoma cruzi:  4-aminopyrazolopyrimidine in the treatment of experimental Chagas' disease</span></div><div class="casAuthors">Avila, Jose Luis; Avila, Angela; Munoz, Edgar; Monzon, Hector</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Parasitology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-40</span>CODEN:
                <span class="NLM_cas:coden">EXPAAA</span>;
        ISSN:<span class="NLM_cas:issn">0014-4894</span>.
    </div><div class="casAbstract">An allopurinol metabolite, 4-aminopyrazolopyrimidine (I)  [2380-63-4] was tested on 2 different strains of mice (NMRI-IVIC and C57B1/6J) that had been infected 4 days earlier with the virulent Ya strain of T. cruzi.  Low doses of 4-aminopyrazolopyrimidine (0.125-0.500 mg/kg daily for 10 days) decreased parasitemia and increased survival time, without any evidence of toxicity, compared with untreated animals.  When tested in vitro, 4-aminopyrazolopyrimidine was 6-fold more active than allopurinol as a trypanostatic drug.  The low therapeutic doses of 4-aminopyrazolopyrimidine suggest that this drug may be useful in the treatment of acute Chagas' disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP8o85VWcFO7Vg90H21EOLACvtfcHk0lh0mtwUVNLyUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXislE%253D&md5=8021f22a66dfd87930828eb8072cd4a1</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2F0014-4894%2883%2990067-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-4894%252883%252990067-X%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DA.%26aulast%3DMun%25CC%2585oz%26aufirst%3DE.%26aulast%3DMonz%25C3%25B3n%26aufirst%3DH.%26atitle%3DTrypanosoma%2520Cruzi%253A%25204-Aminopyrazolopyrimidine%2520in%2520the%2520Treatment%2520of%2520Experimental%2520Chagas%25E2%2580%2599%2520Disease%26jtitle%3DExp.%2520Parasitol.%26date%3D1983%26volume%3D56%26spage%3D236%26epage%3D240%26doi%3D10.1016%2F0014-4894%2883%2990067-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnaro, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scortichini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Revisiting Tubercidin against Kinetoplastid Parasites: Aromatic Substitutions at Position 7 Improve Activity and Reduce Toxicity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ejmech.2018.12.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30677668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=689-705&author=F.+Hulpiaauthor=G.+D.+Campagnaroauthor=M.+Scortichiniauthor=K.+Van+Heckeauthor=L.+Maesauthor=H.+P.+de+Koningauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=Revisiting+Tubercidin+against+Kinetoplastid+Parasites%3A+Aromatic+Substitutions+at+Position+7+Improve+Activity+and+Reduce+Toxicity&doi=10.1016%2Fj.ejmech.2018.12.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting tubercidin against kinetoplastid parasites: aromatic substitutions at position 7 improve activity and reduce toxicity</span></div><div class="casAuthors">Hulpia, Fabian; Campagnaro, Gustavo Daniel; Scortichini, Mirko; Van Hecke, Kristof; Maes, Louis; de Koning, Harry P.; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">689-705</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The nucleoside antibiotic tubercidin displays strong activity against different target organisms, but it is notoriously toxic to mammalian cells.  The effects of tubercidin against T. brucei parasites inspired us to synthesize several C7 substituted analogs for in vitro evaluation in order to find suitable hit compds.  C7 Deazaadenosines substituted with electron-poor Ph groups were found to have micromolar activity against T. brucei in vitro.  Replacement of the Ph for a pyridine ring gave compd. 13 (I), with submicromolar potency and much-attenuated cytotoxicity compared to tubercidin.  The veterinary pathogen T. congolense was equally affected by I in vitro.  Transporter studies in T. b. brucei indicated that I is taken up efficiently by both the P1 and P2 adenosine transporters, making the occurrence of transporter-related resistance and cross-resistance with diamidine drugs such as diminazene aceturate and pentamidine as well as with melaminophenyl arsenicals unlikely.  Evaluation of the in vitro metabolic stability of analog I indicated that this analog was significantly metabolized in mouse microsomal fractions, precluding further in vivo evaluation in mouse models of HAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgQp1BYeSEgrVg90H21EOLACvtfcHk0lh0mtwUVNLyUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWisLg%253D&md5=a906448d453a9f56667c2383871ae7b1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.050%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DCampagnaro%26aufirst%3DG.%2BD.%26aulast%3DScortichini%26aufirst%3DM.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DRevisiting%2520Tubercidin%2520against%2520Kinetoplastid%2520Parasites%253A%2520Aromatic%2520Substitutions%2520at%2520Position%25207%2520Improve%2520Activity%2520and%2520Reduce%2520Toxicity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D689%26epage%3D705%26doi%3D10.1016%2Fj.ejmech.2018.12.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">França da Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Gama
Jaen Batista, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Nazaré
C. Soeiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel 7-Aryl 7-Deazapurine 3′-Deoxy-Ribofuranosyl Nucleosides with Potent Activity against Trypanosoma Cruzi</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9287</span>– <span class="NLM_lpage">9300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00999</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00999" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9287-9300&author=F.+Hulpiaauthor=K.+Van+Heckeauthor=C.+Fran%C3%A7a+da+Silvaauthor=D.+da+Gama%0AJaen+Batistaauthor=L.+Maesauthor=G.+Caljonauthor=M.+de+Nazar%C3%A9%0AC.+Soeiroauthor=S.+Van+Calenbergh&title=Discovery+of+Novel+7-Aryl+7-Deazapurine+3%E2%80%B2-Deoxy-Ribofuranosyl+Nucleosides+with+Potent+Activity+against+Trypanosoma+Cruzi&doi=10.1021%2Facs.jmedchem.8b00999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi</span></div><div class="casAuthors">Hulpia, Fabian; Van Hecke, Kristof; Franca da Silva, Cristiane; da Gama Jaen Batista, Denise; Maes, Louis; Caljon, Guy; de Nazare C. Soeiro, Maria; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9287-9300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chagas disease is the leading cause of cardiac-related mortality in Latin American countries where it is endemic.  Trypanosoma cruzi, the disease-causing pathogen, is unable to synthesize purines de novo, necessitating salvage of preformed host purines.  Therefore, purine and purine-nucleoside analogs might constitute an attractive source for identifying antitrypanosomal hits.  In this study, structural elements of two purine-nucleoside analogs (i.e., cordycepin and a recently discovered 7-substituted 7-deazaadenosine) led to the identification of novel nucleoside analogs with potent in vitro activity.  The structure-activity relationships of substituents at C-7 were investigated, ultimately leading to the selection of compd. I, with a C-7 para-chlorophenyl group, for in vivo evaluation.  This deriv. showed complete suppression of T. cruzi Y-strain blood parasitemia when orally administered twice daily for 5 days at 25 mg/kg and was able to protect infected mice from parasite-induced mortality.  However, sterile cure by immunosuppression could not be demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu4_FX3ZIQTrVg90H21EOLACvtfcHk0lhgJWQd43qhEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtr3J&md5=8f8e1c28b33a6c674a3a3b31ee2e5998</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00999%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DFran%25C3%25A7a%2Bda%2BSilva%26aufirst%3DC.%26aulast%3Dda%2BGama%2BJaen%2BBatista%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3Dde%2BNazar%25C3%25A9%2BC.%2BSoeiro%26aufirst%3DM.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Novel%25207-Aryl%25207-Deazapurine%25203%25E2%2580%25B2-Deoxy-Ribofuranosyl%2520Nucleosides%2520with%2520Potent%2520Activity%2520against%2520Trypanosoma%2520Cruzi%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9287%26epage%3D9300%26doi%3D10.1021%2Facs.jmedchem.8b00999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnaro, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzahrani, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfayez, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungogo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Structure–Activity Relationship Exploration of 3′-Deoxy-7-Deazapurine Nucleoside Analogues as Anti-Trypanosoma Brucei Agents</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2045</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.0c00105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.0c00105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Wms7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=2045-2056&author=F.+Hulpiaauthor=G.+D.+Campagnaroauthor=K.+J.+Alzahraniauthor=I.+A.+Alfayezauthor=M.+A.+Ungogoauthor=D.+Mabilleauthor=L.+Maesauthor=H.+P.+de+Koningauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=Structure%E2%80%93Activity+Relationship+Exploration+of+3%E2%80%B2-Deoxy-7-Deazapurine+Nucleoside+Analogues+as+Anti-Trypanosoma+Brucei+Agents&doi=10.1021%2Facsinfecdis.0c00105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Exploration of 3'-Deoxy-7-deazapurine Nucleoside Analogues as Anti-Trypanosoma brucei Agents</span></div><div class="casAuthors">Hulpia, Fabian; Campagnaro, Gustavo D.; Alzahrani, Khalid J.; Alfayez, Ibrahim A.; Ungogo, Marzuq A.; Mabille, Dorien; Maes, Louis; de Koning, Harry P.; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human African trypanosomiasis is a neglected tropical disease caused by Trypanosoma brucei parasites.  These protists are unable to produce the purine ring, making them vulnerable to the effects of purine nucleoside analogs.  Starting from 3'-deoxytubercidin (5), a lead compd. with activity against central-nervous-stage human African trypanosomiasis, we investigate the structure-activity relationships of the purine and ribofuranose rings.  The purine ring tolerated only modifications at C7, while from the many alterations of the 3'-deoxyribofuranosyl moiety only the arabino analog 48 showed pronounced antitrypanosomal activity.  Profiling of the most potent analogs against resistant T. brucei strains (resistant to pentamidine, diminazene, and isometamidium) showed reduced dependence on uptake mediated by the P2 aminopurine transporter relative to 5.  The introduction of a 7-substituent confers up to 10-fold increased affinity for the P1 nucleoside transporter while generally retaining high affinity for P2.  Four of the most promising analogs were found to be metabolically stable, earmarking them as suitable backup analogs for lead 5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo714RzopAMBrVg90H21EOLACvtfcHk0lhgJWQd43qhEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Wms7vJ&md5=decf0a4b5ec9712a032589a7257f932b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.0c00105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.0c00105%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DCampagnaro%26aufirst%3DG.%2BD.%26aulast%3DAlzahrani%26aufirst%3DK.%2BJ.%26aulast%3DAlfayez%26aufirst%3DI.%2BA.%26aulast%3DUngogo%26aufirst%3DM.%2BA.%26aulast%3DMabille%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DStructure%25E2%2580%2593Activity%2520Relationship%2520Exploration%2520of%25203%25E2%2580%25B2-Deoxy-7-Deazapurine%2520Nucleoside%2520Analogues%2520as%2520Anti-Trypanosoma%2520Brucei%2520Agents%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2020%26volume%3D6%26spage%3D2045%26epage%3D2056%26doi%3D10.1021%2Facsinfecdis.0c00105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnaro, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roditi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Combining Tubercidin and Cordycepin Scaffolds Results in Highly Active Candidates to Treat Late-Stage Sleeping Sickness</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">5564</span> <span class="refDoi"> DOI: 10.1038/s41467-019-13522-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fs41467-019-13522-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=31804484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGiu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=F.+Hulpiaauthor=D.+Mabilleauthor=G.+D.+Campagnaroauthor=G.+Schumannauthor=L.+Maesauthor=I.+Roditiauthor=A.+Hoferauthor=H.+P.+de+Koningauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=Combining+Tubercidin+and+Cordycepin+Scaffolds+Results+in+Highly+Active+Candidates+to+Treat+Late-Stage+Sleeping+Sickness&doi=10.1038%2Fs41467-019-13522-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness</span></div><div class="casAuthors">Hulpia, Fabian; Mabille, Dorien; Campagnaro, Gustavo D.; Schumann, Gabriela; Maes, Louis; Roditi, Isabel; Hofer, Anders; de Koning, Harry P.; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5564</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">African trypanosomiasis is a disease caused by Trypanosoma brucei parasites with limited treatment options.  Trypanosoma is unable to synthesize purines de novo and relies solely on their uptake and interconversion from the host, constituting purine nucleoside analogs a potential source of antitrypanosomal agents.  Here we combine structural elements from known trypanocidal nucleoside analogs to develop a series of 3'-deoxy-7-deazaadenosine nucleosides, and investigate their effects against African trypanosomes.  3'-Deoxytubercidin is a highly potent trypanocide in vitro and displays curative activity in animal models of acute and CNS-stage disease, even at low doses and oral administration.  Whole-genome RNAi screening reveals that the P2 nucleoside transporter and adenosine kinase are involved in the uptake and activation, resp., of this analog.  This is confirmed by P1 and P2 transporter assays and nucleotide pool anal.  3'-Deoxytubercidin is promising lead to treat late-stage sleeping sickness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr4E0Y-K3IH7Vg90H21EOLACvtfcHk0lhAHviOsxWreA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGiu7fM&md5=61f38420017999128a9571aa55eed43a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-13522-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-13522-6%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DMabille%26aufirst%3DD.%26aulast%3DCampagnaro%26aufirst%3DG.%2BD.%26aulast%3DSchumann%26aufirst%3DG.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DRoditi%26aufirst%3DI.%26aulast%3DHofer%26aufirst%3DA.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DCombining%2520Tubercidin%2520and%2520Cordycepin%2520Scaffolds%2520Results%2520in%2520Highly%2520Active%2520Candidates%2520to%2520Treat%2520Late-Stage%2520Sleeping%2520Sickness%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-019-13522-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnaro, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfayez, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">C6–O-Alkylated 7-Deazainosine Nucleoside Analogues: Discovery of Potent and Selective Anti-Sleeping Sickness Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>, <span class="NLM_elocation-id">112018</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.112018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ejmech.2019.112018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=31931339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&author=F.+Hulpiaauthor=J.+Boutonauthor=G.+D.+Campagnaroauthor=I.+A.+Alfayezauthor=D.+Mabilleauthor=L.+Maesauthor=H.+P.+de+Koningauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=C6%E2%80%93O-Alkylated+7-Deazainosine+Nucleoside+Analogues%3A+Discovery+of+Potent+and+Selective+Anti-Sleeping+Sickness+Agents&doi=10.1016%2Fj.ejmech.2019.112018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">C6-O-alkylated 7-deazainosine nucleoside analogs: Discovery of potent and selective anti-sleeping sickness agents</span></div><div class="casAuthors">Hulpia, Fabian; Bouton, Jakob; Campagnaro, Gustavo D.; Alfayez, Ibrahim A.; Mabille, Dorien; Maes, Louis; de Koning, Harry P.; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112018</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">African trypanosomiasis, a deadly infectious disease caused by the protozoan Trypanosoma brucei spp., is spread to new hosts by bites of infected tsetse flies.  Currently approved therapies all have their specific drawbacks, prompting a search for novel therapeutic agents.  T. brucei lacks the enzymes necessary to forge the purine ring from amino acid precursors, rendering them dependent on the uptake and interconversion of host purines.  This dependency renders analogs of purines and corresponding nucleosides an interesting source of potential anti-T. brucei agents.  In this study, we synthesized and evaluated a series of 7-substituted 7-deazainosine derivs. and found that 6-O-alkylated analogs in particular showed highly promising in vitro activity with EC50 values in the mid-nanomolar range.  SAR investigation of the O-alkyl chain showed that antitrypanosomal activity increased, and also cytotoxicity, with alkyl chain length, at least in the linear alkyl chain series.  However, this could be attenuated by introducing a terminal branch point, resulting in the highly potent and selective analogs,, e.g. I.  No resistance related to transporter-mediated uptake could be identified, earmarking several of these analogs for further in vivo follow-up studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Q09UHPQjMrVg90H21EOLACvtfcHk0lhAHviOsxWreA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjt7g%253D&md5=4e142ef05733e2036e70d4d3a7066544</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.112018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.112018%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DBouton%26aufirst%3DJ.%26aulast%3DCampagnaro%26aufirst%3DG.%2BD.%26aulast%3DAlfayez%26aufirst%3DI.%2BA.%26aulast%3DMabille%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DC6%25E2%2580%2593O-Alkylated%25207-Deazainosine%2520Nucleoside%2520Analogues%253A%2520Discovery%2520of%2520Potent%2520and%2520Selective%2520Anti-Sleeping%2520Sickness%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26doi%3D10.1016%2Fj.ejmech.2019.112018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furquim d’Almeida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 3′-Fluorinated 7-Deazapurine Nucleosides as Antikinetoplastid Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>216</i></span>, <span class="NLM_elocation-id">113290</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ejmech.2021.113290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=33667845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3MXlslSlsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2021&author=J.+Boutonauthor=A.+Furquim+d%E2%80%99Almeidaauthor=L.+Maesauthor=G.+Caljonauthor=S.+Van+Calenberghauthor=F.+Hulpia&title=Synthesis+and+Evaluation+of+3%E2%80%B2-Fluorinated+7-Deazapurine+Nucleosides+as+Antikinetoplastid+Agents&doi=10.1016%2Fj.ejmech.2021.113290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents</span></div><div class="casAuthors">Bouton, Jakob; Furquim d'Almeida, Arno; Maes, Louis; Caljon, Guy; Van Calenbergh, Serge; Hulpia, Fabian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113290</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Kinetoplastid parasites are the causative agents of neglected tropical diseases with an unmet medical need.  These parasites are unable to synthesize the purine ring de novo, and therefore rely on purine salvage to meet their purine demand.  Evaluating purine nucleoside analogs, e.g. I, is therefore an attractive strategy to identify antikinetoplastid agents.  Several anti-Trypanosoma cruzi and anti-Trypanosoma brucei 7-deazapurine nucleosides were previously discovered, with the removal of the 3'-hydroxyl group resulting in a significant boost in activity.  In this work we therefore decided to assess the effect of the introduction of a 3'-fluoro substituent in 7-deazapurine nucleosides on the anti-kinetoplastid activities.  Hence, we synthesized two series of 3'-deoxy-3'-fluororibofuranosyl and 3'-deoxy-3'-fluoroxylofuranosyl nucleosides comprising 7-deazaadenine and -hypoxanthine bases and assayed these for antiparasitic activity.  Several analogs with potent activity against T. cruzi and T. brucei were discovered, indicating that a fluorine atom in the 3'-position is a promising modification for the discovery of antiparasitic nucleosides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXyW0O-mOKLVg90H21EOLACvtfcHk0lhAHviOsxWreA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXlslSlsb8%253D&md5=dfb1b9ee4396909dff6f2cf3bbdff869</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113290%26sid%3Dliteratum%253Aachs%26aulast%3DBouton%26aufirst%3DJ.%26aulast%3DFurquim%2Bd%25E2%2580%2599Almeida%26aufirst%3DA.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26aulast%3DHulpia%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25203%25E2%2580%25B2-Fluorinated%25207-Deazapurine%2520Nucleosides%2520as%2520Antikinetoplastid%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D216%26doi%3D10.1016%2Fj.ejmech.2021.113290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovelace, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waits, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R. S.</span></span> <span> </span><span class="NLM_article-title">Activity of Purine Analogs against Leishmania Donovani in Vivo</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1128/AAC.31.1.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.31.1.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=3566235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2sXpsFKgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1987&pages=111-113&author=J.+D.+Bermanauthor=W.+L.+Hansonauthor=J.+K.+Lovelaceauthor=V.+B.+Waitsauthor=J.+E.+Jacksonauthor=W.+L.+Chapmanauthor=R.+S.+Klein&title=Activity+of+Purine+Analogs+against+Leishmania+Donovani+in+Vivo&doi=10.1128%2FAAC.31.1.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of purine analogs against Leishmania donovani in vivo</span></div><div class="casAuthors">Berman, J. D.; Hanson, W. L.; Lovelace, J. K.; Waits, V. B.; Jackson, J. E.; Chapman, W. L., Jr.; Klein, R. S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-13</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The dose of orally administered 9-deazainosine  [89458-19-5] calcd. to suppress 50% of L. donovani amastigotes in hamster livers was 19 mg/kg per day; 99% of L. organisms were eliminated from the liver and spleen of squirrel monkeys by 50 mg/kg per day.  Because these activities were greater than that of the exptl. clin. agent allopurinol  [315-30-0] and comparable to that of the classical agent parenteral pentavalent antimony, 9-deazainosine should be considered for clin. development for visceral leishmaniasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-9Px_-xYhu7Vg90H21EOLACvtfcHk0lhGtdQEs-yEAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXpsFKgtw%253D%253D&md5=152a92ca73245a50c0f66810ba005938</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.31.1.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.31.1.111%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DJ.%2BD.%26aulast%3DHanson%26aufirst%3DW.%2BL.%26aulast%3DLovelace%26aufirst%3DJ.%2BK.%26aulast%3DWaits%26aufirst%3DV.%2BB.%26aulast%3DJackson%26aufirst%3DJ.%2BE.%26aulast%3DChapman%26aufirst%3DW.%2BL.%26aulast%3DKlein%26aufirst%3DR.%2BS.%26atitle%3DActivity%2520of%2520Purine%2520Analogs%2520against%2520Leishmania%2520Donovani%2520in%2520Vivo%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1987%26volume%3D31%26spage%3D111%26epage%3D113%26doi%3D10.1128%2FAAC.31.1.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waits, V. B.</span></span> <span> </span><span class="NLM_article-title">Leishmania Donovani: Oral Efficacy and Toxicity of Formycin B in the Infected Hamster</span>. <i>Exp. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/0014-4894(83)90065-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0014-4894%2883%2990065-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6617804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3sXlvVOiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1983&pages=215-221&author=J.+D.+Bermanauthor=C.+M.+Keenanauthor=S.+R.+Lambauthor=W.+L.+Hansonauthor=V.+B.+Waits&title=Leishmania+Donovani%3A+Oral+Efficacy+and+Toxicity+of+Formycin+B+in+the+Infected+Hamster&doi=10.1016%2F0014-4894%2883%2990065-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Leishmania donovani:  oral efficacy and toxicity of formycin B in the infected hamster</span></div><div class="casAuthors">Berman, J. D.; Keenan, C. M.; Lamb, S. R.; Hanson, W. L.; Waits, V. B.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Parasitology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-21</span>CODEN:
                <span class="NLM_cas:coden">EXPAAA</span>;
        ISSN:<span class="NLM_cas:issn">0014-4894</span>.
    </div><div class="casAbstract">After oral administration of formycin B  [13877-76-4] (13 mg/kg/day for 4 days) in hamsters infected with L. donovani there was an 85-92% redn. in nos. of parasites in livers of infected animals.  It efficacy by oral administration was approx. 4-8 times that by i.m. administration and 4 times that of the pos. control drug Glucantime by i.m. administration.  The levels of formycin B in serum after the final oral administration of 26 mg/kg/day were 1.4 μg/mL at 1 h and 0.3 μg/mL at 2 h.  The concn. in liver was greater (9.0 μg/mL at 1 h) and declined more slowly.  With this latter dosage or with 104 mg/kg/day there was no acute toxicity of formycin B to bone marrow or formed elements of the blood.  The only statistically significant toxicity to the liver was a doubling of serum total bilirubin levels.  Comparison of the in vivo efficacy of formycin B against L. donovani to the mild acute toxicity of the drug suggests that formycin B has potential as an oral agent against visceral leishmaniasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoteO0rPa_PKbVg90H21EOLACvtfcHk0lhGtdQEs-yEAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlvVOiurw%253D&md5=4dc1ef32ab7eb8eb14270af9e83e6c7d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0014-4894%2883%2990065-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-4894%252883%252990065-6%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DJ.%2BD.%26aulast%3DKeenan%26aufirst%3DC.%2BM.%26aulast%3DLamb%26aufirst%3DS.%2BR.%26aulast%3DHanson%26aufirst%3DW.%2BL.%26aulast%3DWaits%26aufirst%3DV.%2BB.%26atitle%3DLeishmania%2520Donovani%253A%2520Oral%2520Efficacy%2520and%2520Toxicity%2520of%2520Formycin%2520B%2520in%2520the%2520Infected%2520Hamster%26jtitle%3DExp.%2520Parasitol.%26date%3D1983%26volume%3D56%26spage%3D215%26epage%3D221%26doi%3D10.1016%2F0014-4894%2883%2990065-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rainey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santi, D. V.</span></span> <span> </span><span class="NLM_article-title">Inosine Analogs as Anti-Leishmanial Agents</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>02</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1023/A:1016360710842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1023%2FA%3A1016360710842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC2c3gsFClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=02&publication_year=1985&pages=217-220&author=P.+Raineyauthor=P.+A.+Nolanauthor=L.+B.+Townsendauthor=R.+K.+Robinsauthor=J.+J.+Foxauthor=J.+A.+Secristauthor=D.+V.+Santi&title=Inosine+Analogs+as+Anti-Leishmanial+Agents&doi=10.1023%2FA%3A1016360710842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inosine analogs as anti-leishmanial agents</span></div><div class="casAuthors">Rainey P; Nolan P A; Townsend L B; Robins R K; Fox J J; Secrist Iii J A; Santi D V</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">217-20</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">Several criteria were used to select a number of inosine analogs as potential growth inhibitors of the protozoan parasite Leishmania tropica.  Of nine compounds tested, seven showed a high degree of selective toxicity towards L. tropica promastigotes as compared to mouse L1210 cells; these include analogs of formycin B, 7-substituted analogs of 7-deazainosine and analogs of inosine in which the sugar moiety has been modified to confer metabolic stability.  The metabolism of 7-deazainosine in L. tropica promastigotes was shown to involve conversion to cytotoxic adenosine nucleotide analogs (tubercidin derivatives) that become incorporated into RNA.  The results suggest several new classes of compounds which have potential as anti-leishmanial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzuAgJjmR2jpPlX7E30qdzfW6udTcc2eZNE56AQPwBR7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3gsFClsQ%253D%253D&md5=af5f086cd38f852a5ce60a74bd9882b8</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1023%2FA%3A1016360710842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1016360710842%26sid%3Dliteratum%253Aachs%26aulast%3DRainey%26aufirst%3DP.%26aulast%3DNolan%26aufirst%3DP.%2BA.%26aulast%3DTownsend%26aufirst%3DL.%2BB.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DFox%26aufirst%3DJ.%2BJ.%26aulast%3DSecrist%26aufirst%3DJ.%2BA.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DInosine%2520Analogs%2520as%2520Anti-Leishmanial%2520Agents%26jtitle%3DPharm.%2520Res.%26date%3D1985%26volume%3D02%26spage%3D217%26epage%3D220%26doi%3D10.1023%2FA%3A1016360710842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R. S.</span></span> <span> </span><span class="NLM_article-title">Biological Action of Inosine Analogs in <i>Leishmania</i> and <i>Trypanosoma Spp</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1128/AAC.25.2.292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.25.2.292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6712205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2cXhsFSlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=292-295&author=J.+J.+Marrauthor=R.+L.+Berensauthor=N.+K.+Cohnauthor=D.+J.+Nelsonauthor=R.+S.+Klein&title=Biological+Action+of+Inosine+Analogs+in+Leishmania+and+Trypanosoma+Spp&doi=10.1128%2FAAC.25.2.292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Biological action of inosine analogs in Leishmania and Trypanosoma species</span></div><div class="casAuthors">Marr, J. Joseph; Berens, Randolph L.; Cohn, Naomi K.; Nelson, Donald J.; Klein, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">292-5</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The 5-membered heterocyclic ring of 6 inosine analogs was systematically modified, and the compds. were tested for their antiprotozoal activities and toxicity to a mammalian cell line.  All 6 analogs were very active against the 3 protozoan pathogens L. donovani, T. cruzi, and T. gambiense.  Two of the drugs, 9-deazainosine (I)  [89458-19-5] and allopurinol ribonucleoside (II)  [16220-07-8], had very little toxicity for mouse L cells and offer promise as potential chemotherapeutic agents.  Structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsYd6Nd5Mr_7Vg90H21EOLACvtfcHk0lhGtdQEs-yEAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhsFSlsbw%253D&md5=b9ddab79ab0ca49a7d3f07a070dcefb7</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FAAC.25.2.292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.25.2.292%26sid%3Dliteratum%253Aachs%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DCohn%26aufirst%3DN.%2BK.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26aulast%3DKlein%26aufirst%3DR.%2BS.%26atitle%3DBiological%2520Action%2520of%2520Inosine%2520Analogs%2520in%2520Leishmania%2520and%2520Trypanosoma%2520Spp%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1984%26volume%3D25%26spage%3D292%26epage%3D295%26doi%3D10.1128%2FAAC.25.2.292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morishige, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wataya, Y.</span></span> <span> </span><span class="NLM_article-title">Leishmania Donovani: Pilot Study for Evaluation of Therapeutic Effects of Inosine Analogs against Amastigotes in Vitro and in Vivo</span>. <i>Exp. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1006/expr.1995.1082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1006%2Fexpr.1995.1082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=7758547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK2MXms1Sjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=665-671&author=K.+Morishigeauthor=T.+Ajiauthor=A.+Ishiiauthor=T.+Yasudaauthor=Y.+Wataya&title=Leishmania+Donovani%3A+Pilot+Study+for+Evaluation+of+Therapeutic+Effects+of+Inosine+Analogs+against+Amastigotes+in+Vitro+and+in+Vivo&doi=10.1006%2Fexpr.1995.1082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo</span></div><div class="casAuthors">Morishige, Kazuhisa; Aji, Toshiki; Ishii, Akira; Yasuda, Tatsuji; Wataya, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Parasitology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">665-71</span>CODEN:
                <span class="NLM_cas:coden">EXPAAA</span>;
        ISSN:<span class="NLM_cas:issn">0014-4894</span>.
    </div><div class="casAbstract">The inhibition by carbocyclic inosine (C-Ino), 3'-deoxyinosine (3'-dI), and 3'-deoxy-3'-fluoroinosine (3'-FI) of Leishmania donovani amastigotes was examd.  J774.1 cells (a mouse macrophage line) were cultured in GIT medium with lipopolysaccharide and hemin and infected with the parasite.  C-Ino (3 μM) completely inhibited and 3'-dI (30 μM) reduced to 40% the infection rate on Day 6 after infection.  The std. pentostam (30 μM) resulted in a 38% infection rate.  The therapeutic efficacies of nonentrapped free and liposome-entrapped inosine analogs were tested in mice infected with L. donovani.  The mice were injected i.v. five times on alternate days, beginning 2 days after infection.  Treatment with the nonentrapped free inosine analog of C-Ino (100 mg/kg), 3'-dI (100 mg/kg), or 3'-FI (50 mg/kg) resulted in an LDU (Leishmania donovan units) that were 94, 68, or 73% lower, resp., than the control values.  Treatment with the corresponding entrapped inosine analog (10 mg/kg) caused decreases of 90, 69, or 68% LDU, resp.  The entrapped inosine analogs were inhibitory at doses one-fifth to one-tenth of the nonentrapped free inosine analogs.  C-Ino had the strongest inhibitory effect among the three analogs tested in vitro and in vivo.  Liposome-entrapped C-Ino had no severe side effects, although spleen wt. increased.  The agent may be useful as an antileishmanial drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooaYagQp298rVg90H21EOLACvtfcHk0lhS0evNziOxow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1Sjtrk%253D&md5=16ba864567913cfb3e51825eb0560284</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1006%2Fexpr.1995.1082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexpr.1995.1082%26sid%3Dliteratum%253Aachs%26aulast%3DMorishige%26aufirst%3DK.%26aulast%3DAji%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DA.%26aulast%3DYasuda%26aufirst%3DT.%26aulast%3DWataya%26aufirst%3DY.%26atitle%3DLeishmania%2520Donovani%253A%2520Pilot%2520Study%2520for%2520Evaluation%2520of%2520Therapeutic%2520Effects%2520of%2520Inosine%2520Analogs%2520against%2520Amastigotes%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DExp.%2520Parasitol.%26date%3D1995%26volume%3D80%26spage%3D665%26epage%3D671%26doi%3D10.1006%2Fexpr.1995.1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 7-Halogenated 8-Aza-7-Deaza-2′-Deoxyguanosines and Related Pyrazolo[3,4-d]Pyrimidine 2′-Deoxyribonucleosides</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>1998</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1055/s-1998-4483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1055%2Fs-1998-4483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1998&publication_year=1998&pages=207-214&author=F.+Seelaauthor=G.+Becher&title=Synthesis+of+7-Halogenated+8-Aza-7-Deaza-2%E2%80%B2-Deoxyguanosines+and+Related+Pyrazolo%5B3%2C4-d%5DPyrimidine+2%E2%80%B2-Deoxyribonucleosides&doi=10.1055%2Fs-1998-4483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1055%2Fs-1998-4483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1998-4483%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DBecher%26aufirst%3DG.%26atitle%3DSynthesis%2520of%25207-Halogenated%25208-Aza-7-Deaza-2%25E2%2580%25B2-Deoxyguanosines%2520and%2520Related%2520Pyrazolo%255B3%252C4-d%255DPyrimidine%25202%25E2%2580%25B2-Deoxyribonucleosides%26jtitle%3DSynthesis%26date%3D1998%26volume%3D1998%26spage%3D207%26epage%3D214%26doi%3D10.1055%2Fs-1998-4483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulauf, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 7-Alkynylated 8-Aza-7-Deaza-2′-Deoxyadenosines via the Pd-Catalysed Cross-Coupling Reaction</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_fpage">3233</span>– <span class="NLM_lpage">3240</span>, <span class="refDoi"> DOI: 10.1039/A804706E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1039%2Fa804706e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK1cXmtVartbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=3233-3240&author=F.+Seelaauthor=M.+Zulauf&title=Synthesis+of+7-Alkynylated+8-Aza-7-Deaza-2%E2%80%B2-Deoxyadenosines+via+the+Pd-Catalysed+Cross-Coupling+Reaction&doi=10.1039%2FA804706E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 7-alkynylated 8-aza-7-deaza-2'-deoxyadenosines via the Pd-catalyzed cross-coupling reaction</span></div><div class="casAuthors">Seela, Frank; Zulauf, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3233-3240</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis of 7-alkynylated 8-aza-7-deaza-adenine (pyrazolo[3,4-d]pyrimidine) 2'-deoxyribonucleosides is described.  Nucleobase anion-glycosylation of 8-aza-7-deaza-7-iodo-6-methoxy-purine with 2-deoxy-3,5-di-O-( p-toluoyl)-α-D-erythro-pentofuranosyl chloride furnishes the 8-aza-7-deaza-7-iodo-6-methoxy-purine N 1-β-D-2'-deoxyribonucleoside (I) as the main product (38% yield).  After detoluoylation of product I and amination the 7-bromo (II) and the 7-iodo derivs. of 8-aza-7-deaza-2'-deoxyadenosine were obtained.  Compd. II served as the starting material for a series of 7-alkynyl- or 7-alkenyl-8-aza-7-deaza-adenine 2'-deoxynucleoside by employing the Pd0/CuI-catalyzed cross-coupling reaction.  The 7-halogenated or 7-alkynylated nucleosides show a more stable glycosylic bond than does 8-aza-7-deaza-2'-deoxyadenosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5FI62_2tZ77Vg90H21EOLACvtfcHk0lhS0evNziOxow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtVartbo%253D&md5=ade5b3a0307ec2cc36929b6d7c102ec7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1039%2Fa804706e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fa804706e%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DZulauf%26aufirst%3DM.%26atitle%3DSynthesis%2520of%25207-Alkynylated%25208-Aza-7-Deaza-2%25E2%2580%25B2-Deoxyadenosines%2520via%2520the%2520Pd-Catalysed%2520Cross-Coupling%2520Reaction%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1998%26spage%3D3233%26epage%3D3240%26doi%3D10.1039%2FA804706E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mihich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulhern, A. I.</span></span> <span> </span><span class="NLM_article-title">Comparative Study of the Toxicologic Effects of 7-Deazaadenosine (Tubercidin) and 7-Deazainosine</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=5763972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaF1MXms1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1969&pages=116-123&author=E.+Mihichauthor=C.+L.+Simpsonauthor=A.+I.+Mulhern&title=Comparative+Study+of+the+Toxicologic+Effects+of+7-Deazaadenosine+%28Tubercidin%29+and+7-Deazainosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative study of the toxicologic effects of 7-deazaadenosine (tubercidin) and 7-deazainosine</span></div><div class="casAuthors">Mihich, Enrico; Simpson, C. L.; Mulhern, Aurelie I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-23</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Differences were found between the toxicologic effects of tubercidin (7-deazaadenosine) (I) and those of 7-deazainosine (II) which were consistent with the idea that II requires conversion into anabolites of I in order to exert biol. effects.  In rodents treated parenterally, and in dogs treated orally, I was 6-to 20-fold more toxic than II.  Severe local reactions occurred only in rats treated with I.  In contrast, necrosis of the walls of the intrahepatic bile ducts and of the myocardium was found only in rats treated with II.  Pulmonary edema, focal necrosis of hepatic parenchyma, and generalized lymphoid depression were observed after either drug.  After treatment of dogs with I, pneumonia, renal tubular necrosis, and gastrointestinal toxicity were severe, whereas hepatotoxicity was slight and infrequent.  In contrast, after treatment with II, hepatotoxicity was severe, whereas the other toxic effects were insignificant.  Only I caused atrophy of the islets of Langerhans.  Both compds. administered to dogs prolonged the prothrombin time while II increased the serum alk. phosphatase and glutamic oxalacetic transaminase activities.  In view of the lack of local and renal toxicity, II may offer therapeutic advantages over I provided that hepatotoxicity is not a limiting factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-eNcIdqpln7Vg90H21EOLACvtfcHk0lhS0evNziOxow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXms1Gktg%253D%253D&md5=35b5c6b8a06c01302290bb2ba7c1fdc6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMihich%26aufirst%3DE.%26aulast%3DSimpson%26aufirst%3DC.%2BL.%26aulast%3DMulhern%26aufirst%3DA.%2BI.%26atitle%3DComparative%2520Study%2520of%2520the%2520Toxicologic%2520Effects%2520of%25207-Deazaadenosine%2520%2528Tubercidin%2529%2520and%25207-Deazainosine%26jtitle%3DCancer%2520Res.%26date%3D1969%26volume%3D29%26spage%3D116%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Earl, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, L. B.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyrimidine Nucleosides. Part VII. The Synthesis of Certain Pyrazolo [3,4-d] Pyrimidine Nucleosides Related to the Nucleoside Antibiotics Toyocamycin and Sangivamycin</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1039</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570110633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fjhet.5570110633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaE2MXhslWgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1974&pages=1033-1039&author=R.+A.+Earlauthor=L.+B.+Townsend&title=Pyrazolopyrimidine+Nucleosides.+Part+VII.+The+Synthesis+of+Certain+Pyrazolo+%5B3%2C4-d%5D+Pyrimidine+Nucleosides+Related+to+the+Nucleoside+Antibiotics+Toyocamycin+and+Sangivamycin&doi=10.1002%2Fjhet.5570110633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyrimidine nucleosides.  VII.  Synthesis of certain pyrazolo[3,4-d]pyrimidine nucleosides related to the nucleoside antibiotics toyocamycin and sangivamycin</span></div><div class="casAuthors">Earl, Robert A.; Townsend, Leroy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1033-9</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    </div><div class="casAbstract">The condensation of 4-acetamido-3-cyanopyrazolo[3,4-d]pyrimidine with 2,3,5-tri-O-acetyl-β-D-ribofuranosyl chloride, which evolved copius amts. of HCN, was followed by treatment with NaOMe in MeOH to give Me 4-amino-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine-3-formimidate monohydrate (I).  The formimidate function of I was highly reactive and was readily converted into the corresponding carboxamidine, carboxamidoxime, and carboxamidrazone.  Treatment of I with NaHS gave a high yield of the thiocarboxamide, which was then converted into 4-amino-3-cyano-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine.  Aq. base transformed I into 4-amino-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine-3-carboxamide while more vigorous basic hydrolysis gave the corresponding carboxylic acid (II) in nearly quant. yield.  Decarboxylation of II in hot sulfolane gave 68% 4-amino-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine which established the site of ribosylation and anomeric configuration for all nucleosides reported in this investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTexWyTEDBXrVg90H21EOLACvtfcHk0lgruIwziwwHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhslWgsbc%253D&md5=1618d764d9d969f5267a04c9b545eb15</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570110633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570110633%26sid%3Dliteratum%253Aachs%26aulast%3DEarl%26aufirst%3DR.%2BA.%26aulast%3DTownsend%26aufirst%3DL.%2BB.%26atitle%3DPyrazolopyrimidine%2520Nucleosides.%2520Part%2520VII.%2520The%2520Synthesis%2520of%2520Certain%2520Pyrazolo%2520%255B3%252C4-d%255D%2520Pyrimidine%2520Nucleosides%2520Related%2520to%2520the%2520Nucleoside%2520Antibiotics%2520Toyocamycin%2520and%2520Sangivamycin%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1974%26volume%3D11%26spage%3D1033%26epage%3D1039%26doi%3D10.1002%2Fjhet.5570110633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawrelak, S. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activity of Pyrazolo[3,4-d]Pyrimidine Nucleosides and Nucleotides Related to Tubercidin, Toyocamycin, and Sangivamycin</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1015</span>, <span class="refDoi"> DOI: 10.1021/bi00650a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00650a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaE28XhsF2msbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1976&pages=1005-1015&author=S.+M.+Hechtauthor=R.+B.+Fryeauthor=D.+Wernerauthor=T.+Fukuiauthor=S.+D.+Hawrelak&title=Synthesis+and+Biological+Activity+of+Pyrazolo%5B3%2C4-d%5DPyrimidine+Nucleosides+and+Nucleotides+Related+to+Tubercidin%2C+Toyocamycin%2C+and+Sangivamycin&doi=10.1021%2Fbi00650a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activity of pyrazolo[3,4-d]pyrimidine nucleosides and nucleotides related to tubercidin, toyocamycin, and sangivamycin</span></div><div class="casAuthors">Hecht, Sidney M.; Frye, R. Bruce; Werner, Dieter; Fukui, Toshikazu; Hawrelak, S. D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1005-15</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">Title compd. 6-azasangivamycin (I) [55559-56-3] was prepd. from its O-acetylated precursor, while 6-azatoyocamycin (II) [55559-55-2] was prepd. via 4-amino-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine-3-thiocarboxamide (III) [55559-54-1].  III was more cytotoxic to the growth of mouse fibroblasts than 6-azatubercidin (IV) [3258-05-7], killing 3T6 cells at ≤1 μg/ml.  III was a substrate for adenosine deaminase from calf intestinal mucosa with an apparent Km of 125, and 6-azatubercidin 5'-diphosphate triethylammonium salt [59032-36-9] was polymerized by polynucleotide phosphorylase to a homopolymer and copolymers with adenosine.  The copolymers directed the binding of lysyl-tRNA to the A-site of ribosomes from Escherichia coli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7MZhUq0EYtrVg90H21EOLACvtfcHk0lgruIwziwwHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XhsF2msbw%253D&md5=fd25c80355b0f12d09f471226be05b4f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fbi00650a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00650a010%26sid%3Dliteratum%253Aachs%26aulast%3DHecht%26aufirst%3DS.%2BM.%26aulast%3DFrye%26aufirst%3DR.%2BB.%26aulast%3DWerner%26aufirst%3DD.%26aulast%3DFukui%26aufirst%3DT.%26aulast%3DHawrelak%26aufirst%3DS.%2BD.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520Pyrazolo%255B3%252C4-d%255DPyrimidine%2520Nucleosides%2520and%2520Nucleotides%2520Related%2520to%2520Tubercidin%252C%2520Toyocamycin%252C%2520and%2520Sangivamycin%26jtitle%3DBiochemistry%26date%3D1976%26volume%3D15%26spage%3D1005%26epage%3D1015%26doi%3D10.1021%2Fbi00650a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzica, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotring, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, L. B.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyrimidine Nucleosides. 12. Synthesis and Biological Activity of Certain Pyrazolo[3,4-d]Pyrimidine Nucleosides Related to Adenosine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1172</span>, <span class="refDoi"> DOI: 10.1021/jm00142a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00142a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3MXlt1GrtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=1165-1172&author=G.+A.+Bhatauthor=J.+L.+G.+Monteroauthor=R.+P.+Panzicaauthor=L.+L.+Wotringauthor=L.+B.+Townsend&title=Pyrazolopyrimidine+Nucleosides.+12.+Synthesis+and+Biological+Activity+of+Certain+Pyrazolo%5B3%2C4-d%5DPyrimidine+Nucleosides+Related+to+Adenosine&doi=10.1021%2Fjm00142a009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyrimidine nucleosides.  12.  Synthesis and biological activity of certain pyrazolo[3,4-d]pyrimidine nucleosides related to adenosine</span></div><div class="casAuthors">Bhat, Ganapati A.; Montero, Jean Louis G.; Panzica, Raymond P.; Wotring, Linda L.; Townsend, Leroy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1165-72</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Twenty-six title compds., 13 of which were synthesized, were tested for antitumor activity against mouse L1210 leukemia cells both in vitro and in vivo and against P388 leukemia cells in vivo.  I  [3258-05-7] and II  [78586-44-4] showed the greatest inhibition of growth of L1210 cells in vitro, with the activity of II probably resulting from the formation of I by hydrolysis in the aq. medium.  Any alteration of the C4-amino substituent of I resulted in a decrease or loss of antitumor activity.  Certain substitutions at the C3 position of I resulted in compds. with a better antitumor activity than I.  III  [55559-56-3] was the most active compd. giving an increase in life-span of 136% (vs. 48% for I) in L1210-bearing mice and having a significant lethal effect on L1210 cells in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNkThbjLtDvbVg90H21EOLACvtfcHk0lgruIwziwwHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXlt1GrtLw%253D&md5=0b38aaeb90bb57872c8766e7eca35d8b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm00142a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00142a009%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DG.%2BA.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%2BG.%26aulast%3DPanzica%26aufirst%3DR.%2BP.%26aulast%3DWotring%26aufirst%3DL.%2BL.%26aulast%3DTownsend%26aufirst%3DL.%2BB.%26atitle%3DPyrazolopyrimidine%2520Nucleosides.%252012.%2520Synthesis%2520and%2520Biological%2520Activity%2520of%2520Certain%2520Pyrazolo%255B3%252C4-d%255DPyrimidine%2520Nucleosides%2520Related%2520to%2520Adenosine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D1165%26epage%3D1172%26doi%3D10.1021%2Fjm00142a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cottam, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKernan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent
Dailey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revanka, G. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activity of Certain 3,4-Disubstituted Pyrazolo[3,4-d]Pyrimidine Nucleosides1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/jm00375a006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00375a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2cXkvFWgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=1119-1127&author=H.+B.+Cottamauthor=C.+R.+Petrieauthor=P.+A.+McKernanauthor=R.+J.+Goebelauthor=N.+Kent%0ADaileyauthor=R.+B.+Davidsonauthor=R.+K.+Robinsauthor=G.+R.+Revanka&title=Synthesis+and+Biological+Activity+of+Certain+3%2C4-Disubstituted+Pyrazolo%5B3%2C4-d%5DPyrimidine+Nucleosides1&doi=10.1021%2Fjm00375a006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activity of certain 3,4-disubstituted pyrazolo[3,4-d]pyrimidine nucleosides</span></div><div class="casAuthors">Cottam, Howard B.; Petrie, Charles R.; McKernan, Patricia A.; Goebel, Richard J.; Dalley, N. Kent; Davidson, Richard B.; Robins, Roland K.; Revankar, Ganapathi R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1119-27</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Several title ribonucleosides, e.g., I [R = Br, cyano, SMe, NH2, NHMe, NMe2, CONH2, CSNH2, C(:NH)NH2, C(:NOH)NH2; R1 = H, Bz; Z = O, S], were prepd.  I (R = Br, cyano; R1 = Bz; Z = O), obtained by glycosylation of the corresponding heterocycles with 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose, were the key intermediates.  The structural assignment of I (R = cyano, R1 = H, Z = O) was made by single crystal x-ray anal.  All the compds. were tested in vitro against certain viruses, tumor cells, and the parasite Leishmania tropica.  I [R = CSNH2, C(:NH)NH2; R1 = H; Z = O] showed significant activity against Para 3 virus and were potent inhibitors of growth of L1210 and P388 leukemia.  I (R = cyano, R1 = H, Z = S) showed the most significant broad-spectrum antiviral and antitumor activity.  I (R = Br, R1 = H, Z = O) was more active than allopurinol riboside against L. tropica within human macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-_RdnCVReLVg90H21EOLACvtfcHk0lhBW3GmbJtz-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvFWgu78%253D&md5=ad58d842b752d38bb441fd0cc4355890</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm00375a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00375a006%26sid%3Dliteratum%253Aachs%26aulast%3DCottam%26aufirst%3DH.%2BB.%26aulast%3DPetrie%26aufirst%3DC.%2BR.%26aulast%3DMcKernan%26aufirst%3DP.%2BA.%26aulast%3DGoebel%26aufirst%3DR.%2BJ.%26aulast%3DKent%2BDailey%26aufirst%3DN.%26aulast%3DDavidson%26aufirst%3DR.%2BB.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DRevanka%26aufirst%3DG.%2BR.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520Certain%25203%252C4-Disubstituted%2520Pyrazolo%255B3%252C4-d%255DPyrimidine%2520Nucleosides1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1984%26volume%3D27%26spage%3D1119%26epage%3D1127%26doi%3D10.1021%2Fjm00375a006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span> <span> </span><span class="NLM_article-title">1,N6-Etheno-7-Deaza-2,8-Diazaadenosine: Syntheses, Properties and Conversion to 7-Deaza-2,8-Diazaadenosine</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1714</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1039/B418849G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1039%2Fb418849g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=15858655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=1714-1718&author=W.+Linauthor=H.+Liauthor=X.+Mingauthor=F.+Seela&title=1%2CN6-Etheno-7-Deaza-2%2C8-Diazaadenosine%3A+Syntheses%2C+Properties+and+Conversion+to+7-Deaza-2%2C8-Diazaadenosine&doi=10.1039%2FB418849G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">1,N6-Etheno-7-deaza-2,8-diazaadenosine: syntheses, properties and conversion to 7-deaza-2,8-diazaadenosine</span></div><div class="casAuthors">Lin, Wenqing; Li, Hong; Ming, Xin; Seela, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1714-1718</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">1,N6-Etheno-7-deaza-2,8-diazaadenosine (I) was synthesized from 8-aza-7-deazaadenosine (II) in 64% overall yield.  The starting material II was obtained by the direct glycosylation of 8-aza-7-deazaadenine with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (NO2CH3, BF3·Et2O; 77% yield).  I was transformed into 7-deaza-2,8-diazaadenosine.  The fluorescence of I shows an emission max. at 531 nm (phosphate buffer; pH 7.0), which is bathochromically shifted compared to 1,N6-etheno-2-azaadenosine (495 nm).  A conformational anal. was performed in the solid state and in soln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBlDpC-2HSjLVg90H21EOLACvtfcHk0lhBW3GmbJtz-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGqt7c%253D&md5=802b13104d61e3d467db286eb6b1e87e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1039%2Fb418849g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb418849g%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMing%26aufirst%3DX.%26aulast%3DSeela%26aufirst%3DF.%26atitle%3D1%252CN6-Etheno-7-Deaza-2%252C8-Diazaadenosine%253A%2520Syntheses%252C%2520Properties%2520and%2520Conversion%2520to%25207-Deaza-2%252C8-Diazaadenosine%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2005%26volume%3D3%26spage%3D1714%26epage%3D1718%26doi%3D10.1039%2FB418849G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steker, H.</span></span> <span> </span><span class="NLM_article-title">Facile Synthesis of 2′-Deoxyribofuranosides of Allopurinol and 4-Amino-1H-Pyrazolo[3,4-d]Pyrimidine via Phase-Transfer Glycosylation</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1002/hlca.19850680305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fhlca.19850680305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2MXmtFGlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1985&pages=563-570&author=F.+Seelaauthor=H.+Steker&title=Facile+Synthesis+of+2%E2%80%B2-Deoxyribofuranosides+of+Allopurinol+and+4-Amino-1H-Pyrazolo%5B3%2C4-d%5DPyrimidine+via+Phase-Transfer+Glycosylation&doi=10.1002%2Fhlca.19850680305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Facile synthesis of 2'-deoxyribofuranosides of allopurinol and 4-amino-1H-pyrazolo[3,4-d]pyrimidine via phase-transfer glycosylation</span></div><div class="casAuthors">Seela, Frank; Steker, Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">563-70</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    </div><div class="casAbstract">Phase-transfer glycosylation of 4-methoxy-1H-pyrazolo[3,4-d]pyrimidine with 2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl chloride gave the N-1-β-nucleoside I (R = p-MeC6H4CO), its α-D-anomer, and N-2 isomer II (R = p-MeC6H4CO) in 39, 7, and 17.7% yield resp.  These were deacylated with NaOMe/MeOH.  Nucleophilic displacement of the 4-MeO group of I (R = H) and II gave allopurinol and aminopyrazolopyrimidine nucleosides, e.g., I (R = H) gave III and IV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX2HklglFNZbVg90H21EOLACvtfcHk0lhBW3GmbJtz-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXmtFGlu7s%253D&md5=9475720d8e64430c551414ee4bd02bb5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19850680305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19850680305%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DSteker%26aufirst%3DH.%26atitle%3DFacile%2520Synthesis%2520of%25202%25E2%2580%25B2-Deoxyribofuranosides%2520of%2520Allopurinol%2520and%25204-Amino-1H-Pyrazolo%255B3%252C4-d%255DPyrimidine%2520via%2520Phase-Transfer%2520Glycosylation%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1985%26volume%3D68%26spage%3D563%26epage%3D570%26doi%3D10.1002%2Fhlca.19850680305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, E.</span></span> <span> </span><span class="NLM_article-title">Nucleosides, 381) The Ribonucleosides of Allopurinol</span>. <i>Chem. Ber.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1610</span>– <span class="NLM_lpage">1623</span>, <span class="refDoi"> DOI: 10.1002/cber.19811140505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fcber.19811140505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3MXks1amtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1981&pages=1610-1623&author=F.+W.+Lichtenthalerauthor=E.+Cuny&title=Nucleosides%2C+381%29+The+Ribonucleosides+of+Allopurinol&doi=10.1002%2Fcber.19811140505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleosides.  38.  The ribonucleosides of allopurinol</span></div><div class="casAuthors">Lichtenthaler, Frieder W.; Cuny, Eckehard</div><div class="citationInfo"><span class="NLM_cas:title">Chemische Berichte</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1610-23</span>CODEN:
                <span class="NLM_cas:coden">CHBEAM</span>;
        ISSN:<span class="NLM_cas:issn">0009-2940</span>.
    </div><div class="casAbstract">Nucleosides I [R = β-D-ribofuranosyl (Q), R1 = H; R = R1 = Q; R = H, R1 = Q] and II (R2 = R3 = Q; R2 = H, R3 = Q) were prepd. via SnCl4-catalyzed glycosylation of 1-(trimethylsilyl)-4-(trimethylsilyloxy)-1H-pyrazolo[3,4-d]-pyrimidine with acylated ribofuranoses.  CF3SO3SiMe3 as catalyst in addn. produced a O-4-ribosylated compd.  Structures of the products were confirmed by UV and NMR spectroscopy.  The properties of the prepd. nucleosides as inhibitors and/or substrates for xanthine oxidase are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXUBStE6K2vLVg90H21EOLACvtfcHk0lgmGZwGyQjgTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXks1amtb0%253D&md5=9bdb49c8be54908bd40ae4acbd4cb41f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fcber.19811140505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19811140505%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenthaler%26aufirst%3DF.%2BW.%26aulast%3DCuny%26aufirst%3DE.%26atitle%3DNucleosides%252C%2520381%2529%2520The%2520Ribonucleosides%2520of%2520Allopurinol%26jtitle%3DChem.%2520Ber.%26date%3D1981%26volume%3D114%26spage%3D1610%26epage%3D1623%26doi%3D10.1002%2Fcber.19811140505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulauf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, G.</span></span> <span> </span><span class="NLM_article-title">Unexpected Dehalogenation of 3-Bromopyrazolo[3,4-d]Pyrimidine Nucleosides during Nucleobase-Anion Glycosylation</span>. <i>Nucleosides Nucleotides</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1080/07328319708001351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1080%2F07328319708001351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK2sXjtVWltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=305-314&author=F.+Seelaauthor=M.+Zulaufauthor=G.+Becher&title=Unexpected+Dehalogenation+of+3-Bromopyrazolo%5B3%2C4-d%5DPyrimidine+Nucleosides+during+Nucleobase-Anion+Glycosylation&doi=10.1080%2F07328319708001351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Unexpected dehalogenation of 3-bromopyrazolo[3,4-d]pyrimidine nucleosides during nucleobase-anion glycosylation</span></div><div class="casAuthors">Seela, Frank; Zulauf, Matthias; Becher, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides & Nucleotides</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-314</span>CODEN:
                <span class="NLM_cas:coden">NUNUD5</span>;
        ISSN:<span class="NLM_cas:issn">0732-8311</span>.
    
            (<span class="NLM_cas:orgname">Dekker</span>)
        </div><div class="casAbstract">The anion-glycosidation (KOH, MeCN, TDA-1) of 3-bromopyrazolo[3,4-d]-pyrimidines and with 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride furnishes the regioisomeric N1-β-D-2'-deoxyribonucleosides together with the dehalogenated N2-regioisomers.  The dehalogenation takes place after the glycosylation and results from the sensitivity of the N-2 nucleosides toward aq. base.  An addn./elimination mechanism is suggested for the dehalogenation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyWtVyyJ43XLVg90H21EOLACvtfcHk0lgmGZwGyQjgTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtVWltLg%253D&md5=432705032d5b9102ddcda4731386ef3d</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1080%2F07328319708001351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07328319708001351%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DZulauf%26aufirst%3DM.%26aulast%3DBecher%26aufirst%3DG.%26atitle%3DUnexpected%2520Dehalogenation%2520of%25203-Bromopyrazolo%255B3%252C4-d%255DPyrimidine%2520Nucleosides%2520during%2520Nucleobase-Anion%2520Glycosylation%26jtitle%3DNucleosides%2520Nucleotides%26date%3D1997%26volume%3D16%26spage%3D305%26epage%3D314%26doi%3D10.1080%2F07328319708001351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, K.</span></span> <span> </span><span class="NLM_article-title">8-Aza-7-deazaadenine N8- and N8-(B-D-2′-Deoxyribofuranosides): Building Blocks for Automated DNA Synthesis and Properties of Oligodeoxyribonucleotides</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1813</span>– <span class="NLM_lpage">1823</span>, <span class="refDoi"> DOI: 10.1002/hlca.19880710723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fhlca.19880710723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL1MXhsFCku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1988&pages=1813-1823&author=F.+Seelaauthor=K.+Kaiser&title=8-Aza-7-deazaadenine+N8-+and+N8-%28B-D-2%E2%80%B2-Deoxyribofuranosides%29%3A+Building+Blocks+for+Automated+DNA+Synthesis+and+Properties+of+Oligodeoxyribonucleotides&doi=10.1002%2Fhlca.19880710723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">8-Aza-7-deazaadenine N8-and N9-(β-D-2'-deoxyribofuranosides):  building blocks for automated DNA synthesis and properties of oligodeoxyribonucleotides</span></div><div class="casAuthors">Seela, Frank; Kaiser, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1813-23</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    </div><div class="casAbstract">Oligonucleotides with alternating 8-aza-7-deaza-2'-deoxyadenosine (=c7z8Ad I) and dT residues or 4-aminopyrazolo[3,4-d]pyrimidine N2-(β-D-2'-deoxyibofuranoside) (=c7z8A'd1); II and dT residues have been prepd. by solid-phase synthesis using P(III) chem.  Addnl., palindromic oligomers derived from d(C-T-G-G-A-T-C-C-A-G) but contg. I or II instead of dA have been synthesized.  Benzoylation of I or II followed by 4,4'-dimethoxytritylation and subsequent phosphitylation yielded the Me or the cyanoethyl phosphoramidites.  They were employed in automated DNA synthesis.  Alternating oligomers contg. I or II showed increase dTm values compared to those with dA, in particular d(c7z8a'-t)3 with an unusual N2-glycosylic bond.  The palindromic oligomers contg. I or II instead of dA were used as sequence-specific probes in endonuclease Sau 3A phosphodiester hydrolysis.  Whereas replacement of dA outside of the enzymic recognition side reduced the hydrolysis rate, replacement within d(G-A-T-C) abolished phosphodiester hydrolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK512se57cmbVg90H21EOLACvtfcHk0lgmGZwGyQjgTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhsFCku70%253D&md5=9d4d0ae2624f093ea76daccd22038598</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19880710723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19880710723%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DKaiser%26aufirst%3DK.%26atitle%3D8-Aza-7-deazaadenine%2520N8-%2520and%2520N8-%2528B-D-2%25E2%2580%25B2-Deoxyribofuranosides%2529%253A%2520Building%2520Blocks%2520for%2520Automated%2520DNA%2520Synthesis%2520and%2520Properties%2520of%2520Oligodeoxyribonucleotides%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1988%26volume%3D71%26spage%3D1813%26epage%3D1823%26doi%3D10.1002%2Fhlca.19880710723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, M.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-d]Pyrimidine 2′ -Deoxy- and 2′,3′ -Dideoxyribonucleosides: Studies on the Glycosylation of 4-Methoxypyrazolo[3,4-d]Pyrimidine</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1450</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1002/hlca.19930760405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fhlca.19930760405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK3sXmslWmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1993&pages=1450-1458&author=F.+Seelaauthor=H.+Winterauthor=M.+M%C3%B6ller&title=Pyrazolo%5B3%2C4-d%5DPyrimidine+2%E2%80%B2+-Deoxy-+and+2%E2%80%B2%2C3%E2%80%B2+-Dideoxyribonucleosides%3A+Studies+on+the+Glycosylation+of+4-Methoxypyrazolo%5B3%2C4-d%5DPyrimidine&doi=10.1002%2Fhlca.19930760405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo[3,4-d]pyrimidine 2'-deoxy- and 2',3'-dideoxyribonucleosides: studies on the glycosylation of 4-methoxypyrazolo[3,4-d]pyrimidine</span></div><div class="casAuthors">Seela, Frank; Winter, Holger; Moeller, Marianne</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1450-8</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    </div><div class="casAbstract">The glycosylation of the 4-methoxypyrazolo[3,4-d]pyrimidine anion with 1-halo-2-deoxyribose in MeCN/tris[2-(2-methoxyethoxy)ethyl]amine gives N2-deoxynucleoside I (R = toloyl) (29%) together with N1-isomer II (48%) and its α-D-anomer (6%).  The α-D-II is not formed and the yield of the β-D-II increased to 62% when dimethoxyethane is used as solvent and [18]crown-6 as catalyst.  Contrary to 7-deazapurine nucleotides, the triphosphates III (B = R1, R2) showed no appreciable activity against HIV-reverse transcriptase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphfRRENZPrtbVg90H21EOLACvtfcHk0lgmGZwGyQjgTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmslWmurg%253D&md5=4b0dde5f5a3f47eb37ca5e17d350ba85</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19930760405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19930760405%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DM%25C3%25B6ller%26aufirst%3DM.%26atitle%3DPyrazolo%255B3%252C4-d%255DPyrimidine%25202%25E2%2580%25B2%2520-Deoxy-%2520and%25202%25E2%2580%25B2%252C3%25E2%2580%25B2%2520-Dideoxyribonucleosides%253A%2520Studies%2520on%2520the%2520Glycosylation%2520of%25204-Methoxypyrazolo%255B3%252C4-d%255DPyrimidine%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1993%26volume%3D76%26spage%3D1450%26epage%3D1458%26doi%3D10.1002%2Fhlca.19930760405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutaganira, F. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhason, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radke, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddirala, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janetka, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Bakkouri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, L. D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma Gondii</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9976</span>– <span class="NLM_lpage">9989</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01192</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01192" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFensbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9976-9989&author=F.+U.+Rutaganiraauthor=J.+Barksauthor=M.+S.+Dhasonauthor=Q.+Wangauthor=M.+S.+Lopezauthor=S.+Longauthor=J.+B.+Radkeauthor=N.+G.+Jonesauthor=A.+R.+Maddiralaauthor=J.+W.+Janetkaauthor=M.+El+Bakkouriauthor=R.+Huiauthor=K.+M.+Shokatauthor=L.+D.+Sibley&title=Inhibition+of+Calcium+Dependent+Protein+Kinase+1+%28CDPK1%29+by+Pyrazolopyrimidine+Analogs+Decreases+Establishment+and+Reoccurrence+of+Central+Nervous+System+Disease+by+Toxoplasma+Gondii&doi=10.1021%2Facs.jmedchem.7b01192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii</span></div><div class="casAuthors">Rutaganira, Florentine U.; Barks, Jennifer; Dhason, Mary Savari; Wang, Qiuling; Lopez, Michael S.; Long, Shaojun; Radke, Joshua B.; Jones, Nathaniel G.; Maddirala, Amarendar R.; Janetka, James W.; El Bakkouri, Majida; Hui, Raymond; Shokat, Kevan M.; Sibley, L. David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9976-9989</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Calcium dependent protein kinase 1 (CDPK1) is an essential enzyme in the opportunistic pathogen Toxoplasma gondii.  CDPK1 controls multiple processes that are crit. to the intracellular replicative cycle of T. gondii including secretion of adhesins, motility, invasion, and egress.  Remarkably, CDPK1 contains a small glycine gatekeeper residue in the ATP binding pocket making it sensitive to ATP-competitive inhibitors with bulky substituents that complement this expanded binding pocket.  Here the authors explored structure-activity relationships of a series of pyrazolopyrimidine inhibitors of CDPK1 with the goal of increasing selectivity over host enzymes, improving antiparasite potency, and improving metabolic stability.  The resulting lead compd. 24 exhibited excellent enzyme inhibition and selectivity for CDPK1 and potently inhibited parasite growth in vitro.  Compd. 24 was also effective at treating acute toxoplasmosis in the mouse, reducing dissemination to the central nervous system, and decreasing reactivation of chronic infection in severely immunocompromised mice.  These findings provide proof of concept for the development of small mol. inhibitors of CDPK1 for treatment of CNS toxoplasmosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_eZs2pZPQ7Vg90H21EOLACvtfcHk0lgrJD7GDhDkag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFensbzO&md5=27908eedbcadb1132f254fda63336842</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01192%26sid%3Dliteratum%253Aachs%26aulast%3DRutaganira%26aufirst%3DF.%2BU.%26aulast%3DBarks%26aufirst%3DJ.%26aulast%3DDhason%26aufirst%3DM.%2BS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DLong%26aufirst%3DS.%26aulast%3DRadke%26aufirst%3DJ.%2BB.%26aulast%3DJones%26aufirst%3DN.%2BG.%26aulast%3DMaddirala%26aufirst%3DA.%2BR.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DEl%2BBakkouri%26aufirst%3DM.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DSibley%26aufirst%3DL.%2BD.%26atitle%3DInhibition%2520of%2520Calcium%2520Dependent%2520Protein%2520Kinase%25201%2520%2528CDPK1%2529%2520by%2520Pyrazolopyrimidine%2520Analogs%2520Decreases%2520Establishment%2520and%2520Reoccurrence%2520of%2520Central%2520Nervous%2520System%2520Disease%2520by%2520Toxoplasma%2520Gondii%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9976%26epage%3D9989%26doi%3D10.1021%2Facs.jmedchem.7b01192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span> <span> </span><span class="NLM_article-title">Copper-Catalyzed Conversion of Aryl and Heteroaryl Bromides into the Corresponding Chlorides</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">9468</span>– <span class="NLM_lpage">9470</span>, <span class="refDoi"> DOI: 10.1039/c2cc34944b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1039%2Fc2cc34944b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22895409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yqsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=9468-9470&author=X.+Fengauthor=Y.+Quauthor=Y.+Hanauthor=X.+Yuauthor=M.+Baoauthor=Y.+Yamamoto&title=Copper-Catalyzed+Conversion+of+Aryl+and+Heteroaryl+Bromides+into+the+Corresponding+Chlorides&doi=10.1039%2Fc2cc34944b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-catalyzed conversion of aryl and heteroaryl bromides into the corresponding chlorides</span></div><div class="casAuthors">Feng, Xiujuan; Qu, Yiping; Han, Yanlei; Yu, Xiaoqiang; Bao, Ming; Yamamoto, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">76</span>),
    <span class="NLM_cas:pages">9468-9470</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">An efficient method for the synthesis of aryl and heteroaryl chlorides is described.  The reactions of aryl and heteroaryl bromides with tetramethylammonium chloride proceeded smoothly in the presence of a copper catalyst under mild reaction conditions to produce the corresponding chlorides in satisfactory to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzBRc0k_54sLVg90H21EOLACvtfcHk0lgrJD7GDhDkag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yqsbnN&md5=03158cfd263e9f17cc7b0f7355233726</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1039%2Fc2cc34944b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2cc34944b%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DCopper-Catalyzed%2520Conversion%2520of%2520Aryl%2520and%2520Heteroaryl%2520Bromides%2520into%2520the%2520Corresponding%2520Chlorides%26jtitle%3DChem.%2520Commun.%26date%3D2012%26volume%3D48%26spage%3D9468%26epage%3D9470%26doi%3D10.1039%2Fc2cc34944b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, D. d. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soeiro, M. d. N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Pyrrolo[2,3-b]Pyridine (1,7-Dideazapurine) Nucleoside Analogues as Anti-Trypanosoma Cruzi Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8847</span>– <span class="NLM_lpage">8865</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01275</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01275" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8847-8865&author=C.+Linauthor=F.+Hulpiaauthor=C.+F.+da+Silvaauthor=D.+d.+G.+J.+Batistaauthor=K.+Van+Heckeauthor=L.+Maesauthor=G.+Caljonauthor=M.+d.+N.+C.+Soeiroauthor=S.+Van+Calenbergh&title=Discovery+of+Pyrrolo%5B2%2C3-b%5DPyridine+%281%2C7-Dideazapurine%29+Nucleoside+Analogues+as+Anti-Trypanosoma+Cruzi+Agents&doi=10.1021%2Facs.jmedchem.9b01275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrrolo[2,3-b]pyridine (1,7-Dideazapurine) Nucleoside Analogues as Anti-Trypanosoma cruzi Agents</span></div><div class="casAuthors">Lin, Cai; Hulpia, Fabian; da Silva, Cristiane Franca; Batista, Denise da Gama Jaen; Van Hecke, Kristof; Maes, Louis; Caljon, Guy; Soeiro, Maria de Nazare C.; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8847-8865</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trypanosoma cruzi is the causative pathogen of Chagas disease and the main culprit for cardiac-related mortality in Latin-America triggered by an infective agent.  Incapable of synthesizing purines de novo, this parasite depends on acquisition and processing of host-derived purines, making purine (nucleoside) analogs a potential source of antitrypanosomal agents.  In this respect, hitherto 7-deazaadenosine (tubercidin) analogs attracted most attention.  Here, we investigated analogs with an addnl. nitrogen (N1) removed.  Structure-activity relationship investigation showed that C7 modification afforded analogs with potent antitrypanosomal activity.  Halogens and small, linear carbon-based substituents were preferred.  Compd. 11 proved most potent in vitro, showed full suppression of parasitemia in a mouse model of acute infection, and elicited 100% animal survival after oral dosing at 25 mg/kg b.i.d. for 5 and 15 days.  Cyclophosphamide-induced immunosuppression led to recrudescence.  Washout expts. demonstrated a lack of complete clearance of infected cell cultures, potentially explaining the in vivo results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxqDRLq5dJvrVg90H21EOLACvtfcHk0lilejGxYAUNlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegtrjM&md5=c738830ec9f6d33ffce1661a7e12d6e7</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01275%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3Dda%2BSilva%26aufirst%3DC.%2BF.%26aulast%3DBatista%26aufirst%3DD.%2Bd.%2BG.%2BJ.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DSoeiro%26aufirst%3DM.%2Bd.%2BN.%2BC.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Pyrrolo%255B2%252C3-b%255DPyridine%2520%25281%252C7-Dideazapurine%2529%2520Nucleoside%2520Analogues%2520as%2520Anti-Trypanosoma%2520Cruzi%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8847%26epage%3D8865%26doi%3D10.1021%2Facs.jmedchem.9b01275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanefeld, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. J.</span></span> <span> </span><span class="NLM_article-title">One-Pot Synthesis of Tetrasubstituted Pyrazoles—Proof of Regiochemistry</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1039/P19960001545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1039%2FP19960001545" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1996&pages=1545-1552&author=U.+Hanefeldauthor=C.+W.+Reesauthor=A.+J.+P.+Whiteauthor=D.+J.+Williams&title=One-Pot+Synthesis+of+Tetrasubstituted+Pyrazoles%E2%80%94Proof+of+Regiochemistry&doi=10.1039%2FP19960001545"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1039%2FP19960001545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FP19960001545%26sid%3Dliteratum%253Aachs%26aulast%3DHanefeld%26aufirst%3DU.%26aulast%3DRees%26aufirst%3DC.%2BW.%26aulast%3DWhite%26aufirst%3DA.%2BJ.%2BP.%26aulast%3DWilliams%26aufirst%3DD.%2BJ.%26atitle%3DOne-Pot%2520Synthesis%2520of%2520Tetrasubstituted%2520Pyrazoles%25E2%2580%2594Proof%2520of%2520Regiochemistry%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1996%26volume%3D28%26spage%3D1545%26epage%3D1552%26doi%3D10.1039%2FP19960001545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. F.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Carbonylative Transformation of Organic Halides with Formic Acid as the Coupling Partner and CO Source: Synthesis of Carboxylic Acids</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">9710</span>– <span class="NLM_lpage">9714</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.7b01808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.7b01808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=9710-9714&author=F.+P.+Wuauthor=J.+B.+Pengauthor=X.+Qiauthor=X.+F.+Wu&title=Palladium-Catalyzed+Carbonylative+Transformation+of+Organic+Halides+with+Formic+Acid+as+the+Coupling+Partner+and+CO+Source%3A+Synthesis+of+Carboxylic+Acids&doi=10.1021%2Facs.joc.7b01808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Carbonylative Transformation of Organic Halides with Formic Acid as the Coupling Partner and CO Source: Synthesis of Carboxylic Acids</span></div><div class="casAuthors">Wu, Fu-Peng; Peng, Jin-Bao; Qi, Xinxin; Wu, Xiao-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9710-9714</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using formic acid as a carbon monoxide source, DCC as an activator, and Et3N, (E)-arylalkenyl iodides and aryl iodides and bromides and Ph triflate underwent hydroxycarbonylation in the presence of Pd(OAc)2 and Xantphos to yield (E)-cinnamic acids and arylcarboxylic acids in 78-92% and 46-97% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq60-ZZKNrkGbVg90H21EOLACvtfcHk0lilejGxYAUNlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCqs7vE&md5=dcbeabe925978b1f22ca617dd14688f9</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.7b01808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.7b01808%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.%2BP.%26aulast%3DPeng%26aufirst%3DJ.%2BB.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%2BF.%26atitle%3DPalladium-Catalyzed%2520Carbonylative%2520Transformation%2520of%2520Organic%2520Halides%2520with%2520Formic%2520Acid%2520as%2520the%2520Coupling%2520Partner%2520and%2520CO%2520Source%253A%2520Synthesis%2520of%2520Carboxylic%2520Acids%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2017%26volume%3D82%26spage%3D9710%26epage%3D9714%26doi%3D10.1021%2Facs.joc.7b01808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manabe, K.</span></span> <span> </span><span class="NLM_article-title">Trichlorophenyl Formate: Highly Reactive and Easily Accessible Crystalline CO Surrogate for Palladium-Catalyzed Carbonylation of Aryl/Alkenyl Halides and Triflates</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5370</span>– <span class="NLM_lpage">5373</span>, <span class="refDoi"> DOI: 10.1021/ol302593z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol302593z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=5370-5373&author=T.+Uedaauthor=H.+Konishiauthor=K.+Manabe&title=Trichlorophenyl+Formate%3A+Highly+Reactive+and+Easily+Accessible+Crystalline+CO+Surrogate+for+Palladium-Catalyzed+Carbonylation+of+Aryl%2FAlkenyl+Halides+and+Triflates&doi=10.1021%2Fol302593z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Trichlorophenyl Formate: Highly Reactive and Easily Accessible Crystalline CO Surrogate for Palladium-Catalyzed Carbonylation of Aryl/Alkenyl Halides and Triflates</span></div><div class="casAuthors">Ueda, Tsuyoshi; Konishi, Hideyuki; Manabe, Kei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5370-5373</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The high utility of 2,4,6-trichlorophenyl formate, a highly reactive and easily accessible cryst. CO surrogate, is demonstrated.  The decarbonylation with NEt3 to generate CO proceeded rapidly at rt, thereby allowing external-CO-free Pd-catalyzed carbonylation of aryl/alkenyl halides and triflates.  The high reactivity of the CO surrogate enabled carbonylation at rt and significantly reduced the quantities of formate to near-stoichiometric levels.  The obtained trichlorophenyl esters can be readily converted to a variety of carboxylic acid derivs. in high yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUQt4b7-33nrVg90H21EOLACvtfcHk0lilejGxYAUNlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejs7vP&md5=74392d6c4847f88bd452016f5ddd08aa</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fol302593z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol302593z%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DH.%26aulast%3DManabe%26aufirst%3DK.%26atitle%3DTrichlorophenyl%2520Formate%253A%2520Highly%2520Reactive%2520and%2520Easily%2520Accessible%2520Crystalline%2520CO%2520Surrogate%2520for%2520Palladium-Catalyzed%2520Carbonylation%2520of%2520Aryl%252FAlkenyl%2520Halides%2520and%2520Triflates%26jtitle%3DOrg.%2520Lett.%26date%3D2012%26volume%3D14%26spage%3D5370%26epage%3D5373%26doi%3D10.1021%2Fol302593z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manabe, K.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5370</span>– <span class="NLM_lpage">5373</span>, <span class="refDoi"> DOI: 10.1021/ol4026815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol4026815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKks77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=5370-5373&author=T.+Uedaauthor=H.+Konishiauthor=K.+Manabe&title=Palladium-Catalyzed+Fluorocarbonylation+Using+N-Formylsaccharin+as+CO+Source%3A+General+Access+to+Carboxylic+Acid+Derivatives&doi=10.1021%2Fol4026815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives</span></div><div class="casAuthors">Ueda, Tsuyoshi; Konishi, Hideyuki; Manabe, Kei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5370-5373</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Formylsaccharin, an easily accessible cryst. compd., has been employed as an efficient CO source in Pd-catalyzed fluorocarbonylation of aryl halides to afford the corresponding acyl fluorides in high yields.  The reactions use a near-stoichiometric amt. of the CO source (1.2 equiv) and tolerate diverse functional groups.  The acyl fluorides obtained could be readily transformed into various carboxylic acid derivs. such as carboxylic acid, esters, thioesters, and amides in a one-pot procedure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqTUEhxhGH57Vg90H21EOLACvtfcHk0ljSgvbelAbg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKks77O&md5=c3c3e96e8e986e2b8b496bb8846bea07</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fol4026815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol4026815%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DH.%26aulast%3DManabe%26aufirst%3DK.%26atitle%3DPalladium-Catalyzed%2520Fluorocarbonylation%2520Using%2520N-Formylsaccharin%2520as%2520CO%2520Source%253A%2520General%2520Access%2520to%2520Carboxylic%2520Acid%2520Derivatives%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D5370%26epage%3D5373%26doi%3D10.1021%2Fol4026815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molander, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. R.</span></span> <span> </span><span class="NLM_article-title">Suzuki–Miyaura Cross-Coupling Reactions of Potassium Vinyltrifluoroborate with Aryl and Heteroaryl Electrophiles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">9681</span>– <span class="NLM_lpage">9686</span>, <span class="refDoi"> DOI: 10.1021/jo0617013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0617013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCgsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=9681-9686&author=G.+A.+Molanderauthor=A.+R.+Brown&title=Suzuki%E2%80%93Miyaura+Cross-Coupling+Reactions+of+Potassium+Vinyltrifluoroborate+with+Aryl+and+Heteroaryl+Electrophiles&doi=10.1021%2Fjo0617013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Suzuki-Miyaura cross-coupling reactions of potassium vinyltrifluoroborate with aryl and heteroaryl electrophiles</span></div><div class="casAuthors">Molander, Gary A.; Brown, Adam R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9681-9686</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The palladium-catalyzed cross-coupling reaction of potassium vinyltrifluoroborate with aryl electrophiles was described.  Recent progress in optimizing the reaction, as well as outlining the scope and limitations of the reaction were presented.  The cross-coupling reaction could generally be effected using 2 mol % of PdCl2 and 6 mol % of PPh3 as a catalyst system in THF/H2O with Cs2CO3 as a base.  Moderate to good yields were obtained in the presence of a variety of functional groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5MqLzCH3iurVg90H21EOLACvtfcHk0ljSgvbelAbg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCgsrfN&md5=67aef9e362d578497bce6c9f89effcf4</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjo0617013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0617013%26sid%3Dliteratum%253Aachs%26aulast%3DMolander%26aufirst%3DG.%2BA.%26aulast%3DBrown%26aufirst%3DA.%2BR.%26atitle%3DSuzuki%25E2%2580%2593Miyaura%2520Cross-Coupling%2520Reactions%2520of%2520Potassium%2520Vinyltrifluoroborate%2520with%2520Aryl%2520and%2520Heteroaryl%2520Electrophiles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26spage%3D9681%26epage%3D9686%26doi%3D10.1021%2Fjo0617013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oshiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amii, H.</span></span> <span> </span><span class="NLM_article-title">Sodium Bromodifluoroacetate: A Difluorocarbene Source for the Synthesis of Gem -Difluorocyclopropanes</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">2080</span>– <span class="NLM_lpage">2084</span>, <span class="refDoi"> DOI: 10.1055/s-0029-1218754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1055%2Fs-0029-1218754" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=2080-2084&author=K.+Oshiroauthor=Y.+Morimotoauthor=H.+Amii&title=Sodium+Bromodifluoroacetate%3A+A+Difluorocarbene+Source+for+the+Synthesis+of+Gem+-Difluorocyclopropanes&doi=10.1055%2Fs-0029-1218754"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1218754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1218754%26sid%3Dliteratum%253Aachs%26aulast%3DOshiro%26aufirst%3DK.%26aulast%3DMorimoto%26aufirst%3DY.%26aulast%3DAmii%26aufirst%3DH.%26atitle%3DSodium%2520Bromodifluoroacetate%253A%2520A%2520Difluorocarbene%2520Source%2520for%2520the%2520Synthesis%2520of%2520Gem%2520-Difluorocyclopropanes%26jtitle%3DSynthesis%26date%3D2010%26volume%3D99%26spage%3D2080%26epage%3D2084%26doi%3D10.1055%2Fs-0029-1218754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafon, S. W.</span></span> <span> </span><span class="NLM_article-title">Antileishmanial Effect of Allopurinol and Allopurinol Ribonucleoside on Intracellular Forms of Leishmania Donovani</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2398</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(80)90275-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0006-2952%2880%2990275-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=7426045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3MXisFKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1980&pages=2397-2398&author=R.+L.+Berensauthor=J.+J.+Marrauthor=D.+J.+Nelsonauthor=S.+W.+Lafon&title=Antileishmanial+Effect+of+Allopurinol+and+Allopurinol+Ribonucleoside+on+Intracellular+Forms+of+Leishmania+Donovani&doi=10.1016%2F0006-2952%2880%2990275-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani</span></div><div class="casAuthors">Berens, Randolph L.; Marr, J. Joseph; Nelson, Donald J.; LaFon, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2397-8</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Metab. of allopurinol (I)  [315-30-0] and allopurinol ribonucleoside (II)  [16220-07-8] by intracellular amastigotes of L. donovani placed either in suspension, within phagocytic cells of hamster spleen, or within a murine macrophage tissue culture, was the same as in extracellular promastigotes of L. donovani.  Both I and II were effective in eliminating amastigotes from murine macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_zbrfkD_ZqLVg90H21EOLACvtfcHk0ljSgvbelAbg-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXisFKhuw%253D%253D&md5=c6a4b47f199b1c203140d4d776eef78a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2880%2990275-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252880%252990275-0%26sid%3Dliteratum%253Aachs%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26aulast%3DLafon%26aufirst%3DS.%2BW.%26atitle%3DAntileishmanial%2520Effect%2520of%2520Allopurinol%2520and%2520Allopurinol%2520Ribonucleoside%2520on%2520Intracellular%2520Forms%2520of%2520Leishmania%2520Donovani%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1980%26volume%3D29%26spage%3D2397%26epage%3D2398%26doi%3D10.1016%2F0006-2952%2880%2990275-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moorman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span> <span> </span><span class="NLM_article-title">Antiprotozoal Activity of 3′-Deoxyinosine</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(91)90704-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0006-2952%2891%2990704-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1859443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK3MXmt1arsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1991&pages=207-212&author=A.+R.+Moormanauthor=S.+W.+LaFonauthor=D.+J.+Nelsonauthor=H.+H.+Carterauthor=J.+J.+Marrauthor=R.+L.+Berens&title=Antiprotozoal+Activity+of+3%E2%80%B2-Deoxyinosine&doi=10.1016%2F0006-2952%2891%2990704-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Antiprotozoal activity of 3'-deoxyinosine.  Inverse correlation to cleavage of the glycosidic bond</span></div><div class="casAuthors">Moorman, Allan R.; LaFon, Stephen W.; Nelson, Donald J.; Carter, Heidi H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-12</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Two nucleosides related to the known antiprotozoal agent, allopurinol β-D-riboside) (I) were prepd. and evaluated against Leishmania donovani, Trypanosoma cruzi, and T. gambiense.  3'-Deoxyinosine (II) exhibited potent antiprotozoal activity against the three protozoal pathogens with minimal toxicity for host cells.  It was esp. effective against the Columbia strain of T. cruzi reported to be resistant to I.  The antiprotozoal activity of II appeared to be inversely related to the rate of cleavage of the glycosidic bond, as shown by metabolic profiles of II in the various pathogenic hemoflagellates and host cells.  Combining the key structural elements of I and II led to the synthesis of 3'-deoxyallopurinol β-D-riboside (III) which was inactive as an antiprotozoal agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplV7sveQNPMrVg90H21EOLACvtfcHk0ljbjERTCjf_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmt1arsLo%253D&md5=aedbb1500cdb74f8538adfdfa13dfe30</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2891%2990704-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252891%252990704-9%26sid%3Dliteratum%253Aachs%26aulast%3DMoorman%26aufirst%3DA.%2BR.%26aulast%3DLaFon%26aufirst%3DS.%2BW.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26aulast%3DCarter%26aufirst%3DH.%2BH.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26atitle%3DAntiprotozoal%2520Activity%2520of%25203%25E2%2580%25B2-Deoxyinosine%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1991%26volume%3D42%26spage%3D207%26epage%3D212%26doi%3D10.1016%2F0006-2952%2891%2990704-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soeiro, M. d. N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, D. d. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavão, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araújo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiub, C. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lionel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulikowski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrove, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepesheva, G. I.</span></span> <span> </span><span class="NLM_article-title">In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma Cruzi</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4151</span>– <span class="NLM_lpage">4163</span>, <span class="refDoi"> DOI: 10.1128/AAC.00070-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.00070-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=23774435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSns7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=4151-4163&author=M.+d.+N.+C.+Soeiroauthor=E.+M.+de+Souzaauthor=C.+F.+da+Silvaauthor=D.+d.+G.+J.+Batistaauthor=M.+M.+Batistaauthor=B.+P.+Pav%C3%A3oauthor=J.+S.+Ara%C3%BAjoauthor=C.+A.+F.+Aiubauthor=P.+B.+da+Silvaauthor=J.+Lionelauthor=C.+Brittoauthor=K.+Kimauthor=G.+Sulikowskiauthor=T.+Y.+Hargroveauthor=M.+R.+Watermanauthor=G.+I.+Lepesheva&title=In+Vitro+and+In+Vivo+Studies+of+the+Antiparasitic+Activity+of+Sterol+14%CE%B1-Demethylase+%28CYP51%29+Inhibitor+VNI+against+Drug-Resistant+Strains+of+Trypanosoma+Cruzi&doi=10.1128%2FAAC.00070-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi</span></div><div class="casAuthors">Soeiro, Maria de Nazare Correia; Mello de Souza, Elen; Franca da Silva, Cristiane; Batista, Denise da Gama Jaen; Batista, Marcos Meuser; Pavao, Beatriz Philot; Araujo, Julianna Siciliano; Alub, Claudia Alessandra Fortes; Bernardino da Silva, Patricia; Lionel, Jessica; Britto, Constanca; Kim, Kwangho; Sulikowski, Gary; Hargrove, Tatiana Y.; Waterman, Michael R.; Lepesheva, Galina I.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4151-4163</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chagas disease affects more than 10 million people worldwide, and yet, as it has historically been known as a disease of the poor, it remains highly neglected.  Two currently available drugs exhibit severe toxicity and low effectiveness, esp. in the chronic phase, while new drug discovery has been halted for years as a result of a lack of interest from pharmaceutical companies.  Although attempts to repurpose the antifungal drugs posaconazole and ravuconazole (inhibitors of fungal sterol 14α-demethylase [CYP51]) are finally in progress, development of cheaper and more efficient, preferably Trypanosoma cruzi-specific, chemotherapies would be highly advantageous.  We have recently reported that the exptl. T. cruzi CYP51 inhibitor VNI cures with 100% survival and 100% parasitol. clearance both acute and chronic murine infections with the Tulahuen strain of T. cruzi.  In this work, we further explored the potential of VNI by assaying nitro-deriv.-resistant T. cruzi strains, Y and Colombiana, in highly stringent protocols of acute infection.  The data show high antiparasitic efficacy of VNI and its deriv. (VNI/VNF) against both forms of T. cruzi that are relevant for mammalian host infection (bloodstream and amastigotes), with the in vivo potency, at 25 mg/kg twice a day (b.i.d.), similar to that of benznidazole (100 mg/kg/day).  Transmission electron microscopy and reverse mutation tests were performed to explore cellular ultrastructural and mutagenic aspects of VNI, resp.  No mutagenic potential could be seen by the Ames test at up to 3.5 μM, and the main ultrastructural damage induced by VNI in T. cruzi was related to Golgi app. and endoplasmic reticulum organization, with membrane blebs presenting an autophagic phenotype.  Thus, these preliminary studies confirm VNI as a very promising trypanocidal drug candidate for Chagas disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr1uyCnawwErVg90H21EOLACvtfcHk0ljbjERTCjf_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSns7fK&md5=28a51dededa1b97eb13327c5fa92ae76</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1128%2FAAC.00070-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00070-13%26sid%3Dliteratum%253Aachs%26aulast%3DSoeiro%26aufirst%3DM.%2Bd.%2BN.%2BC.%26aulast%3Dde%2BSouza%26aufirst%3DE.%2BM.%26aulast%3Dda%2BSilva%26aufirst%3DC.%2BF.%26aulast%3DBatista%26aufirst%3DD.%2Bd.%2BG.%2BJ.%26aulast%3DBatista%26aufirst%3DM.%2BM.%26aulast%3DPav%25C3%25A3o%26aufirst%3DB.%2BP.%26aulast%3DAra%25C3%25BAjo%26aufirst%3DJ.%2BS.%26aulast%3DAiub%26aufirst%3DC.%2BA.%2BF.%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DLionel%26aufirst%3DJ.%26aulast%3DBritto%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DSulikowski%26aufirst%3DG.%26aulast%3DHargrove%26aufirst%3DT.%2BY.%26aulast%3DWaterman%26aufirst%3DM.%2BR.%26aulast%3DLepesheva%26aufirst%3DG.%2BI.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Studies%2520of%2520the%2520Antiparasitic%2520Activity%2520of%2520Sterol%252014%25CE%25B1-Demethylase%2520%2528CYP51%2529%2520Inhibitor%2520VNI%2520against%2520Drug-Resistant%2520Strains%2520of%2520Trypanosoma%2520Cruzi%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D4151%26epage%3D4163%26doi%3D10.1128%2FAAC.00070-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioset, J.-R.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Screening Approaches for Chagas Disease Drug Discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1417380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1080%2F17460441.2018.1417380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=29235363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Onuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=141-153&author=E.+Chatelainauthor=J.-R.+Ioset&title=Phenotypic+Screening+Approaches+for+Chagas+Disease+Drug+Discovery&doi=10.1080%2F17460441.2018.1417380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening approaches for Chagas disease drug discovery</span></div><div class="casAuthors">Chatelain, Eric; Ioset, Jean-Robert</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-153</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Chagas disease, caused by the parasite Trypanosoma cruzi, is a global public health issue.  Current treatments targeting the parasite are limited to two old nitroheterocyclic drugs with serious side effects.  The need for new and safer drugs has prompted numerous drug discovery efforts to identify compds. suitable for parasitol. cure in the last decade.  Target-based drug discovery has been limited by the small no. of well-validated targets - the latest example being the failure of azoles, T. cruzi CYP51 inhibitors, in proof-of-concept clin. trials; instead phenotypic-based drug discovery has become the main pillar of Chagas R&D.  Rather than focusing on the tech. features of these screening assays, the authors describe the different assays developed and available in the field, and provide a crit. view on their values and limitations in the screening cascade for Chagas drug development.  The application of technol. advances to the field of Chagas disease has led to a variety of phenotypic assays that have not only changed the disease discovery landscape but have also helped us to gain a better understanding of parasite/host interactions.  Recent examples of target resoln. from phenotypic hits will uncover new opportunities for drug discovery for Chagas disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrrfEw_-gq5rVg90H21EOLACvtfcHk0ljbjERTCjf_Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Onuw%253D%253D&md5=44d1f94e26bde67c9c2e784f9de20ea2</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1417380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1417380%26sid%3Dliteratum%253Aachs%26aulast%3DChatelain%26aufirst%3DE.%26aulast%3DIoset%26aufirst%3DJ.-R.%26atitle%3DPhenotypic%2520Screening%2520Approaches%2520for%2520Chagas%2520Disease%2520Drug%2520Discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D141%26epage%3D153%26doi%3D10.1080%2F17460441.2018.1417380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumoulin, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollrath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomko, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burleigh, B.</span></span> <span> </span><span class="NLM_article-title">Glutamine Metabolism Modulates Azole Susceptibility in Trypanosoma Cruzi Amastigotes</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e60226</span> <span class="refDoi"> DOI: 10.7554/eLife.60226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.7554%2FeLife.60226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=33258448" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&author=P.+C.+Dumoulinauthor=J.+Vollrathauthor=S.+S.+Tomkoauthor=J.+X.+Wangauthor=B.+Burleigh&title=Glutamine+Metabolism+Modulates+Azole+Susceptibility+in+Trypanosoma+Cruzi+Amastigotes&doi=10.7554%2FeLife.60226"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.7554%2FeLife.60226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.60226%26sid%3Dliteratum%253Aachs%26aulast%3DDumoulin%26aufirst%3DP.%2BC.%26aulast%3DVollrath%26aufirst%3DJ.%26aulast%3DTomko%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DJ.%2BX.%26aulast%3DBurleigh%26aufirst%3DB.%26atitle%3DGlutamine%2520Metabolism%2520Modulates%2520Azole%2520Susceptibility%2520in%2520Trypanosoma%2520Cruzi%2520Amastigotes%26jtitle%3DeLife%26date%3D2020%26volume%3D9%26doi%3D10.7554%2FeLife.60226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagajyothi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burleigh, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelicks, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanowitz, H. B.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Trypanosoma Cruzi Persistence in Chagas Disease</span>. <i>Cell. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1111/j.1462-5822.2012.01764.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1111%2Fj.1462-5822.2012.01764.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22309180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=634-643&author=F.+Nagajyothiauthor=F.+S.+Machadoauthor=B.+A.+Burleighauthor=L.+A.+Jelicksauthor=P.+E.+Schererauthor=S.+Mukherjeeauthor=M.+P.+Lisantiauthor=L.+M.+Weissauthor=N.+J.+Gargauthor=H.+B.+Tanowitz&title=Mechanisms+of+Trypanosoma+Cruzi+Persistence+in+Chagas+Disease&doi=10.1111%2Fj.1462-5822.2012.01764.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Trypanosoma cruzi persistence in Chagas disease</span></div><div class="casAuthors">Nagajyothi, Fnu; Machado, Fabiana S.; Burleigh, Barbara A.; Jelicks, Linda A.; Scherer, Philipp E.; Mukherjee, Shankar; Lisanti, Michael P.; Weiss, Louis M.; Garg, Nisha J.; Tanowitz, Herbert B.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">634-643</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Trypanosoma cruzi infection leads to development of chronic Chagas disease.  In this article, we provide an update on the current knowledge of the mechanisms employed by the parasite to gain entry into the host cells and establish persistent infection despite activation of a potent immune response by the host.  Recent studies point to a no. of T. cruzi mols. that interact with host cell receptors to promote parasite invasion of the diverse host cells.  T. cruzi expresses an antioxidant system and thromboxane A2 to evade phagosomal oxidative assault and suppress the host's ability to clear parasites.  Addnl. studies suggest that besides cardiac and smooth muscle cells that are the major target of T. cruzi infection, adipocytes and adipose tissue serve as reservoirs from where T. cruzi can recrudesce and cause disease decades later.  Further, T. cruzi employs at least four strategies to maintain a symbiotic-like relationship with the host, and ensure consistent supply of nutrients for its own survival and long-term persistence.  Ongoing and future research will continue to help refining the models of T. cruzi invasion and persistence in diverse tissues and organs in the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1I6SXz7lYUrVg90H21EOLACvtfcHk0lhfqHWNjnF__A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVartbc%253D&md5=4752150f75df2b9582aecfeec3cadfc3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1111%2Fj.1462-5822.2012.01764.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1462-5822.2012.01764.x%26sid%3Dliteratum%253Aachs%26aulast%3DNagajyothi%26aufirst%3DF.%26aulast%3DMachado%26aufirst%3DF.%2BS.%26aulast%3DBurleigh%26aufirst%3DB.%2BA.%26aulast%3DJelicks%26aufirst%3DL.%2BA.%26aulast%3DScherer%26aufirst%3DP.%2BE.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26aulast%3DWeiss%26aufirst%3DL.%2BM.%26aulast%3DGarg%26aufirst%3DN.%2BJ.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26atitle%3DMechanisms%2520of%2520Trypanosoma%2520Cruzi%2520Persistence%2520in%2520Chagas%2520Disease%26jtitle%3DCell.%2520Microbiol.%26date%3D2012%26volume%3D14%26spage%3D634%26epage%3D643%26doi%3D10.1111%2Fj.1462-5822.2012.01764.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, N. W.</span></span> <span> </span><span class="NLM_article-title">Host Cell Invasion by Trypanosoma Cruzi: A Unique Strategy That Promotes Persistence</span>. <i>FEMS Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">734</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1111/j.1574-6976.2012.00333.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1111%2Fj.1574-6976.2012.00333.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22339763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmtlygsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=734-747&author=M.+C.+Fernandesauthor=N.+W.+Andrews&title=Host+Cell+Invasion+by+Trypanosoma+Cruzi%3A+A+Unique+Strategy+That+Promotes+Persistence&doi=10.1111%2Fj.1574-6976.2012.00333.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Host cell invasion by Trypanosoma cruzi: a unique strategy that promotes persistence</span></div><div class="casAuthors">Fernandes, Maria Cecilia; Andrews, Norma W.</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">734-747</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">0168-6445</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The intracellular protozoan parasite Trypanosoma cruzi is the causative agent of Chagas' disease, a serious disorder that affects millions of people in Latin America.  Despite the development of lifelong immunity following infections, the immune system fails to completely clear the parasites, which persist for decades within host tissues.  Cardiomyopathy is one of the most serious clin. manifestations of the disease, and a major cause of sudden death in endemic areas.  Despite decades of study, there is still debate about the apparent preferential tropism of the parasites for cardiac muscle, and its role in the pathol. of the disease.  In this review, we discuss these issues in light of recent observations, which indicate that T. cruzi invades host cells by subverting a highly conserved cellular pathway for the repair of plasma membrane lesions.  Plasma membrane injury and repair is particularly prevalent in muscle cells, suggesting that the mechanism used by the parasites for cell invasion may be a primary determinant of tissue tropism, intracellular persistence, and Chagas' disease pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGx_1AyWMdALVg90H21EOLACvtfcHk0lhfqHWNjnF__A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmtlygsbc%253D&md5=f4eb7f8a85b4948a965bed03a3343481</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1111%2Fj.1574-6976.2012.00333.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1574-6976.2012.00333.x%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DM.%2BC.%26aulast%3DAndrews%26aufirst%3DN.%2BW.%26atitle%3DHost%2520Cell%2520Invasion%2520by%2520Trypanosoma%2520Cruzi%253A%2520A%2520Unique%2520Strategy%2520That%2520Promotes%2520Persistence%26jtitle%3DFEMS%2520Microbiol.%2520Rev.%26date%3D2012%26volume%3D36%26spage%3D734%26epage%3D747%26doi%3D10.1111%2Fj.1574-6976.2012.00333.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matos
Ferreira, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segatto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelape, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira Andrade, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagajyothi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanowitz, H. B.</span></span> <span> </span><span class="NLM_article-title">Evidence for Trypanosoma Cruzi in Adipose Tissue in Human Chronic Chagas Disease</span>. <i>Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1002</span>– <span class="NLM_lpage">1005</span>, <span class="refDoi"> DOI: 10.1016/j.micinf.2011.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.micinf.2011.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=21726660" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1002-1005&author=A.+V.+Matos%0AFerreiraauthor=M.+Segattoauthor=Z.+Menezesauthor=A.+M.+Macedoauthor=C.+Gelapeauthor=L.+de+Oliveira+Andradeauthor=F.+Nagajyothiauthor=P.+E.+Schererauthor=M.+M.+Teixeiraauthor=H.+B.+Tanowitz&title=Evidence+for+Trypanosoma+Cruzi+in+Adipose+Tissue+in+Human+Chronic+Chagas+Disease&doi=10.1016%2Fj.micinf.2011.06.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.micinf.2011.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.micinf.2011.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMatos%2BFerreira%26aufirst%3DA.%2BV.%26aulast%3DSegatto%26aufirst%3DM.%26aulast%3DMenezes%26aufirst%3DZ.%26aulast%3DMacedo%26aufirst%3DA.%2BM.%26aulast%3DGelape%26aufirst%3DC.%26aulast%3Dde%2BOliveira%2BAndrade%26aufirst%3DL.%26aulast%3DNagajyothi%26aufirst%3DF.%26aulast%3DScherer%26aufirst%3DP.%2BE.%26aulast%3DTeixeira%26aufirst%3DM.%2BM.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26atitle%3DEvidence%2520for%2520Trypanosoma%2520Cruzi%2520in%2520Adipose%2520Tissue%2520in%2520Human%2520Chronic%2520Chagas%2520Disease%26jtitle%3DMicrobes%2520Infect.%26date%3D2011%26volume%3D13%26spage%3D1002%26epage%3D1005%26doi%3D10.1016%2Fj.micinf.2011.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayawardhana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span> <span> </span><span class="NLM_article-title">Limited Ability of Posaconazole To Cure Both Acute and Chronic Trypanosoma Cruzi Infections Revealed by Highly Sensitive In Vivo Imaging</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4653</span>– <span class="NLM_lpage">4661</span>, <span class="refDoi"> DOI: 10.1128/AAC.00520-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.00520-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=26014936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ojtb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=4653-4661&author=A.+F.+Franciscoauthor=M.+D.+Lewisauthor=S.+Jayawardhanaauthor=M.+C.+Taylorauthor=E.+Chatelainauthor=J.+M.+Kelly&title=Limited+Ability+of+Posaconazole+To+Cure+Both+Acute+and+Chronic+Trypanosoma+Cruzi+Infections+Revealed+by+Highly+Sensitive+In+Vivo+Imaging&doi=10.1128%2FAAC.00520-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging</span></div><div class="casAuthors">Francisco, Amanda Fortes; Lewis, Michael D.; Jayawardhana, Shiromani; Taylor, Martin C.; Chatelain, Eric; Kelly, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4653-4661</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The antifungal drug posaconazole has shown significant activity against Trypanosoma cruzi in vitro and in exptl. murine models.  Despite this, in a recent clin. trial it displayed limited curative potential.  Drug testing is problematic in exptl. Chagas disease because of difficulties in demonstrating sterile cure, particularly during the chronic stage of infection when parasite burden is extremely low and tissue distribution is ill defined.  To better assess posaconazole efficacy against acute and chronic Chagas disease, we have exploited a highly sensitive bioluminescence imaging system which generates data with greater accuracy than other methods, including PCR-based approaches.  Mice inoculated with bioluminescent T. cruzi were assessed by in vivo and ex vivo imaging, with cyclophosphamide-induced immunosuppression used to enhance the detection of relapse.  Posaconazole was found to be significantly inferior to benznidazole as a treatment for both acute and chronic T. cruzi infections.  Whereas 20 days treatment with benznidazole was 100% successful in achieving sterile cure, posaconazole failed in almost all cases.  Treatment of chronic infections with posaconazole did however significantly reduce infection-induced splenomegaly, even in the absence of parasitol. cure.  The imaging-based screening system also revealed that adipose tissue is a major site of recrudescence in mice treated with posaconazole in the acute, but not the chronic stage of infection.  This in vivo screening model for Chagas disease is predictive, reproducible and adaptable to diverse treatment schedules.  It should provide greater assurance that drugs are not advanced prematurely into clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvZGTQNtj5IrVg90H21EOLACvtfcHk0liUtOGOE39L2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ojtb7I&md5=7e7004aa8c561b591d89b82eaf4437ef</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1128%2FAAC.00520-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00520-15%26sid%3Dliteratum%253Aachs%26aulast%3DFrancisco%26aufirst%3DA.%2BF.%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DJayawardhana%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%2BC.%26aulast%3DChatelain%26aufirst%3DE.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26atitle%3DLimited%2520Ability%2520of%2520Posaconazole%2520To%2520Cure%2520Both%2520Acute%2520and%2520Chronic%2520Trypanosoma%2520Cruzi%2520Infections%2520Revealed%2520by%2520Highly%2520Sensitive%2520In%2520Vivo%2520Imaging%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D4653%26epage%3D4661%26doi%3D10.1128%2FAAC.00520-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karalic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of a Collection of Purine-like C-Nucleosides as Antikinetoplastid Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>212</i></span>, <span class="NLM_elocation-id">113101</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.113101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ejmech.2020.113101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=33385837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3MXitFersQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2021&author=J.+Boutonauthor=L.+Maesauthor=I.+Karalicauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=Synthesis+and+Evaluation+of+a+Collection+of+Purine-like+C-Nucleosides+as+Antikinetoplastid+Agents&doi=10.1016%2Fj.ejmech.2020.113101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents</span></div><div class="casAuthors">Bouton, Jakob; Maes, Louis; Karalic, Izet; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113101</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The kinetoplastid parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are the causative agents of neglected tropical diseases with a serious burden in several parts of the world.  These parasites are incapable of synthesizing purines de novo, and therefore rely on ingenious purine salvage pathways to acquire and process purines from their host.  Purine nucleoside analogs that may interfere with these pathways therefore constitute a privileged source of new antikinetoplastid agents.  In this study, we synthesized a collection of C-nucleosides employing five different heterocyclic nucleobase surrogates.  C-nucleosides are chem. and enzymically stable and allow for extensive structural modification.  Inspired by earlier 7-deazaadenosine nucleosides and known antileishmanial C-nucleosides, we introduced different modifications tailored towards antikinetoplastid activity.  Both adenosine and inosine analogs were synthesized with the aim of discovering new antikinetoplastid hits and expanding knowledge of structure-activity relationships.  Several promising hits with potent activity against Trypanosoma brucei, Trypanosoma cruzi and Leishmania infantum were discovered, and the nature of the nucleobase surrogate was found to have a profound influence on the selectivity profile of the compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBVFrxzW9hVrVg90H21EOLACvtfcHk0liUtOGOE39L2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXitFersQ%253D%253D&md5=dfd862f02fdae48c349d4e354b3cd3a4</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.113101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.113101%26sid%3Dliteratum%253Aachs%26aulast%3DBouton%26aufirst%3DJ.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DKaralic%26aufirst%3DI.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520a%2520Collection%2520of%2520Purine-like%2520C-Nucleosides%2520as%2520Antikinetoplastid%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D212%26doi%3D10.1016%2Fj.ejmech.2020.113101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cottam, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pasquale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, D. A.</span></span> <span> </span><span class="NLM_article-title">New Adenosine Kinase Inhibitors with Oral Antiinflammatory Activity: Synthesis and Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3424</span>– <span class="NLM_lpage">3430</span>, <span class="refDoi"> DOI: 10.1021/jm00074a024</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00074a024" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK3sXmslWmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3424-3430&author=H.+B.+Cottamauthor=D.+B.+Wassonauthor=H.+C.+Shihauthor=A.+Raychaudhuriauthor=G.+Di+Pasqualeauthor=D.+A.+Carson&title=New+Adenosine+Kinase+Inhibitors+with+Oral+Antiinflammatory+Activity%3A+Synthesis+and+Biological+Evaluation&doi=10.1021%2Fjm00074a024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation</span></div><div class="casAuthors">Cottam, Howard B.; Wasson, D. Bruce; Shih, Hsien C.; Raychaudhuri, Anil; Di Pasquale, Gene; Carson, Dennis A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3424-30</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Several 5-iodotubercidin analogs, e.g. I (R = H, Cl, N3, NH2, F, OH, R1 = iodo), were synthesized as potential inhibitors of adenosine kinase by a direct Lewis acid-catalyzed glycosidation procedure using both the preformed carbohydrate and the heterocyclic base as starting materials.  First, each compd. was studied kinetically for inhibition of purified human placental adenosine kinase activity.  The order of potency was: iodotubercidin > hydroxyl > amino ≥deoxy > fluoro> chloro >> azido.  The inhibition appeared to be essentially competitive in nature, although a noncompetitive component of significance for the more potent inhibitors cannot be ruled out.  The order of effectiveness of the compds. in this system, representing a functional inhibition of adenosine kinase in cultured cells, was about the same as that with the purified enzyme, except that the 5'-chloro and 5'-fluoro compds. were ineffective.  The 5'-hydroxyl deriv. was evaluated in vivo in a rat pleurisy inflammation model and displayed biol. activity at a dose of 30 mg/kg given orally.  Finally, the in vitro toxicity of each compd. was assessed in CEM lymphoblasts.  Results indicated that the two most potent inhibitors in the pyrazolo[3,4-d]pyrimidine ring system I (R = OH, NH2) were 15-fold and 75-fold, resp., less growth inhibitory than 5-iodotubercidin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbgMf4ZtjBFLVg90H21EOLACvtfcHk0liUtOGOE39L2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmslWmu7g%253D&md5=1bdc27c0b3a8b3ed0f6f730adad01b88</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm00074a024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00074a024%26sid%3Dliteratum%253Aachs%26aulast%3DCottam%26aufirst%3DH.%2BB.%26aulast%3DWasson%26aufirst%3DD.%2BB.%26aulast%3DShih%26aufirst%3DH.%2BC.%26aulast%3DRaychaudhuri%26aufirst%3DA.%26aulast%3DDi%2BPasquale%26aufirst%3DG.%26aulast%3DCarson%26aufirst%3DD.%2BA.%26atitle%3DNew%2520Adenosine%2520Kinase%2520Inhibitors%2520with%2520Oral%2520Antiinflammatory%2520Activity%253A%2520Synthesis%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D3424%26epage%3D3430%26doi%3D10.1021%2Fjm00074a024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span> <span> </span><span class="NLM_article-title">Silver-Mediated Base Pairs in DNA Incorporating Purines, 7-Deazapurines, and 8-Aza-7-Deazapurines: Impact of Reduced Nucleobase Binding Sites and an Altered Glycosylation Position</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5529</span>– <span class="NLM_lpage">5540</span>, <span class="refDoi"> DOI: 10.1002/chem.201605982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fchem.201605982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=28195414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVyru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=5529-5540&author=H.+Zhaoauthor=P.+Leonardauthor=X.+Guoauthor=H.+Yangauthor=F.+Seela&title=Silver-Mediated+Base+Pairs+in+DNA+Incorporating+Purines%2C+7-Deazapurines%2C+and+8-Aza-7-Deazapurines%3A+Impact+of+Reduced+Nucleobase+Binding+Sites+and+an+Altered+Glycosylation+Position&doi=10.1002%2Fchem.201605982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Silver-Mediated Base Pairs in DNA Incorporating Purines, 7-Deazapurines, and 8-Aza-7-deazapurines: Impact of Reduced Nucleobase Binding Sites and an Altered Glycosylation Position</span></div><div class="casAuthors">Zhao, Hang; Leonard, Peter; Guo, Xiurong; Yang, Haozhe; Seela, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5529-5540</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Formation of silver-mediated DNA was studied with oligonucleotides incorporating 8-aza-7-deazapurine, 7-deazapurine, and purine nucleosides.  The investigation was performed on non-self-complementary duplexes with one or two modifications and self-complementary duplexes with an alternating dA-dT motif.  Homo base pairs as well as base pair mismatches of dA analogs with dC and Watson-Crick pairs with dT were studied by stoichiometric silver ion titrn. and Tm measurements.  N8-Glycosylated 8-aza-7-deazaadenine forms silver-ion-mediated base pairs capturing two silver ions (low silver content) whereas regularly glycosylated 8-aza-7-deazapurine, 7-deazapurine (c7Ad), and dA do not form comparable structures.  Stable silver-mediated "dA-dC" base pair mismatches were detected for all nucleosides.  Two silver ions per base pair are bound by 8-aza-7-deazapurine whereas c7Ad binds only one silver ion.  The situation is different when the equiv. of silver ions were increased to the no. of total base pairs.  Surprisingly, in 12-mer duplexes as well as in related 25-mer duplexes every base pair consumed one silver ion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv9wjZzEeA2bVg90H21EOLACvtfcHk0lhLiq92H4asnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVyru78%253D&md5=4a9b63042fc3b4afc342b88b8f7c57d7</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2Fchem.201605982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201605982%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSeela%26aufirst%3DF.%26atitle%3DSilver-Mediated%2520Base%2520Pairs%2520in%2520DNA%2520Incorporating%2520Purines%252C%25207-Deazapurines%252C%2520and%25208-Aza-7-Deazapurines%253A%2520Impact%2520of%2520Reduced%2520Nucleobase%2520Binding%2520Sites%2520and%2520an%2520Altered%2520Glycosylation%2520Position%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D5529%26epage%3D5540%26doi%3D10.1002%2Fchem.201605982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraybill, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blethrow, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Inhibitor Scaffolds as New Allele Specific Kinase Substrates</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">12118</span>– <span class="NLM_lpage">12128</span>, <span class="refDoi"> DOI: 10.1021/ja0264798</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0264798" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD38Xnt1Sju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=12118-12128&author=B.+C.+Kraybillauthor=L.+L.+Elkinauthor=J.+D.+Blethrowauthor=D.+O.+Morganauthor=K.+M.+Shokat&title=Inhibitor+Scaffolds+as+New+Allele+Specific+Kinase+Substrates&doi=10.1021%2Fja0264798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor scaffolds as new allele specific kinase substrates</span></div><div class="casAuthors">Kraybill, Brian C.; Elkin, Lisa L.; Blethrow, Justin D.; Morgan, David O.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12118-12128</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The elucidation of protein kinase signaling networks is challenging due to the large size of the protein kinase superfamily (>500 human kinases).  Here the authors describe a new class of orthogonal triphosphate substrate analogs for the direct labeling of analog-specific protein kinase targets.  These analogs were constructed as derivs. of the Src family kinase inhibitor PP1 and were designed based on the crystal structures of PP1 bound to HCK and N6-(benzyl)-ADP bound to c-Src (T338G).  3-Benzylpyrazolopyrimidine triphosphate (3-benzyl-PPTP) proved to be a substrate for a mutant of the MAP kinase p38 (p38-T106G/A157L/L167A).  3-Benzyl-PPTP was preferred by v-Src (T338G) (kcat/Km = 3.2 × 106 min-1 M-1) over ATP or the previously described ATP analog, N6-(benzyl) ATP.  For the kinase CDK2 (F80G)/cyclin E, 3-benzyl-PPTP demonstrated catalytic efficiency (kcat/Km = 2.6 × 104 min-1 M-1) comparable to ATP (kcat/Km = 5.0 × 104 min-1 M-1) largely due to a significantly better Km (6.4 μM vs. 530 μM).  In kinase protein substrate labeling expts. both 3-benzyl-PPTP and 3-phenyl-PPTP prove to be over 4 times more orthogonal than N6-(benzyl)-ATP with respect to the wild-type kinases found in murine splenocyte cell lysates.  These expts. also demonstrate that [γ-32P]-3-benzyl-PPTP is an excellent phosphodonor for labeling the direct protein substrates of CDK2 (F80G)/E in murine splenocyte cell lysates, even while competing with cellular levels (4 mM) of unlabeled ATP.  The fact that this new more highly orthogonal nucleotide is accepted by three widely divergent kinases studied here suggests that it is likely to be generalizable across the entire kinase superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3tyo_B1M5nrVg90H21EOLACvtfcHk0lhLiq92H4asnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xnt1Sju7o%253D&md5=1b88b7669895fe692114dead34700a15</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fja0264798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0264798%26sid%3Dliteratum%253Aachs%26aulast%3DKraybill%26aufirst%3DB.%2BC.%26aulast%3DElkin%26aufirst%3DL.%2BL.%26aulast%3DBlethrow%26aufirst%3DJ.%2BD.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DInhibitor%2520Scaffolds%2520as%2520New%2520Allele%2520Specific%2520Kinase%2520Substrates%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D12118%26epage%3D12128%26doi%3D10.1021%2Fja0264798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Pyrazolo[5,1-d][1,2,3,5]Tetrazine-4(3H)-Ones</span>. <i>J. Comb. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1021/cc900063y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc900063y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSrsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=69-74&author=Y.+Gaoauthor=Y.+Lam&title=Synthesis+of+Pyrazolo%5B5%2C1-d%5D%5B1%2C2%2C3%2C5%5DTetrazine-4%283H%29-Ones&doi=10.1021%2Fcc900063y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Pyrazolo[5,1-d][1,2,3,5]tetrazin-4(3H)-ones</span></div><div class="casAuthors">Gao, Yaojun; Lam, Yulin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-74</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A solid-phase synthesis of 5-aminopyrazoles I (R1 = H, CN, EtO2C, Ph; R2 = H, Me, Ph) has been developed and applied to the prepn. of pyrazolo[5,1-d][1,2,3,5]tetrazin-4(3H)-ones II (R3 = n-hexyl, Ph, 4-ClC6H4, PhCH2, PhCH2CH2).  In this strategy, 5-aminopyrazoles I were converted into pyrazolo[5,1-d][1,2,3,5]tetrazines II in one-pot via diazotization followed cyclocondensation with isocyanates R3NCO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXvMzpwop9LVg90H21EOLACvtfcHk0lhLiq92H4asnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSrsbjI&md5=6ead955becf860d17d892def8d0bec97</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fcc900063y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc900063y%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLam%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520Pyrazolo%255B5%252C1-d%255D%255B1%252C2%252C3%252C5%255DTetrazine-4%25283H%2529-Ones%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2010%26volume%3D12%26spage%3D69%26epage%3D74%26doi%3D10.1021%2Fcc900063y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baffoe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Török, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieglitz, K.</span></span> <span> </span><span class="NLM_article-title">1,3-Disubstituted-4-Aminopyrazolo [3, 4-d] Pyrimidines, a New Class of Potent Inhibitors for Phospholipase D</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1111%2Fcbdd.12319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=24641677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWgu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2014&pages=270-281&author=A.+Kulkarniauthor=P.+Quangauthor=V.+Curryauthor=R.+Keyesauthor=W.+Zhouauthor=H.+Choauthor=J.+Baffoeauthor=B.+T%C3%B6r%C3%B6kauthor=K.+Stieglitz&title=1%2C3-Disubstituted-4-Aminopyrazolo+%5B3%2C+4-d%5D+Pyrimidines%2C+a+New+Class+of+Potent+Inhibitors+for+Phospholipase+D&doi=10.1111%2Fcbdd.12319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">1,3-Disubstituted-4-Aminopyrazolo [3, 4-d] Pyrimidines, a New Class of Potent Inhibitors for Phospholipase D</span></div><div class="casAuthors">Kulkarni, Aditya; Quang, Phong; Curry, Victoriana; Keyes, Renee; Zhou, Weihong; Cho, Hyejin; Baffoe, Jonathan; Toeroek, Bela; Stieglitz, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">270-281</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Phospholipase D enzymes cleave lipid substrates to produce phosphatidic acid, an important precursor for many essential cellular mols.  Phospholipase D is a target to modulate cancer-cell invasiveness.  This study reports synthesis of a new class of phospholipase D inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure.  These mols. were synthesized and used to perform initial screening for the inhibition of purified bacterial phospholipase D, which is highly homologous to the human PLD1.  Initially tested with the bacterial phospholipase D enzyme, then confirmed with the recombinant human PLD1 and PLD2 enzymes, the mols. presented here exhibited inhibition of phospholipase D activity (IC50) in the low-nanomolar to low-micromolar range with both monomeric substrate diC4PC and phospholipid vesicles and micelles.  The data strongly indicate that these inhibitory mols. directly block enzyme/vesicle substrate binding.  Preliminary activity studies using recombinant human phospholipase Ds in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicate inhibition in the mid- to low-nanomolar range for these potent inhibitory novel mols. in a physiol. environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO45njEbsFz7Vg90H21EOLACvtfcHk0lhLiq92H4asnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWgu7%252FI&md5=87816753658d3a5b9830b8aa195bcf9b</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12319%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DA.%26aulast%3DQuang%26aufirst%3DP.%26aulast%3DCurry%26aufirst%3DV.%26aulast%3DKeyes%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DBaffoe%26aufirst%3DJ.%26aulast%3DT%25C3%25B6r%25C3%25B6k%26aufirst%3DB.%26aulast%3DStieglitz%26aufirst%3DK.%26atitle%3D1%252C3-Disubstituted-4-Aminopyrazolo%2520%255B3%252C%25204-d%255D%2520Pyrimidines%252C%2520a%2520New%2520Class%2520of%2520Potent%2520Inhibitors%2520for%2520Phospholipase%2520D%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2014%26volume%3D84%26spage%3D270%26epage%3D281%26doi%3D10.1111%2Fcbdd.12319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickx, S.</span>; <span class="NLM_string-name">Caljon, G.</span>; <span class="NLM_string-name">Maes, L.</span></span> <span> </span><span class="NLM_article-title">In Vitro Growth Inhibition Assays of Leishmania Spp</span>. In  <i>Trypanosomatids: Methods and Protocols</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, P. A. M.</span>; <span class="NLM_string-name">Ginger, M. L.</span>; <span class="NLM_string-name">Zilberstein, D.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2020</span>; pp  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">800</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1007%2F978-1-0716-0294-2_47" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=791-800&author=S.+Hendrickx&author=G.+Caljon&author=L.+Maesauthor=P.+A.+M.+Michels&author=M.+L.+Ginger&author=D.+Zilberstein&title=Trypanosomatids%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1007%2F978-1-0716-0294-2_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-0716-0294-2_47%26sid%3Dliteratum%253Aachs%26aulast%3DHendrickx%26aufirst%3DS.%26atitle%3DIn%2520Vitro%2520Growth%2520Inhibition%2520Assays%2520of%2520Leishmania%2520Spp%26btitle%3DTrypanosomatids%253A%2520Methods%2520and%2520Protocols%26aulast%3DMichels%26aufirst%3DP.%2BA.%2BM.%26pub%3DSpringer%26date%3D2020%26spage%3D791%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Batista, D. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacheco, M. G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branowska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boykin, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soeiro, M. N. C.</span></span> <span> </span><span class="NLM_article-title">Biological, Ultrastructural Effect and Subcellular Localization of Aromatic Diamidines in Trypanosoma Cruzi</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1017/S0031182009991223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1017%2FS0031182009991223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=19765349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2010&pages=251-259&author=D.+G.+J.+Batistaauthor=M.+G.+O.+Pachecoauthor=A.+Kumarauthor=D.+Branowskaauthor=M.+A.+Ismailauthor=L.+Huauthor=D.+W.+Boykinauthor=M.+N.+C.+Soeiro&title=Biological%2C+Ultrastructural+Effect+and+Subcellular+Localization+of+Aromatic+Diamidines+in+Trypanosoma+Cruzi&doi=10.1017%2FS0031182009991223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi</span></div><div class="casAuthors">Batista, D. G. J.; Pacheco, M. G. O.; Kumar, A.; Branowska, D.; Ismail, M. A.; Hu, L.; Boykin, D. W.; Soeiro, M. N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">PARAAE</span>;
        ISSN:<span class="NLM_cas:issn">0031-1820</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">No vaccines or safe chemotherapy are available for Chagas disease.  Pentamidine and related di-cations are DNA minor groove-binders with broad-spectrum anti-protozoal activity.  Therefore our aim was to evaluate the in vitro efficacy of di-cationic compds. - DB1645, DB1582, DB1651, DB1646, DB1670 and DB1627 - against bloodstream trypomastigotes (BT) and intracellular forms of Trypanosoma cruzi.  Cellular targets of these compds. in treated parasites were also analyzed by fluorescence and transmission electron microscopy (TEM).  DB1645, DB1582 and DB1651 were the most active against BT showing IC50 values ranging between 0·15 and 6·9 μm.  All compds. displayed low toxicity towards mammalian cells and DB1645, DB1582 and DB1651 were also the most effective against intracellular parasites, with IC50 values ranging between 7·3 and 13·3 μm.  All compds. localized in parasite nuclei and kDNA (with greater intensity in the latter structure), and DB1582 and DB1651 also concd. in non-DNA-contg. cytoplasmic organelles possibly acidocalcisomes.  TEM revealed alterations in mitochondria and kinetoplasts, as well as important disorganization of microtubules.  Our data provide further information regarding the activity of this class of compds. upon T. cruzi which should aid future design and synthesis of agents that could be used for Chagas disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppDl5GRPyRWbVg90H21EOLACvtfcHk0lg-eYKaT3WFhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOgu7w%253D&md5=a3f30c800b2f2a98b2bdb4b406083969</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1017%2FS0031182009991223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182009991223%26sid%3Dliteratum%253Aachs%26aulast%3DBatista%26aufirst%3DD.%2BG.%2BJ.%26aulast%3DPacheco%26aufirst%3DM.%2BG.%2BO.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DBranowska%26aufirst%3DD.%26aulast%3DIsmail%26aufirst%3DM.%2BA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBoykin%26aufirst%3DD.%2BW.%26aulast%3DSoeiro%26aufirst%3DM.%2BN.%2BC.%26atitle%3DBiological%252C%2520Ultrastructural%2520Effect%2520and%2520Subcellular%2520Localization%2520of%2520Aromatic%2520Diamidines%2520in%2520Trypanosoma%2520Cruzi%26jtitle%3DParasitology%26date%3D2010%26volume%3D137%26spage%3D251%26epage%3D259%26doi%3D10.1017%2FS0031182009991223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timm, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, F. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrick, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakunov, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakunova, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maria
de Nazaré, C. S.</span></span> <span> </span><span class="NLM_article-title">In Vitro and In Vivo Biological Effects of Novel Arylimidamide Derivatives against Trypanosoma Cruzi</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3720</span>– <span class="NLM_lpage">3726</span>, <span class="refDoi"> DOI: 10.1128/AAC.02353-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.02353-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=24752263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3720-3726&author=B.+L.+Timmauthor=P.+B.+da+Silvaauthor=M.+M.+Batistaauthor=F.+H.+G.+da+Silvaauthor=C.+F.+da+Silvaauthor=R.+R.+Tidwellauthor=D.+A.+Patrickauthor=S.+K.+Jonesauthor=S.+A.+Bakunovauthor=S.+M.+Bakunovaauthor=C.+S.+Maria%0Ade+Nazar%C3%A9&title=In+Vitro+and+In+Vivo+Biological+Effects+of+Novel+Arylimidamide+Derivatives+against+Trypanosoma+Cruzi&doi=10.1128%2FAAC.02353-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi</span></div><div class="casAuthors">Timm, Bruno Lisboa; da Silva, Patricia Bernadino; Batista, Marcos Meuser; da Silva, Francisca Hildemagna Guedes; da Silva, Cristiane Franca; Tidwell, Richard R.; Patrick, Donald A.; Jones, Susan Kilgore; Bakunov, Stanislav A.; Bakunova, Svetlana M.; de Nazare C. Soeiro, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3720-3726, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chagas disease (CD), a neglected tropical disease caused by Trypanosoma cruzi, remains a serious public health problem in several Latin American countries.  The available chemotherapies for CD have limited efficacy and exhibit undesirable side effects.  Arom. diamidines and arylimidamides (AIAs) have shown broad-spectrum activity against intracellular parasites, including T. cruzi.  Therefore, our aim was to evaluate the biol. activity of eight novel AIAs (16DAP002, 16SAB079, 18SAB075, 23SMB022, 23SMB026, 23SMB054, 26SMB070, and 27SMB009) against exptl. models of T. cruzi infection in vitro and in vivo.  Our data show that none of the compds. induced a loss of cellular viability up to 32 μM.  Two AIAs, 18SAB075 and 16DAP002, exhibited good in vitro activity against different parasite strains (Y and Tulahuen) and against the two relevant forms of the parasite for mammalian hosts.  Due to the excellent selective indexes of 18SAB075, this AIA was moved to in vivo tests for acute toxicity and parasite efficacy; nontoxic doses (no-obsd.-adverse-effect level [NOAEL], 50 mg/kg) were employed in the tests for parasite efficacy.  In exptl. models of acute T. cruzi infection, 18SAB075 reduced parasitemia levels only up to 50% and led to 40% protection against mortality (at 5 mg/kg of body wt.), being less effective than the ref. drug, benznidazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr65z9kS-zVP7Vg90H21EOLACvtfcHk0lg-eYKaT3WFhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7rN&md5=473b0b02035bd0f8aa64254885d16d2a</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1128%2FAAC.02353-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02353-14%26sid%3Dliteratum%253Aachs%26aulast%3DTimm%26aufirst%3DB.%2BL.%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DBatista%26aufirst%3DM.%2BM.%26aulast%3Dda%2BSilva%26aufirst%3DF.%2BH.%2BG.%26aulast%3Dda%2BSilva%26aufirst%3DC.%2BF.%26aulast%3DTidwell%26aufirst%3DR.%2BR.%26aulast%3DPatrick%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DS.%2BK.%26aulast%3DBakunov%26aufirst%3DS.%2BA.%26aulast%3DBakunova%26aufirst%3DS.%2BM.%26aulast%3DMaria%2Bde%2BNazar%25C3%25A9%26aufirst%3DC.%2BS.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Biological%2520Effects%2520of%2520Novel%2520Arylimidamide%2520Derivatives%2520against%2520Trypanosoma%2520Cruzi%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3720%26epage%3D3726%26doi%3D10.1128%2FAAC.02353-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0002.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) Structures of pyrazolo[3,4-<i>d</i>]pyrimidines. (b) Antitrypanosomal 7-deazapurine nucleosides previously reported by our group. (c) Metabolism of allopurinol in <i>Leishmania</i> spp. and <i>T. cruzi</i>. (c, d) Pyrazolo[3,4-<i>d</i>]pyrimidine nucleosides reported in this study. Throughout the text, purine numbering is used as shown in Figure 1d, while in the experimental part, systematic numbering is employed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Ribofuranose-Modified Pyrazolo[3,4-<i>d</i>]pyrimidine Nucleosides<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NBS, DMF, 60 °C, 91% (for <b>12</b>), NIS, DMF, 80 °C, 93% (for <b>13</b>); (b) NBS, water, 90 °C, 87%; (c) <b>12</b> (for <b>18</b>–<b>20</b>), <b>14</b> (for <b>26</b>–<b>28</b>), or <b>13</b> (for <b>34</b>) BF<sub>3</sub>·OEt<sub>2</sub>, MeNO<sub>2</sub>, reflux, 77% (<b>34</b>); (d) 0.5 M NaOMe in MeOH, 70% over 2 steps (<b>21</b>), 19% over 2 steps (<b>22</b>), 20% over 2 steps (<b>23</b>), 38% over 2 steps (<b>29</b>), 11% over 2 steps (<b>30</b>), 6% over 2 steps (<b>31</b>), 64% (<b>36</b>); (e) Pd/C, H<sub>2</sub>, 1 M aq. NaOAc, MeOH, 61% (<b>4</b>), 82% (<b>24</b>), 66% (<b>25</b>), 54% (<b>2</b>), 83% (<b>32</b>), 80% (<b>33</b>).</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Reagents and Conditions: (a) NBS, DMF, 50 °C; (b) NaOMe, MeOH, 70 °C, 51% Over 2 steps; (c) <b>38</b>, KOH, TDA-1, MeCN, 8%; (d) 7 N NH<sub>3</sub> in MeOH, 90 °C, 76%; (e) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, NaOAc, MeOH, 46%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0006.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Reagents and Conditions: (a) Boronic Acid or Trifluoroborate Salt, Pd(OAc)<sub>2</sub>, TPPTS, Na<sub>2</sub>CO<sub>3</sub> (in the Case of a Boronic Acid) or Cs<sub>2</sub>CO<sub>3</sub> (When a Trifluoroborate Salt Was Used), MeCN/H<sub>2</sub>O 1:2, 16–81% (For All Compounds Except for <b>67</b> and <b>65</b>); (b) Tributylstannylated Heterocycle, Pd(PPh<sub>3</sub>)<sub>4</sub>, CuI, DMF, 24% (<b>67</b>)*, 66% (<b>65</b>)*; (c) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, MeOH, 81%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0007.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Reagents and Conditions: (a) Phenol (for <b>79</b>) or 4-Chlorophenol (for <b>80</b>), CuI, <i>N</i>,<i>N</i>-Dimethylglycine, Cs<sub>2</sub>CO<sub>3</sub>, DMA, 120 °C, 5% (<b>79</b>), 3% (<b>80</b>); (b) CuCl, aq. NH<sub>4</sub>OH (for <b>81</b>) or aq. NHMe (for <b>82</b>) or Pyrrolidine, 1,4-Dioxane/H<sub>2</sub>O 1:2 (for <b>83</b>), 120 °C, 19% (<b>81</b>), 5% (<b>82</b>), 16% (<b>83</b>); (c) Me<sub>4</sub>NCl, Cu<sub>2</sub>O, <span class="smallcaps smallerCapital">l</span>-Proline, 2-Methoxyethanol, 120 °C, 7 days; (d) 0.5 M NaOMe in MeOH, 34% Over 2 Steps</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0008.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Reagents and Conditions: (a) Phenylacetylene, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, DMF/Et<sub>3</sub>N 4:1, 40%; (b) H<sub>2</sub>, Pd(OH)<sub>2</sub>/C, MeOH, 89% (<b>87</b>), 74% (<b>89</b>); (c) (i) Ethynyltrimethylsilane, PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, CuI, DMF/Et<sub>3</sub>N 4:1; (ii) 7 N NH<sub>3</sub> in MeOH, 19%; (d) TMSN<sub>3</sub>, CuI, DMF/MeOH 9:1, 100 °C, 40%; (e) Zn(CN)<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, dppf, DMF, 150 °C, 28%; (f) NaN<sub>3</sub>, NH<sub>4</sub>Cl, LiCl, DMF, 100 °C, 25%; (g) H<sub>2</sub>, Raney Nickel, MeOH, 10%; (h) NH<sub>4</sub>OH, H<sub>2</sub>O<sub>2</sub>, 25%; (i) TMSCF<sub>3</sub>, CuI, KF, DMF/NMP 1:1, Reflux; (j) 0.5 M NaOMe in MeOH, 14% Over 2 Steps</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0009.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Reagents and Conditions: (a)(i) NaH, AcCl, Tetrahydrofuran (THF), 0 °C to RT, (ii) Dimethyl Sulfate, Reflux, (iii) H<sub>2</sub>NNH<sub>2</sub>·H<sub>2</sub>O, Et<sub>3</sub>N, 38% Over 3 Steps; (b) Formamide, 180 °C, 23%; (c) Thioacetamide, Reflux, 36%; (d) <b>98</b>, BF<sub>3</sub>·OEt<sub>2</sub>, MeNO<sub>2</sub>, Reflux; (e) 0.5 M NaOMe in MeOH, 21% Over 2 Steps</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0010.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Reagents and Conditions: (a) Potassium Vinyl Trifluoroborate, Pd(OAc)<sub>2</sub>, PPh<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, DMF/H<sub>2</sub>O 9:1, 100 °C, 38%; (b) K<sub>2</sub>OsO<sub>4</sub>·2H<sub>2</sub>O, NaIO<sub>4</sub>, 2,6-Lutidine, 1,4-Dioxane/H<sub>2</sub>O 3:1, 48%; (c) Morpholine, NaBH<sub>3</sub>CN, AcOH, MeOH/THF 2:1; (d) 0.5 M NaOMe in MeOH, 64% Over 2 Steps (<b>105</b>), 58% Over 2 Steps (<b>107</b>), 29% Over 2 Steps (<b>113</b>), 28% Over 2 Steps (<b>114</b>), 61% Over 2 Steps (<b>115</b>), 44% Over 2 Steps (<b>116</b>); (e) NaClO<sub>2</sub>, NaH<sub>2</sub>PO<sub>4</sub>, H<sub>2</sub>O<sub>2</sub>, THF/H<sub>2</sub>O 6:1, 94%; (f) DAST, CH<sub>2</sub>Cl<sub>2</sub>; (g) Aq. NHMe (<b>109</b>), Pyrrolidine (<b>110</b>), Aniline (<b>111</b>), or Benzylamine (<b>112</b>), HCTU, <i>N</i>,<i>N</i>-Diisopropylethylamine (DIPEA), DMF</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/medium/jm1c00135_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0003.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. <i>In vivo</i> efficacy of <b>44</b> administered orally for 5 days in Swiss mice infected with the Y strain of <i>T. cruzi</i>. Parasitemia curve for <b>44</b> at (A) 0.25 mg/kg/b.i.d, (B) 2.5 mg/kg/b.i.d, (C) 25 mg/kg/b.i.d, and (D) coadministration of <b>44</b> at 2.5 mg/kg + benznidazole (Bz) at 10 mg/kg/b.i.d. Mortality rates were up to 35 dpi (E). ** <i>p</i> value ≤ 0.05.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-7/acs.jmedchem.1c00135/20210331/images/large/jm1c00135_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00135&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i148">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66343" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66343" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 102 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molyneux, D.</span></span> <span> </span><span class="NLM_article-title">Neglected Tropical Diseases</span>. <i>Community Eye Health</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=24023397" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC3sbntVKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2013&pages=21-24&author=D.+Molyneux&title=Neglected+Tropical+Diseases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neglected tropical diseases</span></div><div class="casAuthors">Molyneux David</div><div class="citationInfo"><span class="NLM_cas:title">Community eye health</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">82</span>),
    <span class="NLM_cas:pages">21-4</span>
        ISSN:<span class="NLM_cas:issn">0953-6833</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTShQOFaBBa1bBItaL1WaVAfW6udTcc2eb-Iw7-wCnhXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbntVKhsg%253D%253D&md5=14d2a88bbd27f805c505b2cb5070b31d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMolyneux%26aufirst%3DD.%26atitle%3DNeglected%2520Tropical%2520Diseases%26jtitle%3DCommunity%2520Eye%2520Health%26date%3D2013%26volume%3D26%26spage%3D21%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Houweling, T. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karim-Kos, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kulik, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stolk, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haagsma, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lenk, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardus, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vlas, S. J. de.</span></span> <span> </span><span class="NLM_article-title">Socioeconomic Inequalities in Neglected Tropical Diseases: A Systematic Review</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0004546</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0004546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1371%2Fjournal.pntd.0004546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=27171166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtVOksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&author=T.+A.+J.+Houwelingauthor=H.+E.+Karim-Kosauthor=M.+C.+Kulikauthor=W.+A.+Stolkauthor=J.+A.+Haagsmaauthor=E.+J.+Lenkauthor=J.+H.+Richardusauthor=S.+J.+de.+Vlas&title=Socioeconomic+Inequalities+in+Neglected+Tropical+Diseases%3A+A+Systematic+Review&doi=10.1371%2Fjournal.pntd.0004546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Socioeconomic inequalities in neglected tropical diseases: a systematic review</span></div><div class="casAuthors">Houweling, Tanja A. J.; Kos, Henrike E. Karim; Kulik, Margarete C.; Stolk, Wilma A.; Haagsma, Juanita A.; Lenk, Edeltraud J.; Richardus, Jan Hendrik; de Vlas, Sake J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e0004546/1-e0004546/28</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background Neglected tropical diseases (NTDs) are generally assumed to be concd. in poor populations, but evidence on this remains scattered.  We describe within-country socioeconomic inequalities in nine NTDs listed in the London Declaration for intensified control and/or elimination: lymphatic filariasis (LF), onchocerciasis, schistosomiasis, soil-transmitted helminthiasis (STH), trachoma, Chagas' disease, human African trypanosomiasis (HAT), leprosy, and visceral leishmaniasis (VL).  Methodol. We conducted a systematic literature review, including publications between 2004-2013 found in Embase, Medline (OvidSP), Cochrane Central, Web of Science, Popline, Lilacs, and Scielo.  We included publications in international peer-reviewed journals on studies concerning the top 20 countries in terms of the burden of the NTD under study.  Principal findings We identified 5,516 publications, of which 93 met the inclusion criteria.  Of these, 59 papers reported substantial and statistically significant socioeconomic inequalities in NTD distribution, with higher odds of infection or disease among poor and less-educated people compared with better-off groups.  The findings were mixed in 23 studies, and 11 studies showed no substantial or statistically significant inequality.  Most information was available for STH, VL, schistosomiasis, and, to a lesser extent, for trachoma.  For the other NTDs, evidence on their socioeconomic distribution was scarce.  The magnitude of inequality varied, but often, the odds of infection or disease were twice as high among socioeconomically disadvantaged groups compared with better-off strata.  Inequalities often took the form of a gradient, with higher odds of infection or disease each step down the socioeconomic hierarchy.  Notwithstanding these inequalities, the prevalence of some NTDs was sometimes also high among better-off groups in some highly endemic areas.  Conclusions While recent evidence on socioeconomic inequalities is scarce for most individual NTDs, for some, there is considerable evidence of substantially higher odds of infection or disease among socioeconomically disadvantaged groups.  NTD control activities as proposed in the London Declaration, when set up in a way that they reach the most in need, will benefit the poorest populations in poor countries.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR1bhLRV4WVrVg90H21EOLACvtfcHk0lj8gRGr4cL4kw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtVOksr4%253D&md5=fa759eb40feb2067544edadf955eb9f4</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0004546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0004546%26sid%3Dliteratum%253Aachs%26aulast%3DHouweling%26aufirst%3DT.%2BA.%2BJ.%26aulast%3DKarim-Kos%26aufirst%3DH.%2BE.%26aulast%3DKulik%26aufirst%3DM.%2BC.%26aulast%3DStolk%26aufirst%3DW.%2BA.%26aulast%3DHaagsma%26aufirst%3DJ.%2BA.%26aulast%3DLenk%26aufirst%3DE.%2BJ.%26aulast%3DRichardus%26aufirst%3DJ.%2BH.%26aulast%3DVlas%26aufirst%3DS.%2BJ.%2Bde.%26atitle%3DSocioeconomic%2520Inequalities%2520in%2520Neglected%2520Tropical%2520Diseases%253A%2520A%2520Systematic%2520Review%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2016%26volume%3D10%26doi%3D10.1371%2Fjournal.pntd.0004546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bacon, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottazzi, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotez, P. J.</span></span> <span> </span><span class="NLM_article-title">Global Economic Burden of Chagas Disease: A Computational Simulation Model</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">342</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1016/S1473-3099(13)70002-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS1473-3099%2813%2970002-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=23395248" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC3szmvV2quw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=342-348&author=B.+Y.+Leeauthor=K.+M.+Baconauthor=M.+E.+Bottazziauthor=P.+J.+Hotez&title=Global+Economic+Burden+of+Chagas+Disease%3A+A+Computational+Simulation+Model&doi=10.1016%2FS1473-3099%2813%2970002-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Global economic burden of Chagas disease: a computational simulation model</span></div><div class="casAuthors">Lee Bruce Y; Bacon Kristina M; Bottazzi Maria Elena; Hotez Peter J</div><div class="citationInfo"><span class="NLM_cas:title">The Lancet. Infectious diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">342-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  As Chagas disease continues to expand beyond tropical and subtropical zones, a growing need exists to better understand its resulting economic burden to help guide stakeholders such as policy makers, funders, and product developers.  We developed a Markov simulation model to estimate the global and regional health and economic burden of Chagas disease from the societal perspective.  METHODS:  Our Markov model structure had a 1 year cycle length and consisted of five states: acute disease, indeterminate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death.  Major model parameter inputs, including the annual probabilities of transitioning from one state to another, and present case estimates for Chagas disease came from various sources, including WHO and other epidemiological and disease-surveillance-based reports.  We calculated annual and lifetime health-care costs and disability-adjusted life-years (DALYs) for individuals, countries, and regions.  We used a discount rate of 3% to adjust all costs and DALYs to present-day values.  FINDINGS:  On average, an infected individual incurs US$474 in health-care costs and 0·51 DALYs annually.  Over his or her lifetime, an infected individual accrues an average net present value of $3456 and 3·57 DALYs.  Globally, the annual burden is $627·46 million in health-care costs and 806,170 DALYs.  The global net present value of currently infected individuals is $24·73 billion in health-care costs and 29,385,250 DALYs.  Conversion of this burden into costs results in annual per-person costs of $4660 and lifetime per-person costs of $27,684.  Global costs are $7·19 billion per year and $188·80 billion per lifetime.  More than 10% of these costs emanate from the USA and Canada, where Chagas disease has not been traditionally endemic.  A substantial proportion of the burden emerges from lost productivity from cardiovascular disease-induced early mortality.  INTERPRETATION:  The economic burden of Chagas disease is similar to or exceeds those of other prominent diseases globally (eg, rotavirus $2·0 billion, cervical cancer $4·7 billion) even in the USA (Lyme disease $2·5 billion), where Chagas disease has not been traditionally endemic, suggesting an economic argument for more attention and efforts towards control of Chagas disease.  FUNDING:  Bill & Melinda Gates Foundation, the National Institute of General Medical Sciences Models of Infectious Disease Agent Study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS55IbG9bEjhrqxQ2mb9Pu8fW6udTcc2eZOKpRcUYsq4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3szmvV2quw%253D%253D&md5=5d35649aeaa5fe129246096e3f9d43f6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2813%2970002-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252813%252970002-1%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DB.%2BY.%26aulast%3DBacon%26aufirst%3DK.%2BM.%26aulast%3DBottazzi%26aufirst%3DM.%2BE.%26aulast%3DHotez%26aufirst%3DP.%2BJ.%26atitle%3DGlobal%2520Economic%2520Burden%2520of%2520Chagas%2520Disease%253A%2520A%2520Computational%2520Simulation%2520Model%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2013%26volume%3D13%26spage%3D342%26epage%3D348%26doi%3D10.1016%2FS1473-3099%2813%2970002-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lidani, K. C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrade, F. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damasceno, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrame, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messias-Reason, I. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sandri, T. L.</span></span> <span> </span><span class="NLM_article-title">Chagas Disease: From Discovery to a Worldwide Health Problem</span>. <i>Front. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">166</span>, <span class="refDoi"> DOI: 10.3389/fpubh.2019.00166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.3389%2Ffpubh.2019.00166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=31312626" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BB3MzotVGruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=166&author=K.+C.+F.+Lidaniauthor=F.+A.+Andradeauthor=L.+Baviaauthor=F.+S.+Damascenoauthor=M.+H.+Beltrameauthor=I.+J.+Messias-Reasonauthor=T.+L.+Sandri&title=Chagas+Disease%3A+From+Discovery+to+a+Worldwide+Health+Problem&doi=10.3389%2Ffpubh.2019.00166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chagas Disease: From Discovery to a Worldwide Health Problem</span></div><div class="casAuthors">Lidani Karita Claudia Freitas; Andrade Fabiana Antunes; Bavia Lorena; Messias-Reason Iara J; Sandri Thaisa Lucas; Damasceno Flavia Silva; Beltrame Marcia Holsbach; Sandri Thaisa Lucas</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in public health</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">166</span>
        ISSN:<span class="NLM_cas:issn">2296-2565</span>.
    </div><div class="casAbstract">Carlos Chagas discovered American trypanosomiasis, also named Chagas disease (CD) in his honor, just over a century ago.  He described the clinical aspects of the disease, characterized by its etiological agent (Trypanosoma cruzi) and identified its insect vector.  Initially, CD occurred only in Latin America and was considered a silent and poorly visible disease.  More recently, CD became a neglected worldwide disease with a high morbimortality rate and substantial social impact, emerging as a significant public health threat.  In this context, it is crucial to better understand better the epidemiological scenarios of CD and its transmission dynamics, involving people infected and at risk of infection, diversity of the parasite, vector species, and T. cruzi reservoirs.  Although efforts have been made by endemic and non-endemic countries to control, treat, and interrupt disease transmission, the cure or complete eradication of CD are still topics of great concern and require global attention.  Considering the current scenario of CD, also affecting non-endemic places such as Canada, USA, Europe, Australia, and Japan, in this review we aim to describe the spread of CD cases worldwide since its discovery until it has become a global public health concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdNDVSKB6ie-Lt9HypzAgQfW6udTcc2eZOKpRcUYsq4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MzotVGruw%253D%253D&md5=e22d46895f7c7162d2a98b8787ea6637</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.3389%2Ffpubh.2019.00166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffpubh.2019.00166%26sid%3Dliteratum%253Aachs%26aulast%3DLidani%26aufirst%3DK.%2BC.%2BF.%26aulast%3DAndrade%26aufirst%3DF.%2BA.%26aulast%3DBavia%26aufirst%3DL.%26aulast%3DDamasceno%26aufirst%3DF.%2BS.%26aulast%3DBeltrame%26aufirst%3DM.%2BH.%26aulast%3DMessias-Reason%26aufirst%3DI.%2BJ.%26aulast%3DSandri%26aufirst%3DT.%2BL.%26atitle%3DChagas%2520Disease%253A%2520From%2520Discovery%2520to%2520a%2520Worldwide%2520Health%2520Problem%26jtitle%3DFront.%2520Public%2520Health%26date%3D2019%26volume%3D7%26spage%3D166%26doi%3D10.3389%2Ffpubh.2019.00166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konar, N.</span></span> <span> </span><span class="NLM_article-title">Translational Challenges of Animal Models in Chagas Disease Drug Development: A Review</span>. <i>Drug Des. Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4807</span>– <span class="NLM_lpage">4823</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S90208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.2147%2FDDDT.S90208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=26316715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlsVOhs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=4807-4823&author=E.+Chatelainauthor=N.+Konar&title=Translational+Challenges+of+Animal+Models+in+Chagas+Disease+Drug+Development%3A+A+Review&doi=10.2147%2FDDDT.S90208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Translational challenges of animal models in Chagas disease drug development: a review</span></div><div class="casAuthors">Chatelain, Eric; Konar, Nandini</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">4807-4823</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Chagas disease, or American trypanosomiasis, caused by Trypanosoma cruzi parasite infection is endemic in Latin America and presents an increasing clin. challenge due to migrating populations.  Despite being first identified over a century ago, only two drugs are available for its treatment, and recent outcomes from the first clin. trials in 40 years were lackluster.  There is a crit. need to develop new drugs to treat Chagas disease.  This requires a better understanding of the progression of parasite infection, and standardization of animal models designed for Chagas disease drug discovery.  Such measures would improve comparison of generated data and the predictability of test hypotheses and models designed for translation to human disease.  Existing animal models address both disease pathol. and treatment efficacy.  Available models have limited predictive value for the preclin. evaluation of novel therapies and need to more confidently predict the efficacy of new drug candidates in clin. trials.  This review highlights the overall lack of standardized methodol. and assessment tools, which has hampered the development of efficacious compds. to treat Chagas disease.  We provide an overview of animal models for Chagas disease, and propose steps that could be undertaken to reduce variability and improve predictability of drug candidate efficacy.  New technol. developments and tools may contribute to a much needed boost in the drug discovery process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYtSQwJPq3xrVg90H21EOLACvtfcHk0ljsV4e-ZGdNoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlsVOhs74%253D&md5=085f540a8f4e5cd0ce50dbd7f135468a</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S90208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S90208%26sid%3Dliteratum%253Aachs%26aulast%3DChatelain%26aufirst%3DE.%26aulast%3DKonar%26aufirst%3DN.%26atitle%3DTranslational%2520Challenges%2520of%2520Animal%2520Models%2520in%2520Chagas%2520Disease%2520Drug%2520Development%253A%2520A%2520Review%26jtitle%3DDrug%2520Des.%2520Dev.%2520Ther.%26date%3D2015%26volume%3D9%26spage%3D4807%26epage%3D4823%26doi%3D10.2147%2FDDDT.S90208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Molina, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, I.</span></span> <span> </span><span class="NLM_article-title">Chagas Disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>391</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">94</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(17)31612-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0140-6736%2817%2931612-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=28673423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC1cjktFCrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=391&publication_year=2018&pages=82-94&author=J.+A.+P%C3%A9rez-Molinaauthor=I.+Molina&title=Chagas+Disease&doi=10.1016%2FS0140-6736%2817%2931612-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Chagas disease</span></div><div class="casAuthors">Perez-Molina Jose A; Molina Israel</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">391</span>
        (<span class="NLM_cas:issue">10115</span>),
    <span class="NLM_cas:pages">82-94</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Chagas disease is an anthropozoonosis from the American continent that has spread from its original boundaries through migration.  It is caused by the protozoan Trypanosoma cruzi, which was identified in the first decade of the 20th century.  Once acute infection resolves, patients can develop chronic disease, which in up to 30-40% of cases is characterised by cardiomyopathy, arrhythmias, megaviscera, and, more rarely, polyneuropathy and stroke.  Even after more than a century, many challenges remain unresolved, since epidemiological control and diagnostic, therapeutic, and prognostic methods must be improved.  In particular, the efficacy and tolerability profile of therapeutic agents is far from ideal.  Furthermore, the population affected is older and more complex (eg, immunosuppressed patients and patients with cancer).  Nevertheless, in recent years, our knowledge of Chagas disease has expanded, and the international networking needed to change the course of this deadly disease during the 21st century has begun.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRBg2yQ4XqfsXELvajU9pjPfW6udTcc2eZSDOr0Ucku5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjktFCrsA%253D%253D&md5=780546343990bf2d1774a418bf7f8091</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2817%2931612-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252817%252931612-4%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Molina%26aufirst%3DJ.%2BA.%26aulast%3DMolina%26aufirst%3DI.%26atitle%3DChagas%2520Disease%26jtitle%3DLancet%26date%3D2018%26volume%3D391%26spage%3D82%26epage%3D94%26doi%3D10.1016%2FS0140-6736%2817%2931612-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraday, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gimpelewicz, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hailu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazdins-Helds, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowbray, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacks, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Späth, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarleton, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diagana, T. T.</span></span> <span> </span><span class="NLM_article-title">Drug Discovery for Kinetoplastid Diseases: Future Directions</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">152</span>– <span class="NLM_lpage">157</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.8b00298</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.8b00298" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFSjs7bK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=152-157&author=S.+P.+S.+Raoauthor=M.+P.+Barrettauthor=G.+Dranoffauthor=C.+J.+Faradayauthor=C.+R.+Gimpelewiczauthor=A.+Hailuauthor=C.+L.+Jonesauthor=J.+M.+Kellyauthor=J.+K.+Lazdins-Heldsauthor=P.+M%C3%A4serauthor=J.+Mengelauthor=J.+C.+Mottramauthor=C.+E.+Mowbrayauthor=D.+L.+Sacksauthor=P.+Scottauthor=G.+F.+Sp%C3%A4thauthor=R.+L.+Tarletonauthor=J.+M.+Spectorauthor=T.+T.+Diagana&title=Drug+Discovery+for+Kinetoplastid+Diseases%3A+Future+Directions&doi=10.1021%2Facsinfecdis.8b00298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Drug Discovery for Kinetoplastid Diseases: Future Directions</span></div><div class="casAuthors">Rao, Srinivasa P. S.; Barrett, Michael P.; Dranoff, Glenn; Faraday, Christopher J.; Gimpelewicz, Claudio R.; Hailu, Asrat; Jones, Catherine L.; Kelly, John M.; Lazdins-Helds, Janis K.; Maser, Pascal; Mengel, Jose; Mottram, Jeremy C.; Mowbray, Charles E.; Sacks, David L.; Scott, Phillip; Spath, Gerald F.; Tarleton, Rick L.; Spector, Jonathan M.; Diagana, Thierry T.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">152-157</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Kinetoplastid parasites have caused human disease for millennia.  Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT).  Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality.  Despite the gains, no new chem. or biol. entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis.  Advances in tools for drug discovery and novel insights into the biol. of the host-parasite interaction may provide opportunities for accelerated progress.  Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_wyT4PtSqeLVg90H21EOLACvtfcHk0ljnmnwG14HKhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFSjs7bK&md5=022096794907a0266ed69859bafc7040</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.8b00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.8b00298%26sid%3Dliteratum%253Aachs%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DBarrett%26aufirst%3DM.%2BP.%26aulast%3DDranoff%26aufirst%3DG.%26aulast%3DFaraday%26aufirst%3DC.%2BJ.%26aulast%3DGimpelewicz%26aufirst%3DC.%2BR.%26aulast%3DHailu%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DC.%2BL.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26aulast%3DLazdins-Helds%26aufirst%3DJ.%2BK.%26aulast%3DM%25C3%25A4ser%26aufirst%3DP.%26aulast%3DMengel%26aufirst%3DJ.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26aulast%3DMowbray%26aufirst%3DC.%2BE.%26aulast%3DSacks%26aufirst%3DD.%2BL.%26aulast%3DScott%26aufirst%3DP.%26aulast%3DSp%25C3%25A4th%26aufirst%3DG.%2BF.%26aulast%3DTarleton%26aufirst%3DR.%2BL.%26aulast%3DSpector%26aufirst%3DJ.%2BM.%26aulast%3DDiagana%26aufirst%3DT.%2BT.%26atitle%3DDrug%2520Discovery%2520for%2520Kinetoplastid%2520Diseases%253A%2520Future%2520Directions%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2019%26volume%3D5%26spage%3D152%26epage%3D157%26doi%3D10.1021%2Facsinfecdis.8b00298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Field, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horn, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrie, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Anti-Trypanosomatid Drug Discovery: An Ongoing Challenge and a Continuing Need</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1038/nrmicro.2016.193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fnrmicro.2016.193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=28239154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2017&pages=217-231&author=M.+C.+Fieldauthor=D.+Hornauthor=A.+H.+Fairlambauthor=M.+A.+J.+Fergusonauthor=D.+W.+Grayauthor=K.+D.+Readauthor=M.+De+Ryckerauthor=L.+S.+Torrieauthor=P.+G.+Wyattauthor=S.+Wyllieauthor=I.+H.+Gilbert&title=Anti-Trypanosomatid+Drug+Discovery%3A+An+Ongoing+Challenge+and+a+Continuing+Need&doi=10.1038%2Fnrmicro.2016.193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need</span></div><div class="casAuthors">Field, Mark C.; Horn, David; Fairlamb, Alan H.; Ferguson, Michael A. J.; Gray, David W.; Read, Kevin D.; De Rycker, Manu; Torrie, Leah S.; Wyatt, Paul G.; Wyllie, Susan; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-231</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The WHO recognizes human African trypanosomiasis, Chagas disease and the leishmaniases as neglected tropical diseases.  These diseases are caused by parasitic trypanosomatids and range in severity from mild and self-curing to near invariably fatal.  Public health advances have substantially decreased the effect of these diseases in recent decades but alone will not eliminate them.  In this Review, we discuss why new drugs against trypanosomatids are required, approaches that are under investigation to develop new drugs and why the drug discovery pipeline remains essentially unfilled.  In addn., we consider the important challenges to drug discovery strategies and the new technologies that can address them.  The combination of new drugs, new technologies and public health initiatives is essential for the management, and hopefully eventual elimination, of trypanosomatid diseases from the human population.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIBpRGL7YaP7Vg90H21EOLACvtfcHk0ljnmnwG14HKhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjsVSms7Y%253D&md5=1585d954d6eb695196a6c8921a84e300</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrmicro.2016.193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrmicro.2016.193%26sid%3Dliteratum%253Aachs%26aulast%3DField%26aufirst%3DM.%2BC.%26aulast%3DHorn%26aufirst%3DD.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DTorrie%26aufirst%3DL.%2BS.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DAnti-Trypanosomatid%2520Drug%2520Discovery%253A%2520An%2520Ongoing%2520Challenge%2520and%2520a%2520Continuing%2520Need%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2017%26volume%3D15%26spage%3D217%26epage%3D231%26doi%3D10.1038%2Fnrmicro.2016.193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De
Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baragaña, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duce, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Challenges and Recent Progress in Drug Discovery for Tropical Diseases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>559</i></span>,  <span class="NLM_fpage">498</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0327-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fs41586-018-0327-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30046073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=559&publication_year=2018&pages=498-506&author=M.+De%0ARyckerauthor=B.+Baraga%C3%B1aauthor=S.+L.+Duceauthor=I.+H.+Gilbert&title=Challenges+and+Recent+Progress+in+Drug+Discovery+for+Tropical+Diseases&doi=10.1038%2Fs41586-018-0327-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Challenges and recent progress in drug discovery for tropical diseases</span></div><div class="casAuthors">De Rycker, Manu; Baragana, Beatriz; Duce, Suzanne L.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">559</span>
        (<span class="NLM_cas:issue">7715</span>),
    <span class="NLM_cas:pages">498-506</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries.  These diseases predominantly affect the world's poorest people.  Currently available drugs are inadequate for the majority of these diseases, and there is an urgent need for new treatments.  This Review discusses some of the challenges involved in developing new drugs to treat these diseases and highlights recent progress.  While there have been notable successes, there is still a long way to go.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-L8-tHy6aTbVg90H21EOLACvtfcHk0ljRPqDuXxvwQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt7zP&md5=3bc57ce68776462cf6a053efa276a989</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0327-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0327-4%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DBaraga%25C3%25B1a%26aufirst%3DB.%26aulast%3DDuce%26aufirst%3DS.%2BL.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DChallenges%2520and%2520Recent%2520Progress%2520in%2520Drug%2520Discovery%2520for%2520Tropical%2520Diseases%26jtitle%3DNature%26date%3D2018%26volume%3D559%26spage%3D498%26epage%3D506%26doi%3D10.1038%2Fs41586-018-0327-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">WHO</span>.  <i>Regional Strategic Framework for Elimination of Kala-Azar
from the
Sout-East Asia Region (2005-2015)</i>; New Delhi, <span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=WHO&title=Regional+Strategic+Framework+for+Elimination+of+Kala-Azar%0Afrom+the%0ASout-East+Asia+Region+%282005-2015%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3D%26jtitle%3DRegional%2520Strategic%2520Framework%2520for%2520Elimination%2520of%2520Kala-Azar%250Afrom%2520the%250ASout-East%2520Asia%2520Region%2520%25282005-2015%2529%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burza, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Croft, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boelaert, M.</span></span> <span> </span><span class="NLM_article-title">Leishmaniasis</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>392</i></span>,  <span class="NLM_fpage">951</span>– <span class="NLM_lpage">970</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(18)31204-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0140-6736%2818%2931204-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30126638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BB3c7pvFyrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=392&publication_year=2018&pages=951-970&author=S.+Burzaauthor=S.+L.+Croftauthor=M.+Boelaert&title=Leishmaniasis&doi=10.1016%2FS0140-6736%2818%2931204-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Leishmaniasis</span></div><div class="casAuthors">Burza Sakib; Croft Simon L; Boelaert Marleen</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">392</span>
        (<span class="NLM_cas:issue">10151</span>),
    <span class="NLM_cas:pages">951-970</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leishmaniasis is a poverty-related disease with two main clinical forms: visceral leishmaniasis and cutaneous leishmaniasis.  An estimated 0·7-1 million new cases of leishmaniasis per year are reported from nearly 100 endemic countries.  The number of reported visceral leishmaniasis cases has decreased substantially in the past decade as a result of better access to diagnosis and treatment and more intense vector control within an elimination initiative in Asia, although natural cycles in transmission intensity might play a role.  In east Africa however, the case numbers of this fatal disease continue to be sustained.  Increased conflict in endemic areas of cutaneous leishmaniasis and forced displacement has resulted in a surge in these endemic areas as well as clinics across the world.  WHO lists leishmaniasis as one of the neglected tropical diseases for which the development of new treatments is a priority.  Major evidence gaps remain, and new tools are needed before leishmaniasis can be definitively controlled.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKr3d5VSglcRJ5E29YNGvQfW6udTcc2eYFZtd5gXPqBLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7pvFyrtw%253D%253D&md5=48f443a91163f1595a494000eb21f877</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2818%2931204-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252818%252931204-2%26sid%3Dliteratum%253Aachs%26aulast%3DBurza%26aufirst%3DS.%26aulast%3DCroft%26aufirst%3DS.%2BL.%26aulast%3DBoelaert%26aufirst%3DM.%26atitle%3DLeishmaniasis%26jtitle%3DLancet%26date%3D2018%26volume%3D392%26spage%3D951%26epage%3D970%26doi%3D10.1016%2FS0140-6736%2818%2931204-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, A.</span></span> <span> </span><span class="NLM_article-title">Chemotherapeutics of Visceral Leishmaniasis: Present and Future Developments</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>145</i></span>,  <span class="NLM_fpage">481</span>– <span class="NLM_lpage">489</span>, <span class="refDoi"> DOI: 10.1017/S0031182017002116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1017%2FS0031182017002116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=29215329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGjs7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=145&publication_year=2018&pages=481-489&author=S.+Sundarauthor=A.+Singh&title=Chemotherapeutics+of+Visceral+Leishmaniasis%3A+Present+and+Future+Developments&doi=10.1017%2FS0031182017002116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapeutics of visceral leishmaniasis: present and future developments</span></div><div class="casAuthors">Karunaweera, Nadira D.; Ferreira, Marcelo U.; Sundar, Shyam; Singh, Anup</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">145</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">481-489</span>CODEN:
                <span class="NLM_cas:coden">PARAAE</span>;
        ISSN:<span class="NLM_cas:issn">0031-1820</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">A review.  SUMMARY : Treatment of Visceral Leishmaniasis (VL), a neglected tropical disease, is very challenging with few treatment options.  Long duration of treatment and drug toxicity further limit the target of achieving VL elimination.  Chemotherapy remains the treatment of choice.  Single dose of liposomal amphotericin B (LAmB) and multidrug therapy (LAmB + miltefosine, LAmB + paromomycin (PM), or miltefosine + PM) are recommended treatment regimen for treatment of VL in Indian sub-continent.  Combination therapy of pentavalent antimonials (Sbv) and PM in East Africa and LAmB in the Mediterranean region/South America remains the treatment of choice.  Various drugs having anti-leishmania properties are in preclin. phase and need further development.  An effective treatment and secondary prophylaxis of HIV-VL co-infection should be developed to decrease treatment failure and drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9DhyRkDYkJbVg90H21EOLACvtfcHk0ljRPqDuXxvwQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGjs7zK&md5=de333aebe0baa82c8c005e2138ecf5b0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1017%2FS0031182017002116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182017002116%26sid%3Dliteratum%253Aachs%26aulast%3DSundar%26aufirst%3DS.%26aulast%3DSingh%26aufirst%3DA.%26atitle%3DChemotherapeutics%2520of%2520Visceral%2520Leishmaniasis%253A%2520Present%2520and%2520Future%2520Developments%26jtitle%3DParasitology%26date%3D2018%26volume%3D145%26spage%3D481%26epage%3D489%26doi%3D10.1017%2FS0031182017002116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, S.</span></span> <span> </span><span class="NLM_article-title">Current and Emerging Medications for the Treatment of Leishmaniasis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1251</span>– <span class="NLM_lpage">1265</span>, <span class="refDoi"> DOI: 10.1080/14656566.2019.1609940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1080%2F14656566.2019.1609940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=31063412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlert7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1251-1265&author=J.+Chakravartyauthor=S.+Sundar&title=Current+and+Emerging+Medications+for+the+Treatment+of+Leishmaniasis&doi=10.1080%2F14656566.2019.1609940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Current and emerging medications for the treatment of leishmaniasis</span></div><div class="casAuthors">Chakravarty, Jaya; Sundar, Shyam</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1251-1265</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Leishmaniasis is a vector-borne neglected tropical disease which manifests as visceral leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocutaneous leishmaniasis (MCL).  The current drugs are toxic, duration of treatment is long, there is regional variation in efficacy, and emergence of resistance is common.  This manuscript is based on literature derived from PubMed and reviews the current and emerging medications for the treatment of leishmaniasis.  A single dose of liposomal amphotericin B (L-AmB) and multidrug therapy are the best options for VL in the Indian subcontinent (ISC), while a combination of pentavalent antimonials and paromomycin remains the treatment of choice for VL in Africa where efficacious and safe regimens are needed for HIV-VL coinfection.  L-AmB at a total dose of 18-21 mg/kg is the recommended regimen for VL in the Mediterranean region, South America and for HIV-VL coinfection.  Treatment of CL varies from observation, local or systemic therapy depending on severity of lesions, etiol. species and its potential to develop into mucosal leishmaniasis.  The monitoring of single-dose L-AmB and combination therapy in the ISC is essential.  Effective short-course combination therapy is needed for the treatment of post-kala-azar dermal leishmaniasis and HIV-VL.  Better evidence for treatment is still needed along with safer and shorter treatment options for CL and MCL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKTdQKa9ror7Vg90H21EOLACvtfcHk0lht3S0WsiNZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlert7k%253D&md5=e7e601b3669b6ae0ef17173d757958ba</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1080%2F14656566.2019.1609940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2019.1609940%26sid%3Dliteratum%253Aachs%26aulast%3DChakravarty%26aufirst%3DJ.%26aulast%3DSundar%26aufirst%3DS.%26atitle%3DCurrent%2520and%2520Emerging%2520Medications%2520for%2520the%2520Treatment%2520of%2520Leishmaniasis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2019%26volume%3D20%26spage%3D1251%26epage%3D1265%26doi%3D10.1080%2F14656566.2019.1609940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">DNDi</span>. <span> </span><span class="NLM_article-title">2019 R&D portfolio
in review: Leishmaniasis
– DNDi</span>. <a href="https://www.dndi.org/2020/media-centre/news-views-stories/news/leishmaniasis-rnd-portfolio-update/" class="extLink">https://www.dndi.org/2020/media-centre/news-views-stories/news/leishmaniasis-rnd-portfolio-update/</a> (accessed Apr 20, <span class="NLM_year">2020</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=DNDi&title=2019+R%26D+portfolio%0Ain+review%3A+Leishmaniasis%0A%E2%80%93+DNDi"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3D2019%2520R%2526D%2520portfolio%250Ain%2520review%253A%2520Leishmaniasis%250A%25E2%2580%2593%2520DNDi%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Be, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hein, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caridha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciotti, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pybus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreishman-Deitrick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathison, C. J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerario, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chianelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibney, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiricek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggimann, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luneau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudewicz, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10773</span>– <span class="NLM_lpage">10781</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00499</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00499" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2jurzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10773-10781&author=A.+Nagleauthor=A.+Biggartauthor=C.+Beauthor=H.+Srinivasauthor=A.+Heinauthor=D.+Caridhaauthor=R.+J.+Sciottiauthor=B.+Pybusauthor=M.+Kreishman-Deitrickauthor=B.+Bursulayaauthor=Y.+H.+Laiauthor=M.-Y.+Gaoauthor=F.+Liangauthor=C.+J.+N.+Mathisonauthor=X.+Liuauthor=V.+Yehauthor=J.+Smithauthor=I.+Lerarioauthor=Y.+Xieauthor=D.+Chianelliauthor=M.+Gibneyauthor=A.+Bermanauthor=Y.-L.+Chenauthor=J.+Jiricekauthor=L.+C.+Davisauthor=X.+Liuauthor=J.+Ballardauthor=S.+Khareauthor=F.+K.+Eggimannauthor=A.+Luneauauthor=T.+Groesslauthor=M.+Shapiroauthor=W.+Richmondauthor=K.+Johnsonauthor=P.+J.+Rudewiczauthor=S.+P.+S.+Raoauthor=C.+Thompsonauthor=T.+Tuntlandauthor=G.+Spraggonauthor=R.+J.+Glynneauthor=F.+Supekauthor=C.+Wiesmannauthor=V.+Molteni&title=Discovery+and+Characterization+of+Clinical+Candidate+LXE408+as+a+Kinetoplastid-Selective+Proteasome+Inhibitor+for+the+Treatment+of+Leishmaniases&doi=10.1021%2Facs.jmedchem.0c00499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases</span></div><div class="casAuthors">Nagle, Advait; Biggart, Agnes; Be, Celine; Srinivas, Honnappa; Hein, Andreas; Caridha, Diana; Sciotti, Richard J.; Pybus, Brandon; Kreishman-Deitrick, Mara; Bursulaya, Badry; Lai, Yin H.; Gao, Mu-Yun; Liang, Fang; Mathison, Casey J. N.; Liu, Xiaodong; Yeh, Vince; Smith, Jeffrey; Lerario, Isabelle; Xie, Yongping; Chianelli, Donatella; Gibney, Michael; Berman, Ashley; Chen, Yen-Liang; Jiricek, Jan; Davis, Lauren C.; Liu, Xianzhong; Ballard, Jaime; Khare, Shilpi; Eggimann, Fabian Kurt; Luneau, Alexandre; Groessl, Todd; Shapiro, Michael; Richmond, Wendy; Johnson, Kevin; Rudewicz, Patrick J.; Rao, Srinivasa P. S.; Thompson, Christopher; Tuntland, Tove; Spraggon, Glen; Glynne, Richard J.; Supek, Frantisek; Wiesmann, Christian; Molteni, Valentina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">10773-10781</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Visceral leishmaniasis is responsible for up to 30,000 deaths every year.  Current treatments have shortcomings that include toxicity and variable efficacy across endemic regions.  Previously, we reported the discovery of GNF6702, a selective inhibitor of the kinetoplastid proteasome, which cleared parasites in murine models of leishmaniasis, Chagas disease, and human African trypanosomiasis.  Here, we describe the discovery and characterization of LXE408(I), a structurally related kinetoplastid-selective proteasome inhibitor currently in Phase 1 human clin. trials.  Furthermore, we present high-resoln. cryo-EM structures of the Leishmania tarentolae proteasome in complex with LXE408, which provides a compelling explanation for the noncompetitive mode of binding of this novel class of inhibitors of the kinetoplastid proteasome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFHqvdoR1fT7Vg90H21EOLACvtfcHk0lht3S0WsiNZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2jurzM&md5=30d8293eed0e94a7bdb75c9d794f52ce</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00499%26sid%3Dliteratum%253Aachs%26aulast%3DNagle%26aufirst%3DA.%26aulast%3DBiggart%26aufirst%3DA.%26aulast%3DBe%26aufirst%3DC.%26aulast%3DSrinivas%26aufirst%3DH.%26aulast%3DHein%26aufirst%3DA.%26aulast%3DCaridha%26aufirst%3DD.%26aulast%3DSciotti%26aufirst%3DR.%2BJ.%26aulast%3DPybus%26aufirst%3DB.%26aulast%3DKreishman-Deitrick%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DMathison%26aufirst%3DC.%2BJ.%2BN.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYeh%26aufirst%3DV.%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DLerario%26aufirst%3DI.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DChianelli%26aufirst%3DD.%26aulast%3DGibney%26aufirst%3DM.%26aulast%3DBerman%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.-L.%26aulast%3DJiricek%26aufirst%3DJ.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DEggimann%26aufirst%3DF.%2BK.%26aulast%3DLuneau%26aufirst%3DA.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DRichmond%26aufirst%3DW.%26aulast%3DJohnson%26aufirst%3DK.%26aulast%3DRudewicz%26aufirst%3DP.%2BJ.%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DThompson%26aufirst%3DC.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DSupek%26aufirst%3DF.%26aulast%3DWiesmann%26aufirst%3DC.%26aulast%3DMolteni%26aufirst%3DV.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520Clinical%2520Candidate%2520LXE408%2520as%2520a%2520Kinetoplastid-Selective%2520Proteasome%2520Inhibitor%2520for%2520the%2520Treatment%2520of%2520Leishmaniases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10773%26epage%3D10781%26doi%3D10.1021%2Facs.jmedchem.0c00499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ajakane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Álvarez-Pedraglio, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brand, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantizani-Perez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cleghorn, L. A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copley, R. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daugan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hindley, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miguel-Siles, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norval, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna-Cabello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodland, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pena, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quesada-Campos, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revill, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Gomez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shishikura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, V. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinks, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Underwood, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span> <span> </span><span class="NLM_article-title">Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1180</span>– <span class="NLM_lpage">1202</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01218</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01218" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFGhtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1180-1202&author=M.+G.+Thomasauthor=M.+De+Ryckerauthor=M.+Ajakaneauthor=S.+Albrechtauthor=A.+I.+%C3%81lvarez-Pedraglioauthor=M.+Boescheauthor=S.+Brandauthor=L.+Campbellauthor=J.+Cantizani-Perezauthor=L.+A.+T.+Cleghornauthor=R.+C.+B.+Copleyauthor=S.+D.+Crouchauthor=A.+Dauganauthor=G.+Drewesauthor=S.+Ferrerauthor=S.+Ghidelli-Disseauthor=S.+Gonzalezauthor=S.+L.+Greshamauthor=A.+P.+Hillauthor=S.+J.+Hindleyauthor=R.+M.+Loweauthor=C.+J.+MacKenzieauthor=L.+MacLeanauthor=S.+Manthriauthor=F.+Martinauthor=J.+Miguel-Silesauthor=V.+L.+Nguyenauthor=S.+Norvalauthor=M.+Osuna-Cabelloauthor=A.+Woodlandauthor=S.+Pattersonauthor=I.+Penaauthor=M.+T.+Quesada-Camposauthor=I.+H.+Reidauthor=C.+Revillauthor=J.+Rileyauthor=J.+R.+Ruiz-Gomezauthor=Y.+Shishikuraauthor=F.+R.+C.+Simeonsauthor=A.+Smithauthor=V.+C.+Smithauthor=D.+Spinksauthor=L.+Stojanovskiauthor=J.+Thomasauthor=S.+Thompsonauthor=T.+Underwoodauthor=D.+W.+Grayauthor=J.+M.+Fiandorauthor=I.+H.+Gilbertauthor=P.+G.+Wyattauthor=K.+D.+Readauthor=T.+J.+Miles&title=Identification+of+GSK3186899%2FDDD853651+as+a+Preclinical+Development+Candidate+for+the+Treatment+of+Visceral+Leishmaniasis&doi=10.1021%2Facs.jmedchem.8b01218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of GSK3186899/DDD853651 as a preclinical development candidate for the treatment of visceral leishmaniasis</span></div><div class="casAuthors">Thomas, Michael G.; De Rycker, Manu; Ajakane, Myriam; Albrecht, Sebastian; Alvarez-Pedraglio, Ana Isabel; Boesche, Markus; Brand, Stephen; Campbell, Lorna; Cantizani-Perez, Juan; Cleghorn, Laura A. T.; Copley, Royston C. B.; Crouch, Sabrinia D.; Daugan, Alain; Drewes, Gerard; Ferrer, Santiago; Ghidelli-Disse, Sonja; Gonzalez, Silvia; Gresham, Stephanie L.; Hill, Alan P.; Hindley, Sean J.; Lowe, Rhiannon M.; MacKenzie, Claire J.; MacLean, Lorna; Manthri, Sujatha; Martin, Franck; Miguel-Siles, Juan; Nguyen, Van Loc; Norval, Suzanne; Osuna-Cabello, Maria; Woodland, Andrew; Patterson, Stephen; Pena, Imanol; Quesada-Campos, Maria Teresa; Reid, Iain H.; Revill, Charlotte; Riley, Jennifer; Ruiz-Gomez, Jose Ramon; Shishikura, Yoko; Simeons, Frederick R. C.; Smith, Alasdair; Smith, Victoria C.; Spinks, Daniel; Stojanovski, Laste; Thomas, John; Thompson, Stephen; Underwood, Tim; Gray, David W.; Fiandor, Jose M.; Gilbert, Ian H.; Wyatt, Paul G.; Read, Kevin D.; Miles, Timothy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1180-1202</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The leishmaniases are diseases that affect millions of people across the world, in particular visceral leishmaniasis (VL) which is fatal unless treated.  Current std. of care for VL suffers from multiple issues and there is a limited pipeline of new candidate drugs.  As such, there is a clear unmet medical need to identify new treatments.  This paper describes the optimization of a phenotypic hit against Leishmania donovani, the major causative organism of VL.  The key challenges were to balance soly. and metabolic stability while maintaining potency.  Herein, strategies to address these shortcomings and enhance efficacy are discussed, culminating in the discovery of preclin. development candidate GSK3186899/DDD853651 (1) for VL.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3K_YbhzFzXbVg90H21EOLACvtfcHk0lizlPnTxf8zUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFGhtLfP&md5=6c0c7ed8d7b5b38b6fe1eb5bbe655bb1</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01218%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DM.%2BG.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DAjakane%26aufirst%3DM.%26aulast%3DAlbrecht%26aufirst%3DS.%26aulast%3D%25C3%2581lvarez-Pedraglio%26aufirst%3DA.%2BI.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DBrand%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DL.%26aulast%3DCantizani-Perez%26aufirst%3DJ.%26aulast%3DCleghorn%26aufirst%3DL.%2BA.%2BT.%26aulast%3DCopley%26aufirst%3DR.%2BC.%2BB.%26aulast%3DCrouch%26aufirst%3DS.%2BD.%26aulast%3DDaugan%26aufirst%3DA.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DFerrer%26aufirst%3DS.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DGonzalez%26aufirst%3DS.%26aulast%3DGresham%26aufirst%3DS.%2BL.%26aulast%3DHill%26aufirst%3DA.%2BP.%26aulast%3DHindley%26aufirst%3DS.%2BJ.%26aulast%3DLowe%26aufirst%3DR.%2BM.%26aulast%3DMacKenzie%26aufirst%3DC.%2BJ.%26aulast%3DMacLean%26aufirst%3DL.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DF.%26aulast%3DMiguel-Siles%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DV.%2BL.%26aulast%3DNorval%26aufirst%3DS.%26aulast%3DOsuna-Cabello%26aufirst%3DM.%26aulast%3DWoodland%26aufirst%3DA.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DPena%26aufirst%3DI.%26aulast%3DQuesada-Campos%26aufirst%3DM.%2BT.%26aulast%3DReid%26aufirst%3DI.%2BH.%26aulast%3DRevill%26aufirst%3DC.%26aulast%3DRiley%26aufirst%3DJ.%26aulast%3DRuiz-Gomez%26aufirst%3DJ.%2BR.%26aulast%3DShishikura%26aufirst%3DY.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DV.%2BC.%26aulast%3DSpinks%26aufirst%3DD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DThomas%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DS.%26aulast%3DUnderwood%26aufirst%3DT.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26atitle%3DIdentification%2520of%2520GSK3186899%252FDDD853651%2520as%2520a%2520Preclinical%2520Development%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Visceral%2520Leishmaniasis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1180%26epage%3D1202%26doi%3D10.1021%2Facs.jmedchem.8b01218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyllie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crouch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rycker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gresham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbaniak, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otto, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojanovski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeons, F. R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manthri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLean, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuccotto, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homeyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pflaumer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boesche, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastry, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connolly, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berriman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghidelli-Disse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiandor, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyatt, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlamb, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miles, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, I. H.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 12 Is a Drug Target for Visceral Leishmaniasis</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>560</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">197</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0356-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fs41586-018-0356-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30046105" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=560&publication_year=2018&pages=192-197&author=S.+Wyllieauthor=M.+Thomasauthor=S.+Pattersonauthor=S.+Crouchauthor=M.+De+Ryckerauthor=R.+Loweauthor=S.+Greshamauthor=M.+D.+Urbaniakauthor=T.+D.+Ottoauthor=L.+Stojanovskiauthor=F.+R.+C.+Simeonsauthor=S.+Manthriauthor=L.+M.+MacLeanauthor=F.+Zuccottoauthor=N.+Homeyerauthor=H.+Pflaumerauthor=M.+Boescheauthor=L.+Sastryauthor=P.+Connollyauthor=S.+Albrechtauthor=M.+Berrimanauthor=G.+Drewesauthor=D.+W.+Grayauthor=S.+Ghidelli-Disseauthor=S.+Dixonauthor=J.+M.+Fiandorauthor=P.+G.+Wyattauthor=M.+A.+J.+Fergusonauthor=A.+H.+Fairlambauthor=T.+J.+Milesauthor=K.+D.+Readauthor=I.+H.+Gilbert&title=Cyclin-Dependent+Kinase+12+Is+a+Drug+Target+for+Visceral+Leishmaniasis&doi=10.1038%2Fs41586-018-0356-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis</span></div><div class="casAuthors">Wyllie, Susan; Thomas, Michael; Patterson, Stephen; Crouch, Sabrinia; De Rycker, Manu; Lowe, Rhiannon; Gresham, Stephanie; Urbaniak, Michael D.; Otto, Thomas D.; Stojanovski, Laste; Simeons, Frederick R. C.; Manthri, Sujatha; MacLean, Lorna M.; Zuccotto, Fabio; Homeyer, Nadine; Pflaumer, Hannah; Boesche, Markus; Sastry, Lalitha; Connolly, Paul; Albrecht, Sebastian; Berriman, Matt; Drewes, Gerard; Gray, David W.; Ghidelli-Disse, Sonja; Dixon, Susan; Fiandor, Jose M.; Wyatt, Paul G.; Ferguson, Michael A. J.; Fairlamb, Alan H.; Miles, Timothy J.; Read, Kevin D.; Gilbert, Ian H.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">560</span>
        (<span class="NLM_cas:issue">7717</span>),
    <span class="NLM_cas:pages">192-197</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world.  There is an urgent need for the development of new, effective treatments for this disease.  Here we describe the development of an anti-leishmanial drug-like chem. series based on a pyrazolopyrimidine scaffold.  The leading compd. from this series (7, DDD853651/GSK3186899) is efficacious in a mouse model of visceral leishmaniasis, has suitable physicochem., pharmacokinetic and toxicol. properties for further development, and has been declared a preclin. candidate.  Detailed mode-of-action studies indicate that compds. from this series act principally by inhibiting the parasite cdc-2-related kinase 12 (CRK12), thus defining a druggable target for visceral leishmaniasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWvpd9EzGFxLVg90H21EOLACvtfcHk0lizlPnTxf8zUg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtl2jt77I&md5=bea43a232049ade6ed9abea3e0510221</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0356-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0356-z%26sid%3Dliteratum%253Aachs%26aulast%3DWyllie%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DPatterson%26aufirst%3DS.%26aulast%3DCrouch%26aufirst%3DS.%26aulast%3DDe%2BRycker%26aufirst%3DM.%26aulast%3DLowe%26aufirst%3DR.%26aulast%3DGresham%26aufirst%3DS.%26aulast%3DUrbaniak%26aufirst%3DM.%2BD.%26aulast%3DOtto%26aufirst%3DT.%2BD.%26aulast%3DStojanovski%26aufirst%3DL.%26aulast%3DSimeons%26aufirst%3DF.%2BR.%2BC.%26aulast%3DManthri%26aufirst%3DS.%26aulast%3DMacLean%26aufirst%3DL.%2BM.%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DHomeyer%26aufirst%3DN.%26aulast%3DPflaumer%26aufirst%3DH.%26aulast%3DBoesche%26aufirst%3DM.%26aulast%3DSastry%26aufirst%3DL.%26aulast%3DConnolly%26aufirst%3DP.%26aulast%3DAlbrecht%26aufirst%3DS.%26aulast%3DBerriman%26aufirst%3DM.%26aulast%3DDrewes%26aufirst%3DG.%26aulast%3DGray%26aufirst%3DD.%2BW.%26aulast%3DGhidelli-Disse%26aufirst%3DS.%26aulast%3DDixon%26aufirst%3DS.%26aulast%3DFiandor%26aufirst%3DJ.%2BM.%26aulast%3DWyatt%26aufirst%3DP.%2BG.%26aulast%3DFerguson%26aufirst%3DM.%2BA.%2BJ.%26aulast%3DFairlamb%26aufirst%3DA.%2BH.%26aulast%3DMiles%26aufirst%3DT.%2BJ.%26aulast%3DRead%26aufirst%3DK.%2BD.%26aulast%3DGilbert%26aufirst%3DI.%2BH.%26atitle%3DCyclin-Dependent%2520Kinase%252012%2520Is%2520a%2520Drug%2520Target%2520for%2520Visceral%2520Leishmaniasis%26jtitle%3DNature%26date%3D2018%26volume%3D560%26spage%3D192%26epage%3D197%26doi%3D10.1038%2Fs41586-018-0356-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khare, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnes, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathison, C. J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myburgh, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillespie, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stinson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, I. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groessl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federe, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, H. X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venable, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spraggon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottram, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buckner, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, S. P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuntland, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molteni, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glynne, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Supek, F.</span></span> <span> </span><span class="NLM_article-title">Proteasome Inhibition for Treatment of Leishmaniasis, Chagas Disease and Sleeping Sickness</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>537</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/nature19339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fnature19339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=27501246" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=537&publication_year=2016&pages=229-233&author=S.+Khareauthor=A.+S.+Nagleauthor=A.+Biggartauthor=Y.+H.+Laiauthor=F.+Liangauthor=L.+C.+Davisauthor=S.+W.+Barnesauthor=C.+J.+N.+Mathisonauthor=E.+Myburghauthor=M.-Y.+Gaoauthor=J.+R.+Gillespieauthor=X.+Liuauthor=J.+L.+Tanauthor=M.+Stinsonauthor=I.+C.+Riveraauthor=J.+Ballardauthor=V.+Yehauthor=T.+Groesslauthor=G.+Federeauthor=H.+X.+Y.+Kohauthor=J.+D.+Venableauthor=B.+Bursulayaauthor=M.+Shapiroauthor=P.+K.+Mishraauthor=G.+Spraggonauthor=A.+Brockauthor=J.+C.+Mottramauthor=F.+S.+Bucknerauthor=S.+P.+S.+Raoauthor=B.+G.+Wenauthor=J.+R.+Walkerauthor=T.+Tuntlandauthor=V.+Molteniauthor=R.+J.+Glynneauthor=F.+Supek&title=Proteasome+Inhibition+for+Treatment+of+Leishmaniasis%2C+Chagas+Disease+and+Sleeping+Sickness&doi=10.1038%2Fnature19339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness</span></div><div class="casAuthors">Khare, Shilpi; Nagle, Advait S.; Biggart, Agnes; Lai, Yin H.; Liang, Fang; Davis, Lauren C.; Barnes, S. Whitney; Mathison, Casey J. N.; Myburgh, Elmarie; Gao, Mu-Yun; Gillespie, J. Robert; Liu, Xianzhong; Tan, Jocelyn L.; Stinson, Monique; Rivera, Ianne C.; Ballard, Jaime; Yeh, Vince; Groessl, Todd; Federe, Glenn; Koh, Hazel X. Y.; Venable, John D.; Bursulaya, Badry; Shapiro, Michael; Mishra, Pranab K.; Spraggon, Glen; Brock, Ansgar; Mottram, Jeremy C.; Buckner, Frederick S.; Rao, Srinivasa P. S.; Wen, Ben G.; Walker, John R.; Tuntland, Tove; Molteni, Valentina; Glynne, Richard J.; Supek, Frantisek</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">537</span>
        (<span class="NLM_cas:issue">7619</span>),
    <span class="NLM_cas:pages">229-233</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths annually.  The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp., resp.  These parasites have similar biol. and genomic sequence, suggesting that all three diseases could be cured with drugs that modulate the activity of a conserved parasite target.  However, no such mol. targets or broad spectrum drugs have been identified to date.  Here we describe a selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection.  GNF6702 inhibits the kinetoplastid proteasome through a non-competitive mechanism, does not inhibit the mammalian proteasome or growth of mammalian cells, and is well-tolerated in mice.  Our data provide genetic and chem. validation of the parasite proteasome as a promising therapeutic target for treatment of kinetoplastid infections, and underscore the possibility of developing a single class of drugs for these neglected diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_PXMn1-tj_7Vg90H21EOLACvtfcHk0lhqaC_npCSu7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVyhtr%252FL&md5=a05e7ce0f6b912b3003c5b3f42a005bb</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnature19339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature19339%26sid%3Dliteratum%253Aachs%26aulast%3DKhare%26aufirst%3DS.%26aulast%3DNagle%26aufirst%3DA.%2BS.%26aulast%3DBiggart%26aufirst%3DA.%26aulast%3DLai%26aufirst%3DY.%2BH.%26aulast%3DLiang%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DL.%2BC.%26aulast%3DBarnes%26aufirst%3DS.%2BW.%26aulast%3DMathison%26aufirst%3DC.%2BJ.%2BN.%26aulast%3DMyburgh%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.-Y.%26aulast%3DGillespie%26aufirst%3DJ.%2BR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DJ.%2BL.%26aulast%3DStinson%26aufirst%3DM.%26aulast%3DRivera%26aufirst%3DI.%2BC.%26aulast%3DBallard%26aufirst%3DJ.%26aulast%3DYeh%26aufirst%3DV.%26aulast%3DGroessl%26aufirst%3DT.%26aulast%3DFedere%26aufirst%3DG.%26aulast%3DKoh%26aufirst%3DH.%2BX.%2BY.%26aulast%3DVenable%26aufirst%3DJ.%2BD.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DShapiro%26aufirst%3DM.%26aulast%3DMishra%26aufirst%3DP.%2BK.%26aulast%3DSpraggon%26aufirst%3DG.%26aulast%3DBrock%26aufirst%3DA.%26aulast%3DMottram%26aufirst%3DJ.%2BC.%26aulast%3DBuckner%26aufirst%3DF.%2BS.%26aulast%3DRao%26aufirst%3DS.%2BP.%2BS.%26aulast%3DWen%26aufirst%3DB.%2BG.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DTuntland%26aufirst%3DT.%26aulast%3DMolteni%26aufirst%3DV.%26aulast%3DGlynne%26aufirst%3DR.%2BJ.%26aulast%3DSupek%26aufirst%3DF.%26atitle%3DProteasome%2520Inhibition%2520for%2520Treatment%2520of%2520Leishmaniasis%252C%2520Chagas%2520Disease%2520and%2520Sleeping%2520Sickness%26jtitle%3DNature%26date%3D2016%26volume%3D537%26spage%3D229%26epage%3D233%26doi%3D10.1038%2Fnature19339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
den Kerkhof, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowbray, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braillard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickx, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Pharmacodynamics of Three Novel Antileishmanial Lead Series</span>. <i>Int. J. Parasitol. Drugs Drug Resist.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/j.ijpddr.2018.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ijpddr.2018.01.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=29425734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC1MvpvVGksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=81-86&author=M.+Van%0Aden+Kerkhofauthor=D.+Mabilleauthor=E.+Chatelainauthor=C.+E.+Mowbrayauthor=S.+Braillardauthor=S.+Hendrickxauthor=L.+Maesauthor=G.+Caljon&title=In+Vitro+and+in+Vivo+Pharmacodynamics+of+Three+Novel+Antileishmanial+Lead+Series&doi=10.1016%2Fj.ijpddr.2018.01.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo pharmacodynamics of three novel antileishmanial lead series</span></div><div class="casAuthors">Van den Kerkhof M; Mabille D; Hendrickx S; Maes L; Chatelain E; Mowbray C E; Braillard S; Caljon G</div><div class="citationInfo"><span class="NLM_cas:title">International journal for parasitology. Drugs and drug resistance</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Three new chemical series (bicyclic nitroimidazoles, aminopyrazoles and oxaboroles) were selected by Drugs for Neglected Diseases initiative as potential new drug leads for leishmaniasis.  Pharmacodynamics studies included both in vitro and in vivo efficacy, cross-resistance profiling against the current antileishmanial reference drugs and evaluation of their cidal activity potential.  METHODS:  Efficacy against the reference laboratory strains of Leishmania infantum (MHOM/MA(BE)/67/ITMAP263) and L. donovani (MHOM/ET/67/L82) was evaluated in vitro on intracellular amastigotes and in vivo in the early curative hamster model.  Cidal activity was assessed over a period of 15 days in an in vitro 'time-to-kill' assay.  Cross-resistance was assessed in vitro on a panel of L. infantum strains with different degrees of resistance to either antimony, miltefosine or paromomycin.  RESULTS:  All lead compounds showed potent and selective in vitro activity against the Leishmania strains tested and no cross-resistance could be demonstrated against any of the current antileishmanial drugs.  Cidal activity was obtained in vitro for all series within 15 days of exposure with some differences noted between L. donovani and L. infantum.  When evaluated in vivo, all lead compounds showed high efficacy and no adverse effects were observed.  CONCLUSIONS:  The new lead series were shown to have cidal pharmacodynamic activity.  The absence of cross-resistance with any of the current antileishmanial drugs opens possibilities for combination treatment to reduce the likelihood of treatment failures and drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQt-RwWhLKvZ9FxYDaSSP8XfW6udTcc2eYE6OklqfaLobntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvpvVGksA%253D%253D&md5=5f9deeb9bb4c0be92959b159b4008452</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpddr.2018.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpddr.2018.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2Bden%2BKerkhof%26aufirst%3DM.%26aulast%3DMabille%26aufirst%3DD.%26aulast%3DChatelain%26aufirst%3DE.%26aulast%3DMowbray%26aufirst%3DC.%2BE.%26aulast%3DBraillard%26aufirst%3DS.%26aulast%3DHendrickx%26aufirst%3DS.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DCaljon%26aufirst%3DG.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Pharmacodynamics%2520of%2520Three%2520Novel%2520Antileishmanial%2520Lead%2520Series%26jtitle%3DInt.%2520J.%2520Parasitol.%2520Drugs%2520Drug%2520Resist.%26date%3D2018%26volume%3D8%26spage%3D81%26epage%3D86%26doi%3D10.1016%2Fj.ijpddr.2018.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Huijsduijnen, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaneko, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mowbray, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmatz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slingsby, B. T.</span></span> <span> </span><span class="NLM_article-title">Hit and Lead Criteria in Drug Discovery for Infectious Diseases of the Developing World</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">758</span>, <span class="refDoi"> DOI: 10.1038/nrd4683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fnrd4683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=26435527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1SitL7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=751-758&author=K.+Katsunoauthor=J.+N.+Burrowsauthor=K.+Duncanauthor=R.+H.+Van+Huijsduijnenauthor=T.+Kanekoauthor=K.+Kitaauthor=C.+E.+Mowbrayauthor=D.+Schmatzauthor=P.+Warnerauthor=B.+T.+Slingsby&title=Hit+and+Lead+Criteria+in+Drug+Discovery+for+Infectious+Diseases+of+the+Developing+World&doi=10.1038%2Fnrd4683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Hit and lead criteria in drug discovery for infectious diseases of the developing world</span></div><div class="casAuthors">Katsuno, Kei; Burrows, Jeremy N.; Duncan, Ken; van Huijsduijnen, Rob Hooft; Kaneko, Takushi; Kita, Kiyoshi; Mowbray, Charles E.; Schmatz, Dennis; Warner, Peter; Slingsby, B. T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">751-758</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reducing the burden of infectious diseases that affect people in the developing world requires sustained collaborative drug discovery efforts.  The quality of the chem. starting points for such projects is a key factor in improving the likelihood of clin. success, and so it is important to set clear go/no-go criteria for the progression of hit and lead compds.  With this in mind, the Japanese Global Health Innovative Technol. (GHIT) Fund convened with experts from the Medicines for Malaria Venture, the Drugs for Neglected Diseases initiative and the TB Alliance, together with representatives from the Bill & Melinda Gates Foundation, to set disease-specific criteria for hits and leads for malaria, tuberculosis, visceral leishmaniasis and Chagas disease.  Here, we present the agreed criteria and discuss the underlying rationale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFQHFz6z3D_rVg90H21EOLACvtfcHk0lhqaC_npCSu7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1SitL7O&md5=6cd6d7c8ca3a85d64f24915da8e1120c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnrd4683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4683%26sid%3Dliteratum%253Aachs%26aulast%3DKatsuno%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DJ.%2BN.%26aulast%3DDuncan%26aufirst%3DK.%26aulast%3DVan%2BHuijsduijnen%26aufirst%3DR.%2BH.%26aulast%3DKaneko%26aufirst%3DT.%26aulast%3DKita%26aufirst%3DK.%26aulast%3DMowbray%26aufirst%3DC.%2BE.%26aulast%3DSchmatz%26aufirst%3DD.%26aulast%3DWarner%26aufirst%3DP.%26aulast%3DSlingsby%26aufirst%3DB.%2BT.%26atitle%3DHit%2520and%2520Lead%2520Criteria%2520in%2520Drug%2520Discovery%2520for%2520Infectious%2520Diseases%2520of%2520the%2520Developing%2520World%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D751%26epage%3D758%26doi%3D10.1038%2Fnrd4683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span> <span> </span><span class="NLM_article-title">Purine Metabolism in Trypanosoma Cruzi</span>. <i>Mol. Biochem. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1016/0166-6851(81)90049-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0166-6851%2881%2990049-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6166862" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3MXkvFelsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1981&pages=187-196&author=R.+L.+Berensauthor=J.+J.+Marrauthor=S.+W.+LaFonauthor=D.+J.+Nelson&title=Purine+Metabolism+in+Trypanosoma+Cruzi&doi=10.1016%2F0166-6851%2881%2990049-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Purine metabolism in Trypanosoma cruzi</span></div><div class="casAuthors">Berens, Randolph L.; Marr, J. Joseph; LaFon, Stephen W.; Nelson, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Biochemical Parasitology</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">187-96</span>CODEN:
                <span class="NLM_cas:coden">MBIPDP</span>;
        ISSN:<span class="NLM_cas:issn">0166-6851</span>.
    </div><div class="casAbstract">Culture forms of T. cruzi are incapable of synthesizing purines de novo from formate, glycine, or serine and require an exogenous purine for growth.  Adenine, hypoxanthine, guanine, xanthine, and their resp. ribonucleosides are equal in their abilities to support growth.  Radiolabeled purine bases, with the exception of guanine, are stable and are converted to their resp. ribonucleotides directly by phosphoribosyltransferase activity.  Guanine is both converted to its ribonucleotide and deaminated to xanthine.  Purine nucleosides are not hydrolyzed to any extent but are converted to their resp. ribonucleotides.  This conversion may involve a rate-limiting ribonucleoside cleaving activity or a purine nucleoside kinase or phosphotransferase activity.  The apparent order of salvage efficiency for the bases and their resp. ribonucleosides is adenine > hypoxanthine > guanine > xanthine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtRLwTwe5Mk7Vg90H21EOLACvtfcHk0lhqO9K8YKcweA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXkvFelsLo%253D&md5=bb238018e74aa307b1651f2242ef76aa</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2F0166-6851%2881%2990049-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0166-6851%252881%252990049-9%26sid%3Dliteratum%253Aachs%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DLaFon%26aufirst%3DS.%2BW.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26atitle%3DPurine%2520Metabolism%2520in%2520Trypanosoma%2520Cruzi%26jtitle%3DMol.%2520Biochem.%2520Parasitol.%26date%3D1981%26volume%3D3%26spage%3D187%26epage%3D196%26doi%3D10.1016%2F0166-6851%2881%2990049-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Carter, N. S.</span>; <span class="NLM_string-name">Yates, P.</span>; <span class="NLM_string-name">Arendt, C. S.</span>; <span class="NLM_string-name">Boitz, J. M.</span>; <span class="NLM_string-name">Ullman, B.</span></span> <span> </span><span class="NLM_article-title">Purine and Pyrimidine Metabolism in Leishmania</span>. In  <i>Drug Targets in Kinetoplastid Parasites</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumder, H. K.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">154</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1007%2F978-0-387-77570-8_12" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=141-154&author=N.+S.+Carter&author=P.+Yates&author=C.+S.+Arendt&author=J.+M.+Boitz&author=B.+Ullmanauthor=H.+K.+Majumder&title=Drug+Targets+in+Kinetoplastid+Parasites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-77570-8_12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-77570-8_12%26sid%3Dliteratum%253Aachs%26aulast%3DCarter%26aufirst%3DN.%2BS.%26atitle%3DPurine%2520and%2520Pyrimidine%2520Metabolism%2520in%2520Leishmania%26btitle%3DDrug%2520Targets%2520in%2520Kinetoplastid%2520Parasites%26aulast%3DMajumder%26aufirst%3DH.%2BK.%26pub%3DSpringer%26date%3D2008%26spage%3D141%26epage%3D154" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boitz, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ullman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jardim, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, N. S.</span></span> <span> </span><span class="NLM_article-title">Purine Salvage in Leishmania: Complex or Simple by Design?</span>. <i>Trends Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.pt.2012.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.pt.2012.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22726696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVGntb3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2012&pages=345-352&author=J.+M.+Boitzauthor=B.+Ullmanauthor=A.+Jardimauthor=N.+S.+Carter&title=Purine+Salvage+in+Leishmania%3A+Complex+or+Simple+by+Design%3F&doi=10.1016%2Fj.pt.2012.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Purine salvage in Leishmania: complex or simple by design?</span></div><div class="casAuthors">Boitz, Jan M.; Ullman, Buddy; Jardim, Armando; Carter, Nicola S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Parasitology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">345-352</span>CODEN:
                <span class="NLM_cas:coden">TPRACT</span>;
        ISSN:<span class="NLM_cas:issn">1471-4922</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Purine nucleotides function in a variety of vital cellular and metabolic processes including energy prodn., cell signaling, synthesis of vitamin-derived cofactors and nucleic acids, and as determinants of cell fate.  Unlike their mammalian and insect hosts, Leishmania cannot synthesize the purine ring de novo and are absolutely dependent upon them to meet their purine requirements.  The obligatory nature of purine salvage in these parasites, therefore, offers an attractive paradigm for drug targeting and, consequently, the delineation of the pathway has been under scientific investigation for over 30 years.  Here, we review recent developments that reveal how purines flux in Leishmania and offer a potential Achilles' heel' for future validation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX93wTv2RJSbVg90H21EOLACvtfcHk0lhqO9K8YKcweA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVGntb3I&md5=9a95c3fbcc61a93d668ca813ad971c07</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.pt.2012.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pt.2012.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DBoitz%26aufirst%3DJ.%2BM.%26aulast%3DUllman%26aufirst%3DB.%26aulast%3DJardim%26aufirst%3DA.%26aulast%3DCarter%26aufirst%3DN.%2BS.%26atitle%3DPurine%2520Salvage%2520in%2520Leishmania%253A%2520Complex%2520or%2520Simple%2520by%2520Design%253F%26jtitle%3DTrends%2520Parasitol.%26date%3D2012%26volume%3D28%26spage%3D345%26epage%3D352%26doi%3D10.1016%2Fj.pt.2012.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Veken, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goeminne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haemers, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustyns, K.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of the Purine Salvage Pathway: A Valuable Approach for Antiprotozoal Chemotherapy?</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2456</span>– <span class="NLM_lpage">2481</span>, <span class="refDoi"> DOI: 10.2174/092986710791556023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.2174%2F092986710791556023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=20491648" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpslSksL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=2456-2481&author=M.+Bergauthor=P.+Van+der+Vekenauthor=A.+Goeminneauthor=A.+Haemersauthor=K.+Augustyns&title=Inhibitors+of+the+Purine+Salvage+Pathway%3A+A+Valuable+Approach+for+Antiprotozoal+Chemotherapy%3F&doi=10.2174%2F092986710791556023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the purine salvage pathway: a valuable approach for antiprotozoal chemotherapy?</span></div><div class="casAuthors">Berg, M.; Van der Veken, P.; Goeminne, A.; Haemers, A.; Augustyns, K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2456-2481</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  For many years, the purine salvage pathway of parasitic protozoa has been regarded as an attractive chemotherapeutic target.  Parasitic protozoa lack de novo synthesis and rely entirely on the purine salvage pathway to meet their purine demands.  Because of the great phylogenetic difference between parasite and host, there are often sufficient distinctions that can be exploited to design specific inhibitors for the parasitic enzymes.  As a result, this pathway has been thoroughly investigated over the last twenty years.  It is only quite recently that the genome studies of Trypanosoma, Leishmania and Plasmodium have been published.  Based on these genomic data however, the existence of bypass mechanisms by other enzymes and transporter systems could be suggested.  Taking into account such proposition, the question might arise as to whether inhibition of a single salvage enzyme will be able or not to cause parasite death or growth arrest.  In this paper, the key enzymes in the purine salvage pathways of relevant pathogenic species from the genera Trypanosoma, Leishmania and Plasmodium are reviewed.  Their potential as drug targets is critically evaluated and where possible, correlated to literature data on antiparasitic activity of their inhibitors.  While many studies over the past ten years have yielded contradictory results, this review attempts to clarify these findings by discussing the latest elements of progress in the field.  Addnl., as part of a broader discussion on substrate analog types of inhibitors, special attention is paid to iminoribitol derivs., serving as transition state analogs of nucleoside-processing enzymes and comprising the most potent inhibitors reported for purine salvage enzymes.  More specifically, the development of three generations of immucillins and a newer series of N-(arylmethyl-) substituted iminoribitol derivs. will be discussed.  Finally, this review also covers subversive substrates of salvage enzymes: compds. that are transformed by enzymic activity into cytotoxic agents.  Although not by directly intervening in the process of purine recovery, the subversive substrate approach might deliver antiprotozoal compds. that rely on salvage enzymes for their activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwcrBmQ1eWHbVg90H21EOLACvtfcHk0lhqO9K8YKcweA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpslSksL4%253D&md5=7fde49d9ce5a02260ec9ea9ae21e9d44</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F092986710791556023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986710791556023%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DM.%26aulast%3DVan%2Bder%2BVeken%26aufirst%3DP.%26aulast%3DGoeminne%26aufirst%3DA.%26aulast%3DHaemers%26aufirst%3DA.%26aulast%3DAugustyns%26aufirst%3DK.%26atitle%3DInhibitors%2520of%2520the%2520Purine%2520Salvage%2520Pathway%253A%2520A%2520Valuable%2520Approach%2520for%2520Antiprotozoal%2520Chemotherapy%253F%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2010%26volume%3D17%26spage%3D2456%26epage%3D2481%26doi%3D10.2174%2F092986710791556023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Kouni, M. H.</span></span> <span> </span><span class="NLM_article-title">Potential Chemotherapeutic Targets in the Purine Metabolism of Parasites</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">309</span>, <span class="refDoi"> DOI: 10.1016/S0163-7258(03)00071-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0163-7258%2803%2900071-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=12951162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvV2qs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2003&pages=283-309&author=M.+H.+El%0AKouni&title=Potential+Chemotherapeutic+Targets+in+the+Purine+Metabolism+of+Parasites&doi=10.1016%2FS0163-7258%2803%2900071-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Potential chemotherapeutic targets in the purine metabolism of parasites</span></div><div class="casAuthors">el Kouni, Mahmoud H.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-309</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Parasites are responsible for a wide variety of infectious diseases in human as well as in domestic and wild animals, causing an enormous health and economical blight.  Current containment strategies are not entirely successful and parasitic infections are on the rise.  In the absence of availability of antiparasitic vaccines, chemotherapy remains the mainstay for the treatment of most parasitic diseases.  However, there is an urgent need for new drugs to prevent or combat some major parasitic infections because of lack of a single effective approach for controlling the parasites (e.g., trypanosomiasis) or because some serious parasitic infections developed resistance to presently available drugs (e.g., malaria).  The rational design of a drug is usually based on biochem. and physiol. differences between pathogens and host.  Some of the most striking differences between parasites and their mammalian host are found in purine metab.  Purine nucleotides can be synthesized by the de novo and/or the so-called "salvage" pathways.  Unlike their mammalian host, most parasites studied lack the pathways for de novo purine biosynthesis and rely on the salvage pathways to meet their purine demands.  Moreover, because of the great phylogenic sepn. between the host and the parasite, there are in some cases sufficient distinctions between corresponding enzymes of the purine salvage from the host and the parasite that can be exploited to design specific inhibitors or "subversive substrates" for the parasitic enzymes.  Furthermore, the specificities of purine transport, the first step in purine salvage, diverge significantly between parasites and their mammalian host.  This review highlights the unique transporters and enzymes responsible for the salvage of purines in parasites that could constitute excellent potential targets for the design of safe and effective antiparasitic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoihVOC8nfcRbVg90H21EOLACvtfcHk0lhpY63Q9tl4-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvV2qs7c%253D&md5=5555db1e6dcb372302fbbdfb1e868371</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2803%2900071-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252803%252900071-8%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BKouni%26aufirst%3DM.%2BH.%26atitle%3DPotential%2520Chemotherapeutic%2520Targets%2520in%2520the%2520Purine%2520Metabolism%2520of%2520Parasites%26jtitle%3DPharmacol.%2520Ther.%26date%3D2003%26volume%3D99%26spage%3D283%26epage%3D309%26doi%3D10.1016%2FS0163-7258%2803%2900071-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Datta, A. K.</span>; <span class="NLM_string-name">Datta, R.</span>; <span class="NLM_string-name">Sen, B.</span></span> <span> </span><span class="NLM_article-title">Antiparasitic Chemotherapy</span>. In  <i>Drug Targets in Kinetoplastid Parasites</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majumder, H. K.</span></span>, Ed.; <span class="NLM_series">Advances In Experimental Medicine and Biology</span>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2008</span>; pp  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">132</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1007%2F978-0-387-77570-8_10" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&pages=116-132&author=A.+K.+Datta&author=R.+Datta&author=B.+Senauthor=H.+K.+Majumder&title=Drug+Targets+in+Kinetoplastid+Parasites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1007%2F978-0-387-77570-8_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-0-387-77570-8_10%26sid%3Dliteratum%253Aachs%26aulast%3DDatta%26aufirst%3DA.%2BK.%26atitle%3DAntiparasitic%2520Chemotherapy%26btitle%3DDrug%2520Targets%2520in%2520Kinetoplastid%2520Parasites%26aulast%3DMajumder%26aufirst%3DH.%2BK.%26pub%3DSpringer%26date%3D2008%26spage%3D116%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pfaller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span> <span> </span><span class="NLM_article-title">Antileishmanial Effect of Allopurinol</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">469</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1128/AAC.5.5.469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.5.5.469" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=4462464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaE2cXkvVKnsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=1974&pages=469-472&author=M.+A.+Pfallerauthor=J.+J.+Marr&title=Antileishmanial+Effect+of+Allopurinol&doi=10.1128%2FAAC.5.5.469"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Antileishmanial effect of allopurinol</span></div><div class="casAuthors">Pfaller, Michael A.; Marr, J. Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-72</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Allopurinol (I) [315-30-0] inhibited the growth of Leishmania braziliensis in vitro at concns. attainable in human tissues and body fluids.  I apparently acted by blocking the de novo synthesis of pyrimidines as a result of allopurinol ribonucleotide formation.  Although I is a known inhibitor of xanthine oxidase, the absence of this enzyme in L. braziliensis suggests that the toxicity of I is not due to inhibition of the interconversion of pteridines.  I is not toxic to humans, indicating its potential clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQcPhCgTcE77Vg90H21EOLACvtfcHk0lhpY63Q9tl4-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2cXkvVKnsbo%253D&md5=7ae6fecd4f42670a310d37371288ad26</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FAAC.5.5.469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.5.5.469%26sid%3Dliteratum%253Aachs%26aulast%3DPfaller%26aufirst%3DM.%2BA.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26atitle%3DAntileishmanial%2520Effect%2520of%2520Allopurinol%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1974%26volume%3D5%26spage%3D469%26epage%3D472%26doi%3D10.1128%2FAAC.5.5.469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Looker, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Action of Pyrazolopyrimidines in Leishmania Donovani</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>261</i></span>,  <span class="NLM_fpage">9412</span>– <span class="NLM_lpage">9415</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)67670-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0021-9258%2818%2967670-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2424909" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL28XkvFCgtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=261&publication_year=1986&pages=9412-9415&author=D.+L.+Lookerauthor=J.+J.+Marrauthor=R.+L.+Berens&title=Mechanisms+of+Action+of+Pyrazolopyrimidines+in+Leishmania+Donovani&doi=10.1016%2FS0021-9258%2818%2967670-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of action of pyrazolopyrimidines in Leishmania donovani</span></div><div class="casAuthors">Looker, Douglas L.; Marr, J. Joseph; Berens, Randolph L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">261</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9412-15</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">The antileishmanial actions were investigated of the pyrazolopyrimidines allopurinol, thiopurinol, and aminopurinol.  These compds. affect several metabolic processes.  The first is the inhibition of GMP reductase by the IMP analogs allopurinol ribonucleoside monophosphate and thiopurinol ribonucleoside monophosphate, which reduces the organism's ability to synthesize ATP from guanine.  Second, interconversion of adenine nucleotides to guanine nucleotides is curtailed by the inhibition of IMP dehydrogenase by these same IMP analogs.  Third, the IMP analogs reduce intracellular UTP content.  The 4th affect is increased catabolism of RNA and consequent redn. of protein synthesis.  This latter effect is due to the adenine nucleotide analogs aminopurinol ribonucleoside mono-, di-, and(or) triphosphates, metabolic products of both allopurinol and aminopurinol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGondHCSHPGLe7Vg90H21EOLACvtfcHk0lhpY63Q9tl4-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XkvFCgtb4%253D&md5=712ea292003f95dbb21b134793341855</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2967670-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252967670-7%26sid%3Dliteratum%253Aachs%26aulast%3DLooker%26aufirst%3DD.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26atitle%3DMechanisms%2520of%2520Action%2520of%2520Pyrazolopyrimidines%2520in%2520Leishmania%2520Donovani%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1986%26volume%3D261%26spage%3D9412%26epage%3D9415%26doi%3D10.1016%2FS0021-9258%2818%2967670-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steele
da Cruz, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span> <span> </span><span class="NLM_article-title">Effect of Allopurinol on Trypanosoma Cruzi: Metabolism and Biological Activity in Intracellular and Bloodstream Forms</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">657</span>– <span class="NLM_lpage">661</span>, <span class="refDoi"> DOI: 10.1128/AAC.22.4.657</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.22.4.657" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6817705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL38XmtFags7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1982&pages=657-661&author=R.+L.+Berensauthor=J.+J.+Marrauthor=F.+S.+Steele%0Ada+Cruzauthor=D.+J.+Nelson&title=Effect+of+Allopurinol+on+Trypanosoma+Cruzi%3A+Metabolism+and+Biological+Activity+in+Intracellular+and+Bloodstream+Forms&doi=10.1128%2FAAC.22.4.657"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of allopurinol on Trypanosoma cruzi:  metabolism and biological activity in intracellular and bloodstream forms</span></div><div class="casAuthors">Berens, Randolph L.; Marr, J. Joseph; Da Cruz, Fernando Steele; Nelson, Donald J.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">657-61</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">Expts. with radiolabeled allopurinol (I) and anal. of the metabolic products of I. by high-performance liq. chromatog. showed that both the blood stream and the intracellular forms of T. cruzi metabolize I in the same manner in tissue culture as has been shown for the epimastigotes in vitro.  The metabolic pathways for pyrazolopyrimidines in the pathogenic forms were demonstrated with organisms isolated from infected animals and a tissue culture system infected with T. cruzi.  Treatment of infected tissue culture with I eradicated the infection.  Thus I may be useful in chemotherapy of T. cruzi infections, a supposition which has been borne out in one animal study.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokkGfe4ULE87Vg90H21EOLACvtfcHk0lhwFqK8y0ntnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XmtFags7s%253D&md5=393810b236a94152f70d9c3a22f64be3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1128%2FAAC.22.4.657&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.22.4.657%26sid%3Dliteratum%253Aachs%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DSteele%2Bda%2BCruz%26aufirst%3DF.%2BS.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26atitle%3DEffect%2520of%2520Allopurinol%2520on%2520Trypanosoma%2520Cruzi%253A%2520Metabolism%2520and%2520Biological%2520Activity%2520in%2520Intracellular%2520and%2520Bloodstream%2520Forms%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1982%26volume%3D22%26spage%3D657%26epage%3D661%26doi%3D10.1128%2FAAC.22.4.657" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bugge, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elion, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span> <span> </span><span class="NLM_article-title">Metabolism of Pyrazolo(3,4-d)Pyrimidines in Leishmania Braziliensis and Leishmania Donovani. Allopurinol, Oxipurinol, and 4-Aminopyrazolo(3,4-d)Pyrimidine</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1979</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">3959</span>– <span class="NLM_lpage">3964</span>, <span class="refDoi"> DOI: 10.1016/S0021-9258(18)50680-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2FS0021-9258%2818%2950680-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=438170" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaE1MXksFans7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1979&pages=3959-3964&author=D.+J.+Nelsonauthor=C.+J.+Buggeauthor=G.+B.+Elionauthor=R.+L.+Berensauthor=J.+J.+Marr&title=Metabolism+of+Pyrazolo%283%2C4-d%29Pyrimidines+in+Leishmania+Braziliensis+and+Leishmania+Donovani.+Allopurinol%2C+Oxipurinol%2C+and+4-Aminopyrazolo%283%2C4-d%29Pyrimidine&doi=10.1016%2FS0021-9258%2818%2950680-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism of pyrazolo(3,4-d)pyrimidines in Leishmania braziliensis and Leishmania donovani.  Allopurinol, oxipurinol, and 4-aminopyrazol(3,4-d)pyrimidine</span></div><div class="casAuthors">Nelson, Donald J.; Bugge, Christopher J. L.; Elion, Gertrude B.; Berens, Randolph L.; Marr, J. Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1979</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3959-64</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    </div><div class="casAbstract">L. donovani And L. brasiliensis grown in culture formed mM concns. of allopurinol ribonucleoside 5'-monophosphate from allopurinol.  In addn., allopurinol 1-ribonucleoside, oxipurinol riboside 5'-monophosphate, and 3 new metabolites of allopurinol, namely, 4-aminopyrazolo[3,4-d]pyrimidine ribonucleoside 5'-monophosphate and the corresponding di- and triphosphates (1-ribosyl 4-aminopyrazolo[3,4-d]pyrimidine 5'-diphosphate and 1-ribosyl 4-aminopyrazolo[3,4-d]pyrimidine 5'-triphosphate) were identified in the parasitic cells.  They were formed via a unique amination reaction from 1-ribosyl allopurinol 5'-phosphate, analogous to the conversion of IMP to AMP.  Allopurinol was incorporated into RNA of L. donovani in the form of 4-aminopyrazolo[3,4-d]pyrimidine.  Adenine reversed the growth inhibition of allopurinol and prevented its metab. to all of the ribonucleotide metabolites.  L. donovani Was 2-4-fold more active in its metab. of allopurinol to ribonucleotides than L. brasiliensis.  4-Aminopyrazolo[3,4-d]pyrimidine inhibited cell growth and resulted in high intracellular levels of 1-ribosyl allopurinol 5'-phosphate and smaller amts. of the 4-aminopyrazolo[3,4-d]pyrimidine ribonucleotides.  The metab. of allopurinol to 4-aminopyrazolo[3,4-d]pyrimidine ribonucleotides and its resultant cytotoxicity occurs in these parasitic protozoans, but not in mammalian cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3nzWss9u057Vg90H21EOLACvtfcHk0lhwFqK8y0ntnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1MXksFans7w%253D&md5=00cc84c89faddbeb85965cca4c4139e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2FS0021-9258%2818%2950680-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0021-9258%252818%252950680-3%26sid%3Dliteratum%253Aachs%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26aulast%3DBugge%26aufirst%3DC.%2BJ.%26aulast%3DElion%26aufirst%3DG.%2BB.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26atitle%3DMetabolism%2520of%2520Pyrazolo%25283%252C4-d%2529Pyrimidines%2520in%2520Leishmania%2520Braziliensis%2520and%2520Leishmania%2520Donovani.%2520Allopurinol%252C%2520Oxipurinol%252C%2520and%25204-Aminopyrazolo%25283%252C4-d%2529Pyrimidine%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1979%26volume%3D254%26spage%3D3959%26epage%3D3964%26doi%3D10.1016%2FS0021-9258%2818%2950680-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kager, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellde, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hockmeyer, W. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyerly, W. H.</span></span> <span> </span><span class="NLM_article-title">Allopurinol in the Treatment of Visceral Leishmaniasis</span>. <i>Trans. R. Soc. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">559</span>, <span class="refDoi"> DOI: 10.1016/0035-9203(81)90198-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0035-9203%2881%2990198-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6275579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaL387gvVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1981&pages=556-559&author=P.+A.+Kagerauthor=P.+H.+Reesauthor=B.+T.+Welldeauthor=W.+T.+Hockmeyerauthor=W.+H.+Lyerly&title=Allopurinol+in+the+Treatment+of+Visceral+Leishmaniasis&doi=10.1016%2F0035-9203%2881%2990198-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Allopurinol in the treatment of visceral leishmaniasis</span></div><div class="casAuthors">Kager P A; Rees P H; Wellde B T; Hockmeyer W T; Lyerly W H</div><div class="citationInfo"><span class="NLM_cas:title">Transactions of the Royal Society of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">556-9</span>
        ISSN:<span class="NLM_cas:issn">0035-9203</span>.
    </div><div class="casAbstract">Allopurinol was used in the treatment of 10 patients with kala-azar.  Of six patients who had previously failed to respond satisfactorily to Pentostam, "cures" were achieved in four.  However, it was necessary to add Pentostam to the allopurinol in one, and another relapsed after apparent "cure" but again responded to allopurinol.  The response of four patients who had had no previous treatment for kala-azar was less satisfactory.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTpqVgoOiW2dWGmni0r9GoKfW6udTcc2ebR5DGfZTrmrLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL387gvVKqsg%253D%253D&md5=2383fe9c6e0a82b7d67293208441e0ee</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2F0035-9203%2881%2990198-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0035-9203%252881%252990198-X%26sid%3Dliteratum%253Aachs%26aulast%3DKager%26aufirst%3DP.%2BA.%26aulast%3DRees%26aufirst%3DP.%2BH.%26aulast%3DWellde%26aufirst%3DB.%2BT.%26aulast%3DHockmeyer%26aufirst%3DW.%2BT.%26aulast%3DLyerly%26aufirst%3DW.%2BH.%26atitle%3DAllopurinol%2520in%2520the%2520Treatment%2520of%2520Visceral%2520Leishmaniasis%26jtitle%3DTrans.%2520R.%2520Soc.%2520Trop.%2520Med.%2520Hyg.%26date%3D1981%26volume%3D75%26spage%3D556%26epage%3D559%26doi%3D10.1016%2F0035-9203%2881%2990198-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span> <span> </span><span class="NLM_article-title">Allopurinol in the Treatment of American Cutaneous Leishmaniasis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>326</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1056/NEJM199203123261105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1056%2FNEJM199203123261105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1738379" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaK387kvFKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=326&publication_year=1992&pages=741-744&author=S.+Martinezauthor=J.+J.+Marr&title=Allopurinol+in+the+Treatment+of+American+Cutaneous+Leishmaniasis&doi=10.1056%2FNEJM199203123261105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Allopurinol in the treatment of American cutaneous leishmaniasis</span></div><div class="casAuthors">Martinez S; Marr J J</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">326</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">741-4</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">BACKGROUND:  Pentavalent antimony, the generally accepted treatment for leishmaniasis, is given parenterally, and it is expensive and not readily available in developing countries.  An inexpensive, orally administered compound would be a substantial advance in treatment.  Previous studies in vitro have shown synergism between allopurinol and pentavalent antimony in tissue-culture systems.  We designed this clinical study to determine whether synergism could be demonstrated in patients.  METHODS:  We performed a randomized, controlled study of the efficacy of allopurinol plus meglumine antimoniate (Glucantime), as compared with meglumine antimoniate alone, in patients with cutaneous leishmaniasis, who were recruited from a village in southeastern Colombia.  In addition, those who declined injections were treated with allopurinol alone, and those who declined any treatment were considered controls.  All the patients were followed for one year after the completion of treatment.  Lesions that healed completely at three months and remained healed during follow-up were considered to be cured.  RESULTS:  The cure rate for patients treated with meglumine antimoniate was 36 percent; the addition of allopurinol increased the rate to 74 percent (P less than 0.001).  Treatment with allopurinol alone yielded a cure rate of 80 percent (P less than 0.001).  There were no cures among the untreated patients.  There was no significant difference between the cure rate with allopurinol plus meglumine antimoniate and that with allopurinol alone.  No major toxic effects were observed.  CONCLUSIONS:  For the treatment of American cutaneous leishmaniasis, the combination of allopurinol and meglumine antimoniate is significantly more effective than meglumine antimoniate alone, probably because of the efficacy of allopurinol alone, which appears to be as good as the combination.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSNXdU_H-LfSresJRIHUP1ofW6udTcc2eY34gI1AMFiZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK387kvFKhsg%253D%253D&md5=efec3086cf1e7e43210c1b6aeeff5cc8</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1056%2FNEJM199203123261105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199203123261105%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26atitle%3DAllopurinol%2520in%2520the%2520Treatment%2520of%2520American%2520Cutaneous%2520Leishmaniasis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1992%26volume%3D326%26spage%3D741%26epage%3D744%26doi%3D10.1056%2FNEJM199203123261105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yaich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Charfeddine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masmoudi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masmoudi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaghdhane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hachicha, J.</span></span> <span> </span><span class="NLM_article-title">Atypical Presentation of Cutaneous Leishmaniasis in a Renal Transplant Recipient Successfully Treated with Allopurinol and Fluconazole</span>. <i>Ann. Saudi Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">187</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.5144/0256-4947.2012.01.7.1510</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.5144%2F0256-4947.2012.01.7.1510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22750767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC38jmsVanuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=187-191&author=S.+Yaichauthor=K.+Charfeddineauthor=A.+Masmoudiauthor=M.+Masmoudiauthor=S.+Zaghdhaneauthor=H.+Turkiauthor=J.+Hachicha&title=Atypical+Presentation+of+Cutaneous+Leishmaniasis+in+a+Renal+Transplant+Recipient+Successfully+Treated+with+Allopurinol+and+Fluconazole&doi=10.5144%2F0256-4947.2012.01.7.1510"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Atypical presentation of cutaneous leishmaniasis in a renal transplant recipient successfully treated with allopurinol and fluconazole</span></div><div class="casAuthors">Yaich Soumaya; Charfeddine Khaled; Masmoudi Abderrahmen; Masmoudi Mondher; Zaghdhane Sawssen; Turki Hamida; Hachicha Jamil</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Saudi medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-91</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Leishmaniasis is a zoonotic infection acquired through the bite of a female sandfly, which introduces the amastigotes of Leishmania into the bloodstream.  Cutaneous leishmaniasis is rare after solid organ transplantation.  Its diagnosis is difficult in immunosuppressed patients.  We report a case of isolated cutaneous leishmaniasis in a renal transplant patient resident in an endemic area.  The patient was successfully treated with allopurinol and fluconazole and has remained relapse-free for 44 months.  The diagnosis of cutaneous leishmaniasis must be considered in immunosuppressed patients living in endemic areas.  Our report shows that cutaneous leishmaniasis may complicate the clinical course of kidney transplant recipients and its presentation can be atypical.  Conventional treatment with pen.tavalent antimonial agents can cause many side effects; of particular concern in renal transplant pa.tients are pancreatitis and nephrotoxicity.  These latter may be avoided by using a combination of allopurinol and fluconazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTr0KPWBOwAdySm0e6ZOaemfW6udTcc2eY34gI1AMFiZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jmsVanuw%253D%253D&md5=8aa65523822398d80f82b375413be1bd</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.5144%2F0256-4947.2012.01.7.1510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5144%252F0256-4947.2012.01.7.1510%26sid%3Dliteratum%253Aachs%26aulast%3DYaich%26aufirst%3DS.%26aulast%3DCharfeddine%26aufirst%3DK.%26aulast%3DMasmoudi%26aufirst%3DA.%26aulast%3DMasmoudi%26aufirst%3DM.%26aulast%3DZaghdhane%26aufirst%3DS.%26aulast%3DTurki%26aufirst%3DH.%26aulast%3DHachicha%26aufirst%3DJ.%26atitle%3DAtypical%2520Presentation%2520of%2520Cutaneous%2520Leishmaniasis%2520in%2520a%2520Renal%2520Transplant%2520Recipient%2520Successfully%2520Treated%2520with%2520Allopurinol%2520and%2520Fluconazole%26jtitle%3DAnn.%2520Saudi%2520Med.%26date%3D2013%26volume%3D33%26spage%3D187%26epage%3D191%26doi%3D10.5144%2F0256-4947.2012.01.7.1510" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Travi, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordeiro-da-Silva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dantas-Torres, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miró, G.</span></span> <span> </span><span class="NLM_article-title">Canine Visceral Leishmaniasis: Diagnosis and Management of the Reservoir Living among Us</span>. <i>PLoS Neglected Trop. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0006082</span> <span class="refDoi"> DOI: 10.1371/journal.pntd.0006082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1371%2Fjournal.pntd.0006082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=29324838" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlCqsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2018&author=B.+L.+Traviauthor=A.+Cordeiro-da-Silvaauthor=F.+Dantas-Torresauthor=G.+Mir%C3%B3&title=Canine+Visceral+Leishmaniasis%3A+Diagnosis+and+Management+of+the+Reservoir+Living+among+Us&doi=10.1371%2Fjournal.pntd.0006082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Canine visceral leishmaniasis: Diagnosis and management of the reservoir living among us</span></div><div class="casAuthors">Travi, Bruno L.; Cordeiro-Da-silva, Anabela; Dantas-Torres, Filipe; Miro, Guadalupe</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Neglected Tropical Diseases</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">e0006082/1-e0006082/13</span>CODEN:
                <span class="NLM_cas:coden">PNTDAM</span>;
        ISSN:<span class="NLM_cas:issn">1935-2735</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">This article reviews essential topics of canine visceral leishmaniasis (CVL) due to Leishmania infantum infection.  It focuses on the current serol. and mol. diagnostic methods used in epidemiol. research and veterinary clinics to diagnose CVL and includes new point-of-care (POC) tests under development.  The efficacy of different treatment regimens on the clin. improvement and infectiousness of dogs is also addressed.  In the last section, the review provides a crit. appraisal of the effectiveness of different control measures that have been implemented to curb disease transmission.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxMU6S0x9PM7Vg90H21EOLACvtfcHk0lhJ8r7meuEcdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlCqsbw%253D&md5=736a08d02966c55d51dc5497f2019b0c</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pntd.0006082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pntd.0006082%26sid%3Dliteratum%253Aachs%26aulast%3DTravi%26aufirst%3DB.%2BL.%26aulast%3DCordeiro-da-Silva%26aufirst%3DA.%26aulast%3DDantas-Torres%26aufirst%3DF.%26aulast%3DMir%25C3%25B3%26aufirst%3DG.%26atitle%3DCanine%2520Visceral%2520Leishmaniasis%253A%2520Diagnosis%2520and%2520Management%2520of%2520the%2520Reservoir%2520Living%2520among%2520Us%26jtitle%3DPLoS%2520Neglected%2520Trop.%2520Dis.%26date%3D2018%26volume%3D12%26doi%3D10.1371%2Fjournal.pntd.0006082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallerano, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sosa, R. R.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Efficacy of Allopurinol in Patients with Chronic Chagas’ Disease</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">166</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.1990.43.159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.4269%2Fajtmh.1990.43.159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2117857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaK3czlvVaqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=1990&pages=159-166&author=R.+H.+Galleranoauthor=J.+J.+Marrauthor=R.+R.+Sosa&title=Therapeutic+Efficacy+of+Allopurinol+in+Patients+with+Chronic+Chagas%E2%80%99+Disease&doi=10.4269%2Fajtmh.1990.43.159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease</span></div><div class="casAuthors">Gallerano R H; Marr J J; Sosa R R</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of tropical medicine and hygiene</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">159-66</span>
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    </div><div class="casAbstract">Laboratory and animal studies have demonstrated that pyrazolopyrimidines have significant activity against Trypanosoma cruzi.  This clinical investigation was to ascertain the efficacy of allopurinol in the treatment of chronic Chagas' disease.  Of 307 patients studied, 91 were untreated; the remaining 216 were divided into 4 treatment groups.  These corresponded to 600 or 900 mg/day of allopurinol for 60 days and benznidazole or nifurtimox at conventional dosage regimens.  Patients were evaluated clinically, serologically, and parasitologically.  Allopurinol was found to be as efficacious as the conventional therapeutic modalities in eliminating the parasitemia and rendering patients seronegative.  Adverse reactions occurred in 11% of patients who received allopurinol and in 30% of those receiving nitrofurans.  Reactions with the conventional therapy were more frequent and of a more serious nature.  Oral allopurinol is as effective as the nitrofurans, but has none of the side effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ4Xi6EugJj5A20zIbnCCI3fW6udTcc2eY34gI1AMFiZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czlvVaqtg%253D%253D&md5=eab7ec02286f0b682174021e0ef2a918</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.1990.43.159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.1990.43.159%26sid%3Dliteratum%253Aachs%26aulast%3DGallerano%26aufirst%3DR.%2BH.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DSosa%26aufirst%3DR.%2BR.%26atitle%3DTherapeutic%2520Efficacy%2520of%2520Allopurinol%2520in%2520Patients%2520with%2520Chronic%2520Chagas%25E2%2580%2599%2520Disease%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D1990%26volume%3D43%26spage%3D159%26epage%3D166%26doi%3D10.4269%2Fajtmh.1990.43.159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luquetti, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DA Silva, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rassi, A. G.</span></span> <span> </span><span class="NLM_article-title">Specific Treatment for Trypanosoma Cruzi: Lack of Efficacy of Allopurinol in the Human Chronic Phase of Chagas Disease</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">61</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.2007.76.58</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.4269%2Fajtmh.2007.76.58" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=17255230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktlejt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2007&pages=58-61&author=A.+Rassiauthor=A.+O.+Luquettiauthor=A.+Rassiauthor=G.+G.+Rassiauthor=S.+G.+Rassiauthor=I.+G.+DA+Silvaauthor=A.+G.+Rassi&title=Specific+Treatment+for+Trypanosoma+Cruzi%3A+Lack+of+Efficacy+of+Allopurinol+in+the+Human+Chronic+Phase+of+Chagas+Disease&doi=10.4269%2Fajtmh.2007.76.58"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Short report: specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease</span></div><div class="casAuthors">Rassi, Anis; Luquetti, Alejandro Ostermayer; Rassijr, Anis; Rassi, Gustavo Gabriel; Rassi, Sergio Gabriel; Garcia Da Silva, Ionizete; Rassi, Alexandre Gabriel</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">58-61</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    
            (<span class="NLM_cas:orgname">American Society of Tropical Medicine and Hygiene</span>)
        </div><div class="casAbstract">Thirty-five individuals from endemic areas of Central Brazil (age range, 18-64 years; 19 women) in the chronic phase of Chagas disease, with pos. serol. and presence of circulating parasites detected by one or more recent pos. xenodiagnosis, were selected for this study.  Allopurinol (900 mg/d) or placebo was administered in a double-blind clin. trial for 60 days.  After codes were broken, 23 had been allocated to the intervention group and 12 to the placebo group.  Side effects were obsd. in 11 patients in the intervention group and in 1 in the placebo group.  Seventeen patients in the intervention group and 10 in the placebo group completed the trial.  Follow-up was performed by monthly xenodiagnosis and serol. tests every 3 mo during the first year and at the end of the trial.  Xenodiagnosis remained pos. in all 17 of the treated group and in all 10 of the placebo group.  Serol. tests were persistently pos. in both groups after treatment.  We concluded that, at the doses used, allopurinol was not effective to clear, in our region, Trypanosoma cruzi from peripheral blood of infected individuals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDebZNxHa-QbVg90H21EOLACvtfcHk0liOUNmxpB0Hgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktlejt7s%253D&md5=e482171bd4958bf756d26502c242db6c</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.2007.76.58&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.2007.76.58%26sid%3Dliteratum%253Aachs%26aulast%3DRassi%26aufirst%3DA.%26aulast%3DLuquetti%26aufirst%3DA.%2BO.%26aulast%3DRassi%26aufirst%3DA.%26aulast%3DRassi%26aufirst%3DG.%2BG.%26aulast%3DRassi%26aufirst%3DS.%2BG.%26aulast%3DDA%2BSilva%26aufirst%3DI.%2BG.%26aulast%3DRassi%26aufirst%3DA.%2BG.%26atitle%3DSpecific%2520Treatment%2520for%2520Trypanosoma%2520Cruzi%253A%2520Lack%2520of%2520Efficacy%2520of%2520Allopurinol%2520in%2520the%2520Human%2520Chronic%2520Phase%2520of%2520Chagas%2520Disease%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D2007%26volume%3D76%26spage%3D58%26epage%3D61%26doi%3D10.4269%2Fajtmh.2007.76.58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Apt, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arribada, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulantay, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solari, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mundaca, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coronado, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gil, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osuna, A.</span></span> <span> </span><span class="NLM_article-title">Itraconazole or Allopurinol in the Treatment of Chronic American Trypanosomiasis: The Results of Clinical and Parasitological Examinations 11 Years Post-Treatment</span>. <i>Ann. Trop. Med. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1179/136485905X75403</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1179%2F136485905X75403" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=16297286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD28XislymsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2005&pages=733-741&author=W.+Aptauthor=A.+Arribadaauthor=I.+Zulantayauthor=A.+Solariauthor=G.+S%C3%A1nchezauthor=K.+Mundacaauthor=X.+Coronadoauthor=J.+Rodr%C3%ADguezauthor=L.+C.+Gilauthor=A.+Osuna&title=Itraconazole+or+Allopurinol+in+the+Treatment+of+Chronic+American+Trypanosomiasis%3A+The+Results+of+Clinical+and+Parasitological+Examinations+11+Years+Post-Treatment&doi=10.1179%2F136485905X75403"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment</span></div><div class="casAuthors">Apt, W.; Arribada, A.; Zulantay, I.; Solari, A.; Sanchez, G.; Mundaca, K.; Coronado, X.; Rodriguez, J.; Gil, L. C.; Osuna, A.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Tropical Medicine & Parasitology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">733-741</span>CODEN:
                <span class="NLM_cas:coden">ATMPA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-4983</span>.
    
            (<span class="NLM_cas:orgname">Maney Publishing</span>)
        </div><div class="casAbstract">Eleven years after they had been given itraconazole or allopurinol for the treatment of chronic American trypanosomiasis, 109 adult patients were checked for electrocardiog. abnormalities and evidence of Trypanosoma cruzi infection.  The parasitol. investigations included xenodiagnosis, in which the feces of Triatoma infestans that had fed on the patients were checked under the microscope for flagellates.  In addn., a PCR-based assay and a hybridization assay were used to test blood samples from the patients, and feces from the Tri. infestans that had fed on the patients, for Try. cruzi DNA.  For the data anal., the patients were divided into four groups known as normal/normal, abnormal/normal, normal/abnormal and abnormal/abnormal, according to whether the patients had been found to have normal or abnormal electrocardiograms (ECG) shortly before the first treatment and to have normal or abnormal ECG when checked at the 11-yr follow-up.  The 51 normal/normal and 24 normal/abnormal patients were assumed to have been in the 'indeterminate' phase of the disease when they were treated, whereas the 16 abnormal/normal and 18 abnormal/abnormal patients all had evidence of chagasic cardiopathy at that time.  When checked 11 years post-treatment, 40 (78.4%), 17 (70.8%), 14 (87.5%) and 17 (94.4%) of these patients, resp., were each found pos. for Try. cruzi in at least one of the parasitol. tests.  The hybridization assay, whether applied to human blood or bug feces, appeared a significantly more sensitive test than the PCR-based assays or microscopically assessed xenodiagnosis (P<0.05).  Only the 21 patients who appeared to be neg. for Try. cruzi could be considered parasitol. cured (although all still appeared to have anti-Try. cruzi antibodies in their blood).  Only 13 of these parasitol. cured patients (seven of those treated with itraconazole and six of those given allopurinol) had normal ECG at the 11-yr follow-up.  In Chile at least, itraconazole, which caused fewer adverse effects than the allopurinol while being no less effective at preventing cardiopathy, appears to be the drug of choice to treat chronic American trypanosomiasis in adults.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrckGyi5P5YE7Vg90H21EOLACvtfcHk0liXEsQ9DHsCYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XislymsA%253D%253D&md5=23cc548c5a9b02864044d5c0a5138e60</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1179%2F136485905X75403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1179%252F136485905X75403%26sid%3Dliteratum%253Aachs%26aulast%3DApt%26aufirst%3DW.%26aulast%3DArribada%26aufirst%3DA.%26aulast%3DZulantay%26aufirst%3DI.%26aulast%3DSolari%26aufirst%3DA.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DG.%26aulast%3DMundaca%26aufirst%3DK.%26aulast%3DCoronado%26aufirst%3DX.%26aulast%3DRodr%25C3%25ADguez%26aufirst%3DJ.%26aulast%3DGil%26aufirst%3DL.%2BC.%26aulast%3DOsuna%26aufirst%3DA.%26atitle%3DItraconazole%2520or%2520Allopurinol%2520in%2520the%2520Treatment%2520of%2520Chronic%2520American%2520Trypanosomiasis%253A%2520The%2520Results%2520of%2520Clinical%2520and%2520Parasitological%2520Examinations%252011%2520Years%2520Post-Treatment%26jtitle%3DAnn.%2520Trop.%2520Med.%2520Parasitol.%26date%3D2005%26volume%3D99%26spage%3D733%26epage%3D741%26doi%3D10.1179%2F136485905X75403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branco, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vianna, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buffolo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, E. E.</span></span> <span> </span><span class="NLM_article-title">Chagas’ Disease Reactivation after Heart Transplantation: Efficacy of Allopurinol Treatment</span>. <i>J. Heart Lung Transplant. Off. Publ. Int. Soc. Heart Transplant.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">988</span>– <span class="NLM_lpage">992</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=8913915" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaK2s%252FntV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1996&pages=988-992&author=D.+R.+Almeidaauthor=A.+C.+Carvalhoauthor=J.+N.+Brancoauthor=A.+P.+Pereiraauthor=L.+Correaauthor=P.+V.+Viannaauthor=E.+Buffoloauthor=E.+E.+Martinez&title=Chagas%E2%80%99+Disease+Reactivation+after+Heart+Transplantation%3A+Efficacy+of+Allopurinol+Treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Chagas' disease reactivation after heart transplantation: efficacy of allopurinol treatment</span></div><div class="casAuthors">Almeida D R; Carvalho A C; Branco J N; Pereira A P; Correa L; Vianna P V; Buffolo E; Martinez E E</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">988-92</span>
        ISSN:<span class="NLM_cas:issn">1053-2498</span>.
    </div><div class="casAbstract">BACKGROUND:  Chagas' disease is a parasitic infection that provokes a severe form of dilated cardiomyopathy.  In the initial experience with heart transplantation with Chagas' disease, a high rate of acute reactivation has been reported.  Although benzinidazole and nifurtimox are effective in the treatment of reactivation or of the acute phase of the disease they are associated with important adverse effects.  Allopurinol has substantial activity against Trypanosoma cruzi in vitro, in the experimental laboratory and in chronic human Chagas' disease; however, there is no information regarding its action in Chagas' reactivation after heart transplantation.  METHODS AND RESULTS:  We describe two patients with Chagas' disease who underwent heart transplantation.  The first one had asthenia, anorexia, and several painful subcutaneous nodules in the legs after transplantation; biopsy showed an inflammatory infiltrate with intracytoplasmatic nests of Trypanosoma cruzi, confirmed by immunohistochemical stains with monoclonal antibodies specific to parasitic antigens.  Allopurinol (600 mg/day) produced complete regression of the symptoms and the nodules with a negative control biopsy within 2 weeks.  Treatment was maintained for 2 months.  Mild leukopenia developed which improved after azathioprine reduction, and no further side-effects were noted.  The second patient had sudden heart failure months after transplantation; endomyocardial biopsy showed myocardial fibers infested with Trypanosoma, and a concomitantly performed right heart catheterization showed a low cardiac index and highfilling pressures.  The patient received allopurinol at a daily dose of 900 mg and conventional treatment for heart failure.  Echocardiogram showed improved wall motion and decreased left ventricular dimensions, and control biopsy showed no inflammatory activity; cardiac index and filling pressures normalized.  Treatment was maintained for 2 months without side effects.  The two patients have not had recurrences and were in New York Heart Association functional class I 12 and 3 months, respectively, after discontinuation of allopurinol.  CONCLUSIONS:  Allopurinol seems to be safe and effective in treating Chagas' disease reactivation after heart transplantation.  A larger number of case studies seems to be necessary to properly evaluate its role in the treatment of Chagas' disease reactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQy3SAtRClh_oJKJbLTgsvCfW6udTcc2eYon9mdodZUDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s%252FntV2ruw%253D%253D&md5=58ba77e146289080606ef7faddc4b487</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlmeida%26aufirst%3DD.%2BR.%26aulast%3DCarvalho%26aufirst%3DA.%2BC.%26aulast%3DBranco%26aufirst%3DJ.%2BN.%26aulast%3DPereira%26aufirst%3DA.%2BP.%26aulast%3DCorrea%26aufirst%3DL.%26aulast%3DVianna%26aufirst%3DP.%2BV.%26aulast%3DBuffolo%26aufirst%3DE.%26aulast%3DMartinez%26aufirst%3DE.%2BE.%26atitle%3DChagas%25E2%2580%2599%2520Disease%2520Reactivation%2520after%2520Heart%2520Transplantation%253A%2520Efficacy%2520of%2520Allopurinol%2520Treatment%26jtitle%3DJ.%2520Heart%2520Lung%2520Transplant.%2520Off.%2520Publ.%2520Int.%2520Soc.%2520Heart%2520Transplant.%26date%3D1996%26volume%3D15%26spage%3D988%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bestetti, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theodoropoulos, T. A. D.</span></span> <span> </span><span class="NLM_article-title">A Systematic Review of Studies on Heart Transplantation for Patients with End-Stage Chagas’ Heart Disease</span>. <i>J. Card. Failure</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">249</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1016/j.cardfail.2008.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.cardfail.2008.10.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=19327627" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BD1M3ktFWnuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=249-255&author=R.+B.+Bestettiauthor=T.+A.+D.+Theodoropoulos&title=A+Systematic+Review+of+Studies+on+Heart+Transplantation+for+Patients+with+End-Stage+Chagas%E2%80%99+Heart+Disease&doi=10.1016%2Fj.cardfail.2008.10.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic review of studies on heart transplantation for patients with end-stage Chagas' heart disease</span></div><div class="casAuthors">Bestetti Reinaldo B; Theodoropoulos Tatiana A D</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cardiac failure</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">249-55</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Uncertainties regarding indications for the procedure, proper immunosuppressive regimen, and the fear of Trypanosoma cruzi infection reactivation are major concerns regarding heart transplantation (HTx) for patients with end-stage Chagas' heart disease.  METHODS AND RESULTS:  To review indications for HTx, current immunosuppressive therapy, posttransplant morbidities, and outcome in Chagas' heart transplant recipients.  Review of articles linking HTx and Chagas' disease at PubMed and Scielo database from 1966 onward.  HTx can reasonably be indicated in patients with an annual probability of death of 70%.  HTx has been associated with a similar incidence of rejection episodes in Chagas' and non-Chagas' heart transplant recipients.  A lower incidence of infection episodes has been observed in Chagas' in comparison to non-Chagas' heart transplant recipients.  T. cruzi infection reactivation is easily treated with either benznidazole or allopurinol and portends a very low mortality rate.  Other posttransplant morbidities have a similar incidence in Chagas' and in non-Chagas' patients.  Survival probability for Chagas' HTx recipients at 1 month, 1 year, 4 years, and 10 years follow-up is 83%, 71%, 57%, and 46%, respectively.  Such an outcome is better than that seen in non-Chagas' heart transplant recipients.  CONCLUSIONS:  HTx is safe and efficacious for patients with end-stage Chagas' heart disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRgfCKqUWhJHq91pGlMMoT5fW6udTcc2eYon9mdodZUDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3ktFWnuw%253D%253D&md5=41735832c552e0a1802103ffa849dc9c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.cardfail.2008.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cardfail.2008.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DBestetti%26aufirst%3DR.%2BB.%26aulast%3DTheodoropoulos%26aufirst%3DT.%2BA.%2BD.%26atitle%3DA%2520Systematic%2520Review%2520of%2520Studies%2520on%2520Heart%2520Transplantation%2520for%2520Patients%2520with%2520End-Stage%2520Chagas%25E2%2580%2599%2520Heart%2520Disease%26jtitle%3DJ.%2520Card.%2520Failure%26date%3D2009%26volume%3D15%26spage%3D249%26epage%3D255%26doi%3D10.1016%2Fj.cardfail.2008.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Looker, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span> <span> </span><span class="NLM_article-title">The Synergistic Action of Pyrazolopyrimidines and Pentavalent Antimony against Leishmania Donovani and L. braziliensis</span>. <i>Am. J. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.4269/ajtmh.1988.39.250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.4269%2Fajtmh.1988.39.250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2845824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL1cXmt1WqtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1988&pages=250-255&author=S.+Martinezauthor=D.+L.+Lookerauthor=R.+L.+Berensauthor=J.+J.+Marr&title=The+Synergistic+Action+of+Pyrazolopyrimidines+and+Pentavalent+Antimony+against+Leishmania+Donovani+and+L.+braziliensis&doi=10.4269%2Fajtmh.1988.39.250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis</span></div><div class="casAuthors">Martinez, Samuel; Looker, Douglas L.; Berens, Randolph L.; Marr, J. Joseph</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">250-5</span>CODEN:
                <span class="NLM_cas:coden">AJTHAB</span>;
        ISSN:<span class="NLM_cas:issn">0002-9637</span>.
    </div><div class="casAbstract">When tested in a human macrophage tissue culture system infected with L. dinovani and L. braziliensis, pentostam showed inhibitory synergism with both allopurinol and allopurinol riboside.  Thus, pyrazolopyrimidines and pentavalent antimony appear to show promise for the treatment of Leishmania infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrICtFk7Kp1fLVg90H21EOLACvtfcHk0lhwAQam5usA1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1cXmt1WqtbY%253D&md5=0e8a2ee40d6d178316cfd2779fa2fef8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.4269%2Fajtmh.1988.39.250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4269%252Fajtmh.1988.39.250%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez%26aufirst%3DS.%26aulast%3DLooker%26aufirst%3DD.%2BL.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Synergistic%2520Action%2520of%2520Pyrazolopyrimidines%2520and%2520Pentavalent%2520Antimony%2520against%2520Leishmania%2520Donovani%2520and%2520L.%2520braziliensis%26jtitle%3DAm.%2520J.%2520Trop.%2520Med.%2520Hyg.%26date%3D1988%26volume%3D39%26spage%3D250%26epage%3D255%26doi%3D10.4269%2Fajtmh.1988.39.250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chunge, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gacmra, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muigai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasunna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rashid, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chulay, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anabwani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oster, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bryceson, A. D. M.</span></span> <span> </span><span class="NLM_article-title">Visceral Leishmaniasis Unresponsive to Antimonial Drugs III. Successful Treatment Using a Combination of Sodium Stibogluconate plus Allopurinol</span>. <i>Trans. R. Soc. Trop. Med. Hyg.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">715</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1016/0035-9203(85)90200-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0035-9203%2885%2990200-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=3006296" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADyaL287lt1ykuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=1985&pages=715-718&author=C.+N.+Chungeauthor=G.+Gacmraauthor=R.+Muigaiauthor=K.+Wasunnaauthor=J.+R.+Rashidauthor=J.+D.+Chulayauthor=G.+Anabwaniauthor=C.+N.+Osterauthor=A.+D.+M.+Bryceson&title=Visceral+Leishmaniasis+Unresponsive+to+Antimonial+Drugs+III.+Successful+Treatment+Using+a+Combination+of+Sodium+Stibogluconate+plus+Allopurinol&doi=10.1016%2F0035-9203%2885%2990200-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Visceral leishmaniasis unresponsive to antimonial drugs. III. Successful treatment using a combination of sodium stibogluconate plus allopurinol</span></div><div class="casAuthors">Chunge C N; Gachihi G; Muigai R; Wasunna K; Rashid J R; Chulay J D; Anabwani G; Oster C N; Bryceson A D</div><div class="citationInfo"><span class="NLM_cas:title">Transactions of the Royal Society of Tropical Medicine and Hygiene</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">715-8</span>
        ISSN:<span class="NLM_cas:issn">0035-9203</span>.
    </div><div class="casAbstract">Five patients with long-standing visceral leishmaniasis who were unresponsive to sodium stibogluconate, 20 mg antimony/kg body-weight once or twice daily, were treated for 14 to 54 days with a combination of sodium stibogluconate at the same dose plus allopurinol at a dose of 20 mg/kg body-weight per day in three divided doses.  This combination was safe and effective.  Negative splenic aspirate smears were obtained from all patients within 19 days, and none has relapsed in at least 12 months of follow-up.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQm7dzyzHzslEPI-fCgwosgfW6udTcc2eYon9mdodZUDLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL287lt1ykuw%253D%253D&md5=0849a550325dbdfa335b3e4cf2b34f41</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2F0035-9203%2885%2990200-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0035-9203%252885%252990200-7%26sid%3Dliteratum%253Aachs%26aulast%3DChunge%26aufirst%3DC.%2BN.%26aulast%3DGacmra%26aufirst%3DG.%26aulast%3DMuigai%26aufirst%3DR.%26aulast%3DWasunna%26aufirst%3DK.%26aulast%3DRashid%26aufirst%3DJ.%2BR.%26aulast%3DChulay%26aufirst%3DJ.%2BD.%26aulast%3DAnabwani%26aufirst%3DG.%26aulast%3DOster%26aufirst%3DC.%2BN.%26aulast%3DBryceson%26aufirst%3DA.%2BD.%2BM.%26atitle%3DVisceral%2520Leishmaniasis%2520Unresponsive%2520to%2520Antimonial%2520Drugs%2520III.%2520Successful%2520Treatment%2520Using%2520a%2520Combination%2520of%2520Sodium%2520Stibogluconate%2520plus%2520Allopurinol%26jtitle%3DTrans.%2520R.%2520Soc.%2520Trop.%2520Med.%2520Hyg.%26date%3D1985%26volume%3D79%26spage%3D715%26epage%3D718%26doi%3D10.1016%2F0035-9203%2885%2990200-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Torrus, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boix, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massa, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portilla, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Mateo, M.</span></span> <span> </span><span class="NLM_article-title">Fluconazole plus Allopurinol in Treatment of Visceral Leishmanlasis</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1042</span>– <span class="NLM_lpage">1043</span>, <span class="refDoi"> DOI: 10.1093/jac/37.5.1042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1093%2Fjac%2F37.5.1042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=8737162" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK28XjvVWqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1996&pages=1042-1043&author=D.+Torrusauthor=V.+Boixauthor=B.+Massaauthor=J.+Portillaauthor=M.+P%C3%A9rez-Mateo&title=Fluconazole+plus+Allopurinol+in+Treatment+of+Visceral+Leishmanlasis&doi=10.1093%2Fjac%2F37.5.1042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Fluconazole plus allopurinol in treatment of visceral leishmaniasis</span></div><div class="casAuthors">Torrus, Diego; Boix, Vicente; Massa, Beatriz; Portilla, Joaquin; Perez-Mateo, Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1042-1043</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Saunders</span>)
        </div><div class="casAbstract">A review with 6 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrop-7LawXHPbVg90H21EOLACvtfcHk0ljhFCIK0AP9lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjvVWqsL8%253D&md5=3fbde71c3bc66ff1bb495c958a34b9fc</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1093%2Fjac%2F37.5.1042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252F37.5.1042%26sid%3Dliteratum%253Aachs%26aulast%3DTorrus%26aufirst%3DD.%26aulast%3DBoix%26aufirst%3DV.%26aulast%3DMassa%26aufirst%3DB.%26aulast%3DPortilla%26aufirst%3DJ.%26aulast%3DP%25C3%25A9rez-Mateo%26aufirst%3DM.%26atitle%3DFluconazole%2520plus%2520Allopurinol%2520in%2520Treatment%2520of%2520Visceral%2520Leishmanlasis%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D1996%26volume%3D37%26spage%3D1042%26epage%3D1043%26doi%3D10.1093%2Fjac%2F37.5.1042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grosso, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alarcon, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laucella, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichera, L. E.</span></span> <span> </span><span class="NLM_article-title">Combined Treatment with Benznidazole and Allopurinol in Mice Infected with a Virulent Trypanosoma Cruzi Isolate from Nicaragua</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">1225</span>– <span class="NLM_lpage">1233</span>, <span class="refDoi"> DOI: 10.1017/S0031182013000176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1017%2FS0031182013000176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=23507037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlCltr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2013&pages=1225-1233&author=N.+L.+Grossoauthor=M.+L.+Alarconauthor=J.+Buaauthor=S.+A.+Laucellaauthor=A.+Riarteauthor=L.+E.+Fichera&title=Combined+Treatment+with+Benznidazole+and+Allopurinol+in+Mice+Infected+with+a+Virulent+Trypanosoma+Cruzi+Isolate+from+Nicaragua&doi=10.1017%2FS0031182013000176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Combined treatment with benznidazole and allopurinol in mice infected with a virulent Trypanosoma cruzi isolate from Nicaragua</span></div><div class="casAuthors">Grosso, Noelia L.; Alarcon, Micaela Lopez; Bua, Jaqueline; Laucella, Susana A.; Riarte, Adelina; Fichera, Laura E.</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1225-1233</span>CODEN:
                <span class="NLM_cas:coden">PARAAE</span>;
        ISSN:<span class="NLM_cas:issn">0031-1820</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">We evaluated the effect of chemotherapy with a sequential combined treatment of a low dose of benznidazole and allopurinol, in different schedules of administration, in exptl. models of acute and chronic Trypanosoma cruzi infection.  Mice were infected with Nicaragua T. cruzi isolate, a virulent parasite from an endemic area of Nicaragua, genotyped as TcI (Grosso et al. ).  We assessed survival rate, IgG levels, histopathol. studies and quantified parasitemia.  A 15% survival rate was recorded in untreated mice during the acute phase of T. cruzi infection.  Allopurinol administered immediately after benznidazole treatment was able to reduce parasitemia and attenuate tissue damage by reducing inflammation.  Trypanosoma cruzi-specific antibodies also decreased in 40-50% of the treated mice.  The addn. of allopurinol during the chronic phase showed the highest beneficial effect, not only by reducing parasitemia but also by lowering the degree of inflammation and fibrosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2L191XBdRfrVg90H21EOLACvtfcHk0ljhFCIK0AP9lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlCltr7L&md5=f64cd4f947f6831f22bbb3c3355afb65</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1017%2FS0031182013000176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182013000176%26sid%3Dliteratum%253Aachs%26aulast%3DGrosso%26aufirst%3DN.%2BL.%26aulast%3DAlarcon%26aufirst%3DM.%2BL.%26aulast%3DBua%26aufirst%3DJ.%26aulast%3DLaucella%26aufirst%3DS.%2BA.%26aulast%3DRiarte%26aufirst%3DA.%26aulast%3DFichera%26aufirst%3DL.%2BE.%26atitle%3DCombined%2520Treatment%2520with%2520Benznidazole%2520and%2520Allopurinol%2520in%2520Mice%2520Infected%2520with%2520a%2520Virulent%2520Trypanosoma%2520Cruzi%2520Isolate%2520from%2520Nicaragua%26jtitle%3DParasitology%26date%3D2013%26volume%3D140%26spage%3D1225%26epage%3D1233%26doi%3D10.1017%2FS0031182013000176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Mazliah, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lococo, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertocchi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albareda, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armenti, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarleton, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laucella, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viotti, R.</span></span> <span> </span><span class="NLM_article-title">Sequential Combined Treatment with Allopurinol and Benznidazole in the Chronic Phase of Trypanosoma Cruzi Infection: A Pilot Study</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">424</span>– <span class="NLM_lpage">437</span>, <span class="refDoi"> DOI: 10.1093/jac/dks390</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1093%2Fjac%2Fdks390" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=23104493" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXntVerug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=424-437&author=D.+E.+Perez-Mazliahauthor=M.+G.+Alvarezauthor=G.+Cooleyauthor=B.+E.+Lococoauthor=G.+Bertocchiauthor=M.+Pettiauthor=M.+C.+Albaredaauthor=A.+H.+Armentiauthor=R.+L.+Tarletonauthor=S.+A.+Laucellaauthor=R.+Viotti&title=Sequential+Combined+Treatment+with+Allopurinol+and+Benznidazole+in+the+Chronic+Phase+of+Trypanosoma+Cruzi+Infection%3A+A+Pilot+Study&doi=10.1093%2Fjac%2Fdks390"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study</span></div><div class="casAuthors">Perez-Mazliah, D. E.; Alvarez, M. G.; Cooley, G.; Lococo, B. E.; Bertocchi, G.; Petti, M.; Albareda, M. C.; Armenti, A. H.; Tarleton, R. L.; Laucella, S. A.; Viotti, R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">424-437</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: Even though the use of combined drugs has been proved to be effective in other chronic infections, assessment of combined treatment of antiparasitic drugs in human Chagas' disease has not been performed.  Herein, a pilot study was conducted to evaluate the tolerance and side effects of a sequential combined treatment of two antiparasitic drugs, allopurinol and benznidazole, in the chronic phase of Trypanosoma cruzi infection.  Patients and methods Changes in total and T. cruzi-specific T and B cells were monitored during a median follow-up of 36 mo.  Allopurinol was administered for 3 mo (600 mg/day) followed by 30 days of benznidazole (5 mg/kg/day) in 11 T. cruzi-infected subjects.  Results The combined sequential treatment of allopurinol and benznidazole was well tolerated.  The levels of T. cruzi-specific antibodies significantly decreased after sequential combined treatment, as detd. by conventional serol. and by a multiplex assay using recombinant proteins.  The frequency of T. cruzi-specific interferon-γ-producing T cells significantly increased after allopurinol treatment and decreased to background levels following benznidazole administration in a substantial proportion of subjects evaluated.  The levels of total naive (CD45RA + CCR7 + CD62L+) CD4 + and CD8 + T cells were restored after allopurinol administration and maintained after completion of the combined drug protocol, along with a decrease in T cell activation in total peripheral CD4 + and CD8 + T cells.  Conclusions This pilot study shows that the combination of allopurinol and benznidazole induces significant modifications in T and B cell responses indicative of a redn. in parasite burden, and sustains the feasibility of administration of two antiparasitic drugs in the chronic phase of Chagas' disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgcoMlINj1t7Vg90H21EOLACvtfcHk0ljhFCIK0AP9lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXntVerug%253D%253D&md5=2530fe5c18a45bd862bd6f85e23799b7</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdks390&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdks390%26sid%3Dliteratum%253Aachs%26aulast%3DPerez-Mazliah%26aufirst%3DD.%2BE.%26aulast%3DAlvarez%26aufirst%3DM.%2BG.%26aulast%3DCooley%26aufirst%3DG.%26aulast%3DLococo%26aufirst%3DB.%2BE.%26aulast%3DBertocchi%26aufirst%3DG.%26aulast%3DPetti%26aufirst%3DM.%26aulast%3DAlbareda%26aufirst%3DM.%2BC.%26aulast%3DArmenti%26aufirst%3DA.%2BH.%26aulast%3DTarleton%26aufirst%3DR.%2BL.%26aulast%3DLaucella%26aufirst%3DS.%2BA.%26aulast%3DViotti%26aufirst%3DR.%26atitle%3DSequential%2520Combined%2520Treatment%2520with%2520Allopurinol%2520and%2520Benznidazole%2520in%2520the%2520Chronic%2520Phase%2520of%2520Trypanosoma%2520Cruzi%2520Infection%253A%2520A%2520Pilot%2520Study%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2013%26volume%3D68%26spage%3D424%26epage%3D437%26doi%3D10.1093%2Fjac%2Fdks390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rial, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scalise, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">López Alarcón, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteva, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Búa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benatar, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prado, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riarte, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fichera, L. E.</span></span> <span> </span><span class="NLM_article-title">Experimental Combination Therapy Using Low Doses of Benznidazole and Allopurinol in Mouse Models of Trypanosoma Cruzi Chronic Infection</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">313</span>, <span class="refDoi"> DOI: 10.1017/S0031182018001567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1017%2FS0031182018001567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30301480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvFOitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2019&pages=305-313&author=M.+S.+Rialauthor=M.+L.+Scaliseauthor=M.+L%C3%B3pez+Alarc%C3%B3nauthor=M.+I.+Estevaauthor=J.+B%C3%BAaauthor=A.+F.+Benatarauthor=N.+G.+Pradoauthor=A.+R.+Riarteauthor=L.+E.+Fichera&title=Experimental+Combination+Therapy+Using+Low+Doses+of+Benznidazole+and+Allopurinol+in+Mouse+Models+of+Trypanosoma+Cruzi+Chronic+Infection&doi=10.1017%2FS0031182018001567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection</span></div><div class="casAuthors">Rial, Marcela Silvina; Scalise, Maria Lujan; Lopez Alarcon, Micaela; Esteva, Monica Ines; Bua, Jacqueline; Benatar, Alejandro Francisco; Prado, Nilda Graciela; Riarte, Adelina Rosa; Fichera, Laura Edith</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-313</span>CODEN:
                <span class="NLM_cas:coden">PARAAE</span>;
        ISSN:<span class="NLM_cas:issn">0031-1820</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">This study evaluated the effectiveness of low doses of benznidazole (BNZ) on continuous administration (BNZc), combined with allopurinol (ALO), in C57BL/6J and C3H/HeN mice infected with Trypanosoma cruzi Nicaragua strain and T. cruzi Sylvio-X10/4 clone.  TcN-C57BL/6J was also treated with intermittent doses of BNZ (BNZit).  The drug therapy started 3 mo post infection (pi) in the chronic phase of mice with heart disease progression, followed-up at 6 mo pi.  TcN-C57BL/6J treated with BNZc was also monitored up to 12 mo pi by serol. and ECG.  These mice showed severe elec. abnormalities, which were not obsd. after BNZc or BNZit.  ALO only showed pos. interaction with the lowest dose of BNZ.  A clear parasitic effect, with significant redns. in antibody titers and parasitic loads, was achieved in all models with low doses of BNZ, and a 25% redn. of the conventional dose showed more efficacy to inhibit the development of the pathol.  However, BNZ 75 showed partial efficacy in the TcSylvio-X10/4-C3H/HeN model.  In our exptl. designs, C57BL/6J allowed to clearly define a chronic phase, and through reproducible efficacy indicators, it can be considered a good preclin. model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocelUukkwBSbVg90H21EOLACvtfcHk0lgVrewWKGp8tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvFOitLo%253D&md5=9551e9f9b2c8ec872dd373627290ec25</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1017%2FS0031182018001567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182018001567%26sid%3Dliteratum%253Aachs%26aulast%3DRial%26aufirst%3DM.%2BS.%26aulast%3DScalise%26aufirst%3DM.%2BL.%26aulast%3DL%25C3%25B3pez%2BAlarc%25C3%25B3n%26aufirst%3DM.%26aulast%3DEsteva%26aufirst%3DM.%2BI.%26aulast%3DB%25C3%25BAa%26aufirst%3DJ.%26aulast%3DBenatar%26aufirst%3DA.%2BF.%26aulast%3DPrado%26aufirst%3DN.%2BG.%26aulast%3DRiarte%26aufirst%3DA.%2BR.%26aulast%3DFichera%26aufirst%3DL.%2BE.%26atitle%3DExperimental%2520Combination%2520Therapy%2520Using%2520Low%2520Doses%2520of%2520Benznidazole%2520and%2520Allopurinol%2520in%2520Mouse%2520Models%2520of%2520Trypanosoma%2520Cruzi%2520Chronic%2520Infection%26jtitle%3DParasitology%26date%3D2019%26volume%3D146%26spage%3D305%26epage%3D313%26doi%3D10.1017%2FS0031182018001567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casanova, M. A.</span></span> <span> </span><span class="NLM_article-title">Comparative Effects of 4-Aminopyrazolopyrimidine, Its 2′-Deoxyriboside Derivative, and Allopurinol on in Vitro Growth of American Leishmania Species</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1982</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">385</span>, <span class="refDoi"> DOI: 10.1128/AAC.22.3.380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.22.3.380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6982678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL38XlslylsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1982&pages=380-385&author=J.+L.+Avilaauthor=M.+A.+Casanova&title=Comparative+Effects+of+4-Aminopyrazolopyrimidine%2C+Its+2%E2%80%B2-Deoxyriboside+Derivative%2C+and+Allopurinol+on+in+Vitro+Growth+of+American+Leishmania+Species&doi=10.1128%2FAAC.22.3.380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative effects of 4-aminopyrazolopyrimidine, its 2'-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species</span></div><div class="casAuthors">Avila, Jose L.; Casanova, Maria A.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1982</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">380-5</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">When assayed on promastigotes of 10 American Leishmania isolates (including L. brasiliensis and L. mexicana), 4-aminopyrazolopyrimidine (APP) was severalfold more active than allopurinol (HPP) as a leishmanistatic drug.  There were some intraspecific and interspecific differences among the isolates in their susceptibility to the inhibitory effects of APP and allopurinol.  APP-2'-deoxyriboside did not affect the 10 isolates tested.  This was surprising, because allopurinol riboside has previously been shown to be more active than allopurinol.  In all of the American Leishmania isolates tested, the metab. of [14C]6-APP resulted in a high level of HPP-ribose-5'-P and lower levels of APP-ribose-5'-P, APP-ribose-5'-PP, and APP-ribose-5'-PPP.  MP, LR, LBY, and JAP isolates strongly converted APP into APP derivs., thus perhaps explaining their greater susceptibility to the inhibitory effects of APP.  With the 10 American Leishmania isolates tested, several purines reversed the inhibitory effects of HPP, but only adenine countered the inhibitory effects of APP.  This suggests biochem. differences in the mechanisms of action of HPP and APP.  Finally, and contrary to previous claims, the reversal by purines of the HPP-induced growth inhibition was not a Leishmania species-specific effect.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWCnonE7IZHrVg90H21EOLACvtfcHk0lgVrewWKGp8tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XlslylsLk%253D&md5=78ba3b1320b477b70702262f95c68246</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1128%2FAAC.22.3.380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.22.3.380%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DJ.%2BL.%26aulast%3DCasanova%26aufirst%3DM.%2BA.%26atitle%3DComparative%2520Effects%2520of%25204-Aminopyrazolopyrimidine%252C%2520Its%25202%25E2%2580%25B2-Deoxyriboside%2520Derivative%252C%2520and%2520Allopurinol%2520on%2520in%2520Vitro%2520Growth%2520of%2520American%2520Leishmania%2520Species%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1982%26volume%3D22%26spage%3D380%26epage%3D385%26doi%3D10.1128%2FAAC.22.3.380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revankar, G. R.</span></span> <span> </span><span class="NLM_article-title">Activity of Purine Analogs against Leishmania Tropica within Human Macrophages in Vitro</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1128/AAC.24.2.233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.24.2.233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6638989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3sXltlegsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1983&pages=233-236&author=J.+D.+Bermanauthor=L.+S.+Leeauthor=R.+K.+Robinsauthor=G.+R.+Revankar&title=Activity+of+Purine+Analogs+against+Leishmania+Tropica+within+Human+Macrophages+in+Vitro&doi=10.1128%2FAAC.24.2.233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of purine analogs against Leishmania tropica within human macrophages in vitro</span></div><div class="casAuthors">Berman, Jonathan D.; Lee, Linda S.; Robins, Roland K.; Revankar, Ganapathi R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-6</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The activity of purine analogs against L. tropica in human monocyte-derived macrophages in vitro was detd.  Formycin B  [13877-76-4], formycin A  [6742-12-7], their monophosphates, and formycin A triphosphate  [19495-11-5] all had ED50 of 0.02-0.04 μM and eliminated 90% of organisms at ≤0.5 μM.  Allopurinol ribonucleoside  [16220-07-8] was much less active; the ED50 was 76-190 μM.  7-Deazainosine  [2862-16-0] had a low ED50 (0.2 μM), but only 80% of organisms were eliminated at 4 μM.  Thio derivs. were as active as or less active than the parent compds.  Certain inosine analogs appear to be much more active than others against macrophage-contained Leishmania specie that are found in human lesions.  However, because toxicity to the human macrophage hosts generally paralleled antileishmanial activity, the more active compds. might also be more toxic to human cells.  The activity of 3-deazaguanosine (50% ED, 3.6 μM) in this model suggests that guanosine derivs. may have potential as antileishmanial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolOvj1aH11z7Vg90H21EOLACvtfcHk0lgVrewWKGp8tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXltlegsLk%253D&md5=7c0af1e0c9cf1b459849a062c50d2799</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1128%2FAAC.24.2.233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.24.2.233%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DJ.%2BD.%26aulast%3DLee%26aufirst%3DL.%2BS.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DRevankar%26aufirst%3DG.%2BR.%26atitle%3DActivity%2520of%2520Purine%2520Analogs%2520against%2520Leishmania%2520Tropica%2520within%2520Human%2520Macrophages%2520in%2520Vitro%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1983%26volume%3D24%26spage%3D233%26epage%3D236%26doi%3D10.1128%2FAAC.24.2.233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J.</span></span> <span> </span><span class="NLM_article-title">Purine Analogs as Chemotherapeutic Agents in Leishmaniasis and American Trypanosomiasis</span>. <i>J. Lab. Clin. Med.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">119</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1906917" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1KhsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=1991&pages=111-119&author=J.+Marr&title=Purine+Analogs+as+Chemotherapeutic+Agents+in+Leishmaniasis+and+American+Trypanosomiasis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis</span></div><div class="casAuthors">Marr, J. Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Laboratory and Clinical Medicine</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">111-19</span>CODEN:
                <span class="NLM_cas:coden">JLCMAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2143</span>.
    </div><div class="casAbstract">A review with 36 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_-WLUULNBu7Vg90H21EOLACvtfcHk0linxmn01GwNlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1KhsLc%253D&md5=909fb57d877c9d8d2227d939da69fb4c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMarr%26aufirst%3DJ.%26atitle%3DPurine%2520Analogs%2520as%2520Chemotherapeutic%2520Agents%2520in%2520Leishmaniasis%2520and%2520American%2520Trypanosomiasis%26jtitle%3DJ.%2520Lab.%2520Clin.%2520Med.%26date%3D1991%26volume%3D118%26spage%3D111%26epage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polegre, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span> <span> </span><span class="NLM_article-title">Biological Action of Pyrazolopyrimidine Derivatives against Trypanosoma Cruzi. Studies in Vitro and in Vivo</span>. <i>Comp. Biochem. Physiol., Part C: Comp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">54</span>, <span class="refDoi"> DOI: 10.1016/0742-8413(87)90143-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0742-8413%2887%2990143-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2881726" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=1987&pages=49-54&author=J.+Avilaauthor=M.+A.+Polegreauthor=R.+K.+Robins&title=Biological+Action+of+Pyrazolopyrimidine+Derivatives+against+Trypanosoma+Cruzi.+Studies+in+Vitro+and+in+Vivo&doi=10.1016%2F0742-8413%2887%2990143-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2F0742-8413%2887%2990143-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0742-8413%252887%252990143-5%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DPolegre%26aufirst%3DM.%2BA.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26atitle%3DBiological%2520Action%2520of%2520Pyrazolopyrimidine%2520Derivatives%2520against%2520Trypanosoma%2520Cruzi.%2520Studies%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DComp.%2520Biochem.%2520Physiol.%252C%2520Part%2520C%253A%2520Comp.%2520Pharmacol.%26date%3D1987%26volume%3D86%26spage%3D49%26epage%3D54%26doi%3D10.1016%2F0742-8413%2887%2990143-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polegre, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span> <span> </span><span class="NLM_article-title">Action of Pyrazolopyrimidine Derivatives on American Leishmania Spp. Promastigotes</span>. <i>Comp. Biochem. Physiol., Part C: Comp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">285</span>– <span class="NLM_lpage">289</span>, <span class="refDoi"> DOI: 10.1016/0742-8413(86)90124-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0742-8413%2886%2990124-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=2871990" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=285-289&author=J.+Avilaauthor=M.+A.+Polegreauthor=A.+Avilaauthor=R.+K.+Robins&title=Action+of+Pyrazolopyrimidine+Derivatives+on+American+Leishmania+Spp.+Promastigotes&doi=10.1016%2F0742-8413%2886%2990124-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2F0742-8413%2886%2990124-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0742-8413%252886%252990124-6%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DPolegre%26aufirst%3DM.%2BA.%26aulast%3DAvila%26aufirst%3DA.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26atitle%3DAction%2520of%2520Pyrazolopyrimidine%2520Derivatives%2520on%2520American%2520Leishmania%2520Spp.%2520Promastigotes%26jtitle%3DComp.%2520Biochem.%2520Physiol.%252C%2520Part%2520C%253A%2520Comp.%2520Pharmacol.%26date%3D1986%26volume%3D83%26spage%3D285%26epage%3D289%26doi%3D10.1016%2F0742-8413%2886%2990124-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avila, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mun̅oz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monzón, H.</span></span> <span> </span><span class="NLM_article-title">Trypanosoma Cruzi: 4-Aminopyrazolopyrimidine in the Treatment of Experimental Chagas’ Disease</span>. <i>Exp. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/0014-4894(83)90067-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0014-4894%2883%2990067-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6413238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2cXislE%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1983&pages=236-240&author=J.+Avilaauthor=A.+Avilaauthor=E.+Mun%CC%85ozauthor=H.+Monz%C3%B3n&title=Trypanosoma+Cruzi%3A+4-Aminopyrazolopyrimidine+in+the+Treatment+of+Experimental+Chagas%E2%80%99+Disease&doi=10.1016%2F0014-4894%2883%2990067-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Trypanosoma cruzi:  4-aminopyrazolopyrimidine in the treatment of experimental Chagas' disease</span></div><div class="casAuthors">Avila, Jose Luis; Avila, Angela; Munoz, Edgar; Monzon, Hector</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Parasitology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-40</span>CODEN:
                <span class="NLM_cas:coden">EXPAAA</span>;
        ISSN:<span class="NLM_cas:issn">0014-4894</span>.
    </div><div class="casAbstract">An allopurinol metabolite, 4-aminopyrazolopyrimidine (I)  [2380-63-4] was tested on 2 different strains of mice (NMRI-IVIC and C57B1/6J) that had been infected 4 days earlier with the virulent Ya strain of T. cruzi.  Low doses of 4-aminopyrazolopyrimidine (0.125-0.500 mg/kg daily for 10 days) decreased parasitemia and increased survival time, without any evidence of toxicity, compared with untreated animals.  When tested in vitro, 4-aminopyrazolopyrimidine was 6-fold more active than allopurinol as a trypanostatic drug.  The low therapeutic doses of 4-aminopyrazolopyrimidine suggest that this drug may be useful in the treatment of acute Chagas' disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP8o85VWcFO7Vg90H21EOLACvtfcHk0linxmn01GwNlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXislE%253D&md5=8021f22a66dfd87930828eb8072cd4a1</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2F0014-4894%2883%2990067-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-4894%252883%252990067-X%26sid%3Dliteratum%253Aachs%26aulast%3DAvila%26aufirst%3DJ.%26aulast%3DAvila%26aufirst%3DA.%26aulast%3DMun%25CC%2585oz%26aufirst%3DE.%26aulast%3DMonz%25C3%25B3n%26aufirst%3DH.%26atitle%3DTrypanosoma%2520Cruzi%253A%25204-Aminopyrazolopyrimidine%2520in%2520the%2520Treatment%2520of%2520Experimental%2520Chagas%25E2%2580%2599%2520Disease%26jtitle%3DExp.%2520Parasitol.%26date%3D1983%26volume%3D56%26spage%3D236%26epage%3D240%26doi%3D10.1016%2F0014-4894%2883%2990067-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnaro, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scortichini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Revisiting Tubercidin against Kinetoplastid Parasites: Aromatic Substitutions at Position 7 Improve Activity and Reduce Toxicity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>164</i></span>,  <span class="NLM_fpage">689</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.12.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ejmech.2018.12.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=30677668" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVWisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=164&publication_year=2019&pages=689-705&author=F.+Hulpiaauthor=G.+D.+Campagnaroauthor=M.+Scortichiniauthor=K.+Van+Heckeauthor=L.+Maesauthor=H.+P.+de+Koningauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=Revisiting+Tubercidin+against+Kinetoplastid+Parasites%3A+Aromatic+Substitutions+at+Position+7+Improve+Activity+and+Reduce+Toxicity&doi=10.1016%2Fj.ejmech.2018.12.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting tubercidin against kinetoplastid parasites: aromatic substitutions at position 7 improve activity and reduce toxicity</span></div><div class="casAuthors">Hulpia, Fabian; Campagnaro, Gustavo Daniel; Scortichini, Mirko; Van Hecke, Kristof; Maes, Louis; de Koning, Harry P.; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">164</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">689-705</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The nucleoside antibiotic tubercidin displays strong activity against different target organisms, but it is notoriously toxic to mammalian cells.  The effects of tubercidin against T. brucei parasites inspired us to synthesize several C7 substituted analogs for in vitro evaluation in order to find suitable hit compds.  C7 Deazaadenosines substituted with electron-poor Ph groups were found to have micromolar activity against T. brucei in vitro.  Replacement of the Ph for a pyridine ring gave compd. 13 (I), with submicromolar potency and much-attenuated cytotoxicity compared to tubercidin.  The veterinary pathogen T. congolense was equally affected by I in vitro.  Transporter studies in T. b. brucei indicated that I is taken up efficiently by both the P1 and P2 adenosine transporters, making the occurrence of transporter-related resistance and cross-resistance with diamidine drugs such as diminazene aceturate and pentamidine as well as with melaminophenyl arsenicals unlikely.  Evaluation of the in vitro metabolic stability of analog I indicated that this analog was significantly metabolized in mouse microsomal fractions, precluding further in vivo evaluation in mouse models of HAT.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgQp1BYeSEgrVg90H21EOLACvtfcHk0lhJUyLIFe1VFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVWisLg%253D&md5=a906448d453a9f56667c2383871ae7b1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.12.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.12.050%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DCampagnaro%26aufirst%3DG.%2BD.%26aulast%3DScortichini%26aufirst%3DM.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DRevisiting%2520Tubercidin%2520against%2520Kinetoplastid%2520Parasites%253A%2520Aromatic%2520Substitutions%2520at%2520Position%25207%2520Improve%2520Activity%2520and%2520Reduce%2520Toxicity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D164%26spage%3D689%26epage%3D705%26doi%3D10.1016%2Fj.ejmech.2018.12.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">França da Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Gama
Jaen Batista, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Nazaré
C. Soeiro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel 7-Aryl 7-Deazapurine 3′-Deoxy-Ribofuranosyl Nucleosides with Potent Activity against Trypanosoma Cruzi</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">9287</span>– <span class="NLM_lpage">9300</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00999</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00999" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKqtr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=9287-9300&author=F.+Hulpiaauthor=K.+Van+Heckeauthor=C.+Fran%C3%A7a+da+Silvaauthor=D.+da+Gama%0AJaen+Batistaauthor=L.+Maesauthor=G.+Caljonauthor=M.+de+Nazar%C3%A9%0AC.+Soeiroauthor=S.+Van+Calenbergh&title=Discovery+of+Novel+7-Aryl+7-Deazapurine+3%E2%80%B2-Deoxy-Ribofuranosyl+Nucleosides+with+Potent+Activity+against+Trypanosoma+Cruzi&doi=10.1021%2Facs.jmedchem.8b00999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel 7-Aryl 7-Deazapurine 3'-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi</span></div><div class="casAuthors">Hulpia, Fabian; Van Hecke, Kristof; Franca da Silva, Cristiane; da Gama Jaen Batista, Denise; Maes, Louis; Caljon, Guy; de Nazare C. Soeiro, Maria; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9287-9300</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Chagas disease is the leading cause of cardiac-related mortality in Latin American countries where it is endemic.  Trypanosoma cruzi, the disease-causing pathogen, is unable to synthesize purines de novo, necessitating salvage of preformed host purines.  Therefore, purine and purine-nucleoside analogs might constitute an attractive source for identifying antitrypanosomal hits.  In this study, structural elements of two purine-nucleoside analogs (i.e., cordycepin and a recently discovered 7-substituted 7-deazaadenosine) led to the identification of novel nucleoside analogs with potent in vitro activity.  The structure-activity relationships of substituents at C-7 were investigated, ultimately leading to the selection of compd. I, with a C-7 para-chlorophenyl group, for in vivo evaluation.  This deriv. showed complete suppression of T. cruzi Y-strain blood parasitemia when orally administered twice daily for 5 days at 25 mg/kg and was able to protect infected mice from parasite-induced mortality.  However, sterile cure by immunosuppression could not be demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu4_FX3ZIQTrVg90H21EOLACvtfcHk0lhJUyLIFe1VFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKqtr3J&md5=8f8e1c28b33a6c674a3a3b31ee2e5998</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00999%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DFran%25C3%25A7a%2Bda%2BSilva%26aufirst%3DC.%26aulast%3Dda%2BGama%2BJaen%2BBatista%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3Dde%2BNazar%25C3%25A9%2BC.%2BSoeiro%26aufirst%3DM.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Novel%25207-Aryl%25207-Deazapurine%25203%25E2%2580%25B2-Deoxy-Ribofuranosyl%2520Nucleosides%2520with%2520Potent%2520Activity%2520against%2520Trypanosoma%2520Cruzi%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D9287%26epage%3D9300%26doi%3D10.1021%2Facs.jmedchem.8b00999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnaro, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alzahrani, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfayez, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ungogo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Structure–Activity Relationship Exploration of 3′-Deoxy-7-Deazapurine Nucleoside Analogues as Anti-Trypanosoma Brucei Agents</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2045</span>– <span class="NLM_lpage">2056</span>, <span class="refDoi"> DOI: 10.1021/acsinfecdis.0c00105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.0c00105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Wms7vJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=2045-2056&author=F.+Hulpiaauthor=G.+D.+Campagnaroauthor=K.+J.+Alzahraniauthor=I.+A.+Alfayezauthor=M.+A.+Ungogoauthor=D.+Mabilleauthor=L.+Maesauthor=H.+P.+de+Koningauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=Structure%E2%80%93Activity+Relationship+Exploration+of+3%E2%80%B2-Deoxy-7-Deazapurine+Nucleoside+Analogues+as+Anti-Trypanosoma+Brucei+Agents&doi=10.1021%2Facsinfecdis.0c00105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship Exploration of 3'-Deoxy-7-deazapurine Nucleoside Analogues as Anti-Trypanosoma brucei Agents</span></div><div class="casAuthors">Hulpia, Fabian; Campagnaro, Gustavo D.; Alzahrani, Khalid J.; Alfayez, Ibrahim A.; Ungogo, Marzuq A.; Mabille, Dorien; Maes, Louis; de Koning, Harry P.; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2045-2056</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Human African trypanosomiasis is a neglected tropical disease caused by Trypanosoma brucei parasites.  These protists are unable to produce the purine ring, making them vulnerable to the effects of purine nucleoside analogs.  Starting from 3'-deoxytubercidin (5), a lead compd. with activity against central-nervous-stage human African trypanosomiasis, we investigate the structure-activity relationships of the purine and ribofuranose rings.  The purine ring tolerated only modifications at C7, while from the many alterations of the 3'-deoxyribofuranosyl moiety only the arabino analog 48 showed pronounced antitrypanosomal activity.  Profiling of the most potent analogs against resistant T. brucei strains (resistant to pentamidine, diminazene, and isometamidium) showed reduced dependence on uptake mediated by the P2 aminopurine transporter relative to 5.  The introduction of a 7-substituent confers up to 10-fold increased affinity for the P1 nucleoside transporter while generally retaining high affinity for P2.  Four of the most promising analogs were found to be metabolically stable, earmarking them as suitable backup analogs for lead 5.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo714RzopAMBrVg90H21EOLACvtfcHk0lhJUyLIFe1VFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Wms7vJ&md5=decf0a4b5ec9712a032589a7257f932b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.0c00105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.0c00105%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DCampagnaro%26aufirst%3DG.%2BD.%26aulast%3DAlzahrani%26aufirst%3DK.%2BJ.%26aulast%3DAlfayez%26aufirst%3DI.%2BA.%26aulast%3DUngogo%26aufirst%3DM.%2BA.%26aulast%3DMabille%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DStructure%25E2%2580%2593Activity%2520Relationship%2520Exploration%2520of%25203%25E2%2580%25B2-Deoxy-7-Deazapurine%2520Nucleoside%2520Analogues%2520as%2520Anti-Trypanosoma%2520Brucei%2520Agents%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2020%26volume%3D6%26spage%3D2045%26epage%3D2056%26doi%3D10.1021%2Facsinfecdis.0c00105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnaro, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schumann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roditi, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Combining Tubercidin and Cordycepin Scaffolds Results in Highly Active Candidates to Treat Late-Stage Sleeping Sickness</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">5564</span> <span class="refDoi"> DOI: 10.1038/s41467-019-13522-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1038%2Fs41467-019-13522-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=31804484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlGiu7fM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&author=F.+Hulpiaauthor=D.+Mabilleauthor=G.+D.+Campagnaroauthor=G.+Schumannauthor=L.+Maesauthor=I.+Roditiauthor=A.+Hoferauthor=H.+P.+de+Koningauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=Combining+Tubercidin+and+Cordycepin+Scaffolds+Results+in+Highly+Active+Candidates+to+Treat+Late-Stage+Sleeping+Sickness&doi=10.1038%2Fs41467-019-13522-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Combining tubercidin and cordycepin scaffolds results in highly active candidates to treat late-stage sleeping sickness</span></div><div class="casAuthors">Hulpia, Fabian; Mabille, Dorien; Campagnaro, Gustavo D.; Schumann, Gabriela; Maes, Louis; Roditi, Isabel; Hofer, Anders; de Koning, Harry P.; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5564</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">African trypanosomiasis is a disease caused by Trypanosoma brucei parasites with limited treatment options.  Trypanosoma is unable to synthesize purines de novo and relies solely on their uptake and interconversion from the host, constituting purine nucleoside analogs a potential source of antitrypanosomal agents.  Here we combine structural elements from known trypanocidal nucleoside analogs to develop a series of 3'-deoxy-7-deazaadenosine nucleosides, and investigate their effects against African trypanosomes.  3'-Deoxytubercidin is a highly potent trypanocide in vitro and displays curative activity in animal models of acute and CNS-stage disease, even at low doses and oral administration.  Whole-genome RNAi screening reveals that the P2 nucleoside transporter and adenosine kinase are involved in the uptake and activation, resp., of this analog.  This is confirmed by P1 and P2 transporter assays and nucleotide pool anal.  3'-Deoxytubercidin is promising lead to treat late-stage sleeping sickness.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr4E0Y-K3IH7Vg90H21EOLACvtfcHk0lj-GAK4CThiPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlGiu7fM&md5=61f38420017999128a9571aa55eed43a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-13522-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-13522-6%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DMabille%26aufirst%3DD.%26aulast%3DCampagnaro%26aufirst%3DG.%2BD.%26aulast%3DSchumann%26aufirst%3DG.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DRoditi%26aufirst%3DI.%26aulast%3DHofer%26aufirst%3DA.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DCombining%2520Tubercidin%2520and%2520Cordycepin%2520Scaffolds%2520Results%2520in%2520Highly%2520Active%2520Candidates%2520to%2520Treat%2520Late-Stage%2520Sleeping%2520Sickness%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26doi%3D10.1038%2Fs41467-019-13522-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campagnaro, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alfayez, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mabille, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Koning, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">C6–O-Alkylated 7-Deazainosine Nucleoside Analogues: Discovery of Potent and Selective Anti-Sleeping Sickness Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>, <span class="NLM_elocation-id">112018</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.112018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ejmech.2019.112018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=31931339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&author=F.+Hulpiaauthor=J.+Boutonauthor=G.+D.+Campagnaroauthor=I.+A.+Alfayezauthor=D.+Mabilleauthor=L.+Maesauthor=H.+P.+de+Koningauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=C6%E2%80%93O-Alkylated+7-Deazainosine+Nucleoside+Analogues%3A+Discovery+of+Potent+and+Selective+Anti-Sleeping+Sickness+Agents&doi=10.1016%2Fj.ejmech.2019.112018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">C6-O-alkylated 7-deazainosine nucleoside analogs: Discovery of potent and selective anti-sleeping sickness agents</span></div><div class="casAuthors">Hulpia, Fabian; Bouton, Jakob; Campagnaro, Gustavo D.; Alfayez, Ibrahim A.; Mabille, Dorien; Maes, Louis; de Koning, Harry P.; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112018</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">African trypanosomiasis, a deadly infectious disease caused by the protozoan Trypanosoma brucei spp., is spread to new hosts by bites of infected tsetse flies.  Currently approved therapies all have their specific drawbacks, prompting a search for novel therapeutic agents.  T. brucei lacks the enzymes necessary to forge the purine ring from amino acid precursors, rendering them dependent on the uptake and interconversion of host purines.  This dependency renders analogs of purines and corresponding nucleosides an interesting source of potential anti-T. brucei agents.  In this study, we synthesized and evaluated a series of 7-substituted 7-deazainosine derivs. and found that 6-O-alkylated analogs in particular showed highly promising in vitro activity with EC50 values in the mid-nanomolar range.  SAR investigation of the O-alkyl chain showed that antitrypanosomal activity increased, and also cytotoxicity, with alkyl chain length, at least in the linear alkyl chain series.  However, this could be attenuated by introducing a terminal branch point, resulting in the highly potent and selective analogs,, e.g. I.  No resistance related to transporter-mediated uptake could be identified, earmarking several of these analogs for further in vivo follow-up studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3Q09UHPQjMrVg90H21EOLACvtfcHk0lj-GAK4CThiPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjt7g%253D&md5=4e142ef05733e2036e70d4d3a7066544</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.112018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.112018%26sid%3Dliteratum%253Aachs%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3DBouton%26aufirst%3DJ.%26aulast%3DCampagnaro%26aufirst%3DG.%2BD.%26aulast%3DAlfayez%26aufirst%3DI.%2BA.%26aulast%3DMabille%26aufirst%3DD.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3Dde%2BKoning%26aufirst%3DH.%2BP.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DC6%25E2%2580%2593O-Alkylated%25207-Deazainosine%2520Nucleoside%2520Analogues%253A%2520Discovery%2520of%2520Potent%2520and%2520Selective%2520Anti-Sleeping%2520Sickness%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26doi%3D10.1016%2Fj.ejmech.2019.112018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furquim d’Almeida, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of 3′-Fluorinated 7-Deazapurine Nucleosides as Antikinetoplastid Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>216</i></span>, <span class="NLM_elocation-id">113290</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2021.113290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ejmech.2021.113290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=33667845" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3MXlslSlsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=216&publication_year=2021&author=J.+Boutonauthor=A.+Furquim+d%E2%80%99Almeidaauthor=L.+Maesauthor=G.+Caljonauthor=S.+Van+Calenberghauthor=F.+Hulpia&title=Synthesis+and+Evaluation+of+3%E2%80%B2-Fluorinated+7-Deazapurine+Nucleosides+as+Antikinetoplastid+Agents&doi=10.1016%2Fj.ejmech.2021.113290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of 3'-fluorinated 7-deazapurine nucleosides as antikinetoplastid agents</span></div><div class="casAuthors">Bouton, Jakob; Furquim d'Almeida, Arno; Maes, Louis; Caljon, Guy; Van Calenbergh, Serge; Hulpia, Fabian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">216</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113290</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Kinetoplastid parasites are the causative agents of neglected tropical diseases with an unmet medical need.  These parasites are unable to synthesize the purine ring de novo, and therefore rely on purine salvage to meet their purine demand.  Evaluating purine nucleoside analogs, e.g. I, is therefore an attractive strategy to identify antikinetoplastid agents.  Several anti-Trypanosoma cruzi and anti-Trypanosoma brucei 7-deazapurine nucleosides were previously discovered, with the removal of the 3'-hydroxyl group resulting in a significant boost in activity.  In this work we therefore decided to assess the effect of the introduction of a 3'-fluoro substituent in 7-deazapurine nucleosides on the anti-kinetoplastid activities.  Hence, we synthesized two series of 3'-deoxy-3'-fluororibofuranosyl and 3'-deoxy-3'-fluoroxylofuranosyl nucleosides comprising 7-deazaadenine and -hypoxanthine bases and assayed these for antiparasitic activity.  Several analogs with potent activity against T. cruzi and T. brucei were discovered, indicating that a fluorine atom in the 3'-position is a promising modification for the discovery of antiparasitic nucleosides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXyW0O-mOKLVg90H21EOLACvtfcHk0lj-GAK4CThiPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXlslSlsb8%253D&md5=dfb1b9ee4396909dff6f2cf3bbdff869</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2021.113290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2021.113290%26sid%3Dliteratum%253Aachs%26aulast%3DBouton%26aufirst%3DJ.%26aulast%3DFurquim%2Bd%25E2%2580%2599Almeida%26aufirst%3DA.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26aulast%3DHulpia%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%25203%25E2%2580%25B2-Fluorinated%25207-Deazapurine%2520Nucleosides%2520as%2520Antikinetoplastid%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D216%26doi%3D10.1016%2Fj.ejmech.2021.113290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovelace, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waits, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chapman, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R. S.</span></span> <span> </span><span class="NLM_article-title">Activity of Purine Analogs against Leishmania Donovani in Vivo</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1987</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1128/AAC.31.1.111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.31.1.111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=3566235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2sXpsFKgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=1987&pages=111-113&author=J.+D.+Bermanauthor=W.+L.+Hansonauthor=J.+K.+Lovelaceauthor=V.+B.+Waitsauthor=J.+E.+Jacksonauthor=W.+L.+Chapmanauthor=R.+S.+Klein&title=Activity+of+Purine+Analogs+against+Leishmania+Donovani+in+Vivo&doi=10.1128%2FAAC.31.1.111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of purine analogs against Leishmania donovani in vivo</span></div><div class="casAuthors">Berman, J. D.; Hanson, W. L.; Lovelace, J. K.; Waits, V. B.; Jackson, J. E.; Chapman, W. L., Jr.; Klein, R. S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1987</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-13</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The dose of orally administered 9-deazainosine  [89458-19-5] calcd. to suppress 50% of L. donovani amastigotes in hamster livers was 19 mg/kg per day; 99% of L. organisms were eliminated from the liver and spleen of squirrel monkeys by 50 mg/kg per day.  Because these activities were greater than that of the exptl. clin. agent allopurinol  [315-30-0] and comparable to that of the classical agent parenteral pentavalent antimony, 9-deazainosine should be considered for clin. development for visceral leishmaniasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-9Px_-xYhu7Vg90H21EOLACvtfcHk0lg344OQJjS7zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2sXpsFKgtw%253D%253D&md5=152a92ca73245a50c0f66810ba005938</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1128%2FAAC.31.1.111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.31.1.111%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DJ.%2BD.%26aulast%3DHanson%26aufirst%3DW.%2BL.%26aulast%3DLovelace%26aufirst%3DJ.%2BK.%26aulast%3DWaits%26aufirst%3DV.%2BB.%26aulast%3DJackson%26aufirst%3DJ.%2BE.%26aulast%3DChapman%26aufirst%3DW.%2BL.%26aulast%3DKlein%26aufirst%3DR.%2BS.%26atitle%3DActivity%2520of%2520Purine%2520Analogs%2520against%2520Leishmania%2520Donovani%2520in%2520Vivo%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1987%26volume%3D31%26spage%3D111%26epage%3D113%26doi%3D10.1128%2FAAC.31.1.111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keenan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamb, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanson, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waits, V. B.</span></span> <span> </span><span class="NLM_article-title">Leishmania Donovani: Oral Efficacy and Toxicity of Formycin B in the Infected Hamster</span>. <i>Exp. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1983</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">215</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1016/0014-4894(83)90065-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0014-4894%2883%2990065-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6617804" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3sXlvVOiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=1983&pages=215-221&author=J.+D.+Bermanauthor=C.+M.+Keenanauthor=S.+R.+Lambauthor=W.+L.+Hansonauthor=V.+B.+Waits&title=Leishmania+Donovani%3A+Oral+Efficacy+and+Toxicity+of+Formycin+B+in+the+Infected+Hamster&doi=10.1016%2F0014-4894%2883%2990065-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Leishmania donovani:  oral efficacy and toxicity of formycin B in the infected hamster</span></div><div class="casAuthors">Berman, J. D.; Keenan, C. M.; Lamb, S. R.; Hanson, W. L.; Waits, V. B.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Parasitology</span>
        (<span class="NLM_cas:date">1983</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">215-21</span>CODEN:
                <span class="NLM_cas:coden">EXPAAA</span>;
        ISSN:<span class="NLM_cas:issn">0014-4894</span>.
    </div><div class="casAbstract">After oral administration of formycin B  [13877-76-4] (13 mg/kg/day for 4 days) in hamsters infected with L. donovani there was an 85-92% redn. in nos. of parasites in livers of infected animals.  It efficacy by oral administration was approx. 4-8 times that by i.m. administration and 4 times that of the pos. control drug Glucantime by i.m. administration.  The levels of formycin B in serum after the final oral administration of 26 mg/kg/day were 1.4 μg/mL at 1 h and 0.3 μg/mL at 2 h.  The concn. in liver was greater (9.0 μg/mL at 1 h) and declined more slowly.  With this latter dosage or with 104 mg/kg/day there was no acute toxicity of formycin B to bone marrow or formed elements of the blood.  The only statistically significant toxicity to the liver was a doubling of serum total bilirubin levels.  Comparison of the in vivo efficacy of formycin B against L. donovani to the mild acute toxicity of the drug suggests that formycin B has potential as an oral agent against visceral leishmaniasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoteO0rPa_PKbVg90H21EOLACvtfcHk0lg344OQJjS7zQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3sXlvVOiurw%253D&md5=4dc1ef32ab7eb8eb14270af9e83e6c7d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2F0014-4894%2883%2990065-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-4894%252883%252990065-6%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DJ.%2BD.%26aulast%3DKeenan%26aufirst%3DC.%2BM.%26aulast%3DLamb%26aufirst%3DS.%2BR.%26aulast%3DHanson%26aufirst%3DW.%2BL.%26aulast%3DWaits%26aufirst%3DV.%2BB.%26atitle%3DLeishmania%2520Donovani%253A%2520Oral%2520Efficacy%2520and%2520Toxicity%2520of%2520Formycin%2520B%2520in%2520the%2520Infected%2520Hamster%26jtitle%3DExp.%2520Parasitol.%26date%3D1983%26volume%3D56%26spage%3D215%26epage%3D221%26doi%3D10.1016%2F0014-4894%2883%2990065-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rainey, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fox, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Secrist, J. A.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santi, D. V.</span></span> <span> </span><span class="NLM_article-title">Inosine Analogs as Anti-Leishmanial Agents</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>02</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">220</span>, <span class="refDoi"> DOI: 10.1023/A:1016360710842</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1023%2FA%3A1016360710842" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A280%3ADC%252BC2c3gsFClsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=02&publication_year=1985&pages=217-220&author=P.+Raineyauthor=P.+A.+Nolanauthor=L.+B.+Townsendauthor=R.+K.+Robinsauthor=J.+J.+Foxauthor=J.+A.+Secristauthor=D.+V.+Santi&title=Inosine+Analogs+as+Anti-Leishmanial+Agents&doi=10.1023%2FA%3A1016360710842"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Inosine analogs as anti-leishmanial agents</span></div><div class="casAuthors">Rainey P; Nolan P A; Townsend L B; Robins R K; Fox J J; Secrist Iii J A; Santi D V</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical research</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">217-20</span>
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    </div><div class="casAbstract">Several criteria were used to select a number of inosine analogs as potential growth inhibitors of the protozoan parasite Leishmania tropica.  Of nine compounds tested, seven showed a high degree of selective toxicity towards L. tropica promastigotes as compared to mouse L1210 cells; these include analogs of formycin B, 7-substituted analogs of 7-deazainosine and analogs of inosine in which the sugar moiety has been modified to confer metabolic stability.  The metabolism of 7-deazainosine in L. tropica promastigotes was shown to involve conversion to cytotoxic adenosine nucleotide analogs (tubercidin derivatives) that become incorporated into RNA.  The results suggest several new classes of compounds which have potential as anti-leishmanial agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTzuAgJjmR2jpPlX7E30qdzfW6udTcc2eYl-F6Tdep30bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2c3gsFClsQ%253D%253D&md5=af5f086cd38f852a5ce60a74bd9882b8</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1023%2FA%3A1016360710842&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1016360710842%26sid%3Dliteratum%253Aachs%26aulast%3DRainey%26aufirst%3DP.%26aulast%3DNolan%26aufirst%3DP.%2BA.%26aulast%3DTownsend%26aufirst%3DL.%2BB.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DFox%26aufirst%3DJ.%2BJ.%26aulast%3DSecrist%26aufirst%3DJ.%2BA.%26aulast%3DSanti%26aufirst%3DD.%2BV.%26atitle%3DInosine%2520Analogs%2520as%2520Anti-Leishmanial%2520Agents%26jtitle%3DPharm.%2520Res.%26date%3D1985%26volume%3D02%26spage%3D217%26epage%3D220%26doi%3D10.1023%2FA%3A1016360710842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohn, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, R. S.</span></span> <span> </span><span class="NLM_article-title">Biological Action of Inosine Analogs in <i>Leishmania</i> and <i>Trypanosoma Spp</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">292</span>– <span class="NLM_lpage">295</span>, <span class="refDoi"> DOI: 10.1128/AAC.25.2.292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.25.2.292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=6712205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2cXhsFSlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=292-295&author=J.+J.+Marrauthor=R.+L.+Berensauthor=N.+K.+Cohnauthor=D.+J.+Nelsonauthor=R.+S.+Klein&title=Biological+Action+of+Inosine+Analogs+in+Leishmania+and+Trypanosoma+Spp&doi=10.1128%2FAAC.25.2.292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Biological action of inosine analogs in Leishmania and Trypanosoma species</span></div><div class="casAuthors">Marr, J. Joseph; Berens, Randolph L.; Cohn, Naomi K.; Nelson, Donald J.; Klein, Robert S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">292-5</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    </div><div class="casAbstract">The 5-membered heterocyclic ring of 6 inosine analogs was systematically modified, and the compds. were tested for their antiprotozoal activities and toxicity to a mammalian cell line.  All 6 analogs were very active against the 3 protozoan pathogens L. donovani, T. cruzi, and T. gambiense.  Two of the drugs, 9-deazainosine (I)  [89458-19-5] and allopurinol ribonucleoside (II)  [16220-07-8], had very little toxicity for mouse L cells and offer promise as potential chemotherapeutic agents.  Structure-activity relations are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsYd6Nd5Mr_7Vg90H21EOLACvtfcHk0liaVnnXD26LKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXhsFSlsbw%253D&md5=b9ddab79ab0ca49a7d3f07a070dcefb7</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FAAC.25.2.292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.25.2.292%26sid%3Dliteratum%253Aachs%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DCohn%26aufirst%3DN.%2BK.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26aulast%3DKlein%26aufirst%3DR.%2BS.%26atitle%3DBiological%2520Action%2520of%2520Inosine%2520Analogs%2520in%2520Leishmania%2520and%2520Trypanosoma%2520Spp%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1984%26volume%3D25%26spage%3D292%26epage%3D295%26doi%3D10.1128%2FAAC.25.2.292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morishige, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aji, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wataya, Y.</span></span> <span> </span><span class="NLM_article-title">Leishmania Donovani: Pilot Study for Evaluation of Therapeutic Effects of Inosine Analogs against Amastigotes in Vitro and in Vivo</span>. <i>Exp. Parasitol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>80</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">671</span>, <span class="refDoi"> DOI: 10.1006/expr.1995.1082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1006%2Fexpr.1995.1082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=7758547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK2MXms1Sjtrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=1995&pages=665-671&author=K.+Morishigeauthor=T.+Ajiauthor=A.+Ishiiauthor=T.+Yasudaauthor=Y.+Wataya&title=Leishmania+Donovani%3A+Pilot+Study+for+Evaluation+of+Therapeutic+Effects+of+Inosine+Analogs+against+Amastigotes+in+Vitro+and+in+Vivo&doi=10.1006%2Fexpr.1995.1082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Leishmania donovani: pilot study for evaluation of therapeutic effects of inosine analogs against amastigotes in vitro and in vivo</span></div><div class="casAuthors">Morishige, Kazuhisa; Aji, Toshiki; Ishii, Akira; Yasuda, Tatsuji; Wataya, Yusuke</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Parasitology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">665-71</span>CODEN:
                <span class="NLM_cas:coden">EXPAAA</span>;
        ISSN:<span class="NLM_cas:issn">0014-4894</span>.
    </div><div class="casAbstract">The inhibition by carbocyclic inosine (C-Ino), 3'-deoxyinosine (3'-dI), and 3'-deoxy-3'-fluoroinosine (3'-FI) of Leishmania donovani amastigotes was examd.  J774.1 cells (a mouse macrophage line) were cultured in GIT medium with lipopolysaccharide and hemin and infected with the parasite.  C-Ino (3 μM) completely inhibited and 3'-dI (30 μM) reduced to 40% the infection rate on Day 6 after infection.  The std. pentostam (30 μM) resulted in a 38% infection rate.  The therapeutic efficacies of nonentrapped free and liposome-entrapped inosine analogs were tested in mice infected with L. donovani.  The mice were injected i.v. five times on alternate days, beginning 2 days after infection.  Treatment with the nonentrapped free inosine analog of C-Ino (100 mg/kg), 3'-dI (100 mg/kg), or 3'-FI (50 mg/kg) resulted in an LDU (Leishmania donovan units) that were 94, 68, or 73% lower, resp., than the control values.  Treatment with the corresponding entrapped inosine analog (10 mg/kg) caused decreases of 90, 69, or 68% LDU, resp.  The entrapped inosine analogs were inhibitory at doses one-fifth to one-tenth of the nonentrapped free inosine analogs.  C-Ino had the strongest inhibitory effect among the three analogs tested in vitro and in vivo.  Liposome-entrapped C-Ino had no severe side effects, although spleen wt. increased.  The agent may be useful as an antileishmanial drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooaYagQp298rVg90H21EOLACvtfcHk0liaVnnXD26LKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXms1Sjtrk%253D&md5=16ba864567913cfb3e51825eb0560284</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1006%2Fexpr.1995.1082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexpr.1995.1082%26sid%3Dliteratum%253Aachs%26aulast%3DMorishige%26aufirst%3DK.%26aulast%3DAji%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DA.%26aulast%3DYasuda%26aufirst%3DT.%26aulast%3DWataya%26aufirst%3DY.%26atitle%3DLeishmania%2520Donovani%253A%2520Pilot%2520Study%2520for%2520Evaluation%2520of%2520Therapeutic%2520Effects%2520of%2520Inosine%2520Analogs%2520against%2520Amastigotes%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DExp.%2520Parasitol.%26date%3D1995%26volume%3D80%26spage%3D665%26epage%3D671%26doi%3D10.1006%2Fexpr.1995.1082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 7-Halogenated 8-Aza-7-Deaza-2′-Deoxyguanosines and Related Pyrazolo[3,4-d]Pyrimidine 2′-Deoxyribonucleosides</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>1998</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1055/s-1998-4483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1055%2Fs-1998-4483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1998&publication_year=1998&pages=207-214&author=F.+Seelaauthor=G.+Becher&title=Synthesis+of+7-Halogenated+8-Aza-7-Deaza-2%E2%80%B2-Deoxyguanosines+and+Related+Pyrazolo%5B3%2C4-d%5DPyrimidine+2%E2%80%B2-Deoxyribonucleosides&doi=10.1055%2Fs-1998-4483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1055%2Fs-1998-4483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-1998-4483%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DBecher%26aufirst%3DG.%26atitle%3DSynthesis%2520of%25207-Halogenated%25208-Aza-7-Deaza-2%25E2%2580%25B2-Deoxyguanosines%2520and%2520Related%2520Pyrazolo%255B3%252C4-d%255DPyrimidine%25202%25E2%2580%25B2-Deoxyribonucleosides%26jtitle%3DSynthesis%26date%3D1998%26volume%3D1998%26spage%3D207%26epage%3D214%26doi%3D10.1055%2Fs-1998-4483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulauf, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of 7-Alkynylated 8-Aza-7-Deaza-2′-Deoxyadenosines via the Pd-Catalysed Cross-Coupling Reaction</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_fpage">3233</span>– <span class="NLM_lpage">3240</span>, <span class="refDoi"> DOI: 10.1039/A804706E</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1039%2Fa804706e" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK1cXmtVartbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&pages=3233-3240&author=F.+Seelaauthor=M.+Zulauf&title=Synthesis+of+7-Alkynylated+8-Aza-7-Deaza-2%E2%80%B2-Deoxyadenosines+via+the+Pd-Catalysed+Cross-Coupling+Reaction&doi=10.1039%2FA804706E"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of 7-alkynylated 8-aza-7-deaza-2'-deoxyadenosines via the Pd-catalyzed cross-coupling reaction</span></div><div class="casAuthors">Seela, Frank; Zulauf, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3233-3240</span>CODEN:
                <span class="NLM_cas:coden">JCPRB4</span>;
        ISSN:<span class="NLM_cas:issn">0300-922X</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis of 7-alkynylated 8-aza-7-deaza-adenine (pyrazolo[3,4-d]pyrimidine) 2'-deoxyribonucleosides is described.  Nucleobase anion-glycosylation of 8-aza-7-deaza-7-iodo-6-methoxy-purine with 2-deoxy-3,5-di-O-( p-toluoyl)-α-D-erythro-pentofuranosyl chloride furnishes the 8-aza-7-deaza-7-iodo-6-methoxy-purine N 1-β-D-2'-deoxyribonucleoside (I) as the main product (38% yield).  After detoluoylation of product I and amination the 7-bromo (II) and the 7-iodo derivs. of 8-aza-7-deaza-2'-deoxyadenosine were obtained.  Compd. II served as the starting material for a series of 7-alkynyl- or 7-alkenyl-8-aza-7-deaza-adenine 2'-deoxynucleoside by employing the Pd0/CuI-catalyzed cross-coupling reaction.  The 7-halogenated or 7-alkynylated nucleosides show a more stable glycosylic bond than does 8-aza-7-deaza-2'-deoxyadenosine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5FI62_2tZ77Vg90H21EOLACvtfcHk0liaVnnXD26LKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmtVartbo%253D&md5=ade5b3a0307ec2cc36929b6d7c102ec7</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1039%2Fa804706e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fa804706e%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DZulauf%26aufirst%3DM.%26atitle%3DSynthesis%2520of%25207-Alkynylated%25208-Aza-7-Deaza-2%25E2%2580%25B2-Deoxyadenosines%2520via%2520the%2520Pd-Catalysed%2520Cross-Coupling%2520Reaction%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1998%26spage%3D3233%26epage%3D3240%26doi%3D10.1039%2FA804706E" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mihich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simpson, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulhern, A. I.</span></span> <span> </span><span class="NLM_article-title">Comparative Study of the Toxicologic Effects of 7-Deazaadenosine (Tubercidin) and 7-Deazainosine</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1969</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">116</span>– <span class="NLM_lpage">123</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=5763972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaF1MXms1Gktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1969&pages=116-123&author=E.+Mihichauthor=C.+L.+Simpsonauthor=A.+I.+Mulhern&title=Comparative+Study+of+the+Toxicologic+Effects+of+7-Deazaadenosine+%28Tubercidin%29+and+7-Deazainosine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative study of the toxicologic effects of 7-deazaadenosine (tubercidin) and 7-deazainosine</span></div><div class="casAuthors">Mihich, Enrico; Simpson, C. L.; Mulhern, Aurelie I.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1969</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">116-23</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    </div><div class="casAbstract">Differences were found between the toxicologic effects of tubercidin (7-deazaadenosine) (I) and those of 7-deazainosine (II) which were consistent with the idea that II requires conversion into anabolites of I in order to exert biol. effects.  In rodents treated parenterally, and in dogs treated orally, I was 6-to 20-fold more toxic than II.  Severe local reactions occurred only in rats treated with I.  In contrast, necrosis of the walls of the intrahepatic bile ducts and of the myocardium was found only in rats treated with II.  Pulmonary edema, focal necrosis of hepatic parenchyma, and generalized lymphoid depression were observed after either drug.  After treatment of dogs with I, pneumonia, renal tubular necrosis, and gastrointestinal toxicity were severe, whereas hepatotoxicity was slight and infrequent.  In contrast, after treatment with II, hepatotoxicity was severe, whereas the other toxic effects were insignificant.  Only I caused atrophy of the islets of Langerhans.  Both compds. administered to dogs prolonged the prothrombin time while II increased the serum alk. phosphatase and glutamic oxalacetic transaminase activities.  In view of the lack of local and renal toxicity, II may offer therapeutic advantages over I provided that hepatotoxicity is not a limiting factor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-eNcIdqpln7Vg90H21EOLACvtfcHk0liaVnnXD26LKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1MXms1Gktg%253D%253D&md5=35b5c6b8a06c01302290bb2ba7c1fdc6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMihich%26aufirst%3DE.%26aulast%3DSimpson%26aufirst%3DC.%2BL.%26aulast%3DMulhern%26aufirst%3DA.%2BI.%26atitle%3DComparative%2520Study%2520of%2520the%2520Toxicologic%2520Effects%2520of%25207-Deazaadenosine%2520%2528Tubercidin%2529%2520and%25207-Deazainosine%26jtitle%3DCancer%2520Res.%26date%3D1969%26volume%3D29%26spage%3D116%26epage%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Earl, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, L. B.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyrimidine Nucleosides. Part VII. The Synthesis of Certain Pyrazolo [3,4-d] Pyrimidine Nucleosides Related to the Nucleoside Antibiotics Toyocamycin and Sangivamycin</span>. <i>J. Heterocycl. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1974</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1033</span>– <span class="NLM_lpage">1039</span>, <span class="refDoi"> DOI: 10.1002/jhet.5570110633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fjhet.5570110633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaE2MXhslWgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1974&pages=1033-1039&author=R.+A.+Earlauthor=L.+B.+Townsend&title=Pyrazolopyrimidine+Nucleosides.+Part+VII.+The+Synthesis+of+Certain+Pyrazolo+%5B3%2C4-d%5D+Pyrimidine+Nucleosides+Related+to+the+Nucleoside+Antibiotics+Toyocamycin+and+Sangivamycin&doi=10.1002%2Fjhet.5570110633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyrimidine nucleosides.  VII.  Synthesis of certain pyrazolo[3,4-d]pyrimidine nucleosides related to the nucleoside antibiotics toyocamycin and sangivamycin</span></div><div class="casAuthors">Earl, Robert A.; Townsend, Leroy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Heterocyclic Chemistry</span>
        (<span class="NLM_cas:date">1974</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1033-9</span>CODEN:
                <span class="NLM_cas:coden">JHTCAD</span>;
        ISSN:<span class="NLM_cas:issn">0022-152X</span>.
    </div><div class="casAbstract">The condensation of 4-acetamido-3-cyanopyrazolo[3,4-d]pyrimidine with 2,3,5-tri-O-acetyl-β-D-ribofuranosyl chloride, which evolved copius amts. of HCN, was followed by treatment with NaOMe in MeOH to give Me 4-amino-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine-3-formimidate monohydrate (I).  The formimidate function of I was highly reactive and was readily converted into the corresponding carboxamidine, carboxamidoxime, and carboxamidrazone.  Treatment of I with NaHS gave a high yield of the thiocarboxamide, which was then converted into 4-amino-3-cyano-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine.  Aq. base transformed I into 4-amino-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine-3-carboxamide while more vigorous basic hydrolysis gave the corresponding carboxylic acid (II) in nearly quant. yield.  Decarboxylation of II in hot sulfolane gave 68% 4-amino-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine which established the site of ribosylation and anomeric configuration for all nucleosides reported in this investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTexWyTEDBXrVg90H21EOLACvtfcHk0lgVqpTI8OfgQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2MXhslWgsbc%253D&md5=1618d764d9d969f5267a04c9b545eb15</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fjhet.5570110633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjhet.5570110633%26sid%3Dliteratum%253Aachs%26aulast%3DEarl%26aufirst%3DR.%2BA.%26aulast%3DTownsend%26aufirst%3DL.%2BB.%26atitle%3DPyrazolopyrimidine%2520Nucleosides.%2520Part%2520VII.%2520The%2520Synthesis%2520of%2520Certain%2520Pyrazolo%2520%255B3%252C4-d%255D%2520Pyrimidine%2520Nucleosides%2520Related%2520to%2520the%2520Nucleoside%2520Antibiotics%2520Toyocamycin%2520and%2520Sangivamycin%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1974%26volume%3D11%26spage%3D1033%26epage%3D1039%26doi%3D10.1002%2Fjhet.5570110633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frye, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukui, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawrelak, S. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activity of Pyrazolo[3,4-d]Pyrimidine Nucleosides and Nucleotides Related to Tubercidin, Toyocamycin, and Sangivamycin</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1005</span>– <span class="NLM_lpage">1015</span>, <span class="refDoi"> DOI: 10.1021/bi00650a010</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00650a010" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaE28XhsF2msbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1976&pages=1005-1015&author=S.+M.+Hechtauthor=R.+B.+Fryeauthor=D.+Wernerauthor=T.+Fukuiauthor=S.+D.+Hawrelak&title=Synthesis+and+Biological+Activity+of+Pyrazolo%5B3%2C4-d%5DPyrimidine+Nucleosides+and+Nucleotides+Related+to+Tubercidin%2C+Toyocamycin%2C+and+Sangivamycin&doi=10.1021%2Fbi00650a010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activity of pyrazolo[3,4-d]pyrimidine nucleosides and nucleotides related to tubercidin, toyocamycin, and sangivamycin</span></div><div class="casAuthors">Hecht, Sidney M.; Frye, R. Bruce; Werner, Dieter; Fukui, Toshikazu; Hawrelak, S. D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1005-15</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    </div><div class="casAbstract">Title compd. 6-azasangivamycin (I) [55559-56-3] was prepd. from its O-acetylated precursor, while 6-azatoyocamycin (II) [55559-55-2] was prepd. via 4-amino-1-(β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine-3-thiocarboxamide (III) [55559-54-1].  III was more cytotoxic to the growth of mouse fibroblasts than 6-azatubercidin (IV) [3258-05-7], killing 3T6 cells at ≤1 μg/ml.  III was a substrate for adenosine deaminase from calf intestinal mucosa with an apparent Km of 125, and 6-azatubercidin 5'-diphosphate triethylammonium salt [59032-36-9] was polymerized by polynucleotide phosphorylase to a homopolymer and copolymers with adenosine.  The copolymers directed the binding of lysyl-tRNA to the A-site of ribosomes from Escherichia coli.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7MZhUq0EYtrVg90H21EOLACvtfcHk0lgVqpTI8OfgQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XhsF2msbw%253D&md5=fd25c80355b0f12d09f471226be05b4f</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fbi00650a010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00650a010%26sid%3Dliteratum%253Aachs%26aulast%3DHecht%26aufirst%3DS.%2BM.%26aulast%3DFrye%26aufirst%3DR.%2BB.%26aulast%3DWerner%26aufirst%3DD.%26aulast%3DFukui%26aufirst%3DT.%26aulast%3DHawrelak%26aufirst%3DS.%2BD.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520Pyrazolo%255B3%252C4-d%255DPyrimidine%2520Nucleosides%2520and%2520Nucleotides%2520Related%2520to%2520Tubercidin%252C%2520Toyocamycin%252C%2520and%2520Sangivamycin%26jtitle%3DBiochemistry%26date%3D1976%26volume%3D15%26spage%3D1005%26epage%3D1015%26doi%3D10.1021%2Fbi00650a010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montero, J. L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panzica, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wotring, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, L. B.</span></span> <span> </span><span class="NLM_article-title">Pyrazolopyrimidine Nucleosides. 12. Synthesis and Biological Activity of Certain Pyrazolo[3,4-d]Pyrimidine Nucleosides Related to Adenosine</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1165</span>– <span class="NLM_lpage">1172</span>, <span class="refDoi"> DOI: 10.1021/jm00142a009</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00142a009" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3MXlt1GrtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=1165-1172&author=G.+A.+Bhatauthor=J.+L.+G.+Monteroauthor=R.+P.+Panzicaauthor=L.+L.+Wotringauthor=L.+B.+Townsend&title=Pyrazolopyrimidine+Nucleosides.+12.+Synthesis+and+Biological+Activity+of+Certain+Pyrazolo%5B3%2C4-d%5DPyrimidine+Nucleosides+Related+to+Adenosine&doi=10.1021%2Fjm00142a009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolopyrimidine nucleosides.  12.  Synthesis and biological activity of certain pyrazolo[3,4-d]pyrimidine nucleosides related to adenosine</span></div><div class="casAuthors">Bhat, Ganapati A.; Montero, Jean Louis G.; Panzica, Raymond P.; Wotring, Linda L.; Townsend, Leroy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1165-72</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Twenty-six title compds., 13 of which were synthesized, were tested for antitumor activity against mouse L1210 leukemia cells both in vitro and in vivo and against P388 leukemia cells in vivo.  I  [3258-05-7] and II  [78586-44-4] showed the greatest inhibition of growth of L1210 cells in vitro, with the activity of II probably resulting from the formation of I by hydrolysis in the aq. medium.  Any alteration of the C4-amino substituent of I resulted in a decrease or loss of antitumor activity.  Certain substitutions at the C3 position of I resulted in compds. with a better antitumor activity than I.  III  [55559-56-3] was the most active compd. giving an increase in life-span of 136% (vs. 48% for I) in L1210-bearing mice and having a significant lethal effect on L1210 cells in vitro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNkThbjLtDvbVg90H21EOLACvtfcHk0lgVqpTI8OfgQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXlt1GrtLw%253D&md5=0b38aaeb90bb57872c8766e7eca35d8b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm00142a009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00142a009%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DG.%2BA.%26aulast%3DMontero%26aufirst%3DJ.%2BL.%2BG.%26aulast%3DPanzica%26aufirst%3DR.%2BP.%26aulast%3DWotring%26aufirst%3DL.%2BL.%26aulast%3DTownsend%26aufirst%3DL.%2BB.%26atitle%3DPyrazolopyrimidine%2520Nucleosides.%252012.%2520Synthesis%2520and%2520Biological%2520Activity%2520of%2520Certain%2520Pyrazolo%255B3%252C4-d%255DPyrimidine%2520Nucleosides%2520Related%2520to%2520Adenosine%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26spage%3D1165%26epage%3D1172%26doi%3D10.1021%2Fjm00142a009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cottam, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrie, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKernan, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goebel, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kent
Dailey, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robins, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Revanka, G. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Activity of Certain 3,4-Disubstituted Pyrazolo[3,4-d]Pyrimidine Nucleosides1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1119</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/jm00375a006</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00375a006" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2cXkvFWgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1984&pages=1119-1127&author=H.+B.+Cottamauthor=C.+R.+Petrieauthor=P.+A.+McKernanauthor=R.+J.+Goebelauthor=N.+Kent%0ADaileyauthor=R.+B.+Davidsonauthor=R.+K.+Robinsauthor=G.+R.+Revanka&title=Synthesis+and+Biological+Activity+of+Certain+3%2C4-Disubstituted+Pyrazolo%5B3%2C4-d%5DPyrimidine+Nucleosides1&doi=10.1021%2Fjm00375a006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological activity of certain 3,4-disubstituted pyrazolo[3,4-d]pyrimidine nucleosides</span></div><div class="casAuthors">Cottam, Howard B.; Petrie, Charles R.; McKernan, Patricia A.; Goebel, Richard J.; Dalley, N. Kent; Davidson, Richard B.; Robins, Roland K.; Revankar, Ganapathi R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1119-27</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Several title ribonucleosides, e.g., I [R = Br, cyano, SMe, NH2, NHMe, NMe2, CONH2, CSNH2, C(:NH)NH2, C(:NOH)NH2; R1 = H, Bz; Z = O, S], were prepd.  I (R = Br, cyano; R1 = Bz; Z = O), obtained by glycosylation of the corresponding heterocycles with 1-O-acetyl-2,3,5-tri-O-benzoyl-D-ribofuranose, were the key intermediates.  The structural assignment of I (R = cyano, R1 = H, Z = O) was made by single crystal x-ray anal.  All the compds. were tested in vitro against certain viruses, tumor cells, and the parasite Leishmania tropica.  I [R = CSNH2, C(:NH)NH2; R1 = H; Z = O] showed significant activity against Para 3 virus and were potent inhibitors of growth of L1210 and P388 leukemia.  I (R = cyano, R1 = H, Z = S) showed the most significant broad-spectrum antiviral and antitumor activity.  I (R = Br, R1 = H, Z = O) was more active than allopurinol riboside against L. tropica within human macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg-_RdnCVReLVg90H21EOLACvtfcHk0ljeoq9q24FYjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXkvFWgu78%253D&md5=ad58d842b752d38bb441fd0cc4355890</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm00375a006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00375a006%26sid%3Dliteratum%253Aachs%26aulast%3DCottam%26aufirst%3DH.%2BB.%26aulast%3DPetrie%26aufirst%3DC.%2BR.%26aulast%3DMcKernan%26aufirst%3DP.%2BA.%26aulast%3DGoebel%26aufirst%3DR.%2BJ.%26aulast%3DKent%2BDailey%26aufirst%3DN.%26aulast%3DDavidson%26aufirst%3DR.%2BB.%26aulast%3DRobins%26aufirst%3DR.%2BK.%26aulast%3DRevanka%26aufirst%3DG.%2BR.%26atitle%3DSynthesis%2520and%2520Biological%2520Activity%2520of%2520Certain%25203%252C4-Disubstituted%2520Pyrazolo%255B3%252C4-d%255DPyrimidine%2520Nucleosides1%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1984%26volume%3D27%26spage%3D1119%26epage%3D1127%26doi%3D10.1021%2Fjm00375a006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span> <span> </span><span class="NLM_article-title">1,N6-Etheno-7-Deaza-2,8-Diazaadenosine: Syntheses, Properties and Conversion to 7-Deaza-2,8-Diazaadenosine</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1714</span>– <span class="NLM_lpage">1718</span>, <span class="refDoi"> DOI: 10.1039/B418849G</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1039%2Fb418849g" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=15858655" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjslGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=1714-1718&author=W.+Linauthor=H.+Liauthor=X.+Mingauthor=F.+Seela&title=1%2CN6-Etheno-7-Deaza-2%2C8-Diazaadenosine%3A+Syntheses%2C+Properties+and+Conversion+to+7-Deaza-2%2C8-Diazaadenosine&doi=10.1039%2FB418849G"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">1,N6-Etheno-7-deaza-2,8-diazaadenosine: syntheses, properties and conversion to 7-deaza-2,8-diazaadenosine</span></div><div class="casAuthors">Lin, Wenqing; Li, Hong; Ming, Xin; Seela, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1714-1718</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">1,N6-Etheno-7-deaza-2,8-diazaadenosine (I) was synthesized from 8-aza-7-deazaadenosine (II) in 64% overall yield.  The starting material II was obtained by the direct glycosylation of 8-aza-7-deazaadenine with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (NO2CH3, BF3·Et2O; 77% yield).  I was transformed into 7-deaza-2,8-diazaadenosine.  The fluorescence of I shows an emission max. at 531 nm (phosphate buffer; pH 7.0), which is bathochromically shifted compared to 1,N6-etheno-2-azaadenosine (495 nm).  A conformational anal. was performed in the solid state and in soln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBlDpC-2HSjLVg90H21EOLACvtfcHk0ljeoq9q24FYjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjslGqt7c%253D&md5=802b13104d61e3d467db286eb6b1e87e</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1039%2Fb418849g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb418849g%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DMing%26aufirst%3DX.%26aulast%3DSeela%26aufirst%3DF.%26atitle%3D1%252CN6-Etheno-7-Deaza-2%252C8-Diazaadenosine%253A%2520Syntheses%252C%2520Properties%2520and%2520Conversion%2520to%25207-Deaza-2%252C8-Diazaadenosine%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2005%26volume%3D3%26spage%3D1714%26epage%3D1718%26doi%3D10.1039%2FB418849G" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steker, H.</span></span> <span> </span><span class="NLM_article-title">Facile Synthesis of 2′-Deoxyribofuranosides of Allopurinol and 4-Amino-1H-Pyrazolo[3,4-d]Pyrimidine via Phase-Transfer Glycosylation</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1985</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">563</span>– <span class="NLM_lpage">570</span>, <span class="refDoi"> DOI: 10.1002/hlca.19850680305</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fhlca.19850680305" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL2MXmtFGlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1985&pages=563-570&author=F.+Seelaauthor=H.+Steker&title=Facile+Synthesis+of+2%E2%80%B2-Deoxyribofuranosides+of+Allopurinol+and+4-Amino-1H-Pyrazolo%5B3%2C4-d%5DPyrimidine+via+Phase-Transfer+Glycosylation&doi=10.1002%2Fhlca.19850680305"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Facile synthesis of 2'-deoxyribofuranosides of allopurinol and 4-amino-1H-pyrazolo[3,4-d]pyrimidine via phase-transfer glycosylation</span></div><div class="casAuthors">Seela, Frank; Steker, Herbert</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">563-70</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    </div><div class="casAbstract">Phase-transfer glycosylation of 4-methoxy-1H-pyrazolo[3,4-d]pyrimidine with 2-deoxy-3,5-di-O-p-toluoyl-α-D-erythro-pentofuranosyl chloride gave the N-1-β-nucleoside I (R = p-MeC6H4CO), its α-D-anomer, and N-2 isomer II (R = p-MeC6H4CO) in 39, 7, and 17.7% yield resp.  These were deacylated with NaOMe/MeOH.  Nucleophilic displacement of the 4-MeO group of I (R = H) and II gave allopurinol and aminopyrazolopyrimidine nucleosides, e.g., I (R = H) gave III and IV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrX2HklglFNZbVg90H21EOLACvtfcHk0ljeoq9q24FYjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXmtFGlu7s%253D&md5=9475720d8e64430c551414ee4bd02bb5</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19850680305&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19850680305%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DSteker%26aufirst%3DH.%26atitle%3DFacile%2520Synthesis%2520of%25202%25E2%2580%25B2-Deoxyribofuranosides%2520of%2520Allopurinol%2520and%25204-Amino-1H-Pyrazolo%255B3%252C4-d%255DPyrimidine%2520via%2520Phase-Transfer%2520Glycosylation%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1985%26volume%3D68%26spage%3D563%26epage%3D570%26doi%3D10.1002%2Fhlca.19850680305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lichtenthaler, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuny, E.</span></span> <span> </span><span class="NLM_article-title">Nucleosides, 381) The Ribonucleosides of Allopurinol</span>. <i>Chem. Ber.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">1610</span>– <span class="NLM_lpage">1623</span>, <span class="refDoi"> DOI: 10.1002/cber.19811140505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fcber.19811140505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3MXks1amtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=1981&pages=1610-1623&author=F.+W.+Lichtenthalerauthor=E.+Cuny&title=Nucleosides%2C+381%29+The+Ribonucleosides+of+Allopurinol&doi=10.1002%2Fcber.19811140505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleosides.  38.  The ribonucleosides of allopurinol</span></div><div class="casAuthors">Lichtenthaler, Frieder W.; Cuny, Eckehard</div><div class="citationInfo"><span class="NLM_cas:title">Chemische Berichte</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1610-23</span>CODEN:
                <span class="NLM_cas:coden">CHBEAM</span>;
        ISSN:<span class="NLM_cas:issn">0009-2940</span>.
    </div><div class="casAbstract">Nucleosides I [R = β-D-ribofuranosyl (Q), R1 = H; R = R1 = Q; R = H, R1 = Q] and II (R2 = R3 = Q; R2 = H, R3 = Q) were prepd. via SnCl4-catalyzed glycosylation of 1-(trimethylsilyl)-4-(trimethylsilyloxy)-1H-pyrazolo[3,4-d]-pyrimidine with acylated ribofuranoses.  CF3SO3SiMe3 as catalyst in addn. produced a O-4-ribosylated compd.  Structures of the products were confirmed by UV and NMR spectroscopy.  The properties of the prepd. nucleosides as inhibitors and/or substrates for xanthine oxidase are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXUBStE6K2vLVg90H21EOLACvtfcHk0ljKel_iqDeQBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXks1amtb0%253D&md5=9bdb49c8be54908bd40ae4acbd4cb41f</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1002%2Fcber.19811140505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19811140505%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenthaler%26aufirst%3DF.%2BW.%26aulast%3DCuny%26aufirst%3DE.%26atitle%3DNucleosides%252C%2520381%2529%2520The%2520Ribonucleosides%2520of%2520Allopurinol%26jtitle%3DChem.%2520Ber.%26date%3D1981%26volume%3D114%26spage%3D1610%26epage%3D1623%26doi%3D10.1002%2Fcber.19811140505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zulauf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becher, G.</span></span> <span> </span><span class="NLM_article-title">Unexpected Dehalogenation of 3-Bromopyrazolo[3,4-d]Pyrimidine Nucleosides during Nucleobase-Anion Glycosylation</span>. <i>Nucleosides Nucleotides</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">305</span>– <span class="NLM_lpage">314</span>, <span class="refDoi"> DOI: 10.1080/07328319708001351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1080%2F07328319708001351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK2sXjtVWltLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=305-314&author=F.+Seelaauthor=M.+Zulaufauthor=G.+Becher&title=Unexpected+Dehalogenation+of+3-Bromopyrazolo%5B3%2C4-d%5DPyrimidine+Nucleosides+during+Nucleobase-Anion+Glycosylation&doi=10.1080%2F07328319708001351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Unexpected dehalogenation of 3-bromopyrazolo[3,4-d]pyrimidine nucleosides during nucleobase-anion glycosylation</span></div><div class="casAuthors">Seela, Frank; Zulauf, Matthias; Becher, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Nucleosides & Nucleotides</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">305-314</span>CODEN:
                <span class="NLM_cas:coden">NUNUD5</span>;
        ISSN:<span class="NLM_cas:issn">0732-8311</span>.
    
            (<span class="NLM_cas:orgname">Dekker</span>)
        </div><div class="casAbstract">The anion-glycosidation (KOH, MeCN, TDA-1) of 3-bromopyrazolo[3,4-d]-pyrimidines and with 2-deoxy-3,5-di-O-(p-toluoyl)-α-D-erythro-pentofuranosyl chloride furnishes the regioisomeric N1-β-D-2'-deoxyribonucleosides together with the dehalogenated N2-regioisomers.  The dehalogenation takes place after the glycosylation and results from the sensitivity of the N-2 nucleosides toward aq. base.  An addn./elimination mechanism is suggested for the dehalogenation reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyWtVyyJ43XLVg90H21EOLACvtfcHk0ljKel_iqDeQBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXjtVWltLg%253D&md5=432705032d5b9102ddcda4731386ef3d</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1080%2F07328319708001351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07328319708001351%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DZulauf%26aufirst%3DM.%26aulast%3DBecher%26aufirst%3DG.%26atitle%3DUnexpected%2520Dehalogenation%2520of%25203-Bromopyrazolo%255B3%252C4-d%255DPyrimidine%2520Nucleosides%2520during%2520Nucleobase-Anion%2520Glycosylation%26jtitle%3DNucleosides%2520Nucleotides%26date%3D1997%26volume%3D16%26spage%3D305%26epage%3D314%26doi%3D10.1080%2F07328319708001351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaiser, K.</span></span> <span> </span><span class="NLM_article-title">8-Aza-7-deazaadenine N8- and N8-(B-D-2′-Deoxyribofuranosides): Building Blocks for Automated DNA Synthesis and Properties of Oligodeoxyribonucleotides</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">1813</span>– <span class="NLM_lpage">1823</span>, <span class="refDoi"> DOI: 10.1002/hlca.19880710723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fhlca.19880710723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL1MXhsFCku70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1988&pages=1813-1823&author=F.+Seelaauthor=K.+Kaiser&title=8-Aza-7-deazaadenine+N8-+and+N8-%28B-D-2%E2%80%B2-Deoxyribofuranosides%29%3A+Building+Blocks+for+Automated+DNA+Synthesis+and+Properties+of+Oligodeoxyribonucleotides&doi=10.1002%2Fhlca.19880710723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">8-Aza-7-deazaadenine N8-and N9-(β-D-2'-deoxyribofuranosides):  building blocks for automated DNA synthesis and properties of oligodeoxyribonucleotides</span></div><div class="casAuthors">Seela, Frank; Kaiser, Klaus</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1813-23</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    </div><div class="casAbstract">Oligonucleotides with alternating 8-aza-7-deaza-2'-deoxyadenosine (=c7z8Ad I) and dT residues or 4-aminopyrazolo[3,4-d]pyrimidine N2-(β-D-2'-deoxyibofuranoside) (=c7z8A'd1); II and dT residues have been prepd. by solid-phase synthesis using P(III) chem.  Addnl., palindromic oligomers derived from d(C-T-G-G-A-T-C-C-A-G) but contg. I or II instead of dA have been synthesized.  Benzoylation of I or II followed by 4,4'-dimethoxytritylation and subsequent phosphitylation yielded the Me or the cyanoethyl phosphoramidites.  They were employed in automated DNA synthesis.  Alternating oligomers contg. I or II showed increase dTm values compared to those with dA, in particular d(c7z8a'-t)3 with an unusual N2-glycosylic bond.  The palindromic oligomers contg. I or II instead of dA were used as sequence-specific probes in endonuclease Sau 3A phosphodiester hydrolysis.  Whereas replacement of dA outside of the enzymic recognition side reduced the hydrolysis rate, replacement within d(G-A-T-C) abolished phosphodiester hydrolysis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoK512se57cmbVg90H21EOLACvtfcHk0ljKel_iqDeQBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXhsFCku70%253D&md5=9d4d0ae2624f093ea76daccd22038598</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19880710723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19880710723%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DKaiser%26aufirst%3DK.%26atitle%3D8-Aza-7-deazaadenine%2520N8-%2520and%2520N8-%2528B-D-2%25E2%2580%25B2-Deoxyribofuranosides%2529%253A%2520Building%2520Blocks%2520for%2520Automated%2520DNA%2520Synthesis%2520and%2520Properties%2520of%2520Oligodeoxyribonucleotides%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1988%26volume%3D71%26spage%3D1813%26epage%3D1823%26doi%3D10.1002%2Fhlca.19880710723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, M.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[3,4-d]Pyrimidine 2′ -Deoxy- and 2′,3′ -Dideoxyribonucleosides: Studies on the Glycosylation of 4-Methoxypyrazolo[3,4-d]Pyrimidine</span>. <i>Helv. Chim. Acta</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1450</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1002/hlca.19930760405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fhlca.19930760405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK3sXmslWmurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1993&pages=1450-1458&author=F.+Seelaauthor=H.+Winterauthor=M.+M%C3%B6ller&title=Pyrazolo%5B3%2C4-d%5DPyrimidine+2%E2%80%B2+-Deoxy-+and+2%E2%80%B2%2C3%E2%80%B2+-Dideoxyribonucleosides%3A+Studies+on+the+Glycosylation+of+4-Methoxypyrazolo%5B3%2C4-d%5DPyrimidine&doi=10.1002%2Fhlca.19930760405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazolo[3,4-d]pyrimidine 2'-deoxy- and 2',3'-dideoxyribonucleosides: studies on the glycosylation of 4-methoxypyrazolo[3,4-d]pyrimidine</span></div><div class="casAuthors">Seela, Frank; Winter, Holger; Moeller, Marianne</div><div class="citationInfo"><span class="NLM_cas:title">Helvetica Chimica Acta</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1450-8</span>CODEN:
                <span class="NLM_cas:coden">HCACAV</span>;
        ISSN:<span class="NLM_cas:issn">0018-019X</span>.
    </div><div class="casAbstract">The glycosylation of the 4-methoxypyrazolo[3,4-d]pyrimidine anion with 1-halo-2-deoxyribose in MeCN/tris[2-(2-methoxyethoxy)ethyl]amine gives N2-deoxynucleoside I (R = toloyl) (29%) together with N1-isomer II (48%) and its α-D-anomer (6%).  The α-D-II is not formed and the yield of the β-D-II increased to 62% when dimethoxyethane is used as solvent and [18]crown-6 as catalyst.  Contrary to 7-deazapurine nucleotides, the triphosphates III (B = R1, R2) showed no appreciable activity against HIV-reverse transcriptase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphfRRENZPrtbVg90H21EOLACvtfcHk0ljKel_iqDeQBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmslWmurg%253D&md5=4b0dde5f5a3f47eb37ca5e17d350ba85</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1002%2Fhlca.19930760405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fhlca.19930760405%26sid%3Dliteratum%253Aachs%26aulast%3DSeela%26aufirst%3DF.%26aulast%3DWinter%26aufirst%3DH.%26aulast%3DM%25C3%25B6ller%26aufirst%3DM.%26atitle%3DPyrazolo%255B3%252C4-d%255DPyrimidine%25202%25E2%2580%25B2%2520-Deoxy-%2520and%25202%25E2%2580%25B2%252C3%25E2%2580%25B2%2520-Dideoxyribonucleosides%253A%2520Studies%2520on%2520the%2520Glycosylation%2520of%25204-Methoxypyrazolo%255B3%252C4-d%255DPyrimidine%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D1993%26volume%3D76%26spage%3D1450%26epage%3D1458%26doi%3D10.1002%2Fhlca.19930760405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rutaganira, F. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhason, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radke, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maddirala, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janetka, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Bakkouri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sibley, L. D.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma Gondii</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9976</span>– <span class="NLM_lpage">9989</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01192</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01192" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFensbzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9976-9989&author=F.+U.+Rutaganiraauthor=J.+Barksauthor=M.+S.+Dhasonauthor=Q.+Wangauthor=M.+S.+Lopezauthor=S.+Longauthor=J.+B.+Radkeauthor=N.+G.+Jonesauthor=A.+R.+Maddiralaauthor=J.+W.+Janetkaauthor=M.+El+Bakkouriauthor=R.+Huiauthor=K.+M.+Shokatauthor=L.+D.+Sibley&title=Inhibition+of+Calcium+Dependent+Protein+Kinase+1+%28CDPK1%29+by+Pyrazolopyrimidine+Analogs+Decreases+Establishment+and+Reoccurrence+of+Central+Nervous+System+Disease+by+Toxoplasma+Gondii&doi=10.1021%2Facs.jmedchem.7b01192"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii</span></div><div class="casAuthors">Rutaganira, Florentine U.; Barks, Jennifer; Dhason, Mary Savari; Wang, Qiuling; Lopez, Michael S.; Long, Shaojun; Radke, Joshua B.; Jones, Nathaniel G.; Maddirala, Amarendar R.; Janetka, James W.; El Bakkouri, Majida; Hui, Raymond; Shokat, Kevan M.; Sibley, L. David</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9976-9989</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Calcium dependent protein kinase 1 (CDPK1) is an essential enzyme in the opportunistic pathogen Toxoplasma gondii.  CDPK1 controls multiple processes that are crit. to the intracellular replicative cycle of T. gondii including secretion of adhesins, motility, invasion, and egress.  Remarkably, CDPK1 contains a small glycine gatekeeper residue in the ATP binding pocket making it sensitive to ATP-competitive inhibitors with bulky substituents that complement this expanded binding pocket.  Here the authors explored structure-activity relationships of a series of pyrazolopyrimidine inhibitors of CDPK1 with the goal of increasing selectivity over host enzymes, improving antiparasite potency, and improving metabolic stability.  The resulting lead compd. 24 exhibited excellent enzyme inhibition and selectivity for CDPK1 and potently inhibited parasite growth in vitro.  Compd. 24 was also effective at treating acute toxoplasmosis in the mouse, reducing dissemination to the central nervous system, and decreasing reactivation of chronic infection in severely immunocompromised mice.  These findings provide proof of concept for the development of small mol. inhibitors of CDPK1 for treatment of CNS toxoplasmosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR_eZs2pZPQ7Vg90H21EOLACvtfcHk0li0lITX44274Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFensbzO&md5=27908eedbcadb1132f254fda63336842</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01192%26sid%3Dliteratum%253Aachs%26aulast%3DRutaganira%26aufirst%3DF.%2BU.%26aulast%3DBarks%26aufirst%3DJ.%26aulast%3DDhason%26aufirst%3DM.%2BS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLopez%26aufirst%3DM.%2BS.%26aulast%3DLong%26aufirst%3DS.%26aulast%3DRadke%26aufirst%3DJ.%2BB.%26aulast%3DJones%26aufirst%3DN.%2BG.%26aulast%3DMaddirala%26aufirst%3DA.%2BR.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DEl%2BBakkouri%26aufirst%3DM.%26aulast%3DHui%26aufirst%3DR.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DSibley%26aufirst%3DL.%2BD.%26atitle%3DInhibition%2520of%2520Calcium%2520Dependent%2520Protein%2520Kinase%25201%2520%2528CDPK1%2529%2520by%2520Pyrazolopyrimidine%2520Analogs%2520Decreases%2520Establishment%2520and%2520Reoccurrence%2520of%2520Central%2520Nervous%2520System%2520Disease%2520by%2520Toxoplasma%2520Gondii%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9976%26epage%3D9989%26doi%3D10.1021%2Facs.jmedchem.7b01192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, Y.</span></span> <span> </span><span class="NLM_article-title">Copper-Catalyzed Conversion of Aryl and Heteroaryl Bromides into the Corresponding Chlorides</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">9468</span>– <span class="NLM_lpage">9470</span>, <span class="refDoi"> DOI: 10.1039/c2cc34944b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1039%2Fc2cc34944b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22895409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1yqsbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2012&pages=9468-9470&author=X.+Fengauthor=Y.+Quauthor=Y.+Hanauthor=X.+Yuauthor=M.+Baoauthor=Y.+Yamamoto&title=Copper-Catalyzed+Conversion+of+Aryl+and+Heteroaryl+Bromides+into+the+Corresponding+Chlorides&doi=10.1039%2Fc2cc34944b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-catalyzed conversion of aryl and heteroaryl bromides into the corresponding chlorides</span></div><div class="casAuthors">Feng, Xiujuan; Qu, Yiping; Han, Yanlei; Yu, Xiaoqiang; Bao, Ming; Yamamoto, Yoshinori</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Communications (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">76</span>),
    <span class="NLM_cas:pages">9468-9470</span>CODEN:
                <span class="NLM_cas:coden">CHCOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-7345</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">An efficient method for the synthesis of aryl and heteroaryl chlorides is described.  The reactions of aryl and heteroaryl bromides with tetramethylammonium chloride proceeded smoothly in the presence of a copper catalyst under mild reaction conditions to produce the corresponding chlorides in satisfactory to excellent yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzBRc0k_54sLVg90H21EOLACvtfcHk0li0lITX44274Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1yqsbnN&md5=03158cfd263e9f17cc7b0f7355233726</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1039%2Fc2cc34944b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2cc34944b%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DY.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DM.%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DCopper-Catalyzed%2520Conversion%2520of%2520Aryl%2520and%2520Heteroaryl%2520Bromides%2520into%2520the%2520Corresponding%2520Chlorides%26jtitle%3DChem.%2520Commun.%26date%3D2012%26volume%3D48%26spage%3D9468%26epage%3D9470%26doi%3D10.1039%2Fc2cc34944b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulpia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, D. d. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Hecke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soeiro, M. d. N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Pyrrolo[2,3-b]Pyridine (1,7-Dideazapurine) Nucleoside Analogues as Anti-Trypanosoma Cruzi Agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8847</span>– <span class="NLM_lpage">8865</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01275</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01275" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslegtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8847-8865&author=C.+Linauthor=F.+Hulpiaauthor=C.+F.+da+Silvaauthor=D.+d.+G.+J.+Batistaauthor=K.+Van+Heckeauthor=L.+Maesauthor=G.+Caljonauthor=M.+d.+N.+C.+Soeiroauthor=S.+Van+Calenbergh&title=Discovery+of+Pyrrolo%5B2%2C3-b%5DPyridine+%281%2C7-Dideazapurine%29+Nucleoside+Analogues+as+Anti-Trypanosoma+Cruzi+Agents&doi=10.1021%2Facs.jmedchem.9b01275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrrolo[2,3-b]pyridine (1,7-Dideazapurine) Nucleoside Analogues as Anti-Trypanosoma cruzi Agents</span></div><div class="casAuthors">Lin, Cai; Hulpia, Fabian; da Silva, Cristiane Franca; Batista, Denise da Gama Jaen; Van Hecke, Kristof; Maes, Louis; Caljon, Guy; Soeiro, Maria de Nazare C.; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8847-8865</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Trypanosoma cruzi is the causative pathogen of Chagas disease and the main culprit for cardiac-related mortality in Latin-America triggered by an infective agent.  Incapable of synthesizing purines de novo, this parasite depends on acquisition and processing of host-derived purines, making purine (nucleoside) analogs a potential source of antitrypanosomal agents.  In this respect, hitherto 7-deazaadenosine (tubercidin) analogs attracted most attention.  Here, we investigated analogs with an addnl. nitrogen (N1) removed.  Structure-activity relationship investigation showed that C7 modification afforded analogs with potent antitrypanosomal activity.  Halogens and small, linear carbon-based substituents were preferred.  Compd. 11 proved most potent in vitro, showed full suppression of parasitemia in a mouse model of acute infection, and elicited 100% animal survival after oral dosing at 25 mg/kg b.i.d. for 5 and 15 days.  Cyclophosphamide-induced immunosuppression led to recrudescence.  Washout expts. demonstrated a lack of complete clearance of infected cell cultures, potentially explaining the in vivo results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxqDRLq5dJvrVg90H21EOLACvtfcHk0li0lITX44274Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslegtrjM&md5=c738830ec9f6d33ffce1661a7e12d6e7</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01275%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DC.%26aulast%3DHulpia%26aufirst%3DF.%26aulast%3Dda%2BSilva%26aufirst%3DC.%2BF.%26aulast%3DBatista%26aufirst%3DD.%2Bd.%2BG.%2BJ.%26aulast%3DVan%2BHecke%26aufirst%3DK.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DSoeiro%26aufirst%3DM.%2Bd.%2BN.%2BC.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Pyrrolo%255B2%252C3-b%255DPyridine%2520%25281%252C7-Dideazapurine%2529%2520Nucleoside%2520Analogues%2520as%2520Anti-Trypanosoma%2520Cruzi%2520Agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8847%26epage%3D8865%26doi%3D10.1021%2Facs.jmedchem.9b01275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanefeld, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rees, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, A. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. J.</span></span> <span> </span><span class="NLM_article-title">One-Pot Synthesis of Tetrasubstituted Pyrazoles—Proof of Regiochemistry</span>. <i>J. Chem. Soc., Perkin Trans. 1</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1552</span>, <span class="refDoi"> DOI: 10.1039/P19960001545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1039%2FP19960001545" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=1996&pages=1545-1552&author=U.+Hanefeldauthor=C.+W.+Reesauthor=A.+J.+P.+Whiteauthor=D.+J.+Williams&title=One-Pot+Synthesis+of+Tetrasubstituted+Pyrazoles%E2%80%94Proof+of+Regiochemistry&doi=10.1039%2FP19960001545"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1039%2FP19960001545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FP19960001545%26sid%3Dliteratum%253Aachs%26aulast%3DHanefeld%26aufirst%3DU.%26aulast%3DRees%26aufirst%3DC.%2BW.%26aulast%3DWhite%26aufirst%3DA.%2BJ.%2BP.%26aulast%3DWilliams%26aufirst%3DD.%2BJ.%26atitle%3DOne-Pot%2520Synthesis%2520of%2520Tetrasubstituted%2520Pyrazoles%25E2%2580%2594Proof%2520of%2520Regiochemistry%26jtitle%3DJ.%2520Chem.%2520Soc.%252C%2520Perkin%2520Trans.%25201%26date%3D1996%26volume%3D28%26spage%3D1545%26epage%3D1552%26doi%3D10.1039%2FP19960001545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X. F.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Carbonylative Transformation of Organic Halides with Formic Acid as the Coupling Partner and CO Source: Synthesis of Carboxylic Acids</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">9710</span>– <span class="NLM_lpage">9714</span>, <span class="refDoi"> DOI: 10.1021/acs.joc.7b01808</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.joc.7b01808" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCqs7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2017&pages=9710-9714&author=F.+P.+Wuauthor=J.+B.+Pengauthor=X.+Qiauthor=X.+F.+Wu&title=Palladium-Catalyzed+Carbonylative+Transformation+of+Organic+Halides+with+Formic+Acid+as+the+Coupling+Partner+and+CO+Source%3A+Synthesis+of+Carboxylic+Acids&doi=10.1021%2Facs.joc.7b01808"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Carbonylative Transformation of Organic Halides with Formic Acid as the Coupling Partner and CO Source: Synthesis of Carboxylic Acids</span></div><div class="casAuthors">Wu, Fu-Peng; Peng, Jin-Bao; Qi, Xinxin; Wu, Xiao-Feng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">9710-9714</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Using formic acid as a carbon monoxide source, DCC as an activator, and Et3N, (E)-arylalkenyl iodides and aryl iodides and bromides and Ph triflate underwent hydroxycarbonylation in the presence of Pd(OAc)2 and Xantphos to yield (E)-cinnamic acids and arylcarboxylic acids in 78-92% and 46-97% yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq60-ZZKNrkGbVg90H21EOLACvtfcHk0lgeVIznLqn_WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCqs7vE&md5=dcbeabe925978b1f22ca617dd14688f9</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.joc.7b01808&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.joc.7b01808%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.%2BP.%26aulast%3DPeng%26aufirst%3DJ.%2BB.%26aulast%3DQi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DX.%2BF.%26atitle%3DPalladium-Catalyzed%2520Carbonylative%2520Transformation%2520of%2520Organic%2520Halides%2520with%2520Formic%2520Acid%2520as%2520the%2520Coupling%2520Partner%2520and%2520CO%2520Source%253A%2520Synthesis%2520of%2520Carboxylic%2520Acids%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2017%26volume%3D82%26spage%3D9710%26epage%3D9714%26doi%3D10.1021%2Facs.joc.7b01808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manabe, K.</span></span> <span> </span><span class="NLM_article-title">Trichlorophenyl Formate: Highly Reactive and Easily Accessible Crystalline CO Surrogate for Palladium-Catalyzed Carbonylation of Aryl/Alkenyl Halides and Triflates</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">5370</span>– <span class="NLM_lpage">5373</span>, <span class="refDoi"> DOI: 10.1021/ol302593z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol302593z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=5370-5373&author=T.+Uedaauthor=H.+Konishiauthor=K.+Manabe&title=Trichlorophenyl+Formate%3A+Highly+Reactive+and+Easily+Accessible+Crystalline+CO+Surrogate+for+Palladium-Catalyzed+Carbonylation+of+Aryl%2FAlkenyl+Halides+and+Triflates&doi=10.1021%2Fol302593z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Trichlorophenyl Formate: Highly Reactive and Easily Accessible Crystalline CO Surrogate for Palladium-Catalyzed Carbonylation of Aryl/Alkenyl Halides and Triflates</span></div><div class="casAuthors">Ueda, Tsuyoshi; Konishi, Hideyuki; Manabe, Kei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5370-5373</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The high utility of 2,4,6-trichlorophenyl formate, a highly reactive and easily accessible cryst. CO surrogate, is demonstrated.  The decarbonylation with NEt3 to generate CO proceeded rapidly at rt, thereby allowing external-CO-free Pd-catalyzed carbonylation of aryl/alkenyl halides and triflates.  The high reactivity of the CO surrogate enabled carbonylation at rt and significantly reduced the quantities of formate to near-stoichiometric levels.  The obtained trichlorophenyl esters can be readily converted to a variety of carboxylic acid derivs. in high yields.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUQt4b7-33nrVg90H21EOLACvtfcHk0lgeVIznLqn_WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejs7vP&md5=74392d6c4847f88bd452016f5ddd08aa</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fol302593z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol302593z%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DH.%26aulast%3DManabe%26aufirst%3DK.%26atitle%3DTrichlorophenyl%2520Formate%253A%2520Highly%2520Reactive%2520and%2520Easily%2520Accessible%2520Crystalline%2520CO%2520Surrogate%2520for%2520Palladium-Catalyzed%2520Carbonylation%2520of%2520Aryl%252FAlkenyl%2520Halides%2520and%2520Triflates%26jtitle%3DOrg.%2520Lett.%26date%3D2012%26volume%3D14%26spage%3D5370%26epage%3D5373%26doi%3D10.1021%2Fol302593z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ueda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konishi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manabe, K.</span></span> <span> </span><span class="NLM_article-title">Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">5370</span>– <span class="NLM_lpage">5373</span>, <span class="refDoi"> DOI: 10.1021/ol4026815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol4026815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFKks77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=5370-5373&author=T.+Uedaauthor=H.+Konishiauthor=K.+Manabe&title=Palladium-Catalyzed+Fluorocarbonylation+Using+N-Formylsaccharin+as+CO+Source%3A+General+Access+to+Carboxylic+Acid+Derivatives&doi=10.1021%2Fol4026815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Fluorocarbonylation Using N-Formylsaccharin as CO Source: General Access to Carboxylic Acid Derivatives</span></div><div class="casAuthors">Ueda, Tsuyoshi; Konishi, Hideyuki; Manabe, Kei</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5370-5373</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">N-Formylsaccharin, an easily accessible cryst. compd., has been employed as an efficient CO source in Pd-catalyzed fluorocarbonylation of aryl halides to afford the corresponding acyl fluorides in high yields.  The reactions use a near-stoichiometric amt. of the CO source (1.2 equiv) and tolerate diverse functional groups.  The acyl fluorides obtained could be readily transformed into various carboxylic acid derivs. such as carboxylic acid, esters, thioesters, and amides in a one-pot procedure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqTUEhxhGH57Vg90H21EOLACvtfcHk0lgeVIznLqn_WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFKks77O&md5=c3c3e96e8e986e2b8b496bb8846bea07</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fol4026815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol4026815%26sid%3Dliteratum%253Aachs%26aulast%3DUeda%26aufirst%3DT.%26aulast%3DKonishi%26aufirst%3DH.%26aulast%3DManabe%26aufirst%3DK.%26atitle%3DPalladium-Catalyzed%2520Fluorocarbonylation%2520Using%2520N-Formylsaccharin%2520as%2520CO%2520Source%253A%2520General%2520Access%2520to%2520Carboxylic%2520Acid%2520Derivatives%26jtitle%3DOrg.%2520Lett.%26date%3D2013%26volume%3D15%26spage%3D5370%26epage%3D5373%26doi%3D10.1021%2Fol4026815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molander, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. R.</span></span> <span> </span><span class="NLM_article-title">Suzuki–Miyaura Cross-Coupling Reactions of Potassium Vinyltrifluoroborate with Aryl and Heteroaryl Electrophiles</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">9681</span>– <span class="NLM_lpage">9686</span>, <span class="refDoi"> DOI: 10.1021/jo0617013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0617013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCgsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2006&pages=9681-9686&author=G.+A.+Molanderauthor=A.+R.+Brown&title=Suzuki%E2%80%93Miyaura+Cross-Coupling+Reactions+of+Potassium+Vinyltrifluoroborate+with+Aryl+and+Heteroaryl+Electrophiles&doi=10.1021%2Fjo0617013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Suzuki-Miyaura cross-coupling reactions of potassium vinyltrifluoroborate with aryl and heteroaryl electrophiles</span></div><div class="casAuthors">Molander, Gary A.; Brown, Adam R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9681-9686</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The palladium-catalyzed cross-coupling reaction of potassium vinyltrifluoroborate with aryl electrophiles was described.  Recent progress in optimizing the reaction, as well as outlining the scope and limitations of the reaction were presented.  The cross-coupling reaction could generally be effected using 2 mol % of PdCl2 and 6 mol % of PPh3 as a catalyst system in THF/H2O with Cs2CO3 as a base.  Moderate to good yields were obtained in the presence of a variety of functional groups.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5MqLzCH3iurVg90H21EOLACvtfcHk0liqpA0jrqfLOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCgsrfN&md5=67aef9e362d578497bce6c9f89effcf4</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjo0617013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0617013%26sid%3Dliteratum%253Aachs%26aulast%3DMolander%26aufirst%3DG.%2BA.%26aulast%3DBrown%26aufirst%3DA.%2BR.%26atitle%3DSuzuki%25E2%2580%2593Miyaura%2520Cross-Coupling%2520Reactions%2520of%2520Potassium%2520Vinyltrifluoroborate%2520with%2520Aryl%2520and%2520Heteroaryl%2520Electrophiles%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2006%26volume%3D71%26spage%3D9681%26epage%3D9686%26doi%3D10.1021%2Fjo0617013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oshiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morimoto, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amii, H.</span></span> <span> </span><span class="NLM_article-title">Sodium Bromodifluoroacetate: A Difluorocarbene Source for the Synthesis of Gem -Difluorocyclopropanes</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">2080</span>– <span class="NLM_lpage">2084</span>, <span class="refDoi"> DOI: 10.1055/s-0029-1218754</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1055%2Fs-0029-1218754" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=2080-2084&author=K.+Oshiroauthor=Y.+Morimotoauthor=H.+Amii&title=Sodium+Bromodifluoroacetate%3A+A+Difluorocarbene+Source+for+the+Synthesis+of+Gem+-Difluorocyclopropanes&doi=10.1055%2Fs-0029-1218754"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1055%2Fs-0029-1218754&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-0029-1218754%26sid%3Dliteratum%253Aachs%26aulast%3DOshiro%26aufirst%3DK.%26aulast%3DMorimoto%26aufirst%3DY.%26aulast%3DAmii%26aufirst%3DH.%26atitle%3DSodium%2520Bromodifluoroacetate%253A%2520A%2520Difluorocarbene%2520Source%2520for%2520the%2520Synthesis%2520of%2520Gem%2520-Difluorocyclopropanes%26jtitle%3DSynthesis%26date%3D2010%26volume%3D99%26spage%3D2080%26epage%3D2084%26doi%3D10.1055%2Fs-0029-1218754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafon, S. W.</span></span> <span> </span><span class="NLM_article-title">Antileishmanial Effect of Allopurinol and Allopurinol Ribonucleoside on Intracellular Forms of Leishmania Donovani</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2397</span>– <span class="NLM_lpage">2398</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(80)90275-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0006-2952%2880%2990275-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=7426045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaL3MXisFKhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1980&pages=2397-2398&author=R.+L.+Berensauthor=J.+J.+Marrauthor=D.+J.+Nelsonauthor=S.+W.+Lafon&title=Antileishmanial+Effect+of+Allopurinol+and+Allopurinol+Ribonucleoside+on+Intracellular+Forms+of+Leishmania+Donovani&doi=10.1016%2F0006-2952%2880%2990275-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Antileishmanial effect of allopurinol and allopurinol ribonucleoside on intracellular forms of Leishmania donovani</span></div><div class="casAuthors">Berens, Randolph L.; Marr, J. Joseph; Nelson, Donald J.; LaFon, Stephen W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2397-8</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Metab. of allopurinol (I)  [315-30-0] and allopurinol ribonucleoside (II)  [16220-07-8] by intracellular amastigotes of L. donovani placed either in suspension, within phagocytic cells of hamster spleen, or within a murine macrophage tissue culture, was the same as in extracellular promastigotes of L. donovani.  Both I and II were effective in eliminating amastigotes from murine macrophages.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_zbrfkD_ZqLVg90H21EOLACvtfcHk0liqpA0jrqfLOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3MXisFKhuw%253D%253D&md5=c6a4b47f199b1c203140d4d776eef78a</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2880%2990275-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252880%252990275-0%26sid%3Dliteratum%253Aachs%26aulast%3DBerens%26aufirst%3DR.%2BL.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26aulast%3DLafon%26aufirst%3DS.%2BW.%26atitle%3DAntileishmanial%2520Effect%2520of%2520Allopurinol%2520and%2520Allopurinol%2520Ribonucleoside%2520on%2520Intracellular%2520Forms%2520of%2520Leishmania%2520Donovani%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1980%26volume%3D29%26spage%3D2397%26epage%3D2398%26doi%3D10.1016%2F0006-2952%2880%2990275-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moorman, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaFon, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marr, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berens, R. L.</span></span> <span> </span><span class="NLM_article-title">Antiprotozoal Activity of 3′-Deoxyinosine</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(91)90704-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2F0006-2952%2891%2990704-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1859443" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK3MXmt1arsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1991&pages=207-212&author=A.+R.+Moormanauthor=S.+W.+LaFonauthor=D.+J.+Nelsonauthor=H.+H.+Carterauthor=J.+J.+Marrauthor=R.+L.+Berens&title=Antiprotozoal+Activity+of+3%E2%80%B2-Deoxyinosine&doi=10.1016%2F0006-2952%2891%2990704-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Antiprotozoal activity of 3'-deoxyinosine.  Inverse correlation to cleavage of the glycosidic bond</span></div><div class="casAuthors">Moorman, Allan R.; LaFon, Stephen W.; Nelson, Donald J.; Carter, Heidi H.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">207-12</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">Two nucleosides related to the known antiprotozoal agent, allopurinol β-D-riboside) (I) were prepd. and evaluated against Leishmania donovani, Trypanosoma cruzi, and T. gambiense.  3'-Deoxyinosine (II) exhibited potent antiprotozoal activity against the three protozoal pathogens with minimal toxicity for host cells.  It was esp. effective against the Columbia strain of T. cruzi reported to be resistant to I.  The antiprotozoal activity of II appeared to be inversely related to the rate of cleavage of the glycosidic bond, as shown by metabolic profiles of II in the various pathogenic hemoflagellates and host cells.  Combining the key structural elements of I and II led to the synthesis of 3'-deoxyallopurinol β-D-riboside (III) which was inactive as an antiprotozoal agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplV7sveQNPMrVg90H21EOLACvtfcHk0liqpA0jrqfLOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXmt1arsLo%253D&md5=aedbb1500cdb74f8538adfdfa13dfe30</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2891%2990704-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252891%252990704-9%26sid%3Dliteratum%253Aachs%26aulast%3DMoorman%26aufirst%3DA.%2BR.%26aulast%3DLaFon%26aufirst%3DS.%2BW.%26aulast%3DNelson%26aufirst%3DD.%2BJ.%26aulast%3DCarter%26aufirst%3DH.%2BH.%26aulast%3DMarr%26aufirst%3DJ.%2BJ.%26aulast%3DBerens%26aufirst%3DR.%2BL.%26atitle%3DAntiprotozoal%2520Activity%2520of%25203%25E2%2580%25B2-Deoxyinosine%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1991%26volume%3D42%26spage%3D207%26epage%3D212%26doi%3D10.1016%2F0006-2952%2891%2990704-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Soeiro, M. d. N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Souza, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, D. d. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavão, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Araújo, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aiub, C. A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lionel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Britto, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulikowski, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hargrove, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waterman, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lepesheva, G. I.</span></span> <span> </span><span class="NLM_article-title">In Vitro and In Vivo Studies of the Antiparasitic Activity of Sterol 14α-Demethylase (CYP51) Inhibitor VNI against Drug-Resistant Strains of Trypanosoma Cruzi</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4151</span>– <span class="NLM_lpage">4163</span>, <span class="refDoi"> DOI: 10.1128/AAC.00070-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.00070-13" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=23774435" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlSns7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2013&pages=4151-4163&author=M.+d.+N.+C.+Soeiroauthor=E.+M.+de+Souzaauthor=C.+F.+da+Silvaauthor=D.+d.+G.+J.+Batistaauthor=M.+M.+Batistaauthor=B.+P.+Pav%C3%A3oauthor=J.+S.+Ara%C3%BAjoauthor=C.+A.+F.+Aiubauthor=P.+B.+da+Silvaauthor=J.+Lionelauthor=C.+Brittoauthor=K.+Kimauthor=G.+Sulikowskiauthor=T.+Y.+Hargroveauthor=M.+R.+Watermanauthor=G.+I.+Lepesheva&title=In+Vitro+and+In+Vivo+Studies+of+the+Antiparasitic+Activity+of+Sterol+14%CE%B1-Demethylase+%28CYP51%29+Inhibitor+VNI+against+Drug-Resistant+Strains+of+Trypanosoma+Cruzi&doi=10.1128%2FAAC.00070-13"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi</span></div><div class="casAuthors">Soeiro, Maria de Nazare Correia; Mello de Souza, Elen; Franca da Silva, Cristiane; Batista, Denise da Gama Jaen; Batista, Marcos Meuser; Pavao, Beatriz Philot; Araujo, Julianna Siciliano; Alub, Claudia Alessandra Fortes; Bernardino da Silva, Patricia; Lionel, Jessica; Britto, Constanca; Kim, Kwangho; Sulikowski, Gary; Hargrove, Tatiana Y.; Waterman, Michael R.; Lepesheva, Galina I.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4151-4163</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chagas disease affects more than 10 million people worldwide, and yet, as it has historically been known as a disease of the poor, it remains highly neglected.  Two currently available drugs exhibit severe toxicity and low effectiveness, esp. in the chronic phase, while new drug discovery has been halted for years as a result of a lack of interest from pharmaceutical companies.  Although attempts to repurpose the antifungal drugs posaconazole and ravuconazole (inhibitors of fungal sterol 14α-demethylase [CYP51]) are finally in progress, development of cheaper and more efficient, preferably Trypanosoma cruzi-specific, chemotherapies would be highly advantageous.  We have recently reported that the exptl. T. cruzi CYP51 inhibitor VNI cures with 100% survival and 100% parasitol. clearance both acute and chronic murine infections with the Tulahuen strain of T. cruzi.  In this work, we further explored the potential of VNI by assaying nitro-deriv.-resistant T. cruzi strains, Y and Colombiana, in highly stringent protocols of acute infection.  The data show high antiparasitic efficacy of VNI and its deriv. (VNI/VNF) against both forms of T. cruzi that are relevant for mammalian host infection (bloodstream and amastigotes), with the in vivo potency, at 25 mg/kg twice a day (b.i.d.), similar to that of benznidazole (100 mg/kg/day).  Transmission electron microscopy and reverse mutation tests were performed to explore cellular ultrastructural and mutagenic aspects of VNI, resp.  No mutagenic potential could be seen by the Ames test at up to 3.5 μM, and the main ultrastructural damage induced by VNI in T. cruzi was related to Golgi app. and endoplasmic reticulum organization, with membrane blebs presenting an autophagic phenotype.  Thus, these preliminary studies confirm VNI as a very promising trypanocidal drug candidate for Chagas disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr1uyCnawwErVg90H21EOLACvtfcHk0liNC6xTMwpfwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlSns7fK&md5=28a51dededa1b97eb13327c5fa92ae76</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1128%2FAAC.00070-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00070-13%26sid%3Dliteratum%253Aachs%26aulast%3DSoeiro%26aufirst%3DM.%2Bd.%2BN.%2BC.%26aulast%3Dde%2BSouza%26aufirst%3DE.%2BM.%26aulast%3Dda%2BSilva%26aufirst%3DC.%2BF.%26aulast%3DBatista%26aufirst%3DD.%2Bd.%2BG.%2BJ.%26aulast%3DBatista%26aufirst%3DM.%2BM.%26aulast%3DPav%25C3%25A3o%26aufirst%3DB.%2BP.%26aulast%3DAra%25C3%25BAjo%26aufirst%3DJ.%2BS.%26aulast%3DAiub%26aufirst%3DC.%2BA.%2BF.%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DLionel%26aufirst%3DJ.%26aulast%3DBritto%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DSulikowski%26aufirst%3DG.%26aulast%3DHargrove%26aufirst%3DT.%2BY.%26aulast%3DWaterman%26aufirst%3DM.%2BR.%26aulast%3DLepesheva%26aufirst%3DG.%2BI.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Studies%2520of%2520the%2520Antiparasitic%2520Activity%2520of%2520Sterol%252014%25CE%25B1-Demethylase%2520%2528CYP51%2529%2520Inhibitor%2520VNI%2520against%2520Drug-Resistant%2520Strains%2520of%2520Trypanosoma%2520Cruzi%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2013%26volume%3D57%26spage%3D4151%26epage%3D4163%26doi%3D10.1128%2FAAC.00070-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ioset, J.-R.</span></span> <span> </span><span class="NLM_article-title">Phenotypic Screening Approaches for Chagas Disease Drug Discovery</span>. <i>Expert Opin. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">153</span>, <span class="refDoi"> DOI: 10.1080/17460441.2018.1417380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1080%2F17460441.2018.1417380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=29235363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Onuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=141-153&author=E.+Chatelainauthor=J.-R.+Ioset&title=Phenotypic+Screening+Approaches+for+Chagas+Disease+Drug+Discovery&doi=10.1080%2F17460441.2018.1417380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Phenotypic screening approaches for Chagas disease drug discovery</span></div><div class="casAuthors">Chatelain, Eric; Ioset, Jean-Robert</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-153</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Chagas disease, caused by the parasite Trypanosoma cruzi, is a global public health issue.  Current treatments targeting the parasite are limited to two old nitroheterocyclic drugs with serious side effects.  The need for new and safer drugs has prompted numerous drug discovery efforts to identify compds. suitable for parasitol. cure in the last decade.  Target-based drug discovery has been limited by the small no. of well-validated targets - the latest example being the failure of azoles, T. cruzi CYP51 inhibitors, in proof-of-concept clin. trials; instead phenotypic-based drug discovery has become the main pillar of Chagas R&D.  Rather than focusing on the tech. features of these screening assays, the authors describe the different assays developed and available in the field, and provide a crit. view on their values and limitations in the screening cascade for Chagas drug development.  The application of technol. advances to the field of Chagas disease has led to a variety of phenotypic assays that have not only changed the disease discovery landscape but have also helped us to gain a better understanding of parasite/host interactions.  Recent examples of target resoln. from phenotypic hits will uncover new opportunities for drug discovery for Chagas disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrrfEw_-gq5rVg90H21EOLACvtfcHk0liNC6xTMwpfwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Onuw%253D%253D&md5=44d1f94e26bde67c9c2e784f9de20ea2</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1080%2F17460441.2018.1417380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F17460441.2018.1417380%26sid%3Dliteratum%253Aachs%26aulast%3DChatelain%26aufirst%3DE.%26aulast%3DIoset%26aufirst%3DJ.-R.%26atitle%3DPhenotypic%2520Screening%2520Approaches%2520for%2520Chagas%2520Disease%2520Drug%2520Discovery%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2018%26volume%3D13%26spage%3D141%26epage%3D153%26doi%3D10.1080%2F17460441.2018.1417380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dumoulin, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vollrath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomko, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burleigh, B.</span></span> <span> </span><span class="NLM_article-title">Glutamine Metabolism Modulates Azole Susceptibility in Trypanosoma Cruzi Amastigotes</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e60226</span> <span class="refDoi"> DOI: 10.7554/eLife.60226</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.7554%2FeLife.60226" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=33258448" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&author=P.+C.+Dumoulinauthor=J.+Vollrathauthor=S.+S.+Tomkoauthor=J.+X.+Wangauthor=B.+Burleigh&title=Glutamine+Metabolism+Modulates+Azole+Susceptibility+in+Trypanosoma+Cruzi+Amastigotes&doi=10.7554%2FeLife.60226"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.7554%2FeLife.60226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.60226%26sid%3Dliteratum%253Aachs%26aulast%3DDumoulin%26aufirst%3DP.%2BC.%26aulast%3DVollrath%26aufirst%3DJ.%26aulast%3DTomko%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DJ.%2BX.%26aulast%3DBurleigh%26aufirst%3DB.%26atitle%3DGlutamine%2520Metabolism%2520Modulates%2520Azole%2520Susceptibility%2520in%2520Trypanosoma%2520Cruzi%2520Amastigotes%26jtitle%3DeLife%26date%3D2020%26volume%3D9%26doi%3D10.7554%2FeLife.60226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagajyothi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machado, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burleigh, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jelicks, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisanti, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garg, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanowitz, H. B.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of Trypanosoma Cruzi Persistence in Chagas Disease</span>. <i>Cell. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">634</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1111/j.1462-5822.2012.01764.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1111%2Fj.1462-5822.2012.01764.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22309180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38XmsVartbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2012&pages=634-643&author=F.+Nagajyothiauthor=F.+S.+Machadoauthor=B.+A.+Burleighauthor=L.+A.+Jelicksauthor=P.+E.+Schererauthor=S.+Mukherjeeauthor=M.+P.+Lisantiauthor=L.+M.+Weissauthor=N.+J.+Gargauthor=H.+B.+Tanowitz&title=Mechanisms+of+Trypanosoma+Cruzi+Persistence+in+Chagas+Disease&doi=10.1111%2Fj.1462-5822.2012.01764.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Trypanosoma cruzi persistence in Chagas disease</span></div><div class="casAuthors">Nagajyothi, Fnu; Machado, Fabiana S.; Burleigh, Barbara A.; Jelicks, Linda A.; Scherer, Philipp E.; Mukherjee, Shankar; Lisanti, Michael P.; Weiss, Louis M.; Garg, Nisha J.; Tanowitz, Herbert B.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Microbiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">634-643</span>CODEN:
                <span class="NLM_cas:coden">CEMIF5</span>;
        ISSN:<span class="NLM_cas:issn">1462-5814</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Trypanosoma cruzi infection leads to development of chronic Chagas disease.  In this article, we provide an update on the current knowledge of the mechanisms employed by the parasite to gain entry into the host cells and establish persistent infection despite activation of a potent immune response by the host.  Recent studies point to a no. of T. cruzi mols. that interact with host cell receptors to promote parasite invasion of the diverse host cells.  T. cruzi expresses an antioxidant system and thromboxane A2 to evade phagosomal oxidative assault and suppress the host's ability to clear parasites.  Addnl. studies suggest that besides cardiac and smooth muscle cells that are the major target of T. cruzi infection, adipocytes and adipose tissue serve as reservoirs from where T. cruzi can recrudesce and cause disease decades later.  Further, T. cruzi employs at least four strategies to maintain a symbiotic-like relationship with the host, and ensure consistent supply of nutrients for its own survival and long-term persistence.  Ongoing and future research will continue to help refining the models of T. cruzi invasion and persistence in diverse tissues and organs in the host.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1I6SXz7lYUrVg90H21EOLACvtfcHk0lgLZ0EXFP4gtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmsVartbc%253D&md5=4752150f75df2b9582aecfeec3cadfc3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1111%2Fj.1462-5822.2012.01764.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1462-5822.2012.01764.x%26sid%3Dliteratum%253Aachs%26aulast%3DNagajyothi%26aufirst%3DF.%26aulast%3DMachado%26aufirst%3DF.%2BS.%26aulast%3DBurleigh%26aufirst%3DB.%2BA.%26aulast%3DJelicks%26aufirst%3DL.%2BA.%26aulast%3DScherer%26aufirst%3DP.%2BE.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DLisanti%26aufirst%3DM.%2BP.%26aulast%3DWeiss%26aufirst%3DL.%2BM.%26aulast%3DGarg%26aufirst%3DN.%2BJ.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26atitle%3DMechanisms%2520of%2520Trypanosoma%2520Cruzi%2520Persistence%2520in%2520Chagas%2520Disease%26jtitle%3DCell.%2520Microbiol.%26date%3D2012%26volume%3D14%26spage%3D634%26epage%3D643%26doi%3D10.1111%2Fj.1462-5822.2012.01764.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, N. W.</span></span> <span> </span><span class="NLM_article-title">Host Cell Invasion by Trypanosoma Cruzi: A Unique Strategy That Promotes Persistence</span>. <i>FEMS Microbiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">734</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1111/j.1574-6976.2012.00333.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1111%2Fj.1574-6976.2012.00333.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=22339763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmtlygsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2012&pages=734-747&author=M.+C.+Fernandesauthor=N.+W.+Andrews&title=Host+Cell+Invasion+by+Trypanosoma+Cruzi%3A+A+Unique+Strategy+That+Promotes+Persistence&doi=10.1111%2Fj.1574-6976.2012.00333.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Host cell invasion by Trypanosoma cruzi: a unique strategy that promotes persistence</span></div><div class="casAuthors">Fernandes, Maria Cecilia; Andrews, Norma W.</div><div class="citationInfo"><span class="NLM_cas:title">FEMS Microbiology Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">734-747</span>CODEN:
                <span class="NLM_cas:coden">FMREE4</span>;
        ISSN:<span class="NLM_cas:issn">0168-6445</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The intracellular protozoan parasite Trypanosoma cruzi is the causative agent of Chagas' disease, a serious disorder that affects millions of people in Latin America.  Despite the development of lifelong immunity following infections, the immune system fails to completely clear the parasites, which persist for decades within host tissues.  Cardiomyopathy is one of the most serious clin. manifestations of the disease, and a major cause of sudden death in endemic areas.  Despite decades of study, there is still debate about the apparent preferential tropism of the parasites for cardiac muscle, and its role in the pathol. of the disease.  In this review, we discuss these issues in light of recent observations, which indicate that T. cruzi invades host cells by subverting a highly conserved cellular pathway for the repair of plasma membrane lesions.  Plasma membrane injury and repair is particularly prevalent in muscle cells, suggesting that the mechanism used by the parasites for cell invasion may be a primary determinant of tissue tropism, intracellular persistence, and Chagas' disease pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGx_1AyWMdALVg90H21EOLACvtfcHk0lgLZ0EXFP4gtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmtlygsbc%253D&md5=f4eb7f8a85b4948a965bed03a3343481</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1111%2Fj.1574-6976.2012.00333.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1574-6976.2012.00333.x%26sid%3Dliteratum%253Aachs%26aulast%3DFernandes%26aufirst%3DM.%2BC.%26aulast%3DAndrews%26aufirst%3DN.%2BW.%26atitle%3DHost%2520Cell%2520Invasion%2520by%2520Trypanosoma%2520Cruzi%253A%2520A%2520Unique%2520Strategy%2520That%2520Promotes%2520Persistence%26jtitle%3DFEMS%2520Microbiol.%2520Rev.%26date%3D2012%26volume%3D36%26spage%3D734%26epage%3D747%26doi%3D10.1111%2Fj.1574-6976.2012.00333.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matos
Ferreira, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segatto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macedo, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gelape, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira Andrade, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagajyothi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherer, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teixeira, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanowitz, H. B.</span></span> <span> </span><span class="NLM_article-title">Evidence for Trypanosoma Cruzi in Adipose Tissue in Human Chronic Chagas Disease</span>. <i>Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1002</span>– <span class="NLM_lpage">1005</span>, <span class="refDoi"> DOI: 10.1016/j.micinf.2011.06.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.micinf.2011.06.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=21726660" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1002-1005&author=A.+V.+Matos%0AFerreiraauthor=M.+Segattoauthor=Z.+Menezesauthor=A.+M.+Macedoauthor=C.+Gelapeauthor=L.+de+Oliveira+Andradeauthor=F.+Nagajyothiauthor=P.+E.+Schererauthor=M.+M.+Teixeiraauthor=H.+B.+Tanowitz&title=Evidence+for+Trypanosoma+Cruzi+in+Adipose+Tissue+in+Human+Chronic+Chagas+Disease&doi=10.1016%2Fj.micinf.2011.06.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.micinf.2011.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.micinf.2011.06.002%26sid%3Dliteratum%253Aachs%26aulast%3DMatos%2BFerreira%26aufirst%3DA.%2BV.%26aulast%3DSegatto%26aufirst%3DM.%26aulast%3DMenezes%26aufirst%3DZ.%26aulast%3DMacedo%26aufirst%3DA.%2BM.%26aulast%3DGelape%26aufirst%3DC.%26aulast%3Dde%2BOliveira%2BAndrade%26aufirst%3DL.%26aulast%3DNagajyothi%26aufirst%3DF.%26aulast%3DScherer%26aufirst%3DP.%2BE.%26aulast%3DTeixeira%26aufirst%3DM.%2BM.%26aulast%3DTanowitz%26aufirst%3DH.%2BB.%26atitle%3DEvidence%2520for%2520Trypanosoma%2520Cruzi%2520in%2520Adipose%2520Tissue%2520in%2520Human%2520Chronic%2520Chagas%2520Disease%26jtitle%3DMicrobes%2520Infect.%26date%3D2011%26volume%3D13%26spage%3D1002%26epage%3D1005%26doi%3D10.1016%2Fj.micinf.2011.06.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francisco, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayawardhana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatelain, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J. M.</span></span> <span> </span><span class="NLM_article-title">Limited Ability of Posaconazole To Cure Both Acute and Chronic Trypanosoma Cruzi Infections Revealed by Highly Sensitive In Vivo Imaging</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">4653</span>– <span class="NLM_lpage">4661</span>, <span class="refDoi"> DOI: 10.1128/AAC.00520-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.00520-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=26014936" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ojtb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=4653-4661&author=A.+F.+Franciscoauthor=M.+D.+Lewisauthor=S.+Jayawardhanaauthor=M.+C.+Taylorauthor=E.+Chatelainauthor=J.+M.+Kelly&title=Limited+Ability+of+Posaconazole+To+Cure+Both+Acute+and+Chronic+Trypanosoma+Cruzi+Infections+Revealed+by+Highly+Sensitive+In+Vivo+Imaging&doi=10.1128%2FAAC.00520-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging</span></div><div class="casAuthors">Francisco, Amanda Fortes; Lewis, Michael D.; Jayawardhana, Shiromani; Taylor, Martin C.; Chatelain, Eric; Kelly, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4653-4661</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The antifungal drug posaconazole has shown significant activity against Trypanosoma cruzi in vitro and in exptl. murine models.  Despite this, in a recent clin. trial it displayed limited curative potential.  Drug testing is problematic in exptl. Chagas disease because of difficulties in demonstrating sterile cure, particularly during the chronic stage of infection when parasite burden is extremely low and tissue distribution is ill defined.  To better assess posaconazole efficacy against acute and chronic Chagas disease, we have exploited a highly sensitive bioluminescence imaging system which generates data with greater accuracy than other methods, including PCR-based approaches.  Mice inoculated with bioluminescent T. cruzi were assessed by in vivo and ex vivo imaging, with cyclophosphamide-induced immunosuppression used to enhance the detection of relapse.  Posaconazole was found to be significantly inferior to benznidazole as a treatment for both acute and chronic T. cruzi infections.  Whereas 20 days treatment with benznidazole was 100% successful in achieving sterile cure, posaconazole failed in almost all cases.  Treatment of chronic infections with posaconazole did however significantly reduce infection-induced splenomegaly, even in the absence of parasitol. cure.  The imaging-based screening system also revealed that adipose tissue is a major site of recrudescence in mice treated with posaconazole in the acute, but not the chronic stage of infection.  This in vivo screening model for Chagas disease is predictive, reproducible and adaptable to diverse treatment schedules.  It should provide greater assurance that drugs are not advanced prematurely into clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvZGTQNtj5IrVg90H21EOLACvtfcHk0lgLZ0EXFP4gtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ojtb7I&md5=7e7004aa8c561b591d89b82eaf4437ef</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1128%2FAAC.00520-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00520-15%26sid%3Dliteratum%253Aachs%26aulast%3DFrancisco%26aufirst%3DA.%2BF.%26aulast%3DLewis%26aufirst%3DM.%2BD.%26aulast%3DJayawardhana%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DM.%2BC.%26aulast%3DChatelain%26aufirst%3DE.%26aulast%3DKelly%26aufirst%3DJ.%2BM.%26atitle%3DLimited%2520Ability%2520of%2520Posaconazole%2520To%2520Cure%2520Both%2520Acute%2520and%2520Chronic%2520Trypanosoma%2520Cruzi%2520Infections%2520Revealed%2520by%2520Highly%2520Sensitive%2520In%2520Vivo%2520Imaging%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D4653%26epage%3D4661%26doi%3D10.1128%2FAAC.00520-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bouton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karalic, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caljon, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Calenbergh, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of a Collection of Purine-like C-Nucleosides as Antikinetoplastid Agents</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>212</i></span>, <span class="NLM_elocation-id">113101</span> <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.113101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1016%2Fj.ejmech.2020.113101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=33385837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BB3MXitFersQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=212&publication_year=2021&author=J.+Boutonauthor=L.+Maesauthor=I.+Karalicauthor=G.+Caljonauthor=S.+Van+Calenbergh&title=Synthesis+and+Evaluation+of+a+Collection+of+Purine-like+C-Nucleosides+as+Antikinetoplastid+Agents&doi=10.1016%2Fj.ejmech.2020.113101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of a collection of purine-like C-nucleosides as antikinetoplastid agents</span></div><div class="casAuthors">Bouton, Jakob; Maes, Louis; Karalic, Izet; Caljon, Guy; Van Calenbergh, Serge</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">212</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113101</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The kinetoplastid parasites Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp. are the causative agents of neglected tropical diseases with a serious burden in several parts of the world.  These parasites are incapable of synthesizing purines de novo, and therefore rely on ingenious purine salvage pathways to acquire and process purines from their host.  Purine nucleoside analogs that may interfere with these pathways therefore constitute a privileged source of new antikinetoplastid agents.  In this study, we synthesized a collection of C-nucleosides employing five different heterocyclic nucleobase surrogates.  C-nucleosides are chem. and enzymically stable and allow for extensive structural modification.  Inspired by earlier 7-deazaadenosine nucleosides and known antileishmanial C-nucleosides, we introduced different modifications tailored towards antikinetoplastid activity.  Both adenosine and inosine analogs were synthesized with the aim of discovering new antikinetoplastid hits and expanding knowledge of structure-activity relationships.  Several promising hits with potent activity against Trypanosoma brucei, Trypanosoma cruzi and Leishmania infantum were discovered, and the nature of the nucleobase surrogate was found to have a profound influence on the selectivity profile of the compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBVFrxzW9hVrVg90H21EOLACvtfcHk0lgBrBxqy27gNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXitFersQ%253D%253D&md5=dfd862f02fdae48c349d4e354b3cd3a4</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.113101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.113101%26sid%3Dliteratum%253Aachs%26aulast%3DBouton%26aufirst%3DJ.%26aulast%3DMaes%26aufirst%3DL.%26aulast%3DKaralic%26aufirst%3DI.%26aulast%3DCaljon%26aufirst%3DG.%26aulast%3DVan%2BCalenbergh%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520a%2520Collection%2520of%2520Purine-like%2520C-Nucleosides%2520as%2520Antikinetoplastid%2520Agents%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D212%26doi%3D10.1016%2Fj.ejmech.2020.113101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cottam, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wasson, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shih, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raychaudhuri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Pasquale, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, D. A.</span></span> <span> </span><span class="NLM_article-title">New Adenosine Kinase Inhibitors with Oral Antiinflammatory Activity: Synthesis and Biological Evaluation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">3424</span>– <span class="NLM_lpage">3430</span>, <span class="refDoi"> DOI: 10.1021/jm00074a024</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00074a024" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADyaK3sXmslWmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=3424-3430&author=H.+B.+Cottamauthor=D.+B.+Wassonauthor=H.+C.+Shihauthor=A.+Raychaudhuriauthor=G.+Di+Pasqualeauthor=D.+A.+Carson&title=New+Adenosine+Kinase+Inhibitors+with+Oral+Antiinflammatory+Activity%3A+Synthesis+and+Biological+Evaluation&doi=10.1021%2Fjm00074a024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">New adenosine kinase inhibitors with oral antiinflammatory activity: synthesis and biological evaluation</span></div><div class="casAuthors">Cottam, Howard B.; Wasson, D. Bruce; Shih, Hsien C.; Raychaudhuri, Anil; Di Pasquale, Gene; Carson, Dennis A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3424-30</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Several 5-iodotubercidin analogs, e.g. I (R = H, Cl, N3, NH2, F, OH, R1 = iodo), were synthesized as potential inhibitors of adenosine kinase by a direct Lewis acid-catalyzed glycosidation procedure using both the preformed carbohydrate and the heterocyclic base as starting materials.  First, each compd. was studied kinetically for inhibition of purified human placental adenosine kinase activity.  The order of potency was: iodotubercidin > hydroxyl > amino ≥deoxy > fluoro> chloro >> azido.  The inhibition appeared to be essentially competitive in nature, although a noncompetitive component of significance for the more potent inhibitors cannot be ruled out.  The order of effectiveness of the compds. in this system, representing a functional inhibition of adenosine kinase in cultured cells, was about the same as that with the purified enzyme, except that the 5'-chloro and 5'-fluoro compds. were ineffective.  The 5'-hydroxyl deriv. was evaluated in vivo in a rat pleurisy inflammation model and displayed biol. activity at a dose of 30 mg/kg given orally.  Finally, the in vitro toxicity of each compd. was assessed in CEM lymphoblasts.  Results indicated that the two most potent inhibitors in the pyrazolo[3,4-d]pyrimidine ring system I (R = OH, NH2) were 15-fold and 75-fold, resp., less growth inhibitory than 5-iodotubercidin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbgMf4ZtjBFLVg90H21EOLACvtfcHk0lgBrBxqy27gNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmslWmu7g%253D&md5=1bdc27c0b3a8b3ed0f6f730adad01b88</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fjm00074a024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00074a024%26sid%3Dliteratum%253Aachs%26aulast%3DCottam%26aufirst%3DH.%2BB.%26aulast%3DWasson%26aufirst%3DD.%2BB.%26aulast%3DShih%26aufirst%3DH.%2BC.%26aulast%3DRaychaudhuri%26aufirst%3DA.%26aulast%3DDi%2BPasquale%26aufirst%3DG.%26aulast%3DCarson%26aufirst%3DD.%2BA.%26atitle%3DNew%2520Adenosine%2520Kinase%2520Inhibitors%2520with%2520Oral%2520Antiinflammatory%2520Activity%253A%2520Synthesis%2520and%2520Biological%2520Evaluation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D3424%26epage%3D3430%26doi%3D10.1021%2Fjm00074a024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seela, F.</span></span> <span> </span><span class="NLM_article-title">Silver-Mediated Base Pairs in DNA Incorporating Purines, 7-Deazapurines, and 8-Aza-7-Deazapurines: Impact of Reduced Nucleobase Binding Sites and an Altered Glycosylation Position</span>. <i>Chem. – Eur. J.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">5529</span>– <span class="NLM_lpage">5540</span>, <span class="refDoi"> DOI: 10.1002/chem.201605982</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1002%2Fchem.201605982" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=28195414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsVyru78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=5529-5540&author=H.+Zhaoauthor=P.+Leonardauthor=X.+Guoauthor=H.+Yangauthor=F.+Seela&title=Silver-Mediated+Base+Pairs+in+DNA+Incorporating+Purines%2C+7-Deazapurines%2C+and+8-Aza-7-Deazapurines%3A+Impact+of+Reduced+Nucleobase+Binding+Sites+and+an+Altered+Glycosylation+Position&doi=10.1002%2Fchem.201605982"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Silver-Mediated Base Pairs in DNA Incorporating Purines, 7-Deazapurines, and 8-Aza-7-deazapurines: Impact of Reduced Nucleobase Binding Sites and an Altered Glycosylation Position</span></div><div class="casAuthors">Zhao, Hang; Leonard, Peter; Guo, Xiurong; Yang, Haozhe; Seela, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5529-5540</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Formation of silver-mediated DNA was studied with oligonucleotides incorporating 8-aza-7-deazapurine, 7-deazapurine, and purine nucleosides.  The investigation was performed on non-self-complementary duplexes with one or two modifications and self-complementary duplexes with an alternating dA-dT motif.  Homo base pairs as well as base pair mismatches of dA analogs with dC and Watson-Crick pairs with dT were studied by stoichiometric silver ion titrn. and Tm measurements.  N8-Glycosylated 8-aza-7-deazaadenine forms silver-ion-mediated base pairs capturing two silver ions (low silver content) whereas regularly glycosylated 8-aza-7-deazapurine, 7-deazapurine (c7Ad), and dA do not form comparable structures.  Stable silver-mediated "dA-dC" base pair mismatches were detected for all nucleosides.  Two silver ions per base pair are bound by 8-aza-7-deazapurine whereas c7Ad binds only one silver ion.  The situation is different when the equiv. of silver ions were increased to the no. of total base pairs.  Surprisingly, in 12-mer duplexes as well as in related 25-mer duplexes every base pair consumed one silver ion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv9wjZzEeA2bVg90H21EOLACvtfcHk0lgBrBxqy27gNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsVyru78%253D&md5=4a9b63042fc3b4afc342b88b8f7c57d7</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2Fchem.201605982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201605982%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSeela%26aufirst%3DF.%26atitle%3DSilver-Mediated%2520Base%2520Pairs%2520in%2520DNA%2520Incorporating%2520Purines%252C%25207-Deazapurines%252C%2520and%25208-Aza-7-Deazapurines%253A%2520Impact%2520of%2520Reduced%2520Nucleobase%2520Binding%2520Sites%2520and%2520an%2520Altered%2520Glycosylation%2520Position%26jtitle%3DChem.%2520%25E2%2580%2593%2520Eur.%2520J.%26date%3D2017%26volume%3D23%26spage%3D5529%26epage%3D5540%26doi%3D10.1002%2Fchem.201605982" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kraybill, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkin, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blethrow, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Inhibitor Scaffolds as New Allele Specific Kinase Substrates</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">12118</span>– <span class="NLM_lpage">12128</span>, <span class="refDoi"> DOI: 10.1021/ja0264798</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja0264798" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD38Xnt1Sju7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2002&pages=12118-12128&author=B.+C.+Kraybillauthor=L.+L.+Elkinauthor=J.+D.+Blethrowauthor=D.+O.+Morganauthor=K.+M.+Shokat&title=Inhibitor+Scaffolds+as+New+Allele+Specific+Kinase+Substrates&doi=10.1021%2Fja0264798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor scaffolds as new allele specific kinase substrates</span></div><div class="casAuthors">Kraybill, Brian C.; Elkin, Lisa L.; Blethrow, Justin D.; Morgan, David O.; Shokat, Kevan M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">12118-12128</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The elucidation of protein kinase signaling networks is challenging due to the large size of the protein kinase superfamily (>500 human kinases).  Here the authors describe a new class of orthogonal triphosphate substrate analogs for the direct labeling of analog-specific protein kinase targets.  These analogs were constructed as derivs. of the Src family kinase inhibitor PP1 and were designed based on the crystal structures of PP1 bound to HCK and N6-(benzyl)-ADP bound to c-Src (T338G).  3-Benzylpyrazolopyrimidine triphosphate (3-benzyl-PPTP) proved to be a substrate for a mutant of the MAP kinase p38 (p38-T106G/A157L/L167A).  3-Benzyl-PPTP was preferred by v-Src (T338G) (kcat/Km = 3.2 × 106 min-1 M-1) over ATP or the previously described ATP analog, N6-(benzyl) ATP.  For the kinase CDK2 (F80G)/cyclin E, 3-benzyl-PPTP demonstrated catalytic efficiency (kcat/Km = 2.6 × 104 min-1 M-1) comparable to ATP (kcat/Km = 5.0 × 104 min-1 M-1) largely due to a significantly better Km (6.4 μM vs. 530 μM).  In kinase protein substrate labeling expts. both 3-benzyl-PPTP and 3-phenyl-PPTP prove to be over 4 times more orthogonal than N6-(benzyl)-ATP with respect to the wild-type kinases found in murine splenocyte cell lysates.  These expts. also demonstrate that [γ-32P]-3-benzyl-PPTP is an excellent phosphodonor for labeling the direct protein substrates of CDK2 (F80G)/E in murine splenocyte cell lysates, even while competing with cellular levels (4 mM) of unlabeled ATP.  The fact that this new more highly orthogonal nucleotide is accepted by three widely divergent kinases studied here suggests that it is likely to be generalizable across the entire kinase superfamily.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3tyo_B1M5nrVg90H21EOLACvtfcHk0liNwc2ksszZDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xnt1Sju7o%253D&md5=1b88b7669895fe692114dead34700a15</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fja0264798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja0264798%26sid%3Dliteratum%253Aachs%26aulast%3DKraybill%26aufirst%3DB.%2BC.%26aulast%3DElkin%26aufirst%3DL.%2BL.%26aulast%3DBlethrow%26aufirst%3DJ.%2BD.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DInhibitor%2520Scaffolds%2520as%2520New%2520Allele%2520Specific%2520Kinase%2520Substrates%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2002%26volume%3D124%26spage%3D12118%26epage%3D12128%26doi%3D10.1021%2Fja0264798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis of Pyrazolo[5,1-d][1,2,3,5]Tetrazine-4(3H)-Ones</span>. <i>J. Comb. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1021/cc900063y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cc900063y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSrsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=69-74&author=Y.+Gaoauthor=Y.+Lam&title=Synthesis+of+Pyrazolo%5B5%2C1-d%5D%5B1%2C2%2C3%2C5%5DTetrazine-4%283H%29-Ones&doi=10.1021%2Fcc900063y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Pyrazolo[5,1-d][1,2,3,5]tetrazin-4(3H)-ones</span></div><div class="casAuthors">Gao, Yaojun; Lam, Yulin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Combinatorial Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-74</span>CODEN:
                <span class="NLM_cas:coden">JCCHFF</span>;
        ISSN:<span class="NLM_cas:issn">1520-4766</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A solid-phase synthesis of 5-aminopyrazoles I (R1 = H, CN, EtO2C, Ph; R2 = H, Me, Ph) has been developed and applied to the prepn. of pyrazolo[5,1-d][1,2,3,5]tetrazin-4(3H)-ones II (R3 = n-hexyl, Ph, 4-ClC6H4, PhCH2, PhCH2CH2).  In this strategy, 5-aminopyrazoles I were converted into pyrazolo[5,1-d][1,2,3,5]tetrazines II in one-pot via diazotization followed cyclocondensation with isocyanates R3NCO.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKXvMzpwop9LVg90H21EOLACvtfcHk0liNwc2ksszZDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSrsbjI&md5=6ead955becf860d17d892def8d0bec97</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fcc900063y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcc900063y%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLam%26aufirst%3DY.%26atitle%3DSynthesis%2520of%2520Pyrazolo%255B5%252C1-d%255D%255B1%252C2%252C3%252C5%255DTetrazine-4%25283H%2529-Ones%26jtitle%3DJ.%2520Comb.%2520Chem.%26date%3D2010%26volume%3D12%26spage%3D69%26epage%3D74%26doi%3D10.1021%2Fcc900063y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kulkarni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keyes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baffoe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Török, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stieglitz, K.</span></span> <span> </span><span class="NLM_article-title">1,3-Disubstituted-4-Aminopyrazolo [3, 4-d] Pyrimidines, a New Class of Potent Inhibitors for Phospholipase D</span>. <i>Chem. Biol. Drug Des.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">270</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1111/cbdd.12319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1111%2Fcbdd.12319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=24641677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlWgu7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2014&pages=270-281&author=A.+Kulkarniauthor=P.+Quangauthor=V.+Curryauthor=R.+Keyesauthor=W.+Zhouauthor=H.+Choauthor=J.+Baffoeauthor=B.+T%C3%B6r%C3%B6kauthor=K.+Stieglitz&title=1%2C3-Disubstituted-4-Aminopyrazolo+%5B3%2C+4-d%5D+Pyrimidines%2C+a+New+Class+of+Potent+Inhibitors+for+Phospholipase+D&doi=10.1111%2Fcbdd.12319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">1,3-Disubstituted-4-Aminopyrazolo [3, 4-d] Pyrimidines, a New Class of Potent Inhibitors for Phospholipase D</span></div><div class="casAuthors">Kulkarni, Aditya; Quang, Phong; Curry, Victoriana; Keyes, Renee; Zhou, Weihong; Cho, Hyejin; Baffoe, Jonathan; Toeroek, Bela; Stieglitz, Kimberly</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">270-281</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Phospholipase D enzymes cleave lipid substrates to produce phosphatidic acid, an important precursor for many essential cellular mols.  Phospholipase D is a target to modulate cancer-cell invasiveness.  This study reports synthesis of a new class of phospholipase D inhibitors based on 1,3-disubstituted-4-amino-pyrazolopyrimidine core structure.  These mols. were synthesized and used to perform initial screening for the inhibition of purified bacterial phospholipase D, which is highly homologous to the human PLD1.  Initially tested with the bacterial phospholipase D enzyme, then confirmed with the recombinant human PLD1 and PLD2 enzymes, the mols. presented here exhibited inhibition of phospholipase D activity (IC50) in the low-nanomolar to low-micromolar range with both monomeric substrate diC4PC and phospholipid vesicles and micelles.  The data strongly indicate that these inhibitory mols. directly block enzyme/vesicle substrate binding.  Preliminary activity studies using recombinant human phospholipase Ds in in vivo cell assays measuring both transphosphatidylation and head-group cleavage indicate inhibition in the mid- to low-nanomolar range for these potent inhibitory novel mols. in a physiol. environment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO45njEbsFz7Vg90H21EOLACvtfcHk0liNwc2ksszZDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlWgu7%252FI&md5=87816753658d3a5b9830b8aa195bcf9b</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12319%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DA.%26aulast%3DQuang%26aufirst%3DP.%26aulast%3DCurry%26aufirst%3DV.%26aulast%3DKeyes%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DBaffoe%26aufirst%3DJ.%26aulast%3DT%25C3%25B6r%25C3%25B6k%26aufirst%3DB.%26aulast%3DStieglitz%26aufirst%3DK.%26atitle%3D1%252C3-Disubstituted-4-Aminopyrazolo%2520%255B3%252C%25204-d%255D%2520Pyrimidines%252C%2520a%2520New%2520Class%2520of%2520Potent%2520Inhibitors%2520for%2520Phospholipase%2520D%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2014%26volume%3D84%26spage%3D270%26epage%3D281%26doi%3D10.1111%2Fcbdd.12319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickx, S.</span>; <span class="NLM_string-name">Caljon, G.</span>; <span class="NLM_string-name">Maes, L.</span></span> <span> </span><span class="NLM_article-title">In Vitro Growth Inhibition Assays of Leishmania Spp</span>. In  <i>Trypanosomatids: Methods and Protocols</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, P. A. M.</span>; <span class="NLM_string-name">Ginger, M. L.</span>; <span class="NLM_string-name">Zilberstein, D.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York, NY</span>, <span class="NLM_year">2020</span>; pp  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">800</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1007%2F978-1-0716-0294-2_47" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=791-800&author=S.+Hendrickx&author=G.+Caljon&author=L.+Maesauthor=P.+A.+M.+Michels&author=M.+L.+Ginger&author=D.+Zilberstein&title=Trypanosomatids%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1007%2F978-1-0716-0294-2_47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-0716-0294-2_47%26sid%3Dliteratum%253Aachs%26aulast%3DHendrickx%26aufirst%3DS.%26atitle%3DIn%2520Vitro%2520Growth%2520Inhibition%2520Assays%2520of%2520Leishmania%2520Spp%26btitle%3DTrypanosomatids%253A%2520Methods%2520and%2520Protocols%26aulast%3DMichels%26aufirst%3DP.%2BA.%2BM.%26pub%3DSpringer%26date%3D2020%26spage%3D791%26epage%3D800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Batista, D. G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacheco, M. G. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Branowska, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismail, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boykin, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soeiro, M. N. C.</span></span> <span> </span><span class="NLM_article-title">Biological, Ultrastructural Effect and Subcellular Localization of Aromatic Diamidines in Trypanosoma Cruzi</span>. <i>Parasitology</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1017/S0031182009991223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1017%2FS0031182009991223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=19765349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVOgu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2010&pages=251-259&author=D.+G.+J.+Batistaauthor=M.+G.+O.+Pachecoauthor=A.+Kumarauthor=D.+Branowskaauthor=M.+A.+Ismailauthor=L.+Huauthor=D.+W.+Boykinauthor=M.+N.+C.+Soeiro&title=Biological%2C+Ultrastructural+Effect+and+Subcellular+Localization+of+Aromatic+Diamidines+in+Trypanosoma+Cruzi&doi=10.1017%2FS0031182009991223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi</span></div><div class="casAuthors">Batista, D. G. J.; Pacheco, M. G. O.; Kumar, A.; Branowska, D.; Ismail, M. A.; Hu, L.; Boykin, D. W.; Soeiro, M. N. C.</div><div class="citationInfo"><span class="NLM_cas:title">Parasitology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">PARAAE</span>;
        ISSN:<span class="NLM_cas:issn">0031-1820</span>.
    
            (<span class="NLM_cas:orgname">Cambridge University Press</span>)
        </div><div class="casAbstract">No vaccines or safe chemotherapy are available for Chagas disease.  Pentamidine and related di-cations are DNA minor groove-binders with broad-spectrum anti-protozoal activity.  Therefore our aim was to evaluate the in vitro efficacy of di-cationic compds. - DB1645, DB1582, DB1651, DB1646, DB1670 and DB1627 - against bloodstream trypomastigotes (BT) and intracellular forms of Trypanosoma cruzi.  Cellular targets of these compds. in treated parasites were also analyzed by fluorescence and transmission electron microscopy (TEM).  DB1645, DB1582 and DB1651 were the most active against BT showing IC50 values ranging between 0·15 and 6·9 μm.  All compds. displayed low toxicity towards mammalian cells and DB1645, DB1582 and DB1651 were also the most effective against intracellular parasites, with IC50 values ranging between 7·3 and 13·3 μm.  All compds. localized in parasite nuclei and kDNA (with greater intensity in the latter structure), and DB1582 and DB1651 also concd. in non-DNA-contg. cytoplasmic organelles possibly acidocalcisomes.  TEM revealed alterations in mitochondria and kinetoplasts, as well as important disorganization of microtubules.  Our data provide further information regarding the activity of this class of compds. upon T. cruzi which should aid future design and synthesis of agents that could be used for Chagas disease therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppDl5GRPyRWbVg90H21EOLACvtfcHk0lj3ofje9zyePw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVOgu7w%253D&md5=a3f30c800b2f2a98b2bdb4b406083969</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1017%2FS0031182009991223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS0031182009991223%26sid%3Dliteratum%253Aachs%26aulast%3DBatista%26aufirst%3DD.%2BG.%2BJ.%26aulast%3DPacheco%26aufirst%3DM.%2BG.%2BO.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DBranowska%26aufirst%3DD.%26aulast%3DIsmail%26aufirst%3DM.%2BA.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DBoykin%26aufirst%3DD.%2BW.%26aulast%3DSoeiro%26aufirst%3DM.%2BN.%2BC.%26atitle%3DBiological%252C%2520Ultrastructural%2520Effect%2520and%2520Subcellular%2520Localization%2520of%2520Aromatic%2520Diamidines%2520in%2520Trypanosoma%2520Cruzi%26jtitle%3DParasitology%26date%3D2010%26volume%3D137%26spage%3D251%26epage%3D259%26doi%3D10.1017%2FS0031182009991223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Timm, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batista, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, F. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">da Silva, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patrick, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakunov, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakunova, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maria
de Nazaré, C. S.</span></span> <span> </span><span class="NLM_article-title">In Vitro and In Vivo Biological Effects of Novel Arylimidamide Derivatives against Trypanosoma Cruzi</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">3720</span>– <span class="NLM_lpage">3726</span>, <span class="refDoi"> DOI: 10.1128/AAC.02353-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=10.1128%2FAAC.02353-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=24752263" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=3720-3726&author=B.+L.+Timmauthor=P.+B.+da+Silvaauthor=M.+M.+Batistaauthor=F.+H.+G.+da+Silvaauthor=C.+F.+da+Silvaauthor=R.+R.+Tidwellauthor=D.+A.+Patrickauthor=S.+K.+Jonesauthor=S.+A.+Bakunovauthor=S.+M.+Bakunovaauthor=C.+S.+Maria%0Ade+Nazar%C3%A9&title=In+Vitro+and+In+Vivo+Biological+Effects+of+Novel+Arylimidamide+Derivatives+against+Trypanosoma+Cruzi&doi=10.1128%2FAAC.02353-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo biological effects of novel arylimidamide derivatives against Trypanosoma cruzi</span></div><div class="casAuthors">Timm, Bruno Lisboa; da Silva, Patricia Bernadino; Batista, Marcos Meuser; da Silva, Francisca Hildemagna Guedes; da Silva, Cristiane Franca; Tidwell, Richard R.; Patrick, Donald A.; Jones, Susan Kilgore; Bakunov, Stanislav A.; Bakunova, Svetlana M.; de Nazare C. Soeiro, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3720-3726, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Chagas disease (CD), a neglected tropical disease caused by Trypanosoma cruzi, remains a serious public health problem in several Latin American countries.  The available chemotherapies for CD have limited efficacy and exhibit undesirable side effects.  Arom. diamidines and arylimidamides (AIAs) have shown broad-spectrum activity against intracellular parasites, including T. cruzi.  Therefore, our aim was to evaluate the biol. activity of eight novel AIAs (16DAP002, 16SAB079, 18SAB075, 23SMB022, 23SMB026, 23SMB054, 26SMB070, and 27SMB009) against exptl. models of T. cruzi infection in vitro and in vivo.  Our data show that none of the compds. induced a loss of cellular viability up to 32 μM.  Two AIAs, 18SAB075 and 16DAP002, exhibited good in vitro activity against different parasite strains (Y and Tulahuen) and against the two relevant forms of the parasite for mammalian hosts.  Due to the excellent selective indexes of 18SAB075, this AIA was moved to in vivo tests for acute toxicity and parasite efficacy; nontoxic doses (no-obsd.-adverse-effect level [NOAEL], 50 mg/kg) were employed in the tests for parasite efficacy.  In exptl. models of acute T. cruzi infection, 18SAB075 reduced parasitemia levels only up to 50% and led to 40% protection against mortality (at 5 mg/kg of body wt.), being less effective than the ref. drug, benznidazole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr65z9kS-zVP7Vg90H21EOLACvtfcHk0lj3ofje9zyePw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKjt7rN&md5=473b0b02035bd0f8aa64254885d16d2a</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1128%2FAAC.02353-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02353-14%26sid%3Dliteratum%253Aachs%26aulast%3DTimm%26aufirst%3DB.%2BL.%26aulast%3Dda%2BSilva%26aufirst%3DP.%2BB.%26aulast%3DBatista%26aufirst%3DM.%2BM.%26aulast%3Dda%2BSilva%26aufirst%3DF.%2BH.%2BG.%26aulast%3Dda%2BSilva%26aufirst%3DC.%2BF.%26aulast%3DTidwell%26aufirst%3DR.%2BR.%26aulast%3DPatrick%26aufirst%3DD.%2BA.%26aulast%3DJones%26aufirst%3DS.%2BK.%26aulast%3DBakunov%26aufirst%3DS.%2BA.%26aulast%3DBakunova%26aufirst%3DS.%2BM.%26aulast%3DMaria%2Bde%2BNazar%25C3%25A9%26aufirst%3DC.%2BS.%26atitle%3DIn%2520Vitro%2520and%2520In%2520Vivo%2520Biological%2520Effects%2520of%2520Novel%2520Arylimidamide%2520Derivatives%2520against%2520Trypanosoma%2520Cruzi%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D3720%26epage%3D3726%26doi%3D10.1128%2FAAC.02353-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i145"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00135">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_43733"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00135?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00135</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">HPLC traces of selected final compounds and copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra of synthesized compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00135/suppl_file/jm1c00135_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00135/suppl_file/jm1c00135_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00135/suppl_file/jm1c00135_si_001.pdf">jm1c00135_si_001.pdf (8.54 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00135/suppl_file/jm1c00135_si_002.csv">jm1c00135_si_002.csv (10.71 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00135&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00135%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-7%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00135" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799e03c7d513c76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
